summarized Hodgkin lymphoma first lymphomas recognized specific disease entity . Recent studies highlighted heterogeneity diseases associated eponym warranting clarification . Chimeric antigen receptor (CAR) T-cell therapies demonstrated efficacy relapsed/refractory large B-cell lymphoma (LBCL) associated cytokine release syndrome (CRS) neurological events (NE) We wanted " A 56-year-old woman diagnosis diffuse large B-cell lymphoma dyspnea, weakness left upper extremity vocal cord paralysis . She underwent cervical, thoracal lumbosacral magnetic resonance imaging (MRI) However" " Primary cardiac lymphoma (PCL) extremely rare fatal fatal heart neoplasm . Primary cardiac non-Hodgkin lymphoma (NHL) uncommon, considering rarity pericardial diffuse large B-cell lymphoma (" " C-MYC expression immunohistochemical stain (IHC) shown independent prognostic factor DLBCL . In clinical setting, MYC stain currently evaluated manual quantification minimum positivity cut-off 40% ." " Human immunodeficiency virus (HIV) infected patient caused patient suffer Garcin syndrome . In study, report parapharyngeal diffuse large B-cell lymphoma human immunodeficiency virus (HIV) infected patient caused" " Chronic lymphocytic leukemia (CLL) experience histological transformation aggressive lymphoma called ""Richter's transformation"" This transformation usually leads diffuse large B cell lymphoma, though cases T cell lymphoma identified ." 115 DLBCL patients admitted hospital treatment June 2020 June 2021 . 115 DLBCL patients admitted hospital treatment June 2020 June 2021 . 65 healthy subjects received physical examination hospital period selected healthy control group . " Primary mediastinal B-cell lymphoma (PMBCL) rare type diffuse large B-cell lymphoma . PMBCL typically presents large, fast-growing tumor limited mediastinum . R-CHOP commonly used" Tumour cells develop accumulating changes genome result changes main cellular processes . Aberrations basic processes replication chromatin reassembly particularly important genomic (in)stability . " The main function cartilage oligomeric matrix protein (COMP) maintain synthesis stability extracellular matrix interacting collagen . At present, relatively studies role protein tumors . This study aimed explore relationship COMP pan-cancer, analyzed diagnostic prognostic" " Follicular lymphoma (FL) generally indolent B cell lymphoproliferative disorder transformed follicular center B cells . FL characterized diffuse lymphadenopathy, bone marrow involvement, splenomegaly. Cytopen" " We report case middle-aged man unusual case bullous lichen sclerosus complicated morphea . He showed initial recurrent flaccid bullae, followed ivory-white sclerotic plaques extensive skin sclerosis, additional walking disorder" Meta-analysis research explored findings previous studies highlighted efficacy of HD and/or IT CNS prophylaxis in DLBCL patients intermediate high risk . Aim is to answer following research questions: (1) Is difference CNS relaps rel " Isatuximab (Isa, anti-CD38 antibody) combination cemiplimab (Cemi) combination cemiplimab (Cemi) isatuximab (Isa, anti-CD38 antibody" Circulating tumor DNA (ctDNA) become investigated analyte blood . It shed tumor circulation represents subset total cell-free DNA (cfDNA) pool released peripheral blood . Direct comparisons effectiveness of novel therapies diffuse large B-cell lymphoma (DLBCL) treatment landscape range head-to-head randomized phase 3 trials would time-consuming costly . Comparative effectiveness studies using real-world data (R Patients with diffuse large B-cell lymphoma (DLBCL) undergo HCT 2008 2020 . DLBCL underwent HCT 2008 2020 . DLBCL underwent HCT 2008 2020 . DLBCL underwent HCT 2008 2020 . " Febrile neutropenia risk prediction models important clinical practice, external validation limited ." " 61-year-old man presented three distinct tumors concurrently 2021: noninvasive urothelial carcinoma bladder, diffuse large B-cell lymphoma, squamous cell carcinoma lung . MPMs defined coexistence at least two" " Epstein-Barr virus (EBV) considered carcinogenic virus, associated high risk poor prognosis lymphoma patients . We aimed identify immunological microenvironment molecular signatures lead poor prognosis EBV+ lymphoma patients . Differential genes" " The incidence cardiac lymphoma is low, mainly occurs secondary non-Hodgkin's lymphoma, particularly diffuse large B-cell lymphoma ." Macrophage-capping protein (CAPG) discovered play crucial part regulator various cancers . It still remains unclear regarding regulatory mechanism of DLBCL . " Diffuse large B-cell lymphoma (DLBCL) common aggressive non-Hodgkin lymphoma, 10% DLBCL cases primarily occur gastrointestinal tract . Primary gastrointestinal-DLBCL (pGI-DLBC" RNA expression profiling using next-generation sequencing provides reliable reproducible information biology cancer . RNA expression profiling using next-generation sequencing provides reliable reproducible information biology cancer . " Primary adrenal lymphoma (PAL) extremely rare entity, cases reported . Symptoms atypical, making difficult obtain accurate early diagnosis ." We investigated clinicopathologic features 5 follicular lymphomas (FL) transformed morphologic diffuse large B-cell lymphomas (DLBCL) primary mediastinal large B-cell lymphoma (PMBL) lymphoma (PM " WHO classification haematolymphoid tumours worldwide accepted reference malignant tumours myeloid lymphoid system . The REAL classification 1994 laid foundations WHO volumes, continous development specification date [3, 5, 6]. In 5" Metal ions play role pathogenesis lymphoma . Metal ions play role pathogenesis lymphoma . High-dose methotrexate (HD-MTX) standard therapy primary central nervous system lymphoma (PCNSL) prognosis remains poor . Because 90% PCNSL diffuse large B-cell lymphoma (DLBC We present case older male adult adult adult adult primary spinal diffuse large B-cell lymphoma (DLBCL) presenting spinal cord compression treated surgery followed high dose methotrexate combination RCHOP . " Recent reports suggest aggressive non-Hodgkin lymphomas might benefit concomitantly receiving statins rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine (On" " PSENHLs diffuse large B-cell lymphomas commonly caused chronic inflammatory process, chronic infection, autoimmune disease . The majority PSENHLs diffuse large B-cell lymphomas are commonly caused chronic inflammatory process, chronic infection, autoimmune" Diffuse large B cell lymphoma (DLBCL) aggressive subtype non-Hodgkin lymphoma accounts third NHL cases . A significant proportion of treated DLBCL patients develop refractory relapsed disease due drug resistance Intravascular large B-cell lymphoma (IVLBCL) uncommon lymphoma aggressive clinical course characterized selective growth tumor cells within vessels . Pathogenesis still uncertain little information underlying genomic alterations . " Diffuse large B cell lymphoma (DLBCL) involve almost organ, prognosis patients DLBCL different primary sites varies greatly . 5-Hydroxymethylcytosine (5hmC) plays vital role tumor" CAR-T cell therapy approved patients with leukemia diffuse large B-cell lymphoma . Its use subsequent toxicities expected rise coming years . Cytokine release syndrome observed 40% patients . " Single-centre study aimed determine clinicopathological characteristics prognosis patients co-existing FL DLBCL components (FL/DLBCL) Among 56 FL/DLBCL cases analysed, 67.9% germinal centre" The subclassification of diffuse large B-cell lymphoma (DLBCL) germinal center B-cell-like (GCB) activated B-cell-like (GCB) activated B-cell-like (ABC " Diffuse large B-cell lymphoma (DLBCL) common type B-cell lymphoma . Multilobated subtype DLBCL observed since 1970s, little known clinical significance unique variant era rituximab" Antiretroviral therapy may alter susceptibility nonkeratinocyte skin cancers (NKSCs) improving immunity people living HIV (PLWH) Using linked data HIV cancer registries 12 US states/regions ART era (1996- circulating tumor DNA (ctDNA) has been developed to detect lymphoma sensitively tumor-derived DNA . This article discusses various methods ctDNA detection clinical context applied variety lymphoma subtypes . Diffuse large B cell lymphoma (DLBCL) common pathological subtype non-Hodgkin lymphoma (NHL) common type adult lymphoma . New drug targets therapeutic methods urgently needed . " 64-year-old man underwent liver transplantation, presented chest pain exertional dyspnea, developed huge cardiac mass within 2 months passed away day 3 hospitalization . Histological examination revealed diffuse large B-cell lymphoma (DL" 19-year-old man diagnosed with large B-cell lymphoma undergoing chemotherapy presented recurrent emesis weight loss . Endoscopic ultrasound-guided gastroenterostomy using lumen-apposing metal stent performed bypass obstruction . Subsequently " Patients cartilage-hair hypoplasia (CHH) increased risk of non-Hodgkin lymphoma basal cell carcinoma . Lymphoma diagnosis remains unexplored, but clinical course, response therapy outcome lymphomas CHH" Primary human herpesvirus 8 (HHV8)-unrelated effusion large B-cell lymphoma (ELBCL) recognized new clinical entity . Pathogenesis therapeutic strategies remain largely unknown . PD-L1 human lymphomas were analyzed using hyperspectral imaging (HSI) and fluorescent multiplex immunohistochemistry (mIHC) We analyzed expression PD-L1 human lymphomas using hyperspectral imaging ( " Patients angioimmunoblastic T-cell lymphoma (AITL) treated cyclophosphamide, doxorubicin, vincristine prednisone without etoposide (CHO(E)" Gene expression involved B lymphocyte differentiation maturation within germinal center (GC) regulated epigenetically lymphomas . Episodes play critical roles pathogenesis of GC-driven lymphomas . " Given mixed evidence carcinogenicity current-use herbicides, studied relationship occupational herbicide use risk non-Hodgkin's lymphoma (NHL) NHL is a large, pooled study of 10 case-control studies ." " Adaptor protein transducin β-like 1 (TBL1X) homolog TBL1XR1 shown upregulated solid tumors hematologic malignancies, overexpression associated poor clinical outcomes . Dysregulation T" " Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma around world . R-CHOP significantly improved patient outcomes, subset patients still poor outcome ." " Splenocolic fistula extremely rare condition described literature . A fistula connects bowel organs, urinary bladder small intestine, small intestine . It occurs cases splenic tumors, including splenic diffuse large B cell lymphoma ." " Despite mounting evidence causal role increasing number lymphoma subtypes, studies systematically tested entire spectrum Hodgkin non-Hodgkin lymphomas presence Epstein-Barr virus (EBV) Here, describe prevalence EBV large, unselected" " Coronavirus disease 2019 (COVID-19) spread worldwide . Vaccination recommended one effective countermeasures control pandemic prevent worsening symptoms . However, adverse effects attracting attention ." This subtype CNS lymphoma diffuse large B-cell Epstein-Barr virus-positive . Its accurate presurgical diagnosis often unfeasible appears ring-enhancing lesions mimicking glioblastoma metastasis . Dogs diffuse large B-cell lymphoma (DLBCL) diagnosed with diffuse large B-cell lymphoma (DLBCL) diagnosed with inferior survival times . Specific biomarkers inflammation identified prognostic indicators dogs DLBCL . Burkitt lymphoma accounts majority pediatric non-Hodgkin lymphomas less common significantly lethal diagnosed adults . We sought to identify somatic changes underlie lymphomagenesis aBL molecular features associate clinical disparities within pBL aBL " POLARIX study shown improvement standard backbone rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone frontline setting . In relapsed refractory setting, two unique" PLD epirubicin (PLD) dose intensity survival outcomes . The study showed PLD epirubicin similar efficacy (overall survival (OS) p = 0.776; progressio . Double-expressor lymphoma (DEL) associated poor prognosis . R-CHOP DA-EPOCH-R first-line therapy patients DEL urgently needed . " Ocular adnexal lymphoma relatively rare disease one common malignancies ocular adnexa, incidence steadily increasing . Ocular adnexal lymphoma consists mainly four histopathological subtypes non-Hodgkin B" We report establishment novel activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell line . TMD12 cells isolated pleural effusion patient relapse passaged continuously vitro >4 years . " Clonality assays antigen receptor rearrangement used adjunct examinations lymphoproliferative diseases . Canine diffuse large B cell lymphomas (DLBCL), cutaneous pla, cutaneous pla, and diffuse large B" Primary adrenal lymphoma (PAL) aggressive form lymphoma associated adrenal insufficiency (AI) cases . It requires histologic confirmation unlike cases primary AI . Primary orbital lymphoma accounts essential part adult orbital malignancies . It accounts for <1% non-Hodgkin's lymphoma cases . Orbital diffuse large B-cell lymphoma (DLBCL) one prevalent subtype Diffuse large B-cell lymphoma (DLBCL) common subtype adult lymphomas . Patients often difficulty tolerating standard chemotherapy regimens due comorbidities . " Chinese patients follicular lymphoma (FL) limited. Here, conducted retrospective study explore initial treatment strategies . Chinese patients newly diagnosed Tianjin Medical University Cancer Institute Hospital March 2002 August 2020. A total 926 FL patients enrolled. The median" Inhibitors targeting Bruton's tyrosine kinase (BTK) revolutionized treatment various B-cell malignancies . PD-1/PD-L1 pathway pathway played role in PD-1/PD-L1 pathway . Thirty-four cases (64.2%) showed high expression PD-L1 . Previous studies shown diffuse large B-cell lymphoma (DLBCL) subtype B-cell antigen receptor complex-associated protein beta chain (CD79B) myeloid differentiation primary response 88 mutations (MYD88) inferior 56-year-old patient underwent tracheal sleeve pneumonectomy . Complex pulmonary aspergilloma invading almost entire right lung carina . " Elderly Prognostic Index (EPI) based integration simplified geriatric assessment, hemoglobin levels and hemoglobin levels . EPI validated predict overall survival of older patients with diffuse large B-cell lymphoma (DLBCL)" " A 57-year-old male came hospital complaining abdominal pain complaining of abdominal pain . He underwent abdominal computed tomography contrast, showed full-thickness wall thickening ileocecal region . He underwent lower gastrointestinal endosc" The role of Helicobater pylori eradication treatment high-grade diffuse large B-cell lymphoma (DLBCL) is unclear . We performed systematic review meta-analysis of currently available data . Cardiac lymphoma (CL) rare life-threatening clinical condition . Most cases diagnosed late period . Most cases diagnosed late period . " Diffuse large B-cell lymphoma (DLBCL) common type lymphoma worldwide, accounting 40% cases . IL-20 expressed frequently follicular lymphoma (94%) Burkitt lymphoma (81%) and mantle c lymph" " Methotrexate-associated lymphoproliferative disorder (MTX-LPD) occur oral cavity, cases palatal involvement reported . Chemotherapy may needed remission withdrawal MTX ." Patients renal impairment (RI) typically excluded trials evaluating chimeric antigen receptor (CAR) T cell therapies . We evaluated outcomes patients receiving standard care (SOC) CAR T cell therapy relapsed/refractory (R/R) " We retrospectively reviewed renal pathology profiles January 2010 December 2021, 28 patients B-cell LPD combined intact renal biopsy data included . There 20 men eight women aging 41 79 years time renal biopsy (median age 62 years)" Core needle biopsies (CNB) may not meet increasing tissue requirements clinical trials . Core needle biopsies may not meet increasing tissue requirements . This potentially lead selective enrollment patients undergo excisional biopsy . Relationship between Epstein-Barr virus-encoded small RNA (EBER) early treatment lymphoma remains unclear . We explored discrepancies PEDL variables associated with PEDL variables associated with PEDL variables . Median PEDL Autologous stem cell transplantation (ASCT) chimeric antigen receptor (CAR) T-cells two therapeutic options relapsed/refractory diffuse large B-cell lymphoma . Both intensive potentially curative therapies differ efficacy toxicity B-cell lymphoma 6 (BCL6) protooncogene adult pediatric cancers . First identified diffuse large B-cell lymphoma (DLBCL) acts repressor tumor suppressor TP53 . BCL6 expression normal Lymphomas affecting sublingual glands extremely rare case reports currently available . Lymphomas affecting sublingual glands extremely rare case reports currently available . Aim current study describe clinicopathological features series lymphomas involving sublingual glands . EFS24 established endpoint diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) role undefined MCL . To evaluate prognostic role EFS24 MCL. " Until recently, molecular bases disease subtypes unclear . Specific genetic characteristics distinguish subtypes respective systemic counterparts ." 107 patients OL treated 14-year period Polish hematological centers . Median patient age 60 years (range 51-71) Median patient age 60 years (range 51-71) Median patient age 60 years (range 51-71) " Long non-coding RNAs (lncRNAs) confirmed connected tumor proliferation, apoptosis, metastasis recurrence . Previous studies indicated lncRNA calcium voltage-gated channel subunit α1 G (CACNA" Duodenal-type follicular lymphoma (D-FL) recognized rare entity accounts approximately 4% primary gastrointestinal lymphomas . D-FL follows indolent clinical course compared common nodal FL generally considered better prognosis . " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease existing prognosis systems based clinical variables difficult stratify patients accurately . Nutritional indices play meaningful role prognosis solid tumors, whereas effect DLBCL still equ" Central nervous system (CNS) lesions peripheral neuropathy rare among patients non-Hodgkin's lymphoma (NHL) Central nervous system (CNS) lesions peripheral neuropathy rare among patients non-Hodgkin " Diffusion large B cell lymphoma (DLBCL) developed range new treatment programs based characteristics disease, bringing us era immune-chemotherapy . However, effectiveness molecular mechanisms of targeted-immunotherapy remain unclear . Targeted-" 59-year-old male enlargement treated with Burkitt-like lymphoma (BLL) Cytogenetics revealed absence of absence MYC rearrangement involving MYC rearrangement involving MYC rearrangement Nail changes well-known phenomenon T-cell lymphoma reported widely B-cell lymphomas Hodgkin lymphomas . Next-generation sequencing (NGS) elucidates diffuse large B-cell lymphoma (DLBCL) genetic characteristics . Study included 20 patients DLBCL. Diffuse large B-cell lymphoma (DLBCL) common aggressive non-Hodgkin's lymphoma (NHL) accounting 30%-40% adult NHL . Primary testicular (PT) lymphoma uncommon extran " Diffuse large B-cell lymphoma (DLBCL) heterogeneous non-Hodgkin's lymphoma great clinical challenge . Machine learning (ML) attracted substantial attention diagnosis, prognosis, treatment diseases ." " Primary pancreatic lymphoma rare; commonly described subtype diffuse large B-cell lymphoma . Although morphologically similar lymphoproliferative lesions found locations, clinically mimic epithelial neoplasm . The differential diagnosis important due due different" " Primary central nervous system lymphoma (PCNSL) rare lymphoma central nervous system, usually diffuse large B cell phenotype . Stereotactic biopsy followed histopathology diagnostic standard . However, limited material available CNS biopsies" " We pooled data eight nested case-control studies investigate subtype-specific relationships analytes . Using polytomous regression, calculated odds ratios (ORs) 95% confidence intervals (CIs) relating study-specific analyte tertiles" " Chimeric antigen receptor (CAR)-T cell therapy T cell malignancies faces major challenges including fratricide CAR-T cells product contamination blasts . Allogeneic CAR-T cells, generated healthy donor T cells, provide" " Lisocabtagene maraleucel (liso-cel) shown promising efficacy clinical trials . We present health-related quality life (HRQOL) results TRANSFORM study, first comparative analysis liso-cel vs standard" " The testis may infiltrated hematological neoplasias, but entities present primary testicular diseases . According data, testis mainly involved diffuse large B‑cell lymphomas (~70% cases)" " Non-Hodgkin's lymphoma (NHL) monoclonal proliferation lymphoid cells B lineage . 29-year-old female patient presented low-grade fever, cough, anemia, weight loss, tender left" Axicabtagene ciloleucel (axi-cel) tisagenleclecleucel (tisa-cel) demonstrated impressive clinical activity relapsed/refractory (R/R) diffuse large Central nervous system (CNS) lymphomas (CNSLs) varied clinical presentations mimic neuroinflammatory disease . This report describes two patients initially received diagnosis neuroinflammatory disorders refractory treatment protracted time course . The Food Drug Administration approved lisocabtagene maraleucel (Breyanzi) Treat large B-cell lymphoma adults relapsed refractory first-line treatment . Cyin-dependent protein kinase 6 (CDK6) expression diffuse large B-cell lymphoma (DLBCL) expression . CDK6 alterations DLBCL related functional networks analyzed c-BioPortal Gene Set En " We aimed compare prognostic predictive ability current clinical scoring indices DLBCL elderly patients treated R-CODP regimen (rituximab, cyclophosphamide, pegylated liposomal doxorubicin," " Six cases lineage switch lymphoma myeloid neoplasms . Lymphoma relapse common clinical work, lineage switch relapse rare ." " In treatment primary central nervous system lymphoma (PCNSL) intraoperative rapid pathological diagnosis dramatically change surgical strategy, accurate diagnostic methods required . In April 2020, adopted intraoperative rapid immunohistochemistry (IHC) addition conventional rapid" " We performed epidemiological survival analysis of 9,143 PI-NHL cases age 18 years identified SEER 18 database period 2000 - 2015 . Totally, 8,568 patients included survival analysis . Cause-specific survival (CSS) overall survival" " Secondary CNS lymphoma (SCNSL) lacks clear standard care historically carries poor prognosis . Aggressive histologies predominate, notably diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma lower absolute incidence" Conditioning chemotherapy (CCT) shown essential optimal efficacy chimeric antigen receptor (CAR) T-cell therapy . 86 (50%) received bridging therapy post-leukapheresis . Median DLIx 0.5 × Cytomegalovirus (CMV) among common viral infections solid organ transplantation (SOT) Authors used linked data US SOT registry 32 cancer registries . Poisson regression used compare cancer incidence across CMV risk groups Treatment relapsed/refractory diffuse large B-cell lymphoma remains challenge . Treatment relapsed/refractory diffuse large B-cell lymphoma remains challenge . " Bruton tyrosine kinase inhibitors (BTKis) interrupt B-cell receptor signaling thereby could potentially reactivate hepatitis B virus (HBV) However, data risk HBV reactivation (HBVr) was sparse" " Secondary haemophagocytic lymphohistiocytosis (sHLH) life-threatening disorder described setting infections, neoplastic immune dysregulations ." " Study looked at specific β-glucan, exopolysaccharide (EPS-1) derived Aureobasidium pullulans (CGMCC 20363) The study compared rituximab alone, EPS" Anthracycline-induced cardiotoxicity irreversible cardiac cell injury . This study designed analyze influencing factors AISC patients diffuse large B-cell lymphoma (DLBCL) treated (R)-CHOP chemotherapy regimen . " The combination rituximab, lenalidomide, Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib, followed chemotherapy, shown high efficacy patients newly diagnosed diffuse large B-cell" Axicabtagene ciloleucel treatment. Rapid immune context changes occur tumor microenvironment axicabtagene ciloleucel treatment. Rapid immune context changes occur tumor microenvironment axicabtagene cil The objective retrospective study evaluate CD25 expression prognostic indicator dogs B-cell lymphoma (BCL) diagnosed commonly used noninvasive diagnostics (cytology flow cytometry [FC] treated CHOP chemotherapy) Lymph node " Diffuse large B-cell lymphoma (DLBCL) rare disease crude annual incidence rate 3.8 cases per 100,000 people . Primary cervical lymphoma rare, accounting 0.008% cervical malignancies ." " Data Surveillance, Epidemiology, End Results (SEER) 2000-2018 utilized develop epidemiological model . Model . Estimates DLBCL prevalence gauge impact rapidly emerging treatment landscape ." " The frequency aggressive subtypes B-cell non-Hodgkin lymphoma (B-NHL) are B-NHL, high-grade B-cell lymphomas (HGBL) MYC BCL2 and" " Diffuse large B cell lymphoma (DLBCL) common type NHL, accounting 40% NHL cases, one aggressive lymphomas . DLBCL widespread individuals aged 50 years old, maximum incidence seventh decade, may also occur younger patients" 40% patients with diffuse large B cell lymphoma (DLBCL) experienced relapse refractory (R/R) lymphoma standard first R-CHOP therapy . IL-6 reportedly associated chemotherapy resistance rituximab Foreign body-type giant cell reaction typically biological immunological reaction typically biological immunological reaction . The effectiveness of comprehensive geriatric assessment (CGA) improving health outcomes cancer settings is unclear . We evaluated whether CGA improve health-related quality life (HRQOL) older people cancer starting anticancer treatment . " The optimal treatment older adults diffuse large B-cell lymphoma (DLBCL) needs explored due patient comorbidities, standard immunochemotherapy intolerance, unfavourable genetic features . We phase 2 trial ibrutinib" Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment hematologic malignancies . Half patients refractory large B cell lymphomas achieve durable responses CD19-targeting CAR-T treatment . Failure mechanisms identified " Primary central nervous system lymphoma (PCNSL) rare aggressive extranodal diffuse large B cell lymphoma . Despite apparent immunopathological homogeneity, PCNSL displays wide variability outcome ." This study aimed analyze clinical features survival primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL) It established independently validate prognostic nomogram individual risk prediction . Data 24 patients Renmin Hospital Wuhan University " 500 patients simulated using distributions metabolic tumor volume, standardized uptake value, maximal distance largest lesion another lesion another lesion, WHO performance status age age . These data used predict progression 2 years based existing logistic regression model . Using simulated" Diffuse large B-cell lymphoma (DLBCL) common adults' non-Hodgkin's lymphoma . Relapse mainly occurs within two years diagnosis poor prognosis . Relapse two years less frequent better prognosis " We aimed detect clinicopathological features immune microenvironment double-hit/triple-hit lymphoma gastrointestinal tract (GI-DHL/THL) identify best diagnostic strategies . A total 114 cases, including 15 GI-DHL" " Primary diffuse large B-cell lymphoma (DLBCL) central nervous system (PCNSL) rare disorder increasing incidence past decades . MATRix regimen (high-dose methotrexate (HD-MTX), high" A large amount of evidence accumulated suggesting Toll-like receptor (TLR) signals involved driving chronic lymphocytic leukemia (CLL) cell proliferation . Direct vivo evidence still lacking . We addressed possibility pharmacologically inhibiting genetically inactivating " CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) showed poor prognosis rituximab era, limited research genetic characteristics cell origin (COO) We aimed demonstrate molecular characteristics CD5" " Plasmablastic lymphoma (PBL) is highly aggressive B cell non-Hodgkin lymphoma . PBL is associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection ." Patients lymphoma also infected Hepatitis B virus (HBV) poor prognosis . This could partly explained delay premature termination anti-tumor treatment HBV reactivation . Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tumor Tum " The cardiac localization metastases rare condition, often found autopsy . Lymphoma among primary cancers often involved, case patient cardiac involvements discovered extension assessment imaging ." Diffuse large B-cell lymphoma originates B lymphocytes fatal hematological malignancy . Circular RNAs increasingly reported promising biological target cancer therapy . Role DLBCL remains poorly studied . Aryl hydrocarbon receptor-interacting protein (AIP) co-chaperone heat shock proteins nuclear receptors . Loss-of-function heterozygote germline mutations lead predisposition growth hormone- prolactin-secre Methotrexate-associated lymphoproliferative disorder (MTX-LPD) occurs patients rheumatoid arthritis (RA) treated methotrexate (MTX) MTX-LPD typically associated Epstein- " Red blood cell distribution width (RDW) reported associated clinical outcomes multiple cancer . However, prognostic role PCNS-DLBCL yet evaluated ." " Syncope may many different causes, requiring careful identification . Syncope may many different causes, requiring careful identification . Head neck tumors involving carotid artery cause syncope associate carotid sinus syndrome . Syncope may early sole sign" Pulmonary infections account large proportion of life-threatening adverse events occur chemotherapy patients diffuse large B-cell lymphoma (DLBCL) Chimeric antigen receptor T cell (CAR-T) therapy emerged highly effective relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) 40% patients achieved sustained responses . Diffuse large B-cell lymphoma (DLBCL) highly aggressive form non-Hodgkin lymphoma . Long noncoding RNA (lncRNA) evaluated prognostic markers various carcinomas . " Eukaryotic translation initiation factor (eIF) 4A plays essential role unwinding secondary structure messenger RNA (mRNA) upstream start codon . It actively pursued viable target circumvents dependency oncogenic signaling, significant factor" " Double-hit lymphoma (DHL) aggressive large B cell lymphoma associated poor prognosis R-CHOP chemotherapy . The optimal treatment unknown, outcomes might improved intensive induction regimens consolidative high-dose chemotherapy autologous stem" Burkitt lymphoma (BL) concept high-grade B-cell lymphomas (HGBCL) allows degree refinement . BL remains prototypic HGBCL diagnostic criteria largely unchanged . HGBCL MYC BCL2 HG SET MYND domain containing 3 (SMYD3) HMT upregulated various tumors promotes malignancy . High SMYD3 expression significantly associated poor progression-free survival patients DLBCL . " Diffuse large B-cell lymphoma (DLBCL) common type non- Hodgkin’s lymphoma (NHL) However, primary skeletal muscle involvement DLBCL extremely rare, comprising less 1% extranod" " Epigenetic modifications contribute lymphomagenesis . EC1 presented abundant TP53, MYD88, HIST1H1D, HIST1H1C, KMT2D EZH2 mutations inferior prognosis" " CNS relapse brain parenchyma, eyes, leptomeninges uncommon complication diffuse large B-cell lymphoma . CNS relapse brain parenchyma, eyes, leptomeninges uncommon devastating complication diffuse large B-" " Non-Hodgkin lymphoma (NHL) composed heterogeneous collection subtypes considerable differences genetics, biology aetiology . We pooled data nine case-control studies examine association moderate-to-vigorous intensity physical activity" Apatinib (an inhibitor targeting VEGFR-2) enhances chemosensitivity ABT-199 diffuse large B-cell lymphoma (DLBCL) Apatinib (an inhibitor targeting VEGFR-2) enhances Hypeptics imaging-based approach may help diagnosis diffuse large B-cell lymphoma (DLBCL) Study looked at 22 pathological DLBCL specimens . " MYD88 oncogene activates nuclear factor κB pathway in DLBCL . Ten MYD88 mutated variants detected 32% of cases . MYD88 L265P mutation frequently occurs DLBCL poor prognosis, clinical" " MALT lymphoma extremely rarely arise extrahepatic biliary tract . Here, report case bile duct MALT lymphoma diagnosed direct cholangioscopy ." Contrast-enhanced ultrasonography (CEUS) plus D-dimer levels prognosis patients diffuse large B-cell lymphoma (DLBCL) was studied . 186 patients confirmed DLBCL . " Bromo- Extra-Terminal domain (BET) family proteins strong preclinical antitumor activity multiple tumor models, including lymphomas . Limited single-agent activity reported clinical setting." " We investigated prevalence prognostic value surface expression PD-L1, PD1, CD30, copy number 9p24.1 (PD-L1 region) mutations . We investigated prevalence prognostic value surface expression PD-L1" " Diffuse large B-cell lymphoma (DLBCL) characterized strong biological, morphological, clinical . heterogeneity, patients treated immunochemotherapy relatively homogeneous way . NanoString platform analyzed series 197 homogeneously treated DLBCL" " Low lymphocyte-to-monocyte-ratio (LMR) associated unfavorable survival patients diffuse large B-cell lymphoma (DLBCL) To date, however, impact LMR survival has not been seen ." Diffuse large B-cell lymphoma (DLBCL) is common type non-Hodgkin lymphoma . DLBCL is a common type non-Hodgkin lymphoma . " Pola-R-CHOP trial showed improved progression-free survival (PFS) compared R-CHOP untreated intermediate- high-risk DLBCL . Of 174 respondents, academic centers (82%) United States (57%)" NK cells could potentially promote tumour immune evasion disease propagation . NK cells isolated peripheral blood (PB) 26 DLBCL patients 13 age-ma . " Tisagenlecleucel demonstrated high response rates . Adults relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) was studied in JULIET trial . However, lack response CAR" Aggressive large B-cell lymphoma (LBCL) variable outcomes . Current prognostic tools use factors risk stratification inadequately identify patients high risk refractory disease relapse initial treatment . Diffuse large B-cell lymphoma (DLBCL) common invasive type non-Hodgkin lymphoma . Primary drug resistance treatment DLBCL observed. Primary drug resistance treatment DLBCL observed. Axicabtagene ciloleucel (axi-cel) anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved relapsed/refractory large B cell lymphoma (LBCL) Several single nucleotide polymorphisms (SNPs) associated susceptibility Hodgkin lymphoma (HL) diffuse large B-cell lymphoma (DLBCL) identified . Aim study identify susceptibility loci HL DLBCL Polish patients . The study was published in the journal Human Evolution . Despite favorable results CAR T-cell therapy relapsed/refractory large B-cell lymphoma (R/R LBCL) challenges remain . We delineated relative clinical benefit novel approaches compared currently approved CAR T-cell therapies " HLH 242 patients malignancies-related lymphoid malignancies (42.0%, 233/555) common causes . Epstein-Barr virus (69.0%, 100/145) common pathogen among cases infections-" " CAR-T cell therapy promising effects, patients resistant treatment, leaving limited options . We retrospectively studied three R/R diffuse large B-cell lymphoma patients resistant CAR-T cell therapy ." There limited published data clinical characteristics outcomes patient population . The outcomes patients i were diagnosed lymphoma following immunosuppressive therapy autoimmune conditions . " Hepatitis E virus (HEV) infection immunocompetent patients lead chronic hepatitis liver failure . However, burden HEV infection cancer patients largely unknown . We studied characteristics HEV infection patients tertiary care cancer center United States" Diffuse large B-cell lymphoma (DLBCL) patients reported cardiac manifestations . 11% of DLBCL patients diagnosis arrhythmias . 11% DLBCL patients diagnosis arrhythmias . 32 immunocompetent patients biopsy-proven diffuse large B-cell type lymphoma brain evaluated pre-treatment MRI examinations August 2014 April 2020 . " The prediction primary treatment failure (PTF) necessary patients diffuse large B-cell lymphoma (DLBCL) since serves prominent means improving front-line outcomes . The final model contrastive objective optimization, named contrastive hybrid learning model" Bruton tyrosine kinase inhibitors (BTKi) transformed therapeutic landscape chronic lymphocytic leukaemia (CLL) non-Hodgkin lymphoma . Primary acquired resistance BTKi seen due variety mechanisms including " The management large malignant tracheo-esophageal fistulas (TEF) standardized. Herein, report case malignant TEF associated esophageal post-transplant lymphoproliferative disorder (PT" Rituximab become standard treatment non-Hodgkin lymphoma . Clinical studies demonstrated efficacy rituximab combination standard chemotherapies treatment follicular lymphoma (FL) diffuse large B cell lymphoma ( " Intussusception adults rare occurrence approximately 5% malignancy cause comprises half number . The management adult intussusception generally surgical, due higher likelihood malignancy underlying cause ." De novo CD5 + diffuse large B-cell lymphoma (DLBCL) poor survival era immunochemotherapy . De novo CD5 + diffuse large B-cell lymphoma (DLBCL) poor survival era immun Classic Hodgkin lymphoma (CHL) patients may infrequently present prior recurrent disease discordant histology resembling non-Hodgkin lymphomas . These include primary mediastinal large B-cell lymphoma (PMBL) Swedish Lymphoma register 2007-2014 followed relapse death using multistate models study patient trajectories . Achieving lasting remission at 2 years good indicator favourable prognosis long term Diffuse large B-cell lymphoma (DLBC Epcoritamab CD3xCD20 bispecific antibody (bsAb) induces T-cell-mediated cytotoxicity CD20-positive B cells . Target engagement crosslinking CD3 CD20 (trimer formation " Human epidermal growth factor receptor 2 (HER2)-targeted treatment options, including dual HER2 blockade, improved prognosis patients HER2-positive breast cancer (BC) Patients HER2-positive breast cancer (BC) present" Transesophageal ultrasound-guided bronchoscopic aspiration (EUS-B-FNA) allowed minimally invasive simultaneous diagnosis evaluation degree invasion echocardiography . EUS-B-FNA may useful evaluation diagnosis " Jaundice caused wide variety disorders adults including pancreatic malignancy . Most pancreatic malignancies primary origin . However, malignancies, including lymphomas, may present secondary pancreatic masses ." " Diffuse large B-cell lymphoma (DLBCL) prevalent subtype non-Hodgkin's lymphoma (NHL) This subtype present various extranodal sites, including brain, bones, intestines" Previous studies evaluating influence statins survival patients diffuse large B cell lymphoma (DLBCL) showed inconsistent results . This systematic review meta-analysis conducted investigate whether statin use correlated survival . " CD19-directed CAR T cells greatly improved outcomes B-cell malignancies, significant limitations therapy . CD19-directed CAR T cells greatly improved outcomes B-cell malignancies, significant limitations therapy ." Regulatory T cells (Tregs) induce immune responses may contribute immune escape tumors . Accumulation Tregs tumors represents critical barrier anti-tumor immunity immunotherapy . Germinal center B (GCB) cells provide niche support development angioimmunoblastic T-cell lymphoma . Subclones drive Richter transformation (RT) chronic lymphocytic leukemia seeded early . Subclones drive Richter transformation (RT) chronic lymphocytic leukemia seeded early . " Diffuse large B cell lymphoma (DLBCL) one usual types adult lymphoma heterogeneousness . We systematically explored DLBCL gene expression dataset provided publicly available clinical information patients GEO . In research, 928 DLBC" " Recent evidence shown exosomes deliver siRNA tumor tissues mice . Here, reduce immunogenicity, selected immature dendritic cells (DCs) produce exosomes ." Diffuse large B-cell lymphoma (DLBCL) curable first-line chemoimmunotherapy patients relapsed/refractory (R/R) DLBCL still face poor prognosis . CD19- " B-cell lymphoma, unclassifiable, features intermediate diffuse large B-cell lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma (BCLu-DLBCL/cHL) Also referred" " We used hospital-based cancer registry data in Japan to extract cases adrenal malignancies histologically confirmed, diagnosed, initially treated 2012-2015 . For survival analysis, used data 2008-2009 cohort estimate 5-year overall survival (" CAR-T cell therapy emerged effective treatment refractory hematological malignancies . Hospital-wide retrospective study included 71 patients requiring ICU admission July 2017 December 2020 included 71 patients (median age 60 years [37-68 Primary breast lymphoma (PBL) rare malignant breast tumor . Study aimed elucidate sonographic characteristics PBL explore value ultrasonography preoperative diagnosis PBL using Breast Imaging Reporting Data System (BI-RADS) This study assessed impact adherence guidelines-recommended diagnostic testing treatment selection overall survival (OS) patients diffuse large B-cell lymphoma (DLBCL) initiated rituximab-based first line treatment (1-LOT Axicabtagene ciloleucel (axi-cel) found superior clinical outcomes compared standard care (SOC) second-line large B-cell lymphoma (2L LBCL) second-line large " Diffuse large B cell lymphoma, otherwise specified (DLBCL, NOS) common type non-Hodgkin lymphoma (NHL) Diffuse large B cell lymphoma, otherwise specified (DLBCL," " Non-Hodgkin lymphoma (NHLHL) haematolymphoid neoplasm affect nodal extra-nodal sites . It rare disease oral cavity, accounting 2% extra-nodal lymph" Renal manifestations associated associated hematolymphoid malignancies known . Renal manifestations associated hematolymphoid malignancies known . " Marginal zone lymphoma (MZL) rare, slow-growing/indolent B cell lymphoid neoplasm accounting 10.5% 11.8% B cell lymphomas . MZL originates mature B" Diffuse large B-cell lymphoma (DLBCL) frequently occurring subtype lymphoma . Fundamental processes underlying pathogenesis of DLBCL remain little understood . " AI-based tool rapidly extracts FDG-PET imaging metrics DLBCL . On availability scan, combination clinical data, approach generates clinically informative risk scores . Overall, 1268 patients previously untreated DLBCL phase III GOYA trial (" N-methyl-D-aspartate receptor (NMDAR) ionotropic glutamate (Glu) receptor widely expressed central nervous system (CNS) We present case patient atypical clinical manifestations positive anti-NMDAR Plasmablastic lymphoma (PBL) aggressive rare subtype non-Hodgkin lymphoma standard-of-care therapy . Germinal center-derived lymphomas follicular lymphoma (FL) diffuse large B cell lymphoma (DLBCL) characterized frequent mutations histone-modifying genes . Epigenetic mechanisms DNA hypermethylation and histone " Zanubrutinib, next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor, shows great efficacy treatment B cell malignancies . Some patients may experience series side effects treatment" Richter transformation (RT) paradigmatic evolution of chronic lymphocytic leukemia (CLL) aggressive large B cell lymphoma conferring dismal prognosis . The mechanisms driving RT remain largely unknown . An estimated 30-40% patients diffuse large B cell lymphoma (DLBCL) either relapse refractory disease first-line chemoimmunotherapy . CD19-targeted chimeric antigen receptor (CAR) T- " Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) total knee arthroplasty (TKA) rare . We described case PCDLBCL TKA, whose cutaneous mass develops around surgical sites," Little known presence existence existence existence of diffuse large B-cell lymphoma (DLBCL) Little known presence existence of little known presence existence of diffuse large B-cell lymphoma (DLBCL) A 53-year-old male presented 1-month history hyperpyrexia . The clinical manifestations revealed hemophagocytic lymphohistiocytosis (HLH) After treated HLH-1994 (dexam " 40% of patients with diffuse large B-cell lymphoma experience relapse refractory disease . Despite effectiveness immuno-chemotherapy, 40% patients experience relapse refractory disease ." Vitamin D insufficiency potentially modifiable risk factor poor outcomes newly diagnosed large B-cell lymphoma (LBCL) Role circulating vitamin D concentrations relapsed/refractory LBCL treated CD19-directed chimeric antigen Extranodal diffuse B cell lymphoma (DBCL) represents 30 58% non-Hodgkin's lymphoma . One major problems DBCL high likelihood disease relapse following treatment . Diffuse large B-cell lymphoma (DLBCL) aggressive type non-Hodgkin lymphoma . Many DLBCL patients poor prognosis . This study investigated key metabolism-related genes potential mechanisms . Protein phosphatase SHP-1 negatively regulates several oncogenic tyrosine kinases plays tumor suppressive role . Direct SHP-1 agonists used evaluate potential therapeutic implication SHP-1 DLBCL . " Richter's Syndrome (RS) aggressive transformation CLL, usually clonally-related diffuse large B-cell lymphoma (DLBCL) characterized frequent TP53 mutations, intrinsic chemoresistance poor survival . TP53-independent" HIV-1 matrix protein p17 found associated lymphoma development vitro . HIV-1 matrix protein p17 found associated lymphoma development vitro . HIV-1 p17 AIDS-related lymphoma. " Neutrophil-to-lymphocyte ratio (NLR), biomarker systematic inflammation, confirmed prognostic factor many malignant diseases . Neutrophils lymphocyte subsets DLBCL patients dynamics along chemoimmun" " On rare occasions, secondary Epstein-Barr virus (EBV)-associated B-cell lymphoma develop patients angioimmunoblastic T-cell lymphoma (AITL) Here, describe tumor microenvironment mutation features patient" Primary breast lymphoma (PBL) rare subtype non-Hodgkin's lymphoma (NHL) rapid progression high risk central nervous system metastasis . 16 sequenced target panel 112 genes related lymphoma . " Type B lactic acidosis commonly seen hematological malignancies, especially lymphomas . It considered oncological emergency associated high mortality poor outcomes treated promptly ." " Diffuse large B-cell lymphoma (DLBCL) nowadays curable disease frontline treatment R-CHOP, 30-40% patients still unresponsive relapse thereafter . 30-40% patients still unresponsive relapse thereafter . New" " CD5-positive diffuse large B-cell lymphoma (DLBCL) clinically rare subtype DLBCL aggressive clinical manifestations poor prognosis . It demonstrated prognostic nutritional index (PNI), indicator nutritional status systemic inflammation, significant" " BCL10, key activator NF-κB downstream oncogenic B-cell receptor signaling, mutated nearly 40% BN2/C1 genetic subtype diffuse large B-cell lymphoma ." R-CHOP standard first line therapy cures 60% patients . Salvage high-dose chemotherapy autologous stem cell transplant remains standard second-line treatment . " In recent years, efficacy 5-aminolevulinic acid photodynamic diagnosis (5-ALA PDD) reported various types brain tumors, including malignant glioma . We report 17 consecutive patients intraventricular tumors ." The case 53-year-old man diagnosed PCNSL tectal plate reported . The patient referred hospital 1-month history disorientation magnetic resonance imaging showed hydrocephalus enhancing lesion tectum . " Amyloidoma, otherwise known tumoral amyloidosis, is localized deposition amyloid (AL-type AA type) without systemic amyloidosis . It rarest form tissue amyloid deposition, 7% am" Biomarkers accurately predict outcome DLBCL patients urgently needed . Biomarkers accurately predict outcome DLBCL patients urgently needed . Primary immunodeficiencies (PIDs) acquired declines immune cell counts or/function . Secondary immunodeficiencies (SIDs) acquired declines immune cell counts or/function . The common type SID decreased antibody level occurring " 49-year-old man presented several-month history melena, unintentional weight loss . Further evaluation capsule endoscopy showed patchy erythematous mucosa jejunum creating suspicion Crohn's Disease ." Kawasaki et al. provide hints that lymphoma cells exposed polatuzumab vedotin rituximab potential mechanism resistance . Diffuse large B-cell lymphoma (DLBCL) high-grade non-Hodgkin lymphoma increased incidence among people living HIV-infection (PLWH) Although frequency reportedly attenuated antiretroviral " Dasatinib, second-generation tyrosine kinase inhibitor (TKI), used treatment chronic myeloid leukemia, BCR::ABL1-positive (CML) Complicated pleural pericardial effusions" Mice overexpressing BCL6 B cell-specific immunoglobulin heavy chain . chain μ intron promoter (Iμ-Bcl6Tg/+ mice develop B cell lymphomas " Gemcitabine-based regimens effective salvage therapy RR lymphoma patients eligible ASCT, limited data transplant-ineligible (TIE) patients . We identified 33 patients: 54.5% diffuse large Bcell lymphoma (" Axicabtagene ciloleucel (axi-cel) improved event-free survival (EFS) compared standard care (SOC) salvage chemoimmunotherapy followed autologous stem cell transplant . Study Real-world evidence comparing efficacy chimeric antigen receptor (CAR) T-cell therapy previous standard care (SOC) refractory large B-cell lymphoma (LBCL) scarce . We observed superior effi. We CAR T cell therapy transformed salvage approach relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) Maintaining disease control CAR T cell infusion product manufacturing (so-called bridging therapy) Richter transformation (RT) development high-grade lymphoma patients B-cell chronic lymphocytic leukemia (CLL) small lymphocytic lymphoma (SLL) A small percentage CLL patients develop aggressive histologic transformation diffuse " HIV-associated lymphoma (HAL) common malignancy South Africa . Due high prevalence HIV, HIV, HIV-associated lymphoma (HAL) common malignancy . However, paucity literature literature has been lacking" " Adult kidney transplant recipient developed diffuse large B cell lymphoma distal ureter setting new allograft nephropathy . Early intervention, reduction immunosuppression, surgical reconstruction chemotherapy salvaged allograft kidney averted fatal" Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin's lymphoma (NHL) accounts approximately 25% NHLs developed countries . Most patients present advanced disease 60% presenting stage 3 4 Primary central nervous system lymphoma (PCNSL) rare cranial malignant haematological tumour . We report 3 cases cerebellar PCNSL underwent neuronavigation microsurgery . The operation performed author 3 author " Data describing progression events incomplete long-term survival outcomes yet established . In patients with B-cell cancer, diffuse large B-cell lymphoma (DLBCL), heterogeneous clinical efficacy outcomes observed presence 'cured' (long-" " 55-year-old female referred recurrent unilateral anterior hypopyon anterior uveitis . All laboratory tests, review systems ocular sampling results unremarkable ." " B-cell non-Hodgkin's lymphoma includes several subtypes, notably Diffuse Large B-Cell Lymphoma (DLBCL) Each presentation defining characteristic, CD5 positivity notoriously known poor prognostic factor" " High-dose methotrexate administered concurrently R-CHOP (RM-CHOP) commonly used regimen, data outcomes achieved regimen limited ." " Chimeric antigen receptor (CAR) T-cell therapy revolutionized treatment various B-cell malignancies . However, cause serious adverse effects like immune effector cell-associated neurotoxicity syndrome (ICANS) ICANS attributed disruption" Post-transplant lymphoproliferative disorder (PTLD) heterogeneous lymphoid cell disorder occurs solid organ hematopoietic stem cell transplantation . We present rare case PCNS-PTLD misdiagnosed gl Clonal hematopoiesis indeterminate potential (CHIP) common patients hematologic malignancies . Recent publications provide evidence CHIP may affect chimeric antigen receptor T-cell therapy efficacy . " Primary cutaneous peripheral T-cell lymphomas T-follicular helper phenotype (pcTFH-PTCL) poorly characterized . Often compared to, corresponding with, mycosis fungoides (MF), Séz" Odronextamab CD20 × CD3 bispecific antibody demonstrated durable responses manageable safety profile patients R/R B-NHL first-in-human trial . " Disulfide (DSF) shown anticancer effects, effect DLBCL remains unclear . B-cell lymphoma 6 (BCL6) oncogene required survival required survival ." Lymphoma conjunctiva ocular malignancy derived clonal proliferation lymphocytes . Majority conjunctival lymphoma extranodal marginal zone B-Cell lymphoma (EMZL) Majority conjunctival lymphoma ext APRIL BAFF receptor activity was neutralizing TNF receptor ligands APRIL BAFF receptor activity . It impacted protein translation production of MM cells . It modulates translation efficiency ATM interactor (ATMIN/ACSIZ) " Review highlights recent studies furthering clinical development of selinexor . Selinexor, novel exportin-1 inhibitor, treatment multiple myeloma non-Hodgkin lymphomas ." Diffuse large B-cell lymphoma (DLBCL) aggressive lymphoma variable clinical outcomes prediction prognosis remains important long-term remission . We performed serial serum soluble interleukin-2 receptor (sIL-2R " The endothelial activation stress index (EASIX) score reported predict overall survival (OS) hematological cancers . However, validated prognostic marker diffuse large B-cell lymphoma (DLBCL) date was reviewed ." We retrospectively analyzed SARS-CoV-2 vaccination antibody responses cohort 273 patients lymphoproliferative disorders plasma cell dyscrasias seen single tertiary cancer center . We found antibody response rate SARS-CoV- " Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) uncommon non-Hodgkin lymphoma subtype, clinical pathological characteristics remain unclear . PCNS-DLBCL patient data retrospectively" Diffuse large B-cell lymphoma (DLBCL) biologically clinically clinically heterogeneous disease requires personalized clinical treatment . Cyogenetic abnormalities genetic mutations widely applied prognostic stratification DLBCL . Increasing evidence demonstrated deregulated epigenetic Immunotherapy T cells genetically modified chimeric antigen receptors (CARs) shown significant clinical efficacy patients relapsed/refractory B-cell lymphoma . 50% treated patients benefit therapy due either absence response relapse or relapse . Eluc " Primary brainstem lymphoma (PBSL) rare malignant. An understanding disease lacking. We aimed characterize clinical features, estimate survival, explore survival-related factors PBSL." Adriamycin (doxorubicin) important traditional drug exhibits cytotoxicity Diffuse Large B-cell Lymphoma (DLBCL) Doxorubicin affects DLBCL cells stages cell cycle Diffuse large B-cell lymphoma (DLBCL) represents frequent lymphoma adults . Prognosis DLBCL patients may evaluated prominent clinical/laboratory parameters pattern gene expression . " Diffuse Large Bcell Lymphoma (DLBCL) is a relapsed/refractory setting . Of 7,877 patients DLBCL, 367 patients DHL 61 were treated with CAR Tcell therapy ." " Diffuse large B cell lymphoma comprises heterogeneous group B cell-derived tumors, different degrees aggressiveness, defined cellular origin tissue microenvironment . Study demonstrate lymphoma cells display surface phenotype, IgH V-region somatic mutations," Primary vitreoretinal lymphoma great masquerader provides diagnostic challenge . Steroid treatment presumed uveitis interfere correct diagnosis vitreoretinal lymphoma . The larynx rare site extranodal non-Hodgkin lymphoma (NHL) accounting less 1% primary laryngeal neoplasms . The larynx rare site extranodal non- " Axicabtagene ciloleucel (Yescarta) approved use of second-line drug for large B-cell lymphoma resistant to, relapse within 12 months of, first-line chemoimmunotherapy ." Tafasitamab lenalidomide approved second-line treatment diffuse large B-cell lymphoma (DLBCL) based single-arm phase II study . This combination superior routine immunochemotherapy regimens comparing matched observational We performed retrospective analysis 1767 DLBCL patients . We found patients hyperglycemia tend higher age (age>60 years) and hyperglycemia tend higher age (age>60 years) Lung collision tumor consisting squamous cell carcinoma lung diffuse large B-cell lymphoma extremely rare . Collision tumors consisting lung cancer malignant lymphoma extremely rare . Managing double-expressor lymphomas (DEL) controversial given dearth data lack standardized guidelines high-risk subset lymphomas . We performed largest analysis date exploring R-CHOP vs DA-EPOCH-R DEL . Adults " This study compared efficacy, safety immunogenicity of ripertamab (SCT400) rituximab (Mabthera) and ripertamab (SCT400) rituximab" " Refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) patients' failure salvage chemotherapy extremely worse prognoses . Herein, 14 R/R DLBCL patients failed salvage" " Primary cutaneous lymphomas rare group diseases, estimated incidence 0.5-1 case per 100,000 people per year . Cutaneous B-cell lymphomas are rare group diseases, estimated incidence 0.5-1 case per 100" Immune checkpoint inhibitors may represent promising strategy boosting immune responses boosting immune responses . Studies suggest immune checkpoint inhibitors may represent promising strategy boosting immune responses . " CC chemokine receptor 2 (CCR2) found involved tumor growth, angiogenesis, epithelial mesenchymal transition, metastasis, immune escape . CCR2 overexpression first identified poor prognostic predictor diffuse" " Wrist drop common presentation neurology. Wrist drop common presentation neurology. To localize lesion, clinicians focus testing finger extension, elbow flexion semipronated forearm, elbow extension among muscle groups identifying dermatomes numbness" " CD19-directed chimeric antigen receptor (CAR) T cell therapies approved treatment relapsed/refractory aggressive B cell lymphomas . We present multicenter retrospective study among centers prescribe either commercial product or commercial product evaluate usage patterns," " Liver-X-Receptors control Mo polarization/inflammatory response, pharmacological modulation clinical investigation treat human cancers, including lymphomas . Comparing bulk tumors purified malignant normal B-cells, found intriguing association NR1H3," " Gboxin promising inhibitor OXPHOS, specifically inhibits growth many kinds cancer cell lines . Diffuse large B-cell lymphoma (DLBCL) aggressive B-cell non-Hodgkin's lymphoma ." " Lymphoma gastrointestinal tract commonly occurs stomach, small intestine around ileocecal region . Usually gastrointestinal lymphoma occurs secondary widespread nodal disease rarely found primary site ." Patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) benefit available therapies . We examined combinations cereblon E3 ligase modulator (CELMoD) agent avadomide (CC Patient initially diagnosed triple hit high-grade B cell lymphoma (HGBL-TH) Diagnosed with high-grade B cell lymphoma (HGBL-TH) Diagnosed with germinal center diffuse large B cell " Chimeric antigen receptor (CAR) T-cell therapy represents new strategy treating lymphoid malignancies . Mechanic mechanism remains poorly understood . Several toxicities including cytokine release syndrome (CRS), neurotoxicity, neurotoxicity linked" Genomic profiling of tumor cells samples revealed tumor cells samples shared common mutations . Genomic profiling of tumor cells revealed tumor cells samples shared common mutations . Image texture analysis (radiomics) uses radiographic images quantify characteristics may identify tumour heterogeneity associated patient outcomes . Using fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG- " The multicenter, phase Ib CC-122-DLBCL-001 dose-expansion study (NCT02031419) explored cereblon E3 ligase modulator (CELMoD) agent avad" There remains unmet clinical need identify patients with diffuse large B-cell lymphoma (DLBCL) would benefit central nervous system (CNS) prophylaxis . " A 58-year-old male diagnosed splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U) diagnosed splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-" " CAR-T therapy profoundly altered treatment landscape non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, multiple myeloma . CAR-T therapies have shown high overall response rate durable remissions patients failed standard" " Axicabtagene ciloleucel (axi-cel) received marketing authorisation Canada treatment relapsed refractory large B-cell lymphoma two lines systemic therapy . The objective analysis determine, societal public healthcare pay" Pediatric-type follicular lymphoma (PTFL) rare recently recognized subtype nodal follicular B-cell lymphoma . Four cases PTFL initially evaluated fine needle aspiration (FNA) biopsy retrieved institutions' databases . " PILOT, open-label, phase 2 trial done 18 clinical sites USA, included adults aged 18 years older . PILOT, open-label, phase 2 trial done 18 clinical sites USA, included adults aged 18 years older" First comparative analysis of patient-reported outcomes (PROs) chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy . Second-line relapsed/refractory large B-cell lymphoma " A systematic search of the literature databases was performed . Three reviewers independently screened literature, extracted data, assessed quality included studies ." Kaposi sarcoma herpesvirus (KSHV) / human herpesvirus 8 (HHV-8) led recognition primary effusion lymphoma (PEL) distinct lymphoproliferative disorder . " CAR T-cell therapy emerged potentially transformative immunotherapy certain B-cell malignancies including relapsed/refractory diffuse large B-cell lymphoma (DLBCL) In Italy, CAR T-cell therapies awarded innovation status" " Primary central nervous system lymphoma (PCNSL) responds favorably radiation, chemotherapy targeted drug therapy . However survival usually worse, treatment-related drug resistance recurrence recurrence recurrence still clinical problems solved urgently ." APR-246 compound shift mutant p53 exhibits anti-cancer effects . APR-246 facilitates binding restored p53 mutants target genes transcription . TP53 mutations correlate inferior survival many cancers . " Pancreatic cancer highly lethal malignancy often presenting advanced disease characterized resistance standard chemotherapy . Immune-based therapies checkpoint inhibition largely ineffective pancreatic cancer categorized immunologically ""cold tumor""" Centrosome spindle pole-associated protein (Centrosome spindle pole-associated protein) Centrosome spindle pole-associated protein (CSPL) is a protein that binds the spindle pole-associated protein . " Primary hepatic lymphoma (PHL) rare malignant tumor, occurring 0.016% non-Hodgkin's lymphoma (NHL) The common histological subtype diffuse large B-cell lymphoma (DL" " Authors proposed method diagnosis invasive mucinous adenocarcinoma lungs based on CT radiomic features . 34 cases of primary pulmonary lymphoma, 12 cases of nodular mass type, 12 cases nodular mass type, 19 cases non" Hans' criteria could accurately predict chemotherapy resistance disease progression patients treated standard R-CHOP therapy . There need identify better biomarker predictors enhance assisted selection chemotherapy regimens DLBCL patients . Lymphomas localized kidney rare entity may challenging diagnose . Lymphomas localized kidney rare entity may challenging diagnose . " Richter syndrome mostly due direct transformation chronic lymphocytic leukaemia (CLL) clone, documented immunoglobulin heavy-chain variable region (IGHV) rearrangement CLL RS cells . In rare cases characterized better" " Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) rare aggressive type cutaneous B-cell lymphoma poor prognosis low therapeutic response . 5-year survival rate 50% efficiently" " Immunotherapy evolved powerful tool treatment B-cell malignancies, patient outcomes improved combining therapeutic antibodies conventional chemotherapy . Here, show addition venetoclax (VEN), specific Bcl-2 inhibitor, potently enhanced effi ." We evaluated impact liposomal doxorubicin (NPLD) supercharge-containing therapy . 81 adult patients advanced-stage DLBCL (n = 53) c-HL (n = 28) received front Little population-level evidence prevalence cardiovascular disease (CVD) individuals diagnosed potentially curable cancer . Little population-level evidence prevalence cardiovascular disease (CVD) individuals diagnosed potentially curable cancer. We investigated CVD rates patients common potentially cur Neoplasms intestinal tract uncommon rabbits . Primary intestinal lymphoma intestinal tract rare . Neoplastic cells three cases large (8 μm diameter) one case intermediate cells (5 μm diameter) " The benefit radiation therapy (RT) becomes uncertain treatment early stage diffuse large B-cell lymphoma (DLBCL) era rituximab, positron emission topography (PET), computed tomography (CT) era r" " 37-year-old male diagnosed stage IV gastric DLBCL . Diagnosed with stage IV gastric DLBCL and underwent R-CHOP chemotherapy . After six cycles treatment, complete remission achieved . But afterwards, patient presented" " Necroptosis, relatively novel programmed cell death, involved development multiple tumors . Diffusion large B-cell lymphoma (DLBCL) becomes promising, patients still progress relapse refractory stage ." Aim assess incremental costs chimeric antigen receptor (CAR) T-cell therapy . German third-party payer perspective . German budget impact model established 6-year period . " 54-year-old male presented epigastric pain, presented epigastric pain . Gastric diffuse large B-Cell lymphoma presented brief review differentiating pathological subtypes ." Renal involvement lymphoma commonly associated widespread nodal extranodal lymphoma . Renal involvement lymphoma commonly associated widespread nodal extranodal lymphoma . Treatment Diffuse Large B-Cell Lymphoma (DLBCL) elderly aims achieve disease remission minimizing treatment-related toxicities . Non-anthracycline-based regimens commonly used patients cardiac contraindications anticipated Secondary central nervous system (CNS) relapses uncommon yet devastating complication diffuse large B cell lymphoma (DLBCL) Relapses uncommon yet devastating complication diffuse large B cell lymphoma (DLBCL) Although several prophyl " Dichotomous decision trees developed survival status 3, 12, 24, 60 months . Dichotomous decision trees developed survival status 3, 12, 24, 60 months ." " Primary bone lymphoma rare type lymphoid neoplasm favorable prognosis . Amongst PB-NHL, diffuse large Bcell lymphoma represents majority cases . 45-year-old male male patient admitted hospital large right jaw mass pain" " A 55-year-old male patient presented us jaundice right upper quadrant pain . Investigations showed elevated alkaline phosphatase, lactate dehydrogenase, total bilirubin, total bilirubin, normal" Angioimmunoblastic T-cell lymphoma (AITL) recognized rare variant peripheral T-cell lymphoma . AITL was initially presented extranodal disease form fluorodeoxyglucose (F) " A 51-year-old Caucasian man presented headache, ear pain, blurry vision eyes . Diagnosed with systemic diffuse large B cell lymphoma ." " Fifteen secondary metabolites, including five new sesquiterpenoids (1-5), one new benzofuranoid (10), one new benzofuranoid (10), one new ophiobolin sesterterpen" " Phase I/II clinical study conducted examine safety, tolerability, pharmacokinetics, efficacy 10-min dosing bendamustine . Patients previously untreated indolent B-cell non-Hodgkin lymphoma (i" Gorham's lymphangiomatosis Gorham-Stout disease (GSD) rare skeletal condition unknown etiology characterized progressive bone loss nonmalignant proliferation vascular lymphatic channels within affected bone . " Primary thyroid lymphoma extremely rare thyroid malignancy . Usually occurs patients with preexisting Hashimoto thyroiditis . Common type non-Hodgkin's lymphoma B-cell origin, particularly diffuse large B-cell lymphoma" " APG-2575 novel BCL-2 selective inhibitor, demonstrated anti-tumor activity hematologic malignancies . Homoharringtonine (HHT), alkaloid, exhibited anti-AML activity ." Diffuse large B cell lymphoma (DLBCL) common B cell non-Hodgkin lymphoma remains incurable around 40% patients . Common B cell non-Hodgkin lymphoma remains incurable around 40 The role allogeneic hematopoietic cell transplantation (allo-HCT) CAR T- treatment cells hematologic malignancies currently controversial . Prolonged remissions several years follow-up suggest curative " Primary breast lymphoma (PBL) managed differently among centers using surgery, systemic therapy and/or radiation . We conducted retrospective cohort study using de-identified data NCDB ." " Secondary CNS lymphoma (SCNSL) rare frequently fatal complication systemic lymphoma . There standard treatment SCNSL, patients develop SCNSL diagnosis frontline therapy often receive highly intensive chemotherapy regimens ." " R-CCOP regimen (rituximab, cytoxan, pegylated liposomal doxorubicin [PLD], vincristine, prednisone, prednisone) attenuated R" " Diffuse large B-cell lymphoma (DLBCL) represents common subtype aggressive lymphoma . Roughly 60-65% patients cured chemoimmunotherapy rituximab, cyclophosphamide, dox" Lymphomas heterogeneous group disorders arise primarily lymphoid tissue categorized based histological features immunophenotypes . The distribution frequency different types lymphoma vary different parts world . This study aimed document frequency clinicopathological characteristics various types lymphoma population Growing number neuroimaging studies reported chemotherapy might impair brain functions . Post-chemotherapy group showed higher metabolism right hippocampus parahippocampal gyrus . MicroRNA (miR)-411-5p/BCL2 interacting protein 3 (BNIP3) pathway . MicroRNA (miR)-411-5p/BCL2 interacting protein 3 (BNIP3) pathway " SARS-CoV-2 constantly mutating, new coronavirus Omicron spread many countries around world . Anexelekto (AXL) transmembrane protein biological functions promoting cell growth, migration, aggregation" " Study aimed to comprehensively elucidate potential functions of SHCBP1 multiple cancer types . The comprehensive analyses SHCBP1 various tumors, including gene expression, diagnosis, prognosis, immune-related features, genetic altera ." " An elderly, immunocompetent woman presented orbital mass biopsied proven EBV-associated lymphoma . The authors performed literature search review suggested presentation rare infrequently reported ophthalmic literature . More research needed to fully ascertain importance" The majority patients large B-cell lymphoma treated axicabtagene ciloleucel (axi-cel) treated axicabtagene ciloleucel (axi-cel) developed cytokine release " Diffuse large B-cell lymphoma (DLBCL) heterogeneous malignant lymphoma distinct characteristics . Patients treatment failure standard immunochemotherapy worse prognosis, implies necessity uncover novel targets ." " Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) rare form non-Hodgkin's lymphoma . While CNS relapse common, systemic relapse rare consensus optimal treatment . This paper presents unusual" Aberrant epigenetic changes could trigger metabolic disorders human cancer cells . This study planed uncover biological roles epigenetic SPOP/CHAF1A axis modulating tumor autophagy . Primary cardiac lymphoma extremely rare malignancy. Primary cardiac lymphoma extremely rare malignancy. Primary cardiac lymphoma extremely rare malignancy. Primary cardiac lymphoma extremely rare malignancy. The gastrointestinal (GI) tract common site extra-nodal involvement non-Hodgkin's lymphoma (NHL) The features GI NHLs remain unclear . The aim study clarify endoscopic characteristics GI NHLs . " Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies have approved relapsed/refractory aggressive diffuse large B cell lymphoma 2 lines therapy ." T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) rare aggressive variant diffuse large B-cell lymphoma (DLBCL) usually affects young middle-aged patients . The tumor micro " HMGB1 potential biomarker therapeutic target various human diseases . However, systematic, comprehensive pan-cancer analysis HMGB1 human cancers remains reported . HMGB1 overexpressed malignant tissues, including lymphoid neoplasm diffuse large" Sarcopenia adverse prognostic factor diffuse large B-cell lymphoma . Differing lymphoma cell infiltration psoas major femoral bone marrow reported . Treatment high-dose chemotherapy followed autologous stem cell transplantation (ASCT) considered standard care (SOC) second-line treatment relapsed refractory large B-cell lymphoma (LBCL) Outcomes included " Recent data indicate MIR142 frequently mutated miRNA gene one frequently mutated noncoding elements cancers . Mutations occurring predominantly blood cancers, especially blood cancers ." Polatuzumab vedotin (Pola) antibody-drug conjugate targets B-cell antigen CD79b . It approved combination bendamustine rituximab (Rit) relapsed/ref We prospectively analyzed blood lymphocyte immunophenotyping (LIP) of newly CNS-DLBCL referred institution December 2013 January 2020 . LIP analysis performed rituximab chemotherapy administration . Fifty-three patients included median " Indoleamine 2,3-dioxygenase 1 (IDO1) key regulator catalyzes commitment step kynurenine pathway immune system . Role of role IDO1 DLBCL progression remains elusive ." MCD/C5 genetic subclass diffuse large B-cell lymphoma (DLBCL) is a subtype of MCD/C5 genetic subclass . Premalignant cell-of-origin exhibiting MCD-like dependencies remains Failure CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy patients relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is emerging clinical problem An emergent laparotomy acute abdomen 90-year-old woman performed . A pelvic mass 12 × 9 cm fistulized left colon found presence gas free liquid within abdomen . " Machine-learning analysis Center 1 dataset revealed important features building 2-year EFS . The predictive model built Center 1 dataset yielded 79% sensitivity, 83% specificity, 69% positive predictive value, 89% negat ." An 85-year-old woman presented ataxia deterioration cognitive functions . Magnetic resonance imaging showed solitary mass lesion cerebral falx contrast-enhanced T1-weighted imaging . Gross total resection lesion involving dura mater 34-year-old pregnant woman with chronic heel pain . 34-year-old pregnant woman with lower extremity trauma . Unresponsive conservative treatment . Diagnosed with Stage I-AE diffuse large B-cell lymphoma . Diffuse large B cell lymphoma (DLBCL) exhibits tightly complexity immune landscape . We identified two immune infiltration subtypes DLBCL patients based 28 immune cell types . Considering convenient application immune infiltrati might be convenient application . To investigate systemic immune-inflammation index (SII) prognostic factors establish nomogram based SII prediction survival . One hundred fifty-five DLBCL patients randomized primary (N = 100) validation (N = 55) cohorts Patients newly diagnosed diffuse large B-cell lymphoma (DLBCL) achieve progression-free survival (PFS) 24 months (PFS24) immunochemotherapy (IC) excellent overall survival (OS) excellent overall survival ( " B-cell non-Hodgkin lymphomas (B-NHLs) common lymphoproliferative malignancy . Despite targeted therapies, bone marrow involvement remains challenge treating aggressive B-NHLs ." The LNH03-6B trial phase 3 randomized trial evaluating efficacy first-Line R-CHOP delivered every 2 weeks (R-CHOP14) 3 weeks (R-CHOP21) diffuse large B-cell lymph Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin's lymphoma considerable heterogeneity different clinical prognosis . Plasma metabomics used forecast occurrence prognosis of DLBCL rarely addressed . " Richter syndrome (RS) recognized, namely, diffuse large B-cell lymphoma (DLBCL) Hodgkin's lymphoma (HL) variant . Clonal relationship, defined identity immunoglobulin heavy chain variable (IGH" " Primary ventricular lymphoma (PVL) extremely rare commonly misdiagnosed disease . Previous studies predominantly case reports, literature regarding diagnosis treatment PVL limited ." " Epstein-Barr virus is a risk factor developing lymphoma . EBV seropositivity present > 90% world's population . EBV causes clinical symptoms, common fever, lymphadenopathy phary ." " Primary mediastinal B-cell lymphoma (PMBL) currently curable 85-95% patients . Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, occasionally intensive protocols ." Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor response . 30% patients prolonged cytopenia appearing unmet need optimal treatment . Lenalidomide-based schedules reverse rituximab refractoriness lymphoma . 78 patients unsuitable autologous stem cell transplant received treatment following schedule . Diffuse large B-cell lymphoma (DLBCL) common lymphoid neoplasm dogs humans . Diffuse large B-cell lymphoma (DLBCL) common lymphoid neoplasm dogs humans . We performed integrated " Non-Hodgkin's lymphoma (NHL) second common non-epithelial malignant tumor cervicofacial region . Among aggressive NHL, common histological type diffuse large B cell lymphoma (DLBCL" " Primary lymphoma colon extremely rare . Symptoms non-specific, abdominal pain, bloody diarrhea, unintentional weight loss, unintentional weight loss, night sweats, changes bowel habits ." " Immune-based therapeutic treatments CD19 Chimeric Antigen Receptor (CAR) T cell therapies dramatically changed treatment landscape . However, remains unmet need developing novel therapies improve clinical outcomes ." Ataxia-telangiectasia (AT) type primary immunodeficiency characterized autosomal recessive mode inheritance . AT is an autosomal recessive mode inheritance usually presents progressive cerebellar ataxia early life . The long non-coding RNA (lncRNA)-mRNA regulation network plays important role development diffuse large B-cell lymphoma (DLBCL) This study uses bioinformatics find innovative regulation axis DLBCL provide Diffuse large B-cell lymphoma (DLBCL) heterogeneous neoplasm characterized common subtype non-Hodgkin lymphoma (NHL) Despite 60-70% patients cured R-CHOP therapeutic regimen " The appendix considered appendage little value often treated disdainfully, part evolutionary process, grossing table, grossing table, microscope archiving specimens slides . Data indicating importance gut immunity origin pseudomyxoma, pseudomyxoma, space" Chemotherapy-induced posterior reversible encephalopathy (PresPresPresPresPresPres syndrome) syndrome rare event . Its recurrence reusing incriminated molecules remains unpredictable . Chimeric antigen receptor (CAR) T-cell therapy individualized immunotherapy genetically reprograms patient's T cells target eliminate cancer cells . CAR T-cell therapy patients relapsed/refractory (r/r) B Epstein-Barr virus persists small portion B cells primary infection etiologically associated multiple lymphoma subtypes . We evaluated clinical utility EBV real-time quantitative PCR comparison widely used Epstein-Barr virus-encoded RNA (E Large B-cell lymphoma (LBCL) primary refractory relapsed within 12 months first-line therapy high risk poor outcomes . Auto-based salvage immunochemotherapy autologous haematopoietic stem " Primary central nervous system lymphoma (PCNSL) rarely originates hypothalamus . Hypothalamic PCNSL present various symptoms specific dysfunction hypothalamus, including consciousness disturbance, cognitive impairment, hypopituitarism, diabetes ins" " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma potentially curable disease . Heterogenous, prognosis poor tumor cells harbor fusions involving MYC BCL2 MY" CD19-negative diffuse large B-cell lymphoma central nervous system relapse following CD19-directed CAR T-cell treatment . Absence CD19 expression tumour cells presented challenge flow cytometry evaluation . " Intravascular lymphoma (IVL) rare extranodal non-Hodgkin lymphoma . We performed retrospective analysis 55 IVL patients treated institution 2003-2018 . Median age diagnosis 68 years, 64% males ." Diffuse Large B Cell Lymphoma (DLBCL) poses major barrier diagnosis treatment . Aim identify potential biomarkers for DLBCL . Differentially expressed genes screened DLBCL corresponding normal tissues . " Diffusion large B-cell lymphoma (DLBCL) involving side diaphragm involving side diaphragm remains unclear . Survival assessed presence, contiguity, number extranodal lesions ." Chemotherapy regimens containing rituximab (RTX) extensively used treat diffuse large B cell lymphoma (DLBCL) Chemotherapy regimens containing rituximab (RTX) extensively used treat diffuse large " Diffuse large B cell lymphoma (DLBCL) group biologically heterogeneous tumors different prognoses . The tumor microenvironment plays vital role tumorigenesis development DLBCL, activated memory CD4 ." Intravascular large B cell lymphoma (IVLBCL) presents non-specific symptoms extremely difficult diagnosis make despite extensive workup . It rarely presents endocrinologic abnormalities . CHROMR (cholesterol induced regulator metabolism RNA) may differentially expressed different rituximab-resistant diffuse large B lymphoma cell lines . LncRNA differentially expressed diffuse large B cell lines varying degrees resistance rit Plasmablastic lymphoma (PBL) rare variant diffuse large B-cell lymphoma (DLBCL) associated human immunodeficiency virus (HIV-positive) patients . It accounts 2% acquired immune deficiency syndrome BCL2 inhibitor venetoclax approved treat different hematological malignancies . Common genetic alteration causing resistance venetoclax chronic lymphocytic leukemia (CLL) B-cell lymphoma . POLARIX study demonstrated 6.5% improvement 2-year progression-free survival (PFS) difference overall survival (OS) safety using pola-R-CHP compared standard R-CHOP . We evaluated cost- " Cancer-related cognitive impairment (CRCI) recognised adverse consequence cancer treatment . This study assessed feasibility collecting longitudinal data on cognition patients newly diagnosed, aggressive lymphoma undergoing standard therapy curative intent via self-report ." Classical hairy cell leukemia (cHCL) related mature lymphoid B-cell neoplasms . Majority cHCL cases harbor BRAFV600E mutation . Majority cHCL cases harbor BRAFV600E mutation . " The author of the journal's first article on the new drug, lenalidomide . The author of the journal's first article on the drug ." " This study aimed assessing prevalence association association lymphoma patients AITD . Graves' disease (GD) Hashimoto's thyroiditis (HT) common types autoimmune thyroid diseases (AITD) Moreover, autoimmune diseases like HT higher risk developing" Transthyretin amyloid cardiomyopathy considered rare pathology considered rare pathology . Recent studies show significant prevalence patients with degenerative aortic stenosis heart failure preserved ejection fraction . " Complications may occur initial manifestation lymphoma, treatment course, late following complete disease remission . Complications associated worse prognosis increased mortality ." " Seventy-five patients sMPMTs (5.8%) among 1285 lymphoma newly diagnosed August 2004 April 2020 enrolled . In patients indolent lymphoma, sMPMTs worse prognosis without sMPMTs" Anti-CD19 chimeric antigen receptor T-cell immunotherapy (CAR-T) standard treatment relapsed refractory B-cell non-Hodgkin lymphomas . Lymphodepleting chemotherapy critical component CAR The FEbrile Neutropenia ChEmotherapy (FENCE) score developed estimate risk febrile neutropenia (FN) first cycle chemotherapy externally validated . We aimed validate FENCE score based risk groups This payer model compares lifetime costs/benefits CAR T cell-treated patients R/R LBCL USA . " Patients inborn errors immunity (IEI) higher risk developing cancer, especially lymphoma . Researchers identify validated disease-causing -associated germline mutations 14 23 patients involving ATM, BACH2, BLM, CD70, CD70" Cell surface calcium (Ca) is calcium from the cell surface . Cell surface calcium (Ca) is calcium from the cell surface . Cell surface calcium (Ca) is calcium from the cell surface . " axicabtagene ciloleucel (axi-cel) demonstrated high rates durable response relapsed/refractory (r/r) follicular lymphoma (FL) patients . Here, outcomes ZUMA" " Roughly one third diffuse large B cell lymphoma (DLBCL) patients experience relapsed refractory disease, prognosis unsatisfactory . It thus important identify patients who respond poorly first-line treatment ." Diffuse large B cell lymphoma (DLBCL) common non-Hodgkin lymphoma (NHL) common non-Hodgkin lymphoma (NHL) globally . Long non-coding ribose " Neurolymphomatosis (NL) infiltration cranial nerves nerves roots peripheral nervous system lymphoma, usually B-cell non-Hodgkin's lymphoma . It uncommon initial presentation disease lead extremely heterogeneous clinical manifestations ." " Central nervous system (CNS) involvement patients chronic lymphocytic leukaemia (CLL) rare and, present, frequently asymptomatic . We describe case symptomatic leptomeningeal leukaemic involvement atyp" Multiplexed immune cell profiling tumor microenvironment (TME) cancer improved understanding cancer immunology . " Red meat SFA intakes increase NHL risk, fish PUFA intakes decrease NHL risk . Red meat PUFA intakes increase NHL risk, fish PUFA intakes decrease NHL risk . Red meat SFA intakes increase NHL risk, fish PUFA intakes" L-MIND study retrospectively compared patient-level matched observational cohorts treated National Cancer Care Network (NCCN/European Society Medical Oncology (ESMO) listed systemic therapies relapsed/refractory diffuse large B- Chimeric antigen receptor T-cell (CAR-T) therapy revolutionary cancer treatment modality . Reprogrammed CAR-T cells stimulate T-cell mediated immune response antigen-expressing malignant cells leading cell death . Initial results Chimeric antigen receptor T-cell therapy (CAR-T) major advance managing aggressive relapsed refractory B-cell lymphomas . There substantial variability across transplantation cellular therapy programs assessing managing post-CAR-T failures . Tirabrutinib is a promising option bridging therapy ASCT . The optimal therapy for relapsed primary diffuse large B-cell lymphoma (DLBCL) central nervous system (CNS) remains unclear . Tirab The use immune-checkpoint inhibitor (ICI) therapy significantly improved patient outcomes . ICI treatment potential cause variety immune-related adverse events (irAEs) affect tissue organ . Selinexor first-in-class inhibitor nuclear exportin XPO1 recently approved US Food Drug Administration treatment multiple myeloma diffuse large B-cell lymphoma . Survival extrapolations axicabtagene ciloleucel using ZUMA-1 data validated compared . Axicabtagene ciloleucel indicated treatment relapse refractory diffuse large B-cell lymphoma Primary breast lymphoma (PBL) uncommon type breast malignancy . Its clinical presentation radiographic findings non-specific overlap breast carcinoma . The treatment PBL differs significantly breast carcinomas . Primary mediastinal large B-cell lymphoma (PMBCL) rare type diffuse large B-cell lymphoma . Significant features overlap Hodgkin's lymphoma . 42-year-old Chinese male patient PMBCL misdiagn Primary endometrial lymphomas rare malignancies female genital tract usually involved secondary site . 49-year-old postmenopausal female diagnosed 49-year-old postmenopausal female . Pap smear followed cervical polyp biopsy suggestive " Adenosine deaminase (ADA) plays important role immune response, includes two isoenzymes: ADA1 ADA2 . Study aims explore roles ADA1 ADA2 cancers ." Cellular therapies transformed treatment relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) Patients typically respond well salvage chemotherapy . About 40% of DLBCL patients across three different trials achieved complete remission JADPRO Live Virtual 2021 discussed treatment for diffuse large B-cell lymphoma (DLBCL) Presenters discussed updates treatment for DLBCL . DLBCL affected COVID-19 pandemic . " 42-year-old female transferred center regional hospital 5-day history flushing, fatigue, chest pressure . CT scan revealed large mediastinal mass cardiac involvement ." Extranodal involvement recognized poor prognostic factor diffuse large B-cell lymphoma (DLBCL) in study . Median follow-up time 13 months one-year progression-free survival (PFS; 83.3% The study shows BCL10 mutants fall at least two functionally distinct classes . The CARD11-BCL10-MALT1- signal amplification complexes form due polymerization BCL10 subunits . " Plasmablastic myeloma (PBM) blastic morphologic variant plasma cell myeloma less favorable prognosis non-blastic morphology . PBM rare, without clear-cut definition detailed clinicopathologic features literature ." Fifty-one patients received RED combined CHOP regimen . Median follow-up 31 months . " Concurrent follicular lymphoma (FL) diffuse large B-cell lymphoma (DLBCL) considered important pathological feature cell lymphoma . However, clinicopathological information prognostic factors cases scarce ." " Tumor cells secrete extracellular vesicles (EVs) carry bioactive cell surface markers, programmed death-ligand 1 (PD-L1) They modulate immune responses inhibit anti-tumor responses" " Text-mining tool, Abstrackr, may potentially reduce workload burden title abstract screening (Stage 1) using screening prioritization truncation ." Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphomas (NHLs) worldwide . Diffuse large B-cell lymphoma (DLBCL) common type non- " Lymphomatosis cerebri atypical form primary central nervous system lymphoma (PCNSL) frequently causes rapid progression dementia . The lesion dramatically shrank, enhancements identified MRI ." " PI3K/HDAC dual inhibitors DLBCL paid much attention, especially RR-DLBCL . RR-DLBCL suppress growth solid tumors hematologic malignancies ." " There increased risk of congestive heart failure (CHF) following anthracycline-based chemotherapy patients Diffuse Large B-cell lymphoma (DLBCL) Little known risk factors CHF, cardiovascular events (CVE)," Intravascular large B cell lymphoma (IVL) rare subtype diffuse large B cell lymphoma confined small blood vessels predilection CNS involvement . The prognosis IVL CNS involvement (CNS-IVL) extremely poor Malignant lymphomas represent approximately 5% malignant neoplasms head neck . Malignant lymphomas represent approximately 5% malignant neoplasms head neck . The head neck region second frequent anatomical site extra-nodal lymphomas Guanine nucleotide exchange factor (GEF) protein complexes likely become increasingly relevant development new therapeutics targeting small GTPases targeting small GTPases . Syx (also known PLEKHG5 humans) Rho " A minority patients diagnosed diffuse large B-cell lymphoma (DLBCL) undergo surgery initiation systemic therapy . The aim study explore characteristics patients undergoing surgery prior systemic therapy (surgfirst) and predictors surgfirst, survival outcomes ." Chimeric antigen receptor T-cells (CAR-Ts) known revolutionary living drugs turned tables conventional cancer treatments . B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBC " This study aimed propose new user-friendly, cost effective robust risk model facilitate risk stratification diffuse large B-cell lymphoma (DLBCL) treated frontline R-CHOP regimens . Data 998 patients de novo DL" " CD2 costimulatory protein expressed mature T/NK-cells, particular memory T-cells . Loss of CD58 expression one frequently reported diffuse large B-cell lymphomas (DLBCL) Loss of CD58 expression one frequently" We evaluated therapeutic potential combining monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 mitochondrial respiratory Complex I inhibitor IACS-010759 . We evaluated therapeutic potential combining monocarboxylate transporter " We tested combination Obinutuzumab DHAP treating R/R DLBCL . The primary end point rate rate complete metabolic response (CMR) Secondary end points stem cell mobilization, stem cell mobilization, stem cell engraft" " Development primary mediastinal B-cell lymphoma (PMBL) driven cumulative genomic aberrations . PMBL distinguishes tumor B-cell malignancies, including biologically related diffuse large B-cell lymphoma ." The management locally advanced oral cavity squamous cell carcinoma (LA-OCScc) elderly patients multiple comorbidities difficult . Intra-arterial chemotherapy 40 mg/m Intra-arterial chemoradiotherapy may Zinc oxide nanoparticles (ZnO NPs) show anti-cancer activity . Diffuse Large B-cell Lymphoma (DLBCL) type B-cell malignancies unsatisfying treatment outcomes . A man 80s presented hypotension respiratory failure unsuccessfully treated septic shock . Diagnosed hypopituitarism due insufficient secretion anterior pituitary hormone . Condition temporarily improved following hormone replacement therapy . Axicabtagene ciloleucel (axi-cel) standard-of-care patients relapsed refractory (r/r) large B cell lymphoma received 2 lines prior therapy . Patients receiving axi Auto-HCT feasible older DLBCL patients . Auto-HCT feasible older DLBCL patients . Auto-HCT patients aged 60 69 years (n = 363) versus 60 69 years (n = 363) Auto- Dual blockade Bruton's tyrosine kinase ibrutinib selinexor potential deepen responses patients chronic lymphocytic leukemia (CLL) non-Hodgkin lymphoma (NHL) patients . Epstein-Barr virus (EBV) associated various types human malignancies programmed death ligand (PD-L) 1 expression neoplastic cells . EBV-associated malignant lymphomas lymphoproliferative disorders ( Epstein-Barr virus (EBV) infection often observed B-cell lymphomas . A subset Burkitt lymphoma (BL) expresses EBV latent membrane proteins 1 2A (LMP1 LMP2A) addition typical " In commentary Wang, Wu, Xia, Xia, Wang, Wu, Xia, colleagues, Clinical Translational Medicine, 2022, sum discuss recent evidence regulation relevance transcription factor c-FOS diffuse large B cell lymphoma cells treated epigen" " There 133 patients OAL, median age 65 years (range 23-97) slight female predominance (male: female = 1:1.46), ( In largest single-center study OAL found OAL Ann-Arbor" EBV associated lymphoproliferative disorders (EBV LPD) known complication following solid organ hematopoietic stem cell transplantation . The disturbance immune system leads lack control latent EBV-infected B-cells Plasmablastic lymphoma (PBL) rare aggressive variant diffuse large B cell lymphoma . Very cases PBL colon reported HIV negative patients . " MEAM regimen consists ranimustine (MCNU), etoposide (ETP), cytarabine (Ara-C), melphalan (MEL) widely used auto-peripheral blood stem" " GOYA study patients DLBCL received first-line rituximab obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)" 30-year-old female presented abdominal fullness . Abdominal CT revealed bilateral huge ovarian masses moderate amount ascites . The patient received six cycles chemotherapy RCHOP regimen . Diffuse large B-cell lymphoma (DLBCL) subtype non-Hodgkin lymphoma (NHL) highest incidence . Subtype accounting approximately one-third NHL cases . " Diffuse Large B-cell Lymphoma (DLBCL) is aggressive cancer B cells, common pathological type Non-hodgkin's Lymphoma (NHL) typical heterogeneity disease due metastasis, indicates poor prognosis" Tumor protein 53 (Tumor protein 53) is a protein that contains a protein that contains a protein that contains a protein that contains a protein that contains a protein that contains a protein that contains a protein that contains a protein " Lymphoma middle ear mastoid uncommon rarely diagnosed early . Presentations include facial nerve palsy, hearing loss, vestibular dysfunction ." Sarcoidosis lymphoma often share common features . Sarcoidosis lymphoma often share common features . Sarcoidosis lymphoma often share common features . " The purpose study establish accurate prognostic model based important clinical parameters predict overall survival (OS) elderly patients . The Cox regression analysis based data . based data Surveillance, Epidemiology, End Results (SEER) database . A total 1," " 71-year-old woman diagnosed right breast mass, enlarged lymph nodes throughout body, splenic tumor . Diagnosed with right breast mass, enlarged lymph nodes throughout body, splenic tumor . Diagnosed with right breast mass, enlarged lymph" Gastric lymphomas increasingly described literature due development diagnostic techniques increased incidence . Gastric lymphomas increasingly described literature due development diagnostic techniques increased incidence . Gastric lymphomas increasingly described literature due development diagnostic techniques increased incidence . CAR T cells enable vivo proliferation still consistently defined role CAR T bag content never investigated real-life setting . Residual cells obtained washing 61 anti-CD19 CAR T product bags analyzed identify tisagenleclecleucel/ " Cereblon (CRBN), substrate receptor E3 ubiquitin ligase complex CRL4CRBN, target small molecules lenalidomide avadomide avadomide . Upon binding drugs, Aiolos I" " Histological transformation (HT) exceptionally uncommon poorly understood event low-grade indolent B-cell lymphoma transforms aggressive entity, typically diffuse large B-cell lymphoma (DLBCL) Pathogenesis unclear; however, HT associated" CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents promising treatment modality increasing number of B-cell malignancies . But prolonged cytopenias infections substantially contribute toxicity burden CAR-T . Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy facilitated progress treatment refractory/relapsed diffuse large B-cell lymphoma (DLBCL) A well-known adverse event CAR-T therapy " Diffuse large B-cell lymphoma (DLBCL) heterogenous subtype non-Hodgkin lymphoma . Relapsed/refractory disease represents remains unmet medical need, despite introduction novel cellular targeted therapies ." Diffuse large B-cell lymphoma (DLBCL) common lymphoid malignancy high relapse rate 40% . Pronosis disease needs improvement requires understanding molecular mechanism . Subgroup patients develop resistance to Bruton tyrosine kinase (BTK) B-cell lymphoma 2 inhibitors . Subgroup CLL cases transform aggressive lymphoma - called Richter transformation - either targeted therapy or targeted therapy . " Intravascular large B-cell lymphoma (IVLBCL) rare, aggressive, large B-cell non-Hodgkin's lymphoma . The prognosis IVLBCL patients central nervous system recurrence first" " Diffuse large B-cell lymphoma (DLBCL) constitutes 30% non-Hodgkin's lymphomas . It present nodal disease extra nodal disease extra nodal disease . Based site origin, extra nodal" " Despite impressive progress, significant portion patients still experience primary secondary resistance chimeric antigen receptor (CAR) T-cell immunotherapy relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) The mechanism" " Primary small bowel lymphomas rare entity significant morbidity low five-year overall survival even surgery . Diagnosis often delayed due lack clear specific signs, unfamiliarity amongst clinicians, lack screening tools ." Primary bone diffuse large B-cell lymphoma (PD-DLBCL) accounts 80% primary bone lymphoma . We created two nomograms predict overall survival (OS) cancer-specific survival (CSS) patients PD-DLBC " Hairy cell leukaemia (HCL) rare B cell malignancy indolent course leading pancytopaenia due bone marrow infiltration . HCL patients risk developing secondary malignancy, marked likelihood development hemat" " DLBCL bone marrow (BM) peripheral blood (PB) involvement prior cold agglutininin disease (CAD) A minority patients DLBCL present CAD, BM PB involvement CAD quite rare ." Hodgkin variant Richter transformation (HvRT) rare challenging complication chronic lymphocytic leukaemia (CLL) information prognostic factors prognostic factors prognostic factors were considered prognostic factors . Rare cases human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur body cavities without antecedent concurrent solid mass formation . Known association HIV HH Exploring repertoire peptides presented major histocompatibility complexes (MHCs) helps identify targets immunotherapy many hematologic malignancies . Paucity data on diffuse large B-cell lymphomas (DLBCL) Recent reports suggest effective strategy high-grade B-cell lymphoma . One approach involves targeting CD19 antigen B cells autologous-derived chimeric antigen receptor (CAR) cells . The GC reaction results selection B cells acquiring effector Ig secreting ability progressing toward plasmablastic differentiation . This transition associated exclusion GC microenvironment . " DLBCL (diffuse large B-cell non-Hodgkin lymphoma) presenting heart bilateral adrenal involvement . Following six cycles systemic immunochemotherapy R-DA-EPOCH, high methotrexate dose" Intravascular large B-cell lymphoma (lVLBCL) rare type large B-cell lymphoma . We conducted retrospective study IVLBCL patients treated 2000 2016 LYSA cooperative group centers . Thirty-four patients Primary lymphomas central nervous system (PCNSL) mainly diffuse large B-cell lymphomas (DLBCLs) confined central nervous system (CNSL) Molecular drivers PCNSL fully elucidated . " HKII protein level determined immunohistochemistry 159 newly diagnosed DLBCL patients . HKII protein level determined immunohistochemistry . Relationship overall response rate, progression-free survival (PFS), overall survival (OS) analyzed ." Leukemic involvement high grade B cell lymphoma (L-HGBL) rare sparsely described literature . Leukemic involvement high grade B cell lymphoma (L-HGBL) rare sparsely described literature . We IMAGE-I syndrome is a genetic disease caused by biallelic mutations gene encoding DNA polymerase epsilon catalytic subunit 1 . DNA replisome molecular complex plays indispensable roles normal DNA replication . " To explore role clonal hematopoiesis (CH) chimeric antigen receptor (CAR) T-cell therapy outcomes, performed targeted deep sequencing . 114 large B-cell lymphoma patients treated anti-CD19 CAR T" " Primary central nervous system lymphoma (PCNSL) rare non-Hodgkin's lymphoma (NHL) Develops brain, spinal cord, leptomeninges, vitreoretinal space . Majority cases diffuse" This study aimed determine predictive prognostic value baseline metabolic tumor volume (MTV) Peking criteria serial positron emission tomography (PET) scans diffuse large B-cell lymphoma . 300 newly diagnosed patients prospectively treated 2-4 " Multiple primary cancer (MPC) defined one primary tumour diagnosed patient, either simultaneously sequentially . Its incidence low varies reporting among medical centers . Given fact expanding avai avai is a rare case of female patient diagnosed two synchronous" Non-Hodgkin's lymphoma breast rare condition . NHL breast constitute 0.5% malignancies breast . NHL breast constitute nearly 1% cases NHL . " Primary cardiac tumours extremely rare autopsy incidence 0.05% . They present variety symptoms, including life-threatening arrhythmia cardiac tamponade ." DLBCL (diffuse large B cell lymphoma) patients higher initial phase treatment (first cycle effect) Implementation pre-phase treatment definitive chemotherapy shown alleviate side-effects . 71-year-old man laparoscopic distal gastrectomy lymphadenectomy three gastric tumors . Lymph node biopsy revealed CD4+ angioimmunoblastic T-cell lymphoma systemic superficial nodal involvement . Intractable prurigo judged T-cell lymphoma related . " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . Histone deacetylase inhibitors (HDACis) widely applied multiple tumours, expected efficacy observed DL" " Anthracycline first-line chemotherapy drug used treat childhood acute leukemia, may cause cardiac toxicity ." Loncastuximab tesirine (Lonca) chemoimmunotherapy (CIT) assessed patients relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) Analysis Clinical survival data retrospectively collected seven international eye cancer centres . OAL identified 1168 patients . Cox regression used compare ocular adnexal tumour locations all-cause mortality disease-specific mortality . " Patients relapsed refractory large B-cell lymphomas (rrLBCL) achieve long-term remission CD19 chimeric antigen receptor T-cell therapy (CART19) However, half recipients experience treatment failure . We" MYC BCL2 BCL6 rearrangements (double-/triple-hit lymphoma [DTHL] appears mandate fluorescence situ hybridization (FISH) testing large B-cell lymphoma (LBC Fibrin-associated diffuse large B-cell lymphoma (FA-DLBCL) rare entity subset Epstein-Barr virus (EBV)-associated lymphoma) FA-DLBCL generally incidental finding histopathological examinations Magnetic resonance imaging showed tumor right adrenal region . Methotrexate-associated lymphoproliferative disorders appear treatment methotrexate immunosuppressive drug . " Ventricle-predominant PCNSL, arising CNS ventricular system, rare entity . In 90% cases, PCNSL classified diffuse large B-cell lymphoma . Rarely, PCNSL may classified marginal zone" " Bendamustine, bifunctional mechlorethamine alkylating agent, used treatment patients hematologic malignancies. Myelosuppression cytotoxic effect arises quite often bendamustine treatment." " Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) largest common category adult lymphoma . Recurrence treatment resistance occurs one-third cases, triggering progressive stage DLBCL treatment ." Follicular lymphoma common type low-grade non-Hodgkin lymphoma second common type lymphoma . Primary extranodal follicular lymphoma rare compared to nodular follicular lymphoma involving gastrointestinal (GI) " Study: Newly diagnosed diffuse large B cell lymphoma (DLBCL) heterogeneous patient characteristics, treatments conflicting results . Study: Study authors report association PET2 outcomes two large independent prospective cohorts ." Polatuzumab vedotin bendamustine rituximab (Pola-BR) approved treatment transplant-ineligible patients relapsed/refractory DLBCL (R/R DLBCL) " Diffuse large B-cell lymphoma (DLBCL) heterogeneous group varied pathophysiological, genetic, clinical features . DLBCL accounts approximately one-third lymphoma cases worldwide . Survival of DLBCL patients remains low" " Standard treatment for primary central nervous system lymphoma (PCNSL) in countries limited resources remains conventional chemotherapy, without whole brain radiotherapy (WBRT)" This study done investigate role Interim 18-FDG-PET/CT (i-PET) predicting outcome of Diffuse Large B Cell Lymphoma (DLBCL) patients . The Lymphoma registry data base Department Ha " 47-year-old man cardiogenic shock due refractory ventricular tachycardia (VT) necessitates intubation, extracorporeal membrane oxygenation (ECMO) Intubation, extracorp" Non-Hodgkin lymphoma mimicked acute leukemia identified pathology records at Brigham Women's Hospital . Aggressive subtypes non-Hodgkin lymphoma may uncommonly referred clinical oncologists treatment acute leukemia . circulating ne Diffuse large B-cell lymphoma (DLBCL) one type highly heterogeneous lymphoid malignancy 30%~40% patients experiencing treatment failure . Novel risk stratification therapeutic approaches urgently needed . " In past 5 years, 3 chimeric antigen receptor (CAR) T-cell therapies, 2 antibody-drug conjugates (ADCs) and 1 exportin-1 inhibitor approved for relapsed refractory (R/R" Currently available anti-CD19 therapies demonstrated particular promise patients relapsed refractory B-cell non-Hodgkin lymphoma . CD19 target diffuse large B-cell non-Hodgkin lymphoma . Non-Hodgkin lymphomas (NHL) represent common hematologic malignancies . Patient-derived xenografts (PDXs) used various aspects translational research including preclinical validation experimental treatment approaches . Anthracycline-based chemotherapy resistance represents major challenge diffuse large B-cell lymphoma (DLBCL) MiRNA gene expression profiles (n = 47) determined uncover potential chemoresistance mechanisms therapeutic approaches . MiRNA- CD19 CAR-T emerged new standard treatment relapsed/refractory (r/r) large B-cell lymphoma (LBCL) outcomes published date suggest significant variability across countries . We provide results large national cohort patients The megalencephaly-capillary malformation (MCAP) syndrome overgrowth disorder caused mosaic gain-of-function variants . MCAP syndrome overgrowth disorder caused mosaic gain-of-function variants . " MYC BCL2 lead abnormal expression oncoproteins, contribute aggressive clinical characteristics double-hit lymphoma (DHL) An effective therapy DHL remains unmet clinical need ." We performed study assess characteristics risk lymphoma large cohort patients systemic lupus erythematosus (SLE) We studied 2 patients . Primary ovarian lymphoma difficult diagnose clinically pathologically due rare incidence non-specific clinical symptoms . CD47 expressed cancer cells enables macrophage immune evasion . Blocking CD47 using anti-CD47 monoclonal antibodies (mAbs) is a promising strategy . Anti-CD47 mAb TJC4 anti-t " CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved use use use of large B-cell lymphomas . Although host inflammatory tumor microenvironmental markers associate efficacy resistance, tumor-" CD47/SIRPα pathway emerging immune checkpoint new therapeutic target . CD47 expression DLBCL various subtypes organs . Relationship CD47 expression genetic alterations analyzed using panel-based massively parallel sequencing (NGS) " A total 117 lesions identified 90 patients enrolled study . 59 (50%) located ileocecal region, 59 (50%) located ileocecal region, 23 (20%) located ileocecal region ." " Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL) is a WHO classification lymphoid neoplasms since 2016 . EBV+ DLBCL, NOS, aggressive B-cell" Metabolic tumor volume (MTV) total lesion glycolysis (TLG) prognostic predictors patients diffuse large B-cell lymphoma (DLBCL) The objective study evaluate prognostic impact baseline volumetric ABO antibodies occur naturally usually exist alloantibodies . They clinically significant cases transfusions . Biopsy revealed diffuse large B-cell lymphoma . Diffuse large B cell lymphoma (DLBCL) common lymphoma adults . Metabolic reprogramming tumors closely related immune microenvironment. Metabolic reprogramming tumors closely related immune microenvironment. " Rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) used treat patients diffuse large B-cell lymphoma (DLBCL)" " CD5 expression different B-cell lymphomas different clinicopathological prognosis value CD5 expression marginal zone lymphoma undefined . Clinicopathological features, survival outcomes marginal zone lymphoma retrospectively analyzed 204 patients ." " Several recently published trials investigate novel therapies relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) To estimate benefit therapies real-world setting, comprehensive data patients treated clinical routine needed ." chimeric antigen receptor (CAR) T cell therapy targeting CD19 shown favorable outcomes . Increasing number of patients waiting receive treatments . Optimized protocols T cell collection lymphapheresis chimeric antigen receptor (CAR) T cell therapy urgently needed " B cell translocation gene 1 (BTG1) protein belongs BTG/transducer ERBB2 (TOB) family antiproliferative proteins . Members regulate various key cellular processes cell cycle progression, apoptosis, differentiation" We previously reported novel haemoglobin-platelet index (HPI) based anaemia thrombocytopenia useful predict prognosis patients with diffuse large B-cell lymphoma otherwise specified (DLBCL NOS) " Maintaining relative dose intensity (RDI) rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) improves prognosis patients diffuse" " There observance increased occurrence of malignant lymphomas patients rheumatoid arthritis (RA) The increased risk lymphoproliferative disorders linked severity RA disease activity, use disease-modifying agents like methotrexate certain genetic" " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma, combination rituximab chemotherapy standard treatment it. Although rituximab monotherapy remarkable response" " Homozygous disruption of SETD2 yields tumor suppressor effect various cancers . However, SETD2 mutation typically heterozygous diffuse large B-cell lymphomas ." " Diffuse large B cell lymphoma (DLBCL) one common yet aggressive types of B cell lymphoma remains incurable 40% patients . Herein, profile transcriptomes 94,324 cells 17 DLBCLs 3 control samples" " MRI features CNS B-cell lymphoma features CNS B-cell lymphoma facilitate early identification disease . They initially diagnosed CNS demyelination, images compared actual patients demyelinating diseases ." " Rasayana therapy, specially designed anti-cancer treatment regimen clinic, was developed in a 51-year-old female patient . Rasayana therapy, specially designed anti-cancer treatment regimen clinic, was successful ." " Long non-coding RNA (lncRNA) new kind RNA length 200 nucleotides . LncRNAs implicate various tumor progression, including tumorigenesis, proliferation, migration, migration, invasion, invasion, metastasis" The central cavitation occasionally seen pulmonary diffuse large B-cell lymphoma may key imaging feature differential diagnoses . The central cavitation occasionally seen pulmonary diffuse large B-cell lymphoma may key imaging feature differential diagnoses . " Natural killer (NK) cells seem common innate lymphocyte subtypes, they're known ability guide anti-tumor anti-viral responses . Since NK cells lack polymorphic clonotypic receptors, must rely inhibitory receptors" " Diffuse large B-cell lymphoma frequently diagnosed type malignant lymphoma . Most patients diffuse large B-cell lymphoma potentially cured current standard chemotherapeutic regimen rituximab, cyclophos ." " Chimeric antigen receptor T cell (CAR-T) therapy achieved remarkable effects refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) However, many patients receiving CAR-T" " DLBCL-NOS primarily arises maxillary sinus rare hard diagnose due unique anatomy . Present case DLBCL-NOS developed left maxillary sinus 72-year-old male, presented severe toothache resembled acute pulp" This phase 1 study aims evaluate tolerability of recommended phase 2 dose selinexor . 105 patients advanced malignancies enrolled two sites Singapore enrolled . Adverse events graded NCI Common Terminology Criteria Adverse Events v 4. " Anti-CD30 CAR-T potent candidate therapy relapsed/refractory (r/r) CD30+ lymphomas therapy limitations, efficacy needed improved . Multi-center phase II clinical trial (NCT03196830)" Chinese diffuse large B cell lymphoma (DLBCL) was studied . The PRDM1 protein expression detected detected immunohistochemistry (IHC) samples . " Muscular dystrophies are a heterogeneous group genetically inherited degenerative disorders . Chimeric antigen receptor (CAR) T-cell immunotherapy lymphoma patients inherited degenerative diseases, muscular dystrophies, previously reported ." High rates relapsed refractory diffuse large B-cell lymphoma (DLBCL) patients life-threatening side effects associated immunochemotherapy make urgent need develop new therapies . Self-assembling polypeptidic nanoparticle Lymphoid enhancer-binding factor 1 (LEF1) transcription factor involved T-cell maturation usually absent mature B cells . Previous studies shown aberrant LEF1 expression sensitive specific marker chronic lymphocytic leukemia/small Chimeric Antigen Receptor T-cell therapy (CART) lacking; preliminary data suggests geriatric assessments cumulative illness rating score may useful tools . Validated metrics optimize older adult patient selection Chimeric Antigen Receptor T " Chimeric antigen receptor (CAR) T cell products available treat relapsed/refractory B-lymphoblastic leukaemia/lymphoma (B-ALL), diffuse large B-cell lymphoma, mantle-" " Axicabtagene ciloleucel (Axi-Cel, 2 × 10) developed decision analysis model . Model developed based data ZUMA-1 SCHOLAR-1 trials ." R-CHOP without radiotherapy standard treatment limited-stage diffuse large B-cell lymphoma (DLBCL) R-CHOP without radiotherapy standard treatment standard treatment . B-cell receptor (BCR) critically contributes development of diffuse large B-cell lymphoma (DLBCL) Little known mechanism regulating BCR expression regulating BCR expression . The purpose case report present case cytomegalovirus (CMV) retinitis patient diffuse large B-cell lymphoma (DLBCL) post-CD19 chimeric antigen receptor (CAR) T-cell therapy . " The heredity malignant blood disorders, leukemias, lymphomas myeloma, far largely unknown . The inheritance non-Mendelian, combination genomic parental imprinting feto-maternal microchimerism" Activated B-cell-like (ABC)-diffuse large B-cell lymphoma (ABC-DLBCL) common subtype non-Hodgkin's lymphoma poor prognosis . Survival ABC-DLBCL MYC expression associates poor outcome diffuse large B-cell lymphoma (DLBCL) MyC promotes neo-vasculature development . Examination relationship may uncover novel pathogenic regulatory circuitry well anti-angiogenic strategies DLBCL Secondary central nervous system lymphoma (SCNSL) associated poor prognosis new therapeutic approaches needed . The pivotal trial led US Food Drug Administration (FDA) approval axicabtagene ciloleucel . Tafasitamab plus lenalidomide (TAFA + LEN) received accelerated US Food Drug Administration approval . The study investigates relative efficacy TAFA + LEN versus comparator treatments . " In March 2021, U.S. Food Drug Administration granted accelerated approval axicabtagene ciloleucel, CD19-directed chimeric antigen receptor T-cell therapy . Treatment adult patients relapsed refractory foll" " Diffuse large B-cell lymphoma (DLBCL) is common subtype non-Hodgkin lymphoma, highly heterogeneous invasive . Majority DLBCL patients show good response rituximab plus cycloph" " Lymphomas breast rare neoplasms arise breast lymphoid tissue characterised neoplastic B T cells . Breast lymphomas arising B cells include, diffuse large B cell lymphoma, follicular lymphoma, extra-nodal" " The MDS Video Challenge continues one widely attended sessions International Congress . We reviewed previous Video Challenge cases present selection cases incorporated imaging findings . We compiled ""imaging pearls"" two anthologies ." " BRD4 is considered major driver cancer cell growth new target cancer therapy . Over 30 targeted inhibitors currently preclinical clinical trials currently preclinical clinical trials significant inhibitory effects various tumors, including acute myelogenous leukemia (AML), diffuse" We present two clinical cases suspected intrathoracic malignancy repeated unsuccessful diagnostic procedures . We present two clinical cases suspected intrathoracic malignancy repeated unsuccessful diagnostic procedures . " The incidence of diffuse large B-cell lymphoma (DLBCL) increases age older DLBCL commonly related poor prognosis . Older DLBCL presented advanced disease stage, elevated serum lactate dehydrogenase, poor performance status" " A 71-year-old male presented bilateral, slowly enlarging, swelling eyelids . Computed tomography scan images showed bilateral symmetric, hyperdense, hyperdense, circumferential masses lacrimal glands occupying orbital" " Diffuse large B-cell lymphoma (DLBCL) common lymphoma subtype . Treatment DLBCL improved greatly recent decades, thousands papers published . We conducted bibliometric analysis literature DLBCL treatment ." A distinct nutritional disturbance linked cancer recognized associated negative outcomes . The aim review integrate current knowledge interactions malnutrition lymphoma address relevant pertinent questions . Assessment host-related factors crucial aspect comprehensive management cancer patients . CD19-directed chimeric antigen receptor T cells (CAR T) approved treatment adults relapsed/refractory diffuse large B cell lymphoma (DLBCL) following at least two lines therapy . This study describes real-world Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma . 30%-40% affected patients develop relapsed refractory disease frequently precludes infamous outcome . New machine learning model " Chimeric antigen receptor T (CAR-T) cell therapy shown substantial efficacy refractory hematopoietic malignancies . However, frequently causes cytokine release syndrome (CRS) treatment-specific adverse event ." " Richter's transformation (RT) occurs chronic (CLL) transforms aggressive lymphoma . Despite improvements treatment CLL, prognosis RT remains poor ." " In pituitary sella, coexistence pituitary adenoma primary pituitary lymphoma is exceedingly rare . Thus far, six cases reported ." Primary pleural lymphoma rare type lymphoma rare type lymphoma accounts ​​0.3% non-Hodgkin's lymphomas . The rarity nonspecific clinical presentation primary pleural lymphomas pose diagnostic challenge clinicians . " In case report, aim describe rare case recurrent diffuse large B-cell lymphoma (DLBCL) in remission . DLBCL recurrence central nervous system (CNS) involvement ." " Kiiacylphnols A-H, eight previously undescribed polycyclic polyprenylated acylphloroglucinols (PPAPs) were obtained . Hypericum przewalski" " Odronextamab hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody binds CD3 T cells CD20 B cells . We aimed evaluate safety antitumour activity o" Targeting PD-1/PD-1/PD-L1/L1/L2 (programmed cell death protein 1/programmed cell death ligand 1/ligand 2) pathway combined immunosuppressive signal " Follicular lymphoma (FL) morphologically clinically diverse, mutations epigenetic regulators alongside t(14;18) identified disease-initiating events . Identification additional mutational entities confirms cancer's heterogeneity, whether mutational data resolved" Patients lymphoma increased risk venous thromboembolism (VTE) Study found patients with diffuse large B cell lymphoma increased risk of venous thromboembolism . The prognosis patients relapsed diffuse large B-cell lymphoma (DLBCL) remains poor current options . Here prospectively evaluated combination pixantrone obinutuzumab six cycles patients relapsed refractory DL " The efficacy salvage treatment diffuse large B-cell lymphoma (DLBCL) patients relapse progress (rrDLBCL) initial therapy limited . Efficacy safety ofatumumab iphosphamide, etoposide cy" Profiling circulating tumor DNA (ctDNA) bloodstream shows promise noninvasive cancer detection . We developed 'epigenetic expression inference cell-free DNA-sequencing' (EPIC-seq) Fbw7 promotes apoptosis diffuse large B-cell lymphoma (DLBCL) Fbw7-mediated ubiquitination Stat3 . This study aimed identify mechanism Fbw7-mediated aerobic glycolysis " The aim study describe clinical presentation, management strategies, outcomes case series primary lacrimal sac tumors . The aim study describe clinical presentation, management strategies, outcomes case series primary lacrimal sac tumors ." The primary diffuse large B-cell lymphoma (DLBCL) uterine cervix is extremely rare . The primary diffuse large B-cell lymphoma (DLBCL) uterine cervix is extremely rare . CAR T cell therapy second relapse relapse diffuse large B-cell lymphoma (DLBCL) shown favorable efficacy clinical trials . Little known health care resource utilization (HCRU) costs CAR T cell therapy patients treated real-world settings . " Kyoto Prognostic Index (KPI) proposed novel prognostic model DLBCL, accurately identify especially high-risk patients . DLBCL patients defined as high-risk patients defined by conventional International Prognostic Index (IPI" " Metabolic tumor volume (MTV) assessed pretreatment 18F-FDG PET/CT shown significant prognostic value across many lymphoma types . MTV assessment reported recent works impact outcome lymphomas, focus Hodgkin lymphoma (HL" " Coxiella burnetii (the causative agent Q fever) pathogenesis B-cell non-Hodgkin lymphoma (NHL) suggested, although supporting studies show conflicting evidence . We assessed whether association present performing detailed" " Tafasitamab Fc-modified monoclonal antibody binds CD19, cell-surface antigen broadly expressed various types B-cell non-Hodgkin's lymphoma (NHL) Antibody-" " In 2022, 100 000 non-Hodgkin lymphoma (NHL) diagnoses expected, yet risk factors confirmed . Data six US-based cohorts (568 717 individuals) used examine body size risk NHL . Over 20 years" 55-year-old female reported 10-month history painless decline vision right eye . Optical coherence tomography revealed hyperreflective nod . " This study aimed to reduce wait times patients refractory relapsed aggressive blood cancer newly gain access treatment access treatment access treatment earlier disease course . Using data from the JULIET clinical trial, first identified number additional patients diffuse large B-" " Loncastuximab tesirine-lpyl (ADC Therapeutics) anti-CD19 antibody-drug conjugate consists anti-CD19 antibody cytotoxic alkylating agent, SG3199" Interleukin-1 receptor-related kinase 4 (IRAK4) plays essential role hyperactive TLR signalling seen B-cell lymphomas . Inhibitors activated B-cell subtype human diffuse large B- Diffuse large B-cell lymphoma (DLBCL) common histologic subtype non-Hodgkin lymphoma (NHL) common histologic subtype non-Hodgkin lymphoma (NHL) Diffuse large B-cell lymphoma (DLBCL) common subtype lymphoma dogs multicentric form . Study aimed assemble 41 variants previously reported genes investigate variants canine DLBCL using Agena MassARRAY platform . " Primary diffuse large B-cell lymphoma bone (PB-DLBCL) rare type extra-nodal lymphoma bone (PB-DLBCL) rare type extra-nodal lymphoma bone . Clinical characteristics," " Four rituximab biosimilars have received regulatory approval European Medicines Agency and/or US Food Drug Administration . CT-P10 first rituximab biosimilar approved agency, 2017 2018, respectively ." We investigated prognostic value pretreatment patient-reported outcomes (PROs) patients . We investigated patients receiving obinutuzumab/rituximab/rituximab plus chemotherapy GOYA phase III study . Limo-domain 2 (LMO2) critical regulator hematopoietic cell development overexpressed T-LL due chromosomal abnormalities . T-LL is aggressive malignancy immature T-cells poor overall survival ( Burkitt's lymphoma gallbladder mimicking gallbladder adenocarcinoma . Malignant lymphoma rare form gallbladder malignancy . Diffuse large B-cell lymphoma (DLBCL) common lymphoid tumor among non-Hodgkin lymphomas (30-40% cases) This type lymphoma characterized significant differences treatment response response response heterogeneity clinical traits " Lymphoma second common malignancy head neck area, affecting nodal extranodal sites, including oral soft hard tissues, usually form non-Hodgkin's lymphoma (NHL) Lymphomas jaws," CD19-directed chimeric antigen receptor (CAR) T cells evolved new standard-of-care treatment for patients relapsed/refractory (r/r) large B-cell lymphoma (LBCL) Report first High-risk large B-cell lymphoma (LBCL) poor outcomes standard first-line chemoimmunotherapy . ZUMA-12 study evaluated axicabtagene ciloleucel (axi- " Steap1 gene expression, function, prognostic value and molecular subtypes cancers investigated . STEAP1 involved functional enrichment of anal anal tumors ." " 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years older underwent therapeutic intervention Tohoku Niigata area Japan retrospectively reviewed . Clinicopathological risk factors poor prognosis investigated elderly" " Primary pancreatic lymphoma (PPL) rare, mimicking pancreatic ductal adenocarcinoma (PDAC) clinically radiologically . The common clinical symptom jaundice, followed abdominal pain, weight loss, diarrhea" A man history chronic lymphocytic leukemia (CLL) remission multiple rapidly growing lumps recent 2 months . FDG PET/CT demonstrated disseminated FDG-avid nodal extranodal lesions including unusual locations nasopharyn 118 cases CD3- CD20-extramedullary leukemias/lymphomas (2.4% 4977 cases) CD45 positive 68% cases . Forty-nine (41%) cases anaplastic " The international prognostic index (IPI) revised IPI (R-IPI) used determine prognosis diffuse large B-cell lymphoma (DLBCL) scoring systems insufficient identify high-risk patients . Recently, prognostic" Diffuse large B-cell lymphoma (DLBCL) characterized clinical molecular heterogeneity . Heterogeneity rarely taken account standard-of-care treatment approaches . New classification systems have been developed based molecular genetic features . Emerging therapeutic agents may " Diffuse large B cell lymphoma (DLBCL) common aggressive lymphoid malignancy, immunosuppressive microenvironment affecting clinical outcome . Interleukin (IL)-13 overexpression observed multiple solid tumors contributes tumor" " High-grade B-cell lymphoma translocations involving MYC BCL2 BCL6, usually referred double hit lymphoma (DHL) aggressive hematological malignance distinct genetic features poor clinical prognosis . Current standard" " High-grade B-cell lymphoma (HGBL) recently introduced category aggressive, mature B-cell lymphomas . Burkitt lymphoma exhibits aggressive course . Leukaemic presentation, though known various types mature B-cell mature" " Serum miR130b overexpressed diffuse large B-cell lymphoma (DLBCL), inducing Th17 cell alterations . miR130b detected quantitative real-time PCR serum samples 532 newly diagnosed DLBCL patients" Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) rare aggressive form mature B-cell lymphoma commonly found elder males . Genetic features poorly understood . 76 PT-DLBCL patients median age 65 ( " We determined first- second-line regimens, including stem cell transplantations, diffuse large B cell lymphoma (DLBCL) patients aged ≥20 yr (n = 1,888), registered Belgian Cancer Registry (2013-2015" " Intravascular large B-cell lymphoma (IVLBCL) rare, clinically aggressive form of large B-cell lymphoma . Despite intravascular location, leukemic phase disease seems uncommon ." Diffuse large B-cell lymphoma (DLBCL) comprises 43% non-Hodgkin lymphomas South Africa due high seroprevalence human immunodeficiency virus (HIV) infection southern African region PET radiomics feature prognosis patients primary gastrointestinal diffuse large B cell lymphoma (PGI-DLBCL) treated R-CHOP-like regimen . 140 PGI-DLBCL patients underwent pre-therapy . A " Most follicular lymphomas show t(14;18)/IGH-BCL2 translocation, rearrangement (R) negative cases exist . A series 140 FL patients BCL2, BCL6, MYC gene" Bruton tyrosine kinase (BTK) inhibitors disrupt BCR signaling disrupt BCR signaling . CG-806 (luxeptinib) dual BTK/SYK inhibitor clinical development hematologic malignancies . In " In last 10-15 years, way treat cancers dramatically changed towards precision medicine approaches . Precision medicine approaches are based on selective targeting signaling pathways critical detrimentally activated cancer cells ." " Central nervous system (CNS) lymphomas rare malignancies characterised lymphoid infiltration brain, spinal cord, cranial nerves, cranial nerves, meninges and/or eyes . Most CNS lymphomas diffuse large B-cell" " DLBCL confirmed bone marrow splenic biopsies . After treatment lymphoma, respiratory fai was found to be a rare case of lymphoma ." " Tumor microenvironment (TME) critical regulator development malignant lymphoma . Therapeutics targeting TME, especially immune checkpoint molecules, changing treatment strategy lymphoma . Overall response therapeutics diffuse large B-cell lymphoma (" Chimeric antigen receptor (CAR) T cell therapy novel therapy patients relapsed refractory hematologic malignancies . Most CAR T cell therapy recipients experience clinical features immune effector cell-associated neurotoxicity syndrome (ICANS Treatment Diffuse Large B Cell Lymphoma (DLBCL) patients rituximab CHOP treatment regimen associated frequent intrinsic acquired resistance . New bispecific fully human fusion protein comprising extracellular domains SIRPα Pituitary insufficiencies usually associated lymphoma pituitary gland . There cases lymphoma originating extra pituitary gland hypopituitarism . There cases lymphoma originating extra pituitary gland hypopituit We compared safety two types devices homogeneous monocentric population diffuse large B-cell lymphoma (DLBCL) patients treated first-line immunochemotherapy . We compared safety two types devices homogeneous monocentric population diffuse large Meta-analysis aimed evaluate prognostic value sarcopenia patients DLBCL . Twelve studies were conducted to assess the prognosis of patients treated with chemotherapy . The current trends lymphoma cases Saudi Arabia long-term survival unknown . The current trends lymphoma cases Saudi Arabia long-term survival unknown . Plasmablastic lymphoma rapidly progressive CD20 negative large cell non-Hodgkin lymphoma poor outcome . It occurs mostly immunocompromised individuals predilection extranodal sites . Cancer immunotherapies aimed support harness patient's immune system recognize destroy cancer cells . Preclinical clinical studies based use use use use use T cells recently NK cells genetically modified chimeric antigen receptors retargeting adoptive cell therapy towards tumor cells " Diffusion large B-cell lymphoma (DLBCL) characterized huge degree clinical prognostic heterogeneity . Currently, urgent need highly specific sensitive biomarkers predict therapeutic response DLBCL ." " Lymphomatosis cerebri (LC) rare variant primary central nervous system lymphoma (PCNSL) It characterized diffuse infiltration atypical lymphoid cells mass formation little contrast enhancement magnetic resonance imaging (MRI) Interestingly," " Diffuse large B cell lymphoma (DLBCL) histological subtype non-Hodgkin's lymphoma, representing approximately 30% . The common primary extranodal sites DLBCL gastrointestinal (GI) tract" " Diffusion large B-cell lymphoma (DLBCL) continues increase era rituximab-containing chemotherapy reigns almost two decades . As mid-2000s, >95% c c was >95% c as" " Cancer cell metabolism including aerobic glycolysis, amino acid fatty acid metabolism, extensively studied . Metabolic reprogramming major hallmark cancer, promotes cancer cell proliferation, progression metastasis, well provokes resistance chemotherapeutic drugs ." " Treatment response diffuse large B-cell lymphoma (DLBCL) heterogenous. Treatment response response diffuse large B-cell lymphoma (DLBCL) heterogenous. Hans algorithm (using 30% cut-offs CD10," " Diffuse large B-cell lymphoma (DLBCL) common lymphoma subtype . Despite proven efficacy combined immunochemotherapy (R-CHOP) majority patients, 40% of DLBCL patients respond relapse consequently poor prog" Gastrosplenic fistula rare potentially fatal clinical entity unknown healthcare providers . Gastrosplenic fistula rare potentially fatal clinical entity unknown healthcare providers . Gastrosplenic fistula arising diffuse large B cell lymphoma 60-year- 46 cases of Diffuse Large B-cell lymphoma abnormally expressed CD5 protein abnormally expressed CD5 protein . MyD88 gene is frequently mutated genes MYD88 . Primary lymphoma concurrent teratoma ovary exceedingly rare . Report first case primary follicular lymphoma concurrent mature ovarian cystic teratoma . GLUT-3 expression levels 91 DLBCL patients evaluated immunohistochemistry . The relationships GLUT-3 expression level clinicopathological characteristics progression-free survival (PFS) DLBCL patients analyzed . The correlation GLUT Anti-CD19 chimeric antigen receptor T cell therapy (CAR19) represents critical treatment modality for patients relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Most patients The primary endpoint overall response rate (ORR) was overall response rate . Autologous stem cell transplantation-ineligible rrDLBCL patients were treated with R 375 mg/m . A previous International Lymphoma Epidemiology (InterLymphoma Epidemiology) Consortium evaluation joint associations five immune gene variants autoimmune conditions reported interactions B-cell response-mediated autoimmune conditions . The endocannabinoid system increasingly implicated pathogenesis progression various human cancers . Increased levels of 2-AG and OEA demonstrated human diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL Non-Hodgkin's lymphoma (NHL) head neck combining clinical medicine pathology pathology rare . Four hundred sixty-one patients NHL head neck region diagnosed histological biopsy retrospectively analyzed . " Jejunocolic fistula, late complication intestinal lymphoma, rare entity five reported cases literature . Young male presenting left lateral neck mass 5 years ago progressed superior vena cava syndrome . Despite radiotherapy two cycles chemotherapy, still tum" " Study examined real-world treatment patterns curative intent, adverse events, health care resource utilization costs . Patients claim LBCL treatment, claim LBCL treatment, and understand unmet medical need ." " Finnish Cancer Registry data histological diagnosis tumor location (2007-2017) cases diffuse large B-cell lymphoma . During 2007-2017, 392 new cases PCNSL reported (195 males, 197 females) The average age-adjusted" Polatuzumab vedotin (PV) antibody-drug conjugate targeting CD79b targeting CD79b approved patients relapsed/refractory large B-cell lymphoma (LBCL) Patients relapse " The standard care treatment strategy patients relapsed refractory large B-cell lymphoma (LBCL) high-dose chemotherapy followed autologous stem cell transplantation (ASCT) chemotherapy sensitive suitable patients . Because treatment intensity," Diffuse large B-cell lymphoma (DLBCL) highly aggressive subtype lymphoma related autoimmune diseases (AIDs) Primary B-cell receptor-mediated AIDs associated poor clinical outcome DLBCL . " There poor prognosis diffuse large B-cell lymphoma (DLBCL) is one common types non-Hodgkin lymphoma (NHL) Through gene expression profiles, study intends reveal potential subtypes among patients DLBC" " Epigenetic reprogramming hallmark lymphomagenesis, however role reshaping tumor microenvironment still well understood . Epigenetic reprogramming hallmark lymphomagenesis, however role reshaping tumor microenvironment still well understood ." Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease defined using number well-established molecular subsets . Application non-negative matrix factorization (NMF) whole exome sequence data previously used identify six distinct Post-transplant lymphoproliferative disease (PTLD) life-threatening complication solid-organ transplantation (SOT) We present incidence outcomes PTLD cohort 5365 SOT recipients 20-year period two UK transplant centres " HIV-associated plasmablastic lymphoma (PBL) treated cyclophosphamide, doxorubicin, oncovin, prednisone (CHOP) chemotherapy . 12-year retrospective clinical chart review" Individuals with HBV infected hepatitis B virus (HBX) infected hepatitis B virus (HBV) infected DLBCL . infected hepatitis B virus (HBX) upregulated expression lncNBAT1 . Upregulation reduced sensitivity DL " This study conducted order study clinical characteristics, prognostic factors, treatment outcomes patients primary central nervous system lymphoma (PCNSL) The data total 5,166 PCNSL patients diagnosed 2000 2018 Surveillance, Epidemiology, End Results (" To assess prognostic value Bcl2 Bcl6 primary cutaneous diffuse large B-cell lymphoma (pcDLBCL) systematic review meta-analysis . Electronic databases searched inception April 2021 studies reporting Bcl2 Bcl6 Tafasitamab (TAF) plus lenalidomide (LEN) novel treatment option patients relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) eligible autologous stem Lung cancer one common causes cancer-related deaths worldwide . During treatment lung cancer patients might develop another malignant neoplasm . Synonymous pulmonary adenocarcinoma leptomeningeal large B-cell lymphoma reported literature Primary choroidal lymphoma usually indolent B-cell lymphoma rarely progresses extraocular sites . Diagnosed with diffuse large B-cell lymphoma (DLBL) progressed brain parenchyma 4 mo. Diagnosed with " Interferon regulatory factor 8 (IRF-8) transcription suppressor functions associations transcription factors, contributing growth differentiation bone marrow cells activation macrophages . IRF-8 expression profoundly affects pathogenic processes ranging infections blood diseases . Inter" We conducted multicenter prospective study whether comprehensive geriatric assessment (CGA) predict adverse events (AEs) chemotherapy elderly patients . Patients aged ≥ 65 years newly diagnosed DLBCL underwent pretreatment baseline CGA consisting of six assessment tools Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma (NHL) common non-Hodgkin lymphoma (NHL) limited-stage DLBCL defined stage Vitreoretinal lymphoma (VRL) subtype diffuse large B-cell lymphoma sight- life-threatening vast majority patients . Lymphoma cells infiltrate vitreous body and/or subretinal space exhibit clinical signs " Parsaclisib, potent, selective, next-generation PI3Kδ inhibitor, shown clinical benefit patients relapsed refractory B-cell lymphoma . We undertook phase Ib study (CITADEL-111)" Primary cardiac lymphomas account 1-2% malignant primary cardiac tumours . Only 197 cases PCL reported 1949 2009 . We studied efficacy safety combined treatment programmed cell death 1 (PD-1) inhibitors anti-CD19 chimeric antigen receptor (CAR) T-cell therapy . Patients relapsed/refractory (R/R) diffuse large B HIV-positive man was diagnosed with 18F-FDG PET/CT metabolic characterization mass pancreas . Histopathological results revealed Epstein-Barr virus (EBV) associated large B-cell lymphoma pancreatitis caused cyt " Platinum-containing therapy standard treatment relapsed Diffuse Large B-Cell Lymphoma (DLBCL) treatment limited drug resistance leading relapse . Cisplatin resistance linked impairments DNA damage response, several DNA repair proteins identified as" " Report incidence malignant hematologic neoplasms oral cavity according experience two oral maxillofacial pathology institutions North Carolina, USA . A 10-year retrospective review carried records patients ECU SoDM UNC Adams SoD." " Thymic cysts rare lesions (1-5% mediastinal masses) and, times, incidental findings . The coexistence lymphoma thymic cyst rare ." " Primary pulmonary lymphoma (PPL) rare clonal lymphoproliferative lung disease . The present study analyzes clinical features, imaging data, pathologic characteristics, treatment, prognosis PPL patients ." " Diffuse large B-cell lymphoma (DLBCL) commonest subtype lymphoma, standard CHOP treatment choice, standard CHOP treatment choice, 42% patients received rituximab, 29% patients lost follow" Concomitant diagnosis non-Hodgkin lymphoma (NHL) acute myeloid leukemia secondary chronic chronic myeloproliferative neoplasms (MPNs) rarely reported . MPNs may second neoplasm " Plasmablastic lymphoma (PBL) aggressive rare variant diffuse large B-cell lymphoma, thought occur immunocompromised individuals, specifically HIV-positive patients . We report case 27-year-old Saudi male P" " Chronic lymphocytic leukemia (CLL) low-grade B cell lymphoma circulating cells, often revealed hyperlymphocytosis . Numerous genetic alterations mutations exist CLL. CLL cells highly dependent b-cell receptor stimulation micro" " Primary central nervous system lymphoma (PCNSL) specific subtype non-Hodgkin lymphoma . PCNSL highly heterogeneous disease, pathogenesis yet fully elucidated . Further studies needed guide individualized therapy improve prog" Patients presented hospital heart-related symptoms . Echocardiography showed massive masses atrium positron emission tomography-computed tomography-computed tomography (PET/CT) revealed hypermetabolism invasiveness . The prognostic importance ABO blood group non-Hodgkin lymphoma largely unknown . We aim investigate prognostic significance blood groups survival diffuse large B-cell lymphoma (DLBCL) patients . 412 people (206 DL Primary Cutaneous B-cell lymphoma (PCBCL) is a primary cutaneous diffuse large B-cell lymphoma . PCBCL is a primary cutaneous follicle centre lymphoma . PCBCL is a primary cut Phase 1b trial evaluated two anti-CD20-based triplet combinations . Patients treated with anti-CD20-based triplet combinations . CXCL chemokines (CXCLs) small cytokines signal proteins secreted cells proven linked to development of many kinds cancer . CXCLs diffuse large B-cell lymphoma (DLBCL) remain studied 50% patients relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) relapse post-autologous stem cell transplant (ASCT) role salvage therapy well defined . " FDG PET/MR compared PET/CT patient cohort including Hodgkins lymphoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, high-grade B-cell lymphoma baseline response assessment ." " Non-Hodgkin's lymphomas group lymphoid neoplasms, diffuse large B-cell lymphoma (DLBCL) common subtype . Genetic alterations involving c-MYC, BCL-2, BCL" A 4-year-old castrated male domestic shorthair cat continuous cough brought private veterinary clinic detailed examination . Radiography thoracic cavity revealed severe radiopaque region caudal lobe right lung . At 108 days initial visit Hodgkin lymphoma (NLPHL) show variable histological growth patterns . Previous studies suggest NLPHL histological variants represent progression forms NLPHL THRLBCL transformation aggressive disease . " 13 cases of primary cutaneous lymphoma associated chronic lymphedema reported international studies . Histopathology showed hyperkeratosis epidermis, acanthosis, significant edema superficial dermis, diffuse mononuclear infiltration der" Borrelia skin lymphomas results controversial . A similar association shown shown shown Helicobacter pylori gastric lymphomas (MALT type) Primary adrenal lymphoma (PAL) rare type non-Hodgkin's lymphoma (NHL) Rare type non-Hodgkin's lymphoma (NHL) Recent reports New England Journal Medicine highlight successful application novel targeted therapies . These findings encourage us pursue mechanism-based therapeutic uses make DLBCL curable era precision medicine . " 3D FDG-PET scans using deep learning approach validate value prognosis . Segmentation performance evaluated six metrics, including Dice similarity coefficient (DSC), Jaccard similarity coefficient (JSC)" " Diffuse Large B-Cell Lymphoma (R/R DLBCL) evolving rapidly due emergence novel drugs, histone deacetylase inhibitors (HDACis) important example ." 72 cases of oral maxillofacial plasmablastic lymphomas (PBL) were reviewed retrospectively reviewed 10-year period . The prevalence PBL 0.6% diagnosed head neck lesions . PBL presented mean age 39 " HIV-negative, immunocompetent elderly male presented painful solitary tender lesion right anterior lateral thigh . A preliminary diagnosis osteomyelitis (right femur) possibly infected dynamic compression plate made following initial ultrasound MRI right lower extrem" Diffuse large-B-cell lymphoma (DLBCL) is common subtype B Cell Non-Hodgkin lymphoma (B-NHL) is one lymphoid malignancies poor prognosis worldwide . Non Molecular biomarker tests inform clinical management genomic heterogeneous hematological malignancies . Available routine care largely depends supporting supporting health economic evidence . Anthracycline-based chemotherapy rituximab recommended first-line treatment . Radiotherapy (RT) considered therapeutic option local disease control patients solitary localized lesions . Patients cancer treated chemotherapy risk cardiovascular toxicity . 96 patients diagnosed with diffuse large B-cell lymphoma received chemotherapy . 96 patients diagnosed with chemotherapy received chemotherapy . " Lisocabtagene maraleucel (liso-cel) autologous, CD19-directed, chimeric antigen receptor T-cell product treatment adult patients relapsed refractory large B-cell lymphoma (" DLBCL is rare rare diffuse large B-cell lymphoma (DLBCL) Vietnam War combat veteran significant Agent Orange exposure untreated hepatitis C infection . " Hypercalcemia variety causes, primary hyperparathyroidism malignancies frequently reported . Hypercalcemia variety causes, primary hyperparathyroidism malignancies frequently reported ." Fever unknown origin (FUO) defined fever higher 38.3ºC at least three weeks . Focal fever is difficult diagnostic challenge carries well 200 differential diagnoses . " Hyperlactemia rare potentially fatal complication hematologic malignancies, well oncological emergency, requires fast diagnosis early therapeutic management . Hyperlactemia rare potentially fatal complication hematologic malignancies, well oncological" " OTUD7B deubiquitinase reported prognostic factor various solid tumors . OTUD7B deubiquitinase reported prognostic factor various solid tumors . However, prognostic value lymphoma patients remains unclear ." Chimeric antigen receptor-modified T cells (CAR-T) targeting CD19 produced high durable response refractory response refractory response refractory relapsed diffuse large B-cell lymphoma . There evidence CRS immune Twenty-six patients identified . The mean age presentation 60.84 ± 13 . Diffuse large B-cell lymphoma (DLBCL) harbors defects proliferation pathway . We performed multiparameter analysis proteins expressed different cell cycle phases correlated clinical parameters head neck DLBCLs . Thirty-nine DLBCL Chimeric antigen receptor T (CAR-T) cell therapy demonstrated promising efficacy several kinds blood cancers . It essential effectively generate potent safer CAR-T cells gene editing technologies immune cell therapy . " The combination atezolizumab, monoclonal antibody targets programmed death-ligand 1 (PD-L1) inhibits interaction PD-L1 receptors . Tazemetostat, EZH2 inhibitor," HIV-related PBL dismal prognosis. The aggressive clinical course disease may lead development rapid-growing swellings . To develop externally validate models incorporating PET radiomics signature (R-signature) obtained cross-combination method predicting survival patients diffuse large B-cell lymphoma (DLBCL) A total 383 patients DLBCL two medical centres Nicaraguan male history treated systemic diffuse large B-cell lymphoma . Cytological analysis vitreous confirmed B-cell lymphoma . Mantle cell lymphoma (MCL) biologically clinically clinically heterogeneous would benefit prognostic biomarkers guide management . Circulating tumor DNA (ctDNA) novel prognostic biomarker diffuse large B-cell lymphoma may applicability M Autologous hematopoietic stem cell transplantation (ASCT chimeric antigen receptor T-cell therapy (CART) salvage therapies utilised treatment relapsed refractory (R/R) diffuse large B- Flow cytometry technology is a new technique to identify lymphoma patients . It is used to identify stage subtype diseases such as lymphoma . 91-year-old woman presented acute pain mandibular region initially suspicious odontogenic abscess . No significant findings seen orthopantomography (OPG) almost complete edentulism made diagnosis abscess unlikely . 54-year-old immunocompetent woman presented primary T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL) central nervous system without systemic involvement . Diagnosed with TCH Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) characterized morphologically numerous small lymphocytes pale nodules composed prolymphocytes paraimmunoblasts known proliferation centers (PCs) Patients CLL undergo " The common symptoms primary gastrointestinal (GI) lymphoma non-specific, nausea, vomiting, diarrhea, diarrhea, weight loss, abdominal pain . The rare acute symptoms include bowel obstruction, intussusception, perforation . Primary small" " Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) infection lead broad spectrum lung diseases, including infectious diseases tumors . Recently, wide application bronchoscopes cytopathology bronchoal" 15 children (15 years above) diffuse large B-cell lymphoma treated MCP-842 protocol reported . Eleven 15 presented advanced (stage-III/IV) disease . At median follow-up 44 months (range: 16 " Diffuse large B-cell lymphoma (DLBCL) highly heterogeneous non-Hodgkin lymphoma, prognosis DLBCL patients widely affected multivariables . X-Tile program divided ferritin three groups" Methotrexate (MTX) folate antagonist often given high doses (≥500 mg/m) All patients receive first cycle HDMTX hospital ensure tolerate well . MYD88/CD79B-mutated (MCD) genotype genetic subgroup diffuse large B-cell lymphoma (DLBCL) co-occurrence MYD88/CD79B-mutated (M " Subcutaneous (SC) rituximab may beneficial terms convenience tolerability, potentially fewer less severe administration-related reactions (ARRs) compared intravenous (IV) form . This report presents results phase IIIb study conducted" " Lymphoproliferative disorder (LPD) shown occur treatment methotrexate (MTX) Currently, MTX-LPD become widely recognized, mechanism prognostic factors remain unclear ." ZUMA-7 trial demonstrated superiority second-line chimeric antigen receptor (CAR) T cell therapy . The ZUMA-7 trial demonstrated superiority second-line chimeric antigen receptor (CAR) T cell therapy standard care chemotherapy " Follicular lymphoma (FL) characterized indolent clinical course high relapse rate, often exhibits diffuse pattern beyond follicular area ." 28-year-old female patient active difficult-to-treat systemic lupus erythematosus (SLE) diagnosed liver-dominant diffused large B-cell lymphoma . A 66-year-old female patient visited hospital goiter dyspnea . Diagnosed diffuse large B-cell lymphoma thyroid core needle biopsy . After c After c After c " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin's lymphoma, hence, comprehensive understanding based gene expression profile imperative . This study aimed identify novel important mutant genes DLBCL central" Small intestine colon (PIC-DLBCL) changed significantly past decades . Treatment modalities primary diffuse large B-cell lymphoma Small intestine colon (PIC-DLBCL) changed significantly past decades . We retrospectively analyzed medical records 308 newly diagnosed patients DLBCL admitted Fujian Medical University Union Hospital January 2011 December 2018 . We studied potential prognostic roles pretreatment plasma D-dimer levels patients DLBCL. " Cancer one greatest threats mankind, associated highest rates morbidity comorbidity . At present, cancer one greatest threats mankind, associated highest rates morbidity comorbidity . Recently, advancements molecular biology led in-depth understanding underlying path" A 68-year-old man presented high fever unknown origin 3 weeks non-productive cough 1 week . A chest computed tomography (CT) scan revealed multiple nodules ground glass opacities (GGO) lungs . After treatment " Few clinical studies reported use of Ibrutinib, covalent Bruton Tyrosine kinase (BTKK inhibitor) in relapsed refractory diffuse large B cell lymphoma (RR DLBCL) Few" " There 100 driver gene mutations patients diffuse large B-cell lymphoma (DLBCL), clinical significance remains unclear . There 100 driver gene mutations patients diffuse large B-cell lymphoma (DLBCL) There 100 driver gene mutations patients" Machine learning developed approach stratify patients DLBCL four subgroups based survival characteristics . Model reliably predicted four survival subgroups validated using independent groups patients . Lymphomas nasal cavity paranasal sinuses (NPS) rare. Lymphomas nasal cavity paranasal sinuses (NPS) rare. Knowledge sinonasal B-cell lymphoma (SNBCL) " Granulocyte-colony stimulating factor (G-CSF) widely used preventing neutropenia, large vessel vasculitis recognized one severe adverse events . 78-year-old woman fever right cervical pain developed administration filgr" Recent first-line randomized controlled trials (RCTs) patients diffuse large B-cell lymphoma (DLBCL) shown negative results . We conducted Delphi-method survey lymphoma experts United States define recommendations essential potentially unnecessary enrollment " 47 classical Hodgkin lymphoma patients, 48 non-Hodgkin lymphoma patients, 48 non-Hodgkin lymphoma patients, 30 healthy controls recruited . The expression inhibitory receptors evaluated using SYBR Green real-" Diffuse large B-cell lymphoma (DLBCL) prevalent subtype non-Hodgkin lymphoma aggressive malignancy tumor growing rapidly organs like lymph nodes . The pathogenesis of DLBCL clear prognosis DL Diffuse large B-cell lymphoma accounts approximately 30% 40% non-Hodgkin's lymphomas . Diffuse large B-cell lymphoma accounts approximately 30% 40% non-Hodgkin's lymphomas HIV-associated cancers are common causes death HIV-infected populations . Acquired immune deficiency syndrome-related lymphoma (ARL) still common condition leading cause HIV/AIDS-related . Diffuse large B-cell lymphoma common histologic subtype non-Hodgkin lymphoma . " Primary central nervous system lymphoma (PCNSL) received attention inferior prognosis . Less known incidence rate, histological type, survival rate PCNSL, especially 2010s ." Chimeric Antigen Receptor T cells (CAR-T) outbreaking treatment option relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Cytokine release syndrome 40% patients diffuse large cell lymphoma (DLBCL) still poor prognosis . DLBCL patients treated with doxorubicin risk cardiac failure . Growing evidence suggests antitumor cardioprotective activity exerted estrogen 183 adults undergoing ATG-free CBT were diagnosed with PTLD in 183 adults undergoing ATG-free CBT . CBT ATG use well-known PTLD risk factor. Little known regarding clinical features PTLD ATG Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma (NHL) common subtype non-Hodgkin's lymphoma (DLBCL) common Oncogene-induced replication stress characterizes many aggressive cancers . Identifying tumors high levels of replication stress remains challenging . Burkitt lymphoma (BL) diffuse large B-cell lymphoma (DLBCL) aggressive B-NHL (B-NHL) aggressive B-NHL) aggressive B-cell non-Hodgkin lymph " R-CHOP immunochemotherapy leads complete remission 60-70% patients remain progression-free 5 years . Given median age 65, relevant disentangle DLBCL therapy influence health care use among survivors ." " Diffuse large B-cell lymphoma (DLBCL) accounts 40% non-Hodgkin lymphoma, 30% 40% patients succumb relapsed/refractory disease (rrDLBCL) Patients rr" " Circulating tumor DNA (ctDNA) assessment sensitive, potentially prognostic tool setting . We assessed baseline ctDNA identify patients R/R DLBCL high risk relapse receiving polatuzumab vedotin bendamustine" Diffuse large B-cell lymphoma (DLBCL) represents common form non-Hodgkin lymphoma (NHL) still incurable large fraction patients . Tetraspanin CD37 highly expressed mature B lymph Polatuzumab (Pola)-based regimens chimeric antigen receptor T (CAR T) cells provide superior outcome compared conventional chemoimmunotherapy patients relapsed/refractory diffuse large B cell lymphoma (R Hypersensitivity pneumonitis (HP) interstitial lung disease resulting immune-mediated response susceptible sensitized individuals various inhaled antigens environment . Imaging diagnosis usually based high-resolution CT findings . Diffuse large B cell lymphoma common type lymphoma common type lymphoma common type lymphoma . Diffuse large B cell lymphoma common type lymphoma common type lymphoma . The tumor microenvironment rich immune response either T cells mac Human immunodeficiency virus (HIV) infection predisposes patients development lymphomas . Coinfection human herpesvirus 8 (HHV8) particular associated development aggressive lymphomas . DLBCL extensive cardiac involvement diagnosed diagnosed autopsy " Cyclin-dependent kinase 12 (CDK12) transcription-associated kinase participates various cellular processes . However, regulatory role progression diffuse large B-cell lymphoma (DLBCL) is still controversial ." Diffuse large B-cell lymphoma (DLBCL) common type lymphatic tumor . Extranodal DLBCLs exhibit initial symptoms maxilla mandible rare . DLBCL clinically classified moderate highly malignant lymphatic " Primary cutaneous B-cell lymphoma (PCBCL) rare neoplasm . It believed antigenic stimulation chronic inflammation basis pathogenesis . PCBCL arising surgical scar, particular, inguinal hernioplasty ." " Somatic point mutations FOXO1 transcription factor reported non-Hodgkin lymphoma including diffuse large B-cell lymphoma, follicular lymphoma Burkitt lymphoma . These alterations associated poor prognosis resistance therapy ." " Diffuse large B-cell lymphoma (DLBCL) common hematological malignancy . Half patients DLBCL achieve long-term remission, majority remaining patients succumb disease . Normal iron homeostasis implicated carcinogenesis progression" " Selinexor novel, oral drug approved treat patients relapsed/refractory DLBCL . Despite number treatment options, patients diffuse large B-cell lymphoma (DLBCL) whose disease become refractory treatment poor" Diffuse large B-cell lymphoma (DLBCL) prevalent subtype non-Hodgkin's lymphoma (NHL) accounting 30% adult NHL worldwide . DNA damage Myc-induced transformation well-known contributing " Non-Hodgkin's lymphoma (NHL) children young adolescents Netherlands since 1990 . NHL subtypes comprised lymphoblastic lymphoma (LBL), Burkitt lymphoma (BL), diffuse large B-cell lymphoma" " Cancer risk elevated patients with inflammatory bowel disease (IBD) A comprehensive investigation cancer risk older patients (≥66 years age) needed, understudied population high risk ." Chidamide ability enhance sensitivity rituximab-resistant tumors . Chidamide ability enhance sensitivity rituximab-resistant tumors . Centromere protein U ( We performed pan-cancer analysis evaluate role of Centromere protein U . Centromere protein U ( We performed pan-cancer analysis evaluate role . Results of pan-cancer analysis demonstrated . The outcome patients large B cell lymphoma (LBCL) respond to classical immunochemotherapy regimen time relapsed within 1 year following chemoimmunotherapy poor . The Scholar-One-Study showed long-term event-free " B-cell non-Hodgkin lymphomas (B-NHLs) highly heterogenous genetic, phenotypic, clinical appearance . B-NHLs may contribute poor outcome diseases, suggesting personalized precision-medic" Lympho plasmacytoma distinct type diffuse large B cell lymphoma predominantly seen HIV-positive patients . Lympho plasmacytoma distinct type diffuse large B cell lymphoma predominantly seen HIV-positive patients . " Cox proportional hazard regression (CPH) model relies proportional hazard (PH) assumption: hazard variables independent time . CPH widely used identify prognostic markers transcriptome. However, comprehensive investigation PH assumption transcriptomic data lacked. The whole transcript" Diffuse large B-cell lymphoma (DLBCL) complex invasive tumour occurs mainly among elderly . We analysed relationship ageing-related genes (AG) DLBCL prognosis . Diffuse large B cell lymphoma (DLBCL) common hematological malignancy adults adults . Ferroptosis iron-dependent programmed cell death caused cell death caused lipid peroxidation . Potential functions ferroptosis " The FDA approved new type antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), called ADCT-402, April 23, 2021, relapsed refractory" Splenic lymphomas primary splenic angiosarcoma (PSA) 2 common histological types splenic cancers . Study aimed investigate clinical characteristics survival outcomes patients splenic lymphomas PSA . " Genomic analyses immensely advanced conception of diffuse large B cell lymphoma (DLBCL) In review, summarize current knowledge biology DLBCL complexity discuss potential implications precision medicine ." " There are currently four chimeric antigen receptor (CAR) T cell products approved . These products differ construct, indication, manufacturing, clinical trial design, toxicity profile, and toxicity profile . Encouraging early data also emerging use of products additional" " Non-Hodgkin lymphomas hypothalamus pituitary rare . They usually remain clinically silent onset compressive features affecting surrounding structures . Patients commonly present diabetes insipidus, headaches, ophthalmoplegia and/" " Pixantrone novel aza-anthracenedione antineoplastic activity, currently approved multiply relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Even real-life data limited." Intravascular large B-cell lymphoma (IVLBCL) rare form large B-cell non-Hodgkin lymphoma . The diagnosis challenging frequently made biopsy. " Diffuse large B cell lymphoma (DLBCL) successfully treated combination immuno-chemotherapy, relapse resistant disease occurs ~ 40% patients . Little known regarding relapsed/refractory DLBCL (rrDLBC" " Positron emission tomography/computed tomography (PET/CT) used staging lymphomas . Modern imaging software exact measures total metabolic tumour volumes (tMTV) determined, semi-fully-automated manner ." Diffuse large B-cell lymphoma (DLBCL) type non-Hodgkin Lymphoma commonly presenting solid tumor either nodal extra-nodal manifestations . " Lymphomas global challenge many decades despite measures prevention management, incidence continues increase . Non-Hodkin's Lymphomas Hodgkin's Lymphomas Hodgkin's Lymphomas common etiologies environmental, genetic alteration, radiation" " 80-year-old patient had back pain associated pathological T9 fracture . Spinal cord compression paraparesis detected detected managed radiotherapy . Primary bone lymphoma uncommon malignancy, responsible 3% bone tumors ." " EZH2-Y641 gain-of-function mutation one significant diffuse large B-cell lymphoma (DLBCL) Activating mutations EZH2 promote cell proliferation, tumorigenesis, metastasis ." Chimeric antigen receptor T (CAR-T) cells targeting CD19 result durable responses approximately 40% DLBCL patients . We evaluated outcomes 13 DLBCL patients relapsed CAR-T cells treated loncastuximab " Limited information exists regarding inpatient treatment patterns, outcomes, resource-use, costs perspective third-party payers Germany . The aim study collect evaluate routine inpatient care data fill aforementioned gaps ." CT imaging findings of diffuse large B cell lymphoma (DLBCL) mucosa-associated lymphoid tissue (MALT) lymphoma thyroid gland . This study included 18 patients who had been diagnosed with primary thyroid lymphoma . Long noncoding RNAs (lncRNAs) crucial functions tumorigenesis metastasis cancers . N. N. N. N. N. N. N. N. N. N. N. N. N. " This open-label, phase 1b study assessing safety, tolerability, preliminary efficacy pharmacokinetics combination atezolizumab obinutuzumab . Combination may enhance recruitment innate adaptive immunity effective CD20+ B" The objective review identify sources variability cost-effectiveness analyses chimeric antigen receptor T-cell (CAR-T) therapies . The objective review identify sources variability cost-effectiveness analyses chimeric antigen receptor T-cell (CAR-T No head-to-head trials compared efficacy tisagenlecleucel vs historical treatments . This study indirectly compared overall survival (OS) overall response rate (ORR) associated tisagenlecleucel . " Hepatitis B virus (HBV) infection associated increased risk B-cell lymphomas . Here, showed 24% follicular lymphoma (FL) Chinese patients HBsAg+. Compared HBsAg- FL patients, HBs" " Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) primary cutaneous follicle center lymphoma diffuse population large cells (PCFCL-LC) primary cutaneous follicle center lymph" MicroRNAs (miRNAs) participate comprehensive biological process several cancer types . MicroRNAs (miRNAs) participate comprehensive biological process several cancer types . There studies comparing prognosis mature T-cell lymphoma (TCL) people HIV (PWH) people without HIV (PWH) people without HIV (PWoH) AIDS-defining B-cell lymphomas (A We modeled clinical course cohort of diffuse large B-cell lymphoma (DLBCL) patients prior cardiovascular diseases (CVDs) using multistate modeling framework . Data 2600 patients DLBCL diagnosed with DLBCL diagnosed 2000 PCBCLs group Non-Hodgkin's B-cell lymphomas . They group Non-Hodgkin's B-cell lymphomas originating usually confined skin . PCBCLs represent approximately one fourth primary cut " A 54-year-old man complained growing nodule left upper arm, diagnosed diffuse large B-cell lymphoma . After chemotherapy, restaging scan showed complete remission involved lesions except increased activity prior surgical site ." Not patients eligible CAR-T given relatively high risk complications limited availability . Here discuss promising novel biologic therapies introduced last years go ongoing clinical trials field . " SUMOylation post-translational modification proteins regulates proteins' localization, turnover function . Aberrant SUMOylation frequently found cancers origin remains elusive ." We report 18F-FDG 68Ga-DOTA-FAPI-04 PET/CT findings breast lymphoma 60-year-old woman . Primary breast lymphoma rare form extranodal lymphoma rare form extran " Diffuse large B-cell lymphomas (DLBCL) broadly dependent anaplerotic metabolism regulated mitochondrial SIRT3 . SIRT3 depletion led ATF4 downregulation cell death, rescued ectopic ATF4 expression ." Cervical thymoma rare thymic epithelial neoplasm . Evidence supports increased risk second primary malignancies patients thymoma . 70% of patients large B-cell lymphoma (LBCL) treated axicabtagene ciloleucel (axi-cel) achieve partial response (PR) stable disease (SD) day 30 (D " In issue issue of the American Rifle Rifle Association, the NRA is featured in a new book, ""The Rifle Rifle Association"" The NRA is featured in a new book, ""The Rifle Rifle Association""" " Diffuse large B cell lymphoma (DLBCL) spindle cell morphology rare variant seen extranodal regions . Because spindle cell dominant morphology lymphoma extremely unusual, diagnosis easily missed many organ systems ." " Secondary central nervous system large B-cell lymphoma (SCNSL) rare, generally poor prognosis . There limited data role autologous stem cell transplantation (ASCT) high-risk patients . We explored study treatment outcomes" " An 84-year-old man presented dysphagia 20 days . Gastric diffuse large B-cell lymphoma gastric adenocarcinoma . After 4 courses chemotherapy, except lesion biopsy-proven gastric ad" " Chimeric antigen receptor T (CAR-T) cells show good efficacy treatment relapsed refractory B-cell tumors, acute B-cell leukemia (ALL) diffuse large B-cell lymphoma (DLBCL) The" Zanubrutinib second-generation Bruton's tyrosine kinase inhibitor . Its safety effectiveness central nervous system (CNS) lymphoma along distribution brain ability cross blood-brain barrier (BBB) remain unknown . " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma worldwide . However, still limited information expression programmed cell death ligand-1 (PD-L1), type 1 trans" Treatment CD19 chimeric antigen receptor (CAR) T cells innovative therapeutic approach . Patients relapsed/refractory diffuse large B cell lymphoma (r/rDLBCL) B-lineage acute lymphoblastic leukemia ( " There 218 eyes 127 patients isolated VRL confirmed presumed diffuse large B-cell subtype absence known known known CNS systemic lymphoma . 52 (40%) male, 118 (90%) Caucasian, 52 (40%) male, 118 (90" Anti-CD19 chimeric antigen receptor (CAR)-T therapy inducing serious neurotoxicity patients diffuse large B-cell lymphoma (DLBCL) recognized . We report exceptional presentation acute myelopathy refractory DLBCL following " Cardinal B-Symptoms obstipation constituted presentation patient diagnosed postoperatively case primary non-metastatic NHL . Adolescent population among rarest compromised groups, especially males ." Circulating tumor DNA (ctDNA) emerging versatile biomarker noninvasive genotyping response monitoring specific B-cell lymphomas . Studies conducted explore ctDNA-based mutation profiling across non-Hodgkin lymphomas ( " Epstein-Barr virus-infected B cells found high frequency peripheral T cell lymphoma . After chemotherapy, T cell lymphoma population decreased, B cell population expanded form EBV-positive di ." Studies comparing efficacy safety R-CHOP modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-90 (NHL-BFM-90) regimens children adolescents diffuse large B-cell lymph Extranodal natural killer/T-cell lymphoma (ENKTL) diffuse large B-cell lymphoma (DLBCL) belong different subtypes non-Hodgkin's lymphoma . Appropriate biomarkers " Prophylactic high-dose methotrexate (HD-MTX) often used in patients high risk of relapse . Despite limited evidence demonstrating efficacy, there is no evidence of optimal delivery method ." " Activated phosphoinositide 3-kinase 3-kinase δ syndrome (APDS) autosomal dominant primary immunodeficiency caused acquired gene function mutation (GOF) APDS variety clinical phenotypes, particularly recurrent" The study was published in CMAR journal CMAR journal . It retracts article to retract article . Chronic lymphocytic leukemia (CLL) remains area unmet need patients progress novel therapies . The development cellular therapies CLL hindered CLL induced immunosuppression . Recent progress various methods immunomodulation may help overcome limitation C BCL6 is an oncogenic driver diffuse large B cell lymphoma 6 (BCL6) oncogenic driver diffuse large B cell lymphoma (DLBCL) mediates lymphomagenesis transcriptional repression target genes " Intravenous high-dose methotrexate (HD-MTX) recommended CNS prophylaxis, optimal timing dose elucidated ." A 54-year-old man presented profound obstructive shock . Investigations revealed right atrial mass causing severe right ventricular inflow obstruction . The patient treated emergency balloon catheter intervention relieve obstruction . " Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) relatively rare malignancy, optimal approaches diagnosis management ." " In diffuse large B-cell lymphoma (DLBCL), bone marrow involvement (BMI) important clinical implication component staging International Prognostic Index . Study aimed determine whether molecular analysis immunoglobulin heavy chain (IgH" " The oncofetal protein insulin-like growth factor 2 mRNA binding protein-3 (IMP3) expressed various cancers . In study, examined diagnostic utility IMP3 immunohistochemistry context intravascular large B-cell lymph" " Diffuse large B-cell lymphoma (DLBCL) molecularly clinically heterogeneous, clinically heterogeneous, subtyped according genetic alterations, cell-of-origin, microenvironmental signatures using high-throughput genomic data" " DCDS0780A, anti-CD79B ADC THIOMAB technology (TDC) consistently conjugates two anti-neoplastic molecules per antibody . This phase 1 study enrolled 60 patients with B-NHL" Recent studies investigated role Helicobacter pylori infection development gastric mucosa-associated lymphoid tissue (MALT lymphoma) It estimated approximately 0.1% people infected H. pylori develop gastric MALT lymph The aim study evaluate prognostic relevance early risk stratification DLBCL develop new stratification system combines interim evaluation IPI. The baseline International Prognostic Index (IPI) sufficient initial risk stratification patients diffuse large B-cell " We aim review radiological findings case DLBCL treated ibrutinib, important tyrosine kinase inhibitor used lymphoid neoplasias . Herein, present case systemic aspergillosis fatal outcome case case" " Plasmablastic lymphoma rare B-cell lymphoma is linked to immunocompromised patients . Cases documented affect gastrointestinal tract, those, three cases found involve esophagus ." " Absolute count circulating monocytes proposed independent prognostic factor diffuse large B-cell lymphoma (DLBCL) Monocyte nomenclature includes various subsets pro-, anti-inflammatory, suppressive functions, clinical relevance DLBCL" 72-year-old man referred to urology outpatient department for hemi-scrotal swelling . Initial investigation found heterogenous enlargement left testis epididymis soft tissue mass extending inguinal canal . CT detected soft " An 18-year-old woman presented progressive oesophageal dysphagia, weight loss night sweats 6-month period . Oesophagogastroduodenoscopy revealed diffuse luminal narrowing normal mucosa . A" " The multicohort, phase 1 KEYNOTE-155 study evaluated safety antitumor activity PD-1 inhibitor pembrolizumab plus CDK9 inhibitor dinaciclib . The study evaluated safety antitumor activity PD" 77-year-old man reported 5 months syncopal episodes . He found diffuse large B-cell lymphoma encasing left internal carotid artery impeding blood flow . Recurrent syncope non-cardiac lymphomas are exceedingly " Primary bone lymphoma (PBL) rare distinct clinicopathological disease, usually occurring pelvis, spine, ribs . To date, cases reported beginning patella ." Plasmablastic lymphoma (PBL) represents rare aggressive subtype diffuse large B cells lymphoma (DLBCL) associated human immunodeficiency virus (HIV) Prognosis remains poor despite various treatment approaches . " Diffuse large B-cell lymphoma (DLBCL) heterogeneous group large lymphoid B cell malignancy distinct clinical genetic features . Recently, the disease has been identified as a cancerous cancerous lymphoma ." B-cell non-Hodgkin lymphoma (B-NHL) evolution treatment complicated high prevalence relapses . Malignant B cells interact tumor-supportive lymph node (LN) bone marrow (BM) microen " Histone deacetylases (HDAC) clinically validated attractive epigenetic drug targets human cancers . Several HDAC inhibitors approved cancer treatment date, however, clinical applications limited due poor pharmacokinetics, bioavailability, selectivity HDAC" 60 patients high-risk lymphoid malignancies underwent 2-step allo-HCT 2008 2020 . Majority patients received haploidentical stem cell grafts (82%) Majority patients received haploidentical stem cell grafts Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment shifting long short treatment duration . Still unclear whether shortening treatment duration cause harm . TP53 disruption established diffuse large B-cell lymphoma (DLBCL) TP53 disruption established diffuse large B-cell lymphoma (DLBCL) TP53 mutated 11/125 (9%) cases; 60/125 patients Axicabtagene ciloleucel (AC) FDA-approved anti-CD19 autologous chimeric antigen receptor T-cell (CAR-T) therapy refractory diffuse large B cell lymphoma (DL 81-year-old patient treated chemotherapy for chemotherapy adrenal gland diffuse large B-cell lymphoma . Primary Sjögren's Syndrome (pSS) carries highest risk non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases . Study reassively analyzed 121 patients diagnosed with NHL according 62-year-old woman diagnosed diffuse large B-cell lymphoma . Diagnosed with diffuse large B-cell lymphoma . Enzymes TET family methylcytosine dioxygenases undergo frequent mutational functional inactivation human cancers . Recurrent loss-of-function mutations TET proteins frequent human diffuse large B cell lymphoma (DL Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma five-year survival 60%-70% chemoimmunotherapy consisting R-CHOP combination (ritux " The treatment landscape of diffuse large B-cell lymphoma (DLBCL) recently changed . Adult patients diagnosed DLBCL received ≥ 3L January 1, 2014 selected COTA database ." " Diffuse large B-cell lymphoma (DLBCL) is common lymphoma subtype, localized 25% 30% patients . Prognosis patients limited-stage DLBCL (LS-DLBCL) excellent 10-" Inadequate molecular clinical stratification patients high-risk diffuse large B-cell lymphoma (DLBCL) clinical challenge hampering establishment personalized therapeutic options . We studied translational significance liquid biopsy uniformly treated trial cohort . Pretreatment There scarcity data India impact cell origin (COO) outcomes diffuse large B-cell lymphoma (DLBCL) There scarcity data India impact cell origin (COO) outcomes diffuse large B-cell lymphoma (DLBCL The objective review assess efficacy safety of lenalidomide monotherapy patients . Patients were patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) Patients were evaluated for efficacy and In Pakistan 76.4% NHLs diagnosed DLBCLs . The survival R-CHOP better compared DA-REPOCH treatment regimen . " Bing-Neel syndrome (BNS) remains rare complication Waldenstrom Macroglobulinemia . Given paucity disease, treatment guidelines based small clinical trials limited participants . Here, present case primary CNS diffuse large B" " Research looked at 1,495 documents, compiled whole-exome sequencing data several studies . Created data set including 92 observations RRDLBCL (Relapsed refractory diffuse large B-cell lymphoma)" Cancer-secreted exosomes recognized indispensable mediators exchange cargo cancer immune cells . M2-phenotype tumor-associated macrophages function promoting tumor progression drug resistance . " Diffuse large B cell lymphoma (DLBCL) aggressive malignancy traditionally treated anthracycline-based chemotherapy . We describe 5 CD19-targeted therapies, 3 chimeric antigen receptor (CAR)-T cell" " Primary female genital system lymphoma (PFGSL) infrequent entity . All genital organs may affected, PFGSLs localized cervix, uterine body, ovaries . The clinical manifestations nonspecific, complicates timely diagnosis" " CD19 CAR-T cells (Yescarta® Kymriah® Breyanzi®), approved relapsed refractory diffuse large B cell lymphomas (DLBCL) at two previous lines therapy . These immunother" CAR-T Cells opened new doors cellular immunotherapies . CAR-T Cells opened new doors . CAR-T Cells benefited accelerated approval procedure many countries . Ferroptosis regulators markers downloaded FerrDb database . Transcriptome profiling data collected cancer genome atlas (TCGA) Transcriptome data corresponding clinical information DLBCL downloaded . Signal transducer activator activator transcription 3 (STAT3) transcription factor candidate therapeutic option human cancers . But underlying mechanism STAT3 pathogenesis diffuse large B-cell lymphoma (DLBCL) yet established . " Gastric diffuse large B-cell lymphoma (DLBCL) often associated Helicobacter pylori infection . Early stage could treated H. pylori eradication therapy, classified sensitive group resistant group . MiRNAs targets" Plasmablastic lymphoma (PBL) increasingly described extra orally non-HIV-infected persons . Study comparatively analysed clinico-pathologic features oral PBLs (n = 55) and previously published extra-oral " Loncastuximab tesirine-lpyl (ADC Therapeutics) anti-CD19 antibody-drug conjugate, recently approved treatment . Preclinical data demonstrated selectivity efficacy drug vitro vivo models ." Study evaluated association breast cancer incidence NHL . Estrogen protective function lymphomagenesis . Estrogen protective function lymphomagenesis . " Tumor-infiltrating immune cells prognostic significance attractive therapeutic targets . Yet, clinical significance of diffuse large B-cell lymphoma (DLBCL) unclear . We characterized T cells, macrophages, spatial interactions" Frailty significant risk factor poor outcomes among older patients . We present automatically derived electronic frailty screening tool (FRAIL score) predictor patient outcomes . " Lymphomas represent around 10% head neck neoplasms, among diffuse large B-cell lymphoma (DLBCL) common histologic subtype . Lymphomas represent around 10% head neck neoplasms, among diffuse" " Diffuse large B-cell lymphoma (DLBCL) typically treated rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" Tisagenlecleucel anti-CD19 chimeric antigen receptor T-cell therapy approved diffuse large B-cell lymphoma at two treatment lines . We conducted international phase 3 trial involving patients aggressive lymphoma refractory progressing Bimiralisib orally bioavailable pan-phosphatidylinositol 3-kinase mammalian target rapamycin inhibitor shown activity lymphoma preclinical models . 50 patients enrolled started treatment . Patients treated median 5 prior lines " We present rare case PTL 57-year-old female patient . She presented worsening orthopnoea hoarseness, followed shortness breath, followed shortness breath, followed shortness breath, resulting pulmonary edema cardi" " MicroRNAs (miRNAs) regulate gene expression altering epigenetic status candidate genes . In various cancers, miRNAs regulate gene expression altering epigenetic status candidate genes ." Chromobox (CBX) family proteins classical components polycomb group (PcG) complexes many cancer types . Diffuse large B-cell lymphoma (DLBCL) main pathological type non-Hodgkin lymph " HHV-8 oncogenic Gammaherpesvirinae discovered 1994 HIV pandemic . Cited as cause of Kaposi's sarcoma, also associated occurrence several aggressive B lymphoproliferative disorders . Most occur immun" We developed integrated population pharmacokinetic model investigate loncastuximab tesirine pharmacokinetics (PK) exposure-response relationships relapsed/refractory B cell non-Hodgkin lymphoma . The " Smoothened (SMO), Frizzled-class-G-protein-coupled receptor, central transducer hedgehog (Hh) signaling . Evidence suggests SMO functions cancer biology unrelated canonical Hh signaling" " At present, the world's largest city is in the form of a city in New York City ." " Sarcopenia considered poor prognostic factor several oncological diseases; however, promising results lymphoma available . Sarcopenia considered poor prognostic factor several oncological diseases; however, promising results lymphoma available ." The prognosis patients early relapsed refractory large B-cell lymphoma receipt first-line chemoimmunotherapy poor . DCZ0014 significantly inhibited proliferation activity DLBCL . DCZ0014 is a novel chemical similar berberine . Aggressive B-cell lymphoma heterogeneous entity disparate outcomes based clinical pathological characteristics . Recognition cases high-grade morphology frequently harbor MYC BCL2 and/or BCL6 translocations led separate categorization . " Long non-coding RNAs (lncRNAs) involved various human cancers development, including diffuse large B-cell lymphoma (DLBCL) In particular, lncRNA HAGLROS reported associated several types cancer" The aim study stratifies 33 canine gastrointestinal lymphoma samples according latest World Health Organization classification . Gastrointestinal lymphomas uncommon dogs little known distinct subtypes proliferation rate. Gastrointestinal lymphomas uncommon dogs little known distinct subtypes proliferation rate Anti-CD19 chimeric antigen receptor T-cell therapies shown striking clinical activity diffuse large B-cell lymphoma robust biomarkers predictive responsiveness still needed . " Aim study investigate whether anesthesia promoted relapse dogs diffuse large B-cell lymphoma (DLBCL) Medical records searched dogs DLBCL, complete remission (CR) chemo-immunotherapy protocol . Dogs receiving anesthesia included procedure performed" " The ""Hodgkin-like"" lymphomas include classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte rich large B cell lymphoma, primary mediastinal large B" " Diffuse large B-cell lymphoma (DLBCL) is common malignant proliferative disease lymphatic system . The international prognostic index (IPI) includes age, lactate dehydrogenase (LDH), number ext" " The liver primary site lymphoma rarely seen, usually misdiagnosed hepatocellular carcinoma . DLBCL (62.1%) common subtype. DLBCL (62.1%) common subtype." Chryseobacterium species recognized emerging opportunistic bacterial pathogen nosocomial settings especially debilitated immunosuppressed patients neonates . The ubiquitous distribution nature of the ability form biofilms inherent resistance broad-spectrum " CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel axicabtagene ciloleucel, associated improved outcomes . Cytopenias observed clinical trials products; however, little" " Diffuse large B cell lymphoma (DLBCL) is common type non-Hodgkin lymphoma worldwide, aggressive highly heterogeneous . MiR-665 found lowly expressed serum exosomes DLBCL patients DLBC" " Exosomal microRNAs (miRNAs) potential biomarkers variety tumors, yet studied diffuse large B-cell lymphoma (DLBCL) Here, investigated use exosomal miRNAs to diagnose DLBCL diagnosis" " Diffuse large B-cell lymphoma (DLBC) kind tumor rapid progress poor prognosis . Therefore, necessary explore new biomarkers therapeutic targets . This study aimed screening hub genes weighted gene coexpression network analysis (WGCNA)" Chimeric antigen receptor T-cell (CAR-T) therapy revolutionized management patients diffuse large B-cell lymphoma (DLBCL) refractory relapse immunochemotherapy . This strategy consists genetically modifying patient's T lymph " Chimeric antigen receptor (CAR) T-cell therapy effective treating relapsed refractory B-cell non-Hodgkin lymphoma . However, mortality risk associated immune effector cell-associated neurotoxicity syndrome pseudop" " Use of 18F-FDG PET/CT to establish diagnosis RT patients CLL, use 18F-FDG PET/CT exclude RT cause clinical deterioration patients CLL severe COVID-19 . A 61-year-old" " We compared outcomes patients B-cell malignancies treated clinical trials with CD19 chimeric antigen receptor (CAR) T-cells . We found given CAR T-cell, efficacy toxicity varied depending disease ." " Primary thyroid lymphoma (PTL) rare malignancy, literature limited small case series case reports . We analyzed 2215 PTL patients Surveillance, Epidemiology, End Results database medical records ." " Primary central nervous system-diffuse large B-cell lymphoma (PCNS-DLBCL) rare, extranodal malignant lymphoma carrying poor prognosis . The prognostic impact tumor microenvironment (TME)" Lymphoma third common pediatric neoplasm. Lymphoma third common pediatric neoplasm. In U.S. close 2000 new lymphoma cases diagnosed children every year. " Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) known distinct clinical features . The frequency EBV-positive DLBCL among DLCBL 2.5–14.0%, higher" " To investigate diffuse large B-cell lymphoma lesions central nervous system (CNS) involvement patients vitreoretinal lymphoma (VRL) long-term clinical courses . Seventy-one patients participated study, 45 newly diagnosed VR" Diffuse large B-cell lymphoma (DLBCL) aggressive malignancy arising germinal center post-germinal center B-cells retain many properties normal B-cells . Here show subset DLBCL express cytok Aggressive non-Hodgkin's lymphomas (NHL) refractory standard chemotherapy rarely reported . Few groups aggressive non-Hodgkin's lymphomas (NHL) refractory standard chemotherapy rarely reported . Forty-six untreated elderly patients PI-DLBCL included retrospective study . Twenty-four patients treated surgery (prior chemotherapy) plus chemotherapy (SCT) Twenty-four patients treated surgery (prior chemotherapy) plus chemotherapy (S Cutaneous B-cell lymphomas heterogeneous group rare malignancies whose specific site tropisms site-specific survival well documented . Study seeks to investigate frequency survival of primary secondary cutaneous MZL (pcMZL scM Epstein-Barr virus (EBV) is an important pathogenic factor lymphoma . Circular RNAs (circRNAs) play essential role lymphoma progression . CircRNA screened high-throughput sequencing tumor samples 12 patients DL Machine learning classifier Gradient Boosting achieved best discrimination perfo . Machine learning classifier Gradient Boosting achieved best discrimination perfo . Extra-nodal lymphoma accounts 30-50% non-Hodgkin lymphoma . Cases of cases diffuse large B-cell lymphoma (DLBCL) type are rare . We aimed assess association multimorbidity deprivation short-term mortality among patients diagnosed with diffuse large B-cell (DLBCL) follicular lymphoma (FL) England . We linked English population-based cancer registry electronic health records " Plasmablastic lymphoma (PBL) uncommon aggressive type mature B cell lymphoma rarely involving gastrointestinal (GI) tract . Here, describe case PBL involving colon HIV/Epstein-Barr virus negative immunocompet" " 15-year-old girl diagnosed diffuse large B-cell lymphoma (DLBCL) right breast . Patient received chemotherapy rituximab, achieving complete remission ." " The chemoresistance mechanism diffuse large B-cell lymphoma (DLBCL) still poorly understood, patient prognosis remains unsatisfactory . Study aimed investigate drug resistance mechanisms non-germinal center B-cell-like (non" Most patients show diffuse large B-cell lymphoma (DLBCL) classic Hodgkin lymphoma (CHL) types . Study examined whether programmed cell death-ligand 1 (PD-L1) expression levels associated prognosis Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) occasionally undergoes Richter transformation . CLL evolved mantle cell lymphoma acquiring t(11;14)(q13;q32) C The STAT6 pathway implicated pathogenesis various lymphomas . The STAT6 pathway implicated pathogenesis various lymphomas . The two STAT6 clones differentially expressed lymphoma types . Obinutuzumab polatuzumab polatuzumab vedotin lenalidomide showed tolerability activity . The study recruited patients relapsed refractory follicular lymphoma . Oxidative stress serves important role carcinogenesis . Study investigated clinical significance of oxidative stress prognostic factor diffuse large B-cell lymphoma (DLBCL) venetoclax (a selective BCL-2 inhibitor) administered to patients relapsed/refractory (R/R) previously untreated (1L) non-Hodgkin lymphoma (NHL) phase 1 Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) occasionally occurs following chronic inflammation . The imbalance immune system imbalance causes the imbalance immune system . The lack experimental HHV8-unrelated effusion large B-cell lymphoma models continues hinder pathophysiologic therapeutic investigations disorder . We established novel HHV8-unrelated effusion large B-cell lymphoma cell line Patients relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) poor prognosis low survival rate . Herein presented single case patient R/R tDLBCL successfully Non-Hodgkin lymphoma one common hematological malignancies nodal extranodal sites involvement . The thyroid gland one rarest primary sites . Most cases primary thyroid lymphoma diffuse large B-cell nature . NGS lymphoid panel tissue liquid biopsy common types non-Hodgkin's lymphoma [follicular lymphoma (FL) diffuse large B-cell lymphoma (DLBCL) detected 279 somatiel mutations " Primary mediastinal B-cell lymphoma (PMBCL) rare subtype diffuse large B-cell lymphoma (DLBCL) Despite aggressive course, PMBCL considered curable . DA-EPOCH-R" " We developed algorithm-driven classification lymphomas flow cytometry compared WHO gold standard diagnosis . Overall, 662 samples 662 patients representing 9 disease categories analyzed 9 laboratories ." Richter transformation refers development aggressive lymphoma patients pre-existing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) It carries poor prognosis secondary poor response therapy rapid disease relapse . " Probe capture-based high-resolution sequencing performed 191 patients diagnosed with DLBCL . DLBCL patients treated R-CHOP, R-CHOP, and were treated with R-CHOP ." " Tafasitamab humanized monoclonal antibody binds CD19 antigen, expressed tumor cells patients diffuse large B-cell lymphoma (DLBCL) Tafasitamab evaluated phase 2 single-arm," CD5+ DLBCL is a rare subtype of diffuse large B-cell lymphoma with poor prognosis . Current clinical variables based prognostic systems DLBCL inadequate accurately stratify prognosis . Fatty acid metabolism reportedly associated various cancers . Role pretreatment serum free fatty acid (FFA) levels diffuse large B-cell lymphoma (DLBCL) prognosis still unclear . " Despite impressive efficacy chimeric antigen receptor (CAR) T-cell therapy (CART) B-cell non-Hodgkin lymphomas, durable responses uncommon . Histopathologic molecular features associated treatment failure still unknown ." " The diagnosis contiguous, synchronous meningioma central nervous system B-cell lymphoma rare associated paradoxical treatment paradigms . We performed scoping review of contiguous meningioma B-cell lymphoma . The OVID" " Patients high-risk diffuse large B-cell lymphoma (DLBCL) poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, prednisone," Diffuse large B-cell lymphoma (DLBCL) one common non-Hodgkin lymphoma . It typical specific clinical features . DLBCL revealed abscess rare entity. The splenic abscess associated typhoid venetoclax ibrutinib efficiently kills DLBCL cells vitro . High Bcl-2 expression due either BCL2 amplifications translocations or BCL2 amplifications translocations . High BCL2 expression due " PI-DLBCL is a primary intestinal diffuse large B-cell lymphoma (PI-DLBCL) much lower primary gastric DLBCL . Large-scale analyses of clinical characteristics, molecular features, therapeutic strategies, risk" Angioimmunoblastic T-cell lymphoma (AITL) complicated Epstein-Barr virus (EBV)-positive B-cell lymphoma . B-cell lymphoma may develop simultaneously time AITL diagnosis diagnosis Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease remarkably variable clinical presentation outcome . Hans algorithm subclassified DLBCL prognostically distinct molecular subtypes using immunohistochemistry (IHC) Fine " Richter syndrome chronic lymphocytic leukemia (CLL) typically chemoresistant, poor prognosis . We hypothesized oral Bcl-2 inhibitor venetoclax could sensitize RS chemoimmunotherapy ." " The optimal timing administering high-dose methotrexate (HDMTX) combined (R)CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, with/without" Gastrointestinal (GI) tract common site extranodal lymphoma accounting 30-40% cases . Gastrointestinal (GI) tract common site extranodal lymphoma accounting 30-40% cases . In Western countries Splenic marginal zone lymphoma (SMZL) accounts 1-2.7% lymphomas . Almost patients bone marrow (BM) involvement one-third liver involvement . RD-associated DLBCL distinct subset within category 'DLBCL' exhibiting characteristic biological features clinical behaviour . " Autophagy catabolic mechanism boosting various tumors, including lymphomas . Its presence never studied PCNSLs . Its presence never studied PCNSLs ." " Study: Vaccinations hypothesized play role lymphoma etiology, studies, studies, mixed results, limited data lymphoma subtypes . We studied 2,461 lymphoma cases, 2,253 controls enrolled in 2002 2014 . Participants self-" " Aggressive B-cell lymphomas including diffuse large B-cell lymphoma make majority non-Hodgkin's lymphoma globally . While half patients cured modern chemoimmunotherapy regimens, outcomes relapsed refractory" " New therapies needed patients relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) benefit ineligible stem cell transplant chimeric antigen receptor therapy . CD30-targeted, antibody-drug" " Initial diagnosis lymphoma skin rare occurrence systemic B-cell lymphomas, comprising < 0.3% cases overall . Follicu Follicu Follicu Follicu Follicu Follicu" " Chimeric antigen receptor T-cell (CAR T) therapy offers potentially curative option patients relapsed refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL) Patients treated CAR" Bruton tyrosine kinase (BTK) inhibitors block B-cell receptor (BCR)-dependent NF-κB activation lymphoid malignancies . We modeled development resistance BTK inhibitor ibrutinib activated B " miRNAs reported play important roles tumorigenesis, progression, metastasis . This study aimed explore differentially expressed miRNAs target genes two main subtypes DLBCL . Hub miRNAs identified constructing regulatory network, identified constructing" Epstein-Barr virus persistently infects 95% human adult population . Epstein-Barr virus (EBV) persistently infects 95% human adult population . Even readily transform human B cells infection can transform human B cells infection Among growing number patients hematologic neoplasms hospitalized intensive care unit (ICU) largest proportion patients diagnosed lymphoma . Less attention paid past identifying critically ill patients assessing prognosis patients ICU . Traditional critical care-related scores shown " A 57-year-old male patient presented lower urinary tract symptoms underwent flexible cystoscopy bladder tumor biopsy . Through immediate staging CT scan, tumor bone biopsies diagnosed 16 cm Stage IVa high-grade DLBCL" Chimeric antigen receptor T-cell (CAR-T) therapy successful creating extraordinary clinical outcomes treatment hematologic malignancies including relapsed refractory (R/R) B-cell acute lymphoblastic leukemia (B 92 patients treated within phase IIa study single-agent tafasitamab relapsed refractory B NHL followed five years longer long-term tolerability . Treatment well tolerated outpatient setting hospitalizations needed mild tolerable adverse events Systemic anaplastic large cell lymphoma (ALCL) rare CD30-expressing T-cell non-Hodgkin lymphoma . Risk systemic ALCL highly increased among immunosuppressed individuals . " B cell lymphoma 6 (BCL6) transcriptional repressor deregulated diffuse large B cell lymphoma, peptide aptamer, Apt48, inhibits BCL6 unknown mechanism . We show corepressor binding site BT" " Rituximab anti-CD20 monoclonal antibody approved several diseases, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL)," " Diffuse large B-cell lymphoma (DLBCL) penis rare haematological malignancy, less 30 cases reported literature . Chemotherapy, radiotherapy surgery treatment modalities used; which, chemotherapy su su ." The advent chimeric antigen receptor (CAR)-T cell therapy hailed major breakthrough treatment B cell acute lymphoblastic leukemia (B-ALL) diffuse large B-cell lymphoma (DLBCL) While multiple promising CAR-T cell B-cell lymphoid neoplasms (LN) associated IgG4-RD diagnosed 4-year period analysed . There five men three women median age 76.5 (52-90) years; three synchronous IgG Polatuzumab vedotin (PoV) recently shown promising activity combined rituximab-bendamustine (BR) patients relapsed/refractory (R/R) diffuse large B- Vincristine-related neurotoxicity potentially reversible cause BLVCP rarely described literature . " Overexpression BCL2 protein reported poor prognostic factor diffuse large B-cell lymphoma (DLBCL) However, currently standardized criteria evaluating BCL2 protein expression are evaluating BCL2 protein expression . We defined tumors" " Secondary central nervous system lymphoma rare, occurring 10% non-Hodgkin's lymphoma patients . The prognosis poor, even rarer metastasis large B-cell lymphomas Meckel's cave trigeminal nerve" Diffuse large B-cell lymphoma (DLBCL) comprises least two main biologically distinct entities: germinal center B-cell (GCB) activated B-cell (ABC) subtype . GCB ABC DLBC " G protein nucleolar 3 acts oncoprotein various carcinomas, associated tumor progression . Little known regarding GNL3 function non-Hodgkin lymphoma (NHL) Little known regarding GNL3 function non-Hod" Diffuse large B-cell lymphoma (DLBCL) highly heterogeneous malignancy varied outcomes . We aimed identify core differentially co-expressed hub genes perturbed pathways relevant pathogenesis prognosis . " The aim study present elusive case primary thyroid lymphoma (PTL) Initially thought anaplastic thyroid carcinoma, Rosai Dorfman disease, Rosai Dorfman disease, final diagnosis PTL made ." " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . Lymphoma involving muscle rare accounts 5%; Lymphoma involving muscle rare accounts 5%; furthermore, multiple muscles" " Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) derived diffuse large B-cell lymphoma N.O.S., perhaps affinity nodal THRL" Non-invasive diagnosis staging of diffuse large B-cell lymphoma (DLBCL) achieved using label-free surface-enhanced Raman spectroscopy (SERS) SERS spectra measured serum samples from DLBC " Aberrant microRNA (miR) expression plays important role pathogenesis different types cancers . Aberrant microRNA (miR) expression plays important role pathogenesis different types cancers . Ibrutinib first-in class, oral" " Young Chinese female patient presented mass right breast rapidly increased size approximately 2 months . Upper gastrointestinal endoscopy showed giant serpentine ulcer stomach . Biopsy performed, microscopic inspection revealed fibrous tissue diffusely involved medium large abnormal lymphocytes ." Polatuzumab vedotin plus bendamustine rituximab (pola + BR) received regulatory approvals relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL " Plasma extracellular vesicles (EVs) reported promising source diagnostic prognostic biomarkers various cancers . However, research area needed due due to limitations circulating extracellular vesicles detection methods ." A diverse intratumoral T-cell receptor (TCR) repertoire associated improved survival of diffuse large B-cell lymphoma (DLBCL) treated rituximab/cyclophosphamide/doxorubic " International Prognostic Index (IPI) widely used discriminate prognosis patients diffuse large B-cell lymphoma (DLBCL) Significant need identify novel valuable biomarkers context targeted therapy, immune checkpoint blockade (ICB) Gene expression" " Glycoprotein prostaglandin D2 synthase (PTGDS) member lipocalin superfamily plays dual roles prostaglandins metabolism lipid transport . PTGDS involved various cellular processes including tumorigenesis solid tumors," " Small extracellular vesicles (sEVs) including exosomes, carrying CD20, could involved immunotherapy resistance diffuse large B cell lymphoma (DLBCL) We reported endogenous brain-derived neurotrophic factor/" " Primary testicular lymphoma (PTL) variety extra-nodal lymphoma taking origin testis . Metastasis may occur contralateral testis, bone, central nervous system rarely skin ." CD19 cell surface protein found healthy malignant B cells . CD19 cell surface protein found healthy malignant B cells . It is important target novel treatments non-Hodgkin lymphomas B-cell leukaemia . " In diffuse large B cell lymphoma (DLBCL) tumors belong to ABC GCB gene expression subgroup rely upon chronic active B cell receptor signaling viability, dependency targetable ibrutinib . A phase III trial showed survival" Wilson et al. execute massive genomic analysis order identify putative molecular signatures linked to differential response ibrutinib plus R-CHOP . Diffuse large B-cell lymphoma (DLBCL) fatal heterogenous neoplasm . Recent clinical trials failed partly due nebulous criteria defining high-risk patients . Suggest refined method of diagnosing DEL evaluating concurrent expression BCL 79-year-old man was treated with immunochemotherapy . He was referred to 18FDG PET/CT right persistent lombosciatic radicular pain . Diffuse large B-cell lymphoma (DLBCL) common lymphoid malignancy adults . Eukaryotic translation elongation factor 1A1 (EEF1A1) participates protein translation reported involved tumor progression hep Multimenter retrospective study aimed explore prognostic value Prognostic Nutrition Index (PNI) DLBCL patients using propensity score matched analysis (PSM) A total 990 DLBCL cases recruited 5 centers Huaihai L Coffee-drinking habits risk non-Hodgkin lymphoma (NHL) remain controversial . Coffee-drinking habits are linked to non-Hodgkin lymphoma . " Richter transformation cohort larger, ongoing, phase 1-2, single-arm study evaluating safety activity selective, irreversible Bruton's tyrosine kinase inhibitor acalabrutinib treatment chronic lymphocytic leukaemia" The prognosis early relapse diffuse large B-cell lymphoma (DLBCL) appears poor following autologous stem cell transplantation (ASCT) The aim study contribute data open question whether additional radiotherapy improves outcome . Bruton's tyrosine kinase (BTK)-mediated B-cell-receptor signaling drives lymphomagenesis diffuse large B-cell lymphoma (DLBCL) We investigated clinicopathological significance BTK positivity Previous exposure-response analyses rituximab suggest higher rituximab concentrations associated improvement efficacy . Clinical studies investigating higher rituximab dose mixed results . " Right ventricle outflow tract (RVOT) dysfunction is common long-term complication adult patients . Common causes include valve thromosis, stent fractures, graft calcification ." 48-year-old man came painless lump testicles since 10 months ago . Testicular tumour marker revealed increased LDH . Testicular USG revealed semi-solid spongiform mass right epididymis bilateral " Twenty cases studied 11 years . Clinicopathological profiles, histological details, immunohistochemical (IHC) profiles analyzed . The mean age presentation 6 years ." " S63845 highly specific inhibitor MCL1. protein overexpressed many cancers, including B-cell non-Hodgkin lymphomas . We analyzed mechanisms sensitivity/resistance S63845 preclinical models of diffuse" " A 56-year-old woman presented 3 months history four limbs' numbness glove stocking distribution . Brain whole spine imaging revealed lesions, cerebrospinal fluid showed high protein . A nerve conduction study revealed severe sensorimotor poly" Intravascular large B-cell lymphoma (ILBCL) subtype non-Hodgkin's large B-cell lymphoma characterised neoplastic lymphocyte proliferation within lumen small blood vessels . ILBCL " Primary lymphoma prostate exceedingly rare disease, diffuse large B-cell lymphoma common known subtype small number reported cases . Due low prevalence, chronic lack targeted diagnostic guidelines treatment procedures ." Diffuse large B-cell lymphoma MYC rearrangement defined double/triple-hit lymphoma (DHL/THL) single-hit lymphoma (SHL) inclusion BCL2 BCL6 rearrang " Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shown impressive efficacy treating B-cell malignancies . CBM.CD19 CAR, second-generation anti-CD19 CAR bearing 4-1BB costim" " Ibrutinib Bruton tyrosine kinase inhibitor used treat many hematologic conditions, commonly B-cell lymphomas leukemias . Reportedly, skin rash adverse event 27% treated patients ." " Ibrutinib inhibitor Bruton's tyrosine kinase approved treatment patients chronic lymphocytic leukemia, mantle cell lymphoma Waldenstrom's macroglobulinemia connected toxicities ." " 26 patients intraorbital tumors underwent neurosurgery . Of these, 15 patients underwent neurosurgery . Of these, 15 patients underwent . Six patients included OAL group, pathologically diagnosed ." Intravascular large B-cell lymphomas (IVLBCL) relapse relatively frequent . We sought characterize potential immune escape mechanisms IVLBCLs newer therapies exploit . " Florid lymphoid hyperplasias lower female genital tract, also known pseudolymphoma lymphoma-like lesions, benign lesions displaying histologic features mimic aggressive B-cell lymphomas . Initially described Young colleagues 1985, fewer 100" Over 50% diffuse large B-cell lymphoma (DLBCL) patients diagnosed advanced stage . The prognosis patients advanced-stage DLBCL usually poor frequent recurrence metastasis . Fever due due due due due due to be released in the U.S. on Friday . Fever is due to be released in the U.S. on Friday . Plasmablastic lymphoma (PBL) represents clinically heterogeneous subtype aggressive B-cell non-Hodgkin lymphoma . HIV-positive patients recently revealed several genes associated with PBL pathogenesis . Global mutational PET radiomics seem promising biomarkers various lymphoma subtypes . PET radiomics was used to identify diffuse large B-cell lymphoma (DLBCL) patients treated R-CHOP . Anti-CD19 chimeric antigen receptor T (CAR-T) cells demonstrated activity relapsed/refractory lymphomas . Cytokine release syndrome (CRS) immune effector cell - associated neurotoxicity syndrome (IC " MYR proven inhibitory effects various types cancer . In vitro, MTT assay performed evaluate activity human diffuse large B lymphoma cell TMD-8 tumor cells ." " Hairy cell leukemia (HCL) HCL-like disorders, including HCL variant (HCL-V), splenic diffuse red pulp lymphoma (SDRPL) need appropriate treatment . HCL-like disorders, including" SNPs analysed included SLC2A1 HaeIII HpyCH4V HpyCH4V SNPs . SNPs were linked statistically significantly significantly to the SLC2A1 HaeIII HpyCH4V Ocular adnexal large B-cell lymphomas (OA-LBCLs) per 2016 WHO lymphoma classification (2) determine prevalence . Thirty-four OA-LBCLs were reclassified as OA " Tumor-associated macrophages (TAMs) associated poor prognosis associated poor prognosis . Diffuse large B-cell lymphoma differential infiltration TAMs . As macrophages heterogeneous, immune polarization pathological role warrant" " EBV-related malignancies made every year . 90% adult population globally chronically infected Epstein-Barr virus . It well established EBV associated number malignancies, advances knowledge EBV-related malignancies made every year" " Gene expression profiling vastly used extract genes predict clinical outcome patients diverse cancers, including diffuse large B-cell lymphoma (DLBCL) With aid bioinformatics computational analysis gene expression data, various prognostic gene signatures DLBCL" " We report case heart transplant recipient presented rapidly growing Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma 7 days receiving first dose ChAdOx1 nCoV-19 vaccine . This observation indicates potential" High-throughput sequencing technologies have enabled rapid in-depth portrayal of major lymphoma entities . Majority of lymphoma entities characterized predominant gene mutation (e.g. Waldenström's macroglobulinemia hairy " Lisocabtagene maraleucel (liso-cel) autologous CD19-directed chimeric antigen receptor (CAR) T cell product . Liso-cel, unlike two approved products-axicabtag" " Post CAR-T failures represent new unmet need R/R LBCL . Standard treatment options guide clinicians are, unfortunately, available ." Motor weakness associated central nervous system (CNS) toxicity rarely reported CAR T-cell therapy . Motor weakness associated central nervous system (CNS) toxicity rarely reported CAR T-cell therapy . " Failure CD19-directed chimeric antigen receptor (CAR) T-cell therapy patients large B-cell B non-Hodgkin lymphoma, especially happens early, emerging clinical problem . Immune checkpoint inhibitors becoming therapeutic option patients" 150 ATL cases reveal overarching landscape genetic alterations . We discovered frequent (33%) loss-of-function alterations preferentially targeting CIC long isoform . " Traditional Chinese herbal medicine exhibits anti-inflammatory anti-cancer activities . Pancreatic cancer common malignant tumor high mortality, novel therapeutic options focused ameliorating poor prognosis ." Primary bone marrow diffuse large B-cell lymphoma exceedingly rare form non-Hodgkin lymphoma exceedingly rare form non-Hodgkin lymphoma . The prognostic implications CD5-positivity remain unknown . A 23-year-old woman primary mediastinal large B-cell lymphoma referred 18F-FDG PET/CT staging . Another FDG-avid lesion SUV higher expected corpus luteum cysts found pelvis " Loncastuximab tesirine shown antitumor activity acceptable toxicity profile . Loncastuximab tesirine shown antitumor activity acceptable toxicity profile . The single-arm, open-label phase II LOT" " The human T-cell lymphotropic virus type 1 (HTLV-1) associated aggressive diseases, adult T-cell leukemia/lymphoma (ATLL) However, less known impact HTLV-1 infection non-ATLL" Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) associated poor prognosis despite availability multiple treatment options . Preliminary evidence suggests DLBCL may responsive programmed death ligand 1 " Diffuse large B cell lymphoma (DLBCL) aggressive potentially curable malignancy . Curing highly dependent ability deliver intensive, anthracycline-based chemoimmunotherapy . Nearly one third cases DLBC" " Research suggests better survival among Hispanics diffuse large B-cell lymphoma compared non-Hispanic Whites . However, less known racial/ethnic survival differences are known . Cox proportional hazards regression assessed association race/ethnicity all-cause mortality among FL" " The cachexia index (CXI) potential biomarker cancer cachexia, implications prognosis treatment outcome lung cancer aggressive lymphoma assessed previous studies . 267 patients diagnosed with diffuse large B-cell lymphoma treated rituximab" Apatinib multitarget tyrosine kinase inhibitor marketed China treatment advanced gastric cancer (GC) hepatocellular carcinoma (HCC) It also used off-label treatment many malignancies . Allogeneic transplant (alloHCT) chimeric antigen receptor modified (CAR)-T cell therapy potentially cuarative options . diffuse large B-cell lymphoma (DLBCL) relapsing autologous (auto) Metronomic chemotherapy (mCHEMO) may allow effective tolerable combinations . Novel drugs rapidly moving forward treatment-paradigm non-Hodgkin-lymphomas (NHLs) In situ follicular neoplasia (ISFN t(14;18)(q32;q21) To investigate clonal evolution ISFN DLBCL - transformed FL de novo . 10 cases paired ISFN DLBCL Non-Hodgkin lymphoma optic nerve Human Immunodeficiency Virus (HIV) patient . Different mechanisms proposed lymphomatous involvement optic nerve . We present one case non-Hodgkin lymphoma optic nerve Atraumatic rupture spleen complication certain leukaemias lymphomas . Patients presented emergency department abdominal pain . Patients stopped taking medication abruptly 6 days prior . " Autologous stem cell transplantation (ASCT) standard care patients chemosensitive, relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) diffuse large B cell lymphoma (DLBC" " Two men, one age 66 age 77, and one age 66 age 77, presented vitritis yellow-white subretinal infiltrates . Diagnostic vitrectomy cases revealed diffuse large B-cell lymphoma . Systemic work cases" Diffusion large B cell lymphoma (DLBCL) evolved R/CHOP . Initial therapy has evolved R/CHOP . Early treatment response assessment PET-CT yet established DLBCL . " Diffuse large B-cell lymphoma (DLBCL) highly heterogenous malignancy, early identification patients relapse remains challenging . Circulating tumour DNA (ctDNA) analysed using targeted sequencing based gene panel via recently developed methodology" " Plasmablastic lymphoma, acquired immunodeficiency syndrome defining malignancy, subtype diffuse large B-cell lymphoma . It classically described oral cavity, extraoral presentation rare ." The rarest form of primary cutaneous lymphomas (PCLs) confers poor prognosis . Early treatment chemo-radiation leads appropriate response . " Previously considered subtype diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) recognized World Health Organization independent entity . PMBCL clinicopathologic features separate systemic systemic" A 63-year-old male presented left scrotal swelling ultrasound showed large heterogeneous mass consistent testicular malignancy . Left-sided orchiectomy showed diffuse large B-cell lymphoma . " 10 studies showed no significant difference pooled Absolute Risk Difference (ARD 0.01, 95 % CI) No significant difference pooled Absolute Risk Difference (ARD 0.01, 95 % CI)" " Diffuse large B cell lymphoma, otherwise specified (DLBCL, NOS) frequent non-Hodgkin lymphoma subtype . This aggressive neoplasm may variably express CD30 protein, may used therapeutic target" Diffuse large B-cell lymphoma (DLBCL) aberrant coexpression CD10+BCL6+MUM1+ (DLBCL-AE) genetically characterized . 32/54 (59%) cases classified GC Leukoencephalopathy identified administration anticancer drugs . Symptoms vary neurological symptoms psychiatric symptoms depending site damage . Previous reports suicide attempts due drug-induced leukoencephalopathy . Aim study determine better criterion end-of-treatment PET (EoT-PET) assessment prognostic evaluation patients diffuse large B cell lymphoma (DLBCL) This study aimed develop novel analytic approach based 2-deoxy-2-2-2 . We retrospectively enrolled 152 DLBCL patients divided training cohort (n = 100) and validation cohort (n = 52) A total 12 There limited data post-transplant lymphoproliferative disorder (PTLD) era positron emission tomography (PET) rituximab (R) There limited data post-transplant lymphoproliferative disorder Epidemiological studies demonstrated association hepatitis B virus (HBV) infection B-cell non-Hodgkin lymphoma (NHL) infection B-cell non-Hodgkin lymphoma (NHL) and mainly diffuse " Radioimmunotherapy using 90Y-ibritumomab tiuxetan induce disease control across lymphoma subtypes dose-dependent . In phase 2 study, CD20++ CD20++ study, we" " Formalin-fixed, paraffin-embedded (FFPE) specimens underutilized resource medical research, particularly setting transcriptome sequencing, often degraded . We took advantage exome capture-based RNA-sequencing protocol explore global" " Zanubrutinib, potent selective BTK inhibitor, evaluated patients relapsed refractory (R/R) non-GCB DLBCL . Patients received twice-daily oral oral oral zanubrutin" " Diffuse large B-cell lymphoma (DLBCL) common B-cell malignancy, varying prognosis gold standard rituximab, cyclophosphamide, doxorubicin, vincrist" EBV infection DHL/THL rare (~1.5% of patients with BCL2 and/or BCL6 rearrangements . EBV infection DHL/THL rare (~1.5% of patients with " Lymphomatous effusions patients diffuse large B-cell lymphoma (DLBCL) associated poor prognosis, even worse non-effusion-associated patients stage IV disease . We hypothesized certain genetic abnormalities associated lymphomat" Vitreoretinal lymphoma rarely masquerade infectious retinitis making diagnosis management challenging . Intraocular lymphoma accounts fewer 1% intraocular tumors . " EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, cyclophosphamide, doxorubicin, rituximab) front-line treatment" " MyC activity closely correlated with-and likely driver of-gene signatures related oxidative phosphorylation (OxPhos) DLBCL . OxPhos enzymes, particular mitochondrial electron transport chain (ETC) complexes, may be" " Relapsed refractory diffuse large B-cell lymphoma (DLBCL) cases poor outcome . 373 DLBCL patients homogeneously treated rituximab, cyclophosphamide, doxorubicin" Adoptive immunotherapy using CD19-targeted Chimeric antigen receptor T cells (CAR-T) revolutionized treatment relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Patients treated CD " Ciliary body involvement lymphoma 2013 2019 Peking Union Medical College Hospital (PUMCH) All patients underwent examinations including best corrected visual acuity (BCVA), slit-lamp microscopy, slit-lamp microscopy," " Setting solid organ transplant, recipients approximately doubled risk acquiring dying malignancy . Multiple treatment modalities available post-transplant lymphoproliferative diseases (PTLD) including chemotherapy, radiotherapy, surgery, surgery, immunosupp" Primary gastric lymphomas (PGLs) distinct lymphoproliferative neoplasms described heterogeneous entities clinically molecularly . Their main histological types diffuse large B-cell lymphoma (DLBCL) mucosa- " CD19-targeting chimeric antigen receptor (CAR) T cells become important therapeutic option patients relapsed refractory B cell malignancies . A significant portion patients still benefit therapy owing various resistance mechanisms, including high expression multiple inhibit" " Artesunate (ART), water-soluble derivative artemisinin, reported exert antineoplastic effects via diverse mechanisms various types cancer . Understanding underlying mechanism action ART distinct cancer types indispensable optimizing therapeutic application ART different types cancer" After high dose chemotherapy (HDC) autologous stem cell transplantation (auto-SCT) patients relapsed/refractory diffuse large B cell lymphoma (DLBCL) Hodgkin lymphoma (HL) Hodg Lymphomas ranked fifth common cancer Lebanon . Lymphomas ranked fifth common cancer Lebanon . There concern need information regarding prevalence lymphoid neoplasm particularly Non-Hodgkin lymphoma (NHL) subtypes Lebanese population . Primary gastric lymphoma (PGL) rare clinical entity accounting majority extra-nodal non-Hodgkin lymphoma (EN-NHL) The common histological subtype primary gastric diffuse large B-cell " Epstein-Barr virus (EBV) prevalence across full spectrum lymphoma subtypes, particularly sub-Saharan Africa . EBV prevalence 54% HL, detected classical HL subtypes: mixed-cellularity (n = 3/8" The family PIM serine/threonine kinases includes three highly conserved oncogenes . The family PIM serine/threonine kinases includes three highly conserved oncogenes . " In Europe, median age diagnosis across disease entities 69 years. Incidence generally increases age, reaching maximum 75-99 years . Overall survival patients aged 75 years older haematological malignancies generally poor, particularly acute leukaem" " SOX9 overexpressed preferentially subset diffuse large B-cell lymphomas (DLBCLs) harbor IGH-BCL2 translocations . Silencing SOX9 decreased cell proliferation, induced G1/S" Uterine diffuse large B-cell lymphoma (DLBCL) rare clinical condition . Uterine diffuse large B-cell lymphoma (DLBCL) rare clinical condition . Most studies uterine DLBCL derived case " Cohesin core subunit genes mutated across wide cross-section cancers, germinal center (GC) derived lymphomas . Cohesin core subunit genes mutated across wide cross-section cancers, germinal center (GC" Chimeric antigen receptor T-cell (CAR-T) therapy prosperous treatment patients various types relapsed/refractory (R/R) B-cell malignancies . CAR-T therapy faced serious hindrances combating " In solid tumors, glycolytic cancer stromal cells export lactates monocarboxylate transporter (MCT4) In malignant lymphomas, glycolytic cancer stromal cells export lactates mon" " Health-related quality life (HRQoL) multidimensional concept including physical, emotional, social, cognitive functions, disease symptoms, side effects treatment . Differences HRQoL due gender, existence comorbidities, number" " Busulfan widely used treat malignant diseases, particularly therapeutic intensification prior autologous stem cell graft . Numerous side effects consecutive busulfan described, descriptions pulmonary hypertension exist, bronchiolitis obliterans remains rare complication ." " Bruton tyrosine kinase (BTK) phosphatidylinositol-3-kinase (PI3K) represent parallel, synergistic pathways lymphoma pathogenesis . PI3Kδ inhibition possible mechanism" We aimed investigate detection rate body CT PET/CT sites extracranial disease patients . We aimed investigate detection rate body CT PET/CT sites extracranial disease patients . Subgroup analyses according age EBV status also performed . " We wished examine treatment outcome patterns older diffuse large B-cell lymphoma (DLBCL) patients, focus effect route-to-diagnosis outcome . We wished examine treatment outcome patterns older diffuse large B-cell lymphoma (DL" Neurogenic malignant tumours surrounding sciatic nerve also cause similar symptoms . These tumours often misdiagnosed even mistreated LDH clinical practice . " WHO classification introduced category high-grade B-cell lymphoma (HGBL) includes one poorly understood subset, blastoid-HGBL . Establishing diagnosis distinguishing blastoid-HGBL B-acute lymphobl" Up 60% patients aggressive B-cell lymphoma receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure subsequently poor prognosis . Up 60% patients aggressive B-cell lymphoma receive chimeric antigen receptor (CAR Anti-CD19 chimeric antigen receptor (CAR) T cells show significant efficacy treatment relapse/refractory diffuse large B-cell lymphoma (DLBCL) Treatment using anti-CD19-CAR T-cell therapy PT Primary tonsil diffuse large B cell lymphoma (PT-DLBCL) uncommon disease entity . The role radiation therapy (RT) PT-DLBCL debatable pre-post-rituximab era . Colonic lymphoma represents less 0.5% colorectal neoplasms . Colonic lymphoma represents less 0.5% colorectal neoplasms . Colonoscopy performed by doctors at the hospital . Survival disparities among adolescents young adults (AYA) acute lymphoblastic leukaemia (ALL) well documented . Whether similar disparities exist among AYA aggressive mature B-cell non-Hodgkin lymphoma (B-N " Axicabtagene ciloleucel (axi-cel) autologous chimeric antigen receptor T-cell based anti-CD19 therapy . The ZUMA-1 study, multicenter, single-arm" The prognostic value platelet count diffuse large B-cell lymphoma (DLBCL) extensively investigated . 1007 eligible patients received frontline R-CHOP R-CHO . " The population adolescent young adult (AYA, ages 15-39 years) diffuse large B-cell lymphoma (DLBCL) survivors growing . Long-term overall survival patterns disparities largely unknown ." Diffuse large B cell lymphoma (DLBCL) markedly phenotypically heterogenous disease . Diffuse large B cell lymphoma (DLBCL) markedly phenotypically heterogenous disease . Diffuse large B cell lymphoma " Biological heterogeneity of diffuse large B cell lymphoma (DLBCL) partly driven cell-of-origin subtypes associated genomic lesions . However, dissecting cell states clinical relevance scale remains challenging . Using approach, identified five cell states mal" Ocular adnexal lymphoma vitreoretinal lymphoma vitreoretinal lymphoma rare forms non-Hodgkin lymphoma rare forms non-Hodgkin lymphoma . We present rare case of diffuse large " Diffuse large B-cell lymphoma (DLBCL) biologically clinically heterogeneous disease . Despite good responses standard care frontline chemoimmunotherapy, prognosis relapsed/refractory (R/R) patients remains obscured" " Cancer-induced cachexia associated poor prognosis patients non-Hodgkin lymphoma, unknown extent curable lymphoma treatments affect musculoskeletal system . We retrospectively analyzed 104 newly diagnosed diffuse large B-cell lymph" Consensus lacks regarding association diabetes mellitus (DM) prognosis patients non-Hodgkin lymphoma (NHL) Consensus lacks regarding association diabetes mellitus (DM) prognosis patients non-Hodgkin lymph Germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) diagnosis associated superior long-term outcomes compared non-GCB-DLBCL patients treated conventional chemo-immun Epigenetic alterations contribute progression lymphoma . Epigenetic alterations regulate gene expression involved lymphoma pathogenesis . " Primary mediastinal large B cell lymphoma (PMBCL) aggressive large B cell lymphoma originating mediastinum . Mainly expresses B cell surface molecules, CD19, CD20, CD22, and CD79a" Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved . Axi-cel is a relapsed refractory There high need novel treatment options relapsed refractory diffuse large B-cell lymphoma . Single agent mammalian target rapamycin (mTOR-inhibitor temsirolimus) treatment shown promising efficacy entity . " Exosomes cell-derived nanovesicles diameters 30 150 nm, released upon fusion multivesicular bodies cell surface . They transport nucleic acids, proteins, lipids intercellular communication activate signaling pathways target cells . In cancers" " In CMML, neoplastic monocytes distinguished based immunophenotype . Supportive care myeloid growth factors concomitant extranodal non-Hodgkin Lymphoma safe ." " Diffuse large B-cell lymphoma (DLBCL) common lymphoproliferative invasive invasive disease . Current first-line regimen treatment DLBCL R-CHOP, combination rituximab, cyclophosph" " Diffuse large B-cell lymphoma (DLBCL) is a common type lymphoma common type lymphoma Japan . Previous studies demonstrated patients DLBCL poor prognosis due increased levels of indoleamine 2,3-d" " Gene expression signatures proven potential characterize important cancer phenomena like oncogenic signaling pathway activities, cellular origins tumors, cellular origins tumors, immune cell infiltration tumor tissues . We apply methodology utilizes previously developed concept coherent expression genes signatures identify translatable signatures scoring" Bromodomain extraterminal (BET) proteins transcriptional activators multiple oncogenic processes diffuse large B-cell lymphoma (DLBCL) Bromodomain extraterminal (BET) proteins transcriptional Re-designing services processes meet growing demands chemotherapy services necessary increasing treatments . 36-year-old male diffuse large B-cell lymphoma maintenance rituximab therapy . Diagnosed with mild coronavirus disease 2019 (COVID-19) infection fully recovered . We review preclinical clinical experience first generation Bruton's tyrosine kinase inhibitors B-cell lymphoproliferative diseases . We review preclinical clinical experience first generation Bruton's tyrosine kinase inhibitors B-cell Angioimmunoblastic T-cell lymphoma (AITL) peripheral T-cell lymphoma (PTCL-NOS) remains poorly understood . A subset AITL/PTCL-NOS patients Escalated-R-CHOP-21 compared Standard-R-CHOP-21 compared to standard-R-CHOP-21 . Some studies indicated using 500 mg/m . " R/R PCNSL patients treated R R/R PCNSL patients treated R Fourteen patients (median age: 63 years, median Karnofsky Performance Status: 75%) received R The R This study provides Class IV" " Graft-versus-host disease common complication seen allogenic stem cell transplant, used treat variety hematological malignancies . Graft-versus-host disease allogenic syndrome present variety ways, including symptoms mimicking various" The relative efficacy of autologous hematopoietic cell transplant vs chimeric antigen receptor T-cell (CAR-T) therapy patients achieve partial remission (PR) salvage chemotherapy known . Prophylaxis commonly used prevent central nervous sy stem (CNS) relapse relapse diffuse large B-cell lymphoma (DLBCL) Prophylaxis administered intrathecally(IT) 894 (77%) using A 68-year-old woman presented leg edema diagnosed nephrotic syndrome (NS) Renal biopsy revealed ITG . She underwent six cycles R-CHOP therapy . tirabrutinib administered via nasogastric tubes treat elderly patient primary central nervous system lymphoma (PCNSL) Epstein-Barr virus (EBV) infection known risk factor known drive disease manifestation . Epstein-Barr virus (EBV) infection known risk factor known drive disease manifestation . EBV-negative PTLD pathogenesis unknown . " Diffuse large B cell lymphoma sigmoid colon rectum relatively uncommon aggressive aggressive . Patients often diagnosed late disease present life-threatening complications, hemorrhage, obstruction, perforation, requiring emergent surgical intervention ." " CD47 considered prominent target cancer therapies, CD47 blockade mainly inhibits CD47-SIRP . At present, use common chemotherapy regimen CHOP/R-CHOP diffuse large B-cell lymphoma (DLBCL) shortcomings" " Diffuse large B cell lymphoma (DLBCL) common type non-Hodgkin lymphoma (NHL) occurring predominantly older people . Skeletal muscle lymphoma rare form DLBCL, frequently affecting thigh, upper" The characteristics infections following chimeric antigen receptor T (CAR-T) cells targeting CD19 real-word population obscure . We analyzed infections' characteristics first month among consecutive patients . Lenalidomide response rates 45% relapsed transformed DLBCL . A case of malignant lymphoma maxillary gingiva following biopsy reported . An 84-year-old man referred hospital chief complaints swelling anterior maxillary gingiva . A non-tender swelling ulcer observed . A " French Medical Information Systems Program (PMSI) hospital stays associated administrated drug encoded 9439938 (tisagenleclecleucel, Kymriah®) 9440456 (axicabtagene cil" Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs) occur patients receiving immunosuppressive drugs autoimmune diseases . Clinicopathological genetic features remain unknown . A 70-year-old Japanese man presented massive cardiac tumor associated diffuse large B-cell lymphoma . Standard chemotherapy resulted complete remission . The clinical molecular characteristics localized diffuse large B-cell lymphoma (DLBCL) single nodal (SN) single nodal (SN) single extranodal (SE) involvement remain largely elusive rituximab era " The purpose study determine epidemiology tumors ocular adnexa orbit Japan . There 270 conjunctival eyelid tumors 166 benign 104 malignant 104 malignant . There 102 orbital tumors 55 benign, 47 malignant tumors, 21 cases Ig" Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibit antitumor immunity promote cancer progression . Role mechanism lymphoma still unclear . Non-Hodgkin lymphoma is a well-understood non-Hodgkin lymphoma . The etiology of NHL children adolescents young adults is well understood . We evaluated potential associations with NHL risk population-based study Umbralisib dual inhibitor PI3Kδ casein kinase-1ε (CK1ε) Umbralisib dual inhibitor PI3Kδ casein kinase-1ε (CK1ε " The germinal center B-cell (GCB) activated B-cell (ABC) subtypes diffuse large B-cell lymphoma (DLBCL) significant difference prognosis . This study aimed identify potential hub genes, key" Human germinal center-associated lymphoma (HGAL) adaptor protein specifically expressed germinal center lymphocytes . High expression HGAL predictor prolonged survival of diffuse large B-cell lymphoma (DLBCL) classic " Patients with diffuse large B-cell lymphoma (DLBCL) median age 70 years . Yet, empirical knowledge treatment older patients limited frequently excluded clinical trials . We aimed construct simplified frailty score examine survival treatment-related mortality (TR" Multipotent mesenchymal stromal cells (MSC) key regulators hematopoiesis . We studied changes MSC characteristics patients myeloid leukemia patients lymphoproliferative diseases . " National Cancer Database queried 2004 2016 patients sinonasal DLBCL . National Cancer Database queried 2004 2016 patients sinonasal DLBCL . A total 2,222 patients sinonasal DLBCL analyzed ." Intravascular large B-cell lymphoma (IVLBCL) rare form lymphomas poor prognosis . 54-year-old man died three months symptom onset . Intravascular large B-cell lymphoma (IVLBCL) rare form diffuse large B-cell lymphoma . Malignant B-cells primarily localized lumina small- medium-sized blood vessels without lymphadenopathy . Understanding molecular mechanisms involved DLBCL important identify new therapeutic targets . Diffuse large B-cell lymphoma (DLBCL) is a common type B-cell non-Hodgkin lymphoma adults pathogenesis DLBCL The authors describe novel therapeutic strategy combining bispecific antibody (bsAb) with bispecific antibody (bsAb) Called BL-01 . The bsAb composed fused heavy chain two free light chains pair correctly heavy chain sequences . Epstein-Barr virus (EBV; human herpesvirus 4; HHV-4) Kaposi sarcoma-associated herpesvirus (KSHV) human gammaherpesviruses oncogenic properties . EB Serine/threonine kinase 33 (STK33) implicated cancers . Clinical significance biological functions of diffuse large B cell lymphoma (DLBCL) remain largely unknown . B-cell non-Hodgkin lymphoma (NHL) among ten common malignancies . Survival rates range poor 90% highly depend stage subtype . NHL recurrent translocations juxtaposing oncogene (e.g Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) rare . We investigate 23 Japanese patients PA-DLBCL understand clinicopathologic features biological behavior disease . " Diffuse large B-cell lymphoma (DLBCL) common lymphoma subtype, accounting 30-40% lymphoma diagnoses . Although aggressive, cure achievable approximately 60% cases ." HADHA is overexpressed high-grade lymphoma predictor poor prognosis diffuse large B-cell lymphoma (DLBCL) HADHB forms heterodimer HADHA functions FAO enzyme together HADHA . " Lymphoma-associated macrophages (LAMs) key components lymphoma microenvironment, may impact disease progression response therapy . There two major subtypes LAMs, CD68+ M1 CD163+ M2 and" The role consolidative radiation therapy (RT) advanced-stage diffuse large B-cell lymphoma (DLBCL) is fully established . Patients initially presenting bulky disease initially presented with bulky disease . Effusion-based lymphomas (EBL) usually high-grade B cell non-Hodgkin's lymphomas involve effusion fluid body cavity . They frequently seen HIV-infected individuals biologically driven human herpesvirus- " High-grade B-cell lymphoma (HGBL) is aggressive B-cell lymphomas . HBCLs, NOS, rare heterogeneous; germinal center B-cell phenotype, 45% carry single-" " SARS-CoV-2 patients had follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), multiple" " Epstein-Barr virus (EBV) DNA load common lymphomas . However, remains unclear whether lymphomas correlated Epstein-Barr encoding region (EBER) status ." " 36 patients have splenic marginal zone lymphoma (SMZL) transformation (SMZL-T) We describe 36 patients with SMZL transformation (SMZL-T) In HCB cohort, cumulative incidence transformation 5" Central pontine myelinolysis (CPM) commonly associated osmotic stress rapid correction hyponatraemia . It rarely reported conjunction malignancies . " In primary analysis pivotal JULIET trial tisagenlecleucel, autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, best overall response rate 52% complete response rate 40% 40" Tissue invasion tumor cells induces host inflammatory response . Tumor-associated macrophages (TAMs) could play pro/M2- anti/M1-tumoral function . TAMs frequently infiltrate diffuse large B Epstein-Barr virus (EBV) is a form of Epstein-Barr virus . Epstein-Barr virus is a form of Epstein-Barr virus . Diffuse large B-cell lymphoma (DLBCL) aggressive cancer lymphatic system . About 30% 40% people DLBCL experience relapse 10% refractory first-line treatment usually consisting R-CHOP chemotherapy . " Diffuse large B cell lymphoma (DLBCL) occur nodal and/or extra-nodal sites . After gastrointestinal tract, cutaneous involvement predominates extra-nodal DLBCL . Skin involvement presentation form" " The U.S. Senate will hold a hearing on the economy in New York City on January 1, 2015 . The Senate will hold a hearing on the economy in New York City on January 1, 2015 ." Rituximab implicated precipitating precipitating tumor lysis syndrome (TLS) Patients diffused large B cell lymphoma (DLBCL) Patients received Rituxan newly diagnosed B-cell lymphoma triggered tumor l The central nervous system international prognostic index (CNS-IPI) used widely identification patients with high risk of relapse . The aim study confirms value CNS-IPI predicting CNS relapse . The brainstem critical role regulating cardiac respiratory function also provides motor sensory function face via cranial nerves . The brainstem critical role regulating cardiac respiratory function also provides motor sensory function face via cranial nerves . " Epcoritamab, novel bispecific antibody targets CD3 CD20 induces T-cell-mediated cytotoxic activity CD20+ malignant B cells . Patients relapsed refractory B-cell non-Hod" " There small measurable increased risk lymphoma inflammatory bowel disease [IBD] IBD associated inflamed tissue immunosuppressant use, mainly thiopurines ." " 68-year-old woman presented non-healing urethral ulcer accompanied vulvar pruritus . She failed medical treatment . Her medical history was unremarkable, lacking fever, weight loss unexplained fatigue ." Diffuse Large B Cell Lymphoma (DLBCL) common type Non-Hodkin Lymphoma (NHL) Common type Non-Hodkin Lymphoma (NHL) The aim study assess clinico 48-year-old woman initially diagnosed gallbladder carcinoma lymph nodes metastases contrast-enhanced CT MRI . Extranodal primary lymphoma gallbladder extremely rare . Artificial intelligence-based tools designed assist diagnosis lymphoid neoplasms remain limited . Artificial intelligence-based tools designed assist diagnosis lymphoid neoplasms remain limited . " 41-year-old woman 14-month history of systemic lupus erythematosus (SLE) presented headache, aphasia, agraphia . Laboratory examination revealed mild proteinuria, hypocomplementemia" " Primary immune thrombocytopenia (ITP) characterized isolated low platelet count diagnosis exclusion, contrasting secondary ITP . Positive diagnosis difficult requires extensive investigation . Some underlying conditions associated ITP lymphoproliferative disorders infections" Hong Kong population-based cohort study identified adult patients diagnosed with DLBCL 2000 2018 . We examined association SES levels odds secular trends receipt chemotherapy and/or rituximab . We examined long-term relative survival SES " Flow cytometry plays key role detecting bone marrow (BM) involvement patients diffuse large B-cell lymphoma (DLBCL) To improve detection sensitivity, need explore novel markers . In study, detected expression CD54 lymphoma cells BM" In relapsed/refractory setting treatment large B-cell lymphoma (LBCL) chimeric antigen receptor T-cell (CAR-T) therapy emerged effective treatment modality . Patients often aggressive disease requires prompt treatment form " To advance use circulating tumor DNA (ctDNA) applications, broad clinical validity must tested different treatment settings, including targeted therapies . Using prespecified longitudinal systematic systematic collection plasma samples phase 1/2a LYM1002 trial (" Diffuse large B-cell lymphoma (DLBCL) high cancer-related mortality . Studies supported lncRNAs regulate cancer progression affecting autophagy cells . ARRDC1 antisense RNA 1 (ARRDC1- B-cell lymphoma central nervous system (CNS) rare malignancy diffuse large B-cell lymphoma (DLBCL) variant common . DLBCL high propensity relapse locally within CNS . 79-year-old man " Diffuse large B cell lymphoma (DLBCL) aggressive disease . First-line treatment well defined young patients; however, oldest old patients treatment remains unclear . We performed systematic review of databases published report elderly patients (median age" " Richter syndrome (RS) represents transformation chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) aggressive lymphoma . DLBCL-RS poor outcomes DLBCL-directed therapy; thus," Treatment CD19-directed (CAR) T cells evolved standard care multiply relapsed refractory large B-cell lymphoma (r/r LBCL) A common side effect treatment immune effector cell-associated neurotoxicity syndrome Primary mediastinal large B-cell lymphoma (PMBCL) separate entity World Health Organization's classification . PMBCL distinct molecular signature overlaps nodular sclerosis classic Hodgkin lymphoma (cHL) SADAL study evaluated oral selinexor patients relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) patients relapsed and/or refractory diffuse large B-cell lymphoma Study evaluated lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) patients relapsed refractory large B cell lymphoma ( " Lysine-specific demethylase 1 (LSD1, also known KDM1A) attractive agent treatment cancer . However, anti-tumor effect LSD1 inhibitors diffuse large B-cell lymphoma (DLBCL" Chilean public hospital compare overall survival (OS) previously reported cohort institution . Overall survival (OS) estimated treated patients diagnosis death October 2020 . 55-year-old male patient worsening pain weakness right leg past months . Left sciatic nerve mass biopsied . Initial biopsy results inconclusive . Consider primary bone lymphoma important differential diagnosis osteomyelitis . Consider open biopsy accurate diagnosis . Consider primary bone lymphoma important differential diagnosis osteomyelitis . " Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations histone acetyltransferase CREBBP . Chidamide, novel histone deacetylase (HDAC) inhibitor, effective" " Diffuse large B cell lymphoma (DLBCL) increasing incidence elderly patients poorer prognosis younger patients . We analyzed outcome elderly DLBCL patients, especially factors affecting survival real-life clinical practice ." CD19-specific chimeric antigen receptor T-cell therapy (CAR-T) treatment relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) gives hope patients otherwise dismal prognosis . Therapy " HSP90 critical maintenance cellular proteostasis . HSP90 critical maintenance cellular proteostasis . In cancer cells, HSP90 also becomes nucleating site stabilization multiprotein complexes ." " Kaposi sarcoma (KS) herpesvirus (KSHV), also known human herpesvirus 8, causal agent KS also pathogenetically related several lymphoproliferative disorders . KSHV, similar Epstein-" Primary bone diffuse large B-cell lymphoma (PB-DLBCL) rare extranodal lymphoma subtype . Study elucidates currently unknown genetic background of large clinically well-annotated cohort DLBCL . Covalent Bruton tyrosine kinase inhibitors (BTKi's) B-cell lymphoma 2 (BCL2) inhibitor venetoclax significantly improved outcomes patients chronic lymphocytic leukemia (CLL) Patients SCHOLAR-1 international retrospective study highlighted poor clinical outcomes survival among patients refractory large B-cell lymphoma (LBCL) treated conventional chemotherapy . Axicabtagene ciloleucel (axi- Patients high-risk relapsed aggressive B-cell lymphomas characterized poor prognosis . High-dose chemotherapy followed autologous stem cell transplantation (ASCT) induce durable remissions patients potentially curative . MYC gene rearrangements diffuse large B-cell lymphoma (DLBCL) patients associated poor prognosis . MYC gene rearrangements diffuse large B-cell lymphoma (DLBCL) patients associated poor prognosis " Primary rectal lymphoma extremely rare, accounting approximately 0.05% primary rectal neoplasms ." " Using SEER data, patients diagnosed non-HIV-associated primary central nervous system lymphoma (PCNSL)-diffuse large B-cell lymphoma (PCNSL)-diffuse large B-cell lymphoma (DL" " Diffuse large B cells cerebrospinal fluid (CSF-DLBCs) offered great promise diagnostics . CSF-DLBCs defined based abundant expression B-cell markers, active cell proliferation energy metabolism properties, active" 15-year-old HIV infected male patient presented features heart failure cardiac tamponade . 15-year-old HIV infected male patient presented features heart failure cardiac tamponade . The resected tumour confirmed diffuse large b- Gliomas one common type of primary tumors central nervous system . Previous studies found macrophages actively participate tumor growth . " IT-based tool developed to study massive data related cancer among Saudis . Web-based application developed to provide interactive, quick, easy method reach, extract, compare, visualize cancer data ." B-cell non-Hodgkin's lymphoma (NHL) Hodgkin lymphoma complicating rheumatoid arthritis (RA) identify RA-related factors associated occurrence . HIV infection increases cancer risk linked cancers associated infectious agents classified carcinogenic humans . Lymphomas represent one frequent malignancies among individuals infected HIV . Diffuse large B-cell lymphoma remains leading cancer introduction combined antiretroviral " Diffusion large B-cell lymphoma (DLBCL) includes heterogeneous collection biologically distinct tumours . This heterogeneity currently presents barrier successful deployment novel, biologically targeted therapies ." " Primary cardiac lymphoma (PCL) NHL involves heart and/or pericardium . PCL rare often causes serious complications, diagnostic challenge ." CAR-T cell therapy significant activity poor risk B-cell lymphomas . CAR-T cell therapy associated potentially life-threatening toxicities cytokine release syndrome (CRS) neurotoxicity (NT) " Plasmablastic lymphoma (PBL) represents rare aggressive lymphoma subtype frequently associated immunosuppression . Clinically, patients PBL characterized poor outcome. A hallmark PBL represents plasmacytic differentiation loss B-" " A rare presentation of primary plasmablastic lymphoma (PBL) adrenal gland, lymphomatous meningitis patient living HIV . A rare presentation of primary plasmablastic lymphoma (PBL) adrenal" " The diagnosis plasmablastic lymphoma (PBL), plasmablastic myeloma (PBM), plasmablastic neoplasm (PBN) may arbitrary cases entities indistinct . We conducted scoping review investigate" Tumor mutation burden emerging biomarker immunotherapy . SNV/Indel higher mature mature B-cell lymphoma mature T- NK-cell lymphoma mature T- NK-cell lymphoma . Primary mediastinal B-cell lymphoma (PMBL) rare type aggressive lymphoma typically affecting young female patients . The first-line standard care remains debated . " The common B-cell cancers, chronic lymphocytic leukemia/lymphoma (CLL), follicular diffuse large B-cell (FL, DLBCL) lymphomas, distinct clinical courses, yet overlapping ""cell-of" DNA sequencing changed way understand genetics biology B-cell lymphomas . Large number of recurrently mutated genes likely play important role initiation and/or maintenance cancers . Dissecting involved genes contribute physiology pathology . " Primary central nervous system (CNS) lymphoma uncommon non-Hodgkin disease limited CNS . Other pathologies, including lymphoplasmacytic lymphoma (LPL), exceedingly rare poorly understood . LPL is exceedingly rare" FISH identifies cases of high-grade B-cell lymphomas with aggressive lymphomas . FISH testing is not feasible in resource-limited setting . Lymphomas associated breast implants mostly T-cell type . Majority primary breast lymphomas occurring absence breast implants B-cell origin . Majority primary breast lymphomas occurring absence breast implants B-cell origin . Diffuse Large B Cell Lymphoma (DLBCL) attributed different genetic phenotypic subtypes . Study determine whether metabolic alterations related cell-of-origin subtypes DLBCL find metabolites associated with clinical outcomes . " PNT2258 liposomal formulation encapsulates multiple copies PNT100, native, chemically unmodified, 24-base DNA oligonucleotide designed target regulatory region upstream B-cell lymphoma 2 (BCL2) gene" " Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) rare, aggressive lymphoma characterized skin involvement predominantly lower extremities . Immunochemotherapy without involved-site radiation therapy (ISRT)" " Primary pancreatic lymphomas extremely rare, accounting 0.1-0.5% malignant lymphomas 0.2% primary pancreatic tumors . They occur commonly pancreatic head elderly males, diffuse large B-cell lymphoma common" Avadomide trials challenged neutropenia major adverse event dose-limiting toxicity . Avadomide cereblon E3 ligase modulator potent antitumor immunomodulatory agent . " Interstitial pneumonitis (IP) is fatal complication DLBCL treatment . We retrospectively investigated clinical characteristics risk factors previous IP patients, analyzed survival data . 556 DLBCL patients receiving CHOP-like regimens enrolled 2013" " Non-Hodgkin lymphoma comprises heterogeneous group cancers unresolved aetiology . Environmentally exposed to benzene, benzene established leukemogen, potential cause of non-Hodgkin lymphoma widely debated ." " An inhibitor histone methyltransferase enhancer zeste homologue 2 (EZH2) developed treatment B-cell lymphoma, mechanisms action fully elucidated . We screened genes targeted tazemetostat eleven B-cell" Vitreoretinal lymphoma (VRL) rare subtype diffuse large B-cell lymphoma (DLBCL) considered variant primary central central nervous system lymphoma (PCNSL) The diagnosis VRL requires examination vitre Diffuse large B-cell lymphoma (DLBCL) common type malignant lymphoma (ML) accounting 30%-40% cases non-Hodgkin's lymphoma (NHL) adults . ML maxillary sin " Doxorubicin carries risk congestive heart failure (CHF) Black race suggested risk factor doxorubicin-related cardiotoxicity, data limited . We assessed whether HF occurs higher rates Black patients compared White" Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease respect outcome . Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease respect outcome . We carried histopathologic analysis biomarkers related " DDX3X frequently mutated Burkitt lymphoma, functional basis unknown . DDX3X ubiquitously expressed RNA helicase involved multiple stages RNA biogenesis ." " Secreted protein acidic rich cysteine (SPARC) extracellular matrix-associated protein . Studies revealed SPARC involved cell interaction function including proliferation, differentiation, apoptosis . However, role SPARC cancer controversial, reported promoter suppress" " Merkel cell carcinoma (MCC) rare, rapidly growing, highly malignant cutaneous tumor typically presents elderly males erythematous violaceous plaque nodule sun-exposed areas . Risk factors include long-term ultraviolet (" Primary breast diffuse large B-cell lymphoma (PB-DLBCL) rare localized extranodal lymphoma . It mainly diagnosed pathological examination due lack specific clinical imaging manifestations . Whole-body positron emission tomography-com " Hemophagocytic lymphohistiocytosis (HLH) systemic inflammation disorder secondary immune dysregulation . Patients may present fevers, splenomegaly, bone marrow failure hemophagocytosis, among" " Tafasitamab, Fc-modified, humanized, anti-CD19 monoclonal antibody, combination lenalidomide, demonstrated efficacy transplant-ineligible patients relapsed/refractory (R/" " Peripheral T-cell lymphomas (PTCLs) marked biologic clinical heterogeneity, confounds treatment decisions . Advances circulating tumor DNA (ctDNA) assays using next-generation sequencing (NGS) assays" Patients develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability endothelial activation . The EAS Tisagenlecleucel indicated pediatric young adult patients relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) adult patients r/r diffuse large B-cell lymph Human herpesvirus-8 (HHV8) lymphotropic virus associated different lymphoproliferative disorders . HHV8-related lesions may fully chime with HHV8-related lesions . CC-486 (oral azacitidine) evaluated patients previously untreated intermediate-high-risk DLBCL grade 3B/transformed follicular lymphoma . CC-486 (oral azacitidine) evaluated CC-486 Epidemiological data provided limited inconsistent evidence relationship radiation exposure to lymphoid neoplasms . We classified 553 lymphoid neoplasm cases diagnosed 1950 1994 Life Span Study cohort atomic bomb survivors . Mature B-cell neoplasms represented MALAT1 is linked to pathogenesis progression of several cancers . Potential effect MALAT1 primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) elucidated . Study aimed explore prognostic value M 70 cases of Epstein-Barr virus-related lymphoma in retrospective study . Median age 68.5 years; 79% cases presented advanced-stage disease (III-IV) 79% cases presented advanced-stage disease (III- Richter syndrome (RS) is aggressive lymphoma occurring context chronic lymphocytic leukaemia/small lymphocytic lymphoma . It is associated poor prognosis treated conventional immunochemotherapy . Immune checkpoint blockade shown efficacy B- Lymphomas usually present different occurrence patterns across different geographical locations . Lymphomas usually present different occurrence patterns across different geographical locations . To study spectrum lymphoma subtypes prevalent within Zambian population . Thyroglobulin secreted 660 kDa glycoprotein produced thyroid follicular cells . Thyroglobulin secreted 660 kDa glycoprotein produced thyroid follicular cells . Thyroglobulin strongly expressed normal thyroid Glucan-like B-cell lymphomas acquire N-glycosylation sites selectively Ig complementarity-determining regions (CDRs) antigen-binding sites . Mass spectrometry X-ray crystallography demonstrate Ataxia-telangiectasia (A-T) autosomal recessive chromosomal breakage syndrome caused mutation ATM (A-T mutated) gene . Approximately 10% A-T patients develop lymphoid malignancies " Intravascular large B-cell lymphoma rare malignancy characterized presence lymphoma cells within lumen blood vessels . The annual incidence cases fewer 0.5 cases per 1,000,000 . It usually affects elderly average age diagnosis" Diffuse large B-cell lymphoma (DLBCL) clinically genetically heterogeneous lymphoid malignancy . Mechanisms involved treatment associated immune checkpoints remain unclear . " PNT2258 consists native, chemically unmodified, 24-base DNA oligonucleotide designed target regulatory region upstream BCL2 gene, delivered protective liposome . PNT2258 evaluated this, nonrandomized, open" " Primary cutaneous B-cell lymphomas (PCBCL) comprise 25% cutaneous lymphomas, incidence pediatric population unknown, information pediatric PCBCL mostly gathered individual case reports series single centers . This population-based, retrospective cohort" " Malignant lymphoma head rarely arises outside brain parenchyma primary cranial vault lymphoma (PCVL) PCVL invaded subcutaneous tissue brain, passing skull, occurred mild head trauma reported along review literature ." " Part B modified Magrath regimen (IVAC) +/- rituximab (R) recommended standalone therapy national guidelines management relapsed/refractory Burkitt lymphoma, used non-Hodgkin lymphomas (" Malignant lymphoma cases overlapping gastrointestinal (GI) lesions often encountered . We analysed 190 patients diagnosed GI MLs . Twenty-five (13.2%) patients overlapping GI lesions two segments . " HERV genes co-opted serve host functions, notably viral envelope-derived syncytins involved placentation . Vertebrate genomes contain endogenous retroviruses (ERVs) These ERVs (HERVs) encode replication competent" " 42-year-old fitness instructor presented typical appearing left lateral anal fistula . Biopsy fistulous tract revealed B cell lymphoma, graded 1E . Although chemotherapy cured lymphoma, surgical treatment ligation ligation ligation required heal" " Splenic marginal zone lymphoma (SMZL) rare lymphoproliferative disease involving B-cells affecting elderly patients . SMZL plague peripheral blood bone marrow, spleen, spleen . In total 20% cases carry" " Japanese woman initially misdiagnosed metastatic skull tumor, complicated Trousseau syndrome . In head computed tomography examination vertigo, bone destructive skull tumor covering right frontal, parietal, temporal bones incidentally discovered ." " While epidemiologic association of hepatitis B virus (HBV) infection diffuse large B-cell lymphoma (DLBCL) established, little known pathological characteristics outcome DLBCL arising patients HBV infection . We retrospectively studied cohort" Diffuse large B-cell lymphoma common form non-Hodgkin lymphoma common form non-Hodgkin lymphoma globally . Patients relapsed refractory DLBCL typically experience poor long-term outcomes . Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy newer effective therapeutic option approved patients relapsed/refractory acute lymphoblastic leukemia diffuse large B-cell lymphoma . Primary adrenal lymphoma (PAL) primary renal lymphoma (PRL) rare extranodal lymphomas . Primary adrenal renal lymphomas exhibit high predilection central nervous system (CNS) PARL exhibit high Hepatitis C virus (HCV) infection major public health concern worldwide . HCV-related end-stage liver disease one common indications hepatic transplantation . Chronic hepatitis C also assimilated systemic disease multiple extrahepatic manifestations " Primary mediastinal (thymic) large B-cell lymphoma (PMBL) uncommon large B-cell neoplasm recognized World Health Organization distinct entity basis unique clinical features, histogenesis, phenotype, pathogenetic mechanisms" " CD30 antibody-drug conjugate Brentuximab Vedotin (BV) represents powerful, FDA-approved treatment option CD30 . CD30 antibody-drug conjugate Brentuximab Vedotin (BV)" Bone marrow microenvironment is primary location nurturing multipotent hematopoietic stem cells . Bone marrow (BM) microenvironment primary location nurturing multipotent hematopoietic stem cells . " Anti-CD19 chimeric antigen receptor T (CAR-T) therapy achieved remarkable effects refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) However, high tumor bulk occurs" Terminal deoxynucleotidyl transferase (TdT) expression high grade/large cell B-cell lymphoma (LBCL) indicates B-lymphoblastic lymphoma/leukemia (B-L Diffuse large B-cell (DLBCL) follicular lymphomas (FL) primarily diagnosed amongst older patients . Diagnostic delay associated lower chances cancer survival . CD19-directed chimeric antigen T-cell receptor (CAR-T) therapies revolutionized treatment patients relapsed/refractory (R/R) aggressive B-cell lymphomas (aBCL) The results landmark Z " 30-50% diffuse large B-cell lymphoma (DLBCL) cases may relapse treatment . 30-50% of DLBCL cases may relapse treatment . Statistical computational intelligent models powerful tools assessing prognoses . However," Epstein-Barr virus (EBV) convincingly contributed development of several lymphomas . The disease was reported atypical case EBV-positive DLBCL immunocompetent young male patient . Epstein-Barr virus (EBV) detected variety B-cell lymphomas (BCLs) B-cell lymphoproliferative disorders (B-LPDs) Immunodeficiency considered play key role pathogenesis " The role central nervous system (CNS) prophylaxis high-dose methotrexate (HDMTX) DLBCL controversial . In retrospective study, evaluated efficacy prophylactic HDMTX isolated CNS relapse," Primary pituitary lymphoma (PPL) extremely rare disease poor prognosis . Individual precise treatment PPL remains unknown . " Tisagenlecleucel, novel, effective chimeric antigen receptor T-cell therapy, versus salvage chemotherapy (SC) treatment relapsed refractory diffuse large B-cell lymphoma (r/r DLBCL)" " Recent large-scale genetic studies proposed new genetic classification of diffuse large B-cell lymphoma (DLBCL) However, classification methods complicated introduced clinical practice . We developed simplified algorithm classifying four genetic subtypes-MYD88," R-CHOP one main focuses research patients DLBCL . Recent randomized controlled trials (RCT) shown definitive benefit standard R-CHOP . Here conducted systematic review meta-analysis investigate impact strategy . " A 42-year-old female presented lump central upper abdomen one month evidence icterus . Lab Investigations showed deranged Total Bilirubin/Direct Bilirubin, AST, ALT, ALT, ALP, Am" " Diffuse large B-cell lymphoma (DLBCL) clinically heterogeneous entity, first-line treatment currently consists immuno-chemotherapy regimen (R-CHOP) First-line treatment currently consists immuno-che" " Granulomatous inflammation reported associated Hodgkin non-Hodgkin lymphomas . In 2019, 75-year-old Caucasian male presented hospital enlarged right supraclavicular lymph node ." " Tafasitamab (MOR208) Fc-enhanced, humanized, monoclonal antibody targets CD19 . L-MIND trial, open-label, single-arm, phase II study T" " Antiretroviral therapy (ART) became accessible 2004, program substantially expanded . South Africa high HIV prevalence, associates increased risk lymphoma ." Diffuse large B cell lymphoma frequent aggressive non-Hodgkin lymphoma frequent aggressive non-Hodgkin lymphoma . Interim PET response established Hodgkin Lymphoma tailor therapy results non-Hodgkin Morphological analysis bone marrow essential step diagnosis hematological disease . Morphological differential diagnosis abnormal lymphocytes normal lymphocytes still challenging . Digital pathology methods integrated advances machine learning enable new diagnostic features/algorithms . Diffuse large B-cell lymphoma (DLBCL) common type lymphoma high mutation burdens low response rate immune checkpoint inhibitors . We found that DLBCL patients treated standard immunochemotherapy were treated standard immunochemotherapy . " Plastin-3 (PLS3; actin-binding protein) expression associated human carcinogenesis, including pancreatic ductal adenocarcinoma (PDA) Altered Plastin-3 (PLS" " Diffuse large B-cell lymphoma featuring overexpression MYC B-Cell Lymphoma 2 (double expressor lymphoma, DEL) associated poor outcomes . R-CHOP restricted younger patients based limited evidence low patient numbers" CT-based radiomics approach machine learning predicts Primary Treatment Failure (PTF)-DLBCL initial imaging evaluation . Biomarkers identify Diffuse Large B-Cell Lymphoma (DLBCL) likely refractory first Fimepinostat (CUDC-907) demonstrated efficacy phase 1 study patients relapsed/refractory (R/R) diffuse large high-grade high-grade B-cell lymphomas . Patients were particularly " Tisagenlecleucel CD19-directed, genetically modified, genetically modified, autologous T-cell immunotherapy indicated pediatric young adult patients relapsed/refractory B-cell precursor acute lymphoblastic leukemia adult" " Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous aggressive disease . Patients receive first-line therapy, fails 30-40% patients, either refractory relapse remission . Different clinical genetic biomarkers" " Of 1121 patients follicular lymphoma, 171 showed histological transformation diffuse large B-cell lymphoma . Of these, 76 patients, whose biopsies obtained s, 76 patients, whose biopsies obtained s, whose bi" " In 2017, European Medicines Agency approved rituximab biosimilars (R-biosimilars) treatment diffuse large B-cell lymphoma (DLBCL) Thereafter, Netherlands one first countries implement R-" " First case patient refractory diffuse-large B-cell lymphoma underwent CAR T-cell treatment context SARS-CoV-2 . Irrespective prolonged active SARS-CoV-2, SARS-CoV-" " Diffuse large B-cell lymphoma (DLBCL) common histopathological type non-Hodgkin's lymphoma, may arise various extranodal sites . Little known clinical characteristics survival outcomes primary DLBCL" Primary central nervous system lymphoma (PCNSL) rare form CNS tumor . Common clinical feature PCNSL includes dizziness ataxia . " Lymphomas cancers deriving lymphocytes, arising preferentially secondary lymphoid organs, represent 6th cancer worldwide frequent blood cancer . Majority B cell Non-Hodgkin lymphomas (B-NHL) develop germin" In-situ follicular neoplasia occurs approximately 2-3% reactive lymph nodes . The aim study explore parameters . We identified 25 cases of lymphoma composite lymphoma (CL) and 116 cases of LBCL second primary cancer cHL (cHL-LBCL) 116 cases developing LBCL second primary cancer cHL (cHL Richter syndrome (RS) represents development high-grade lymphoma patients chronic lymphocytic leukaemia (CLL) small lymphocytic lymphoma (SLL) presents diagnostic therapeutic challenge adverse prognosis . Diffuse large B-cell lymphoma (DLBCL) genetically heterogeneous disease complex tumor microenvironment (TME) alterations . We aimed identify high-risk DLBCL specific immune cell signatures TME . " Primary lymphoma visual pathway rare, especially chiasm . Primary lymphoma visual pathway rare, especially chiasm ." Hepatitis C virus (HCV) significant healthcare problem affecting ~1% United States population . Direct oncogenic properties HCV proteins may be possible etiologies . Primary mediastinal large B-cell lymphoma (PMBCL) aggressive B-cell lymphoma arising thymic B-cells clinicopathologic features distinct systemic diffuse large B-cell lymphoma (DLBCL) seen Lomentospora (previously Scedosporium) prolificans is nearly universally fatal rapidly-progressive transplant population . Lomentospora is a nearly universally fatal rapidly-progressive transplant population . Differing tumor cells biopsy specimens hampered elucidation of biology . Recent progress using xenograft models plasma cell-free DNA uncovered genetic features similar activated B-cell type diffuse large B-cell lymphoma . Diffuse large B-cell lymphoma (DLBCL) heterogeneous group diseases variable outcomes . Specific biomarkers stratifying treatment strategies fully investigated . " Diffuse large B-cell lymphoma (DLBCL) one several subtypes non-Hodgkin's lymphoma, one present myriad ways . CD5 positivity leads systemic symptoms, relatively high peripheral tumor load, higher" Cardiac diffuse large B-cell lymphoma (cDLBCL) extremely rare disease . We sought evaluate outcomes cDLBCL pre-rituximab eras . We compared survival (overall lymphoma-specific) Fc γ receptor IIB (FcγRIIB) inhibitory molecule capable reducing antibody immunotherapy efficacy . FcγRIIB protein expression could confer resistance to anti-CD20 monoclonal antibody ( " Single-nucleotide polymorphisms (SNPs) shown influence Fcγ receptor (FcγR) affinity activity, effect treatment response response unclear . We assessed importance efficacy of obinutuzumab rituxim" " Plasmablastic lymphoma (PBL) rare aggressive hematological malignancy . PBL commonly occurs immune incompetent patients, human immunodeficiency virus (HIV), post-transplant status, immunosenescence" Patients with diffuse large B-cell lymphoma (DLBCL) rare associated associated poor prognosis . " Primary cauda equina lymphoma extremely rare entity previously documented 24 reported cases . Primary cauda equina lymphoma represents subtype neurolymphomatosis, occurs lymphoma cells neurotropism ." " 542 patients, 85 (16%) age age, 85 (16%) of patients received therapy . 89% received therapy . Four-year PFS 42% vs. 61% (P < .001) patients with age-related" " Bruton tyrosine kinase inhibitors (BTKi) significantly changed treatment landscape patients B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma" Diffuse large B-cell lymphoma (DLBCL) heterogeneous diagnostic category comprising distinct molecular subtypes characterized diverse genetic aberrations dictate patient outcome . As roughly one-third patients DLBCL cured current standard chemoim " Diffuse large B-cell lymphoma (DLBCL) aggressive, heterogeneous neoplasm prognostication therapeutic decision challenging . MicroRNAs, small RNAs frequently deregulated cancer, stably circulate biofluids," Cancer cells addicted ribosome biogenesis high levels translation . Cancer cells achieved targeting aspects ribosome biogenesis ribosome function . " The right atrium, right ventricle pericardium affected tumour, encased mid/distal portion of the tumour, encased mid/distal portion of the tumour . The right atrium, right" Neurolymphomatosis (NL) rare manifestation malignant lymphoma shows selective infiltration peripheral nervous system . A 72-year-old female exhibited asymmetric motor sensory impairments pain lower limbs progressed five months . Magnetic resonance imaging ( " Chimeric antigen receptor (CAR)-T cell therapies improved outcome many patients relapsed refractory aggressive B-cell lymphomas . In 2017, axicabtagene ciloleucel became first approved CAR-T cell" " DNA released cells peripheral blood known cell-free DNA (cfDNA) representing promising noninvasive source biomarkers could utilized manage Diffuse Large B-Cell Lymphoma (DLBCL), among diseases ." Somatostatin receptors (SSTR) chemokine receptor CXCR4 expressed lymphomas . Targeting tumor cells expressing receptors might add therapeutic opportunities radiolabeled ligands imaging therapy developed . Epstein-Barr virus (EBV) encodes >80 genes nearly 50 non-coding RNAs . EBV associated various types lymphomas lymphoproliferative disorders B-cell also T/NK-cell origin . Mediastinal masses commonly present children may pose diagnostic challenges . This article aids pathologist reviewing hematologic differential diagnosis pediatric mediastinal mass . " Mature lymphomas represent third common cancer pediatric patients . Non-Hodgkin lymphoma accounts approximately 60% lymphoma diagnoses children . Aggressive lymphomas, Burkitt lymphoma, diffuse large B-cell lymphoma, ana" " CD19-targeting chimeric antigen rector (CAR) T-cell products used treatment treatment relapsed/refractory B-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma" MyC BCL-2 levels increased in case double hit lymphomas harboring rearrangements . MyC BCL-2 oncogenes enriched patient's population characterized refractoriness anthracycline-based chemotherapy . " Diffusion large B-cell lymphoma (DLBCL) common, curable cancer . In high-income countries, standard care DLBCL R-CHOP (rituximab, cyclophosphamide, dox" Expanding access chimeric antigen receptor (CAR) T cell therapy administration sites impacts patient travel distances time . We used geographic information system techniques calculate shortest travel distance time patients relapsed/refractory diffuse large B cell lymphoma relapsed " CT imaging findings retrospectively assessed compared according to 2 pathologies clinical outcomes . Multiplicity (86% vs 57%, P < 0.05), nec nec (86% vs 57%) was the highest level of multiplicity (" Plasmablastic lymphoma (PBL) aggressive non-Hodgkin lymphoma . PBL common occurrence children presentation malignant effusion rarely reported . HIV positive adult males . ZUMA-1 (NCT02348216) examined safety efficacy axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma . Circulating tumor-derived DNA (ctDNA) emerging biomarker many cancers . PhasED-seq method uses multiple somatic mutations to improve sensitivity ctDNA detection . " Aggressive large B-cell lymphomas (LBCLs) curable, curable, are curable, previous studies shown inferior outcomes minorities . Nurse navigation programs improve patient outcomes providing patient support ." " Inhibition BCL6 BTB domain results killing Diffuse Large B-cell Lymphoma (DLBL) cells, reducing T-cell dependent germinal center (GC) reaction mice, reversing GC hyperplasia nonhuman" Cranial coronal T1-weighted magnetic resonance imaging contrast enhancement showed sellar irregular lesion . Hematoxylin eosin staining showed two different morphologies . Majority tumor cells medium-sized large cells medium- Tafasitamab humanized monoclonal anti-CD19 antibody recently approved FDA combination lenalidomide treatment . Patients relapse refractory first-line therapy diffuse large B-cell lymphoma (DLBCL 71-year-old woman history back pain recent weight loss presented emergency department hematuria . CT scan performed showed left retroperitoneal mass left renal vein thrombus extended vena cava . Tumor biopsy revealed " An 82-year-old man underwent computed tomography, revealed heterogeneous appearing hypodense adrenal mass gastric mass enlarged lymph nodes neck, mediastinum, abdomen, inguinal region . Upper gastrointestinal endoscopy" Glycoprotein non-metastatic melanoma protein B confirmed related pathogenesis tumors . Potential impact GPNMB progression diffuse large B-cell lymphoma (DLBCL) unclear . Knockdown GPNMB Knockdown GPN Study estimated travel-related economic burden associated site-of-care options among patients relapsed/refractory diffuse large B cell lymphoma . We used geographic information system methods to quantify travel-related economic burden across three site-of Richter's transformation (RT) rare complication arising patients chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) associated overall dismal outcome . The rarity entity poses many challenges understanding biology outcomes seen optimal treatment CAR T-cell therapy revolutionized treatment paradigm various hematologic malignancies . CAR T-cell therapy found efficacious various lymphoid malignancies . CAR T-cell therapeutics offer novel immunotherapeutic approach treat otherwise " For years, patients B-cell non-Hodgkin lymphoma treated traditional first-line therapies fairly acceptable outcome . However, individuals relapsed resistant lymphoma respond treatments, including chemotherapy, immunotherapy, radiotherapy, (or" " Chronic lymphocytic leukemia/small lymphocytic lymphoma indolent B cell lymphoproliferative malignancy typically affecting elderly . Clinical outcomes condition steadily improved result advances therapy . However, increase survival accompanied increased incidence of increased" Diffuse large B-cell lymphoma (DLBCL) arise lymph nodes extranodal sites . DLBCLs rarely present soft tissue upper extremity . " Passive antibody therapy used treat outbreaks viral disease, including ongoing pandemic severe respiratory acute respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) COVID-19 . However, real benefits procedure" " Diffuse large B-cell lymphoma (DLBCL) frequent lymphoid neoplasm among adults . 30-40% patients experience relapse, 5-10% suffer primary refractory disease caused by different mechanisms, including treatment" The objective study estimate lifetime costs patients receiving treatment follicular lymphoma (FL) United States . The objective study estimate lifetime costs patients receiving treatment follicular lymphoma (FL) United States . HIV-associated diffuse large B-cell lymphoma (HIV-DLBCL) compare EBV-positive EBV-positive EBV-negative cases . HIV-DLBCL identified two academic medical centres characterised immunoh " chimeric antigen receptor (CAR) T cell therapy is a form of formative treatment for non-Hodgkin lymphoma . 87 patients in open-label, single-arm phase I/II trial received infusion doses 0." " Radiomics features may predict outcome outcome of diffuse large B-cell lymphoma (DLBCL) Currently, multiple segmentation methods used calculate metabolic tumor volume (MTV) We assessed influence segmentation method discriminative power radi" Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent promising therapy relapsed refractory (r/r) lymphoma leukemia leukemia . The common adverse events immune related include cytokine release syndrome neurotoxicity . SADAL study evaluated single-agent oral selinexor patients RR DLBCL . RR DLBCL demonstrated overall response rate (ORR) 29.1% median duration response (DOR) 9.3 months . R-CHOP-21 standard treatment diffuse large B-cell lymphoma (DLBCL) standard treatment . Paucity evidence focusing number cycles regimens . " Primary diffuse large B-cell (DLBCL) lymphoma central nervous system (CNS) new lymphoma entity . Unlike systemic DLBCL, use anthracycline-based chemotherapy combinations associated disappointing outcomes, due low" The purpose study investigate prognostic value PNI diffuse large B cell lymphoma (DLBCL) Median level PNI 45.90 (range 25.30-139.70) median level PNI 45.90 (range 25 " In recent years, adoptive cell therapy immune effector cells, chimeric antigen receptor-T (CAR-T) cells, natural killer (NK) cells, epitope-specific cytotoxic T lymphocyte (CTL) cells" Plasmablastic lymphoma (PBL) rare aggressive variant diffuse large B-cell lymphoma associated HIV infection . Recently reported immunocompetent solid organ transplant patients . PBL commonly presents extranodal regions oral cavity Thyroid lymphoma suspected case rapid enlargement thyroid gland . Young patient history Hashimoto thyroiditis . " Diffuse large B-cell lymphoma (DLBCL) commonest subtype lymphoma elderly poses unique challenges group patients . Demography, clinical features, associated co-morbidities, first line treatment outcomes hospital costs analysed ." Primary Mediastinal B cell lymphoma (PMBCL) biologically clinically distinct subset diffuse large B cell lymphoma . We analysed outcomes cohort PMBCL patients treated Dose adjusted (DA)-R-EPOCH regimen . " Diffuse large B-cell lymphoma third common primary ocular adnexal lymphoma, common primary ocular malignant disease adults . The authors report single case of diffuse large B-cell lymphoma arising lacrimal sac ." Diffuse large B cell lymphoma (DLBCL) heterogeneous disease normally treated combination chemotherapy combined anti-CD20 monoclonal antibody rituximab . Minority patients relapsed refractory (r/r) Endothelial Activation Stress Index (EASIX) score validated allogeneic hematopoietic stem cell transplant setting . Endothelial activation one mechanisms driving immune-mediated toxicities patients treated chimeric antigen receptor- We retrospectively analyzed 16 cases of B-cell lymphoma cutaneous involvement . We used skin flow cytometry (FCM) techniques to identify clonal neoplastic cells . " Libdock applied 17,931 compounds top 20 selected analysis . Selected compounds performed absorption, distribution, metabolism, excretion (ADME) toxicity prediction ." " Spectral graph convolutional neural networks (GCN) proposed incorporate important information contained graphs gene networks . In standard GCN, one gene network describe relationships among genes . However, genomic applications, due condition- tissue-specific gene function" Gray zone lymphoma is an intermediate classical Hodgkin lymphoma diffuse large B-cell lymphoma . Growing number of unanswered questions still number unanswered questions . " Primary central nervous system lymphomas (PCNSLs) rarely exhibit intratumoral hemorrhage . The median age patients 75 years, male predominance ." Comprehensive geriatric assessment (CGA) used help identify elderly patients with diffuse large B-cell lymphoma (DLBCL) DLBCL received R-mini-CHOP 4-week intervals institute 2008 2019 . CAR-T cells represent new anti-tumor immunotherapy shown clinical efficacy B-cell malignancies . CAR-T cells represent new anti-tumor immunotherapy shown clinical efficacy B-cell malignancies . Diffuse large B cell lymphoma (DLBCL) heterogeneity promotes recurrence anti-CD20-based therapeutic resistance . PDK4 overexpression of DLBCL cells markedly elevated DLBCL cells . Our purpose characterize distinct molecular subtypes diffuse large B cell lymphoma (DLBCL) patients treated rituximab-CHOP (R-CHOP) Samples subtype I displayed poorer overall survival time training set . " 58-year-old male admitted hospital due lasting fever, progressive lymphadenopathy bicytopenia, progressive lymphadenopathy bicytopenia, previously histological diagnosis follicular lymphoma grade 3a Epstein-Barr virus-" " Current therapy options cure substantial numbers patients, however still uncurable disease . Patients respond initial therapy experience relapse treated salvage regimens, eligible aggressive therapy, treatment continued high-dose chemotherapy autologous stem cell transplantation ." Lymphomas remain leading cause morbidity mortality of HIV-positive patients . Treatment outcomes improved due chemotherapy modalities effective antiretroviral therapy . " 93-year-old man admitted 1 week frank jaundice abdominal pain . His medical history included diffuse large B-cell lymphoma treated rituximab cyclophosphamide, hydroxydaunomycin, onc" " Chimeric antigen receptor T-cell (CAR T) therapy capable eliciting durable responses patients relapsed/refractory (R/R) lymphomas . However, treated patients relapse. Patterns failure CAR T previously characterized, may" " Interim FDG-PET (iPET) used clinical trials adapt therapy . However, optimum timing methodology iPET remains controversial . We retrospectively analysed 200 DLBCL patients . FDG-PET routinely performed baseline, 2 cycles (" Anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy . Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) B cell Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions patients relapsed refractory (R/R) large B-cell lymphoma (LBCL) CAR T-cell therapy provides long " The epidemiological clinical data PCLs Thailand lacking. To evaluate frequency, demographic data, clinical characteristics different subtypes PCLs tertiary care university hospital. In total, 137 patients PCLs diagnosed hospital 2008-2017 retrospectively" AZD5991 inhibits Mcl-1 high potency . Bcl-2 effectively targeted lymphoid malignancies . Novel approaches target mitochondrial apoptosis necessary . " Diffuse large B-cell lymphoma (DLBCL) frequent lymphoid malignancy affecting adults . NF-κB transcription factor family activated 2 main pathways, canonical alternative NF-κB activation pathway, different functions . Alternative" " Radiation therapy (RT) versatile roles R/R DLBCL treatment: used peri-transplant setting transplant-eligible candidates, salvage palliation therapy . The introduction chimeric antigen receptor (CAR) T-cell therapy changed landscape" " Rarely, types lymphoma reported patients breast implants, raising possibility pathogenetic relationship breast implants types lymphoma . We report eight cases Epstein-Barr virus (EBV)-positive large B-cell lymphoma associated breast implants ." Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma . Development immunotherapy greatly improves patient prognosis exceptions . Screening better biomarkers prognostic evaluation could contribute treatment DLBCL The prognosis patients relapsed refractory diffuse large B-cell lymphoma (R/R-DLBCL) second-line treatment failure failure extremely poor . This study prospectively observed efficacy safety decitabine modified cis MK-7075 (miransertib) MK-4440 small molecules effectively inhibit Akt entered clinical development . " Anaplastic diffuse large B-cell lymphoma(A-DLBCL) rare morphological subtype characterized presence polygonal, bizarre-shaped tumor cells . Status of A-DLBCL remains unclear ." 56 year-old woman diagnosed with primary intradural spinal lymphoma two years ago . She treated successfully surgical resection postoperative radiotherapy . The role of autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy validated accepted standard treatment patients relapsed diffuse large B-cell lymphoma (DLBCL) However " CD155 frequently overexpressed human malignant tumors, associated poor prognosis . CD155 frequently overexpressed human malignant tumors, associated poor prognosis . Serum sCD155 level significantly elevated DLBCL patients diagnosis controls (" " Diffuse large B cell lymphoma (DLBCL) life-threatening malignant tumor characterized heterogeneous clinical, phenotypic, molecular manifestations . Identifying suitable immune biomarker could improve DLBCL diagnosis ." " Glioblastoma second primary malignancy (SPM) reported prostate cancer, meningiomas, Hodgkin's lymphoma . 50-year-old male presented loss consciousness followed right-sided weakness ." PD1/PDL1 status tumor-infiltrating lymphocytes (TILs) reflects immune function . Previously reported methods evaluating status complex may widely used clinical practice . " Adrenal gland incidentaloma (incidental - sudden, accidental) mass adrenal gland(s) Mass adrenal gland(s), accidentally detected instru-mental examination conducted reasons . Mass represented adrenocortical adenomas without" BCR-PI3K-AKT pathway-dependent cholesterol synthesis may represent positive feedback mechanism responsible pathogenesis of BCR-dependent diffuse large B-cell lymphomas (DLBCLs) Restriction lipid synthesis would affect integrity Diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) two aggressive forms non-Hodgkin lymphomas (NHLs) Spontaneous remission DLBCL rare phenomenon . Imm LAG-3 coreceptor found activated T-lymphocytes activated B-lymphocytes natural killer (NK) cells . CD4 closely related CD4 shares multiple common divergent features . One hundred forty seven patients analyzed . The median age 66 years (ICR 56-76) median age 66 years (ICR 56-76) median age 66 years (ICR 56-76) median age 66 years (IC PD-L2 expression clinicopathological features diffuse large B-cell lymphoma (DLBCL) Study shows positive expression PD-L2 present in 45 181 newly diagnosed patients . The univariable multivariable multivariable Cox regression models employed screen gene signatures . DLBCL overall survival (OS) prediction. The differential expression analysis used identify representative genes high-risk l genes high-risk l . " Using SEER-Medicare, 14,533 patients diagnosed NHL age > 65 were identified . Hospitalizations outpatient visits were grouped into 109 non-malignant conditions ." Diffuse large B-cell lymphoma (DLBCL) common lymphoma represents approximately one third non-Hodgkin lymphomas . 40% patients benefit standard first-line immune-chemotherapeutic treatment (i. " Despite recent success regard targeted therapies, patients TP53 disruption (including deletion and/or mutation) continue poor outcomes compared patients CLL . In article, review common TP53 mutations CLL, recent trials using novel targeted agents CLL patients" MYC protein diffuse large B-cell lymphoma (DLBCL) varies among the patients . MYC protein diffuse large B-cell lymphoma (DLBCL) varies among among stabilities . " Diffuse large B-cell lymphoma (DLBCL) frequent commonly diagnosed subtype NHL, characterized high heterogeneity malignancy, characterized high heterogeneity malignancy, DLBCL patients advanced stages . Serine/threonine" " In staging cancer patients, transient spontaneously reversible bilateral adrenal hypertrophy may mimic secondary localization disease . In staging cancer patients, transient spontaneously reversible bilateral adrenal hypertrophy may mimic secondary localization disease ." " EZH2 inhibitors well tolerated in diffuse large B-cell lymphoma (DLBCL) Herein, aimed uncover genetic pharmacologic opportunities enhance clinical efficacy EZH2 inhibitors DLBCL ." " Hematotoxicity represents frequent chimeric antigen receptor (CAR) T-cell-related adverse event . In multicenter analysis, studied patterns hematopoietic reconstitution evaluated potential predictive markers 258 patients receiving axicab" Gain-of-function mutations TLR adaptor oncoprotein MyD88 drive B cell lymphomagenesis . " 70-year-old woman presented general malaise, acute dyspnoea, platypnoea lactic acidosis . Echocardiography revealed extracardiac shunt, cause orthodeoxia ." " Mid-infrared (MIR) microscopic imaging images compared defined pathological characteristics of lymphoma . MIR images compared defined pathological characteristics indolent versus aggressive versus reactive, germinal centre versus activated cell-of-origin (C" " Tazemetostat selective, reversible, small-molecule inhibitor histone methyltransferase enzyme, enhancer zest homolog 2 (EZH2) In multicenter, open-label, phase II study," " Diffusion large B-cell lymphoma tongue base (BOT) extremely rare entity cases described English literature date . The incidence of BOT non-Hodgkin's lymphoma increases age, commonly sixth decade life observed gender differences" " The search immunological markers ability predicting clinical outcome priority lymphomas, cancer general . It well known immunomodulatory cells, myeloid derived suppressor cells (MDSCs) regulatory T cells (Tregs) recruited tumors" Lymphoma common cancer HIV/AIDS patients . 164 HIV/AIDS patients lymphoma admitted Shanghai Public Health Clinical Center July 2013 December 2020 . Median age patients 43 years old; 90.9% (149/164) " Epigenetic changes, aberrant DNA methylation, contribute cancer clonal expansion disease progression . Identifying subpopulation-level changes heterogeneous sample remains challenging ." Dealing high-dimensional censored data challenging complexities data structure . This article focuses developing variable selection procedure censored high-dimensional data AFT models . " Posttransplant lymphoproliferative disorder (PTLD) rare complication solid organ transplant . 40 patients diagnosed with PTLD 2009 2020 analyzed presentation, treatment strategies, outcomes . Median age diagnosis 52.5 years (range 21.3" " HIV-positive patient was 76-year-old HIV-positive patient . Autopsy revealed disseminated large B-cell lymphoma intravascular distribution involving liver, lymph nodes, spleen, spleen, bone marrow associated fibr" Positron emission tomography/computed tomography (PET/CT) 2 [18 F]fluoro-2-deoxy-d-glucose is essential accurate staging early late therapy response assessment FDG-avid " Secondary CNS involvement systemic lymphomas (SCNSL) uncommon, occurs, usually due diffuse large B cell lymphoma (DLBCL) Three recent unusual cases serve highlight diagnostic challenges ." Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma . Secondary cutaneous involvement of DLBCL patients undergoing regular chemotherapy rare . Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA™) antibody-drug conjugate developed treatment B cell lymphomas . Loncastuxim " Bilateral Primary testicular lymphoma (PTL) rare aggressive aggressive non-Hodgkin extranodal lymphoma . Despite low overall incidence, common testicular cancer elderly. PTL characterized spreading non-contiguous ext" Burkitt's lymphoma (BL) aggressive non-Hodgkin B-cell lymphoma . Superior vena cava obstruction (SVCO) considered rare presentation BL usually associated types non-Hodgkin lymphoma " Intensified immunochemotherapy rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) improves outcomes younger adults diffuse" Excisional biopsy (EB) considered gold standard lymphoma diagnosis . We analyzed patients lymphoma diagnostic biopsy National Cancer Center Hospital 2002-2017 . The proportion CNB utility total biopsy procedures increased 11 48% 15 years . " 48-year-old woman diagnosed primary central nervous system lymphoma (PCNSL) after chemotherapy . After chemotherapy autologous stem cell transplantation, presented continuous high-grade fever . Positron emission tomography-computed" Ibrutinib binds BTKCys481 active B-cell malignancies driven mutated MYD88 . Common patients acquired ibrutinib resistance . KIN-8194 showed potent selective vitro killing MYD88- " U.S. Food Drug Administration granted accelerated approval for selinexor treatment adult patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) In June 2020, U.S. Food Drug Administration granted" " c-MYC plays important role regulating cellular growth apoptosis, aberrantly expressed many human malignancies . Little reported anaplastic large cell lymphoma (ALCL) little reported anaplastic large cell lymphoma (AL" " Crystal-storing histiocytosis (CSH) rare tissue phenomenon usually associated lympho-proliferative diseases . The disease usually involves lungs, lymph nodes, bone marrow, bone marrow, thymus spleen" " CGP performed hybridization-captured, adaptor ligation-based libraries using DNA and/or RNA extracted 314,631 tumor samples . CGP performed hybridization-captured, adaptor ligation-based libraries using" " Diffuse large B-cell lymphoma (DLBCL) is a clinically diverse disease . Given numerous genetic mutations variations associated it, prognostic gene signature related overall survival (OS) clinical implication ." " Recent improvements chemoimmunotherapies, targeted agents, stem cell transplants, cellular therapies revolutionized treatment paradigms patients diffuse large B-cell lymphoma (DLBCL) Even relapsed refractory setting," " Lisocabtagene maraleucel (liso-cel) CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered equal target doses CD8 ." Non-Hodgkin lymphomas (NHL) underestimated causes cancer in West Africa . Chronic viral hepatitis HIV endemic in sub-Saharan Africa . " Primary cardiac lymphoma (PCL) rare present wide variety clinical symptoms, frequently leading delay diagnosis . 81-year-old man treated R-CHOP chemotherapy, complete remission ." " The majority diffuse large B-cell lymphoma (DLBCL) patients develop relapsed refractory disease standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, pred" Venous thromboembolic events (VTE) commonly encountered patients lymphoma . Several risk assessments models (RAM) attempted identify higher risk patients . International Prognostic Index (IPI) clinicopathological tool developed help predict 64-year-old female diagnosed abdominal DEL transformed jejunum follicular lymphoma (FL) 18F-fluorodeoxyglucose (FDG)-positron emission tomography showed diffuse accumulation FDG peritone " The systemic immune-inflammation index (SII) based neutrophil, platelet lymphocyte counts, prognostic biomarker solid cancers . However, prognostic value SII yet validated . This study evaluate role SII predicting survival" Elderly classical Hodgkin lymphoma (cHL) rare disease with dismal prognosis standard treatment . Fitness-based approaches may help design appropriate treatments . Sarcopenia associated increased risk treatment-related toxicities worse survival . " Treatment diffuse large B-cell lymphoma (DLBCL) persons AIDS consists chemotherapy alongside antiretroviral therapy (ART) To determine optimal HIV treatment, drug-drug interactions, drug-drug interactions, toxic effects ART resistance" Diffuse large B-cell lymphoma (DLBCL) used defined germinal center B-like non-germinal center B-like non-germinal center B-like subtypes . The potential biomarkers Approximately 15% patients diffuse large B-cell lymphoma (DLBCL) experience refractory early relapsed disease . Sixty-nine consecutive patients primary rituximab-containing chemoimmunotherapy regarded primary ref " Aggressive large B-cell lymphomas (LBCLs) represent frequent clinically molecularly heterogeneous group tumors . Despite increased diagnostic precision noticeably improved molecular understanding lymphomas, clinical perspectives patients largely remain unchanged ." " 88-year-old female brought emergency department due two rapidly growing painful skin lesions local redness swelling right lower leg . Primary cutaneous diffuse large B-cell lymphoma, leg type, accounts 4% cutaneous lymphomas bears worse" " Effect maintenance therapy remains uncertain, effect maintenance therapy remains uncertain . Effect maintenance therapy remains uncertain, suitable maintenance strategy determined lack direct/indirect comparisons . We performed systematic review Bayesian network meta-analysis (NMA) analyze compare effectiveness different" " Diffuse large B-cell lymphoma (DLBCL) represents group tumors characterized substantial heterogeneity terms pathological biological features, causal factor varied clinical outcome . This variation persisted despite implementation rituximab treatment regimens last 20 years ." " CD30 variably expressed diffuse large B-cell lymphoma (DLBCL) prognostic potential affected patients remains debatable . An electronic systematic review performed using multiple databases, followed quantitative meta-analysis assess frequency CD30 expression positivity" We performed prospective quantification axicabtagene ciloleucel (axi-cel) 21 patients treated aggressive B-cell lymphoma clinic . Median peak CAR-T-cell count 16.14 CAR-T cells " Outcomes diffuse large B-cell lymphoma (DLBCL) were either concurrent transformed indolent lymphoma, treated rituximab, cyclophosphamide, doxorubicin, vincristine" " A 52-year-old man fall incidentally found bilateral adrenal masses (6 cm) CT . His adrenal function tests included plasma metanephrines (normetanephrine, 830) Dexamethasone" EBV-positive HHV8-negative EBL part spectrum EBV-positive diffuse large B-cell lymphoma NOS . This entity labeled primary age-related EBV-associated EBL appears respond well rituxim " FUT8 belongs fucosyltransferase family key enzyme involved N-glycan core fucosylation . Glycosylation changes key molecular events tumorigenesis, progression glycosyltransferases play vital role process" " LncRNA FIRRE contributes proliferation, apoptosis resistance, invasion colorectal cancer diffuse large B-cell lymphoma . Biological function of FIRRE hepatocellular carcinoma (HCC) remains unknown ." Primary central nervous system lymphomas (PCNSL) often present unique histopathological feature aggregative perivascular tumor cells (APVT) The aim study determine hypoxia-induced ERS related APVT formation PCNSL This study explored efficacy lenalidomide plus rituximab patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) including cases secondary central nervous system (CNS) involvement transformed follicular lymph " Plasmablastic lymphoma (PBL) aggressive neoplasm commonly develops HIV-positive patients, usually affecting oral cavity . EBV present majority cases, therefore, playing important role pathogenesis neoplasm . PBL diagnosed 2000" " Lymphomas oral oropharyngeal regions relatively uncommon, diagnosis challenging complex due myriad histopathological subtypes . Lymphomas oral oropharyngeal regions relatively uncommon, diagnosis challenging complex due myriad histopathological subtypes" Patients infused infused with autograft absolute lymphocyte count (A-ALC) was 0.5 × 10 . Patients infused infused with infused autograft absolute lymphocyte count (A-ALC) was 0.5 × A 67-year-old woman underwent medical check-up complaining atypical pain shoulder girdle . She underwent extensive imaging thoraco-abdominal CT scanner demonstrated pancreatic mass . Biopsies revealed simultaneous diffuse large B " Doxorubicin is a mainstay upfront treatment for diffuse large B-cell lymphoma (DLBCL) patients . Administration sometimes hampered coexistence former comorbidities/cardiac issues, especially elderly population . Lip" Patients suffering aggressive systemic peripheral lymphoma primary central nervous system involvement (PCL) rare sparsely investigated population . Recommended treatment regimens include combination intrathecal systemic chemotherapy well whole brain radiotherapy offering relatively poor survival . Primary thyroid lymphoma (PTL) rare disease responds well rituximab-based chemotherapy . 58-year-old lady diffuse large B-cell lymphoma central nervous system involvement increased metabolism distal esophagus . Esophageal candidiasis misdiagnosed malignancy misdiagnosed malignancy high SUVmax may Angioimmunoblastic T-cell lymphoma (AITL) subtype mature T-cell non-Hodgkin lymphoma . Compared diffuse large B-cell lymphoma (DLBCL) patients frequently accompanied B-cell neoplasms represent clinically heterogeneous group hematologic malignancies considerably diverse genomic architecture recently endorsed next-generation sequencing (NGS) studies . LYmphoid NeXt-generation sequencing (LYNX " Cachexia defined involuntary decrease body weight, increase risk death cancer patients reduce quality life . Cachexia defined involuntary decrease body weight, increase risk death cancer patients reduce quality life . Cachexia-inducing factors (CIFs) reported colore" This study aimed explore added prognostic value baseline metabolic volumetric parameters cell origin subtypes . NCCN-IPI (NCCN-IPI) nodal diffuse large B-cell lymphoma (DLBCL) Diffuse large B-cell lymphoma (DLBCL) genetically heterogeneous disease makes prognostic prediction challenging . The rapid development research ferroptosis provides possibility use prognosis cancer patients . Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin's lymphoma prognosis activated B-cell-like (ABC) subtype poor . Although R-CHOP significantly improves survival patients " 53-year-old man presented binocular diplopia, gait instability, dizziness bucking . Diagnosed with PCNSL cranial magnetic resonance imaging (MRI) scan brain biopsy . Next-generation sequencing (NG" CD19-directed chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) tisagenleclecleucel (tisa-cel) approved standard care Radiomics analysis found that a response to chemotherapy was predicted by PET/CT analysis . Forty-five patients received first-line chemotherapy diffuse large B-cell lymphoma (DLBCL) included study . Primary mediastinal involvement rare (5%) very occurring injury very common in Secondary mediastinal involvement systemic disease common (10% 25%) Primary mediastinal disease defined involvement lymphoprol R-CHOP remains treatment choice diffuse large B-cell lymphoma . HIV-Burkitt lymphoma CODOX-M/IVAC proved superior EPOCH large retrospective study . The purpose report describe biopsy-proven ocular sarcoidosis (OS) 67-year-old patient history sarcoidosis diffuse large B-cell lymphoma (DLBCL) The association sarcoidosis mal " Selinexor, first-in-class inhibitor nuclear export protein Exportin-1 (XPO1) recently approved treatment multiple myeloma combination dexamethasone, monotherapy diffuse large B-cell lymphoma ." " Fifty percent of diffuse large B cell lymphoma (DLBCL) cases lack cell-surface expression class I major histocompatibility complex (MHC-I) This escape recognition of cytotoxic T cells, thus escaping recognition" " Geriatric 8 (G8) treatment stratification overall survival (OS) We conducted retrospective, multicentre analysis older patients (≥65 years) DLBCL . The primary endpoint was OS. The total average relative dose intensity" " Anti-CD20 antibody, rituximab, developed address safety, infusion time, patient comfort concerns relating intravenous (i.v.) dosing, approved based upon pharmacokinetic (PK)-clinical bridging strategy ." " Large B-cell lymphomas (LBCLs) constitute subgroup aggressive highly curable lymphoproliferative diseases . Treatment relapsed/refractory (R/R) patients still represents unmet clinical need, novel" " 68-year-old man presented two-week history of ascending, symmetric, sensory neuropathy concerning acute inflammatory demyelinating polyneuropathy . Initial workup negative acquired causes . After three months poor response standard therapies," MRI revealed multiple nodules suggestive lymphoma . Biopsy performed led pathological diagnosis diffuse large B-cell lymphoma . " Cytopenias systemic lupus erythematosus (SLE) require clinical laboratory workup bone marrow examination . Common causes include increase SLE activity, immune-mediated hemolysis, iron deficiency, antiph" Rheumatoid arthritis (RA) common autoimmune disease methotrexate (MTX) widely used first-line therapy . The combination RA MTX associated lymphoproliferative disorders (LPD) The combination RA MTX " 116 patients (48% female, median 64 years) were treated for diffuse large B-cell lymphoma (DLBCL) retrospectively reviewed . The study looked at the prognostic role sarcopenia fat compartment distributions overall survival (" " Lymphoma heterogeneous disease varying clinical manifestations outcomes . Many subtypes lymphoma, Burkitt's lymphoma diffuse large B cell lymphoma, highly aggressive prognosis even conventional chemotherapy radiotherapy . Lymphoma high clinical significance ." " Even patient young female, primary pulmonary diffuse large B-cell lymphoma could considered differential diagnosis of multifocal consolidation lung ." Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma Asia Indonesia . DLBCL could classified according cell origin germinal center B-cell (GCB) subtype Clinical trials involving patients diffuse large B-cell lymphoma (DLBCL) sub-Saharan Africa since antiretroviral therapy (ART) HIV became widely available region . We aimed establish safety efficacy rituximab plus 71-year-old gentleman presented testicular lump following trauma . Ultrasound imaging testicle demonstrated malignancy . Orchidectomy listed . Activating mutations is a key to fighting mutations in the body of the dinosaurs . Activating mutations is a key to fighting mutations in the wild . " Diffuse large B-cell lymphoma (DLBCL) highly heterogeneous disease represents common subtype lymphoma . 60-70% patients cured current standard care frontline setting, but majority remaining patients experience treatment resistance poor clinical outcome ." SCNSL poor prognosis lack effective treatment regimens. SCNSL poor prognosis lack effective treatment regimens. SCNSL poor prognosis lack effective treatment regimens. We aimed establish predictive prognostic risk-stratification model diffuse large B-cell lymphoma (DLBCL) rituximab era . The data 1406 primary DLBCL patients Sun Yat-Sen University Cancer " Diffuse large B-cell lymphoma (DLBCL) characterised marked clinical biological heterogeneity, attributable tumour cells microenvironment . Study investigated circulating subsets blood lymphocytes monocytes monocytes monocytes relationship T cells tumour micro" " 81 cases of lymphoproliferative disorder (PTLD) allogeneic haematopoietic stem cell transplants (allo-HSCT) analysed histopatholgy, immunohistochemistry situ hybridisatio" Lisocabtagene maraleucel (Breyanzi) is a cell-based gene therapy approved for adults . It is approved to treat adults various relapsed refractory large B-cell lymphomas . " Orbital lymphoma is non-Hodgkin lymphoma . Orbital lymphoma either primary secondary or primary secondary . Common symptoms include bilateral unilateral proptosis, swelling, pain, changes visual acuity, diplopia ." " The outcome of diffuse large B-cell lymphoma (DLBCL) patients improved immunochemotherapy combination R-CHOP . An increased rate heart failure well documented following treatment, whereas incidence outcome cardiac complications, example myocardial inf" " Several cancer cells express high levels of A3G, diffuse large B-cell lymphoma cells glioblastomas, show enhanced cell survival ionizing radiation chemotherapy treatments . Previously, showed hA3G promotes (DNA) double" Pracinostat pan-HDACi promising early clinical activity . Diffuse large B-cell lymphoma (DLBCL) includes distinct molecular subsets metabolically defined subtypes . Pracinostat pan-HD We identified patients non-Hodgkin lymphoma (NHL) Hodgkin lymphoma January 2014 December 2015 . Patients categorized 2 groups: sepsis progressive lymphoma . To distinguish sepsis vs. progressive lymphoma patients " Diffusion large B-cell lymphoma (DLBCL) important manifestation within HIV-infected compartment population . HIV able modulate B cells promote lymphomagenesis direct indirect mechanisms, HIV-related DLBCL specific characteristics ." " The synchronous occurrence of primary breast cancer lymphoid tissue malignant tumors rarely reported literature . A 78-year-old woman diagnosed with breast cancer core biopsy, complaint progressively worsening low back pain ." " 44-year-old presenting breathlessness second trimester pregnancy diagnosed pulmonary diffuse large B cell lymphoma (DLBCL) complicated placenta accreta spectrum (PAS) disorder . In pregnancy, treated rituxim" " Circulating tumor DNA (ctDNA) used evaluate prognosis lymphoma . Circulating tumor DNA (ctDNA) used evaluate prognosis lymphoma . However, uniform consensus mechanistic role ctDNA plays prognosis lymphoma ." Loncastuximab tesirine CD19-directed antibody-drug conjugate encouraging phase 1 single-agent antitumour activity acceptable safety non-Hodgkin lymphoma . Patients relapsed refractory diffuse Inadequate diagnostics compromise cancer care across lower-middle-income countries . We hypothesized inexpensive gene expression assay using paraffin-embedded biopsy specimens could distinguish lymphoma subtypes without pathologist input . " Serum glucocorticoid-regulated kinase 1 (SGK1) one frequently mutated genes diffuse large B-cell lymphoma (DLBCL) However, little known function consequence mutation led to assumption SGK1 must" " Nanometer-sized nanometer-sized vesicles emerged promising non-invasive biomarkers cancer diagnosis . Exosomes, nanometer-sized . nanometer-sized . vesicles body fluids, emerged promising non-in" Cardiac lymphomas rare extranodal lymphomas involving primarily secondarily heart and/or pericardium . Cardiac lymphomas rare extranodal lymphomas involving primarily secondarily heart and/or pericardium Ovary involvement non-Hodgkin lymphoma (NHL) rare . We report rare case ovarian NHL adolescence revealed bone metastasis . " MicroRNA (miRNA/miR)-383-5p reported several malignancies, including breast cancer, gastric cancer, ovarian cancer lung adenocarcinoma . function of function diffuse large B-cell lymphoma" " TUC338 emerging novel vital long noncoding RNA (lncRNA) human cancer . Role of role diffuse large B cell lymphoma (DLBCL) remains unknown . High TUC338 closely related advanced Ann Arbor stage," " EBV-positive diffuse large B cell lymphoma, otherwise specified (DLBCL NOS), EBV-positive mucocutaneous ulcer (EBV MCU), EBV-positive mucocutaneous ulcer (" " In patients presumed primary CNS lymphoma (PCNSL), systemic manifestation found small minority . Bone marrow biopsy (BMB) recommended staging, diagnostic value unclear . A retrospective analysis 392 patients presumed PCNSL 3 university hospitals 3 university" " Primary pancreatic lymphoma (PPL) rare disease representing 0.1% malignant lymphomas . We conducted systematic review analyze demographic, diagnostic therapeutic features PPL . This review identified small series single case reports . Data screened, extracted" " EGR1 characterized tumor suppressor leukemia multiple myeloma, role EGR1 lymphoma unknown . EGR1 expression elevated DLBCL compared normal lymphoid tissues level ." " 78-year-old man suffered anemia sigmoid colon cancer, colonoscopy revealed early-stage colorectal cancer diameter 20 mm cecum . Contrast-enhanced computed tomography (CT) revealed bowel wall" " Post-transplant lymphoproliferative disorders (PTLD) exclusively affecting central nervous system-primary CNS-PTLD (pCNS-PTLD) are rare . There standard therapy, previous case series included heterogeneous treatment" Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) located meeting-point ERK p38 MAPK signaling pathways . MNKs modulate translation mRNA involved tumor-associated signaling pathways . " We describe unusual case lymphomatosis cerebri middle-aged lady presenting rapid-onset dementia . The lymphomatous infiltrate, instead forming mass lesions, percolated throughout brain parenchyma ." " Bruton tyrosine kinase inhibitors found effective treatment primary central nervous system diffuse large B cell lymphoma . Vitreoretinal lymphoma (VRL) rare intraocular malignancy, standard treatment approaches defined yet . Bruton" " The cell origin (COO) classification germinal center B cell (GCB) non-GCB types shown predict survival outcomes . In relapsed/refractory (R/R) setting, building evidence COO predict" " Autologous hematopoietic stem cell transplantation (ASCT) standard-of-care treatment many hematologic malignancies . Progression disease ASCT primary cause treatment failure . In Phase Ib trial, studied" " The common liver malignancies hepatocellular carcinoma, intrahepatic cholangiocarcinoma, metastatic tumors are common . Hepatocellular carcinoma intrahepatic cholangioc" Dilemma of treating elderly patients with R-CHOP DI DLBCL often faced clinicians . We conducted systematic review assessing impact R-CHOP DI DLBCL survival outcomes . " Diffuse Large B-Cell Lymphoma (DLBCL) presents high clinical biological biological heterogeneity, tumor microenvironment chracteristics important progression . The aim study evaluate tumor T, B cells, macrophages mast cells distribution" c-Rel DNA-binding activity associated increased with GCBs . GCBs were found to be two independent series 48 DLBCLs and 66 DLBCLs . Relationships c-Rel GCB-DLBCLs remain " Long noncoding RNA (lncRNA) play important role almost kinds human cancers . Linc00908 reported involved development prostate cancer, colorectal cancer gastric cancer functioned oncogene ." " The aim study evaluate effect Controlling Nutritional Status (CONUT) score prognosis patients diffuse large B-cell lymphoma (DLBCL) The CONUT score calculated based serum albumin, total cholesterol lymphocyte lymphocyte levels" Relapsed diffuse large B-cell lymphoma (DLBCL) disease has poor prognosis . Patients extranodal lesions respond poorly CAR-T cells administered intravenously . " Routine follow-up follow-up diffuse large B-cell lymphoma shortened 2 years event-free survival 24 months (EFS24) emerged new milestone . We compared OS age- sex-matched population, analysed factors governing OS" " Neuromyelitis optica spectrum disorder (NMOSD) uncommon antibody-mediated disease central nervous system . NMOSD may present subacute myelopathy, progressing days MRI revealing contiguous inflammatory lesion spinal cord ." Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET) potential guide treatment patients diffuse large B-cell lymphoma (DLBCL) prognostic Polatuzumab vedotin (pola) CD79b-targeted antibody-drug conjugate delivering potent antimitotic agent (monomethyl auristatin E) B cells . This open-label We assessed concordance immunohistochemistry (IHC) gene expression profiling (GEP) determining diffuse large B-cell lymphoma (DLBCL) cell origin (COO) We assessed concordance immunohist We constructed prognostic score persons diffuse large B-cell lymphoma (DLBCL) based infiltrating immune cells . Immune risk score comprised eight types non-lymphoma immune cells calculated using CIBERSORT algorithm . 38-year-old man presented four months worsening dyspnea exertion nonproductive cough . CT neck chest revealed prominent cervical lymph nodes diffusely spread cirrhosis . Gray zone lymphoma (GZL) rare type B-cell lymphoma characterized features diffuse large B-cell lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma (cHL) The prognosis GZL poorer c " A 70-year-old female referred brown-to-gray colored papules nodules lower legs . Diagnosed diffuse large B-cell lymphoma (DLBCL) stomach, myelodysplastic syndrome (MDS" Diffusion large B-cell lymphoma (DLBCL) involving different primary extranodal sites distinct clinicopathological characteristics prognosis . Risk secondary malignant neoplasms (SMNs) DLBCL survivors different primary ext Tisagenlecleucel (tisa-cel) is second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved . Tisagenlecleucel (t The efficacy side effects second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy . The efficacy side effects second-time humanized CD19 chimeric antigen receptor (CD19-CAR) " Primary intestinal diffuse large B-cell lymphoma (PI-DLBCL) rarely reported . We aimed explore role surgery patients PI-DLBCL . Adult PI-DLBCL patients included Surveillance, Epidemiology, End Results database" " 78-year-old male male patient presented palpable masses left breast right groin, pathologically confirmed surgical biopsy breast mucinous carcinoma diffuse large B-cell lymphoma . He underwent whole-body 18-fluorine deoxy" Berberine downregulated expression CD47 DLBCL transcriptional level suppressing c-myc expression . Berberine downregulated expression CD47 DLBCL transcriptional level suppressing c-myc expression . Chimaeric antigen receptor T-cell (CAR T) therapy revolutionized management many haematological malignancies . It associated impressive disease responses relapsed refractory high-grade B-cell non-Hodgkin Selinexor selective inhibitor nuclear export active agent various malignancies . It currently approved relapsed refractory diffuse large B-cell lymphoma well multiple myeloma well multiple myeloma well multiple myeloma . Intestinal microecology plays important role development progression hematological malignancies . Intestinal microecology plays important role development progression hematological malignancies . CAR-T19 monitoring could increase understanding treatment responses relevance patient management . An assay uses fluorochrome-conjugated human recombinant solubinant solubinant solubinant solub . B-cell lymphomas one biologically molecularly heterogeneous group malignancies . B-cell lymphomas one biologically molecularly heterogeneous group malignancies . This study aimed identify prognostic factors patients Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) We conducted retrospective analysis 134 patients diagnosed with WR-DLBCL . " Waldenström macroglobulinemia (WM/lymphoplasmacytic lymphoma) rare indolent B-cell neoplasm, gain-of-function mutation myeloid differentiation primary response" CD19-directed chimeric antigen receptor (CAR) T-cell therapy shown efficacy third-line later treatment patients relapsed/refractory large B-cell lymphoma (LBCL) Using European Organization Research Treatment Cancer Quality Tazemetostat represents first epigenetic therapy approved treatment follicular lymphoma (FL) It inhibits activity enhancer zeste homolog 2 (EZH2) histone methyltransferase . It inhibits activity enhancer z " Synthetic biology adoptive T-cell transfer led promising advances treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL)," " The patients hematological malignancies vulnerable group COVID-19, due immunodeficiency resulting underlying disease oncological treatment significantly impair cellular humoral immunity . Here report beneficial impact passive immunotherapy convalescent plasma treat prolonged" This study utilizes large population national database comprehensively analyze prognosticators overall survival (OS) outcomes . Large cohort sinonasal diffuse large B-cell lymphoma (SN-DLBCL) patients were diagnosed 2004 2015 . Diffusion large B-cell lymphoma (DLBCL) categorized germinal center B-cell (GCB) non-GCB subtype . Recent integrated genomic analyses highlighted importance JAK-STAT3 pathway molecular pathogenesis Over past decade therapies targeting PD-1 axis monoclonal antibodies reinstate host immune function revolutionized clinical management cancers . This dichotomy exemplified B cell lymphomas. " Richter syndrome (RS) defined occurrence aggressive lymphoma, commonly diffuse large B-cell lymphoma, commonly diffuse large B-cell lymphoma (DLBCL) rarely Hodgkin lymphoma (HL) HL is often associated with" " 3-year-old, 3.5-kg, neutered male, domestic shorthair cat presented progressive lethargy, anorexia, coughing, coughing, acute respiratory distress two-week duration . Auscultation detected" Chimeric antigen receptor (CAR) T-cell therapy induce side-effects cytokine release syndrome . The aim study describe management critically ill CAR T-cell recipients intensive care . Vascular endothelial growth factor affects invasiveness solid tumors regulating angiogenesis . It is not clear whether VEGF could used predict prognosis for DLBCL era rituximab-based immunotherapy . Infection-related morbidity mortality increased older patients diffuse large B-cell lymphoma (DLBCL) compared population-matched controls . Key predictive factors infection-related hospitalization treatment rituximab plus cyclophosphamide Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) complicated angioimmunoblastic T-cell lymphoma (AITL) extremely rare typically shows aggressive clinical course unsatisf A 74-year-old man with diffuse large B-cell lymphoma underwent 18F-FDG PET/CT evaluate response chemotherapy . Granulocyte colony-stimulating factor incidentally administered 1 hour FDG administration . Bone marrow FD " Despite central nervous system (CNS) relapse occurring >10% high-risk diffuse large B-cell lymphoma (DLBCL) patients, role CNS-directed prophylaxis is controversial absence randomized controlled trials ." " Primary esophageal lymphoma extremely rare . The frequent site extranodal appearance primary non-Hodgkin's lymphomas (NHL) gastrointestinal (G.I.) tract) However, primary esophageal" 40-year-old man previously treated chemotherapy radiotherapy developed conjunctival lymphoma . He developed conjunctival lymphoma after developing cancer post-radio-chemotherapy . " Fine-needle aspiration cytology (FNAC) lymph nodes, tissue fragments derived follicular structures may observed specimens . We defined tissue fragments follicular tissue fragments follicular tissue fragments (FTF) and investigated differences cytological findings F" Common variable immune deficiency (CVID) confers increased risk lymphoid neoplasms . Median time onset CVID lymphoma 14 years . Patients showed high prevalence preceding immune dysregulation: lymphadenopathy . " diffuse large B-cell lymphoma (DLBCL) still poses substantial therapeutic challenge . Despite development novel targeted drugs, diffuse large B-cell lymphoma (DLBCL) still poses substantial therapeutic challenge ." " 16 patients (28 eyes) recruited from Department Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College Hospital, 2004 2019 . All patients underwent comprehensive ophthalmic examinations ." R-da- EPOCH potentially effective also toxic R-CHOP. R-da- EPOCH potentially effective also toxic R-CHOP. Reliable prognostic classification needed guide treatment decisions. An 81-year-old Japanese female diagnosed with IPMN developed elevated carbohydrate antigen (CA19-9 levels follow-up . Endoscopic ultrasound (EUS) performed revealed suspicious lesion pancreatic tail . " Chimeric antigen receptor T cell (CART) therapy benefited many refractory lymphoma patients, patients experience poor effects . Previous studies shown programmed cell death protein-1 (PD-1) inhibitors improve prolong therapeutic effect CAR-" " B cell lymphoma (BCL) heterogeneous group lymphoid malignancies comprise majority canine lymphomas . Diffuse large B cell lymphoma common lymphoma common lymphoma subtype dogs subtypes (e.g., marginal zone" Primary mediastinal large B-cell lymphoma (PMBCL) distinct clinicopathologic disease types diffuse large B-cell lymphoma (DLBCL) unique prognostic features limited availability clinical data . The current standard treatment newly Primary Lymphoma bone (PBL) uncommon extranodal tumor accounting 1% malignant lymphomas . The incidence PBL rare many aspects remain unknown . Diffuse large B cell lymphoma (DLBCLs) constitute 40% non-Hodgkin lymphoma . We analysed outcomes clinical features based cell origin series patients . A 67-year-old woman history swelling sternoclavicular joint region considered osteoarthritis initially considered osteoarthritis initially . Chest CT found soft tissue mass around sternoclavicular joint . Biopsy demonstrated diffuse large B Foxp3 is a popular music series on Foxp3 . It is a weekly weekly feature on Foxp3 . 21 patients reported EBMT registry received autoSCT PTLD post solid organ transplant (SOT) Median age autoSCT 47 (range: 22-71 years) Median age autoSCT 47 (range: 22-71 " The gastrointestinal (GI) tract home significant portion immune system, interacts daily antigenic milieu contents . Presence white blood cells within walls GI tract upon histologic examination familiar sight GI biopsies-both health disease ." " Chimeric antigen receptor T cell (CAR-T) therapy far proved reliable therapeutic option treatment relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-" Platelet-derived growth factor receptor A (PDGFRA) receptor tyrosine kinase activated mutations 10% gastrointestinal stromal tumors (GISTs) 55% 70% inflammatory fibroid polyps . PDGFRA- " We present rare case primary effusion lymphoma (PEL) 75 year old, HIV-negative male patient multiple comorbidities . Imaging studies revealed massive right pleural effusion significant lung collapse multiple plural soft tissue nodules ." " Human immunodeficiency virus (HIV) infection associated increased risk aggressive lymphoma, especially diffuse large B cell lymphoma (DLBCL) China. We retrospectively studied HIV-infected patients DLBCL 2011 2019." Eligibility criteria randomised control trials (RCT) may becoming increasingly strict . 42 first-line phase III RCTs enrolling DLBCL patients since 1990 identified . Diffuse large B-cell lymphoma (DLBCL) frequent histological subtype primary genitourinary lymphoma . Lymphomatous involvement genitourinary system organs common setting disseminated disease . " CC-122 next-generation cereblon E3 ligase-modulating agent demonstrated promising clinical efficacy . CC-122 induces degradation of IKZF1/3, leading T-cell activation robust cell-autonomous killing" T cells interferon-driven inflammatory signaling contribute to tumor microenvironment . T cells interferon-driven inflammatory signaling contribute to tumor microenvironment . " Primary lymphoma larynx extremely rare, representing less 1% primary laryngeal neoplasms . It consists mainly non-Hodgkin lymphomas (NHLs) It consists mainly non-Hodgkin" " 92-year-old male, history statin/ezetimibe intake, complained pain swelling left forearm . Symptoms aggravated 2 months immunomodulatory therapy . Biopsy protrusion lesion turned primary cutaneous diffuse large B-" Nanotechnology provides exciting opportunities to improve drugs . Nanotechnology-enhanced therapy focusing on diffuse large B-cell lymphoma (DLBCL) is possible . " In 2019, tisagenlecleucel, CD19-directed chimeric antigen receptor T cell therapy, approved r/r DLBCL Japan . There limited treatment options substantial unmet needs adult patients relapsed refractory" " Use of synthetic biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) increased . However, whether ts/bDMARDs associated development clinicopathological features MTX-associated lymphoprolifer" " DCZ0825 novel compound derived pterostilbene osalmide, whose antitumor activities drawn attention . DCZ0825 exhibited high cytotoxicity toward DLBCL cell lines ." " Takotsubo cardiomyopathy (TCM) is stress induced cardiomyopathy . Often seen women older individuals . Often seen women older individuals acute stressors, cause significant hemodynamic compromise ." " Glaucoma uveitis symptoms found left eye 50-year-old woman upon admission hospital . After treatment pathological examination, iris left eye diagnosed DLBCL . Primary enucleation offered therapeutic option ." Burkitt-like lymphoma (B-LL) rare tumor classified high-grade B-cell malignancy . Thirteen dogs histologically proven B-LL were retrospectively selected . " Non-Hodgkin lymphoma (NHL) common type hematological malignant tumor . Common type hematological malignant tumor, composed multiple subtypes originate B lymphocytes, T lymphocytes, natural killer cells ." Long-chain non-coding RNAs (LncRNAs) expressed diffuse large B-cell lymphoma (DLBCL) tissues played regulatory role DLBCL cancer-promoting effect . SNHG8 overexp " Primary lymphoma temporal bone extremely rare, difficult diagnose manage . We report rare case diffuse large B-cell lymphoma 70-year-old- woman, history diabetes ." Refractory/relapsed B cell lymphoma patients received available anti-CD19 chimeric antigen receptor (CAR) T cells . Patients may still experience short duration remission . Central nervous system (CNS) relapse affects 5% diffuse large B-cell lymphoma (DLBCL) patients portends poor prognosis . Prophylactic intravenous high-dose methotrexate (HD-MT " MYC rearrangements (MYC-R) confer unfavorable prognosis large B-cell lymphomas (LBCL) Because low incidence genetic alteration, surrogates screen MYC-R may useful daily practice . Previous studies suggested" The FBXO11 protein involved BCL-6 ubiquitination BCL-6 required germinal center reaction resulting B cell differentiation . The FBXO11 protein involved BCL-6 ubiquitination BCL-6 " Plasmablastic lymphoma (PBL) uncommon human immunodeficiency virus (HIV)-associated lymphoma, predilection develop oral cavity . It usually plasmablastic morphology weak expression B cell-associated markers ." To describe experience performing biopsy post-septal orbital masses core needle computerized tomography guidance (CT-CNB) The medical records patients underwent procedure reviewed . The procedure performed local anesthesia day case basis peribulbar block Diffuse large B-cell lymphoma (DLBCL) frequent non-Hodgkin lymphoma worldwide . R-CHOP cures approximately 70% DLBCL patients . Chimeric antigen receptor (CAR) T-cell therapy genetically modified cellular therapy approved treatment acute lymphocytic leukemia B-cell lymphoma . This therapy requires patients remain hospitalized at least 7 days monitor two black-box warnings: cytok " PET-computed tomography (PET) treatment response evaluation increased diffuse large B-cell lymphoma (DLBCL) Although predictive value of PET-computed tomography is controversial, predictive value of PET-CTs is controversial" " 59-year-old female progressive worsening pain right hypochondrium weight loss . During initial investigation, three liver nodules suggestive liver metastases found . Primary neoplasm id primary neoplasm id found ." " Primary central nervous system lymphoma (PCNSL) uncommon variant extra-nodal non-Hodgkin's lymphoma . Three regions involved PCNSL: brain, spine, vitreus retina . Spinal PC" " CAR-T cells shown extraordinary effects hematologic diseases including chemotherapy-resistant acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) In approach," " T lymphocytes involved therapeutic responses in diffuse large B-cell lymphoma (DLBCL) However, tumor-specific TILs dysfunctional, impaired effector functions . Various mechanisms involved exhaustion, increased expression programmed cell death receptor 1 (" " Infliximab developed nasopharyngeal diffuse large B cell lymphoma . Infliximab discontinued, complete remission achieved following chemotherapy . However, patient subsequently experienced severely symptomatic Crohn's disease relapse ." " Richter syndrome (RS) is associated with poor prognosis for chronic lymphocytic leukemia . Conventional chemotherapy results limited responses, underlining need for novel therapeutic strategies . Study used ex-vaxax and duvelisib to" " Loss-of-function mutations KMT2D striking feature germinal center (GC) lymphomas . We hypothesized inhibition KDM5 family, demethylates H3K4me3/me2, would reestablish H" " PI3Kδ expressed predominately leukocytes overexpressed B-cell-related malignances . PI3Kδ validated promising target cancer therapy, specific PI3Kδ inhibitors approved clinical practice . However," Third-space fluid accumulations may develop worsen cytokine release syndrome (CRS) associated chimeric antigen receptor (CAR) T cell therapy . Pre-existing symptomatic pleural effusions excluded ZUMA-1 trial axic CD19-targeted chimeric antigen receptor (CAR) T cells shown excellent activity in relapsed refractory (R/R) diffuse large B cell lymphoma (DLBCL) CAR T cell therapy associated early toxicities " 58 patients diagnosed with diffuse large B-cell lymphoma diagnosed with rrDLBCL . Diagnosis was initially negative, but new treatments overcome resistance required ." " The incidence synchronous multiple primary malignancies (MPMs), include solid hematological malignancy, considered rare . The incidence synchronous multiple primary malignancies (MPMs), include solid hematological malign" Gastrointestinal lymphoma accounts 20% extranodal lymphoma cases . Gastrointestinal lymphoma accounts 20% extranodal lymphoma cases . Majority gastrointestinal lymphoma originates B cell lineage . " A 67-year-old previously healthy woman presented progressive visual impairment including bitemporal hemianopsia . CT scans chest, abdomen, pelvis, PET-CT, bone marrow biopsy revealed evidence systemic lymphoma ." FNAC plays important role differentiating non-mammary breast metastasis primary malignancy . Metastasis breast extra-mammary origin rare . Metastasis breast extra-mammary origin rare . Richter transformation (RT) development aggressive lymphoma - frequently diffuse large B-cell lymphoma (DLBCL) rarely Hodgkin lymphoma (HL) Richter transformation (RT) development aggressive lymphoma - frequently diffuse large B " MYC-rearranged large B-cell lymphoma BCL2 and/or BCL6 rearrangement, double-hit (DH) triple-hit (TH) lymphoma, associated poor survival standard treatment ." " There may significant histopathologic overlap EBV-positive DLBCL, NOS, diagnoses including angioimmunoblastic T-cell lymphoma (AITL) Resolution differential diagnosis may particularly challenging require extensive investigation clinicopath" " Chromosomal rearrangements involving BCL2, BCL6 MYC commonly found frequent B cell lymphomas . Fowlicular lymphomas (FLs) are follicular lymphomas (FLs) diffuse large B-cell" 140 patients relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) March 1995 November " 512 DLBCL patients underwent BMB received rituximab combined cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) chemotherapy . Lymphoma-" Posttransplant lymphoproliferative disease (PTLD) common malignant complication solid organ transplantation . Gastrointestinal involvement presentation early PTLD occur 25-30% pediatric liver transplant recipients system involved 20% Recurrent gastrointestinal per Inherited genetic risk factors play role multiple myeloma (MM) yet considerable missing heritability exists . Rare risk variants genome-wide association study (GWAS) loci new avenue explore . RNA binding proteins (RBPs) increasingly appreciated essential normal hematopoiesis critical role progression hematological malignancies . But functional consequences of RBPs' role in diffuse large B-cell lymphoma remain unknown . " Primary gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) common gastrointestinal lymphoma, genetic features poorly understood . We performed whole-exome sequencing 25 primary tumor samples patients patients GI-DLBCL 23 matched normal" An 80-year-old woman presented hospital vomiting abdominal distension . Enteroscopy showed type 2 circumferential tumor proximal jejunum 6 cm anal side Treitz ligament . Biopsy showed solid diffuse proliferation large atyp " We retrospectively reviewed diffuse large B-cell lymphoma (DLBCL) patients aged . aged . 50 years, underwent first R-CHOP cycle July 2010 March 2017 . Multivariable logistic regression analysis performed identify factors associated" 57-year-old woman presented complaint lower abdominal discomfort . Computed tomography scan abdomen pelvis revealed mass left adrenal measuring 2.0 cm radiologically considered AML . " We retrospectively evaluated 89 patients DLBCL. All patients were baseline interim interim 18F-FDG PET/CT . Seventy-nine also end-of-treatment PET/CT (EOT-PET) For scan," " Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) indolent small B-cell neoplasm may transform clinically aggressive disease, namely Richter syndrome, usually diffuse large B-cell lymph" " There epidemiological registry Mexico. The information epidemiology country obtained types studies, multicentric studies . A lot improvements survival survival non-Hodgkin lymphoma patients occurred last 20 years ." Diffuse large B-cell lymphoma (DLBCL) aggressive type lymphoma high mortality poor prognosis especially high incidence Asia . Accurate segmentation DLBCL lesions crucial clinical radiation therapy . Manual delineation DLBCL lesions 70-year-old-man presented renal mass diagnosed diffuse large B-cell lymphoma . " 75-year-old woman developed redness swelling truncal skin, spreading lower abdomen left thigh, 2 months admitted hospital . She urgently hospitalised worsening respiratory condition . Diagnosed intravascular large B-cell lymphoma (IV" Chinese patients were diagnosed with renal parenchymal infiltration malignant B-cells . The clinicopathological characteristics outcome entity remain poorly described . Primary non-Hodgkin's lymphoma frontal sinus extremely rare . Epstein-Barr virus (EBV) reported play role development human immunodeficiency virus (HIV)-related malignant lymphomas . Diffuse large B-cell lymphoma (DLBCL) aggressive B-cell lymphoma . The 2016 World Health Organization (WHO) update hematopoietic tumors suggested DLBCL cases subtyped germinal CD5 is a CD5 that can be used to help people with CD5 . CD5 is a CD5 that can be used to help people with CD5 . CD5 is a CD5 that can be used to help people " Renal-occupying lesions positive urine fluorescence situ hybridization (FISH) usually considered urothelial carcinomas . Here, describe 2 cases renal metastases chromosome duplications urine exfoliated cells ." " Polychlorinated biphenyls (PCB) persistent bioaccumulative lipophilic substances, mostly used past industry . Known cancerogenic, PCB suspected increase Non-Hodgkin's Lymphoma (NHL)" Primary bone lymphoma (PBL) rare disease good prognosis . PBL rare disease good prognosis . Most patients diffuse large B-cell l . Most patients diffuse large B-cell l . The programmed cell death protein 1 (PD-1) ligand 1 2 (PD-L1/PD-L2) regulate immune system . Checkpoint pathway exploited malignant cells evade anti-tumor immune response . Selenium (Se) known potential anti-cancer agent also improve function immune cells variety solid tumors . Selenium (Se) known potential anti-cancer agent also improve function immune cells variety solid tumors . Breast implant-associated anaplastic large cell lymphoma relatively uncommon T-cell lymphoma 900 reported cases worldwide April 2020 . Chimeric antigen receptor (CAR) T-cell therapies demonstrated high response rates patients relapsed/refractory large B-cell lymphoma (LBCL) therapies associated 2 CAR T cell-specific potentially severe adverse events ( " 93 NHL patients aged 18 years received HD-MTX therapy dose 5 g/m . 93 NHL patients aged 18 years received HD-MTX therapy dose 5 g/m . There 61 males 32 females, median age 8.8" " Diffuse large B-cell lymphoma (DLBCL) aggressive B-cell lymphoma common type non-Hodgkin's lymphoma (NHL) worldwide . Anaplastic DLBCL rare, clinicopathological" " 90 consecutive cases of PPL were retrospectively analyzed . Forty-seven (52.2%) patients female, median age 54 years old ." " Acute liver failure life-threatening condition commonly caused drug-induced hepatotoxicity viral hepatitides . Rarer causes haemophagocytic lymphohistiocytosis, which carries high mortality ." 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer refractory disease relapse relapse R-CHOP first-line treatment . MTA monomethyl auristatin E developing nanoconjug Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA FNB) become popular method diagnosing various lesions gastrointestinal tract surrounding tissue due accuracy safety . " Non-Hodgkin lymphomas (NHL) commonly diagnosed among people aged 65-74 years, median age diagnosis 67 years . Percentage NHL-related deaths highest among people aged 75-84 years, median age death 76 years" Diffuse large B cell lymphoma (DLBCL) comprises distinct entities due to heterogeneity . The currently used international prognostic index DLBCL prognosis index DLBCL prognosis prediction based clinical factors cannot reflect molecular mechanisms underlying progression " Diffuse large B-cell lymphoma (DBCL) largest subgroup non-Hodgkin's lymphomas . Primary dural lymphoma, primary skull vault lymphoma, primary sternum lymphoma rare lymphomas ." " The role consolidative radiotherapy (RT) complete-remission (CR) following rituximab combined cyclophosphamide, doxorubicin, vincristine, prednisone (R-CH" We retrospectively reviewed records 25 diffuse large B-cell lymphoma (DLBCL) patients breast involvement received chemotherapy January 2000 August 2012 . We compared clinical features prognosis among patients PBL (PBL) and SBL (S " We aimed demonstrate whether PET-CT replace bone marrow biopsy detecting bone marrow involvement subtypes lymphoma . In addition, aimed also reveal whether difference mean survival patients bone marrow involvement via PET-CT biopsy ." " LPDs patients rheumatoid arthritis (RA) were diagnosed without biopsy confirmation . The median age 67 years (interquartile range [IQR], 60-73 years), 77.1% female ." " Diffuse large B-cell lymphoma (DLBCL) extremely heterogeneous tumor entity, makes prognostic prediction challenging . T tumor microenvironment (TME) crucial role fostering restraining tumor development ." " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease, spectrum increasing time. The 2016 World Health Organization (WHO) update hematopoietic tumors recognized prognostic subgroup DLBCL called double" " The revised fourth edition World Health Organization (WHO) Classification Tumours Haematopoietic Lymphoid Tissues (2017) reflects significant advances understanding biology, genetic basis behaviour haematopoietic neopl" " Chimeric antigen receptor (CAR)-T cell therapy genetically-modified cellular immunotherapy . It associated number characteristic toxicities, notably cytokine release syndrome neurotoxicity, laboratory testing aid prediction severity monitoring ." Primary mediastinal large B-cell lymphoma (PMBL) type aggressive B-cell lymphoma typically affects young adults . PMBLs are characterized by presence bulky anterior mediastinal mass . Lymphomas gene expression features features Doxorubicin plays integral role treatment patients with diffuse large B-cell lymphoma (DLBCL) associated significant toxicity . British Columbia Cancer recommend substitution of etoposide doxorubicin standard-dose Primary hepatic lymphoma (PHL) rare malignancy constitutes 0.016% cases non-Hodgkin's lymphoma 0.4% extranodal non-Hodgkin's lymphoma 0. Diffusion large B-cell lymphoma (DLBCL) rarely presents leukemic phase (1) leukemic phase (2) dysregulation TP53 tumor suppressor gene (3) elevated serum lactic acid level . " In Europe, tisagenlecleucel (Kymriah™) marketing authorization treatment relapsed / refractory acute lymphoblastic leukemia (ALL) children young adults . In Europe, tisagenlecleu" Diffuse large B cell Lymphoma (DLBCL) potentially curative lymphoma increasing incidence ageing . Treatment elderly DLBCL patients represents particular challenge due comorbidities performance status . Thirty-eight studies meeting inclusion criteria published MTV I-PET requires consensus semiautomated segmentation method delineates lesions successfully least user interaction . Methods used baseline PET necessarily optimal I-PET lower lesional SUVs I-PET . We evaluated impact event-free survival (EFS24) status 24 months (EFS24) 60 months (EFS60) hematopoietic stem cell transplantation (HSCT) using registry data . Patients underwent Diffuse large B-cell lymphoma (DLBCL) common heterogeneous lymphoid malignancy . The subtype MYC BCL-2 double-expressor lymphoma (DEL) defined aggressive nature poor survival outcome Diffuse large B-cell lymphoma (DLBCL) clinically significant event . Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event . Patients experience early progression refractory disease especially poor outcomes " Diffuse large B cell lymphoma (DLBCL) comprises heterogeneous group diseases different biology, clinical presentations, response treatment . R-CHOP remains mainstay therapy achieve long-term disease control nearly 90% patients presenting limited-" " Neurolymphomatosis (NL) rare manifestation lymphoma, limited evidence optimal management . The largest patient series, 50 cases lymphoma leukemia, published 2010 limited rituximab exposure. This study aims evaluate clinical presentation," " Plasmablastic lymphoma (PBL) rare aggressive B-cell malignancy heterogenous clinical prognostic spectrum . Multiple factors, including age, HIV-MYC-status, determined multiple factors, including age, HIV-" " Malignant ileocolonic fistulas frequently misdiagnosed due nonspecific clinical presentation . These fistulas frequently misdiagnosed due nonspecific clinical presentation . Currently, standardized treatment approach is currently being used to treat these fistulas" Diffuse large B-cell lymphoma (DLBCL) remains high aggressive invasive malignancy enigmatic etiology . Ectopic expression long non-coding RNAs widely involved progression human cancers . High LINC00857 level " Hypoalbuminemia known adverse prognostic factor lymphomas . Yet, unknown axicabtagene ciloleucel (axi-cel) overcomes adverse prognostic impact hypoalbuminemia relapsed/ref" Adult lymphoma patients received HDMTX 4-h infusion without concomitant levetiracetam . Levetiracetam high-dose methotrexate (HDMTX) was used to treat patients with delayed MT Burkitt lymphoma (BL) B cell lymphoma composed monomorphic medium-sized blastic cells . BL characteristic immunophenotype CD10 BCL6 positive BCL6 positive BCL2 negative harbours MYC gene rearrang We report case diffuse large B-cell breast lymphoma presented palpable breast lump male patient . We discuss appropriate workup algorithm palpable breast lump male patient outlined American College Radiology (ACR) Appropriateness Criteria . " Richter Transformation (RT) develops CLL aggressive, therapy-resistant, diffuse large B cell lymphoma (RT-DLBCL) CLL is commonly clonally-related (CLR) concomitant CLL ." " GOYA randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone vs standard-of-care rituximab . Patients" " Non-steroidal anti-inflammatory drugs (NSAIDs) statin drugs may protect development non-Hodgkin lymphoma (NHL) data limited, data limited, particularly NHL subtypes . We evaluated self-reported use" " Lymphoma seventh common type malignancy males females . It may develop location lymphomatous tissue exists . Although extranodal presentation lower limb pelvis uncommon, could present diverse manifestations ." Waldenstrom's macroglobulinemia (WM) indolent B-cell non-Hodgkin lymphoma characterized lymphoplasmacytic histology bone marrow monoclonal IgM . Median survival " Immunotherapy potential strategy resist cancers, due inadequate acknowledge, treatment always effective diffuse large B cell lymphoma (DLBCL) patients . Based current situation, critical systematically investigate immune pattern. According result univariate multivariate multivariate multivariate" " T-cells genetically engineered express chimeric antigen receptor (CAR) shown remarkable results patients B-cell malignancies . CAR T-cell therapy still hampered local immunosuppression significant toxicities, notably cytokine release syndrome (C" " Diffuse large B-cell lymphoma (DLBCL) genomically heterogenous disease comprised many subtypes display significantly different clinical outcomes . Poor clinical outcomes subtypes, imperfect identification high risk individuals otherwise low risk subgroups, demonstrate" Chimeric antigen receptor T-cell therapy axicabtagene ciloleucel (axi-cel) considerably improved survival . The therapy improved survival of adults relapsed/refractory large B-cell lymphoma " Intravascular large B-cell lymphoma (IVLBCL) rare extranodal subtype large B-cell lymphoma typically involves small blood vessels difficult detect . Using computer-assisted search, identified patients histopathologically" " NanoString gene expression assay (DLBCL90) developed, identifies DLBCL cases outcome similar double- triple-hit DLBCL MYC BCL2 rearrangements . This study validates predictive ability DLBCL90" " B-cell non-Hodgkin lymphoma cell survival depends poorly understood immune evasion mechanisms . In melanoma, composition gut microbiota (GMB) associated immune system regulation response immunotherapy ." " Combination therapy durvalumab, anti-programmed death ligand 1 (PD-L1) antibody, danvatirsen (AZD9150) and tremelimumab (an anti-cytot" " The study conducted analyze characteristic cytomorphologic, flow cytometric immunocytochemical immunocytochemical features LRMs serous effusions . The study reviewed 218 effusion samples reported involved lymphoreticular malignancies, cytology," " Diffuse large B-cell lymphoma (DLBCL) rare special subtypes . Anaplastic variant immunophenotypic genotypic genotypic features . Lymphoblastic lymphoma DLBCL, non-other" " The study was published in the journal Nature Resolve, which is published in the journal Nature Resolve ." Hodgkin lymphoma (HL) diffuse large B cell lymphoma (DLBCL) represent 15% 20% lymphoma types . The aim study identify compare circulating serum miRNA (c-miRNA) to peripheral whole blood mi Diffuse large cell B cell lymphoma (DLBCL) accounts approximately 30%-40% non-Hodgkin lymphoma (NHL) cases . Current first line DLBCL treatment results long-term remission 60% " A 28-year-old woman, 15 weeks pregnant, consulted cervical ache left laterocervical mass . Imaging scans revealed large mediastinal mass spread supraclavicular left axillar spaces, including cervicob" " A combination rituximab cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) is standard first-line therapy diffuse large B cell lymphoma (DL" " Between January 1, 2008, December 31, 2018, 828 patients diagnosed DLBCL institution, including 72 patients required ICU admission disease course . Among them, forty-five patients undergoing homogeneous first-line therapy /R-" We analysed discriminating sensitivity sensitivity specificity myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) interleukin-10 (IL-10) cerebrospinal fluid " Twenty-five thirty per cent diffuse large B-cell lymphoma (DLBCL) presents limited stage (I-II) Prognosis generally excellent four six cycles R-CHOP alone (rituximab, cycloph" " Several studies suggested high expression Bcl2 and/or p53 Hodgkin/Reed-Sternberg cells unfavorable prognostic factor Hodgkin lymphoma (HL) However, results field appear contrasting . We aimed assess prognostic value" " Rare neoplasm commonly represents secondary ovarian involvement overt systemic disease, usually non-Hodgkin's type . Ovarian lymphoma rare neoplasm commonly represents secondary ovarian involvement overt systemic disease, usually non-Hodgkin" " Diffuse large B-cell lymphoma (DLBCL) represents common subtype non-Hodgkin lymphoma U.S. U.S. Study conducted describe real-world characteristics, treatment patterns, health care resource" " Sarcoidosis-lymphoma syndrome describes pathological state wherein sarcoidosis lymphoma present . Sarcoidosis lymphoma may occur concurrently, sarcoidosis may precede lymphoma ." Histiocytic sarcoma (HS) rare malignant lymphohematopoietic neoplasm . CT scan revealed 4-year-old male presented hematuria dysuria . Epstein-Barr virus-positive (EBV+) primary central nervous system lymphoma (PCNSL) clinical entity rarely reported young immunocompetent patients . " PD-1 PD-1 PD-L1 shown lasting responses several solid hematological tumors, limited studies evaluate checkpoint molecules PCNSL . In study, investigated PD-1 PD-1 PD-L1 investigated PD-1" Traditional international prognostic index (IPI) partially lost predictive value diffuse large B-cell lymphoma (DLBCL) National Comprehensive Cancer Network-IPI (NCCN-IPI) unable effectively identify high-risk patients " Primary pituitary lymphoma (PPL) represents extremely rare entity . Both patients hypopituitarism, one patient developing right ptosis . MRI FDG-PET/CT depicted sellar mass extended cavernous sinus" " Oral/oropharyngeal diffuse large B-cell lymphoma (DLBCL) high-grade B-cell lymphoma . Most cases involved oral cavity (76.8%) Males females, mean age 60 years, evenly" " In Europe, tisagenlecleucel (Kymriah™) marketing authorization treatment relapsed/refractory B-cell acute lymphoblastic leukemia children young adults relapsed/refractory diffuse large B-" Non-Hodgkin's lymphoma (NHL) currently common malignancy among people living HIV (PLWH) USA . NHL PLWH frequently associated oncogenic viruses . NHL immunocompetent individuals generally associated Oral cancer often causes secondary primary cancers upper gastrointestinal tract . Oral squamous cell carcinoma malignant lymphoma small intestine . 52-year-old HIV-negative man presented mass left sternoclavicular joint . He significant comorbidities latent immunosuppression . Large lymph node measured 36 × 19 mm . Two different types lymphomas presenting simultaneously different sites never reported . This case report highlights rare occurrence . PET/CT imaging metrics are outcome predictors for patients with HL DLBCL . The study was conducted to systematically review literature evaluating clinical utility imaging metrics . DLBCL common type non-Hodgkin lymphoma substantial group patients suffering poor prognosis . DLBCL common type non-Hodgkin lymphoma substantial group patients suffering poor prognosis . " Monocyte/macrophage lineage shown involved promotion protumoral tumor microenvironment resistance treatment B cell lymphomas . However, still poorly described single cell level, tissue samples easily accessible ." Adoptive T cell therapy (ATT) revolutionized treatment cancer patients . A sufficient number functional T cells indispensable ATT efficacy . Several ATT dropouts reported due T cell expansion failure lack T cell persistence . " Primary pancreatic lymphoma rare cause pancreatic mass, diagnosis considered work-up ." Nivolumab used variety advanced malignant tumors. Cases autoimmune diabetes associated Nivolumab therapy reported gradually recent years. Cases autoimmune diabetes associated Nivolumab therapy reported gradually recent years. " In high-dimensional genetic/genomic data, identification genes related clinical survival trait challenging important issue . Right-censored survival outcomes contaminated biomarker data make relevant feature screening difficult ." PCNSL rare extranodal NHL poor prognosis. PCNSL rare extranodal NHL poor prognosis. Tumorigenesis associated hyperactivation BCR downstream NFkB pathways. Tumorigenesis associated Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) standard care untreated diffuse large B-cell lymphoma (DLBCL) Extra-nodal marginal zone B-cell lymphoma (MZBL) mucosa-associated lymphoid tissue indolent lymphoma mostly affecting gastrointestinal tract . The lymphoma initially small-cell morphology (SC-MZ " 59-year-old patient presented confusion, severe back pain, fatigue constipation, fatigue constipation, hypercalcaemia, kidney dysfunction, anaemia multiple osteolytic lesions . Physical examination imaging revealed enlarged lymph nodes . Work-" The prognostic value albumin changes diagnosis end-of-treatment (EoT) diagnosis end-of-treatment (EoT) diffuse large B-cell lymphoma (DLBCL) remains unknown . We retrospectively " Polatuzumab vedotin (Pola) recently gained approval patients, USA Europe-based GO29365 phase IIb trial . Bendamustine omitted three cases due to pre-treatment ." The introduction rituximab CHOP protocol demonstrated improvement PFS OS DLBCL patients early advanced stages . The effect bulky mass outcome DLBCL patients undergoing R-CHOP therapy remained uncertain . " Non-Hodgkin's lymphoma (NHL) encompasses 40 different haematological malignancies, including low high-grade neoplasms, follicular lymphoma (FL) and diffuse large B-cell lymph" Primary thyroid lymphoma (PTL) rare malignant disease common malignant disease common histological type diffuse large B-cell lymphoma (DLBCL) Hashimoto's thyroiditis (HT) closely related pathogenesis PTL . 51 breast lymphoma cases (51) cases (46 patients) 46 patients specific focus patients history breast carcinoma . The overall common subtype diffuse large B-cell lymphoma (BL) followed MALT lymphoma follicular lymphoma We conducted nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)-positive patients . The patients received rituximab-containing regimens induction chemotherapy 30 Japanese medical centers January 2004 December 2014 . The study was published in the journal OCL 2015 . " Current prognostic variables partly explain large outcome heterogeneity diffuse large B cell lymphoma (DLBCL) We aimed investigate utility systems-level protein immune repertoire profiling outcome prognostication DLBCL . In retrospective study, used proximity extension" Notch receptors participate signaling pathway ligand-induced proteolysis frees Notch intracellular domain (NICD) Notch receptors participate signaling pathway ligand-induced proteolysis frees Notch intracellular domain " Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 significantly improved outcomes treatment refractory relapsed large B-cell lymphoma (LBCL) We evaluated long-term course hematologic recovery, immune" " Mannatide (MT), immunomodulator, could enhance immunological response DLBCL patients receiving standard regimens . Suppression antilymphoma effector cells, mainly T cells, key prerequisite tumorigenesis resistance ." Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin's lymphoma (NHL) metastasize extranodal sites . The involvement adrenal glands rare . " This study assessed clinical characteristics gastrointestinal bleeding (GIB), obstruction (GIO), perforation (GIP) patients . The associated overall survival progression-free survival was analyzed . Among 148 patients, 56.8% gastroint was" " Pyothorax-associated lymphoma (PAL) rare disease developing long-term pleural cavity inflammation . Most reported PAL cases history artificial pneumothorax . However, clinical features artificial pneumothorax-unrelated PAL" " We describe clinical, inflammatory immunohistochemical features of a cohort of patients treated chemoimmunotherapy 2010 2015 . We describe clinical, inflammatory immunohistochemical features of a cohort of patients treated chemoimmunotherapy ." " Cytarabine nucleoside analog used chemotherapy regimens treatment multiple hematologic malignancies . One known adverse effects cytarabine, particularly patients receiving high-dose cytarabine (HDAC), drug-induced" " Post-transplant lymphoproliferative disease (PTLD) heterogeneous group diseases develop solid organ hematopoietic stem cells transplantation related intensive immunosuppression regimen . Despite improvement management management PTLD, prog" A 78-year-old man exposure asbestos admitted hospital back pain . Chest computed tomography showed right pleural effusion significant increase size masses right chest wall interval six months . The present study aimed investigate prognostic value baseline . The present study aimed investigate prognostic value baseline . " The Bcl-2-family proteins long known role key regulators apoptosis . Overexpression various members family associated oncogenesis . Its founding member, anti-apoptotic Bcl-2 regulates cell death different levels ." Primary cutaneous diffuse large B-cell lymphomas (pcDLBCLs) rare hematological neoplasms . The pcDLBCL category includes primary cutaneous large B-cell lymphoma leg type (pcDLBC " The common genital localizations cervix, uterine corpus ovary, primary lymphomas fallopian tube quite unusual . The first reported case was primary diffuse large B-cell lymphoma fallopian tube ." Diffuse large B-cell lymphoma (DLBCL) biologically clinically clinically heterogeneous disease . We als. increased understanding intrinsic pathogenesis provided potential therapeutic targets . Role microenvironment DLBCL biology remains less understood . " Richter's transformation (RT) aggressive lymphoma occurs upon progression chronic lymphocytic leukemia (CLL) Transformation associated genetic aberrations CLL phase involving TP53, CDKN2A, MYC, NOTCH1 ." " The phase 2 CAVALLI (NCT02055820) study assessed efficacy safety venetoclax, selective B-cell lymphoma-2 (Bcl-2) inhibitor, rituximab plus cycloph" " 70-year-old woman had anemia, increased C-reactive protein, mild renal failure, serum creatinine level 1.31 mg/dL remarkable proteinuria hematuria . Renal biopsy showed intravascular" " Corticosteroids commonly used management severe toxicities associated chimeric antigen receptor (CAR) T-cell therapy . It remains unclear whether dose, duration, timing may affect clinical efficacy ." " R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) considered standard care diffuse large B cell lymphoma (DLBCL) patients," Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma posttransplant setting . Treatment based chemotherapy; surgery still debated performed select cases . MYC combined Bcl2 and/or Bcl6-based protein expression called double expression lymphoma (DEL) Double expression lymphoma (DEL) is a form of diffuse large B-cell lymphoma . " 71-year-old male patient repeatedly diagnosed pulmonary infection, suspected lung tumour, Kimura disease hospital due cough, expectoration, dyspnoea . Later on, patient visited hospital due heart failure epistaxis . Transt" Chimeric antigen receptor T-cell therapy (CAR T) novel intervention relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) hematologic malignancies . But associated prolonged he " MYC gene locus is frequently referred MYC rearrangements (MYC - R+) Burkitt lymphoma recurrent many subtypes B-cell lymphomas including follicular lymphoma, diffuse large B-cell lymphoma high" transcription factor eomesodermin (EOMES) promotes interleukin (IL)-10 expression CD4 . The transcription factor eomesodermin (EOMES) promotes interleukin (IL)-10 expression CD Diffuse Large B-Cell Lymphoma (DLBCL) major salivary glands rare high-grade malignancy often presents vague symptoms . This study aimed evaluate incidence prognosis population level . " BI 836826 was a phase I dose-escalation trial (NCT02624492) conducted to determine maximum tolerated dose (MTD) and safety/tolerability, preliminary efficacy . Eligible patients received intravenous inf" End-of-treatment (EoT) PET/CT used guide omit radiotherapy (RT) patients primary mediastinal large B-cell lymphoma (PMBCL) We present mature extended results retrospective study evaluating prognostic " Inverted papilloma uncommon neoplasm nasal cavity . It histologically benign tumor, high recurrence local invasion rate . In addition, nasal skull base lymphoma another rare neoplasm. Inverted papilloma uncommon neopl" " Gaining knowledge neoplastic side three main cells-B cells, Follicular Helper T (Tfh) cells, follicular dendritic cells (FDCs) - involved germinal center (GC)" Diffuse large B-cell lymphoma (DLBCL) biologically clinically heterogenous disease . Identifying precise individual survival prognostic models still needed . Long non-coding RNA (lncRNA) SBF2-AS1 highly expressed DLBCL tissues cell lines . Silencing SBF2-AS1 inhibited viability growth of OCI-LY-3 cells . Sil Post-transplant lymphoproliferative disease (PTLD) defined lymphoma occurs solid-organ hematopoietic stem-cell transplantation (HSCT) caused immunosuppression Epstein-Barr virus ( " MicroRNAs (miRNA) small RNA molecules participate posttranscriptional regulation gene expression, emerging biomarkers cancer . Follicular lymphoma (FL) second common non-Hodgkin lymphoma . FL transform aggressive lymph" " Secondary CNS lymphoma rare potentially lethal event patients diffuse large B-cell lymphoma . We aimed assess activity safety intensive, CNS-directed chemoimmunotherapy ." " Brain MRI detected mass right frontal lobe prominent peritumoral edema, suggesting malignant brain tumor . Histopathological examination surgical resection mass confirmed diagnosis diffuse large B-cell lymphoma ." Intravascular large B-cell lymphoma (IVLBCL) unique type extranodal lymphoma characterized selective growth tumor cells small vessels without lymphadenopathy . Greater understanding molecular pathogenesis IVLBCL hampered pauc " The prognosis patients large B-cell lymphoma (LBCL) progresses treatment chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) poor . CAR22 therapy relatively well tolerated, without observed non" Cytarabine etoposide dexamethasone plus rituximab (R-mini-CYVE) was used to evaluate efficacy tolerability of immunochemotherapy regimen . We included pretreated adult patients We present valuable experience handling elderly woman initially treated COVID-19 positive pandemic November 2020 . She needed urgent tracheostomy due nasopharyngeal (NP) diffuse large B-cell lymphoma causing acute airway obstruction KPT-330 (selinexor) is first-in-class CRM1 inhibitor recently approved . Salicylates markedly enhance antitumor activity CRM1 inhibitors extending mechanisms action beyond CRM1 inhibition . " Anti-pituitary-specific transcription factor 1 (PIT-1) hypophysitis (anti-PIT-1 antibody syndrome) thymoma-associated autoimmune disease characterized acquired growth hormone (GH), prolactin (" Vitreoretinal lymphoma (VRL) rare ocular malignancy manifests diffuse large B-cell lymphoma . Early accurate diagnosis essential prevent mistreatment reduce high morbidity mortality associated VRL . The purpose study examine factors associated disparities overall survival (OS) race (OS) race (OS) race) patients . We evaluated clinical features survival among patients diagnosed stage I-IV DLBCL 2004 2014 National Cancer Database (NCDB " Interferon regulatory factor 4 (IRF4) rearrangement commonly detected patients range lymphoproliferative malignancies, including myelomas, large B cell lymphomas and low-grade lymphomas . IRF4" " Follicular lymphoma (FL) indolent, yet generally incurable neoplasia median survival exceeding 10 years . subset FL patients experiences histological transformation (HT) aggressive lymphoma . This affects clinical course prognostic outcome," " LPDs rheumatoid arthritis patients methotrexate (MTX) methotrexate (MTX) discontinuation, achieved spontaneous regression (SR) Among 232 RA patients LPDs, 216 treated MTX onset" Lymphoma female gynecologic tract extremely rare . Lymphoma managed nonsurgically unlike non-lymphomatous malignant tumors . " Non-Hodgkin lymphoma (NHL) oral cavity present pain, swelling radiolucent lesion mimicking endodontic diseases . During surgical phase teeth #4, 6, 7 extracted . During surgical phase" Myocet is a non-pegylated liposomal doxorubicin . The use non-pegylated liposomal doxorubicin is a form of form of form of form of form Tazemetostat is an orally available inhibitor enhancer zeste homolog 2 (EZH2) and histone methyltransferase . It is also an inhibitor of the histone methyltransferase epigenetic regulator cellular differentiation " A case affected seminal vesicles secondary tumor diffuse large B-cell lymphoma reported . Seminal vesicles neoplasms scarce, classified primary secondary . The common case involved extension adjacent tumors, clinically nonspecific ." " Plasmablastic lymphoma (PBL) aggressive high-grade B cell lymphoma, considered variant diffuse large B cell lymphoma, approximately 75% mortality within 6-7 months . We describe unusual case PBL arising maxillary" " Interleukin-1 receptor associated kinase 4 (IRAK4) promising therapeutic target diffuse large B-cell lymphoma driven MYD88 L265P mutant, acting kinase scaffolding protein downstream signaling molecules . Protein" Nijmegen breakage syndrome (NBS) DNA repair disorder characterized combined immunodeficiency high predisposition lymphoid malignancies . Majority NBS patients identified homozygous five base pair deletion . Diagnosing primary mediastinal (thymic) large B-cell lymphoma (PMBCL) challenging clinicopathologic entity shares characteristics lymphomas lacks pathognomonic features . We sought investigate fidelity working diagnosis PMBCL " Diffuse large B-cell lymphoma (DLBCL) heterogenous cancer profound differences survival outcomes . Molecular profiling allowed identification DLBCL subclasses, together clinical prognostic factors, international prognostic index, improved clinical care survival ." " Novel treatment strategies shifted treatment landscape patients diffuse large B-cell lymphoma, particularly relapsed/refractory disease . Uncertainty remains regarding therapeutic value novel agents compared existing salvage chemotherapy regimens . High cost associated agents puts patients health" Involvement peritoneum occurs rarely exceptional exclusive extranodal presentation lymphomas . In cases lymphomas associated rare entity high-grade ones. In cases lymphomas associated rare entity high-grade ones. " R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) was standard therapy patients diffuse large B-cell lymphoma (DLBC" Diffuse large B-cell lymphoma (DLBCL) patients refractory rituximab-based immunochemotherapy dismal prognosis . definition refractory DLBCL remains inconsistent large cohort study data available Asian countries We investigated intratumoral source PD-L1 expression infiltration tumor-associated macrophages (TAMs) large B-cell lymphomas (LBCLs) without MYC-translocation . One hundred twenty-six " 64-year-old Caucasian man LNH Follicular 3a, IV A stage, FLIPI 2 prognostic index follicular lymphoma . He received 8 cycles RCHOP followed rituximab maintenance, complete" " CAR19/22 T cell therapy evaluated efficacy safety of six refractory Burkitt's lymphoma cases . After CAR-T cell therapy, five cases grade 1 one grade 3 cytokine release syndrome . Three patients achieved objective response (" " EBV-PTLD is a rare, severe Epstein-Barr virus-driven disorder . It is a heterogenous disease that may manifest localized disseminated, clinical presentation may differ significantly . Majority EBV-PTLD typically occurs within" The categorization mature B cell neoplasms (MBN) infiltrating blood bone marrow met difficulties . The inclusion of CD148 CD180 routine flow cytometry/FCM panels suggested refine diagnosis . We studied discriminatory ability CD148 CD " TTI-621 (SIRPα-IgG1 Fc) novel checkpoint inhibitor activates antitumor activity blocking CD47 ""don't eat me"" signal . This first-in-human phase I study evaluated" " Anti-apoptotic Bcl-2 critically controls cell death neutralizing pro-apoptotic Bcl-2-family members mitochondria . Bcl-2 proteins also act endoplasmic reticulum, main intr" " DNA methylation regulates gene transcription involved various physiological processes mammals, including development hematopoiesis . It catalyzed DNA methyltransferases including Dnmt1, Dnmt3a, Dnmt3b . For" Sixty-seven patients included HIV seropositive status confirmed 98% (63 64) median viral load 55 587 (IQR 273 582) copies/ml median CD4 count 170 (IQR 249) cells/ BIX-01294 small molecule compound specifically inhibits EHMT2 activity . BIX-01294 small molecule compound specifically inhibits EHMT2 activity . " Primary hepatic lymphoma rare disease, accounting 0.1% malignant liver tumors . Subtype diffuse large B-cell lymphoma (DLBCL) infrequent . In contrast hepatitis C virus, association hepatitis B virus lymphoma" " CD10, BCL6, MUM1 commonly used immunohistochemical stains classifying diffuse large B-cell lymphoma (DLBCL) Classified as a cancer patient . Clinical outcomes--assessed independent ." A 37-year-old man diagnosed with diffuse large B-cell lymphoma two weeks ago visited emergency department sudden dyspnea . He severe respiratory failure saturated percutaneous oxygen 80% (room air) After 1000 mL effusion " Personalized therapies leading increasing number marketing authorizations based single-arm trials, increases demand better post-authorization monitoring strategies . The aim present study estimate power time data accrue population-based registries detecting deviations expected efficacy/safety ." Polatuzumab vedotin approved therapy United States relapsed/refractory diffuse large B-cell lymphoma combination bendamustine rituximab (Pola+BR) Safety efficacy Pola+BR " The common symptom cardiac tumors dyspnea, accounting 64%, followed chest pain, accounting 26% . However, cases paroxysmal supraventricular tachycardia (SVT) major clinical presentation extremely rare ." Japanese patients rheumatoid arthritis (RA) were enrolled in hospitals . We enrolled patients RA aged . 20 years visited participating hospitals . We investigated risk factors LPD using Cox proportional hazard model . " Synchronous occurrences of mantle cell lymphoma (MCL) and intermediate lymphocytic lymphoma are rare . Such cases present diagnostic especially therapeutic challenges, making particular interest study ." " Non-Hodgkin's lymphomas (NHL) are non-Hodgkin's lymphomas . The aim paper report two cases of NHLs mandibular locations detailing different clinical, radiological, histopathological" " Gastric diffuse large B cell lymphoma (DLBCL) represents majority gastric lymphomas . 50.5% males median age 64 years [23-94]. Lugano staging I 16.8%, II1 20.8" " In Europe, tisagenleclecleucel (Kymriah) is a new class anticancer treatment . It consists of genetically modifying autologous allogenic allogenic T-cells ." Multiple lymphomatous polyposis (MLP) is a rare rare entity primary gastrointestinal (GI) lymphoma characterized polypoid lymphomatous tissue long segments gut strong tendency spread throughout GI tract . A 15-year " 38 patients diagnosed DLBCL involving eye ocular adnexal lymphoma (DLBCL) involving eye ocular adnexa 1995 2018 single tertiary institution . 22 patients (22 men, 16 women), 22 (57." Plasmablastic lymphoma (PBL) newly recognized aggressive subtype non-Hodgkin lymphoma . Its rarity hinders testing effective treatment options clinical trials . Aggressive chemotherapy defined intense regimens CHOP (cycloph Primary gastric diffuse large B cell lymphoma (PG-DLBCL) common histological subtype primary gastric lymphoma . The standard care PG-DLBCL patients combination rituximab-based immunochemotherapy " Angiomotin (AMOT) membrane protein aberrantly expressed variety solid tumors . AMOT involved pathological processes tumor proliferation, apoptosis, invasion. However, potential role AMOT pathogenesis diffuse large B-cell lymphoma (DL" " 87 cases of DLBCL90 were analyzed using DNA analysis . DNA profiling, DNA analysis, copy-number analysis, targeted deep sequencing using custom mutation panel 334 genes ." " Diffuse large B cell lymphoma (DLBCL) manifests highly heterogeneous genetic/phenotypic characteristics . DLBCL patients revealed highly recurrent mutations epigenetic regulator genes CREBBP, KMT2D, EZH" The prognosis patients secondary central nervous system lymphoma (SCNSL) poor despite massive advances understanding mutational landscape . Primary diffuse large B-cell lymphoma (DLBCL) still lacking. Primary mediastinal B-cell lymphoma (PMBCL) uncommon subtype non-Hodgkin lymphoma (2-3%) predominantly occurring female young adults . Extrathoracic involvement found 10-20 We analyzed potential biomarkers response ibrutinib plus nivolumab biopsies patients . Patients diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were patients . " Percutaneous core needle biopsy (CNB spleen) rarely performed, due concerns complications low diagnostic yield . Procedure represents potentially useful diagnostic tool, especially patients splenomegaly definitive diagnosis clinical radiological work-up ." Diffuse large B-cell lymphoma (DLBCL) common category non-Hodgkin lymphoma (NHL) common category non-Hodgkin lymphoma (NHL) underlying molecular mechanism remains unclear . Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease . Cell-of-origin classification DLBCL identified activated B cell (ABC) germinal center B cell (GCB) two major subtypes Axicabtagene ciloleucel axi-cel [CD19 chimeric antigen receptor (CAR) T cell] recently approved refractory/relapsed diffuse large B-cell lymphoma . Laboratory tools needed monitoring " Aneurysm-like structure around stent graft enlarged irregularly . Histopathological examination revealed diffuse large B-cell malignant lymphoma . Post-chemotherapy, aneurysm-like structure disappeared without fistula" " Bromodomain extra-terminal domain (BET) proteins epigenetic readers play fundamental role transcription regulation . BET degraders chimeric compounds comprising BET inhibitor, allows binding BET bromodomains, linked small molecule," " Relma-cel (JWCAR029), anti-CD19 product produced commercial-ready process China, evaluated first prospective, single-arm, multicenter, pivotal study CAR-T therapy . China law regulations restrict export patient material" " Approximately one-third extranodal non-Hodgkin lymphomas involve gastrointestinal (GI) tract . Majority diagnosed stomach, duodenum, proximal small intestine ." " Richter Syndrome (RS) defined development aggressive lymphoma context Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL) histology 95% cases . RS genomic landscape shares" " Chemokine receptor CXCR5 selectively expressed B cells . Its principle ligand CXCL13 B lymphocyte chemoattractant . Three polymorphisms CXCR5 gene, rs148351692 C/G" " 52-year-old woman light red mass urethral orifice . Her clinical manifestations included frequent urination, urgency, dysuria, occasionally blood urine . The tumor surgically removed, pathological immunohistochemistry examination confirmed presence of" " 56-year-old man presented long-standing history low back pain 2-month history voiding lower urinary tract symptoms . He denied history urinary retention, trauma, catheterisation constitutional symptoms . Examination revealed lymphadenopathy hepatospl" 71-year-old otherwise healthy man presented complaint at dental clinic chief complaint . Complaint was complaint of mobility involving upper left molar teeth . Surgical exploration involved area performed revealed presence 'jelly like' brown tissue fragments easily . There relative paucity literature PCNSL Indian subcontinent . Eighty-six case of PCNSLs . Eighty-six case . " A 65-year-old Caucasian man admitted department with progressive weakness, dyspepsia, weight loss . Endoscopic biopsies revealed gastric diffuse large B cell lymphoma . Computed tomography scan showed locally advanced bulky gast" Crohn's disease may complicated neoplasia adenocarcinomas lymphomas . Crohn's disease may complicated neoplasia adenocarcinomas lymphomas . This case highlights need tissue biopsy diagnosis suspected CNS malignancy . Comprehensive immune profiling accurate subclassification. Need tissue biopsy diagnosis suspected CNS malignancy. Comprehensive immune profiling accurate subclassification. Cutaneous EBV-positive diffuse large B-cell lymphoma exceptional aggressive neoplasia . Poor prognosis cutaneous lymphoma. Rare presentation presentation dismal clinical course. BCR-mediated lymphoma proliferation may caused activating BCR-pathway mutations and/or active tonic stimulation BCR . BCRs lymphomas frequently described polyreactive . " Neurolymphomatosis (NL) infiltration cranial nerves nerves roots peripheral nervous system lymphoma, usually B-cell non-Hodgkin's lymphoma . It uncommon initial presentation disease lead extremely heterogeneous clinical manifestations ." " Differing large B-cell lymphoma (tDLBCL) occurs significant proportion indolent lymphomas . Novel agents inform management, particularly relapsed refractory (R/R) refractory (R/R)" This Review focuses on use of technology in the U.S. This Review focuses on the use of technology in the U.S. 52-year-old man admitted chest wall mass severe asymptomatic hypoglycemia . Warburg effect causing excess lactate production causing excess lactate production avid glucose consumption . " A 49-year-old woman diagnosed diffuse large B-cell lymphoma left ovary . Two months hysterectomy bilateral salpingo-oophorectomy operation, patient referred 18F-FDG PET/" It is well established HHV8 infection causes Kaposi sarcoma (KS) infection . HHV8 infection causes Kaposi sarcoma (KS) and EBV negative systemic diffu . Histiocytic sarcoma (HS) rare hematolymphoid malignant neoplasm aggressive clinical course . It arise de novo low-grade low-grade B-cell lymphoma . " Diffuse large B cell lymphoma (DLBCL) common lymphoma common lymphoma Western Countries 40% affected individuals still succumb disease . DLBCL heterogenous group disorders, call DLBCL today necessarily disease years ago ." " Primary CNS lymphomas (PCNSLs) aggressive diffuse large B-cell lymphomas (DLBCLs) limited CNS generally poor prognosis . We analyzed clinical, radiological histologic data 24 patients biopsy confirmed DLBC" " The objective study evaluate clinicopathological features treatment composite lymphoma (CL) cervical lymph node enlargement . In study, two cases CL presented . Biopsies enlarged cervical lymph nodes excision revealed two distinct types lymphomas ." Plasmablastic lymphoma (PBL) rare aggressive lymphoma . First described HIV- (human immunodeficiency virus-) infected patients . PBL diagnosed patients immunodeficiencies well immunocompetent patients . " Second-generation anti-CD19 chimeric antigen receptor (CAR) T cells remarkably improved survival patients relapsed refractory B cell malignancies . However, limited clinical results fourth-generation CAR-T cell therapy, factors affecting" " In pediatric adolescent age group, primary cutaneous lymphomas rare, especially cutaneous B-cell lymphomas . World Health Organization: Three main subtypes primary cutaneous B-cell lymphomas primary cutaneous marginal zone B-cell lymph" " First-line rituximab plus cyclophosphamide, doxorubicicin, vincristine, prednisone regimen (R-CHOP) substantially improved outcomes patients diffuse large B-cell lymph" The management severe adverse events (AEs) important safely effectively providing chemotherapy older adults diffuse large B-cell lymphoma (DLBCL) The management severe adverse events (AEs) important safely effectively providing chemotherapy older adults diffuse large B LINC01857 proven involved glioma breast cancer . LINC01857 proven involved glioma breast cancer . Biological function LINC01857 diffuse large B-cell lymphoma (DLBCL) poorly investigated . Primary mediastinal large B-cell lymphoma (PMBL) cells depend constitutive activity NF-κB STAT transcription factors . Reed-Sternberg cells overexpress oncogenic (proviral integration site Moloney mur " French experience managing DHL THL first line using collective data survival tolerance . Historically, double triple hit lymphoma (DHL THL) poor outcomes conventional chemotherapy, currently guideline ." The prognostic value B-cell lymphoma 2 (BCL2) expression de novo diffuse large B-cell lymphoma (DLBCL) treated immunochemotherapy interest define target patient population clinical development BCL2 inhibitors . " Venous thromboembolism (VTE) frequent, potentially lethal complication individuals cancer . Patients brain tumors particularly high risk VTE ." " Adrenal incidentalomas are common in most cases of adrenal masses . These cases challenging diagnosis broad, including metastatic disease, primary adrenal lymphoma, infection ." Patients undergo chimeric antigen receptor T-cell therapy (CAR T-cell therapy) immunosuppressed due multiple factors . While adenovirus BK virus well-known pathogens context hematopoietic stem cell transplant Chimeric antigen receptor T cells (CARTs) CD19 antigen represent effective therapy relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) There diagnostic test able predict patients residual disease relapse reach Study compared clinical outcomes aggressive primary intestinal B-cell lymphomas (aB-PILs) T/natural killer-cell lymphomas (T/NK-PILs) T/natural killer-cell lymphomas (T " Phase II study of high-risk patients with diffuse large B-cell lymphoma (DLBCL) relapse autologous hematopoietic cell transplantation (auto-HCT) In phase II study, investigate long" We tested complementarity metabolic tumor volume (MTV) large cohort diffuse large B-cell lymphoma (DLBCL) patients REMARC trial . MTVs defined using 41% maximum standardized uptake value threshold . Salvianolic acid A (SAA) water-soluble phenolic acid extracted Salvia miltiorrhiza (Danshen) anti-tumor properties . SAA inhibited viability of DLBCL cells inducing cellular " After failure frontline therapy, patients relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) respond first-line salvage chemotherapy recommended second-line salvage chemotherapy . RR-DLBCL treated Gustave" An effective antitumor immune response patients lymphoma would eradicate malignant B cells cure patient disease . Suboptimal antitumor response results persistence subsequent progression patient's disease . The goals immunotherapy therefore restore effective antitumor immune response B cells via germinal center reaction complex complex complex complex . Controlled transcription factors induce suppress large dynamic transcriptional programs . This occurs via recruitment coactivator corepressor complexes . cellular therapy plays major role management many non-Hodgkin lymphomas . Both older newer cell therapies demonstrated impressive responses otherwise poor-prognosis lymphomas . " Indolent lymphomas (focusing follicular lymphoma [FL] prolonged waxing waxing waning course, portion patients experience histologic transformation (HT) HT transformed follicular lymphoma (tFL) may declining, outcomes remain" Non-Hodgkin lymphoma (NHL) hematological malignancy sometimes originate nasal cavities paranasal sinuses . Patients present tumors typically report sinonasal symptoms . Bruton's tyrosine kinase (BTK) member Tec kinase family plays key role in B-cell receptor (BCR)-mediated signaling pathway . Inhibition BTK proven effective therapeutic approach various hematological malign " The effects lymphocyte subtypes, including helper (Th), natural killer (NK), regulatory (Treg) cells, T-cell subtypes, were clearly established . DLBCL patients higher proportion CD4+CD25+ " Tumors frequently subvert major histocompatibility complex complex class I (MHC-I) peptide presentation evade CD8 . Tumors frequently subvert major histocompatibility complex class I (MHC-I Primary diffuse large B-cell lymphoma (DLBCL) central nervous system (PCNS-DLBCL) rare . Thirty-nine patients consecutively diagnosed PCNS-DLBCL . analyzed highlight prognostic value expression programmed Diffuse large B-cell lymphoma (DLBCL) represents around one quarter non-Hodgkin lymphomas United States globally . Activated B-cell (ABC) subtype DLBCL associated higher relapse rates . " Long non-coding RNA urothelial cancer associated 1 (UCA1) reported act carcinogen bladder cancer, role diffuse large B-cell lymphoma (DLBCL) remains unclear . The expression pattern UCA1" Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma worldwide . Approximately 40% patients undergo standard chemoimmunotherapy still present primary refractory disease relapse . " Intravascular large B-cell lymphoma rare, non-mass-forming, extranodal large B-cell lymphoma subtype characterized presence tumor cells lumens vessels . Classical Asian patients presenting skin involvement mostly female, younger" BH3 mimetics like venetoclax target prosurvival Bcl-2 family proteins . We demonstrate Bfl-1 expression render preclinical lymphoma tumor models insensitive Mcl-1 Bcl-2 inhibitors . " Diffuse large B-cell lymphoma (DLBCL) aggressive non-Hodgkin lymphoma heterogenous genetic landscape require multiple assays characterize. Assays determine cell origin (COO), detect translocations, identify mutations" " Diffuse large B-cell lymphoma (DLBCL) aggressive subtype lymphoma, multiple extranodal involvement (ENI) indicates adverse clinical outcomes . The aim study investigate influence oncogenic mutations tumor microenvironment alterations" " Rituximab, first anti-CD20 monoclonal antibody, dramatically improved outcomes patients B-cell lymphoproliferative disorders . Obinutuzumab developed potentiate activity overcome resistance rituxim" 46-year-old woman erythema right breast presented hospital diagnosed stage IV breast cancer . She received 4 courses anthracycline-based regimens 4 courses trastuzumab + pertuzumab + doc In In The U.S. Congress is on a mission to change the world's direction . The U.S. Senate is on a mission to change the direction of the nation's national government . Diffusion large B cell lymphoma (DLBCL) unclassified (UNC) unclassified (UNC) type III gene expression profiling recommended latest update World Health Organization's classification lymphoid neoplasms . " Non-Hodgkin's B cell lymphoma patients often relapse remain refractory therapy . Therapeutic resistance often associated survival signaling via nuclear factor κB (NF-κB) transcription factor, attractive undrugg" Diffuse large B-cell lymphoma (DLBCL) common haematopoietic tumour dogs recognized clinical model human counterpart . " In diffuse large B-cell lymphoma, early assessment treatment response is critical . Early assessment of treatment response is critical for early diagnosis of diffuse large B-cell lymphoma ." Diffuse large B-cell lymphoma (DLBCL) common indication autologous stem cell transplantation (auto-SCT) Common indication autologous stem cell transplantation (auto-SCT) This prospective noninter " Rare single nucleotide polymorphisms (SNPs) likely crucial genetic factor human diseases, including cancer ." Host response diffuse large B-cell lymphoma (HR DLBCL) shares features histologically defined T-cell/histiocyte-rich B-cell lymphoma . HR DLBCL inherently less responsive standard treatment DLBCL Synthetic lethality thought play important role anticancer therapies . Synthetic lethality thought play important role anticancer therapies . The diagnostic prognostic evaluation of primary central nervous system lymphoma (PCNSL) challenging due lack sensitive biomarkers . The present study aimed evaluate value interleukin (IL)-10 context . 91 patients suspected intracranial " Fas highly expressed germinal center (GC) B cells, mutations FAS reported diffuse large B cell lymphoma (DLBCL) mutations . Although GC-derived DLBCL better overall outcomes DLBCL types, cases ref" Rare disease like primary spinal epidural diffuse large B-cell lymphoma considered differential diagnosis patients presenting back pain rapid neurological deterioration lower extremities . " Aberrant B-cell receptor/NF-κB signaling hallmark feature B-cell non-Hodgkin lymphomas, especially diffuse large B-cell lymphoma (DLBCL) Recurrent mutations cascade, example, CD" " Most patients age 60 years older diagnosed with diffuse large B-cell lymphoma (DLBCL) diagnosed age 60 years older . Challenges effective therapy among older individuals include unfavorable biologic features DLBCL, geriatric vulnerabilities, subopt" " Diffuse large B-cell lymphoma (DLBCL) heterogeneous neoplasm diverse genetic abnormalities outcomes . Biopsy biomarkers available predict patient outcome, treatment response progression . Identifying patient-specific biomarkers would allow ""personal" Heavy chain disease rare entity characterized production incomplete immunoglobulin heavy chain without associated light chain . It often associated lymphomas also autoimmune diseases . Primary thyroid lymphomas (PTLs) rare commonly present rapidly enlarging thyroid mass causing obstructive symptoms . Most PTLs B-cell Non-Hodgkin lymphomas (NHL) B-cell Non-H Gray zone lymphoma (GZL) uncommon neoplasm intermediate features classic Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma (DLBCL) It identified World Health Organization (WHO) classification neopl " Hodgkin lymphoma (HL) type lymphoma common throughout western countries . However, detailed mechanisms special biomarkers HL remain investigated . Emerging studies shown long non-coding RNAs play key role human cancers ." Establishing pathologic diagnosis central nervous system (CNS) lymphoma challenging . Management potentially curable disease depends heavily on accurate timely diagnosis . " 42-year-old male presenting persistent hiccups Horner's syndrome . He biopsy-proven diffuse infiltrative large primary CNS B-cell lymphoma involving left fronto-temporal hemisphere, diencephalon brainstem" " The purpose study analyse clinical pathological characteristics, treatments outcomes post-transplant lymphoproliferative disorder (PTLD) lymphoproliferative disorder (PTLD) The overall incidence PTLD paediatric liver transplant recipients centre 1." Chimeric antigen receptor (CAR) T cells (CART) therapies changed continue change treatment paradigms . " Study: Vitreoretinal lymphoma (VRL) chronic inflammation . Using immunoglobulin heavy chain (IGH), disease biomarker myeloid differentiation primary response 88 (MYD88) Study: Remnant vitreous" " B cells various stages maturation, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), Burkitt lymphoma (BL), Burkitt lymphoma (BL), Burkitt lymph" " diffuse large B-cell lymphoma (DLBCL) is most common form non-Hodgkin lymphoma, NHL . Despite great efforts better treatment options better treatment options are still challenges ." Vitamin D is a primary function 25(OH)Vitamin D (VitD) control calcium . Recent evidence associated serum VitD deficiency high aggressiveness worse outcome . Study investigated association VitD blood levels gene expression . Patient developed chemotherapy-associated cardiac dysfunction receiving treatment diffuse large B-cell lymphoma . Patient outcome favorable. Lymphoma common human cancer shows variable geographic incidence worldwide . It fourth common cancer Jordan. Lymphoma common human cancer shows variable geographic incidence worldwide. " The prognosis patients relapsed refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, need alternatives current salvage therapies ." " Rituximab plus polychemotherapy standard care diffuse large B-cell lymphoma (DLBCL) trial . GAINED, randomized phase 3 trial, compared obinutuzumab rituximab" Epstein-Barr virus (EBV) critical EBV-induced B-cell transformation . EBV-induced B-cell transformation . EBV-induced B-cell transformation . EBV-induced B-cell transformation . " miRNA-155 oncogenic miRNA highly expressed B-cell malignancies, particularly non-germinal center B-cell activated B-cell activated B-cell activated B-cell activated B-cell lymphoma (" B-cells via germinal center reaction complex complex multi-step process controlled transcription factors induce suppress large dynamic transcriptional programs . This occurs via recruitment co-activator co-activator co-repressor complexes . " Richter syndrome (RS) is a rare event known as Richter syndrome, with dismal prognosis . Researchers found tissue-RS enriched mutations poor-risk CLL drivers genes DNA damage response (DDR) pathway ." Echocardiogram showed large mass compressing obliterating right atrium . Trans-jugular tissue biopsy performede . Non-Hodgkin lymphoma comprises 2.1% total number cancers South Korea . Diffusion large B cell lymphoma (DLBCL) comprises largest percentage . " TP53 mutation recognized negative prognostic factor patients diffuse large B-cell lymphoma (DLBCL) TP53 mutation recognized negative prognostic factor patients diffuse large B-cell lymphoma (DLBCL) Here, present characteristics A" " Primary central nervous system lymphoma (PCNSL) confined brain, eyes, cerebrospinal fluid without evidence systemic spread . Rarely, PCNSL occurs context immunosuppression (eg, posttransplant lymphoprol" " The study objective investigate effectiveness palliative radiation therapy (RT) patients diffuse large B-cell lymphoma (DLBCL) identify factors, chemotherapy relapsed/refractory (R/R) disease, may influence RT outcomes" Primary central nervous system lymphoma (PCNSL) one least common malignant brain tumors . PCNSL is one least common malignant brain tumors . " Diffuse large B-cell lymphoma common histological subtype . Primary lymphoma breast rare disease, accounting 0.5% primary breast tumors ." " Lymphoma systemic malignancy, originating lymphatic system, accounts 3 4% tumors . There two major subtypes lymphoma, namely, diffuse large B-cell lymphoma (DLBCL) Hodgkin's lymphoma (" Gastrosplenic fistula rare disease involving stomach spleen leads to massive gastrointestinal bleeding . Diffuse large B-cell lymphoma (DLBC) principal pathological cause gastrosplenic fistula . British Society Haematology recognised specific entity included category 'large cell' 'aggressive' lymphomas . These fatal 95% cases. Today cure rate adults entered clinical trials ~70% . " DBL1002 study evaluated association molecular biomarkers clinical response combined treatment ibrutinib plus rituximab, cyclophosphamide, cyclophosphamide, doxorubicin, vincristine" " Primary hepatic lymphoma (PHL) rare malignancy lesions confined liver . It characterized large number monomorphic, medium-sized lymphocytic infiltrates hepatic sinusoid . We collected incidence, mortality, clinical data P" Flow cytometry-based bone marrow involvement (BMI) B cell non-Hodgkin lymphoma (B-NHL) well established . Relevant methodological details often unreported . Chimeric antigen receptor (CAR) T-cell therapy emerged option relapsed/refractory aggressive B-cell lymphomas failed 2 lines therapy . Failures usually occur early infusion. " The cross-talk mitochondrion nucleus regulates cellular functions, including differentiation adaptation stress . Mitochondria supply metabolites epigenetic modifications nuclear-associated activities certain mitochondrial proteins found nucleus ." " Tim-3 signalling, especially genetic characteristics immune microenvironment, diffuse large B cell lymphoma (DLBCL) identified . Six patients DLBCL (6/188, 3.2%) detected COSMIC database ." New treatments needed address persistent unmet clinical needs diffuse large B-cell lymphoma (DLBCL) New treatments needed address persistent unmet clinical needs . Overexpression transferrin receptor 1 (TFR1) common across cancer Lymphomas presently categorized according origin B T lymphocytes . Immature less often mature lymphomas may incorporate rearrangements B- T-cell antigen receptor genes . Lymphoma cells sole genotype hardly concurrently express B- T- " Overall clinical outcome patients diffuse large B cell lymphoma (DLBCL) significantly improved, but patients still experience relapsed/refractory disease . In rituximab era, real-world data relapsed/refract" " Plasmablastic lymphoma (PBL) rare aggressive B-cell lymphoma frequently arises extranodal sites setting immunosuppression . The diagnosis PBL complex, owing frequent solid cohesive growth pattern, often unusual immunophen" To identify optimal treatment rheumatoid arthritis (RA) regression lymphoproliferative disorders (LPDs) The subjects 232 patients RA developed LPD 2000 2017 seven hospitals participating LPD-WG study . Treatment RA resumed " Diffuse large B-cell lymphoma (DLBCL) commonly treated R-CHOP, ~30 50% patients poorly responsive strategy . 50% patients poorly responsive strategy. Geniposide, extract, extract ." " Primary malignant lymphoma rarely occurs female reproductive tract, often misdiagnosed . Lymphoma spontaneous regression even rarer, possible behavior disease ." " This study aimed understand population-level treatment modalities evaluate survival benefits surgical resection primary cardiac lymphoma . The median age 68 years, 80% White, 46% women ." " 141 patients were given 3-4 cycles chemotherapy . During midterm follow-up, total 109 people achieved CR . OS PFS interim PET/CT, Δ SUVmax criterion independent risk factor prognosis ." " The lymphocyte-to-monocyte ratio (LMR) platelet-to-lymphocyte ratio (PLR) reported useful predicting prognosis various malignancies, including diffuse large B-cell lymphoma (DLBC" Diffuse large B-cell lymphoma (DLBCL) major type aggressive B-cell lymphoma (DLBCL) major type aggressive B-cell lymphoma (HGBCL) High-grade B-cell lymph The mammalian orosomucoid-like gene family (Orosomucoid-like gene family) is a gene family of mammals . The mammalian orosomucoid-like gene family (Orosom " Study aimed explore factors affecting efficacy anti-CD19 CAR T-cell adverse reactions therapy . We recruited 11 patients relapsed refractory B-cell lymphoma . The number of anti-CD19 CAR T-cells, proliferation," " Diffuse large B-cell lymphoma (DLBCL) comprises approximately 30% non-Hodgkin lymphomas . Multiple studies demonstrated race-based disparities survival among patients DLBCL across stages disease, era ritux" " Burkitt-like lymphoma 11q aberration was recently updated by WHO . Rare cases aggressive B-cell lymphomas morphology similar to Burkitt lymphoma (BL) present BL-typical immunophenotype, lacked MYC transl" " Subtage B used describe clinical sign observed . In humans B-symptoms refer systemic symptoms lymphoma fever, weight loss, night sweats influence prognosis patients . In canine lymphoma, substage B used describe clinical sign observed ." " Dysregulation processes linked B cell lymphomagenesis . We characterized seven genomic mutational signatures, including two B cell tumor-specific signatures . We identified two major mutational signatures (K1 K2) clustered mutations (kataeg" Different genes constantly turned according miRNAs expression profiles affecting drug response patients . Different genes constantly turned according miRNAs expression profiles affecting drug response patients stability serum plasma makes potential prognostic biomarkers several diseases . Anthracycline chemotherapy commonly used treatment diffuse large B-cell lymphoma (DLBCL) may induce severe cardiac failure cardiac arrhythmia main cause death . The present study aimed investigate prognostic value summed rest score ( HV-associated non-Hodgkin lymphoma (NHL) was studied retrospectively studied . The impact directly acting antivirals outcomes aggressive NHL still investigation . Diffuse large B-cell lymphoma common type non-Hodgkin lymphoma common type non-Hodgkin lymphoma . The prevention hepatitis B virus (HBV) reactivation rituximab treatment diffuse large B-cell lymphoma (DLBCL) is an important HBV-endemic area . This population-based study examines impact antiv Exposome-wide association study performed investigate within single study . European Prospective Investigation Cancer nutrition study . 2402 incident BCL cases diagnosed 475 426 participants followed-up average 14 years . " Bufalin (BF), isolated traditional Chinese medicine Chansu, reported play anticancer role multiple cancer cell types . However, reports effects BF growth DLBCL . In present study, demonstrated BF exerts antitumor activity DL" Adult intussusception represents 5% of adult intussusceptions . Primary gastro-intestinal lymphoma comprises 1%-4% gastro- intestinal malignancies 90% B-cell non-Hodgkin's lymphoma ( " Diffuse large B cell lymphoma (DLBCL) aggressive B-cell malignancy . Circuminary tumor DNA (ctDNA) novel noninvasive, real-time, tumor-specific biomarker harboring tumor-" " We analyzed utility cell-free DNA (cfDNA) prospective population-based cohort determine mutational profile, assess tumor burden, assess tumor burden, estimate impact response rate outcome patients diffuse large B-cell lymphoma (DLBCL)" For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL) For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL) Auto-HCT is standard option for patients . Anti " World Health Organization defined high-grade B-cell lymphoma MYC BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) clinical category . An ""atypical double-hit""" Cell-division cycle 20 (CDC20) overexpressed variety tumor cells negatively regulated wild-type p53 (wtp53) Dysregulation of MDM2-p53 major mechanism promote DLBCL . Epstein-Barr Virus (EBV) programmed death ligand-1 (PD-L1) was linked to PD-L1 . Diffuse large B-cell lymphoma (DLBCL) common form non-H " Diffuse large B-cell lymphoma (DLBCL) aggressive lymphoma often refractory currently available treatments . Recently, new cell therapies approved patients failing two conventional treatments, CAR-T (Chimeric-Antigen-" MicroRNA (miRNA) emerged prognostic biomarkers diffuse large B-cell lymphoma (DLBCL) Researchers used miRNA PCR array to analyze miRNA expression profiles serum samples . Four candidate miRNA identified subsequently evaluated ability to Histone methyltransferase EZH2 antiapoptotic protein Bcl-2 frequently co-occur diffuse large B-cell lymphoma (DLBCL) Tazemetostat vene was found to be a " Gaucher disease type 1 (GD1) common lysosomal storage disease affects nearly 1 40,000 live births . Common genetic disorder Ashkenazi Jewish population phenotypic variation presenting early childhood asymptomatic nonagenarians" Ovarian diffuse large B-cell lymphoma (DLBCL) rare. DLBCL complex type lymphoma. DLBCL complex type lymphoma. The ovarian DLBCL usually harbor favorable prognosis. Current guidelines tend to treat HIV positive (HIV+) patients seronegative counterparts diffuse large B-cell lymphoma (DLBCL) Little known radiotherapy responses differences . A retrospective cohort of consecutive HIV+ DBCL patients Double hit lymphomas (DHL) double expresser lymphomas (DEL) subsets diffuse large B cell lymphomas (DLBCL) increasingly recognised cause treatment failure . This emphasizes need separation of DLBCL cases order prog AID targeting non-Ig loci generate oncogenic DNA lesions . Mice bearing mutation Aicda (AID) promotes antibody class switch recombination (CSR) somatic hypermutation . Exhaustired T cells may explain patients large B-cell lymphoma benefit chimeric antigen receptor (CAR) T cells . Monocyte-like cells infusions likely develop severe neurologic side effects . Intra-tumour heterogeneity lymphoid malignancies encompasses selection genetic events epigenetic regulation transcription programs . Clonal-related neoplastic cell populations unsteadily subjected immune editing metabolic adaptations within different tissue microenvironments . How Diffuse large B-cell lymphoma (DLBCL) molecularly heterogeneous group malignancies frequent genetic abnormalities frequent genetic abnormalities . G-quadruplex (G4) DNA structures may facilitate genomic instability association activation-induced " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma . Front chemoimmunotherapy salvage autologous hematopoietic cell transplant high, CD19-" Little known benefits risks myeloid growth factor administration chimeric antigen receptor (CAR) T-cell therapy . Little known benefits risks myeloid growth factor administration chimeric antigen receptor (CAR) T-cell therapy . NLRP3 inflammasome plays pro-tumorigenic role various malignancies . Potential role lymphomagenesis remains unclear . " The integration rituximab (R-CHOP) cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) Coiffier colleagues first, last, successful modification" " Aftiphilin (AFTPH) plays important role regulating intracellular trafficking, exocytosis, pro-inflammatory response . Potential prognostic role AFTPH cancers remains unclear ." CAR-T cells shown encouraging activity in refractory diffuse large B cell lymphomas . CAR-T cells shown encouraging activity in trials . However concurrent use immunosuppressive agents prohibited CAR-T trials . " Diffuse large B-cell lymphoma represents frequent form involving kidney, advanced stage diagnosis, poor outcome, risk central nervous system relapse adequately treated . Kidney biopsy provide specific early detection cases, helping differential diagnosis frequent entities ." " Immunomonitoring chimeric antigen receptor (CAR) T cells relies primarily quantification peripheral blood, inadequately quantifies biodistribution activation status tissues . Noninvasive molecular imaging CAR T cells PET promising approach ability provide spatial, temporal" Evidence regarding dose-related impact doxorubicin subsequent cardiovascular diseases (CVDs) Asian patients without preexorubicin without preexisting CVDs lacking . 40-year-old man treated Behçet's disease (BD) cyclosporine A (CsA) 14 years . He presented multiple lymphadenopathies fever . Histological examination showed iatrogenic immunodef Lactic acidosis pathophysiologically classified type A type B . The association Type B lactic acidosis malignancy known known Warburg effect . " Diffuse large B-cell lymphoma (DLBCL) constitutes biologically heterogeneous entities . Standard first-line therapies cure 60% patients, rest either refractory experiencing relapse . Heterogeneity DLBCL partly explained cell origin" " High-dose methotrexate (HD-MTX) effective regimen treatment PCNS-DLBCL, MTX-related toxicity remains problem . Primary central nervous system diffuse large B-cell lymphoma (PCNS-DL" Lymphoma common haematological malignancy dogs aetiology largely unknown . Presence canine vector-borne agents (CVBD) lymphoma tissues described causative effects questioned . " NotCH1 mutations occur 10% CLL diagnosis, associated short disease-free interval increased risk Richter's transformation ." Cancer normal cells use multiple antiapoptotic BCL2 proteins prevent cell death . Cancer normal cells use multiple antiapoptotic BCL2 proteins prevent cell death . Therapeutic targeting multiple BCL2 family proteins enhances tumor killing " High-dose chemotherapy (HDC) autologous stem cell transplantation (ASCT) used consolidation first remission (CR1) centres untreated, transformed indolent B-cell lymphoma (Tr-iNHL) evidence" " Rituximab, monoclonal antibody CD-20 antigen, effective treatment B-cell lymphoma may also cause bradyarrythmias ." First case of 54-year-old patient nasal septum nodule . Facial computed tomography (CT) scan showed thickening nasal mucosa 14mm . Plasmablastic lymphoma aggressive variant lymphomas recently distinct diffuse Diffuse large B-cell lymphoma (DLBCL) common subtype lymphoma is a major challenge achieving satisfactory curative effect . The underlying mechanisms also fully illustrated . CircCFL1 malignant progression DLBCL yet fully elucidated . CircRNAs play important role tumorigenesis development . CircRNAs play important role tumorigenesis development . " High-dose chemotherapy autologous stem cell transplantation (ASCT) toxic elderly patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) Therefore, effective tolerable regimens elderly patients urgently needed ." " Drug-induced viral-induced pancreatitis is an uncommon etiologies . Pancreatitis, inflammatory process, lead many complicated outcomes acute respiratory failure, sepsis, death ." " Primary cutaneous T-cell lymphomas mycosis fungoides, Sézary syndrome, lymphoproliferative CD30 . Sézary syndrome, lymphoproliferative CD30 ." Pixantrone aza-anthracenedione significantly reduced cardiotoxicity maintaining good anti-tumor activity . Evidence use of pixantrone context daily clinical practice scarce . " PI3K/AKT/mTOR pathway often activated lymphoma alterations PI3K, PTEN, B-cell receptor signaling, leading dysregulation eIF4A (through regulators, eIF4B, eIF4" Neurologist developed two different hyperkinetic movements due corticospinal tract hyperexcitability . Neurologist developed two different hyperkinetic movements due corticospinal tract hyperexcitability . The association Borrelia burgdorferi primary cutaneous lymphoma still unclear . This systematic review meta-analysis aims define association Borrelia burgdorferi primary cutaneous lymphoma different entities . Japanese patients received pola (1.0 1.8 mg/kg) intravenously every 21 days disease progression intolerance . Intra-patient dose escalation prohibited . Tolerability determined standard 3 + 3 rule . Antitumor " CD19-specific chimeric antigen receptor (CAR) T-cell therapy effective refractory relapsed (R/R) B-cell lymphoma, efficacy hindered existence PD-1/PD-L1 pathway . We found" " Isolated leptomeningeal relapse case cutaneous lymphoma uncommon event case primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) Prophylactic central nervous system (CNS) therapy administered, reduce" " Diffuse large B-cell lymphomas (DLBCLs) clinically genetically heterogeneous tumors . Deregulation diverse biological processes specific B cells, B-cell receptor (BCR) signaling motility regulation, contribute lymphom" " Pulmonary artery pseudoaneurysm (PAP) rare vascular phenomenon high mortality rate, entities enlarge, rupture, lead asphyxiation . Pulmonary mucormycosis (PM) underdiagnosed increasingly seen entity era" Plasmablastic lymphoma (PBL) clinically aggressive lymphoma predilection extranodal sites frequently HIV-associated . The incidence non-Hodgkin lymphoma thought reduced widescale antiretroviral " Trans fatty acid (TFA) intake persists much world, posing ongoing threats public health warrant elucidation . Published evidence suggests positive association self-reported TFA intake non-Hodgkin lymphoma (NHL) risk ." " Histologic analysis gold standard diagnosing follicular lymphoma (FL) transformation . Despite frequency clinical diagnosis, clinical assessment tool yet established FL transformation rituximab era ." The underlying cause relapsed refractory (r/r) diffuse large B-cell lymphoma (DLBCL) is usually related to apoptosis resistance antitumor drugs . Stress-induced premature senescence (SIPS " A 60-year-old woman presented cognitive difficulties, memory loss, social withdrawal, unintentional weight loss, unintentional weight loss, night sweats, work-up ultimately identified multiple brain lesions mediastinal adenopathy . Brain biopsy showed" Study reports unusual case healthy 67-year old male diagnosed isolated right oculomotor nerve palsy (ONP) found underlying B cell lymphoma . Mice reconstituted human immune systems mount cell-mediated immune responses human tumor viruses Epstein Barr virus (EBV) Kaposi sarcoma associated herpesvirus (KSHV) This review summarizes similari similar immune responses " Diffuse large B-cell lymphoma (DLBCL) common subtype lymphoma, accounting approximately 30% 40% non-Hodgkin's lymphomas (NHL) Administration rituximab significantly improved outcomes" " Gallbladder involvement lymphoma extremely rare, 68 cases reported English literature far . Gallbladder involvement lymphoma extremely rare, 68 cases reported English literature far ." " Epirubicin first-line chemotherapeutic drug clinical treatment for diffuse large B cell lymphoma (DLBCL) overexpression of multidrug resistance (MDR) transporter proteins, especially P-glycop" " 75-year-old female diffuse large B-cell lymphoma (DLBCL) developed signs of liver abnormality . Despite initiation chemotherapy, patient deteriorated quickly ." Primary mediastinal B-cell lymphoma (PMBCL) rare tumour different characteristics type lymphomas . Clinical manifestations may vary cause delay diagnosis management . " Epstein-Barr virus causes infectious mononucleosis (IM) In case atypical presentation, lymph node tonsillar biopsies required rule lymphoma ." " Outdoor artificial light night (ALAN) implicated growing number adverse health outcomes . ALAN believed disrupt circadian rhythms associated increased inflammation, one hallmarks cancer ." " Chimeric antigen receptor T cell (CAR-T) therapy approved treatment relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) Here evaluate whether comorbidities, calculated using" " Chimeric antigen receptor (CAR) T-cell therapy approved R/R DLBCL 2 prior lines therapy based data single-arm phase 2 trials, complete responses (CRs) 40% 60% patients ." 15% of patients with diffuse large B-cell lymphoma (DLBCL) have obesity . 15% of patients with DLBCL have obesity . " Cutaneous peripheral T-cell lymphoma, otherwise specified (PTL NOS) aggressive, poorly characterized neoplasm . European Organization Research Treatment Cancer cutaneous lymphoma taskforce (EORTC CLTF) investigated 33 biops" " Previous published data showed impact single-nucleotide polymorphisms VEGF A VEGFR2 genes survival patients various malignancies, among others diffuse large B-cell lymphoma . We investigated role four VEGF-A" " Primary lymphoma uterine cervix infrequent disease, usually affecting perimenopausal women ." Primary lymphoma bone (PLB) extremely rare malignancy arising skeletal system . There consensus best definition PLB is an extremely rare malignancy arising skeletal system . Survival rates calculated using Kaplan-Meier method . " Richter's transformation diffuse large B cell lymphoma often seen . PBL extremely aggressive lymphoma usually treated using CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine prednisone" Exposure pesticides reportedly associated several types cancer . Exposure pesticides reportedly associated several types cancer . " Primary colonic lymphoma rare tumor accounting 0.1%-0.5% colorectal malignancies . Diagnosis was made based on Dawson criteria, ruling extracolonic involvement ." " Study reveals importance recognizing uncommon histologic variants diffuse large B-cell lymphoma, signet-ring cell variant, may result erroneous delayed diagnosis potential impact patient treatment ." " Primary thyroid lymphomas rare . They constitute 2% thyroid malignancies . Preoperative diagnostic confirmation . Allows appropriate therapeutic management, consists chemotherapy without radiotherapy avoid unnecessary surgery ." The prognosis diffuse large B-cell lymphoma (DLBCL) MYC rearrangement (MYC-R) was poor standard immunochemotherapy . Deep learning algorithm detect MYC rearrangement scanned histological slides diffuse large B-cell lymphoma . The H&E-stained slides were used to identify the lymphoma . The overall sensitivity detect MYC rearrangement 0. " T-cell lymphomas extremely poor prognosis . Decades effort focused retrofitting chemotherapy programmes used diseases, CHOP (cyclophosphosphorus)" " Lymphomas presenting effusions could either primary secondary, limited data Taiwan . We retrospectively reviewed effusion lymphomas archives tertiary center July 2011 June 2019 . We identified 59 specimens 43 patients, including 7 cases primary effusion lymphoma" " Matrix metallopeptidase 14 (MMP14) important gene regulation T-cell function . correlation MMP14 expression, prognosis, immune cell infiltration diffuse large B-cell lymphoma (DLBCL) remains unclear" " Diffuse large B-cell lymphoma common subtype non-Hodgkin lymphoma common subtype non-Hodgkin lymphoma . 5-year survival rates first-line setting range 60% 70%, 50%" Meta-analysis conducted study to determine specific prognostic value accurately . PNI overall survival (OS) progression-free . Pooled hazard ratio (HR) 95% confidence interval (CI) calculated assess association PNI overall survival (OS " Clinical trials demonstrating addition rituximab (R) cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) significantly improved outcome, including response rate disease-free survival" Exportin 1 (XPO1) is a protein that upregulation leads inactivation tumor suppressor anti-neoplastic function . XPO1 inhibitors investigated promising targeted anti-cancer therapy . " Pneumocystis pneumonia (PCP) infection diffuse large B-cell lymphoma (DLBCL) patients treated rituximab plus cyclophosphamide, doxorubicin, vincristine" PIWI-interacting RNAs (piRNAs) indicated epigenetic effectors cancer . PIWI-interacting RNAs (piRNAs) indicated epigenetic effectors cancer . Ki67 proliferation index was used to assess non-Hodgkin lymphoma non-Hodgkin lymphoma non-Hodgkin lymphoma non-Hodgkin lymphoma non-Hodgkin lymph " The mutational landscape gray zone lymphoma (GZL) yet established, differences related entities largely unknown . Study found coding sequence mutations 50 Epstein-Barr virus (EBV)-negative GZLs ." " Viral metagenomic technique useful identification viral pathogens potentially existing bone marrow specimens hematologic patients . An infectious etiology proposed many human cancers, rarely specific agents identified ." Reduced-intensity conditioning (RIC) regimens frequently used allogeneic hematopoietic cell transplantation (allo-HCT) patients diffuse large B cell lymphoma (DLBCL) DLBCL is particularly important Multifocal necrotizing leukoencephalopathy (MNL) pathologic condition unknown etiology . Patients prolonged critical illness . Neurotoxic side effects traditional systemic chemotherapy abundantly described . Autologous hematopoietic cell transplant (autoHCT) population well defined modern era . Outcomes patients primary refractory diffuse large B cell lymphoma (DLBCL) were dismal . AutoHCT patients CAR-T cell therapy promising treatment CD19 . Chimeric antigen receptor-T (CAR-T) cell therapy promising treatment CD19 . Lymphoma dreaded complication inflammatory bowel diseases [IBD]. Knowledge lymphoma patients IBD limited epidemiological data description risk factors . We performed systematic review describe clinical characteristics prognosis lymphoma patients IBD . Positron emission computed tomography (PET/CT) patients diffuse large B-cell lymphoma (DLBCL) enrolled prospective clinical trial reviewed test impact quantitative parameters . 138 patients treated rituximab plus cyclophosph " Burkitt lymphoma (BL) aggressive B-cell-malignancy derived germinal-centre B-cells . Curative therapy traditionally requires intensive immunochemotherapy . Recently, immuno-oncological approaches, mod" " Maternal neonatal outcomes of 80 pregnant patients diagnosed non-Hodgkin lymphoma (NHL) 1986 2019 . Of 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP-like (" Diffuse large B-cell lymphoma (DLBCL) mimicking malignant pleural mesothelioma (MPM) A 75-year-old man from New York City was diagnosed with DLBCL mimicking 61-year-old male male known primary central nervous system diffuse large B-cell lymphoma (DLBCL) underwent restaging PET/CT initial peak infection COVID-19 pneumonia within New York region . The aim study highlight several misleading imaging clinical aspects parotid gland lymphoma . The records patients diagnosed lymphoma parotid gland 2005 2017 examined retrospectively . Sixty-seven patients included study. The mean age 61.4 years Abnormal spindle-like microcephaly-associated protein (ASPM) implicated aggressive behavior several malignant tumors . Potential effects of diffuse large B-cell lymphoma (DLBCL) still remain unknown . Activated B-cell (ABC)-diffuse large B-cell lymphomas (DLBCLs) clinically aggressive phenotypically complex malignancies . Partially differentiated antigen-secreting cells (plasmablasts) Death receptor Fas-mediated apoptosis eliminates nonspecific autoreactive B cells also plays major role antitumor immunity . Fas-mediated induction of apoptosis lymphomagenesis remains unknown . PETAL trial considered purely diagnostic value aggressive lymphoma . Surgical resection considered purely diagnostic value aggressive lymphoma . " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . 40% patients relapse complete response refractory therapy . Targeting BTK ibrutinib, inhibitor" Diffuse large B-cell lymphoma (DLBCL) heterogenous disease variable prognosis . Diffuse large B-cell lymphoma (DLBCL) heterogenous disease variable prognosis . Primary pancreatic lymphoma (PPL) extremely rare form extranodal malignant lymphoma . The common histological subtype PPL diffuse large B-cell lymphoma (DLBCL) PPL may often overlap pancreat " Isatuximab monoclonal antibody targeting transmembrane receptor ectoenzyme CD38 . Protein highly expressed hematological malignant cells, including multiple myeloma (MM) Upon binding CD38-expressing" " SUVmax, volume, entropy excellent predictors interim response, areas curves (AUCs) 0.850, 0.805, 0.800, respectively . CR rate significantly lower patients intestinal involvement ." " Diffuse large B-cell lymphoma (DLBCL) osteoporotic fracture common older patients . Exposure R-CHOP (rituximab, cyclophosphamide, doxorubicin, vinc" " Human parvovirus B19 identified polymerase chain reaction (PCR) testing blood presence typical giant proerythroblasts bone marrow . Reactivation human parvovirus B19 exceptional characteristic immunosuppression, anaemia" Double-expressor diffuse large B-cell lymphoma (DLBCL) is a form of diffuse large B-cell lymphoma . Diffuse large B cell lymphoma (DLBCL) highly heterogeneous type non-Hodgkin lymphoma many molecular subtypes distinguished gene expression profiling (GEP) Pathogenesis of DLBCL still unclear . " Post-transplant lymphoproliferative disorder (PTLD) comprises broad spectrum diseases rare serious complication solid organ transplantation . We report case 45-year-old simultaneous pancreas kidney (SPK) transplant recipient diffuse," " Splenic marginal zone lymphoma (SMZL) rare lymphoma (SMZL) rare lymphoma belonging marginal zone lymphoproliferative disorders . Usually, SMZL occurs indolent presentation and, required, standard" BEAM-Campath conditioned allogeneic stem cell transplantation center (BEAM) Campath conditioning developed reduce high transplant-related mortality patients lymphoma delivering intensive antilymphoma immunotherapy . High-grade diffuse large B-cell lymphoma (HG-DLBCL) refers DLBCL MYC BCL2 and/or BCL6 rearrangements (double-hit triple-hit DLBCL) Interleukin-1 receptor-activated kinase 4 (IRAK4) belongs IRAK family serine/threonine kinases plays central role innate immune response . function IRAK4 tumor growth progression remains elusive . " Lisocabtagene maraleucel (liso-cel) autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product . We aimed assess activity safety liso-cel patients rel" The Hodgkin lymphoma (CHL) B-cell non-Hodgkin lymphoma (B-NHL) B-NHL was reported . The cases metachronous synchronous synchronous co-occurrence " The presence of renal cell carcinoma (RCC) hematologic malignancies (HM) patient rarely observed . Male gender lymphoid malignancy predominance, HM usually diagnosed simultaneously RCC ." Ibrutinib might improve efficacy anti-CD19 chimeric antigen receptor (CD19 CAR) T-cell therapy chronic lymphocytic leukemia (CLL) We studied possibility mechanism synergistic effect ibrutinib CAR " A 48-year-old man presented headache lasting 10 d. CT brain showed round, heterogeneous, high-density lesion surrounding edema right t t t . CT brain showed round, heterogeneous, high-density lesion" " Non-Hodgkin lymphomas (NHLs) paranasal sinus uncommon, accounting 0.17-2% NHL cases; especially rare sphenoid sinus ." " Primary central nervous lymphoma aggressive disease without evidence systemic spread annual incidence 7 cases per 1,000,000 people United States." Consolidative radiation therapy (RT) advanced-stage diffuse large B-cell lymphoma (DLBCL) remains controversial . A PET-guided approach selectively administering RT policy British Columbia since 2005 . T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) aggressive variant diffuse large B-cell lymphoma (DLBCL) characterized rare malignant B cells within robust ineffective immune cell infiltrate " Pancytokeratins TTF-1 used working carcinomas unknown primary p63 expressed many cell lineages . The preliminary report clinical team ""suspicious carcinoma"" The preliminary report clinical team ""suspicious carcinoma"" However" We present summary literature regarding kappa lambda immunohistochemistry (IHC) situ hybridization (ISH) evaluation atypical cutaneous mucosal lymphoid infiltrates . Relevant articles 1967 2018 English language identified summarized . Sixty " In poorly draining complex pleural effusions, current management favours image-guided placement smaller bore catheters . We describe experience using IPFT three patients different bleeding risks ." Thirty-two hotspot driver genes examined 145 DLBCL patients . First-line R-CHOP treatment leads dismal outcome necessitates alternative treatment . " Lymphomas frequent neoplasm orbit. Lymphomas frequent neoplasm orbit. However, epidemiology orbital lymphomas well reported. This study aimed provide population-based report epidemiology orbital lymphomas measure trends ." " The IKK-related kinases, IKKε TBK1, IKKε TBK1, essential roles in innate immunity . Toll-like receptors regulate NF-κB signalling . We investigated expression function IKKε TB" Pancreatic lymphomas represent infrequent challenging cytologic diagnosis . Pancreatic lymphomas represent infrequent challenging cytologic diagnosis . We retrieved pancreatic EUS-FNAs performed 10-years institution's database . We correlated cytologic " Follicular lymphoma (FL) well-studied microenvironment-dependent hematological malignancy, crosstalk various involved cell subtypes still fully understood . Seventy-one patients FL available diagnostic paraffin" The polycomb repressive complex 2 maintains transcriptional repression target genes . The polycomb repressive complex 2 (PRC2) maintains transcriptional repression target genes . EZH2 also plays role cancer development progression promoting cancer cell survival invasion . Study investigated whether expression cyclin D2 (CCND2) mRNA activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) correlated efficacy Rituximab combined chemotherapy (R-CH transcription factor EGR-1 rapidly induced anti-CD20 antibodies . EGR-1 results increased calcium influx induced anti-CD20 antibodies . PCNSL is a rare malignant tumor central nervous system lymphoma . Early diagnosis subsequent planning adequate treatment strategy relevant improve survival . Early diagnosis subsequent planning adequate treatment strategy relevant improve survival . " Immune cells tumor microenvironment important prognostic indicator diffuse large B-cell lymphoma (DLBCL) Immune cells tumor microenvironment important prognostic indicator . However, information heterogeneity risk stratification cells limited ." Primary mediastinal large B-cell lymphoma (PMBL) diagnosis challenging needle biopsies . Robust techniques needed to ensure diagnosis lymphoma highly sensitive recently developed therapy protocols . Splenectomy ideal specimen multiparametric diagnosis splenic lymphoma . Splenectomy ideal specimen multiparametric integrative diagnosis splenic lymphoma . Splenectomy ideal specimen multiparametric . " MicroRNA-130a serves role tumorigenesis prognosis numerous human tumors . However, best knowledge, prognostic significance miR-130a PGI-DLBCL remains unknown ." " CD200 membrane protein immunosuppressive function expressed many hematopoietic neoplasms . CD200 shown poor prognostic marker AML PCM; AML, immunomodulatory effect linked ability to induce FoxP" Raman spectroscopy (RS) provide fingerprint-type information biochemical molecules . RS-based blood plasma analysis solid tumors reported recent years . 100 patients relapsed refractory large B-cell lymphoma treated standard care axicabtagene ciloleucel (axi-cel) treated standard care axicabtagene ciloleucel (ax Natural killer cells play critical roles in the development of hematological malignancies . NK cells play critical roles in protection hematological malignancies . But underlying reasons impaired NK cell function remain uncovered . " Approximately one-fourth primary cutaneous lymphomas B-cell derived generally classified three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), primary" Lymphomas heterogeneous group malignant neoplasms lymphocytes precursor cells . Lymphoma seen 3.5% intraoral malignancies second common neoplasm squamous cell carcinoma head neck region . 60-year-old male male fibrin-associated diffuse large B-cell lymphoma (fa-DLBCL) left atrial myxoma . Echocardiography showed mass (63 mm × 33 mm) Sexual Adjustment Questionnaire-Swedish version II (SAQ-SII) patients treated diffuse large B-cell lymphoma describe explore patients' experiences sexuality treatment . Sexuality important part health-related quality life . Brentuximab vedotin (BV) was effective CD30-positive lymphomas . The objectives study standardize evaluate evaluate CD30 intensity flow cytometry (FCM) non-Hodgkin's lymphomas . " CpG oligodeoxynucleotides (CpGs) induce anti-tumor immune response, also cause direct lymphoma cytotoxicity . To improve delivery efficacy CpGs, utilized tri-ethylene modified" " Diffuse large B-cell lymphoma (DLBCL) is common type aggressive non-Hodgkin lymphoma (NHL) Patients initially respond standard R-CHOP therapy, 30-40% develop refractory" " Patients autoimmune diseases (AIDs) may develop lymphoproliferative disorders (LPDs) Treatment immunosuppressive agents (IS) methotrexate (MTX), biological agents, tacrolimus . Some L" Chimeric antigen receptor (CAR) T-cell therapy emerged promising treatment relapsed refractory large B-cell lymphoma (LBCL) Food Drug Administration (FDA) approvals axicabtagene cilole " Lymphomas afflict age groups people, certain types demonstrating female predilection adolescents young adults . Treatment must consider maternal fetal health, management approaches therefore influenced gestational age diagnosis treatment timing delivery ." " Mass spectrometry (MS)-based targeted proteomic techniques, including selected reaction monitoring (SRM), parallel reaction monitoring (PRM), massively parallel data-independent acquisition (DIA) developed . For optimal performance, require fragment ion" R-CHOP is a CHOP CHOP CHOP-like chemotherapy (R-CHOP) for diffuse large B-cell lymphoma (DLBCL) Patients with DLBCL have been identified as patients with R- People living HIV AIDS increased risk Hodgkin non-Hodgkin lymphoma compared HIV-negative individuals . Multiple myeloma leukaemia leukaemia inconsistent low quality risk seem increased . " Adenosine deaminase (ADA) measurement become important tool timely diagnosis of infection . Despite recent decline, tuberculosis (TB) infection still frequent diagnosis Portugal." Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma (NHL) common subtype non-Hodgkin's lymphoma (DLBCL) 30 " Age-related epigenetic dysregulations associated several diseases, including cancer . The number stochastic epigenetic mutations (SEM) suggested biomarker life-course accumulation exposure-related DNA damage . However, predictive role SEMs cancer" " MALT1 inhibitors promising therapeutic agents B-cell lymphomas dependent constitutive aberrant signaling pathways . However, potential limitation signal transduction-targeted therapies could be limited to full impact drugs ." " Digital PCR analysis of 134 patients patients patients DLBCL diagnosis . The MYD88 L265P mutations detected 22 patients, particularly non-GC subtype, CD5-positive, CD5-positive, high absolute monocyte count" " BCL2 comprises clinically significant, yet poorly characterized biological high-risk feature diffuse large B-cell lymphoma (DLBCL) BCL2 comprises clinically significant, yet poorly characterized biological high-risk feature diffuse large B-cell" National Cancer Center China included retrospective study . 50 PI-DLBCL patients accepted standard first-line treatment National Cancer Center China included retrospective study . Survival analysis performed evaluate prognostic risk factors . Herein analyzed survival outcomes chemotherapy-treated patients plasmablastic lymphoma (PBL) diagnosed 2010 2016 (n = 248) The majority patients male (81.9%) younger 60 years (71.0%) younger 60 years 26-year old patient diagnosed adult onset Still's disease . Previously treated large B-cell Non-Hodgkin lymphoma (LBCNHL) chemotherapy haemopoietic stem-cell autograft . aut " Clinical trials chimeric antigen receptors (CARs) targeting CD19 produced impressive results hematological malignancies, including diffuse large B-cell lymphoma (DLBCL) However, notable number patients DLBCL fail achieve remission" " 7 studies met inclusion criteria . The included 7 studies comprised 1578 patients . The included 7 studies comprised 1578 patients . There different MHD: diffuse large B cell lymphoma (DLBCL, 4 stu)" The efficiency upfront consolidation high-dose chemotherapy/autologous stem-cell transplantation (HDCT/ASCT) may influenced induction chemotherapy . The efficiency upfront consolidation high-dose chemotherapy/autologous stem-cell transplantation ( Splenic marginal zone lymphoma (SMZL) rare tumor without uniform treatment approach . Study evaluated survival outcomes patients SMZL according treatment received . " Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) standard treatment diffuse large B-cell lymphoma (DLBCL) R" Diffuse large B-cell lymphoma (DLBCL) common subtype adult non-Hodgkin's lymphoma (NHL) Diffuse large B-cell lymphoma (DLBCL) common subtype adult G-banded karyotyping performed biopsy specimens single-centre IVL cohort comprising intravascular large B-cell lymphoma (IVLBCL) and NK/T-cell lymphoma (IVNKTC " Cases of primary central nervous system lymphoma manifesting hemorrhage rare . Cases of hemorrhage rare, previous studies available ." " The COVID-19 pandemic dramatically challenged care cancer patients, especially active treatment represent vulnerable population SARS-CoV-2 infection . Aggressive lymphoid neoplasms, diffuse large B cell lymphoma high-grade B cell" " Four cases of primary diffuse large B-cell lymphoma cervix treated institution immunochemotherapy radiotherapy . The mean age 50 years (range, 39-62 years) The mean age 50 years (range, 39-62 years)" " High-dose methotrexate (HD-MTX) increasingly used prophylaxis patients with high risk central nervous system (CNS) relapse . However, limited evidence guide whether intercalate HD-MTX (i" Avadomide (CC-122) novel oral cereblon-modulating agent promising activity non-Hodgkin lymphoma . CC-122-NHL-001 phase 1b dose escalation expansion study eight sites France " Between January 2004 December 2019, patients lymphoid neoplasms pleural effusions, ascites, pericardial effusions hospital, reviewed . A total 65 patients lymphoid neoplasms collected period . The top three neopl" " Malignant lymphoma, particularly B-cell non-Hodgkin's lymphoma, one extrahepatic manifestations associated chronic HCV infection . The effectiveness anti-HCV therapy DAAs B-cell non-Hod" Positron emission tomography may helpfull context already reported . Intravascular large B cell lymphoma rare non-Hodgkin large B cell lymphoma disease . " Various chemotherapy regimens used treat patients diffuse large B-cell lymphoma (DLBCL) Various chemotherapy regimens used treat patients diffuse large B-cell lymphoma (DLBCL) However, treatment-related toxicity focus infectious disease" Next-generation sequencing plasma-derived cell-free DNA (cfDNA) detects somatic mutations accurate genotyping tumor biopsy . A distinct diffuse large B-cell lymphoma entity confined central nervous system primary central nervous system primary central Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] tisagenlecleucel [tisa-cel] " Lymphoma prominent spindle cell features morphological variant diffuse large B-cell lymphoma (DLBCL) categorized rare variant WHO classification . Most cases arise skin, two cases reported uterine cervix date ." Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin's lymphoma (NHL) common subtype non-Hodgkin's lymphoma (DLBCL) common Plasmablastic lymphoma (PBL) rare aggressive variant diffuse large B-cell lymphoma . HIV-positive male patients immunosuppressive hosts . Limited number reports HIV-negative PBL immunocompetent patients available " This largest national study OAL date . Patients diagnosed January 1, 1980 December 31, 2017 identified Danish registers, clinical well survival data collected . 387 patients diagnosed with OAL January 1, 1980 December 31, 2017 identified Danish registers, clinical" " 36 patients diagnosed primary DLBCL oropharyngeal maxillofacial region 2009 2017 Department Pathology Hospital Stomatology, Wuhan University . Gene rearrangements BCL2, BCL6, MYC" " Patients diagnosed stage I DLBCL 2001 2015 treated rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) R-CHOP-" Hyperechoic breast lesions rare group breast masses routine practice . Most lesions benign but rarely may malignant . Hyperechoic lesions evaluated using criteria malignant lesions . Diffuse large B-cell lymphoma (DLBCL) heterogeneous entity B-cell lymphoma . Cell-of-origin (COO) classification DLBCL required routine practice World Health Organization classification biological therapeutic insights . High-grade B-cell lymphoma (HGBL) translocations involving MYC BCL2 BCL6 comprises 10% cases . Diffusion large B-cell lymphoma (DLBCL) carries poor prognosis . " The CBM complex, composed proteins CARMA1, BCL10, MALT1, serves multiple pivotal roles mediator T-cell receptor B-cell receptor B-cell receptor-dependent NF-κB induction lymphocyte activation" " MYC oncogenic network represents attractive therapeutic target lymphoma . MYC inhibitors difficult develop. Alternatively, inhibitors epigenetic/ transcriptional regulators, particularly bromodomain extraterminal (BET) family, used modulate" " Peritoneal lymphomatosis extremely rare presentation lymphoma . Due relative low frequency, receives much less attention peritoneal carcinomatosis ." " MicroRNA-155 (MiR-155) involved normal B-cell development lymphomagenesis, affecting cell differentiation, motility, intracellular signaling . MiR-155 potentially involved deregulation B-cell receptor pathway (BC" Neck ultrasonography fine-needle aspiration cytology (FNAC) diagnostic modality choice clinicians routinely work thyroid mass . Hashimoto's thyroiditis presenting goiter particularly challenging . Diffuse large B-cell lymphoma (DLBCL) frequent lymphoma adults . It's well-established c-MYC BCL2 play important roles normal B-cell differentiation tumorigenesis . " Methotrexate (MTX) immunosuppressor widely used treat autoimmune diseases, including rheumatoid arthritis (RA) Serious adverse effects including lymphoma: MTX-associated lymphoproliferative disorder (MTX" " Histiocyte-rich pseudotumors (HRPT) developing postchemoradiation therapy florid response treatment reparative change . Although benign processes, clinically radiologically may mimic recurrent/relapsed disease, benign processes" " Classical Hodgkin lymphoma (cHL) identified universal genetic alterations chromosome 9p24.1, contains chromosome 9p24.1, contains chromosome 9p24.1, contains chromosome 9p24.1, contains chromosome 9" " Despite low frequency variants diffuse large B-cell lymphoma (DLBCL), CD5 is CD5 . Despite low frequency variants diffuse large B-cell lymphoma (DLBCL), CD5 is CD5 ." " The Bromo- Extra-Terminal domain (BET) family proteins act ""readers"" acetylated histones important transcription regulators . The potential targeting BET proteins anti-cancer treatment originated data obtained first series compounds ." " From January 2015 January 2019, identified total 233 dogs 100 cats metastatic disease . Of these, 11.6% (27/233) dogs 13% (13/100) cats ocular metastases . In dogs, neopl" " Plasmablastic lymphoma (PBL) rare form non-Hodgkin lymphoma highly aggressive carries poor prognosis . The preferred regimens PBL include infusional EPOCH (etoposide, prednis" We retrospectively analyzed bone marrow (BM) infiltration pattern pattern consecutive 30 intravascular large B-cell lymphoma (IVLBCL) patients diagnosed random skin biopsy (RSB) patients . BM infiltration lymphoma observed 18 " Chimeric antigen receptor T (CART) cells targeting CD19 shown promising results treatment chronic lymphocytic leukemia (CLL) However, efficacy seems inferior compared compared compared to diffuse large B-cell lymphoma acute lymphoblastic" Metabolic tumor volume (MTV) promising biomarker pretreatment risk diffuse large B-cell lymphoma (DLBCL) Different segmentation methods used predict prognosis equally well give different optimal cutoffs risk stratification . Segment " The purpose study assess risk factors cancer-specific mortality cardiovascular mortality . A total 62,950 patients DLBCL enrolled, 23,302 (37.50%) died cancer 2940 (4.70%) died cardiovascular disease ." " 60-year-old woman presented six months abdominal pain, weight loss diarrhea . She developed non-cirrhotic portal hypertension presented esophageal variceal bleeding . A diffuse large B-cell lymphoma encircling" Most low-grade gastric lymphomas arising mucosa-associated lymphoid tissue (MALT) directly related to mucosa-associated lymphoid tissue (MALT) Most low-grade gastric lymphomas arising mucosa-associated Henoch-Schönlein purpura (HSP) neoplasia rare commonly reported cases solid tumors rather hemotological malignancies . Orbital biopsy revealed diffuse large B-cell lymphoma skin kidney biopsies showed " A 12-year-old boy presented prolonged history headache, fatigue hypertension . Diagnosis was initially thought to be juvenile nephronophthisis . Biopsy revealed primary renal diffuse large B-cell lymphoma ." 75 patients large B-cell lymphoma treated standard care CD19 targeted CAR T-cell product (axicabtagene ciloleucel) Adoptive T-cell therapy challenges immune-mediated toxicities including cytokine Chemotherapy resistance plays major role treatment failure failure diffuse large B cell lymphoma (DLBCL) Exosomes closely related tumor drug resistance . Exosomes closely related tumor drug resistance . " Gastrointestinal bleeding (GIB) common cause hospitalization associated significant morbidity mortality . Hemospray (Cook Medical, Winston-Salem, NC, USA) recently approved modality help treat tumor-related GIB ." " Understanding factors shape immune landscape across hematological malignancies essential immunotherapy development . We integrated 8,000 transcriptomes 2,000 samples multilevel genomics hematological cancers ." " Hemophagocytic lymphohistiocytosis (HLH) rare often fatal disease diagnosed treated promptly . HLH due genetic factors infections, malignancies collagen-associated vascular diseases . Malignancy-associated HLH" " Metformin oral agent type 2 diabetes shown decrease cancer risk lower mortality types cancer . We performed retrospective analysis of patients DLBCL treated front-line chemotherapy . We also performed pre-clinical studies looking effect metformin cell viability," " Risk-stratification essential management tool defining prognosis haematological neoplasms, patient physician perspective ." " Metabolic tumor volume (MTV) promising indicator prognosis diffuse large B-cell lymphoma (DLBCL) The aim present study evaluate different methods calculation basal metabolic tumor volume . 34 patients underwent in relation PFS, show statistically" Cutaneous involvement systemic lymphoma via direct extension rare phenomenon . Historically described patients advanced-stage disease bulky lymphadenopathy . Cutaneous involvement systemic lymphoma via direct extension rare phenomenon . Mantle cell lymphomas (MCLs) prototypic B-cell non-Hodgkin lymphomas defined cyclin D1 gene (CCND1) rearrangements . Rare cases of diffuse large B-cell lymph We retrospectively analyzed data patients diagnosed diffuse large B-cell lymphoma (DLBCL) treated first-line R-CHOP chemotherapy received pegylated G-CSF primary prophylaxis . We aim compare efficacy safety PD-1 expressing TILs associate better survival T-DLBCL . PD-1 expressing TILs associate better survival T-DLBCL . The prognostic value of Ki-67 proliferation index follicular lymphoma (FL) is controversial . This study investigated clinical usefulness two factors Asian FL patients . Japan's national database hospital-based cancer registries estimated cover 67% new cancer cases . We obtained data 6510 adult testicular malignancy patients diagnosed 2012-2015 . The common histology seminoma (60.3% test " Neurolymphomatosis, infiltration peripheral nervous system lymphoid cells, represents uncommon manifestation lymphomas . A 58-year-old woman from previous breast diffuse large B-cell lymphoma treated chemo- radiation-therapy," " Cladribine purine nucleoside analog used treat B-cell chronic lymphocytic leukemia hairy cell leukemia, also functions inhibitor DNA synthesis block repair damaged DNA . The therapeutic role cladribine diffuse large B-cell lymphoma" " Primary cutaneous B-cell lymphomas heterogeneous group lymphoid neoplasms primarily occurring skin . In setting, presence of histopathologic immunohistochemical features cellular immaturity exceedingly rare may represent diagnostic challenge ." UK National Cancer Research Institute initiated prospective study (UKCRN-ID 1760) assess prognostic value early fluorodeoxyoxyglucose (FDG)-positron emission tomography (PET) (PET) (PET Canine B-cell lymphoma represents useful model human diffuse large B-cell lymphoma (DLBCL) Pan-Bromodomain extra-terminal (BET) inhibition targeting BRD2/3/4 The aggressive B cell lymphomas frequently manifest extranodal distribution carry somatic mutations poorly characterized gene TBL1XR1 . TBL1XR1 mutations skew humoral immune response toward generating abnormal immature memory B cells . Next-generation sequencing-based panel testing well practiced field cancer medicine identification target molecules solid tumors . Clinical utility clinical issues surrounding panel testing hematological malignancies yet fully evaluated . " Intravascular proliferations skin clinically heterogeneous may present wide range clinical features, including violaceous papules, nodules, plaques, plaques, unspecific cutaneous lesions . Intravascular proliferations skin clinically heterogeneous may" " Diffuse large B-cell lymphoma (DLBCL) represents grouping clinically biologically heterogeneous tumors . Application advanced molecular technology significantly expanded knowledge of DLBCL pathobiology . Here, review recent molecular analyses could provide paradigm shift new" Cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome notable toxicities CD19 chimeric antigen receptor (CAR) T-cell therapy . CAR T-cell-mediated toxicities involve organ system Primary non-Hodgkin's lymphoma (NHL) urinary bladder exceedingly rare entity accounting 0.2% primary neoplastic lesions . This tumor female predominance; cases seen middle-aged females . It primarily affects urinary Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) common subtype extranodal non-Hodgkin lymphoma (NHL) common subtype extranodal non-Hod Programmed death ligand-1 (PD-L1) microRNA-34a (miR-34a) play crucial roles in GDLBCL progress . The purpose research explore clinical significance PD-L1 miR Histologic transformation (HT) important event adverse prognosis adverse prognosis natural history indolent lymphomas . There minimal data HT Australian setting. To characterise patients biopsy-proven HT outcomes identified tertiary Australian Hospital . All patients Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy demonstrated remarkable efficacy refractory relapsed relapsed diffuse large B cell lymphoma (R/R DLBCL) Therapy failed nearly 25% patients mainly CIK cell immunotherapy improves prognosis patients high-risk diffuse large B cell lymphoma (DLBCL) first complete remission (CR) " Primary pulmonary diffuse large B cell lymphoma (PPDLBCL) extremely rare, fewer 40 cases reported date lack systemic analysis . Present case mimicking metastasis heavily treated patient breast cancer ." " B7 homologue 6 (B7-H6) found up-regulated level multiple cancer cells identified positively correlated inferior clinical features . In non-Hodgkin lymphoma (NHL), roles B7-H6 underlying" " SNHG12 expression associated multiple cancers, including renal cell carcinoma, prostate cancer, cervical cancer, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, hepatocellular carcinoma" Polatuzumab vedotin anti-CD79b antibody conjugated monomethyl auristatin E shown significant clinical activity . Currently FDA-approved combination bendamustine rituximab patients relapsed Study retrospectively investigated predictive accuracy of Deauville 5-point scale (5-PS) quantitative SUV-based assessment patients extranodal (EN) diffuse large B cell lymphoma (DLBCL) The Deauville " Ocular adnexal lymphoma (OAL) involved orbit 44.6%, conjunctiva 32.1%, lacrimal apparatus 14.3% eyelid 8.93% . Extranodal marginal zone B-" Non-Hodgkin lymphoma (NHL) incidence well understood but not well understood . Exposure lymphomagens vary geography. Exposure lymphomagens vary geography. We sought evaluate association urban-rural status racial ethnic Primary mediastinal large B-cell lymphoma (PMBCL) improved integration rituximab . Type primary therapy role radiotherapy (RT) remains ill-defined . " In response T cell-dependent antigens, mature B cells stimulated form germinal centers (GCs) mature B cells stimulated form germinal centers (GCs) mature B cells stimulated form germinal centers (GC" " OAL located eyelid, conjunctiva, lacrimal apparatus orbit included . Main outcome measures age-adjusted incidence rates (IRs) per 1 000 000 population risk (calculated period 2000-2015)" " Diffuse large B-cell lymphoma (DLBCL) highly aggressive malignant tumor, accounting 30-40% non-Hodgkin's lymphoma . Our aim construct novel prognostic models candidate genes based clinical features ." The case 83-year old male patient described. He presented hospital 2 week history intermittent syncope diagnosed atrial fibrillation diagnosed atrial fibrillation . His CBC showed bicytopenia anemia neutropenia neutrop Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) pediatrics commonly occurs iatrogenic immunodeficiency-associated lymphoproliferative disease . This case suggests post " SADAL multicentre, multinational, open-label, phase 2b study done 59 sites 19 countries . Relapsed refractory diffuse large B-cell lymphoma (DLBCL) aggressive cancer median overall survival less 6" " Diffuse large B-cell lymphoma (DLBCL) patients typically treated immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vinc" The impact of bridging therapy (BT) administered leukapheresis chimeric antigen receptor (CAR) T-cell therapy large B-cell lymphoma (LBCL) is unclear . 148 LBCL patients underwent le " Genome-wide association studies identified many genetic risk variants cancers . Esophageal, gastric endometrial cancers, well melanoma, glioma, diffuse large B-cell lymphoma, follicular lymphoma, foll" " Spleen tyrosine kinase (SYK) important enzyme proliferation differentiation hematopoietic tissues . Its role cancer driver well documented liquid tumors; however, cumulative evidence suggested opposite role tumor types ." Histologic transformation follicular lymphoma aggressive lymphoma aggressive lymphoma historically poor prognosis . Routine use anti-CD20 antibody rituximab changed landscape follicular lymphoma outcomes improved select patients . Several biological clinical biomarkers Follicular lymphoma comprises approximately 20-30% cases B-cell lymphomas . Median survival improved significantly modern era. Median survival improved significantly modern era. " Diffuse large B-cell lymphoma (DLBCL) characterized extensive genetic heterogeneity, results unpredictable responses current treatment, R-CHOP, consists cancer drug combination supplemented humanized CD20-targeting monoclonal antibody r" 20%-30% of diffuse large B-cell lymphoma patients experience early disease progression despite R-CHOP chemotherapy treatment . DLBCL patients identify exactly exactly patient resistant R-CHOP therapy experience early relapse . The well-established cell-of-origin (COO) algorithm categorizes diffuse large B-cell lymphoma (DLBCL) subgroups . We aimed develop validate qPCR-based gene expression assay determine COO sub " Multiple myeloma (MM) remains incurable disease regardless recent advances field . The use novel agents daratumumab, elotuzumab, carfilzomib, pomalidomide, among others," " The aim study review compare different prognostic models DLBCL based statistical methods used evaluate performance model, well analyze possible limitations methods . A literature search identified 46 articles proposed 55 different prognostic models DLBCL combining different clinical, laboratory," Outcomes patients relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) ineligible and/or fail high-dose chemotherapy autologous stem cell transplantation second line poor . There The median age 58 years 52% patients men. The median age 58 years 52% patients men. The median age 58 years 52% patients men. The median age 58 years 52% patients men. " Insecticide use linked increased risk non-Hodgkin lymphoma (NHL) epidemiologic studies inconsistent, particularly NHL subtypes . We analyzed 1690 NHL cases, 5131 controls and 1690 NHL cases . NHL overall" Intravascular large B-cell lymphoma (IVLBCL) variant extranodal diffuse large B-cell lymphoma (DLBCL) variant extranodal diffuse large B-cell lymphoma (DLBC 84-year-old male presented oncologist new skin lesions abdomen right thigh . Excisional biopsy followed histopathology immunohistochemistry confirmed diagnosis . Clinical course complicated multiple relapses refractory disease . Ultimately achieved complete Diffuse large B cell lymphoma (DLBCL) common hematological malignancy one frequent non-Hodgkin lymphomas . Large-scale genomic studies defined genetic drivers DLBCL association functional clinical outcomes . The spleen among common extranodal sites Hodgkin non-Hodgkin lymphomas (NHLs) The spleen among common extranodal sites Hodgkin non-Hodgkin lymphomas (N " Non-Hodgkin lymphomas (NHLs) malignant neoplasms lymphatic system . Majority NHLs occur nodal regions, 40% cases appear extranodal sites involving stomach, spleen, Waldey" 110 cases human immunodeficiency virus-associated plasmablastic lymphomas revealed distinct landscape genetic lesions lymphoma entity . 110 cases human immunodeficiency virus-associated plasmablastic lymphomas revealed distinct landscape genetic lesions lymph " The criteria primary bone marrow large B-cell lymphoma (PBMLBCL) yet clearly established . PBMLBCL defined LBCLs presenting initially bone marrow without lymphadenopathy, extramedullary tumour local" Plasmablastic lymphoma (PBL) rare type aggressive large B - cell non-Hodgkin Lymphoma (NHL) initially described HIV positive individuals later described immune-competent individuals . Population-based studies previously showed improvement overall survival (OS) patients diffuse large B-cell lymphoma (DLBCL) received chemoimmunotherapy rituximab . We hypothesized survival DLBCL patients diagnosed United States SARS-CoV-2 infection cause severe pneumonia (COVID-19) There evidence patients comorbidities higher risk severe disease course . The role immunosuppression disease course clear . Primary thyroid lymphomas rare thyroid neoplasms . Mucosa Associated Lymphoid tissue (MALT) lymphoma diffuse large B-cell Non-Hodgkin lymphoma common types . Patients usually present rapidly growing mass neck Richter's transformation (RT) defined transition chronic lymphocytic leukemia (CLL) small lymphocytic leukemia (SLL) aggressive lymphoma . The conversion generally leads diffuse large B-cell lymphoma (DLBCL) " Diffuse large B-cell lymphoma (DLBCL) common type NHL commonly occurs elderly men . Symptoms vary significantly, simply nasal obstruction epistaxis varied cranial neuropathies confusion seen central nervous system (CNS) spread ." " Primary cardiac lymphoma (PCL) involves heart pericardium . PCL pericardial effusion, heart failure, atrioventricular block . Symptoms may vary according cardiac site involved ." " Diffuse large B-cell lymphoma (DLBCL) complex aggressive malignancy originating B lymphocytes characterized extensive clinical, phenotypic molecular heterogeneity . Pathogenesis yet fully elucidated ." Diffuse large B-cell lymphoma (DLBCL) survival rate low. Treatments limited patients relapsed/refractory . Survival rate low. Treatments limited patients relapsed/refractory . Study: Investigate expression SRY-related HMG box 11 (SOX11) paired box domain 5 (PAX5) patients mantle cell lymphoma (MCL) analyze relationship clinical significance . " Multiparameter flow cytometry plays major role rapid diagnostic indication, peripheral blood bone marrow samples instances . After describing important pre-analytical precautions required adequate assessment, immunophenotypic features small-cell large-cell lymphomas describe" " Primary pancreatic lymphoma (PPL) rare disease representing 0.1% malignant lymphomas, lacks well-defined diagnostic therapeutic protocols . Main symptoms abdominal pain (58%) jaundice (47%) Lactate dehydrogen" Liposomal doxorubicin proven reduce cardiotoxicity . Doxorubicin effective single agent treatment non-Hodgkin's lymphoma (NHL) Its use limited cardiac toxicity primarily elderly patients ( Noonan syndrome (NS) reported without clear guidelines treatment prognosis subgroups patients . Germline mutations PTPN11 common cause of NS . Somatic mutations NPM1 occur frequently AML. This study aimed evaluate benefits risks patients diffuse large B-cell lymphoma (DLBCL) treated ibrutinib . The pooled overall response (OR) complete response (CR) partial response (PR) 57.9% " Diffuse large B-cell lymphoma (DLBCL) common histological transformation (HT) follicular lymphoma (FL) Other types HT rare, incidence, histopathology, patient outcomes sufficiently described . 19 cases non-" Primary central nervous system lymphoma (PCNSL) rare type primary extranodal lymphoma (PEL) MyD88 is a rare type of primary extranodal lymphoma (PEL) The importance of rituximab anthracycline remains unknown extremely elderly DLBCL patients . The importance of rituximab anthracycline remains unknown extremely elderly DLBCL patients . " In mature B-cell malignancies, chromosomal translocations often juxtapose oncogenic locus regulatory regions immunoglobulin genes . These genomic rearrangements associate specific clinical/pathological sub-entities in diagnosis treatment" " Based CD25 expression, T follicular helper cells (Tfh) could divided T follicular regulatory (Tfr)-like subset (CD25) Tfh could divided T follicular regulatory (Tfr)-like subset (" " Human Herpesvirus 8 (HHV8) associated wide spectrum B-cell lymphoproliferative disorders, including Primary Effusion Lymphoma, Multicentric Castleman Disease, HHV8-positive Diffuse Large" Total metabolic tumor volume (TMTV) calculated . Total metabolic tumor volume (TMTV) calculated . Primary cutaneous B-cell lymphomas (PCBCLs) comprise group extranodal B-cell non-Hodgkin lymphomas . They include ~25% cutaneous lymphomas classified three major subgroups . Richter syndrome (RS) uncommon evolution chronic lymphocytic leukaemia (CLL) dismal prognosis . Clinical-biological features predicting outcome best therapeutic approach patients remain established . Median overall survival (OS) 5·9 months " We studied 3 children with immune dysregulation syndrome susceptibility infection, lymphadenopathy, hepatosplenomegaly, developmental delay, autoimmunity, lymphoma B-cell (n = 2) T-cell (n" Gray zone lymphoma (GZL) features intermediate large B-cell lymphoma (LBCL) classic Hodgkin lymphoma (cHL) classic Hodgkin lymphoma (cHL) A subset Epstein-Barr virus Programmed cell death receptor 1 (PD-1) ligand (PD-L1) investigated various tumors . Programmed cell death receptor 1 (PD-1) ligand (PD-L1) investigated various tumors . Studies " We aimed investigating the prognostic role neutrophil-to-lymphocyte ratio (NLR) 2 independent cohorts of Latin American patients . The learning cohort composed 274 patients . validation cohort 323 patients, total 597 patients . An" " Tafasitamab (MOR208) Fc-enhanced, humanised, anti-CD19 monoclonal antibody shown preclinical single-agent activity patients relapsed refractory B-cell malign" Due rarity oral lymphoma (OL) aimed evaluate clinical features . English language literature (1980-2019) related . OL searched two electronic databases . Patients (2000-2019) diagnosed OL also selected database Oral Pathology Department institution . 6 " 104 patients diagnosed malignant lymphoma (ML) multiple myeloma (MM) underwent ASCT institution 2007 2018 . The patients included 63 men 41 women median age 58 years (range, 24-70 years)" There immunophenotypic guidelines investigation MYC-rearranged lymphomas . We aimed identify simple immunophenotypic features would help differentiate MYC-rearranged lymphomas . The main purpose study assess whether possible improve prognostic impact international prognostic index (IPI) score combining peripheral blood counts . 520 patients diffuse large B cell lymphoma treated R-CHOP . " Canadian data, including scuba study reported here, support results earlier international studies showing earlier international studies showing reduction preparation administration time sc formulation, lower cost administration, reduced drug wastage fixed sc dosing . Given significant time cost savings s." " A 59-year-old male presented paraaortic lymph node swelling thickening right renal pelvic ureteral wall histologically diagnosed FL, grade 1 . Karyotypic analysis revealed t(14;18)(q32" Clinical data available retinal imaging analyzed . Fifty-eight patients met inclusion criteria . Twenty-one 36 patients treated BBBD therapy bilateral p. p. " Buckley-James method accommodate censoring, propose fused Kolmogorov-Smirnov filter screen irrelevant dependent variables ultrahigh-dimensional survival data . Independent feature screening demonstrated theoretically empirically effective dimension reduction method low computational demanding ." 65-year-old male presented emergency department 4 days severe persistent hiccups . Computed tomography abdomen revealed large invasive bilateral adrenal masses . Adrenal biopsy confirmed diffuse large B-cell lymphoma . Hiccups resolved " The diagnosis large B-cell lymphoma classic Hodgkin lymphoma classic Hodgkin lymphoma (CHL) often straightforward . However, select circumstances, simple diagnoses quite complex . Diagnoses may due uncertainty evaluation morphologic immunophenotypic" " BENTA (B cell Expansion NF-κB T cell Anergy) novel lymphoproliferative disorder caused germline, gain-of-function (GOF) mutations . Similar somatic CARD11 mutations found lymphoid" Paraneoplastic neurological syndromes rare manifestation non-Hodgkin lymphoma make treatment patients challenging . 67-year-old man high grade diffuse large B-cell lymphoma presented severe paraneoplastic Guillain One-carbon metabolism (OCM) plays pivotal role stability integrity DNA mainly regulated B-vitamins . This study aims investigate clinical relevance B-vitamins single nucleotide polymorphisms (SNPs) OCM-related genes Significant racial differences observed incidence clinical outcomes diffuse large B-cell lymphoma (DLBCL) United States . It remains unclear whether genomic differences contribute disparities . Phase 2 trial aimed assess efficacy Burkitt-like approach high-risk DLBCL using dose-intense R-CODOX-M/R-IVAC regimen . Eligible patients aged 18-65 years stage II- CARs are powerful tools redirect antigen-specific T cells independent human lymphocyte antigen (HLA) restriction specifically kill tumor cells . CARs have been used in relapsed/refractory B cell leukemia/lymph cancer patients . " Epstein-Barr virus (EBV) infection correlated several lymphoproliferative disorders, including Hodgkin disease, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and post-transplant lymph" Metabolic heterogeneity (MH) measured using 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) indicates inhomogeneous tumor microenvironment . High Lymphoma common malignancy involving mediastinum challenging diagnose small biopsy specimens . This review provides pattern-based approach help triage small tissue samples diagnosis mediastinal lymphoid proliferations . " Cholecystoenteric fistula (CEF) rare biliary tract surgery, cholecystogastric fistula (CGF) rarest form CEF . Open cholecystectomy closure fistula" CD19-targeting chimeric antigen receptor T-cell (CART) therapy emerged promising treatment relapsed/refractory aggressive B-cell lymphoma (r/rABL) Following leukapheresis preparation C Vitamin D insufficiency associated worse clinical outcomes multiple cancer types . Role roles of roles diffuse large B-cell lymphoma (DLBCL) patients still unclear . We present rare case primary diffuse large B-cell lymphoma thoracic vertebra patient metastatic lung cancer . We present rare case primary diffuse large B-cell lymphoma thoracic vertebra patient . " China evaluate tolerability efficacy of CGA-driven therapy . 78 patients DLBCL aged 60 years aged evaluated using CGA following parameters: age ≥ 80 years, activities daily living (ADL), activities daily living (ADL)," " We compared International Prognostic Index (IPI), Revised (R)-IPI age-adjusted (aa)-IPI prognostic indices . We compared patients with patients with diffuse large B-cell lymphoma (DLBCL)" " EPOCH (etoposide, prednisone, prednisone, vincristine, cyclophosphamide, doxorubicin) preferred regimen HIV-non-Hodgkin lymphomas (" Neurorophil lymphocyte ratio (NLR) lymphocyte monocyte ratio (LMR) may used evaluate prognosis . NLR LMR leukemias widely reported widely reported . " China high endemic area hepatitis B virus (HBV) established epidemiology HBV diffuse large B-cell lymphoma (DLBCL) Research necessary clarify potential link HBV DLBCL, research necessary clarify potential link ." The synchronous presence multiple myeloma (MM) primary malignant tumors (PMTs) rarely reported . This study retrospective trial. analyzed six cases synchronous presence MM PMTs reviewed literature . " In cases suspected intraocular malignancy, vitreous may preferred pathologic sample . Cellularity may insufficient definitive cytopathological diagnosis . Ancillary methodology study vitreous fluid aspiration mutational analysis may assist treatment decisions" 72-year-old woman presented emergency centre acute horizontal diplopia . Neurological examination revealed isolated abducens nerve paresis left . CAR T cells successfully used preceding allogeneic stem cell transplant (alloHCT) patients acute lymphoblastic leukemia . Little known feasibility outcome CAR T cell treatment patients previously allotransplanted lymphoma . " Diffuse large B-cell lymphoma (DLBCL) common subtype NHL responsible 30-40% adult NHL cases globally . Primary renal lymphoma (PRL) quite rare, clinicians try ensure early diagnosis ." Diffuse large B-cell lymphoma (DLBCL) leading cause non-Hodgkin lymphomas . Diffuse large B-cell lymphoma (DLBCL) leading cause non-Hodgkin lymphomas " Primary Central Nervous System Lymphoma (PCNSL) rare invasive extranodal non- Hodgkin lymphoma, vast majority Diffuse Large B-Cell Lymphoma (DLBCL) High-dose met" ECGs obtained around anthracycline-based chemotherapy (AbC) increased 36.8% baseline 48.7% baseline 48.7% prevalence fragmented QRS (fQRS) s . " Germinal centers (GCs) are confined anatomic regions rapidly proliferating B cells . GCs origin malignancy, namely follicular lymphoma (FL), GC B cell-diffuse large B cell lymphoma (GC" Geriatric Nutritional Risk Index (GNRI) combination Charlson Comorbidity Index (CCI) overall survival (OS) elderly DLBCL patients . A multicentre retrospective conducted cohort 451 patients (≥65 years " 86 articles describing 123 cases of CLL ophthalmic involvement associated CLL . CLL-infiltration (52.0%), lymphoma (26.0%), lymphoma (26.0%), infinfiltration (52.0" " Diffuse large B-cell lymphoma (DLBCL) cavitary lung disease rare often difficult differentiate primary lung cancer, granulomatous disease, granulomatous disease, infectious disease based imaging findings alone . DL" " Richter transformation (RT) term used refer development aggressive lymphoma, usually diffuse large B-cell lymphoma type, patient history chronic lymphocytic leukemia . To date, 6 cases RT involving oral maxillofacial region reported ." " Diffuse large B-cell lymphoma (DLBCL) incidence rises increasing age . Rituximab-anthracycline-based regimens offer potential cure also risks adverse events, especially elderly ." Diffuse large B-cell lymphoma (DLBCL) clinically aggressive heterogenous disease . 30% 40% patient ultimately develop relapsed refractory disease . We sought determine conditional survival patients among patients relapsed de novo DLBCL successfully undergoing autologous stem-cell transplant (ASCT) first relapse . Patients followed prospectively ASCT median 5.3 8.2 yea . " Lenalidomide immunomodulatory agent antitumor activity non-Hodgkin lymphoma, acceptable toxicity profile manageable side effects . Lenalidomide immunomodulatory agent antitumor activity non-Hodg" " Egypt one highest hepatitis C virus (HCV) endemic areas . Chronic HCV infection extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL) Diffuse large B-cell lymphoma (DL" " Diffuse large B cell lymphoma (DLBCL) associated aggressive clinical cases poor prognosis despite recent advances disease treatment . In activated B-cell-like (ABC)-DLBCL, severe damaged signaling pathways converge aberrantly" Vertebral pathological compression fracture involving extra-nodal lymphoma impacts negatively quality life HIV-positive patients . The choice safe effective approach palliative care condition remains challenge . The value of the value of the value of the dollar in the world has been reduced to $1 billion . The value of the dollar has been reduced to $1 billion . " Phase 2 trial of 139 patients aged 18 64 years with high risk of central nervous system progression . Survival patients high-risk diffuse large B-cell lymphoma (DLBCL) suboptimal, risk central nervous system (CNS" Study estimation high-dimensional single index models response variable censored . We evaluate finite sample performance proposed procedures via simulation studies . We evaluate finite sample performance proposed procedures via simulation studies . Oncogenic rRNA variants remained elusive for cancer . We identify cancer-specific single-nucleotide variation 18S rRNA nucleotide 1248.U 45.9% patients colorectal carcinoma (CRC) " 49-year-old man presented outpatient clinic complaining nonproductive cough exertional dyspnea two months . He diagnosed large B cell non-Hodgkin's lymphoma seven months previously, tumor almost disappeared four cycles ritux" Plasmablastic lymphoma (PBL) CD20-negative large B-cell lymphoma plasmacytic phenotype dismal prognosis . PBL commonly affects oral cavity HIV-positive individuals . Intravascular large B-cell lymphoma (IVLBCL) rare form diffuse large B-cell lymphoma (DLBCL) arising extranodal sites . PD-L1 expression tumor cells reported IVLBC " Epstein-Barr virus (EBV) prevalent among healthy individuals, implicated numerous reactive neoplastic processes immune system . Epstein-Barr virus (EBV) prevalent among healthy individuals, implicated numerous reactive neoplastic processes immune system" Tracheal tumors rare children manifest symptoms airway obstruction . A 14-year-old boy 5-month history dyspnea wheezing referred hospital . We report final results of phase II trial addressing efficacy feasibility . Patients relapsed DLBCL achieved least partial response salvage chemoimmunotherapy enrolled treated treated lenalidomide 25 mg/day 21 28 days . Primary endpoint 1- Tumor thrombus portal vein without liver parenchymal abnormality extremely rare . Tumor thrombus portal vein without liver parenchymal abnormality extremely rare . " A previously healthy 53-year-old male male male primary membranous nephropathy (positive anti phospholipase A2 antibody) presented hospital worsening cough, shortness breath, hypotension, malaise . During" The aim study evaluate prognostic significance 18-fluorodeoxyglucose ( Twenty-five (age range: 22-82 years) biopsy-proven patients DLBCL nodal involvement underwent staging . Six patients developed rec " Mature B-cell neoplasms fifth common neoplasm. Mature B-cell neoplasms fifth common neoplasm. Due significant heterogeneity clinical genetic levels, current therapies cancers fail provide long-term cures ." Study performed 20 patients 11 diabetes 9 nondiabetics . The study performed 20 patients 11 diabetes 9 nondiabetics . The clinical use first-generation phosphoinositide 3-kinase (PI3K) is a first-generation phosphoinositide 3-kinase (PI3K) The clinical use of PI3K is a first Intravascular large B-cell lymphoma (IVLBCL) rare subtype non-Hodgkin lymphoma uncommon clinical presentations poor prognosis . The purpose study report report clinical features outcome IVLBCL single institution " CD47 signal-regulatory protein-α (SIRPα) inhibits phagocytosis, thus affecting clinical outcomes neoplastic diseases . CD47 upregulation associated poor prognosis several malignancies . SIRP" Diffuse large B cell lymphoma (DLBCL) constitutes frequent subtype non-Hodgkin's lymphomas . DLBCL aggressive disease extranodal involvement seen approximately 30% patients common extranodal sites Yescarta was designated orphan medicinal product included European Medicines Agency's Priority Medicines Scheme . Yescarta was approved for marketing authorization in June 2018 . " Primary testicular lymphoma (PTL) rare, clinically aggressive form extranodal lymphoma . In population-based studies, incidence PTL 0.09-0.26/100.000. The vast majority PTL" This case demonstrates subtle multimodality appearances encountered encountered . The patient was diagnosed with primary bone lymphoma following biopsy . " Canine B-cell lymphoma one common haematopoietic neoplasms veterinary medicine, considered relevant model human diffuse large B-cell lymphoma . Canine CAR-T cell therapy is clinically available canine CAR-" 72-year-old presented three-month history generally unwell . Investigations showed bilateral adrenal masses positive short synacthen test (SST) adrenal insufficiency . Adrenal insufficiency managed hydrocortisone " 74-year-old man received 6 cycles of radiation therapy plus local radiation therapy . Flow cytometry analyses showed CD7 CD20 positivity tumor cells . The frequency CD7-positive DLBCL rare, 11 cases follow-up" A 44-year-old Japanese woman systemic lupus erythematosus (SLE) presented hospital abdominal pain . Radiological endoscopic examinations led diagnosis diffuse large B-cell lymphoma jejunum . Patients S " TAK-659 is first-in-human, dual SYK/FLT3 inhibitor preclinical activity B-cell malignancy models . First-in-human, dose-escalation/expansion study aimed determine safety" " 140 consecutive patients treated primary OAL treated March 2010 September 2017 . Study included women, 61 men and nine women ." " Activating single-nucleotide polymorphisms HOIP, catalytic subunit LUBAC, enriched patients activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) Expression HOIP," " Aggressive B-cell lymphomas present heterogeneous spectrum disease . A primary diagnosis bone marrow (BM) may challenging terms diagnostic classification clinical handling . Aggressive B-cell lymphomas subdivided entities typically present primarily BM, cases BM involvement" " Primary testicular lymphoma (PTL) often appearing focal masses scrotum epididymides, frequent testicular tumor aged men . Study identified 1326 mutations involving 311 genes regions 90 PTL patients next-generation sequencing (NG" " Study compared outcomes patients high-risk DLBCL received frontline rituximab, cycophosphamide, doxorubicin, vincristine, prednisone, cyclophosphamide doxor" Cutaneous B-cell lymphomas (CBCL) rare heterogeneous neoplastic diseases composing 22.5% cutaneous lymphomas . These diseases divided primary secondary cutaneous variants primary cutaneous B-cell lymphoma (PCBC " Since first reported case 1997, 600 women breast implant-associated anaplastic large cell lymphoma (BI ALCL) reported . CD30-positive T-cell lymphoma carries clonal T-cell receptor gene rearrangements ." Venous thromboembolic events (VTE) frequent complication lymphoma . We conducted retrospective analysis compare VTE risk diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) to VTE " This study aimed evaluate incidence prognosis primary cardiac lymphoma (PCL) using Surveillance, Epidemiology, End Results Program (SEER) database . The incidence PCL 0.011/100 000, predominance elderly m ." " Diffuse large B-cell lymphoma (DLBCL) common non Hodgkin lymphoma (NHL) adults, accounts 30% adult NHL cases . New strategies relapsed lymphomas development among antibody-drug conjugates (" " 59-year-old man with large B-cell lymphoma, recently diagnosed renal biopsy, presented emergency department melena, dizziness, epigastric pain . He tachycardic hemoglobin level 6.4 g" Diffuse large B-cell lymphoma (DLBCL) aggressive high-grade disease remains incurable . 40% patients treated R-CHOP immunochemotherapy . A 70-year-old woman large mass right breast. Mammography displayed focal asymmetrical density scattered areas fibroglandular density. Ultrasonography showed tumor predominantly high-level internal echoes. Histological examination showed tumor composed CD20 Primary bone lymphoma (PBL) peculiar extranodal presentation non-Hodgkin's lymphoma . The diagnosis PBL depends combined clinical examination imaging studies . Hematologic malignancies common incidence increasing . Adult obesity associated hematologic malignancies (HM) associated with obesity associated hematologic malignancies (HM) Adult obesity associated hematologic malignancies (HM) " Diffuse large B-cell lymphoma, otherwise specified (DLBCL NOS) subdivided according cell-of-origin (COO) classification germinal centre B-cell (GCB) activated B-cell (" " Preclinical data suggests anti-lymphoma potential statins, metformin cyclooxygenase-2 (COX-2) inhibitors . We performed retrospective population-based study adults aged aged ≥66 years diagnosed diffuse large" A 62-year-old man presented institute diarrhoea dysuria with diarrhoea dysuria background subtotal colectomy end ileostomy biological therapy Crohn's disease . Renal ultrasound suggested left hydroneph " Primary bone marrow lymphoma (PBML) rare clinical entity. Because rarity, standard therapy defined. Prognosis disease poor, studies effective treatments needed." " In 2017, 20,110 people United States diagnosed chronic lymphocytic leukemia (CLL) Of patients, 5-15% ultimately undergo Richter's syndrome (RS) Of patients, 5-15% ultimately undergo Richter's" Hodgkin lymphoma (HL) one frequent cancers occurring young age . Radiation-free method confirm remission status highly desired . Luminex technology evaluate 67 soluble plasma proteins suitability diagnosis confirming remission classical HL (cHL) Obinutuzumab (RO5072759) Plus Chemotherapy Comparison With Rituximab Plus Chemotherapy . Followed Obinutuzumab Rituximab maintenance patients with Untreated Advanced Indol " TME lymphoma pathogenesis is pathogenesis . ""effacement model"" resembled diffuse large B cell lymphoma (DLBCL) implies strong cell autonomous survival paucity non-malignant elements ." HIV-positive patients 60- 200-fold increased incidence of Non-Hodgkin Lymphomas (NHL) Some NHL considered Acquired Immunodeficiency Syndrome (AIDS) defining conditions . Diffuse large B-cell Report: Atrioventricular block due primary cardiac lymphoma attached right atrial septum attached right atrial septum . Surgery reversible surgical debulking effective chemotherapy without need permanent pacemaker . " Recent studies revealed existence of existence genetic subtypes of diffuse large B cell lymphoma (DLBCL) Using clustering methodologies, algorithm determines probability patient's lymphoma belongs one seven genetic subtypes based genetic features ." " Autologous bone marrow transplantation has shown potential curative treatment modalities B-cell lymphoma . Autologous bone marrow transplantation, although widely utilized patients non-Hodgkin lymphoma recurrence, association immunologic" Diffuse large B-cell lymphoma (DLBCL) reported significant association with hepatitis B virus infection . Experimental evidence determine whether components hepatitis B virus expressed lymphoid cells . HBx expression significantly associated high-leve high-le " The treatment outcomes prognosis lymphoma affected various factors hospital types . The 5- 10-year OS whole cohort 62% 52%, re-evaluated ." " Patients with diffuse large B-cell lymphoma (DLBCL) had concurrent hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection distinct clinical features . Nevertheless, prognostic value of HBsAg" Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses patients relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) Cytokine release syndrome (C Chimeric antigen receptor-T cell therapy may associated neurological toxicity (NT) We retrospectively assessed differences concordance among 3 available grading scales . Diffuse large B-cell lymphoma (DLBCL) aggressive type non-Hodgkin lymphoma . The prevalence hypercalcemia neoplasm prognostic significance unclear . We retrospectively evaluated prevalence hypercalcemia Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma (PBL) rare entity diffuse large B-cell lymphoma (DLBCL) The clinicopathological features optimal treatment HIV-negative PBL Study examined association miR-150 expression clinicopathological characteristics of patients PGI-DLBCL . miR-150 expression assessed via reverse transcription-quantitative (RT-q)PCR analysis . Results demonstrated miR- LAG3 digital gene expression tested 309 patients DLBCL treated standard chemoimmunotherapy . LAG3 expression highest CD4+ regulatory T cells (Tregs) also highly expressed CD8+ T cells . LAG Primary vitreoretinal lymphoma (PVRL) high-grade lymphoma affecting vitreous and/or retina . Majority cases histopathologically classified as diffuse large B-cell lymphoma (DLBCL) considered sub Osalmide pterostilbene natural products anticancer activities via different mechanism . DCZ0801 treatment gave rise dose-time-dependent inhibition cell viability determ . " Several types B-cell lymphomas, including primary cutaneous lymphomas systemic lymphomas, may affect skin . Currently, World Health Organization (WHO) classification primary cutaneous B-cell lymphomas include diffuse large B-cell lymphomas" " Lymphangioleiomyomatosis (LAM) characterized cystic lung disease, abdominal tumor involvement axial lymph nodes . LAM characterized cystic lung disease, abdominal tumor involvement axial lymph nodes ." 43-year-old man was diagnosed with haematoma and underwent splenectomy . Diagnosed with diffuse large B-cell lymphoma . Perioperative treatment octanate® (human coagulation factor VIII) en Microsatellite instability (MSI) genomic property cancers defective DNA mismatch repair useful marker cancer diagnosis diagnosis treatment . MSI associated active immune checkpoint blockade therapy response cancer . The study assessed early mortality (within 1 3 months) of patients primary central nervous system lymphoma (PCNSL) identified risk factors associated early mortality . A total 8091 patients PCNSL enrolled enrolled in the study . The In diffuse large B-cell lymphoma (DLBCL) select patients would benefit intensified frontline treatments adding etoposide R-CHOP regimen . The present work included retrospective clinical analysis two patient cohorts vitro study . " Adalimumab (Humira) works blocking interaction tumor necrosis factor alpha cell-surface receptors . Its use approved several autoimmune conditions, including chronic plaque psoriasis, prescribed first-line biologic treatment . Increased risks malign" " CC-90010 novel, oral, reversible, small-molecule BET inhibitor . Bromodomain extra-terminal (BET) proteins epigenetic readers regulate expression genes involved oncogenesis . CC-90010-" " Large B-cell lymphoma IRF4 rearrangement, Burkitt-like lymphoma 11q aberration two provisional lymphoma entities 2017 revision WHO classification lymphoid neoplasms . Despite frequent young patients, knowledge regarding true incidence" Infections first-line therapy DLBCL often associated chemotherapy dose reductions increased mortality . Systemic infections also suggested beneficial promotors immunological responses . Glioblastoma multiforme (GBM) primary central nervous system lymphoma (PCNSL) malignant cerebral tumors . Early precise diagnosis vital subsequent adequate treatment improve prognosis . Reliable biomarkers easily distinguish GBM " Great heterogeneity survival exists patients newly diagnosed diffuse large B-cell lymphoma (DLBCL) Patients treated 1998 2009 frontline rituximab plus cyclophosphamide, doxorubicicin, vincristine" Chronic lymphocytic leukemia (CLL) typically pursues prolonged course . Most commonly diffuse large B-cell lymphoma develops . Transformation classical Hodgkin's lymphoma (cHL) occurs <1% . Plasmablastic transformation A 65-year-old woman presented 1-month history abdominal distention . Ultraspiration showed 11-cm solid mass pelvis . Computed tomography magnetic resonance imaging revealed bilateral (mainly left) ovarian masses pelvis multiple The controlling nutritional status (CONUT score nutritional index) scored nutritional index calculated serum albumin total cholesterol levels lymphocyte counts . Its role predicting clinical outcomes diffuse large B-cell lymphoma (DLBCL) evaluated . " The risk stratification diffuse large B-cell lymphoma (DLBCL) crucial . We analyzed 204 patients primary DLBCL uniformly treated R-CHOP (rituximab, cyclophosphamide, doxorub" " The specific biomarker surface regulatory T cells (Tregs) forkhead/wingeded-helix protein 3 (Foxp3) In contrast, expression interleukin-7 receptor (IL-7R) low negative" " Gene rearrangements MLL/KMT2A RUNX1 major cause therapy-related leukemia . MLL rearrangements major cause infant leukemia, RUNX1 rearrangements frequently detected cord blood ." " Hodgkin lymphoma is an uncommon histologic variant with optimal treatment stage I-II NLPHL undefined . Hodgkin lymphoma was diagnosed in 1995 and underwent forms management, including radiotherapy (RT) and combined modality therapy (" " Gene expression profiling revealed molecular heterogeneity diffuse large B cell lymphoma (DLBCL) humans dogs . Two DLBCL subtypes based cell origin generally recognized, germinal center B (GCB)-like activated B cell (ABC" " We retrospectively reviewed 140 patients stage III IV DLBCL, underwent baseline F-18 FDG PET/CT diagnosis . We assessed prognostic implication bone marrow uptake ." " LncRNA NEAT1 identified tumour driver many human cancers . But underlying mechanism lncRNA NEAT1 diffuse large B-cell lymphoma (DLBCL) progression unclear . The expression levels NEAT1, GLI" " Follicular lymphoma neoplasm derived follicle center B cells . It represents second common non-Hodgkin lymphoma, diffuse large B-cell lymphoma common low-grade mature B-cell lymphoma Western countries" Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is common histologic subtype lymphoid malignancy breast . The aim study identify biomarkers distinct subtypes PB-DLBCLs evaluate prognosis F-fluorodeoxyglucose positron emission tomography (PET/computed tomography) proposed promising biomarkers treatment efficacy diffuse large B-cell lymphoma (DLBCL) We tested ability predict outcome 2 cohorts " Rotating nightshift work plausible risk factor hematologic cancer, epidemiological evidence remains sparse, especially individual subtypes . We prospectively examined association rotating nightshift work hematopoietic cancer risk ." Up one-third diffuse large B cell lymphoma patients develop resistance to R-CHOP regimen . Understanding underlying mechanisms developing therapeutic approaches urgently needed . " The present study retrospectively analyzed 12 patients routinely treated pixantrone monotherapy combinations Institute Oncology Ljubljana, Slovenia, January 2016 October 2018 . All 12 patients refractory lymphoma patients were treated p" " Post-transplant lymphoproliferative disorder (PTLD) rare complication following transplant (solid organ allogeneic) due proliferation lymphoid cells immunosuppressed state . The incidence PTLD follows bimodal distribution," T cell immunoglobulin mucin domain containing 4 (TIMD4) various diseases functions cell malignant behaviors . Biological function of TIMD4 diffuse large B-cell lymphoma (DLBCL) unknown . DNA extracted from tumor samples selected diffuse large B-cell lymphoma (DLBCL) patients . Using clustering techniques applied targeted sequencing data derived large unselected population-based patient cohort full clinical follow-up (n = 928 " A significant number patients liver cirrhosis concomcomitantly develop type solid hematological cancer, including lymphoma . Treatment patients lymphoma cirrhosis challenging physicians due clinical characteristics related cirrhosis, including biochemical functional abnormalities," Non-Hodgkin lymphoma (NHL) sixth common cancer Sub-Saharan Africa . NHL is sixth common cancer Sub-Saharan Africa . NHL is sixth common cancer in Sub-Saharan Africa . " 30% newly diagnosed cases NHL United States (US) diffuse large B-cell lymphoma (DLBCL) type . Arising either nodal extra-nodal lymphatic tissue origin, DLBCL aggressive tumor fatal left" Primary central nervous system lymphoma (PCNSL) rare tumor accounts <1%-4% primary CNS tumor . PCNSL rare tumor accounts <1%-4% primary CNS tumor . " 74-year-old man presented rapid swelling nasal dorsum . Physical examination revealed firm, immobile, non-tender mass . Computed tomography revealed space-occupying lesion subdermal layer nasal dorsum likely fib" " Patients with diffuse large B-cell lymphoma (DLBCL) fail complete planned treatment R-CHOP due toxicity sparsely described . We investigated extent failure complete treatment (six cycles more, three cycles + RT patients stage I disease" The genetic basis of diffuse non-Hodgkin's lymphoma (DNHL) largely unknown now . We conducted large-scale transcriptome-wide association study (TWAS) DNHL identify novel candidates . Echocardiography performed baseline performed baseline Echocardiography performed baseline . A total 74 patients diffuse large B-cell lymphoma received 6 cycles anthracycline-based treatment enrolled . " Primary central nervous system (CNS) lymphoma arises dura mater, denoted term primary dural lymphoma (PDL) This study aimed determining relative incidence, presentation, outcomes PDL ." There limited evidence regarding possible association exposure ambient air pollutants risk non-Hodgkin lymphoma (NHL) Previous epidemiological studies relied crude estimations air pollution exposure and/or small numbers NHL cases . The objective study analyze association " Diffuse large B cell lymphoma (DLBCL) common form non-Hodgkin lymphoma among adults . DLBCL treated chimeric monoclonal antibody CD20, B cell surface protein, named rit" The aim study evaluate efficacy toxicity high-dose rituximab (HD-R) combination autologous stem cell transplantation (auto-SCT) patients relapsed refractory diffuse large B cell lymphoma (DL " Everolimus bendamustine single-agent activity lymphoid hematologic malignancies . In phase I trial, 18 patients treated bendamustine 90 mg/m . Adverse events generally mild mostly hematologic nature" " Intravascular large B-cell lymphoma (IVLBCL) rare disease available standard treatment . We aimed ascertain safety activity R-CHOP (rituximab, cyclophosphamide, doxorubicin" " Second mitochondria-derived activator caspases (Smac) mimetics designed antagonize IAP proteins . Since effect single agents limited, combination treatment represents strategy clinical development ." " Undifferentiated pleomorphic sarcoma (UPS) soft tissue defined sarcoma recognizable line differentiation . During past decades, advances ancillary studies review prior UPS diagnoses narrowed category UPS excluding more-specific malignancies ." " We present image dataset related automated segmentation counting macrophages diffuse large B-cell lymphoma (DLBCL) tissue sections . Until now, information macrophages obtained either indirect way gene expression profiling manual counts immunohistochem" A multicentre retrospective cohort analysis done seven French tertiary centres 1999 2019 . The prognosis lymphoma occurs patients inflammatory bowel disease [IBD] poorly known . Bone marrow aspiration trephine biopsy (BMAT) widely performed adults evaluate haematological malignant conditions . We retrospectively reviewed laboratory data January 2016 December 2016 patients aged 13 ye . " Apatinib new oral tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor-2 (VEGFR-2) inhibit tumour angiogenesis . In phase II, open-label, single-arm," " B-cell non-Hodgkin's lymphoma (NHL) class heterogeneous diseases variable clinical outcomes . Immunosuppression particularly common subtypes lymphoma poor prognosis, underlying mechanism remains unclear ." " Marginal zone lymphoma (MZL) follicular lymphoma (FL) classified indolent B-cell lymphomas dogs . We integrated transcriptome, genome-wide DNA methylation copy number aberration analysis provide insights path" " Epstein-Barr virus-related large-cell transformation marginal zone lymphoma (MZL) occurs 120, 11 5 months initial diagnosis three instances, concurrently one case . Discuss several interesting features of EBV infection ." Aggressive B-cell non-Hodgkin lymphoma accounts 60% NHL children/adolescents . Short intensive multiagent chemotherapy associated five-year event-free survival around 90% . " Diffusion large B-cell lymphoma (DLBCL) heterogeneous group lymphomas are diffuse large B-cell lymphoma (DLBCL) heterogeneous group lymphomas . To better predict outcomes, measured levels various cytokines" " Patients treated non-Hodgkin lymphoma risk cardiovascular adverse events, risk heart failure particularly high . A regimen cyclophosphamide, doxorubicin, vincristine, prednisone, (R-" Radiotherapy potentially important salvage strategy post-chimeric antigen receptor T cell therapy (CART) We reviewed 14 patients treated salvage radiation post-CART progression (SRT) Most received SRT first post-CART relapse A unique case canine renal T-cell lymphoma diagnosed using urine sediment microscopy flow cytometry flow cytometry . The flow cytometric study revealed 83% cells large CD3 . Diffuse large B-cell lymphoma often presents extranodal manifestations involving musculoskeletal system . Shoulder pain particularly worrisome malignancy. Primary appendiceal lymphomas (PAL) type primary gastrointestinal non-Hodgkin lymphoma (PGINHL) incidence <1% . There considerable discordance regard optimal management of PGINHL . Neoplastic transformation germinal center B (GCB) cells may give rise variety different different B cell lymphoma subtypes . The mutations observed cancer-related genes GCB cells related abnormalities immunogenetic mechanisms associated germinal " EZH2 activity targeted orally available orally available EZH2 inhibitor tazemetostat (EPZ-6438) The histone-methyl transferase EZH2, catalytic subunit PRC2 complex" Antibodies directed CD22 used radioimmunotherapy (RIT) clinical trials treat patients diffuse large B-cell lymphoma (DLBCL) promising results . Preclinical models needed to facilitate evaluation optimization new protocols . The retrospective study mainly performed determine clinical symptoms radiological characteristics of primary pulmonary lymphoma (PPL) The study mainly performed determine clinical symptoms radiological characteristics . Risk factors associated chemotherapy-induced thrombocytopenia (CIT) patients diffuse large B-cell lymphoma (DLBCL) still undefined . Study aimed analyze effects of effects of thrombocytopenia Speckle tracking echocardiography (STE) emerged sensitive technique identifying myocardial dysfunction . Little data available appropriate timing perform STE serial assessment anthracycline administration . 59 year old woman ulcerative colitis 20 years. She presented intermittent high fever right sided abdominal pain 3 weeks. CT scan revealed right adnexal mass measuring 71 X 54 mm . Patient underwent bilateral salpingo oophore " CT revealed irregular contoured shaped mass 87x67x79 mm sizes, upper lobe left lung lying paramediastinal area . Since doubt malignancy, positron emission tomography (PET) performed; cavitary lesion left" " CT revealed large tumor replacing entire right kidney, filling right hemi-abdomen travelling ureter bladder retroperitoneal lymphadenopathy . Urine cytology metastatic workup negative . Ultrasound guided renal biopsy" The reverse-phase protein array (RPPA) antibody-based proteomic method quantifies expression of multiple posttranslationally modified proteins . RPPA highly sensitive requires small protein samples . Lipid traits inconsistently linked risk non-Hodgkin lymphoma (NHL) We examined genetically predicted lipid traits risk diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL Sjögren's syndrome (pSS) increased risk developing diffuse large B-cell lymphoma (DLBCL) This study aimed characterize DLBCLs patients pSS . We identified 18 patients DLBCL pSS 22 Study: Small-molecule enhancer zeste homolog 2 inhibitor . An indirect-response model reasonably fit dose-dependent pharmacodynamic responses . An indirect-response model reasonably fit dose-dependent pharmacodynamic responses . Diffuse large B-cell lymphoma (DLBC) subtype lymphoma worst prognosis . Existing treatment methods effective enough due high occurrence metastasis . Identification effective therapeutic targets becoming increasingly important . " Mycosis fungoides (MF) indolent, uncommon, non-Hodgkin T-cell lymphoma skin . It classically presents patches, plaques, tumors may rarely show spread internal organs bone marrow ." " Various grading systems currently used chimeric antigen receptor (CAR) T-cell-related toxicity, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) We compared recently proposed American Society Trans" " MYC alterations diffuse large B-cell lymphoma (DLBCL) investigated long time . MYC alterations include MYC overexpression, MYC translocations, MYC mutations, increased gene copy number MYC ." JULIET phase 2 trial evaluated single infusion tisagenlecleucel adult patients relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) Median follow-up 19. Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL) is a disease associated chronic chronic EBV infection . The diagnosis made careful pathological evaluation . " Post-transplant lymphoproliferative disorder (PTLD) may arise solid organ transplantation . Common subtype resembles diffuse large B cell lymphoma (DLBCL) In DLBCL-type PTLD, anti-" Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease associated varying outcomes . The International Prognostic Index (IPI) standard baseline prognostic assessment patients . The National Cancer Database used identify patients diagnosis DLBC Burkitt lymphoma (BL) diffuse large B-cell lymphoma (DLBCL) was studied . Hematopathologists used different CNNs to assess assistive role in diagnosis . " Non-Hodgkin lymphoma prognosis improved recent years, yet number patients living diagnosis, i.e. prevalence, seldom reported . Prevalence provides measure burden disease, useful healthcare planning optimise resource allocation ." " Height largely determined genetic factors, genetic factors may contribute NHL risk unknown . Height largely determined genetic factors, genetic factors may contribute NHL risk unknown ." " Aggressive large B-cell lymphomas are typically treated anti-CD20 based immunochemotherapy . While treatment effective large proportion patients, become refractory induction therapy experience disease relapse suffer inferior overall prognosis . Novel treatment options needed ." " MYD88 protein staining positive 26/30 (86.67%) cases, 23/30 (76.7%) cases tested positive p65 nucleus . Genetically, MYD88 protein staining positive 26/30 (86" " Diffuse large B-cell lymphoma (DLBCL) genetically clinically heterogeneous . Despite advances genomic subtyping, standard frontline chemoimmunotherapy remained unchanged years . Characterizing drug-gene interactions could support patient-" " The BCL6 proto-oncogene encodes transcriptional repressor, required germinal centers (GCs) formation lymphomagenesis . Previous studies reported constitutive expression BCL6 leads diffuse large B cell lymphoma" " CLL Cancer registry Norway registered 2003-2012 included . After median follow-up 6.6 years, 103 patients (4%) developed SHM . Diffuse large B-cell lymphoma (DLBCL) common (n =" Primary central nervous system lymphoma (PCNSL) may manifest initially eye (termed vitreoretinal lymphoma VRL) non-ocular CNS compartments . PCNSL implies two clinical specialists - ophthalmologists neuro " Primary vitreoretinal lymphoma (PVRL) defined, although researches shown cases of cases diffuse large B-cell lymphoma (DLBCL) The characteristics tumor cells primary vitreoretinal lymphoma (PV" Treatment axicabtagene ciloleucel (Axi-cel) CD19-CAR-T (chimeric antigen receptor T) cells approved refractory/relapsed diffuse large B cell lymphoma (DL " Primary splenic low-grade B-cell lymphoma red pulp comprises hairy cell leukemia (HCL) splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U) SPLL-U rare disease" " Urelumab, fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell natural killer-cell antitumor activity preclinical models ." " Rituximab-based high-dose therapy frequently used diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT) Herein," The selective inhibitor nuclear export (SINE) compounds selinexor (KPT-330) eltanexor (KPT-330) and eltanexor (KPT-8602) target exportin-1 " Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel evaluated global, phase 2 JULIET study adult patients relapsed/refractory diffuse large B-cell lymphoma (DL" " European Medicines Agency recommends granting marketing authorization for Kymriah . European Medicines Agency adopted positive opinion, recommending granting marketing authorization . Kymriah is a pediatric young adult patients 25 years age with B-cell acute lymphobl" " Third-generation (3G) CARs employ two costimulatory domains, resulting improved CAR T-cell efficacy in vitro animal models . This investigator-initiated, phase I dose escalation trial, termed ENABLE, investigate" Many features canine diffuse large B-cell lymphoma resemble ABC form human DLBCL . Almost universal presence double expressing MYC/BCL2 lymphomas . Austrian study assessed clinical characteristics outcome of six Austrian patients GZL less 18 years age . Data management gray zone lymphoma (GZL) children adolescents scarce . Echocardiography showed tumor left ventricle (approximately 35 × 48 mm) protruded left atrium left ventricular outflow tract systole . These findings suggested high risk sudden death resulting aortic valve obstruction tumor C-Myc oncogene keeps cells proliferative . Bcl-2 Bcl-6 grant cells antiapoptotic features . Diffuse large B-cell lymphoma (DLBCL) commonly diagnosed primary non-Hodgkin lymphoma spine induce spinal compression . " Oral lymphoma resemble clinically pathologic entities periapical radiolucencies, dental abscess . Out 45 reported cases, 6 oral lymphomas were misdiagnosed ." " Follicular lymphoma neoplasm derived follicle center B cells, typically centrocytes centrocytes centroblasts, variable proportions according lymphoma grading . It represents second common non-Hodgkin lymph" Frequent mutations Bcl-2 anti-apoptotic protein often implicated diffuse large B-cell lymphoma (DLBCL) often implicated diffuse large B-cell lymphoma (DLBCL) Drug-resistant drugs often implicated Tumor programmed death-ligand 1 (PD-L1) expression diffuse large B-cell lymphoma (DLBCL) associated inferior outcomes . The first-line immunologically-replete setting may opportune time " Composite sequential lymphomas involving classical Hodgkin lymphoma (CHL) rare phenomena . Treatments outcome data poorly covered recent literature . At diagnosis, 70% composite lymphomas presented disseminated extranodal disease ." Non Hodgkin lymphoma (NHL) one immune system cancers . The occurrence progression progression malignant lymphomas depends cellular pathways deregulation . Understanding relationship immune system genetic level malignant transformation critical reach etiology . Microsatellite instability (MSI) investigated prognostic predictive factor chemotherapy colorectal cancer . MSI status diffuse large B-cell lymphomas (DLBCL) thoroughly explored . MSI status DLBCLs analyzed associations MSI clinic " In review, focus new advances regarding diagnostic therapeutic standards aggressive B-cell lymphomas . New ""cell origin"" classification differentiates diffuse large B-cell lymphomas (DLBCL) ABC GCB subtypes became part revised WHO classification" Harboring MYD88 L265P mutation triggers tumors growth activation NF-κB interleukin-1 receptor associated kinase 4 (IRAK4) diffuse large B-cell lymphoma (DLBCL) Study " CAR T cells unique ""living drugs,"" is, gene-edited killer cells recognize kill cancer . CAR T cells unique ""living drugs,"" is, gene-edited killer cells recognize kill cancer . During 30 years development, CAR construct, T" " The majority ocular adnexal (OA) lymphomas (OAL) extranodal marginal zone lymphomas (MZL) showed inconsistent results distribution mutations . The study included 34 OA-MZL, 11" Diffuse large B-cell lymphoma (DLBCL) considered common aggressive subtype lymphoma . A number DLBCL patients fail achieve response currently available therapies develop resistance . We aimed explore role of β-elemene DL " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease characterized high levels of genomic instability activation DNA damage repair pathways . Here, we investigated combination WEE1 inhibitor, AZD1775, cyclophosphamide" " Diffuse Large B Cell Lymphoma (DLBCL) common type non-Hodgkin lymphoma heterogeneous clinically morphologically . Over past decades, significant advances made understanding molecular genesis, leading identification multiple pathways molecules targeted clinical" " CAR T cells aim overcome barriers durable tumor elimination, developed system evaluate CAR T cells pet dogs spontaneous cancer . Pilot trial using CAR T cells treat canine diffuse large B cell lymphoma (DLBCL)" MATRix chemoimmunotherapy regimen highly effective patients newly diagnosed primary diffuse large B-cell lymphoma central nervous system (PCNSL) Patients often older/frailer enrolled clinical trials . " American Society Hematology 2014 implementation quality improvement initiative (QII) institution 2015 . Patients newly diagnosed DLBCL treated January 1, 2006, December 31, 2017, identified ." " EZH2 important epigenetic regulator, role diffuse large B-cell lymphoma (DLBCL) pathogenesis relationship relationship MYC, BCL2, TP53 expression, chromosomal rearrangements, clinical features still poorly" Tisagenlecleucel CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved patients aged <25 years relapsed refractory B cell precursor acute lymphoblastic leukemia (B-ALL) adults rel " Lymphomas malignant lymphoid tumours arising lymphocytic cells . They usually develop lymphoid tissues spread organs; however, primary extra-nodal locations spinal epidural space less common ." " Dysregulated expression BCL-2 family proteins allows cancer cells escape apoptosis . To counter this, BH3-mimetic drugs target inhibit select BCL-2 prosurvival proteins induce apoptosis . Venetocl" Management lesions involving Meckel's cave represent challenge neurosurgeons . Small percentage represented central nervous system lymphomas . " Curcumin harbored anti-tumor potential potential various cancers . Curcumin inhibited cell viability concentration time dependent manner, promoted cell apoptosis arrested cell cycle G2 phase ." " Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients . We analyzed prognostic impact TMTV prognostic indices of DLBCL patients, aged 60 80 years, aged 60 80 years" Fifty cases of Hodgkin lymphoma (CHL) type MTX-LPD were investigated . Cases involved nodal disease associated Epstein-Barr virus . " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease, commonly described cell-of-origin (COO) molecular subtypes . We sought identify novel patient subgroups unsupervised analysis large public dataset gene" Avadomide (CC-122) cereblon-modulating agent immunomodulatory direct antitumor activities . Avadomide monotherapy patients de novo R/R DLBCL transformed lymphoma . Diffuse Large B-cell Lymphoma (DLBCL) treated salvage combination cytotoxic chemotherapy (most often platinum-based) followed high dose myeloablative chemotherapy autologous stem cell transplantation (auto-H " Primary breast lymphoma rare entity accounts 1% malignant breast neoplasms . Given rarity, still consensus best approach, chemotherapy accepted treatment ." " Gastrocolic fistula (GSF) rare entity arises mainly splenic gastric lymphoma . Gastric splenic lymphomas also fistulate organs, including pleura colon ." Cytokine release syndrome well-known complication chimeric antigen receptor T-cell (CAR-T) therapy lead multiorgan dysfunction . Nephrotoxicity of CAR-T therapy unknown . " Bulky residual tumor considered increase risk relapse relapse relapse relapse in diffuse large B-cell lymphoma (DLBCL) patients . Radiotherapy conventionally used reduce risk, evidence controversial . We analyzed 312 DLBCL patients treated 2010" 39-year-old male admitted hospital with diabetes insipidus sequela previously undiagnosed diffuse large B-cell lymphoma . Gastrectomy became necessary hemostasis . " Historically, consensus diagnostic classification high-grade B-cell lymphoma (HGBCL) was high grade B-cell lymphoma (HGBCL) We retrospectively reviewed cases mature HGBCL diagnosed hospital 2015 2018 ." Previous epidemiological studies suggest association hepatitis B virus (HBV) infection B-cell non-Hodgkin lymphoma (B-NHL) with B-NHL . The aim study evaluate clinical characteristics serological indicators of EBV-positive diffuse large B cell lymphoma otherwise specified . Patients EBV-positive diffuse large B cell lymphoma otherwise specified . " Young woman developed, 3 years stopping Rituximab (RTX) prescribed immune thrombocytopenia (ITP) prescribed immune thrombocytopenia (ITP) She died of fatal pulmonary" Lymphoproliferative disease (LPD) one complications methotrexate (MTX) therapy . LPD lesions limited lungs rare show various types of opacity . Four patients with diffuse large B-cell lymphoma (DLBCL) carrying t(9;14)(p13;q32) places PAX5 adjacent immunoglobulin heavy chain (IGH) gene . Ages ranged 63 80 Medical records retrospectively reviewed cancer cases diagnosed 1986 2016 affecting patients aged 19 years younger . Fifty-five (0.77%) POMCs found among 7181 pediatric malignancies . " Differing large B-cell Lymphoma (DLBCL) presents recurrent syncope without cardiac involvement . During workup syncope patient incidentally found extensive mass left thorax, later diagnosed stage 2 bulky disease DLBCL ." There paucity data regarding outcomes response standard therapy patients limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) harbor MYC rearrangement (MYC-R) without BCL2 and Diffuse large B-cell lymphoma (DLBCL) classified germinal center B cell-like (GCB) activated B cell-like (GCB) activated B cell-like (ABC/non-GCB " Diffuse Large B-Cell Lymphoma (DLBCL) clinically biologically heterogeneous disease . The revised Classification Lymphoproliferative diseases published 2016 (WHO, 2016) refined previous DLBLC subtypes ." Crooke cell adenoma (CCA) aggressive corticotroph subtype pituitary adenoma often cyclically elevated blood adrenocorticotropic hormone (ACTH) Preoperative diagnosis challenging especially context functionally silent invasive Hematopoietic cell kinase (HCK) SRC family member aberrantly upregulated B-cell neoplasms dependent MYD88-activating mutations supports growth survival . We showed activation Toll-like receptor Diffuse large B-cell lymphoma (DLBCL) represents 30-40% non-Hodgkin lymphomas (NHL) disease aggressive behavior . DLBCL represents 30-40% non-Hodg Study aimed investigate hub protein related phosphatidylinositol-3-kinase (PI3K/protein kinase B (AKT) signaling pathway . We used proteomics methods (iTRAQ) explore different " Reports dermal sclerosis dogs include scleroderma morphea unknown cause, cicatricial alopecia congenital/hereditary fibrosis . The thickened skin severe collagen deposition, effacing adnexal structures ." " Chromosome 13q deletion [del(13q)], harboring miR-15a/16-1 cluster, harboring miR-15a/16-1 cluster, is one common genetic alterations mature B-" " Diffuse large B-cell lymphoma (DLBCL) remains incurable, thus warranting development new therapies . Previous study determined rafoxanide effective treating multiple myeloma (MM) In present study, tried evaluate" " Contaminated data right-censored survival outcome make associated feature screening even challenging . In article, propose inverse probability-of-censoring weighted Kendall's tau statistic measure association survival trait biomarkers ." T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) extremely rare morphologic subtype diffuse large B-cell lymphoma (DLBCL) extremely rare morphologic subtype . It " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma (NHL) common subtype non-Hodgkin lymphoma (DLBCL) clinical, pathological" " Anti-PD-1 monoclonal antibody pembrolizumab given ASCT patients chemosensitive DLBCL . Pembrolizumab administered 200 mg IV every 3 weeks 8 cycles, starting within 21 days" Chimeric antigen receptor-engineered T (CART) cells promising new treatment option . Chimeric antigen receptor-engineered T (CART) cells promising new treatment option . The ABO blood group reported associated survival several types malignancy . We conducted retrospective study evaluate prognostic significance ABO blood group patients malignant lymphoma . The primary outcome measured association ABO blood group survival . " Systemic inflammatory response associated prognosis diffuse large B cell lymphoma (DLBCL) We investigated systemic factors significantly related clinical outcome relapsed/refractory DLBCL . In patients, high derived neutrophil/lymph" " Circular RNAs large class noncoding RNAs. Smad5 functions cell differentiation, cell proliferation metastasis. Circular RNAs large class noncoding RNAs. Smad5 functions cell differentiation, cell proliferation metastasis" " Post-transplant lymphoproliferative disorder (PTLD) fatal complication solid organ transplantation allogenic hematopoietic stem cell transplantation associated immunosuppressive therapy . Potential manifestations diverse, ranging reactive lymphoid" " Advances immunotherapy, notably antibodies targeting inhibitory immune receptors, become effective standard therapies . Advances immunotherapy, notably antibodies targeting inhibitory immune receptors, become effective standard therapies ." Primary pancreatic lymphoma rare clinical entity representing <0.5% pancreatic cancers 1% extranodal lymphomas . Preoperative distinction adenocarcinoma primary pancreatic lymphoma critical since management prognosis malign Primary adrenal lymphoma (PAL) infrequent malignant disease consensus classification classification . PAL observed worse prognosis compared extrarenal malignant lymphomas diffuse large B-cell lymphoma diffuse large B-cell lymphoma presents common " ImbruVeRCHOP trial investigator-initiated, multicenter, single-arm, open label Phase I/II study patients 61-80 years age newly diagnosed CD20 ." PD-DLBCL is rare aggressive B-cell non-Hodgkin lymphoma . PD-DLBCL therapy often mirrored primary central nervous system lymphoma therapy . aggressive treatment high dose methotrexate-based regimen " Surveillance imaging scans are important for patients with large B cell lymphoma . Some clinical practice guidelines recommend surveillance scanning . However, several studies reported benefit overall survival scans ." 28-year-old primigravida evaluated complaints difficulty urinating pelvic pain 6-weeks duration . Ultrasonography revealed single fetal pole cardiac activity 7 cm mass anterior vagina encased urethra . 71-year-old man has been diagnosed with lymphoproliferative disorder . He underwent deceased donor liver transplantation 2 years prior presentation . " Composite lymphoma well-known diagnostic entity exhibiting synchronous occurrence two distinct types lymphomas specimen . Both patients mediastinal mass, manifested two different histologic components biopsy, one characteristic NSCHL PMBL ." " 68-year-old man, history HZO, admitted emergency department nausea vomiting persisted previous two weeks . Neurological evaluation showed right ptosis, divergent strabismus anisocoria . Blood tests showed high c-" CD45 is still definitive marker for diffuse large B cell lymphoma (DLBCL) CD45 is still definitive marker . " Primary cardiac lymphoma extremely rare malignancy, typically non-Hodgkin's type . Clinical manifestations including dyspnea, arrhythmia, chest pain on, may vary according heart site involved right atrium frequently involved" Varón de 68 años comienza su padecimiento with adenomegalias cervicales axilares . Se realiza biopsia escisional se encuentra linfoma de " Post-transplant lymphoproliferative disorder (PTLD) serious life-threating complication transplantation . Different manifestation, different manifestation, histopathology, higher aggressiveness involvement sites beyond primary lymph node, poorer outcome ." Total metabolic tumor volume (TMTV) measured 510 patients DLBCL participating PETAL trial . The present data provide information prognostic impact total metabolic tumor volume using fixed standardized uptake value (SUV) " Epstein-Barr virus implicated majority cases, specifically B-cell-predominant lymphomas . Post-transplant lymphoproliferative disorder (PTLD) rare complication seen hematologic stem cell (HSC) solid" " Primary Non-Hodgkin's lymphoma lacrimal sac extremely rare . Symptoms usually atypical nonspecific, often leads original misdiagnosis dacryocystitis ." " Curcumin exerts anti-cancer effects, partly targeting microRNAs, human cancers . MiR-21 key oncomir carcinogenesis multiple human cancers ." " Until August 2019, 22 gene medicines approved drug regulatory agencies various countries, relevant reviews combing drugs systematically ." The purpose study assess influence single-nucleotide polymorphisms (SNPs) cytokine genes development diffuse large B-cell lymphoma (DLBCL) One hundred twelve patients 221 controls investigated . A routine mammogram revealed small benign mass described benign appearance . A subsequent ultrasound detected small nodular mass described benign appearance . Patient underwent surgery lumpectomy removal breast implants . " We evaluated second primary papillary thyroid cancer (PTC) risk among 3,175,216 ≥ 1-year adult survivors non-thyroid malignancies US population-based cancer registries (2000-2015) We examined S" " Nine ovarian diffuse large B-cell lymphoma cases were reviewed . FISH analysis detected MYC, BCL2 BCL6 translocations . Whole exome sequencing analysis determined genomic features compared conventional extranodal DLBCL ." Laryngeal stenosis challenging treatment due uncertain etiology . Laryngeal stenosis challenging treatment due uncertain etiology . Laryngeal mucosa smooth . " PIX306 phase 3, randomised, single-blind, multicentre trial conducted adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) grade 3 relapsed . FL" Diffusion large B-cell lymphoma (DLBCL) diagnosis uncertain . We performed 5-year retrospective study patients diagnosed with DLBCL otherwise specified . FISH assays (including two-probe approach MYC; break-apart fusion probes) integrated genomic DNA/RNA sequencing CGP approach set 69 consecutive LBCL cases . CGP approach set 69 consecutive LBCL " Anaplastic variant (av) diffuse large B-cell lymphoma (DLBCL) is still enigmatic disease clinicopathologic distinctiveness . Thirty-one cases previously diagnosed avDLBCL reassessed . Of these, 27 (" There limited clinicopathological data pertaining occurrence primary extranodal lymphoma (pENL) Thailand . Lymphoma present either lymphadenopathy extranodal involvement or lymphadenopathy extranodal involvement . FLYER trial assessed whether four cycles CHOP plus six applications rituximab non-inferior six cycles R-CHOP population patients B-cell non-Hodgkin lymphoma favourable prognosis . Diffuse large B-cell lymphoma (DLBCL) is common type B-cell non-Hodgkin lymphoma (NHL) The ABC subtype associated worse prognosis using rituximab plus cyt Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphomas (DLBCLs) express high levels programmed death ligand 1 (PD-L1) PD-L2 . MicroRNA (mi " Diamond-Blackfan anemia (DBA) rare congenital erythroid aplasia, underlied haploinsufficient mutations genes coding ribosomal proteins (RP) DBA frequently associated somatic malformations," CD37 targeting radioimmunoconjugate targets radioimmunoconjugate . CD37 targeting radioimmunoconjugate targets radioimmunoconjugate . 87-year-old female patient presented May 2018 development painless subcutaneous nodules legs since late 2017 . Cutaneous B-cell lymphomas represent 25% cutaneous lymphomas . " WHO classification of high grade B-cell lymphoma newly defined entities ""High-grade B-cell lymphoma MYC BCL2, and/or BCL6 rearrangements (HGBL-DH/TH)"" """ " Lysine methylation widespread protein post-translational modification showing essentialities versatile cellular process . EZH2, methyltransferase specifically trimethylates lysine 27 histone H3 aberrance several cancers promotes development inhibitors" The association B-cell non-Hodgkin lymphoma (NHL) hepatitis B virus (HBV) well demonstrated epidemiological studies . Most studies concerning association conducted in endemic areas . Little known concerning clinical characteristics HBV- miR-214 involvement progression of diffuse large B-cell lymphoma (DLBCL) expression levels miR-214 PD-L1 determined using quantitative RT-PCR . The expression level PD-L1 determined via immun Plasmablastic lymphoma (PBL) rare variant diffuse large B-cell lymphoma optimal treatment established prognosis remains poor . " IFI16, member IFN-inducible PYHIN-200 gene family, modulates proliferation, survival differentiation different cell lineages . IFI16 expression, regulated differentiation B cells, recently studied B-CLL" High-dose cyclophosphamide given intravenously 3 g/m . High-dose cyclophosphamide given intravenously 3 g/m . " Tisagenlecleucel, CD19-specific autologous chimeric antigen receptor (CAR)-T cell therapy, efficacious treatment relapsed/refractory B-cell precursor acute lymphoblastic leukemia diffuse large B" " A 2-year-old female intact African pygmy hedgehog presented diagnostic investigation 2-month reduction appetite, weight loss recent vomiting . Clinical examination revealed large, firm mass originating left cranial abdomen . Ultrasound-guided fine" Flow cytometry results 191 consecutive lymph node biopsies diagnosed FL DLBCL/HGBL . Light scatter characteristics distinguish grade 3 FL DLBCL/HGBL . Light scatter characteristics distinguish grade 3 FL DLBCL/ Tumour-derived extracellular vesicles (EVs) modulated TAMs polarization reprogrammed TAMs influence progression various tumours . " Non-Hodgkin's lymphoma involve extralymphatic organs, resulting diverse clinical manifestations, especially endocrine organs affected . Until now, patients NHL concomitant bilateral adrenal hypothalamic involvement reported ." " PI3K signaling common feature B-cell neoplasms, including chronic lymphocytic leukemia (CLL) diffuse large B-cell lymphoma (DLBCL) PI3K inhibitors introduced clinic. PI3K inhibitors introduced" Report chemical degrader (UNC6852) targets polycomb repressive complex 2 (PRC2) UNC6852 contains EED226-derived ligand ligand ligand ligand VHL bind WD40 aromatic cage E " Chimeric antigen receptor (CAR) T-cell therapy proven effective relapsed refractory B-cell malignancies, resistance relapses still occur . Better understanding mechanisms influencing CAR T-cell cytotoxicity potential modulation using small" " Macrophages (Mφ) abundantly present tumor microenvironment may predict outcome solid tumors defined lymphoma subtypes . Mφ heterogeneity, mechanisms recruitment, differentiation lymphoma-promoting, alternatively activated M2-like phenotypes" Primary prostatic lymphomas (PPL) exceedingly rare . Up 66 000 lymphoma cases collected submitted submitted central expert review French Lymphopath network . The study looked at whether nano drug-loading system-mediated magnetic-targeted thermochemotherapy could produce better therapeutic effect single chemotherapy reducing use of chemotherapeutic drugs . Protein arginine methyltransferase-5 (PRMT5) overexpressed aggressive B-cell non-Hodgkin's lymphomas . PRMT5 knockdown de-repressed transcription three miRNAs . The aim study identify risk factors central nervous system (CNS) involvement systemic diffuse large B-cell lymphoma (DLBCL) patients . The aim study identified risk factors central nervous system (CNS) involvement systemic diffuse large B " Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) relatively rare, risk factors disease still well understood . Thirty-two patients included retrospective study diagnosed PT-DLBCL treated Fudan University Shanghai Cancer" Differential diagnosis diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) becomes challenge adequate biopsy unavailable . " Hemoglobin (Hgb) concentration diagnosis associated with outcome cancer . Hgb outperformed classical International Prognostic Score seven parameters . Hgb, along age clinical stage, outperformed classical International Prognostic Score seven parameters ." " Follicular lymphoma characterized diffuse lymphadenopathy, bone marrow involvement, splenomegaly. Cytopenias relatively common constitutional symptoms fever, night sweats, weight loss uncommon absence transformation ." " Epstein-Barr virus-associated smooth muscle tumors (SMTs) rare neoplasms found develop immunocompromised patients . The tumors develop anywhere body, 17 reported cases occurring spinal canal ." " Prognostic evaluation using interim positron emission tomography/computed tomography (interim PET/CT; I-PET) remains controversial . For predictor, prognosis patients around cutoff value uncertain . If patients around cutoff value could" " Primary cardiac diffuse large B cell lymphoma (PC-DLBCL) rare kind hematological malignancy, clinical pathologic characteristics, especially Eastern countries, remain unclear . We describe case 57-year-old man presented exert" The objective study evaluate distribution prognostic impact broad range molecular attributes of primary central nervous system lymphoma (PCNSL) using tissue microarray . Patients diagnosed PCNSL initially identified BC Cancer Lymphoid Cancer clinical pathology databases . The genetic molecular abnormalities underlying histological transformation (HT) nodal marginal zone lymphoma (NMZL) diffuse large B-cell lymphoma (DLBCL) are well known . While del(20q12) commonly deleted " 55 patients achieved overall/complete response rate 29%/11%, median progression-free/overall survival (PFS/OS) 2/5·1 months one-year PFS/OS 10/19% following start second" " Diffuse large B-cell lymphoma (DLBCL) aggressive heterogeneous lymphoma standard treatment . 30%-40% patients still fail, know patients candidates alternative therapies ." " Warthin's tumor (WT) composed several cysts lined tall, bilayered oncocytic oncocytic columnar cells lymphoid stroma . Approximately 28 cases lymphoma WT reported, non-Hodgkin" " Relationship of relationship with Pre-miR-27a rs895819 polymorphism risk various cancers is well known . In study, conducted case-control study explore role Pre-miR-27a rs895819 risk DL" " Primary cardiac lymphoma (PCL) rare neoplasm involving heart, pericardium both . Patients PCL median survival approximately 7 months based literature ." Diffuse large B-cell lymphoma (DLBCL) represents common adult lymphoma divided 2 major molecular subtypes: germinal center B-cell-like aggressive activated B-cell-like (ABC) DLBCL Early-phase clinical trial results demonstrated remarkable effectiveness CBT specific lymphoma subtypes . CBT relatively disappointing follicular lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma . 79-year-old man near-complete obstruction upper airways due T-cell prolymphocytic leukemia cells . Surgical resection safely performed . Diffuse large B-cell lymphoma (DLBCL) heterogeneous group lymphomas require multiagent therapy remission induction associated relapse 40% patients . Diffuse large B-cell lymphoma (DLBCL) heterogeneous group lymph A treatment strategy needed hemodialysis-dependent patients end-stage renal disease relapsed/refractory diffuse large B-cell lymphoma (DLBCL) We examined feasibility salvage chemotherapy followed autologous stem-cell transplant Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) unusual subtype Hodgkin lymphoma characterised distinct histopathological clinical presentation . It mostly affects males presents localised disease indolent clinical course majority cases . Diffuse large B-cell lymphoma (DLBCL) aggressive form haematological malignancies relapse/refractory ~ 40% cases . It mostly develops due accumulation various genetic epigenetic variations contribute aggressiveness . " Contrast-enhanced computed tomography (CT) abdomen thorax revealed pathologically enlarged abdominal lymph nodes 156 patients, 93 patients pathologically enlarged lymph nodes abdomen . In 81 cases, diagnosis DLBCL verified histopatholo verified histopath" Multiplex immunofluorescence (mIF) assays offer unique advantage preserving architectural features tumor revealing spatial relationships tumor cells immune cells . " Plasma EBV DNA measurement established prognostic utility EBV-driven lymphomas, serves circulating tumor DNA marker . Utility diffuse large B-cell lymphoma (DLBCL) less certain, given subset DLBCLs EBV-" International Prognostic Index (IPI) widely used score non-Hodgkin lymphoma lacks ability identify high-risk population diffuse large B-cell lymphoma (DLBCL) Low absolute lymphocyte count high monocytes " Approximately 65% patients diffuse large B-cell lymphoma cured first-line therapy . Approximately 10% 15% exhibit primary refractory disease, 20% 25% experience relapse initial response . Eligible patients receive second-line therapy followed" " STAT3, phosphorylated STAT3 (p-STAT3), interleukin (IL-10), interleukin (IL-10) examined 32 PCNSL samples using immunohistochemistry . The relationship IL" " Lymphoma may mimic pancreatic ductal adenocarcinoma (PDA) mass-forming pancreatic lesions . Cytologically, lymphoma pancreas misdiagnosed wide variety of pancreatic neoplastic non" Primary renal lymphoma (PRL) defined non-Hodgkin lymphoma (NHL) restricted kidneys without extensive nodal disease . We conducted analysis assess factors associated overall survival (OS) cause-specific survival (CSS) The cellular homeostasis lymphoid tissues determined continuous interactions mobile hematopoietic cells within specialized microenvironments created sessile stromal cells . In contrast lymph nodes mucosal lymphoid tissues mucosal lymphoid tissues The purpose study assess predictive prognostic value of interim FDG PET (iPET) evaluating early response immunochemotherapy 2 cycles (PET-2) diffuse large B-cell lymphoma (DLBCL) applying 2 different methods interpretation " Diffuse large B-cell lymphoma (DLBCL) characterized clinical molecular heterogeneity . Despite efforts tailor therapy individual patients, treatment remains uniform subset patients poor outcomes . DLBCL information provides potential molecular framework precision medicine-based s ." Meningiomas common benign intracranial tumors accounting 30% non-glial tumors central nervous system (CNS) Meningiomas common benign intracranial tumors accounting 30% non-glial tumors central nervous " CAR-T cell therapy has shown exhilarative clinical efficacy hematological malignancies . Despite progresses made made treating hematological malignancies, challenges still remain use CAR-T cell therapy ." " In Europe, tisagenlecleucel (Kymriah™) approved treatment refractory/relapsed acute lymphoblastic leukemia children young adults well relapsed/refractory diffuse large B-cell lymphoma" Combination therapy frequently cures Diffuse Large B-Cell Lymphomas . We find drugs R-CHOP exhibit low cross-resistance synergistic . " 64 patients POAML admitted First Affiliated Hospital Zhengzhou University January 2006 December 2018 . Median OS time PFS time reached. Median OS time PFS time reached. During period, 3 patients died, none died directly due to cancer" " Oncology trial designers suggested borrowing information similar already completed trials reduce number patients needed current study . Bayesian adaptive ""platform"" trial design uses Bayesian adaptive ""platform"" trial design ." " Diffuse large B-cell lymphoma (DLBCL) is common type non-Hodgkin's lymphoma world, highly heterogeneous . 30-40% patients still cured. Novel treatment options urgently needed ." " The clinical pathologic features IOLs Hospital Clinic Barcelona 1995 2018 retrospectively studied . Twenty-one patients, 12 men (57%), median age 60 (interquartile range, IQR: 18 years), median follow-up 30" " Diffuse large B-cell lymphoma (DLBCL) common type lymphoma . About 20% cases, however, designated specific variants DLBCL . These variants, 13 total, specified basis distinctive morphological immunophenotypic" " The designation high-grade B-cell lymphoma traditionally used general term B-cell lymphomas morphologically aggressive many mitotic figures, often starry-sky pattern, high proliferation rate shown Ki-67 expression . In 2017 revision World" " Feature selection plays key role several fields (e.g., computational biology), making possible treat models fewer variables which, turn, easier explain, providing valuable insights . Feature selection plays key role several fields (e.g., computational biology)," " Primary colorectal diffuse large B-cell lymphoma (DLBCL) rare, clinicopathological genetic features poorly understood . We examined 25 cases of colorectal lymphoma DLBCL-like morphology ." " Feasibility microRNA testing predict treatment outcome evaluated . Twenty-two types of microRNAs associated poor treatment response associated poor treatment response . DLBCL patients aberrant expression miR-155, miR-155, miR" " India third largest population people living HIV/AIDS (PLHA) Lymphoma second common malignancy among PLHA . Lymphoma second common malignancy among PLHA . However, data lacking regarding HIV/AIDS-related" " By late 2018, 2 chimeric antigen receptor T (CAR T) cell products approved US European regulatory authorities ." Non-Hodgkin lymphomas (NHLs) resistant standard therapies (NHLs) resistant standard therapies) have dismal prognosis . Most patients qualify allogeneic hematopoietic cell transplantation (H Magnetic resonance imaging (MRI) revealed well-enhanced mass lesion right cerebellopontine (CP) angle appeared originate cerebellum . During three courses chemotherapy high-dose methotrexate (MTX) leuc " Ophthalmic lymphoma (OL) common orbital tumour, particularly older individuals . Little known epidemiology geographic distribution OL Canada . Descriptive demographic statistics important first step understanding OL burden necessary inform comprehensive national cancer prevention programmes ." " Chimeric antigen receptor (CAR) T-cell therapy novel promising form cellular immunotherapy . CAR T-cell therapy uses genetically engineered, tumour-specific autologous T cells . ICANS (immune effector cell-associated" " Diffuse large B-cell lymphoma (DLBCL) is common non-Hodgkin lymphoma, heterogeneous lymphoma, different clinical manifestations molecular alterations . Several markers currently measured routinely diagnosis, subtyping, prog" We assessed total metabolic tumor volume (TMTV) standardized uptake value (SUV) based interim positron emission tomography (iPET) response . We assessed total metabolic tumor volume (TMTV) standardized uptake value (SUV) The dual expression CD5 MYC protein (DECM) protein (DECM) may arise specific stage de novo diffuse large B-cell lymphoma (DLBCL) DECM significantly correlated worse prognosis either CD5 MY Focus B-cell lymphoproliferative disorders (LPDs) lymphomas associated Epstein-Barr virus (EBV) In diseases-such EBV-positive diffuse large B-cell lymphoma (DLBCL) " The aim study present clinical characteristics, natural history survival outcomes primary gastrointestinal non-Hodgkin lymphomas (PGINHL) pediatric population . A total 452 cases identified [mean age 11.0 (±5.1)" " Pancreatic neuroendocrine tumors (PNETs) rarely found majority PNETs nonfunctioning . At present, patient pancreatic neuroendocrine tumor (PNET), lymphoma, squamous cell carcinoma (SCC" " PD-1/PD-L1 expression levels neoplastic cells tumor microenvironment vary among subtypes . Here, review clinicopathological significa ." Lenalidomide maintenance therapy therapy prolonged progression-free survival (PFS) versus placebo elderly patients . Patients completed European Organisation Research Treatment Cancer quality-of-life que . " The current treatment paradigm, however, largely based 'one-size-fits-all' immune-chemotherapy, is inadequate significant number patients . The current treatment paradigm, however, largely based 'one-size-fits-all" " Hematolymphoid neoplasms, including lymphoma myeloid neoplasms, occur patients sickle cell disease (SCD) and sickle cell disease (SCD) The underlying connection between the two conditions yet fully" MYD88 L265P common mutation lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) is frequent poor-prognosis subtypes diffuse large B " Primary mediastinal large B-cell lymphomas (PMBLs) aggressive tumors typically present large mediastinal masses young women . PMBLs share clinical, transcriptional, molecular features classical Hodgkin lymphoma (cHL)" " CAR T cell immunotherapy may interfere HIV-1 nucleic acid amplification testing . Describe three clinical scenarios including a 16-year-old female B cell acute lymphoblastic leukemia, post CAR T cell immunotherapy, including a 16" " The association Non-Hodgkin lymphomas Hepatitis C virus well documented antiviral treatments facilitate virological hematological response . The recent years, direct acting antivirals made cure possible almost every HCV patient ." 131 patients diagnosed with DLBCL diagnosed in 2002 and relapsed received salvage therapy . Primary treatment included R-CHOP R-CHOP R-CHOP-like regimens . The common salvage regimen R-DeVIC ( " HIV positive woman presented 2-month history of abdominal pain, abdominal distension, night sweats fever . Investigations showed haemoglobin 6.5g/dl, cancer antigen 125 44U/ml (NR 0-35) CD4" " Transvitreal fine-needle aspiration biopsy widely used tissue biopsy technique cases suspected intraocular lymphoma due relative simplicity low trauma . Small sample produced may inadequate diagnostic prognostic analyses due mechanical artefacts, insufficient material, sampling" We retrospectively studied 139 patients newly diagnosed DHL/THL diffuse large B-cell lymphoma . We retrospectively studied 139 patients newly diagnosed DHL/THL diffuse large B-cell lymphoma (including 20 cases CD5 Allogeneic stem cell transplant (alloSCT) considered diffuse large B cell lymphoma (DLBCL) patients chemorefractory disease relapsed autologous SCT . Here present first report alloSCT using R Canine B-cell lymphoma clinically heterogenous disease . Canine B-cell lymphoma clinically heterogenous disease . Epstein-Barr positive diffuse large B-cell lymphoma (EBV) is a positive diffuse large B-cell lymphoma . " Malignant lymphomas cancers immune system characterized enlarged lymph nodes typically spread across many different sites . Many different histological subtypes exist, whose diagnosis typically based sampling (biopsy) single tumor site . Total body examinations computed tomography positron" Anti-CD19 CAR T-cells currently represent transformational therapy relapsed/refractory aggressive B-cell lymphomas . CAR T-cells autologous T-cells transduced chimeric antigen receptor targets modified T- " Venous thromboembolism (VTE) may lead diminished quality life ultimately worse prognosis cancer patients . From 7 academic centers Korea, 235 newly diagnosed PCNSL patients undergoing chemotherapy retrospectively identified period January 2004 September 2018" " Twenty-eight patients identified large B-cell lymphoma uvea . Uveal involvement iris (1 case), ciliary body (1 case), choroidal 14 cases . Panuveal involvement observed 12 cases . Majority" " Joint replacements linked hospital inpatient records examined . Cases diagnosed 2009-2015 aged 50 years included 8,013 mature B-cell neoplasms . Cases diagnosed 2009-2015 aged 50 years included; 8,013 mature B-cell ne" 111 DLBCL patients (78 relapsed 33 refractory) underwent HDC/ASCT institution 2010-2015 . After median follow-up time 4.6 years (interquartile range [IQR] 2.2 DLBCL is diffuse large B-cell lymphoma (DLBCL) diffuse large B-cell lymphoma (DLBCL) The disease-free survival cure 60% patients . Previous studies suggested association HPgV viremia risk lymphomas . We conducted systematic review meta-analysis of 1 cohort study 14 case-control studies . " Epstein Barr virus (EBV)-associated primary central nervous system lymphoma (ePCNSL) is increasingly recognized immunocompromised subjects, including patients receiving systemic immunosuppressive therapy . Here, report first case primary CNS" Monoclonal antibodies targeting CD20 central treatment B-cell lymphomas . Inactivating mutations in mutations in CREB-binding protein (CBP) EP300 common . Knockdown CBP DLBCL shown result aberrant The utility surveillance imaging of autologous hematopoietic cell transplantation (AHCT) relapsed/refractory diffuse large B cell lymphoma (DLBCL) remains unclear . The purpose study determine whether surveillance " 57-year-old Caucasian male presented left-sided chest pain, epigastric pain, melena. Abdominal imaging remarkable large, necrotic mass near tail pancreas extending splenic hilum left kidney" Axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T-cell therapy demonstrated efficacy . The immune activation confers efficacy axi-cel comes price potentially devastating adverse phenomena: cytokine " HIV-infected individuals present higher risk developing malignancies . Herein, presenting unusual case untreated HIV, we present unusual case of untreated HIV ." " miR-181a levels lower activated B-cell- (ABC-) like DLBCL cells . Overexpression of miR-181a resulted G0/G1 cell cycle arrest, increased apoptosis, decreased inv" " Gene expression profiling (GEP) preferably used determine cell origin (COO) However, GEP widely applied clinical practice consequently, several algorithms based immunohistochemistry (IHC) developed ." " Primary cutaneous EBV (Epstein-Barr virus)-positive diffuse large B-cell lymphoma, otherwise specified (DLBCL, NOS), extremely rare disease . 35-year-old Chinese male male multiple ulcer" An elderly man seventh decade life brought hospital worsening mental status . Blood tests revealed anaemia thrombocytopenia elevated lactate dehydrogenase serum lactate levels . CT scan showed bulky thoracic abdominal lymphadenopathy spl " Study: Analysis of mutational, genomic, expression profiles refine DLBCL subtypes . 223 patients de novo DLBCL prospective, multicenter randomized LNH-03B LYSA clinical trials in clinical trials ." " Rituximab chemotherapy led improvements progression-free survival overall survival . Rituximab administration often results transient, non-life-threatening infusion reactions ." Venetoclax highly effective agent chronic lymphocytic leukemia acute myeloid leukemia . Adverse events consistent package labeling despite escalation high doses . S1P receptor S1P receptor S1PR2 downstream adaptor Gα13 inactivated germinal center B-cell subtype diffuse large B-cell lymphoma (DLBCL) silenced S1PR2 rep " MALT1 protease activation canonical nuclear factor signals signals T B cell antigen receptor (TCR/BCR) ligation MALT1 protease activation . Using unbiased mass spectrometry, discover multiple serine phosphory" Chimeric Antigen Receptor T-cells (CAR T-cells) functionally reprogrammed lymphocytes . Can recognize kill tumor cells . " Diffuse large B-cell lymphoma (DLBCL) common histologic subtype non-Hodgkin lymphoma notorious clinical heterogeneity . Patient outcomes predicted cell-of-origin (COO) classification, demonstrating underlying transcription" 74-year-old woman presented persistent left knee pain swelling left knee replacement secondary osteoarthritis . There concern mechanical loosening internal left knee prosthetic joint . We describe exceptionally rare case male patient newly diagnosed advanced human immunodeficiency virus (HIV) infection . We describe exceptionally rare case male patient newly diagnosed advanced human immunodeficiency virus (HIV) infection . The development chimeric antigen receptor (CAR) T-cell therapy select hematological malignancies represents one remarkable therapeutic advances past decade . CD19-targeted CAR T-cell therapy approved relapsed/refractory diffuse large " This phase 1b/2, multicenter, open-label study evaluated ibrutinib plus durvalumab relapsed/refractory follicular lymphoma (FL) diffuse large B-cell lymphoma (DL" Polyploid karyotypes diffuse large B-cell lymphoma (DLBCL) rare carry poor prognosis . Extranodal polyploid lymphoma uncommon . 71-year-old man back pain found ileal Non-Hodgkin's lymphoma accounts less 1% cases colorectal cancer . Non-Hodgkin's lymphoma accounts less 1% cases colorectal cancer . Epstein-Barr virus (EBV) infects people establishes life-long infection controlled host's immune system . The association EBV multiple cancers also means lessons learned strong translational potential . " Primary spinal epidural diffuse large B-cell lymphoma (DLBCL) rare often often easily misdiagnose . DLBCL confirmed surgery ultimately. After 6 cycles chemotherapy R-CHOPE, patient went back normal life without relapse" 'Double-hit' lymphoma (DHL) 'double-expression' lymphoma (DEL) involving gene rearrangement protein expression MYC BCL2/BCL6 recently become commonly used terms . The aim study " Obesity increases risk of many diseases, including malignancies . We found higher body mass index significantly longer overall survival . Patients with higher body mass index significantly longer overall survival ." " A 74-year-old male diffuse large B-cell lymphoma, Ann Arbor stage IV-A, submitted immune-chemotherapy 2014, complete remission disease . Two years later, presented left eye swelling leading exophthalmos" " Elevated serum IL-18 (using mean cutoff) associated numerically lower complete remission, 3-year disease-free survival rates . However, difference statistically significant ." NK cells purified responsive patients (n=10) refractory/relapsed patients (n=10) refractory/relapsed patients (n=12) healthy donors (n=12) NK cells treated plasma-derived The standard first-line treatment primary mediastinal B-cell lymphoma (PMBCL) patients rituximab-based immunochemotherapy was rituximab-based immunochemotherapy . We retrospectively investigated Primary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) represents less 1% non-Hodgkin lymphomas 2%-3% brain tumors . DLBCL occurs sporadically healthy " ABT-199 (venetoclax) exhibited remarkable clinical activity nearly cases chronic lymphocytic leukemia . In contrast, responses usually much less diffuse large B-cell lymphoma (DLBCL) were much less diffuse large B" We previously identified five single nucleotide polymorphisms (SNPs) four susceptibility loci diffuse large B-cell lymphoma (DLBCL) individuals European ancestry large genome-wide association study (GWAS) To elucidate genetic susceptibility " Primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) varies according primary site involved . Primary gastrointestinal, breast, bone, craniofacial, craniofacial, testicular DLBCL" " Hairy cell leukemia (HCL) HCL-like disorders, including HCL variant (HCL-V) splenic diffuse red pulp lymphoma (SDRPL) HCL-like disorders, including HCL variant (" Axicabtagene ciloleucel first U.S. Food Drug Administration-approved autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy treatment . Treatment patients relapsed refractory " Double-hit lymphomas triple-hit lymphomas triple-hit lymphomas (DHL/THL) are associated with chemoresistance inferior survival . However, whether radiation therapy (RT) efficacy altered DHL/THL less" " Hashimoto thyroiditis (HT) primary thyroid lymphoma (PTL) is a primary thyroid lymphoma . PTL is based on antithyroid antibodies, clinical history, pathology and pathology . Thirty-eight studies 1,346" " 85-year-old male patient attended Emergency Department complaining respiratory constitutional symptoms, found bronchial mass causing subtotal atelectasis left lung . Anaplastic large cell lymphoma exceedingly rare type primary pulmonary lymphoma, aggressive clinical course" The aim study explore expression osteopontin (OPN) relationship prognostic factors survival . Expression OPN observed 28% of diffuse large B cell lymphoma (DLBCL) The mean overall survival (OS) was 28% " Rituximab standard treatment non-Hodgkin diffuse large B-cell (DLBCL) follicular (FL) lymphomas . Subcutaneous formulation developed improve resource use intravenous rituximab," Meta-analysis explored prognostic value platelet-to-lymphocyte ratio (PLR) patients diffuse large B-cell lymphoma (DLBCL) Results varied different studies . An elevated level circulating cell-free DNA (cfDNA) associated tumor bulk poor prognosis diffuse large B-cell lymphoma (DLBCL) prognostic significance remains unclear . We investigated association association 5-hydroxymethylcy Salvage immunochemotherapy followed high-dose chemotherapy autologous stem cell transplantation standard-of-care second-line treatment . Patients relapsed/refractory diffuse large B-cell lymphoma first-line R-CH Raoultella planticola osteomyelitis rarely reported literature . The likely source case oral microbiome secondary tooth extraction . " CD20-negative diffuse large B-cell lymphoma (DLBCL) rare entity constitutes 1-2% DLBCLs . Major subtypes include plasmablastic lymphomas (PBLs), primary effusion lymph" Hexokinase II (HXKII) key regulator glucose metabolism converts glucose glucose 6-phosphate . HXKII blocks mitochondria-dependent apoptosis inhibiting release cytochrome c. HXKII overe MALT1 protease activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cells . The mechanism of MALT1 protease inhibition is unclear . " Brain MRI may prevent unnecessary neurosurgical resection, could important obtain viable cells accurate diagnosis stereotactic biopsy extensive necrosis ." " The yield skin biopsies evaluation intravascular lymphoma (IVL) (IVL) largely unknown Western patients . Most data supporting test come Asian populations, prevalence disease presentation seem differ ." " Previously, studies shown increased risks second primary malignancies (SPM) Hodgkin lymphoma non-Hodgkin lymphoma non-Hodgkin lymphoma . Nevertheless, investigation quantifying risks SPM patients diffuse large" Inactivation thought to contribute lymphomagenesis . CREBB-binding protein (CREBBP) EP300 commonly mutated germinal-center-derived B cell lymphomas . " Diffuse large B-cell lymphoma (DLBCL) frequent lymphoma . We established prognostic model using peripheral blood absolute lymphocyte/absolute monocyte counts ratio (LMR), hemoglobin, platelet counts obtained complete blood" High-grade B-cell lymphomas MYC BCL2 and/or BCL6 rearrangements include group diffuse large B-cell lymphomas (DLBCLs) inferior outcomes standard chemoimmunotherapy . Diffuse large B-cell lymphoma (DLBCL) clinically aggressive B-cell non-Hodgkin's lymphoma (NHL) high treatment difficulty high relapse rate . The bromodomain extra-termin " Autologous hematopoietic cell transplantation (AHCT) standard therapy patients chemosensitive, relapsed, diffuse large B cell lymphoma (DLBCL) was studied . 371 adult patients DLBCL underwent" Incorporating bortezomib and/or lenalidomide management plasmablastic lymphoma attractive option due reported high response rates . Concerns of overlapping toxicities deter clinicians incorporating novel agents chemotherapy . Diffuse large B-cell lymphoma (DLBCL) aggressive malignancy antioxidant enzyme peroxiredoxin 6 (Prx6) previously associated adverse outcomes . Its systemic effects DLBCL unknown . Inactivating mutations CREBBP EP300 acetyltransferases among common genetic alterations diffuse large B cell lymphoma (DLBCL) follicular lymphoma (FL) We found CREBBP EP300 modulates common well distinct " IL-6 signaling pathway also active subset diffuse large B-cell lymphoma (DLBCL) patients particularly poor prognosis . We show subset DLBCL cases evolved mechanisms ensure constitutive activation IL-6 signaling pathway, i." Allogeneic hematopoietic stem cell transplant (HSCT) relapsed pediatric non-Hodgkin lymphoma (NHL) often reserved patients certain NHL subtypes high-risk disease . Overall survival (OS Previous studies shown increased risk secondary primary malignancies (SPMs) diffuse large B-cell lymphoma (DLBCL) treatment . Whether stage DLBCL diagnosis affects subtypes SPMs occur previously described . " HIV-related plasmablastic lymphoma (PBL) outcomes patients HIV-related plasmablastic lymphoma (PBL) remain poor . Despite advances treatment, outcomes patients HIV-related plasmablastic lymphoma (" " The Lugano classification published 2014 form basis revising recommendations regarding anatomic staging evaluation disease therapy . This staging system adopted eighth edition Cancer Staging Manual American Joint Committee Cancer. In review, aimed discuss updated staging system malignant lymphomas ." Haploidentical stem cell transplantation (haploSCT) becoming major transplant modality lymphoma . " Formalin-fixed, paraffin-embedded (FFPE), biobanked tissue samples offer invaluable resource clinical biomarker research . We show proteome patterns FFPE PCa tissue samples are similar to those of fresh-" Plasmablastic lymphoma (PBL) is a rare aggressive variant large B-cell lymphoma defined proliferation large neoplastic plasmablasts/immunoblasts . PBL first described distinct entity group 16 patients lymph " Non-Hodgkin lymphoma (NHL) well-elucidated specific catchment areas, influence outcomes . Leveraging regional data population-based cancer registry may provide unique opportunities quantify NHL disparities ." Central nervous system (CNS) relapse relapse diffuse large B-cell lymphoma remains uncommon catastrophic . Stand-alone intrathecal prophylaxis performed era anti-CD20 monoclonal antibody therapy . " The improvements magnetic resonance imaging (MRI) technology concern related increased cancer risk patients lymphoma, also due radiation exposure associated imaging examinations . The improvements magnetic resonance imaging (MRI) technology concern related increased cancer risk patients lymphoma, also due radiation" SNHG16 recognized tumour-promoting factor various types cancer . SNHG16 was overexpressed in diffuse large B-cell lymphoma (DLBCL) " Diffuse large B cell lymphoma (DLBCL) common type non-Hodgkin lymphomas . Despite application rituximab, cyclophosphamide, doxorubicin, vincristine" Benzene chemical widely used industrial settings known hematopoietic toxicity . Young patient presented 17cm chest wall lymphoma purulent drainage mass . B-cell receptor (BCR) signaling pathway components represent promising treatment targets multiple B-cell malignancies including diffuse large B-cell lymphoma (DLBCL) B-cell receptor (BCR) signaling pathway components represent " Collision tumors spine extremely uncommon . Collision tumors spine extremely uncommon . 5 cases literature, none involving osseous spine ." The prognostic value cell origin (COO) classification BCL2 expression well established diffuse large B-cell lymphoma (DLBCL) patients human immunodeficiency virus (HIV) infection recent era . Phenotypic Primary cutaneous B-cell lymphomas group diseases indolent aggressive behavior . Treatment guidelines for B-cell lymphomas vary among institutions . " A retrospective study compiling cases feline lymphoma diagnosed 12 years (2004-2016) Southern Brazil performed . A total 125 cases lymphoma diagnosed cats reviewed, information including age, breed, sex tumour topography collected ." " 63-year-old man presented clinic complaining cough exertional dyspnea . Diagnosed dermatomyositis-associated interstitial lung disease (DM-ILD) typical rashes, elevated creatine kinase level chest high-resolution computed" " Spontaneous splenic rupture (SSR) rare potentially life-threatening entity . Spontaneous splenic rupture (SSR) due neoplastic, infectious, haematological, inflammatory metabolic causes ." " A 68-year-old man admitted hemianopsia, headaches subacute progressive cognitive decline . Angiographic findings similar usually reported compatible vasculitis . Brain biopsy revealed intravascular large B-cell lymphoma (" CTLA4Ig-primed donor lymphocyte infusions (DLIs) found promote natural killer (NK) cell-mediated anti-leukemia effect . Incorporation CTLA4Ig conditioning aided long-term remission " Deficiency DNA double-strand break (DSB) repair mechanisms widely exploited treatment different malignances, including homologous recombination (HR)-deficient breast ovarian cancers . Here demonstrate diffuse large B cell lymphomas (DL" Chronic lymphoproliferative disorders classified according revised 2016 WHO classification . Biopsies mandatory chronic lymphoproliferative disorders blood bone marrow cytologroachical approach sufficient lymphoma entities . Axicabtagene ciloleucel (YESCARTA) and tisagenlecleucel (KYMRIAH) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved Primary pancreatic lymphoma (PPL) uncommon neoplasm clinico-radiologically mimic carcinoma . Endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) serves potential tool identify pancreatic lymph Anti-CD19 chimeric antigen receptor (CAR) T cells represent novel immunotherapy highly effective treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) How tumor micro First two cases patients received allograft intensive care unit (ICU) despite severe septic shock multi-organ failure (MOF) One patient aggressive large B-cell lymphoma. Another patient aggressive large B-cell lymphoma " Authors searched Cochrane MEDLINE/PubMed databases December 1, 2018, studies comparing conventional chemotherapy rituximab (R) to conventional chemotherapy rituximab (R)" Cell-free DNA (cfDNA) analysis detect circulating tumor DNA focused monitoring malignant lymphomas . Clonal hematopoiesis indeterminate potential (CHIP)-associated mutations also detected . MYD88/CD79 JL1 expression bone marrow (BM) lymphoma cells assessed using flow cytometry . JL1 expression bone marrow (BM) lymphoma cells assessed using flow cytometry . An anti-JL1 antibody combined toxic substance targeted " Sjögren's syndrome (SS) chronic systemic autoimmune disease, affecting predominantly exocrine glands . The vast majority lymphomas SS B-cell non-Hodgkin's lymphomas (NHL) SS B-cell non" We aimed estimate frequency intratumoral susceptibility signals (ITSS) susceptibility-weighted imaging (SWI) to determine pretreatment heterogeneity PCNSL predictive response chemotherapy using ITSS SWI . We retrospectively examined 29 immunocomp Study aimed improve sensitivity clonality analysis canine cutaneous plasmacytoma . Clonality analysis based immunoglobulin kappa chain (IGK) locus established . " CD-20 antibody rituximab standard component treatment non-Hodgkin B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) There debate whether intravenous rituximab" " We characterized real-world treatment patterns older (65-74 years) oldest (75-85 years) patients receiving initial therapy (R-CHOP) We evaluated baseline demographics, comorbidities, initial therapy, PFS/" " 61-year-old man originally presented increased abdominal distention associated shortness breath diaphoresis found evidence peritoneal carcinomatosis CT scan . Biopsy confirmed diffuse large B-cell lymphoma, working diagnosis subsequently modified" 69-year-old man had EBV-positive diffuse large B cell lymphoma status post allogeneic bone marrow transplant (BMT) Five months prior presented oncologist three days maculopapular rash . Skin bi " Addition rituximab (R) ""CHOP"" (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of diffuse large B-cell lymphoma" PD-L1 protein expression levels might predict response treatment targeting PD-L1/PD-1 pathway . Treatments targeting PD-L1/PD-1 pathway still poorly elucidated LBCL. Epidemiologic studies show increased risk non-Hodgkin lymphoma (NHL) patients autoimmune disease (AD) Patients autoimmune disease (AD) are due combination shared environmental factors and/or genetic factors . Cascative cascade " Mutations SOCS1 frequent primary mediastinal B-cell lymphoma classical Hodgkin lymphoma classical Hodgkin lymphoma . In latter, SOCS1 mutations affect length encoded protein (major mutations) associated shorter patient survival ." " Signals emanating B-cell receptor (BCR) promote proliferation survival diverse forms B-cell lymphoma . Precision medicine strategies targeting BCR pathway generally effective treating lymphoma, often fail produce durable responses ." " Sepsis occurs infection triggers deranged inflammatory responses . There exists efficacious treatment condition. FX1, novel specific BCL6 BTB inhibitor, able attenuate activity B cell-like diffuse large B cell lymphoma (ABC-DL" " Many patients refractory disease unable to undergo autoHSCT, sizeable proportion patients relapse autoHSCT . By analogy diffuse large B cell lymphoma, patients may treated allogeneic (allo) HSCT curative intent, risk significant" " CARD11 multidomain signaling scaffold protein required antigen receptor signaling NF-κB, c-Jun N-terminal kinase, mTOR, mTOR . Germline mutations critically required normal lymphocyte activation adaptive immune response" We analysed outcomes 62 patients refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) pre-transplantation . A positive pre-transplantation PET/CT Deauville score 5 associated shorter mTORC1 inhibitors produced responses approximately 30% patients setting . mTORC1 inhibitors produced responses approximately 30% patients setting . mTORC1 inhibitors efficacy may limited resistance mechanisms including AKT activation mTORC2 . " Diffuse large B-cell lymphoma (DLBCL) constitutes 25-35% non-Hodgkin lymphomas Western countries . Most relapses occur within 1-2 years diagnosis, however, occurrence relapses 5 years" " 69-year-old man presented severe body aches bone pain ribs pelvis, associated fatigue constipation . Hypercalcaemia, renal dysfunction, anaemia bone lesions (CRAB) constellation signs symptoms collectively referred to CRAB" Ligand-receptor complexes play central role mediating range of processes immunology cancer biology . The ability directly quantify fraction receptors occupied ligand given biospecimen could provide additional valuable clinical research tool assessing whether receptors occupied ligand . " CAR T cell therapy cancers promises revolutionize oncology harnessing powers synthetic biology immunotherapy single agent . CARs targeting B cell associated CD19 demonstrated robust vivo cytolytic activity, expansion, persistence upon antigen exposure . CARs" The predictive value pre-autologous stem cell transplantation (pre-ASCT) positron emission tomography/computed tomography (PET/CT) scans according different criteria remains elusive patients diffuse large B-cell lymphoma Malignant lymphoma still leading cause death among AIDS-related diseases . Malignant lymphoma still leading cause death among AIDS-related diseases . Class-switch recombination (CSR) DNA recombination process replaces immunoglobulin (Ig) constant region isotype best protect pathogen . Dysregulation CSR cause self-reactive BCRs B cell lymphomas " Epstein-Barr virus (EBV)-positive lymphoproliferations occurring first year transplantation EBV-negative lymphoma occurring many years transplantation . In gastrointestinal tract, small large intestine common sites involved ." " Tetraspanin CD37 predominantly expressed cell surface mature B lymphocytes . Tetraspanin CD37 predominantly expressed cell surface mature B lymphocytes . Recently, demonstrated loss CD37 induces spontaneous B-cell lymphoma ." " In present study, aim examine relationship genetic polymorphism . genetic polymorphism . transcriptional expression cyclic AMP response element binding protein (AMP response element binding protein)" Radiotherapy (RT) modality salvage therapy relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) efficacy currently well defined . " Use fine-needle aspiration/needle core biopsy (FNA/CNB) evaluating hematolymphoid processes debated debated . Of 152 cases, 124 (81.6%) resulted diagnoses without excisional biops" Case unexpected death caused undiagnosed undiagnosed intravascular large B-cell lymphoma multi-organ involvement . Histological examination showed diffuse intravascular large B-cell brain lymphoma prominent cerebral involvement . " Plasmablastic lymphoma (PBL) occurs mainly immunocompromised individuals, usually secondary human immunodeficiency virus (HIV) infection . It classically occurs intraorally, described extraoral locations ." " CD5+ DLBCL occurs low frequency (9.2%) of patients . CD5+ DLBCL frequently elderly (60 years) with high-performance status, stage III-IV, stage III-IV, IPI" " Study looked at outcomes of vitreoretinal lymphoma (VRL) presenting without sub-retinal pigment epithelial (sub-RPE) infiltration . Patients VRL single center January 1, 1984, July 30, 2018 ." The B-cell receptor phosphatidylinositol 3-kinase (PI3K) signalling pathways represent important therapeutic targets B-cell lymphomas . The two compounds showed activity activated B-cell-like diffuse large B " chimeric antigen receptor (CAR) T-cell therapy dramatically expanded therapeutic options among high-risk B-cell malignancies . As CAR T-cell utilization evolves, novel challenges generated ." HIV-positive population has higher proportion lymphoproliferative disorders HIV-positive population . HIV infection associated increased risk developing B-cell lymphoproliferative disorders . B-cell lymphoma is a cancer that is often challenging . This article clarifies the diagnosis . " Diffuse large B-cell lymphoma (DLBCL) present number different ways, including primary cutaneous lesion various extranodal sites . Rare DLBCL present clinically subcutaneous mass without visible skin changes without visible" Some patients with diffuse large B-cell lymphoma (DLBCL) present concurrent indolent lymphoma diagnosis . Their outcomes rituximab era fully defined. Using prospectively followed cohort 1324 newly diagnosed DLBCL " The incidence of gastric cancers Taiwan decreased 15.97% per 100,000 in 1996 . The incidence of gastric cancers Taiwan decreased 15.97% in 1996 . The frequent histologic subtype gastric cancer Taiwan adenoc" " MYC rearrangements assessed 13 unpublished single-centre PBL cases . In Asia, PBL much less commonly diagnosed human immunodeficiency virus (HIV)-positive patients (27% versus 84%) In Asia," " Gastric mucosa-associated lymphoid tissue (MALT) lymphoma rare disease, available data gastric MALT lymphoma (GML) Gastric mucosa-associated lymphoid tissue (MALT) lymphoma rare disease" 85 patients China DLBCL underwent baseline interim PET/CT scans treated Department Hematology Peking University Third Hospital November 2012 November 2017 . The purpose study evaluate diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) chronic empyema Causality of HBV infection diffuse large B-cell lymphoma (DLBCL) is not fully understood . Different virological serum markers HBV infection patients HBV infection patients HBV infection DLBCL fully understood . Tisagenlecleucel demonstrated high rates durable responses adult patients relapsed refractory diffuse large B-cell lymphoma (r/r DLBCL) JULIET trial . Most patients (92%) received bridging " Patients received once-daily 560 mg ibrutinib, 375 mg/m . Patients received once-daily 560 mg ibrutinib, 375 mg/m ." " Primary non-Hodgkin lymphoma gastrointestinal tract rare incidence 10-15% non-Hodgkin lymphoma cases 1-4% gastrointestinal tumors . The common sites involved include stomach, small intestines, colon rectum" Study was conducted by the World Health Organisation . It looked at the cases of cats with suspected systemic involvement (SSI) and clinical outcomes . The majority cases exhibi were found to be solitary ocular lymphoma (PSOL) 58-year-old man history rheumatoid arthritis stage IV diffuse large B-cell lymphoma . Diagnosed with vagus nerve palsy . Diagnosed with rapidly progressing left facial vestibulocochlear nerve palsies Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease unclear pathogenesis . DLBCL accounts 30%-35% non-Hodgkin lymphomas (NHLs) aggressive subtype mature B- Red blood cell distribution width (RDW) is a potential prognostic factor in solid hematologic malignancies . We evaluated 121 patients de novo diffuse large B-cell lymphoma (DLBCL) treated standard chemo " Research using mouse lymphoma cell lines resulted many reports glycosylation key regulator distant metastasis mouse lymphoma cells animal models . In contrast, reports experiments examining human lymphoma cell metastasis . The glycosylation pattern human lymph" " R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) standard therapy patients previously untreated diffuse large B-cell lymphomas (DLBCL" " Parathyroid sarcoidosis parathyroid gland rare occurrence . Parathyroid sarcoidosis usually associated parathyroid adenomas, and, therefore, hypercalcaemia common presentation entity ." " Slackia exigua obligate anaerobic coccobacillus associated dental infection, rarely causes extraoral infection . We report two cases monomicrobial bacteremia caused S. exigua isolated two institutions ." Primary rectal lymphoma uncommon heterogeneous malignancy . We hypothesize difference overall survival patients undergoing local resection (LR) radical resection (RR) We hypothesize difference overall survival patients undergoing local resection (LR) radical 8-year-old boy diffuse large B cell lymphoma developed right-sided spontaneous spontaneous pneumothorax pleural effusion recovery septic shock . Daratumumab (Darzalex) first-in-class anti-CD38 antibody approved treatment relapsed/refractory (R/R) multiple myeloma (MM) It also demonstrated clinical activity Walden We conducted Simon's two-stage phase II multicenter trial investigate response rate (primary endpoint) safety six courses Ga101-miniCHOP older patients DLBCL (≥65 years) prospectively defined unfit . 34 patients enrolled Primary central nervous system lymphoma (PCNSL) rare aggressive form diffuse large B-cell lymphoma . Frontline treatment high-dose methotrexate based immunochemotherapy curative majority patients . The iPET/CT findings evaluated Deauville 5-point scale (DS) and Deauville 5-point scale (DS) reduction SUVmax incorporated tumor size (ΔSUVmax*ΔSLD) Analysis " Primary mediastinal large B-cell lymphoma (PMBL) represents clinically pathologically distinct subtype large B-cell lymphomas . Here, performed whole-exome sequencing 95 PMBL ." " Patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, ineligible for, autologous stem cell transplantation (ASCT) dismal prognosis . This phase II study evaluated treatment R-" " CDK9/cyclin T1 found to be a potential therapeutic target for diffuse large B-cell lymphoma (DLBCL) CDK9 inhibitors specifically elevated trimethylation H3K27, speculate due reduced expression JM" Diffuse large B-cell lymphoma (DLBCL) clinically biologically heterogeneous disease . Activated B-cell-like DLBCL characterized NF-κB activation chronic B-cell receptor signaling may targeted lenalidomide " In advanced-stage diffuse large B-cell lymphoma (DLBCL) presence activated B-cell phenotype non-germinal center (GCB) phenotype, coexpression MYC BCL2 immunohistochemistry, co" Continuous Individualized Risk Index (CIRI) method dynamically determines outcome probabilities individual patients . CIRI provides real-time probability of real-time probability . chimeric antigen receptor (CAR) T cells important treatment option led remissions otherwise refractory patients . Most patients large cell lymphoma cured frontline chemoimmunotherapy . The treatment consisted ibrutinib (560 mg/day) disease progression unacceptable toxicity occurred . The primary outcome disease control (DC) was the primary outcome disease control (DC) " Rare adrenal tumours present primary adrenal insufficiency . Most common sites involved stomach, intestine testis . Diffuse large B cell lymphoma (DLBL) originating stomach metastasizing bilateral adrenal glands extremely uncommon occurrence ." " Follicular Lymphoma (FL) indolent lymphoma may various clinical courses . Worldwide, FL second common non-Hodgkin lymphoma (NHL) type diffuse large B-cell lymphoma ." " This study aimed clarify comprehensive clinical, laboratory, pathological imaging features intravascular large B-cell lymphoma (IVLBCL) using data 42 IVLBCL patients diagnosed hospital past 20 years . Characteristic features included persistent fever" Primary mediastinal large B-cell lymphoma (PMBCL) distinct clinico-pathological subtype diffuse large B-cell lymphoma unclear prognostic factors limited clinical data . Optimal treatment role radiotherapy fully defined . " Ferroptosis newly discovered form iron-dependent oxidative cell death characterized lethal accumulation of lipid-based reactive oxygen species (ROS) Ferroptosis has been shown critical regulating growth tumors, hepatocellular carcinoma (H" The clinical course diffuse large B-cell lymphoma (DLBCL) variable lack prognostic markers models relapsed refractory (r/r) DLBCL) Study identify independent factors predict survival rate r/r DLBC High-dose chemotherapy autologous stem cell transplantation (HDT-ASCT) standard care relapsed primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma . Only 50% " Neoplastic cells were characterized by flow cytometry (FC) Using FC, immunophenotyped neoplastic cells 11 cases THRLBCL 11 cases THRLBCL 11 cases DLBCL, NOS (controls" R-CHOP followed consolidative radiation therapy (RT) diffuse large B-cell lymphoma (DLBCL) We analyzed 404 patients Stage I-II DLBCL received six eight cycles . R-CHOP achieved good response One-third diffuse large B-cell lymphoma patients refractory initial treatment relapse . CXCR4 overexpression (CXCR4 overexpression) in patients . " Little reported diagnostic delay in diffuse large B-cell lymphoma (DLBCL) Little reported diagnostic delay reported in patients . A single-centre, retrospective study conducted examine association diagnostic wait time (DWT) and interval initial hospital" " MYC transcription factor key driver lymphomagenesis . AZ5576, selective CDK9 inhibitor, selective CDK9 inhibitor, diffuse large B-cell lymphoma (DLB) MyC induces global changes gene expression contribute cell" Polatuzumab vedotin approved to treat relapsed refractory diffuse large B-cell lymphoma . The drug recognizes CD79b protein B cells . " Primary cardiac tumors especially rare, incidence 0.056% according autopsy reports . Common type myxoma account nearly 70%-80% of them . Only 10% primary cardiac tumors malignant, approximately 95% sarcomas ." " ERG (avian v-ets erythroblastosis virus E26 oncogene homolog), oncoprotein prostate carcinoma Ewing's sarcoma associated poor prognosis patients . Little known ERG lymphoma." " De novo diffuse large B-cell lymphoma (DLBCL) presenting synchronous central nervous system (CNS) systemic disease (synDLBCL) well described excluded clinical trials . Of patients, 96% extranod" " Series of diphenylthiazole derivatives rationally designed, synthesized characterized. Biologically evaluation biochemistry cellular assay indicated that, compounds 5m, 5o, 5o, 6b, 6c, 6c, 6" " Pituitary adenomas (84.6%), followed craniopharyngiomas (3.2%), cystic nonneoplastic lesions (2.8%), cystic nonneoplastic lesions (2.8" " Less than 1500 cases annually of primary central nervous system lymphoma (PCNSL) less 1500 cases annually . Incidence PCNSL remained stable post-highly active antiretroviral therapy era, owing increasing incidence elderly, immun" Burkitt lymphoma (BL) highly aggressive requires intensive chemotherapy approaches successful treatment . New approaches lower toxicity maintain high curability needed currently development . " Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs 2-5% patents" " Intratumor heterogeneity (ITH) plays important role tumor development, metastases, recurrence impact clinical diagnosis, therapeutic responses . In study, used mutant-allele tumor heterogeneity (MATH) whole-exome sequencing data evaluate" " The activated B cell (ABC-like) subtype diffuse large B cell lymphoma (DLBCL) characterized chronic activation signaling initiated immunoglobulin . By analyzing DNA copy number profiles 1000 DLBCL tumors, identified gains 18" Autopsy specimens revealed atypical cells resembling Hodgkin Reed-Sternberg (HRS) cells rich inflammatory background various organs . HRS-like cells infected Epstein-Barr virus (EBV) The HRS-like Diffuse large B-cell lymphoma (DLBCL) accounts 35% non-Hodgkin lymphoma incidence increases age . Epstein Barr virus (EBV) widely spread worldwide. There 10% association EBV DLBC Dogs with Diffuse Large B-Cell Lymphoma (DLBCL) benefit from active immunotherapy traditional chemotherapy . We hypothesized immune cells within neoplastic lymph nodes (LNs) may play role tumor pathobiology treatment response Sixty patients NKTLs twenty-six patients DLBCLs sinonasal region confirmed histopathology underwent high-resolution DWI conventional MRI . The apparent diffusion coefficients (ADCs) conventional MRI features associated NKTLs EBV-positive diffuse large B-cell lymphoma (EBV) was a disease with Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV) NanoString™ platform could detect EBV tumour " 44 patients, diagnosed 2004 2017, fulfilled inclusion criteria, reviewed retrospectively reviewed . 44 patients, diagnosed 2004 2017, fulfilled inclusion criteria, reviewed . CNS involvement diagnosed solely parenchymal 41% ." " French LMB2001 study reviewed . Between February 2001 December 2011, 33 patients 773 (4.3%) relapsed; 27 Burkitt lymphoma six large B-cell histology . Median age diagnosis 10.1 years." Elderly patients may heterogeneous abilities tolerate immunochemotherapy-associated toxicities . Elderly patients may heterogeneous abilities tolerate immunochemotherapy-associated toxicities . We describe morbidity rituximab-chemotherapy combinations among Richter syndrome refers to transformation chronic lymphocytic leukemia assaultive lymphoma . Richter syndrome characterized rapidly growing lymphadenopathy rarely presents extra-nodal involvement . " Richter transformation developed chronic lymphocytic leukemia (CLL) developed chronic lymphocytic leukemia (CLL) well defined . After median follow 67.0 months, median overall survival (OS) 12.0 months ." " 64-year-old woman admitted fever unknown origin, developed nephrotic syndrome hospitalisation . Renal biopsy disclosed intracapillary glomerular invasion intravascular large B cell lymphoma . Clinical biological evolution favourable r" MicroRNA 155 (miR-155) is one extensively studied multifunctional miRNAs . miR-155 orthologs encoded Kaposi's sarcoma-associated herpesvirus (KSHV) Marek's " B-cell receptor (BCR) activity diffuse large B-cell lymphoma (DLBCL) well established, subset patients relapsed DLBCL benefit BCR-targeted therapies . 79 patients DLBCL (nod" " Chimeric antigen receptor (CAR) T-cell therapy dramatically shifted landscape treatment lymphoid malignancies, especially diffuse large B-cell lymphoma (DLBCL) acute lymphoblastic leukemia (ALL) However, continue significant" Pediatric-type follicular lymphoma (PTFL) and large B-cell lymphoma (LBCL) IRF4 rearrangement introduced current WHO classification . Both PTFL pnMZL and pnM " Primary central nervous system lymphoma rare subtype non-Hodgkin lymphoma confined brain, leptomeninges, eye associated relatively poor prognosis compared extranodal diffuse large B-cell lymphomas ." " Primary colonic lymphoma (PCL) rare, heterogeneous, presents therapeutic challenge surgeons . Optimal treatment strategies difficult standardize, leading variation therapy ." Diffuse large B cell lymphomas (DLBCLs) genetically heterogeneous highly proliferative neoplasms derived germinal center (GC) B cells . SIRT3 depletion impaired glutamine flux TCA cycle via glutamate dehyd " Transcription factors commonly deregulated cancer, widely considered difficult target due nonenzymatic mechanism action . Altered expression levels of ETS-transcription factors often observed many different tumors, including lymphomas ." Axicabtagene ciloleucel (axi-cel) CD19-directed chimeric antigen receptor (CAR) T-cell therapy relapsed refractory diffuse large B-cell lymphoma . Bridging therapy " 68-year-old man presented 4-day history painless, left blurred vision . Examination revealed 2 anterior chamber cells, mutton-fat keratic precipitates posterior synechiae . Treatment initiated, eye settled, patient discharged" Natural killer cells heterogeneous population innate lymphocytes are potent anticancer properties . Lack understanding role NK cell diversity antitumor responses hindered advances area . Outcomes of diffuse large B-cell lymphoma patients relapsing autologous hematopoietic cell transplantation (auto-HCT) historically poor . We studied outcomes patients using data 4 transplantation centers . El " 11-month-old female Japanese macaque suddenly died without clinical signs . Necropsy examination revealed nodular mass protruding left ventral aspect larynx, compressing epiglottis anteriorly . Histopathologically, l" HIV-positive man presented clinic with generalised erythroderma . He lost follow-up previous 3 years . He CD4 lymphopenic (100×10) A combination polychemotherapy rituximab improved prognosis . 50% patients experience progression relapse without predictive biologic marker therapeutic response . " The expression programmed cell death ligand 1 (PD-L1) biomarker immunotherapy, approved detection method absent diffuse large B-cell lymphoma (DLBCL) The expression programmed cell death ligand 1 (PD-L" " 80-year-old woman showed imitation behaviour (IB) mimicking gestures visually presented examiner, holding up . By using IB rehabilitation training, flexor-dominated posture upper arm gradually reduced ." Epstein-Barr virus-driven cases need treated reduction immune suppressive medications . " Diffuse large B-cell lymphoma (DLBCL) common subtype B non-Hodgkin lymphoma adults . Current first-line treatment R-CHOP regimen greatly improves patient's prognosis . However, rel" " Primary cardiac lymphoma (PCL) rare kind primary heart tumor, belonging non-Hodgkin's lymphoma . Common symptoms include heart failure, pericardial effusion, malignant arrhythmias . Early diagnosis" The diabetes mellitus (DM) drug metformin targets mechanistic/mammalian target rapamycin inhibits lymphoma growth vitro . We investigated whether metformin affected outcomes newly diagnosed diffuse large B-cell (DLBCL " In paper, novel approach introduced integrating multiple feature selection criteria using hidden Markov model (HMM) For purpose, five feature selection ranking methods including Bhattacharyya distance, entropy, receiver operating characteristic curve, t-test," MYC BCL2 evaluated IHC gene rearrangement real-time PCR (RT-PCR) real-time PCR (RT-PCR) real-time PCR (RT-PCR) real-time PCR ( " Anthracycline dose optimisation treatment diffuse large B-cell lymphoma rarely tested . We aimed find whether R-CEOP70 non-inferior R-CHOP50 less cardiotoxicity, whether R-CE" Given lack consistent data regarding clinico-pathological features clonal lymphomagenesis patients mucosa-associated lymphoid tissue (MALT lymphoma lymphoma histological transformation (HT) systematically analysed 379 patients (32% gastric DNA damage checkpoint kinases ATR WEE1 among key regulators . DNA damage response pathways protecting cells replication stress . ATR WEE1 inhibitors early clinical trials success require greater understanding mechanism action biomarkers patient selection . " The present longitudinal qualitative quantitative study reflects real-life practice pixantrone use . It aims collect data patients' considerations for, expectations experiences pixantrone trajectories quality-of-life (QoL) values Dutch clinical" " Anti-PD-1 anti-CTLA-4 monoclonal antibodies used melanoma, anti-PD-1 also used Hodgkin's lymphoma . Primary central nervous system lymphoma rare form non-Hodgkin" Transverse myelitis quite rare complication hematopoietic stem cell transplantation . 49 year old male male diffuse large B cell lymphoma complete remission developed transverse myelitis . " Cell-free DNA (cfDNA) is one promising non-invasive biomarkers cancer . This approach could interest management management . Diffuse Large B-Cell Lymphoma (DLBCL) patients, common non-Hod" Rituximab anti-CD20 monoclonal antibody approved non-Hodgkin lymphoma (NHL) Study aimed assess relationship antigen mass nonlinear pharmacokinetics rituximab NHL patients . Chimeric antigen receptor (CAR) T cells spark hope patients CD19+ B cell neoplasia . Third-generation CARs incorporating elements shown superiority concerning longevity proliferation . " Primary central nervous system lymphoma (PCNSL) rare form extra-nodal non-Hodgkin lymphoma . PCNSL distinct subtype non-Hodgkin lymphoma, 95% tumors belonging diffuse" " Polatuzumab vedotin, antibody-drug conjugate targeting CD79b component B-cell receptor, demonstrated activity single agent combination rituximab relapsed refractory diffuse large B-cell lymphoma" " 38-year-old male recipient developed post-transplant lymphoproliferative disorders . Post-transplant lymphoproliferative disorders possible complication kidney transplant due chronic immunosuppressive therapy, elevate mortality rate ." Intussusception usually seen pediatric age group rarely seen adults . Intussusception usually seen pediatric age group rarely seen adults . " Pulmonary lymphoma arises primarily lung, extremely rare, secondarily involved lymphoma . The clinical features, management, prognostic factors clearly identified ." " Diffuse large B cell lymphoma (DLBCL) is aggressive cancer B cells, common subtype non-Hodgkin lymphoma (NHL) worldwide . In China, cases DLBCL increase yearly yearly . C" " CX-5461, first-in-class selective rDNA transcription inhibitor, first-in-human, phase I dose-escalation study . Administration CX-5461 intravenously every 3 weeks every 3 weeks 5 cohorts" Studies direct indirect oncogenic mechanisms elucidated pathogenesis HCV-associated B-lymphoma subtypes . These include B-lymphocyte proliferation sustained clonal expansion HCV-envelope protein stimulation B-cell receptors Intravascular large B-cell lymphoma seen less one per million people . Intravascular large B-cell lymphoma seen less one per million people . Richter's transformation (RT) is either diffuse large B cell lymphoma (DLBCL) Hodgkin's lymphoma (HL) Diagnosis requires histologic confirmation tissue biopsy . EOT FDG-PET/CT (PET-CR) correlates long-term outcome patients . Treatment efficacy determined using EOT PET/CT rather progression-free survival (PFS) clinical trials assessing novel drugs . Testicular lymphoma rare malignancy affecting mainly elderly men . Majority representing diffuse large B-cell lymphoma (DLBCL) relapse rate higher nodal DLBCL . Often affecting central nervous system (CNS) dismal There growing recognition primary cutaneous T cell lymphomas skin exhibit follicular helper T cell phenotype best exemplified primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma . The follicular helper T cells evolutionary function common Heterogeneous nuclear ribonucleoprotein K (hnRNP K) RNA-binding protein aberrantly expressed cancers . Reduced hnRNP K expression downmodulates tumor-suppressive programs . Primary mediastinal large B-cell lymphoma (PMBL) classic Hodgkin lymphoma (CHL) common large cell lymphomas arising mediastinum thought closely related histogenetically . CD83 fascin markers CHL " Immune checkpoints, including PD-1/PD-L1, play important role immunosuppression various malignancies . Elevated levels of sPD-L1 associated worse prognosis multiple myeloma diffuse large B cell" The combination ofatumumab bendamustine bendamustine bendamustine and bendamustine elderly patients diffuse large B-cell lymphoma demonstrated modest efficacy compared standard care . The poor response may due patient age high The value adding rituximab chemotherapy children aggressive B-cell non-Hodgkin lymphoma (B-NHL) still insufficiently studied . We enrolled 231 patients [mean age 9 years old (range 2- " DNA damage response (DDR) kinases ATR, Chk1, Wee1 play vital roles response replication stress maintaining cancer genomic stability . Inhibitors kinases currently clinical investigation . Mantle cell lymphoma (MCL)" " The use fine needle aspirates core biopsies acceptable methods obtaining sufficient material hematopoietic neoplasms nonemergent conditions debatable . There are, however, scenarios limited material obtainable due anatomic site," Low pretreatment NK-cell count (NKCC) associated shorter progression-free survival (PFS) follicular lymphoma . Low baseline peripheral blood NKCC associated shorter progression-free survival (PFS) follicular lymphoma . " 50 patients Myc-positive diffuse large B-cell lymphoma retrospectively analyzed . Autologous transplantation performed 23 patients, transplantation performed 27 p. Autologous transplantation performed 23 patients, transplantation performed 27 p." 64-year-old man presented isolated secondary CNS lymphoma involving choroid plexus diffuse pattern . He initially presented obstructive hydrocephalus diffuse choroid plexus lesions . He initially presented obstructive hydrocephalus " Diffuse large B-cell lymphoma (DLBCL) 17-fold likely occur, follows aggressive clinical course frequently presents advanced stages HIV infected (+) individuals compared HIV negative (-) individuals . Molecular pathology underpinning clinical features of DL" " Intravascular large B-cell lymphoma (IVLBCL) rare entity, generally aggressive course may vary based geographic presentation . Clinicopathological treatment data unavailable ." " B cell lymphoma-6 (BCL6) highly expressed germinal center B cells, expression maintained still completely clear . Aryl hydrocarbon receptor interacting protein (AIP) co-chaperone heat shock protein 90 ." Primary cutaneous follicle center lymphoma (PCFCL) rare mature B-cell lymphoma unknown etiology . PCFCL resembles follicular lymphoma (FL) cytomorphologic microarchitectural criteria . FL B cells " A 67-year-old man presented visual acuity hand motion right eye 1 month . Magnetic resonance imaging demonstrated enlargement medial inferior rectus muscles tendons . Tendon enlargement, uncommon Graves' orbitopathy, motivated us perform bi" " CXCL16 (TM-CXCL16) receptor CXCR6 independent risk factor poor survival patients diffuse large B-cell lymphoma (DLBCL) pathogenesis remains unknown . In present study, synergistic effect" " From January 2010 June 2017, collected 15 patients VRL. Twelve patients diffuse large B-cell lymphoma (DLBCL) and 11 primary central nervous system (CNS) DLBCL, one ocular localisation follicular" " Plasmablastic multiple myeloma uncommon morphological variant multiple myeloma aggressive clinical course poor outcome . Its differential diagnosis includes plasmablastic lymphoma, variant diffuse large B-cell lymphoma frequent extranodal presentation" " IL1R8 regulatory receptor belonging IL1R family, negatively regulates NF-κB activation following stimulation IL1R Toll-like receptor family members . IL1R8 deficiency associated development severe autoimmune lupus-like disease ." " 32 follicular lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma (DLBCL) Children's Oncology Group studies . Two DLBCLs (6%) IRF4 rearrangements," " Despite improvement survival survival of diffuse large B-cell lymphoma (DLBCL) introduction rituximab, central nervous system (CNS) relapse continues represent clinical challenge . In diffuse large B-cell lymphoma (DL" Certain tumors rely heavily DNA repair capability survive DNA damage induced chemotherapeutic agents . Certain tumors rely heavily DNA repair capability survive DNA damage induced chemotherapeutic agents . Neutropenia common side effect myelosuppressive chemotherapy . Administration granulocyte colony-stimulating factor used neutropenia prophylaxis . Neutropenia febrile neutropenia " A 24-year-old man history HIV large B cell lymphoma (currently remission) presented fever, dry cough dizziness, dry cough dizziness . His CD4+ count undetectable, HIV viral load 109 295 cop/" " Pathogenic hemizygous variants SH2D1A gene cause X-linked lymphoproliferative (XLP) syndrome . Disease onset typically early childhood, average life expectancy affected males ∼11 years . Disease onset typically early" " Kidney disease varied according underlying underlying lymphoproliferative disorder . Kidney disease varied according underlying underlying lymphoproliferative disorder . In DLBCL, malignant kidney infiltration prominent, resu in DLBCL ." Richter syndrome (Richter syndrome) occurs substantial subset of patients must discontinue therapy chronic lymphocytic leukemia (CLL) RS extremely poor prognosis . " We reviewed diagnostic utility combined fine needle aspiration cytology (FNAC) flow cytometry (FC) diagnosis lymphoid lesions head neck . In total, 1402 patients combined FNAC-FC reports correlated follow-up information . In total" Burkitt lymphoma (BL) serous effusion (SE) specimen summarise characteristics of BL SE . SE cytology histological biopsy diagnoses compared determine concordance rates . SE cytology histological biopsy diagnoses compared determine " Epstein-Barr virus (EBV) linked variety malignancies; endemic Burkitt lymphoma (BL) harbor EBV, whereas subset cases sporadic BL EBV positive . We retrospectively determined herpesvirus seropreval" Refractory relapsed diffuse large B-cell lymphoma (DLBCL) often associates activated B-cell-like (ABC) subtype genetic alterations drive constitutive NF-κB activation impair B-cell terminal differentiation . " Erythropoiesis-stimulating agents (ESAs) may alleviate anemia diffuse large B-cell lymphoma (DLBCL) patients . Many cancer cells express EPO receptors (EPOR), exogenously administered" N-terminal pro-brain-type natriuretic peptide (NT-proBNP) cardiovascular (CV) risk score named FRESCO predicting anthracycline-induced cardiotoxicity (AIC) diffuse A major clinical challenge diffuse large B-cell lymphoma (DLBCL) 40% patients refractory disease relapse initial response therapy result drug-specific molecular resistance . Differential miRNA expression analysis identified miR-155 highly expressed " CD30 expressed variety B-cell lymphomas, Hodgkin lymphoma, primary effusion lymphoma, primary effusion lymphoma, diffuse large B-cell lymphoma subgroup . In normal tissues, CD30 expressed activated B T" 72-year-old woman developed excessive somnolence one symptoms diffuse large B-cell lymphoma central nervous system (CNS) CSF orexin levels recovered near normal values improvement somnolence chemotherapy . Squamous cell carcinoma common laryngeal neoplasm accounts approximately 95% malignant neoplams larynx . Squamous cell carcinoma common laryngeal neoplasm accounts approximately 95% malignant ne Increased tumor burden associated inferior outcomes many lymphoma subtypes . Increased tumor burden associated inferior outcomes many lymphoma subtypes . Epstein-Barr virus (EBV) positive diffuse large B-cell lymphomas associated chronic inflammation (DLBCL-CI) develop patients chronic inflammation without predisposing immunodeficiency . EBV-positive pyothorax " This study aimed develop prognostic nomogram diffuse large B-cell lymphoma (DLBCL) compare traditional prognostic systems . The proposed nomogram provided accurate estimate survival patients DLBCL, especially receiving R-CHOP R-" 30-40% patients treated first-line chemoimmunotherapy still experience relapse refractory DLBCL . Computer-Aided Drug Design (CADD) drug discovery process accounted persistency application computational approaches . Promising efficacy results chimeric antigen receptor (CAR) T-cell therapy tempered safety considerations . " Biologically distinct subtypes diffuse large B-cell lymphoma identified using gene-expression analysis determine cell origin, corresponding germinal centre activated B cell . We aimed investigate whether adding bortezomib standard therapy could improve outcomes patients" " Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma subtype, approximately 50% patients >60 years age . Patients relapsed/refractory (rr) disease poor prog" Recent studies identified germline mutations . Recent studies identified germline mutations . " Intravascular large B cell lymphoma (IVLBCL) rare, aggressive, extranodal large B cell lymphoma characterised growth tumour cells within lumen vessels, particularly capillaries . Programmed cell death" " Diffusion large B-cell lymphoma (DLBCL) cured standard immunochemotherapy R-CHOP . One-third relapses dismal outcome cases . Despite findings, current standard care DLBCL patients st ." Even diffuse large B-cell lymphoma (DLBCL) response rates immune checkpoint blockade therapy limited . DLBCL immune evasion epigenetic repression instead activation antigen-presenting MHC-a dissection mechanisms underlying repression . " Antibody-drug conjugates showed clinical activity tolerability phase 1 trials . The aim multicentre, open-label, phase 2 study compare rituximab plus pola (R-pola) plus pol" Radiation therapy diffuse large B-cell lymphoma (DLBCL) shown improvement progression free survival . Dose Optimization B cell Lymphomas (DOBL) study randomized phase-III . " Organophosphates carbamates are among commonly used insecticides, agricultural residential uses . Previous studies suggested associations non-Hodgkin lymphoma (NHL) chemicals . We evaluated use eleven organophosphate two carbamate" " MDCT features lesions retrospectively reviewed correlated clinicopathological findings . Twenty eight patients (17 men, 11 women; median age, 61.5years) pathologically confirmed PAL included study . All 28 cases non-Hodgkin" Lenalidomide modest single-agent activity comparable newer drugs recurrent diffuse large B cell lymphoma response rates 19% 28% . Survival rates patients non-Hodgkin lymphoma (NHL) improved last decade . Cardiotoxicities remain important adverse consequences treatment chemotherapy radiation . Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . Need to identify novel prognostic factors for DLBCL patients . " Fusarium solani liposormal amphotericin B day 25 cord blood transplantation (CBT) caused increased occurrence of invasive fungal infections due previously rare molds . Fusariosis, allogeneic hematop" " Diffuse large B-cell lymphoma (DLBCL) common form lymphoma, common form lymphoma, 30% DLBCL patients eventually died using first-line chemotherapy regimens . Currently, Bruton tyrosine kin" Intravascular large B-cell lymphoma (ivLBCL) rare blood dyscrasia difficult diagnose . Healthy skin biopsies may prove useful diagnosis condition . " 75-year-old woman history infiltrative ductal carcinoma left breast hospitalised neurological evaluation following repeated falls . During course hospital stay, patient's neurological state deteriorated rapidly, onset marked laboratory-documented inflammatory syndrome observed, together with a" " 27 patients diagnosed PPL First Affiliated Hospital Soochow University enrolled 27 patients diagnosed PPL First Affiliated Hospital Soochow University January 2000 December 2016 . The main manifestations cough, expectoration, bloody sputum fever . The" Study evaluated expression chemokine receptors CXCR4 CCR7 diffuse large B-cell lymphoma (DLBCL) Association CXCR4 CCR7 bone marrow (BM) involvement synergistic effect prognosis still unclear PD-L1 regulates tumorigenesis immune escape from diffuse large B cell lymphoma (DLBCL) The upstream mechanisms PD-L1 regulating tumorigenesis immune escape remained unclear . MALAT1 knocked shRNA. Mi Reducing diagnostic delays cancer major interest worldwide . Reducing diagnostic delays cancer major interest worldwide . Literature diagnostic delays lymphoma remains scarce . " Pesticides commonly used agriculture, previous studies endorsed need to investigate possible association use risk lymphoid malignancies agricultural workers . We investigated relationship ever use 14 selected pesticide chemical groups 33 individual active chemical ingredients ." This case report describes colon lymphoma unique thyroid metastasis . Primary thyroid malignancy frequent secondary secondary . " B cell lymphomas comprise heterogeneous group genetically, biologically, clinically distinct neoplasms . In recent years, advent novel genomics technologies revolutionized understanding molecular pathogenesis lymphoid malignancies ." MYC BCL2 activation initiating events Burkitt's (BL) Follicular Lymphoma (FL) occur later stages subtypes Diffuse Large-B Cell Lymphoma (DLBCL) MyC BCL2 Barasertib (AZD1152) showed promising clinical activity relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients administered 4-day infusion . Nanosinarticle formulation AZD28 " Plasmablastic lymphoma (PBL) rare subtype diffuse large B-cell lymphoma, highly associated HIV Epstein-Barr virus (EBV) infections . It commonly presents extranodal sites, often oral mass" " PD1/PD-L1 expression studied 50 adult post-transplant lymphoproliferative disorders . PD-L1 copy number alterations (CNAs) were thoroughly studied . PD-L1 CNAs, PD-L" " Diffuse large B-cell lymphoma (DLBCL) is aggressive non-Hodgkin lymphoma originating germinal center . DLBCL ideally diagnosed excisional biopsy suspicious lymph node, shows sheets large cells" This phase 2 study enrolled patients with diffuse large B-cell lymphoma . The primary endpoint 5-year freedom local recurrence was 5-year freedom local recurrence . " Of 512 patients, 149 developed recurrent lymphoma . 149 developed recurrent lymphoma . Three-year OS 91.4% recurrence. OS significantly worse relapse ." " Primary cutaneous diffuse large B-cell lymphoma, NOS (PCLBCL/NOS) rare PCLBCL. The aim study identify clinical and/or immunohistochemical markers (in addition Bcl-" One third patients with diffuse large B-cell lymphoma relapse receiving first-line treatment . Relapsed patients may eligible second-line (2L) therapy . CXCR4-directed endoradiotherapy constitutes highly promising targeted therapeutic concept . " Phase 1b study investigating dose escalation BCL2 inhibitor, venetoclax, venetoclax, combination rituximab obinutuzumab cyclophosphamide, doxorubicin, v" Tisagenlecleucel chimeric antigen receptor-T cell therapy facilitates killing CD19 . Tisagenlecleucel chimeric antigen receptor-T cell therapy facilitates killing CD19 . Neurolymphomatosis (NL) infiltration lymphocytes peripheral nervous system haematological malignancy . We describe imaging features NL patient relapsed Burkitt-like non-Hodgkin's lymphoma . Autoimmune inflammatory disease increases risk diffuse large B-cell lymphoma (DLBCL) marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL) findings mature B-cell malign " Sinonasal tract diffuse large B-cell lymphoma (SNT-DLBCL), rare extranodal lymphoma, well characterized . We performed population-based study determine cell-of-origin, clinical presentation impact" Richter's transformation refers to development aggressive lymphoma patients chronic lymphocytic leukaemia (CLL) small lymphocytic lymphoma . Studies shown 2-10% patients CLL develop RT including diffuse large B-cell lymph 228 patients diffuse large B-cell lymphoma (DLBCL) received R-CHOP-based regimens prospective randomized study (NCT01852435) included training cohort . 886 lymphoma patients served validation cohorts . Diffuse large B cell lymphoma (DLBCL) heterogeneous disease treated anti-CD20-based immuno-chemotherapy (R-CHOP) We identified low levels GAPDH predict poor response to R- " Bortezomib rituximab and rituximab were used together patients undergoing allogeneic stem cell transplantation (alloSCT) In phase I/II trial, assessed safety activity bortezom" " HIV viraemia risk non-Hodgkin lymphoma, common cancer people living HIV . We aimed identify key CD4 count HIV RNA (viral load) predictors risk non-Hodgkin lymphoma, overall" One third patients diffuse large B-cell lymphoma (DLBCL) succumb disease partly due to rituximab resistance . Rituximab-induced calcium flux important inducer apoptotic cell death . Bicluster targets assessed using validated messenger RNA (mRNA) targets exhibited average 17.0% (median 19.4%) improved gain certainty . The net gain increased 32.0% (median 33.4%) incorporating " Increasing incidence of diffuse large B-cell lymphoma (DLBCL) ageing populations places significant burden healthcare systems . Co-morbidity, frailty, reduced organ physiological reserve contribute treatment-related complications ." " Parsaclisib (INCB050465) is next-generation, potent, highly selective phosphatidylinositol 3-kinase 3-kinase δ (PI3Kδ) inhibitor . Seventy" " The diagnosis classic Hodgkin lymphoma requires immunohistochemical confirmation cases one argue studies standard-of-care diagnostic workup . The authors propose panel studies primary identification CHL include: CD3, CD20, CD15, CD" " The receptor-tyrosine-kinase-kinase (RTK)-like orphan receptor 1 (ROR1) transmembrane glycoprotein regarded tumor-associated antigen . ROR1 plays important role cancer development, detailed" " Ferroptosis form regulated cell death induced inhibition cystine-glutamate antiporter, system x . Ferroptosis form regulated cell death induced inhibition cystine-glutamate antiporter, system x ." Daratumumab CD38 monoclonal antibody approved treating relapsed/refractory newly diagnosed multiple myeloma . Preclinical daratumumab studies demonstrated cytotoxic activity reduced tumor growth B-cell non- Diffuse large B-cell lymphoma (DLBCL) frequent subtype non-Hodgkin lymphoma . DLBCL frequent subtype non-Hodgkin lymphoma . High total metabolic tumor volume (TM " Primary effusion lymphoma (PEL) aggressive HIV-associated lymphoma relatively poor prognosis era effective HIV therapy . Kaposi sarcoma herpesvirus (KSHV) etiologic agent, ∼80% tumors coin" Intravascular large B-cell lymphoma (IVLBCL) one rarest B-cell non-Hodgkin lymphomas (NHL) one rarest B-cell non-Hodgkin lymphomas " We aimed investigate efficacy side effects bendamustine side effects bendamustine relapsed/refractory lymphoma patients Turkey . In retrospective study, included relapsed/refractory Hodgkin lymphoma (HL) non-" PD-1/PD-L1 is important negative regulators immune cell activation . PD-L1 expressed myeloid cells 85% 95% of DLBCL patients . PD-L1 expressed myeloid cells 85% 95 " CD19-targeting chimeric antigen receptor (CAR)-T cell therapy shown great efficacy patients relapsed/refractory non-Hodgkin lymphoma (NHL) associated serious adverse effects, cytokine release syndrome (" " DrugComboExplorer identifies driver signaling pathways predict synergistic drug combinations . Tool generates driver signaling networks processing DNA sequencing, gene copy number, DNA methylation RNA-seq data individual cancer patients . Tool generates driver signaling networks processing DNA sequencing" Oxidative stress markers antioxidant enzymes previously shown prognostic value associate adverse outcome patients diffuse large B cell lymphoma (DLBCL) Their significance DLBCL prognosis unknown . PD-1/L1 CTLA-4 blockade immunotherapies approved 13 types cancers studied diffuse large B-cell lymphoma (DLBCL) Whether PD-1 CTLA-4 checkpoints active clinically significant DLBCL The prognosis of diffuse large B-cell lymphoma (DLBCL) patients depends lymphoma- patient-related risk factors best estimated international prognostic index (IPI) The aim study determine whether average relative dose intensity (ARD Diffuse large B-cell lymphoma (DLBCL) contributes cancer-related mortality . Increasing evidence reported crucial role long non-coding RNAs (lncRNAs) tumorigenesis . Microarray analysis used screen different A multitude disease processes ranging periodontitis malignancies lead formation solitary ulcer palate . Solo ulcers palate often challenging one diagnose . High-grade B-cell lymphomas (HGBCL) MYC BCL2 or/and BCL6 rearrangements (R) are so-called double/triple-hit lymphomas (DH/TH " In modern era chemotherapy, outcome pediatric non-Hodgkin lymphoma (NHL) continues improve internationally . Limited data information epidemiology survival, however, available Asian countries ." Burkitt-like lymphoma 11q aberration characterized pathological features . Burkitt-like lymphoma 11q aberration characterized pathological features . Burkitt lymphoma 11q aberration characterized pathological features . " Neoplasias affecting aorta usually due variety thoracic abdominal tumors, common primary tumors aortic wall . Those tumors invade abdominal aorta usually sarcomas, able mimic, clinically radiologically, aortic" Standard therapy gastric diffuse large B-cell lymphoma (DLBCL) considered chemotherapy without involved-field radiation therapy . R-CHOP therapy alone widely used DLBCL gastric lesions (DLBCL-GL) " Chronic hepatitis C virus (HCV) infection related increased risk non-Hodgkin lymphomas (NHL) In indolent subtypes, regression NHL reported HCV eradication antiviral therapy (AT) In 2008 Lomb" This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) with posttrans We applied 2017 World Health Organization (WHO) classification criteria categorise series 64 primary cutaneous large B-cell lymphomas (PCLBCL) The aims determine reproducibility prognostic relevance 2017 WHO criteria . Morphology phenotype identified " Finding combinations (i.e., pairs, generally, q-tuples q ≥ 2) genes whose behavior group differs significantly two classes received lot attention . The computational cost finding q-tuple genes scores highest given metric O(G" " Primary cutaneous lymphomas continues largely dominated T-cell lymphomas . However, significant progress has been made towards T-cell lymphomas ." " Large B-cell lymphoma (DLCBL) remains heterogeneous older individuals due comorbid diseases variations disease biology . Despite effective therapies, outcomes diffuse large B-cell lymphoma (DLCBL) remain heterogeneous older individuals" Patients with aggressive B-cell lymphomas (DHL) double-hit lymphoma [DHL] double-expressor lymphoma [DEL] double-expressor lymphoma [DEL] had poor outcomes . Chemo MHC-II-deficient tumors characterized somatically acquired gene mutations reducing MHC-II expression . Low MHC-II expression defines tumors originating centroblast-rich dark zone germinal center (GC) associated inferior prog " Primary non-Hodgkin lymphoma extremely rare entity, condition represents less 0.5% malignant lesions involving mammary gland . As such, paucity relevant clinical data arising Southeast Asia ." " Ewing's sarcoma is rare, highly malignant anaplastic stem cell tumor . Histologically, tumor consists uniform densely packed small monomorphic cells round nuclei . Typical appearance hematoxylin eosin (H" Rituximab plus lenalidomide (R2) DLBCL-PCNSL was a prospective phase II study . The induction treatment consisted eight 28-day cycles R2 . " Follicular lymphoma (FL) common indolent B-cell non-Hodgkin lymphoma (NHL) genetic alterations BCL-2, KMT2B, KMT6 genetic alterations BCL-" " Intravascular large B-cell lymphoma (IVLBCL) distinct disease, neoplastic PD-L1 expression tumor cells may vary among cases . Neoplastic PD-L1 expression found tumor cells located capill" Influenza infection causes significant morbidity mortality patients cancer . Annual influenza vaccination individuals cancer recommended . CAR T-cell therapy field intense research United States since 1980s . Recent approval August 2017 Kymriah (tisagenleclecleucel) opened door broader access CAR T-cell therapy outside clinical trials . Automatically detects bacterial infections . False-positive blood culture results rare patients hematologic malignancies . Taiwan National Health Insurance Research Database retrieved Taiwan National Health Insurance Research Database . Study looked at patients diagnosed chronic hepatitis B (hepatitis B virus [HBV] cohort) without (non-HBV cohort) 2004-2007 retrieved Taiwan CAR T cells expanded clinical use infused back patient's body attack destroy chemotherapy-resistant cancer . Dramatic clinical responses high rates complete remission observed setting CAR T-cell therapy B-cell malignancies . Autopsies showed large embolus dense lymphoma cells extending truncus pulmonalis pulmonary arteries . Autopsies showed large embolus dense lymphoma cells extending truncus pulmonalis pulmonary arteries . Autopsies " 16-year-old female patient presented clinic complaints multiple episodes of generalized tonic clonic seizures, nystagmus, weakness left side body 3 weeks . Repeat magnetic resonance imaging (MRI) brain showed multiple areas signal abnormalities involving" Epstein-Barr virus found almost exclusively activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL) contribution tumour remains poorly understood . EBV-encoded latent membrane protein-1 ( " CD73 expression tumor cells, rather total protein gene levels CD73, associated survival . We found CD73 expression tumor cells, rather total protein gene levels CD73, associated survival . Novel immune checkpoint blockades, including targeting CD73 A" " International Prognostic Index (IPI) used risk stratification long time diffuse large B cell lymphoma (DLBCL) Based new clinical biological prognostic markers, many new prognostic models described . This review aims present progress development" Histologic transformation (also known Richter's transformation) occurs approximately 2% 10% patients associated poor prognosis . Chronic lymphocytic leukemia (CLL) generally characterized indolent disease course . " Methotrexate-associated lymphoproliferative disorders lymphoproliferative disorders lymphoproliferative disease lymphoma patients treated methotrexate autoimmune diseases, rheumatoid arthritis ." " Chimeric antigen receptor modified T (CAR-T) cell therapy CD19 antigen revolutionized therapeutic landscape patients relapsed, refractory B cell non-Hodgkin lymphoma (NHL) Currently, two FDA approved" " A 61-year-old woman chronic lymphocytic leukaemia, Richter's transformation diffuse, large, large, B-cell lymphoma, treated six cycles rituximab, cyclophosphamide, dox" " The aim study assess safety activity ibrutinib combination nivolumab patients relapsed refractory B-cell malignant diseases . 21 hospitals across the world, including Australia, Israel, Poland, Spain, Spain," Rare case pediatric tonsillar cancer reviewed by rare case pediatric tonsillar cancer . Survival analysis performed using Kaplan-Meier analysis . Diffuse large B-cell lymphoma (DLBCL) common form non-Hodgkin's lymphoma . Signal transducer activator activator transcription 3 (STAT3) cytoplasmic transcription many important " Rituximab, chimeric monoclonal antibody targets CD20 cell surface protein . The prognosis primary CNS lymphoma improved use high-dose methotrexate-based chemotherapy, patient outcomes remain poor ." " Post-transplantation lymphoproliferative disorder (PTLD) heterogeneous, potentially life-threatening complication liver transplantation children . 16 pediatric liver transplant recipients developed PTLD February 2001 December 2013 ." " US general population (N=7,147,476) assessed cases US general population (N=7,147,476) 16 different cancer types ascertained 11 cancer registries . Transplant recipients elevated risk of cancer immunosupp" " TAK-243, first small-molecule inhibitor ubiquitin activating enzyme (UAE) enter clinical development . It disrupts ubiquitin signaling global protein ubiquitination diffuse large B-cell lymphoma (DLBC" Central nervous system (CNS) relapse carries poor prognosis diffuse large B-cell lymphoma (DLBCL) Integrating biomarkers CNS-International Prognostic Index (CNS-IPI) risk model may improve identification Meta-analysis aims evaluate associations factors hematological cancer risk adults . Eligible cohort studies sought eligible cohort studies sought . 44 studies included present analyses . Pooled relative risk estimates calculated using random-effects models . Mature B cell lymphomas account approximately 60% cases non-Hodgkin lymphoma (NHL) children adolescents . The outcome patients treated modern regimens resource-intensive settings are excellent . " Raman spectroscopy non-destructive label-free technique providing biochemical tissue fingerprint . The objective present work test Raman spectroscopy suitable tool differentiate lymph nodes affected different conditions, reactive follicular hyperplasia (benign)," Epstein-Barr virus (EBV)-negative extranodal diffuse large B-cell lymphoma (DLBCL) immunohistochemical expression PD-L1 tumor cells . We identified six patients Epstein-Barr virus " We sought develop safe effective outpatient salvage regimen replacing ifosfamide within (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen bendamustine (T(" " Pan-B-cell antigens routinely used diagnosis B-cell lymphoma, include CD19, CD20, CD22 CD79a. Pan-B-cell antigens routinely used diagnosis B-cell lymphoma," " Elderly patients prone encounter adverse factors receive chemotherapy compared younger patients . Addition rituximab reduced dose (RD) cyclophosphamide, doxorubicin, vincristine, vincristine," Most dogs large B-cell lymphoma (LBCL) undergo chemotherapy achieve clinical complete remission (CR) Eventually relapse . Time relapse (TTR) unpredictable . Central nervous sytem recurrence diffuse large B-cell lymphoma uncommon devastating event . Central nervous sytem recurrence diffuse large B-cell lymphoma uncommon devastating event . Modern risk stratification includes clinical biological features . " The Surveillance, Epidemiology, End Results registry queried 1973 2015 patients DLBCL nasal cavity paranasal sinuses . Demographic disease parameters collected . Prognostic disease-specific survival overall survival factors evaluated univariate Kaplan-Me" " A 28-year-old man presented 2 months persistent cough . Large lung abscess involving almost entire right upper lobe . Given extent involvement, surgical candidate ." " Methotrexate, used treat wide range malignancies, one various drugs accountable particular condition . Drug-induced crystalline nephropathies secondary abnormal accumulation crystals leading parenchymal renal injuries ." " 106 extranodal (EN) diffuse large B-cell lymphomas (DLBCLs) stomach (34 cases), intestine (10), cervico-cephalic region (11), cervico-cephalic region (11" International guidelines suggest hepatitis C virus eradication direct-acting antivirals (DAAs) first-line immunochemotherapy (I-CT) patients HCV-positive diffuse large B-cell lymphoma (DLBCL) Patients Diffuse large B cell lymphoma (DLBCL) exhibits pathologic heterogeneity dynamic immunogenic tumor microenvironment (TME) Lack preclinical vitro models of DLBCL TME hinders optimal therapeutic screening . Study describes development integrated Non-Hodgkin lymphoma (NHL)-specific mortality declines as US population ages . Deaths causes NHL become increasingly important treatment decision making older patients NHL . Chemotherapy associated significant toxicity elderly patients treated hematological malignancies. Adequate tools identify best tailored treatment essential. Adequate tools identify best tailored treatment essential. " The so-called ""double-hit"" lymphoma is a ""double-hit"" lymphoma . The so-called ""double-hit"" lymphoma is a ""double-protein-expression"" lymphoma ." " Lymphomas malignant neoplasms lymphocyte cell lines affecting lymph nodes, spleen nonhemopoietic tissues . Of extranodal lymphomas found head neck region, 3-5% malignant lymphomas arise" Two CAR T-cell products approved clinical use U.S. FDA: tisagenlecleucel pediatric acute lymphoblastic leukemia (ALL) adult diffuse large B-cell lymphoma subtypes (DLBCL) CAR PDE4B elevated fatal/refractory fatal/refractory diffuse large B-cell lymphoma (DLBCL) therapeutic efficacy PDE4 inhibitor B-cell lymphoma successfully tested clinical settings . " Extraaxial lymphoma involving trigeminal nerve, uncommon condition presents trigeminal schwannoma, resulted misdiagnosis flawed surgical strategy ." " Intrathecal chemoprophylaxis often administered patients lower rates of central nervous system relapse . Prognostic models, including CNS-International Prognostic Index (IPI), developed aid identifying patients highest risk of relapse ." " Relapsed refractory non-Hodgkin lymphomas often carry poor prognosis pose management challenges . We evaluated safety efficacy dasatinib, broad-spectrum multi-kinase inhibitor relapsed/refractory NHL" " Rituximab (R) infusions doubled to double standard standard CHOEP (cyclophosphamide, doxorubicin, etoposide, etoposide, vincristine, prednis" Axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy . Median follow-up 15·4 months (IQR 13·7-17·3 Bruton tyrosine kinase (BTK) inhibitors (BTKi) attributed acquired acquired acquired BTK/phospholipase C gamma 2 (PLCG2) mutations . " 4% 20% previously treated CLL patients undergo transformation high-grade lymphoma . Richter transformation defined transformation CLL aggressive lymphoma, commonly diffuse large B-cell lymphoma ." IL-10 levels IL-10:IL-10:IL-6 ratio may reveal aggressive lymphomas . IL-10:IL-6 ratio order could reveal aggressive lymphomas . " Of 125 cases, 16 showed lung infiltration (12.8%) of 125 cases, 16 showed lung infiltration (12.8%) of 125 cases . Gross lesions observed lungs consisted masses (25%) nodules (18.7%) of" " Primary CNS lymphomas (PCNSL) rare poor prognosis diffuse large B-cell lymphomas . Brain tumor environment restricted distribution drugs CNS, specific PCNSL patient-derived orthotopic xenograft (PDOX) models" Antiviral therapy (AVT) first-line treatment HCV-related indolent NHL . Diffusion large B-cell lymphoma (DLBCL) requires immediate start chemoimmunotherapy (CIT) Early MYC gene rearrangement present approximately 10% aggressive B-cell lymphomas . Half of patients with MYC rearrangement also harbouring BCL2 gene rearrangement . " Population-based study considered influence rituximab survival children (0-19 years), adolescents, young adults (AYAs, 20-39 years) diffuse large B-cell lymphoma (DLBCL) This population-" Primary cutaneous B-cell lymphomas non-Hodgkin lymphomas present skin without evidence extracutaneous involvement diagnosis . There 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma HOD 2 cases brainstem lymphoma . Trans-synaptic degeneration caused disruption dentatorubro-olivary pathway . " p53 expression MYC extra copies (MYC-EC) reported serve independent adverse prognostic markers patients diffuse large B-cell lymphoma (DLBCL) However, impact p53 expression MYC-EC lymphomas delineated" " Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) unique rare subtype Hodgkin lymphoma (HL) differs clinically, pathologically biologically biologically biologically classic HL . CD20 expression malignant lymphocyte" " Primary lymphoma skull base (PLSB) extremely rare neoplasm much known regarding clinical features of, treatment strategies for, prognoses lesions . We investigated manifestations clinical outcomes Chinese patients PLSB ." " Diffusion large B-cell lymphoma (DLBCL) represents >60% lymphomas . Elderly patients DLBCL heterogeneous population definition elderly varies within literature . Combination rituximab, cyclophosphamide" The GMALL-B-B-ALL/NHL2002 protocol effective Burkitt lymphoma/leukemia (BL) Its role aggressive lymphomas patients patients simultaneous central nervous system (CNS) peripheral involvement unclear . " Hu5F9-G4, also known 5F9, combination anti-CD20 therapy rituximab, may promising treatment forms non-Hodgkin lymphoma . Hu5F9-G4 allows" " Cortactin cytoskeletal-remodeling adaptor protein, playing oncogenic role solid tumors . Little known cortactin expression non-Hodgkin B-cell lymphomas (B-NHLs)" Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) provide prolonged remissions patients advanced B cell lymphoma (B-NHL) via graft-versus-lymphoma effect 88-year-old Japanese man erythrodermic involvement T-cell prolymphocytic leukemia (T-PLL) He history pharyngeal diffuse large B-cell lymphoma successfully treated polychemotherapy diffuse large B-cell lymphoma (DLBCL) sub-Saharan Africa (SSA) poorly described . Outcomes diffuse large B-cell lymphoma (DLBCL) sub-Saharan Africa (SSA) poorly described Elderly patients Epstein-Barr virus (EBV) infection increased risk developing B-cell lymphoproliferative disorder (B-LPD) due immunosenescence . " Primary intestinal diffuse large B-cell lymphoma (iDLBCL) rare . Study investigated clinicopathological features disease understand prognostic value CD5, programmed cell death ligand 1 (PD-L1), Epstein-Barr" " Immunohistochemistry important tool pathologists establish final diagnosis, also inform decisions regarding optimal treatment methods . Universal standard notation expressing immunohistochemical findings expressing immunohistochemical findings ." Primary bone marrow diffuse large B-cell lymphoma (BM-DLBCL) uncommon . We follow case review literature summarizing 107 reported cases of BM-DLBCL . Neutrophil extracellular traps (NETs) promote transition autoimmunity lymphomagenesis . Higher levels of NETs plasma tumor tissues associated with dismal outcome patients DLBCL . Diffuse large B-cell lymphoma (DLBCL) aggressive lymphoid tumor occasionally Epstein-Barr virus (EBV) positive subtyped activated B-cell DLBCL (ABC-DLBCL) germin Human herpesvirus 6B (HHV-6B) DNA frequently detected human samples . Diagnostic assays distinguishing HHV-6B reactivation latency limited. This impaired strategies diagnose treat HHV-6B-associated diseases Chimeric antigen receptor (CAR)-T cell therapy recently developed approach address poor outcomes patient population . Recent advances diffuse large B-cell lymphomas included identification high-risk subtypes characterized multiply relapsed and/or refractory disease " Apatinib tyrosine kinase inhibitor selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) Although apatinib shown promising anti-tumor activity several types tumor, role underlying mechanism non-" Small molecules novel agents targeting aberrant pathways introduced clinical trials targeting recurrent refractory PCNSL patient population . Agents like Bruton tyrosine kinase (BTK) inhibitor ibrutinib immunomodulatory drugs ( " The primary endpoints overall survival, disease-specific survival, progression-free survival, progression-free survival . The median age 64 years, 51% patients (n = 407) male. The majority lymphomas B-cell origin (" " Primary central nervous system lymphoma (PCNSL) rare form non-Hodgkin lymphoma affects brain parenchyma, spinal cord, eyes, cerebrospinal fluid without evidence systemic, non-CNS involvement" " Diffuse large B-cell lymphoma, NOS (DLBCL NOS) commonest extranodal non-Hodgkin lymphoma diagnosed oral maxillofacial region . Prognostic determinants remain undefined" Cardiotoxicity known risk anthracycline treatment . Relative contribution anthracyclines development congestive heart failure (CHF) relative contribution anthracyclines development congestive heart failure (CHF) is unclear . Diffusion large B cell lymphoma (DLBCL) cells widely express BCL2 protein . DLBCL cells harboring PMAIP1/NOXA gene amplification highly sensitive BCL2 small-molecule inhibitors Activating Activists in the U.S. is a non-profit organization . Activists are encouraged to take part in the U.S. government to help people in need of action . This study sought clarify molecular pathways underlying putative evolution of putative evolution lymphomatoid papulosis (LyP) cutaneous anaplastic large-cell lymphoma (c-ALCL) lymph node invasion (LNI Diffuse large B-cell lymphoma (DLBCL) neoplasm morphologically medium large large B-lymphoid cells . The recent WHO classification of tumors hematopoietic lymphoid tissues (Swerdlow " Diffuse large B-cell lymphoma (DLBCL) common hematologic malignancy, however, specific tumor-associated genes signaling pathways yet deciphered . Seventy-four up-regulated 79 down-regulated 79" " 13-year-old boy presented 2-month history of left eyelid swelling, ecchymosis, epiphora . Magnetic resonance imaging revealed lobulated lesion region left lacrimal sac extending left nasolacrimal" Programmed cell death ligand 1 (PD-L1) upregulated various types of haematological malignancies associated immunosuppression . This study aimed investigate expression pattern PD-L1 Epstein-Barr virus ( Diagnosis revealed diagnosis of diffuse large B-cell lymphoma . Diagnosis revealed diagnosis of diffuse large B-cell lymphoma . Non-Hodgkin lymphoma (NHL) primarily diagnosed nodal marginal zone B-cell lymphoma (NMZL) primarily diagnosed nodal marginal zone B-cell lymphoma (NMZL) In follow- Molecular imaging is a form of molecular imaging . The results of this imaging were created by a microscope in a lab in a lab in New York City . " By gene-expression profiling, lymphoma divided three cell-of-origin subtypes distinct molecular clinical features . Most lymphomas arise sporadically, yet familial clustering known, suggesting genetic contribution disease risk . Familial lymphoma cases" " Pheochromocytoma (PHEO) combined primary adrenal lymphoma extremely rare . We describe case locally invasive PHEO combined primary malignant lymphoma . We provide case description biochemical analyses, imaging, pathologic findings ." The recent 2017 update World Health Organization classification lymphomas significant changes previous edition . Subtypes large B cell lymphoma related aggressive B cell lymphomas addressed . Specific subtypes addressed include T cell/histiocyte-rich large B cell lymph " Three patients presented skin lesions with nodular polymorphic infiltrates . Two initially diagnosed classical Hodgkin lymphoma (cHL), hand, last one B-cell lymphoma . All patients treated angioimmunoblastic T-cell" " Comorbidity impacts overall survival amongst patients diffuse large B-cell lymphoma (DLBCL) However, associations comorbidity lymphoma characteristics, treatment selection lymphoma-specific mortality less well known . To examine impact com" We report successful treatment of mesenteric diffuse large B-cell lymphoma (DLBCL) using localized involved site radiation therapy (ISRT) and intensity modulated radiation therapy (IMRT) We report successful treatment of mesenter " Gene expression profiling (GEP) separated diffuse large B-cell lymphoma (DLBCL) two different entities, i.e. activated B cell-like (ABC) germinal center B cell-like (GCB" Diffuse large B cell lymphoma (DLBCL) traced mature B malignance carrying abnormal activation-induced cytidine deaminase (AID) expression . AID activity initially focuses deamination cytidine uracil generate " Bone marrow biopsy (BMB) accepted investigation fever unknown origin (FUO) uncover haematological malignancies, lymphoma, sometimes infections . Advance imaging modalities, 18-fluoro-2-deoxygl" Genomic rearrangements are a form of genetic rearrangements . Genomic rearrangements are a form of genetic rearrangements . " 11-year-old patient developed nausea, vomiting, diplopy day +82 following HSCT . Multiple white matter lesions seen on brain MRI, multiple white matter lesions seen . Histology showed diffuse large B-cell lymphoma high" Middle-aged woman presented painful solitary destructive lesion fifth lumbar vertebra . Initial diagnosis plasma cell neoplasm made based limited histological information obtained fragmented tissue sample . She treated multiple lines chemo/immunotherapy regimens 37-year-old male presented lower urinary tract symptoms with right flank pain . Diagnosed with diffuse large B-cell lymphoma . " Plasmacytomas are discrete, B cell-derived, round cell tumours sometimes difficult distinguish canine cutaneous histiocytomas T cell lymphosarcomas (lymphomas) Diagnosis plasmacytomas" Tumors originating nipple-areolar complex breast rare . 67-year-old woman presented rapidly enlarging tumor areolar region left breast . Study examined efficacy survivorship care plan (SCP) intervention help physicians address survivorship issues . Patients achieved complete remission completion first-linlin . " Cerdulatinib, dual SYK/JAK inhibitor, associations tumor response investigated . Preclinical studies suggest SYK JAK contribute tumor-intrinsic microenvironment-derived survival signals ." BCR blockade diffuse large B-cell lymphoma (DLBCL) remains undefined . Inhibition B-cell receptor (BCR) signaling pathway promising treatment strategy multiple B-cell malignancies . The standard treatment waldeyer's ring DLBCL remains controversial . The standard treatment waldeyer's ring DLBCL remains controversial . This retrospective study evaluated role consolidation radiotherapy (RT) patients stage I/II diffuse Primary cardiac lymphoma (PCL) rare extranodal lymphoma involves heart and/or pericardium . It fatal absence prompt diagnosis adequate therapy . " Using data clinics hospitals throughout Japan, analyzed 9426 cases malignant lymphoma diagnosed 2007-2014 . We show proportion follicular lymphoma methotrexate-associated lymphoproliferative disorder increased time, onset age follicular lymph" Primary breast diffuse large B-cell lymphoma (PB-DLBCL) rare subtype DLBCL limited data patterns failure . Multimenter study aimed define optimum treatment strategy patterns failure PB-DLBCL patients . Fluorescent semiconductor quantum dots (QDs) newfound nanocrystal probes used bioimaging filed recent years . The purpose study evaluate diagnostic value specific QDs coupled rituximab monoclonal antibody CD20 tumor markers Conventional local tumor irradiation (LTI) delivered small daily doses several weeks . Patients ineligible hematopoietic cell transplantation . " Richter's transformation (RT) Ann Arbor stage 1E diffuse large B-cell lymphoma bicep . The patient treated combination chemotherapy cyclophosphamide, doxorubicin, Vincristine prednisone" Cancer associated deletions mutations mainly due misrepaired DNA double-strand breaks (DSBs) Classical nonhomologous end joining (c-NHEJ) homologous recombination (HR) two major DSB repair " Epstein-Barr virus (EBV) well-known association lymphoproliferative disorders B T cell origin . EBV-related B cell lymphoproliferative disorders include Hodgkin Burkitt lymphomas, lymphomat" A 46-year-old woman quiescent lupus presented worsening pleuritic chest pain dyspnoea . Bedside echocardiogram confirmed large pericardial effusion cardiac tamponade . Emergency bed " The protein expression programmed death-ligand 1 (PD-L1) recognised biomarker poor prognosis diffuse large B-cell lymphoma (DLBCL) Study aims to determine PD-L1 DNA status mRNA status, explore" " We performed array-based DNA methylation analyses 26 PCNSL 78 DLBCL . We identified 2847 CpGs differentially methylated PCNSL non-CNS-DLBCL . Remarkably, 6/" " A 76-year-old man 50 years smoking history diagnosed 2012 diffuse interstitial lung disease . He came emergency room presenting progression dyspnoea 1 week, concomitant loss 5 kg weight, anorexia poor general condition ." A 62-year-old Japanese man had radical cystectomy ileal conduit diversion 6 years ago . He was diagnosed with diffuse large B-cell lymphoma . " Certain aggressive non-Hodgkin lymphoma subtypes increasingly treated infusional DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, cycl" " Intravascular large B-cell lymphoma (IVLBCL) without central nervous system (CNS) involvement . Data 21 patients suspected IVLBCL (7 CNS involvement) underwent single (4 patients), double (1" " Primary mediastinal large B-cell lymphoma (PMBCL) recognized distinct entity World Health Organization classification . Currently, diagnosis relies consensus histopathology, clinical variables, presentation, giving rise diagnostic inaccuracy routine practice ." A 4-year-old boy presented fatigue found severe kidney injury requiring haemodialysis . Renal biopsy revealed extensive infiltration primary renal diffuse large B-cell lymphoma . Myeloid differentiation factor 88 (MYD88) signaling plays critical roles in B cells . MyD88 L265P mutation lymphomas are somatically acquired MyD88 L265P mutation lymphomas . The identification concurrent MYC B-cell CLL/lymphoma 2 (BCL2) deregulation opened new era investigation within common subtype aggressive B-cell lymphomas . Emerging biologic subsets new prognostic markers significantly adversely Autoantigens identified sterile α-motif domain containing protein 14 (SAMD14) neural tissue-specific F-actin binding protein I (neurabin-I) autoantigenic targets B-cell receptors ( Diffuse large B-cell lymphoma (DLBCL) main subtype non-Hodgkin lymphoma . 30% patients DLBCL develop resistance relapse after chemotherapy . Study identify potential therapeutic drugs using bioinformatics " 82-year-old man found dead road near home unwitnessed interval 3 h final witness . Diagnosed hypertension mild aortic stenosis (AS) 13 years death, continuously followed medication ." " Primary testicular lymphoma rare lymphoid malignancy, often, histologically, representing diffuse large B-cell lymphoma . The tumor microenvironment limited immune surveillance major impact diffuse large B-cell lymphoma pathogenesis survival, impact" " Primary vitreoretinal lymphoma (PVRL) diagnostic challenge commonly presents partially steroid-responsive vitritis subretinal cream-colored infiltrates . Repeat biopsy revealed diffuse large B-cell lymphoma, brain MRI demo ." 60% patients non-Hodgkin lymphoma (NHL) age >60 years presentation . The purpose study compare potential risks benefits of allogeneic hematopoietic cell transplantation (alloHCT) elderly Proteasome inhibitor bortezomib (BTZ) demonstrated suppress progression DLBCL . Underwent molecular mechanisms BTZ regulates growth of DLBCL cells remain largely unknown . Randomized trials maintenance therapy (MT) diffuse large B cell lymphoma (DLBCL) inconclusive regarding effect overall survival (OS) disease control . We aimed examine efficacy safety MT meta-analysis . " Using population-based cohort analysis older adults diagnosed diffuse large B cell lymphoma (DLBCL) years 2004-2011 . We evaluated association oncologist volume 4 clinical outcomes (receipt chemotherapy, receipt anthracycline" Notch1 signaling immunomodulatory effect T cells amplifying regulatory T (Treg) T helper 2 (Th2) cell responses interleukin-33 (IL-33)-dependent manner . " Two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel tisagenlecleucel tisagenlecleucel, approved United States Food Drug Administration treatment ." " Guidelines de-emphasized role routine surveillance CT scans help patients achieve complete response front-line therapy . Controversy remains, however, role routine surveillance CT highest risk patients treatment failure would remain candidates aggressive salvage therapies . Novel high-" Indolent lymphomas typically prolonged course favorable prognosis . Indolent lymphomas potential undergo transformation aggressive phenotype . " Radiotherapy proved effective consolidate responses induction, may safely avoided certain cases, especially metabolic complete ." Double/triple hit lymphoma recognised distinct entity within heterogeneous group high grade B-cell lymphomas . Diagnosing double hit lymphoma requires identification translocations MYC BCL2 and/or BCL6 . Combined-modality treatment involving immuno-chemotherapy without radiation become mainstay treatment for aggressive lymphomas diffuse large B-cell lymphoma (DLBCL) Long-term goals treatment DLBCL keep improving therapeutic ratio extend Diffuse large B cell lymphoma represents common type non-Hodgkin lymphoma . Around 40% patients relapse exhibit refractory disease . Intensive salvage regimen followed autologous steam cell transplant remains standard care . 60% " Diffuse large B-cell lymphoma (DLBCL) group lymphomas comprising heterogeneous molecular biological subtypes . With standard R-CHOP regimen cyclophosphamide, doxorubicin, vincristine" " The aggressive B-cell lymphomas diverse collection cancers grouped together based clinical behavior derivation B lymphocytes . Simple karyotyping revealed key translocations involving MYC, BCL2, BCL6 impacted lymphoma classification World Health" PD-L1 expression regulation B-cell lymphoma cells limited . Investigating mechanisms control PD-L1 expression B-cell lymphoma cells might identify biomarkers predict efficacy immunotherapy anti-programmed death-1/PD- Primary cutaneous lymphomas heterogeneous group includes 2 main groups primary T- B-cell lymphomas . The authors describe frequent clinical forms cutaneous lymphomas dermoscopic features . Introduction rituximab therapy led improved outcomes . DLBCL progresses aggressively . Posttransplant lymphoproliferative disorder (PTLD) heterogeneous group lymphoid malignant neoplasms arising solid organ transplantation hematopoietic stem cell transplantation . The current World Health Organization classification identified 4 MYC immunohistochemical stain workup large B-cell lymphomas become common hematopathology practice . Incorporation of MYC immunohistochemical stain workup large B-cell lymphomas become common hematopath Diffuse large B-cell lymphoma (DLBCL) one common causes non-Hodgkin's lymphoma (NHL) Some DLBCLs genetic mutations well protein overexpression . These aggressive respond well standard " Tumor necrosis factor receptor-associated factor 6 (TRAF6), (K63) E3-ligase, plays role many biological processes . We found TRAF6 amplifies pAKT signaling DLBCL" " Laparoscopic splenectomy (LS) becomes challenging, uncomfortable risky surgeon patient . Single-port technique hand-assisted devices developed improved field ." " Epstein-Barr virus positive, diffuse large B-cell lymphoma 2-year-old female went develop relapsed/refractory central nervous system (CNS) disease . Despite subsequent treatment third-party EBV-specific" " A 49-year-old woman, known case diffuse large B-cell lymphoma, presented complaints floater eyes since 3 days . Indirect ophthalmoscopy revealed presence vitreous clumps ." " A 37-year-old Hispanic man diagnosed diffuse large B-cell lymphoma (DLBCL) successfully treated surgery chemotherapy . During 4 years, several total-body positron emission tomography MRI scans showed extracardiac lymph" " 40 year old female presented three month history headaches background Myasthenia Gravis (MG) treated azathioprine . CT scan chest abdomen pelvis revealed lesion . Histologically neoplasm large B-cell lymphoma," Orbital lymphomas constitute 50-60% ocular adnexal lymphomas . Orbital lymphomas constitute 50-60% ocular adnexal lymphomas . Orbital lymphoma primarily disease elderly . MYC targeting bromodomain extraterminal protein family inhibitors (BETi) promising treatment strategy lymphoma . BETi MYC silencing upregulates several PI3K pathway genes induces GSK3β S9 " CXC chemokine ligand 9, member ""cytokine milieu"", makes microenvironment lymphoma plays important role occurrence development lymphoma . CXC chemokine ligand 9 underlying mechanism remains largely unknown progression" " Activating mutations adapter protein CARD11 associated diffuse large B cell lymphomas (DLBCLs) predicted arise germinal center (GC) responses . Following T cell-dependent immunization, aCARD11 cells exhibited increased rates" " The proteasome inhibitor bortezomib demonstrated marked preclinical activity combined with vorinostat leukemia, multiple myeloma, mantle cell lymphoma, mantle cell lymphoma (MCL) cells . The present study" " Extranodal lymphoma documented 1215 4907 non-Hodgkin lymphomas diagnosed period (25%) Median age 59 years (range, 1%), Median age 59 years (range, 1%) Study describe clinical epidemiological" The lactate transporter is a lactate transporter . The lactate transporter is a key component of the lactate transporter . " 58 patients were Swiss HIV Cohort Study, diagnosed 2004 2011, compared 326 immunocompetent (IC)-DLBCL patients . Median follow-up 6 years; 5-year overall survival (OS) 68% (95" " Intravascular large B-cell lymphoma (IVLBCL) rare, clinically aggressive lymphoma entity characterized almost exclusive growth large cells within lumen sized blood vessels . The reasons peculiar localization neoplastic cells partially understood . Clin" " EBNA2 EBNA3 locus extend adjacent gp350 gp350 gp42 genes, whose products mediate infection B cells EBV . EBNA3 locus extend adjacent gp350 gp42 genes, whose products mediate infection B" Primary central nervous system lymphoma (PCNSL) rare children immunocompromise important risk factor . 7-year-old girl with T-cell immunodeficiency presented left-sided weakness found right-sided frontal lobe 70-year-old man presented vomiting abdominal pain 2 weeks later diagnosed high-grade lymphoma adrenal glands . He started rituximab-bendamustine chemotherapy regimen . Patient tolerated treatment well without significant side effects " Long non-coding RNAs (lncRNAs) played pivotal roles biological pathways including cell cycle, apoptosis chromatin remodeling . Aberrant expression lncRNAs strongly connected tumor progression metastasis ." Canine diffuse large B-cell lymphoma (DLBCL) associated poor overall survival . Canine diffuse large B-cell lymphoma (DLBCL) associated poor overall survival . Pevonedistat (MLN49 Meta-analysis performed to clarify associations of non-Hodgkin's lymphoma (NHL) risk . The associations anthropometric factors remain inconclusive . " Emodin anthraquinone potent anti-cancer activities . However, molecular mechanism Emodin repressing aggressive NHL remains revealed detail ." " Lymphoma incidence survival adolescent young adult (AYA, defined 15-39 years age) adult patients were assessed using Surveillance, Epidemiology, End Results (SEER) data . From 2000 2014, 431 721 lymphoma" MRI-based 3D texture shape analysis performed evaluate detectable differences between GBM and PCNSL . The performance machine-learning models assessed . " Epstein-Barr virus (EBV) classified two strains, EBV-1 and EBV-2 . EBV-1 readily transforms B cells culture . EBV-1 readily transforms B cells culture . EBV-1" " Anti-CD19 CAR T-cell therapy effected impressive clinical responses B-cell acute lymphoblastic leukemia diffuse large B-cell lymphoma . However, patients respond, relapse antigen loss observed patient subsets ." " A better characterization T-cell subsets microenvironment classical Hodgkin lymphoma (cHL) would help develop immunotherapies . Using multicolor flow cytometry, identified 6 43 cHL tissue samples previously unrecognized subset CD" " Fifty-three cases reviewed Peking University People's Hospital 2002 2017 . In 53 cases, male female ratio 3.4:1, mean age 55.4 years old, median survival time 17.0 months ." " For patients aged 60 years older, treatment relapsed aggressive B-cell lymphomas remains challenging ." The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity preclinical synergy vincristine/rituximab B-cell non-Hodgkin lymphoma (B-NHL) The Lysosomal-associated membrane protein 1 (LAMP1) contributes tumor metastatic potential differentiation . LAMP1 expression greater DLBCL tissues reactive hyperplasia tissues . Autologous T cells genetically modified chimeric antigen receptor (CAR) redirected CD19 potent activity treatment B cell leukemia B cell non-Hodgkin's lymphoma (B-NHL) Immunotherapies treat multiple my " Primary mediastinal lymphomas frequently present residual mass completion first-line therapy . Although percutaneous biopsy may high diagnostic yield initial diagnosis mediastinal lymphomas, biopsy poor accuracy detecting persistent disease residual mass ." " Bromodomain extra-terminal domain inhibitors OTX015 (MK-8628, birabresib) demonstrated preclinical clinical activity hematologic tumors . MicroRNA profiling of diffuse large B-cell lymphoma cells treated" " Seven patients (Five men, two women; median age [range], 66 years [34-75 years] assessed retrospectively . Six cases diffuse large B-cell lymphoma, one case peripherally . Six cases diffuse large B-" " Several newly developed drugs including JQ1 (BET inhibitor), ABT199 (BCL2 inhibitor), bortezomib (proteasome inhibitor), bortezomib (proteasome inhibitor) may" " 59-year-old male with B-cell lymphoma presenting Pancoast syndrome . Symptoms include pain, brachial plexopathy, Horner's syndrome, result extrinsic compression tissues within thoracic inlet ." " We evaluated clinical implications albumin globulin ratio (AGR) patients diffuse large B-cell lymphoma (DLBCL) treated rituximab, cyclophosphamide, doxorubicin, vinc" " The associations of body fatness young age (childhood, adolescence young adulthood; age ≤ 30 years) diffuse large B-cell lymphoma (DLBCL), oesophageal adenocarcinoma, gastric" " PD first-line treatment relatively rare event. Contrast-enhanced CT neck, thorax, abdomen/pelvis routinely performed diagnosis response assessment DLBCL. PD first-line treatment relatively rare event." " Approximately one-fourth cutaneous lymphomas B-cell derived generally classified three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), primary cut" " Diffuse large B-cell lymphoma (DLBCL) particularly aggressive cancer, impacting lives approximately 20,000 people annually United States . Elucidating cellular interactions occur within microenvironment DLBCL tumors crucial successful development therapeutic strategies" " Patients diagnosis MYC-rearranged non-Burkitt aggressive B-cell lymphoma (MYC-R) with double hit lymphoma, high risk developing relapsed/refractory disease, even treated intensive front-" Novartis's CD19-targeting CAR T-cell product Kymriah™ was approved by FDA in April . Kymriah™ is the first U.S. Food Drug Administration approval cellular cancer therapy 2017 . Primary testicular lymphoma rare aggressive lymphoid malignancy . Often representing diffuse large B-cell lymphoma histologically . Tumor-associated macrophages tumor-infiltrating lymphocytes associated survival . " Epstein-Barr virus-negative, CD3-positive DLBCL 53 year-old male, remote history renal transplantation . After standard chemotherapy, patient clinical remission . After standard chemotherapy, patient clinical remission . He relapsed three" Jejunoileal follicular lymphomas (FLs) rare reported undergo histological transformation (HT) Jejunoileal follicular lymphomas (FLs) rare reported undergo histological transformation (HT) We report case " CD5 CD43 expression, CD5 CD43 expression, CD5/CD43 coexpression detected 18 (9%) DLBCL patients . CD5 expression, CD43 expression, CD5/CD43 coexpression detected 18 (" " The pretreatment albumin globulin ratio (AGR) used predict survival several types tumors . However, whether AGR predict outcomes patients diffuse large B-cell lymphoma (DLBCL) remains unclear . We evaluated prognosis value" " Secondary cold agglutinin syndrome (CAS) complicates diseases infections, autoimmune diseases cancers, mostly low-grade lymphomas . CAS treatment associated underlying diseases crucial successful outcome . CAS treatment associated underlying diseases crucial successful outcome ." " FDG-PET/CT current state-of-the-art imaging lymphoma plays central role treatment decisions . At diagnosis, accurate staging crucial appropriate appropriate therapy selection: FDG-PET/CT identify areas lymphoma missed CT alone" There unmet need effective biological therapies relapsed central nervous system (CNS) lymphoma . Lenalidomide active activated activated B-cell type diffuse large B-cell lymphoma rituximab effective CNS lymphoma . Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL) is a disease linked to chronic chronic EBV infection . The diagnosis made careful pathological evaluation . " Between January 2000 October 2016, 4362 patients newly diagnosed malignant lymphoma participating institutions YACHT. The median follow time 41 months. The median age diagnosis 68 years. The median age diagnosis 68 years. The median age diagnosis 68" " Coexpression MYC BCL-2 considered prognostic marker portending poor outcomes . However, prognostic effect BCL-2 BCL-6 expression DLBCL remains controversial ." Sepsis important cause mortality among older adults United States. Sepsis important cause mortality among older adults United States. Sepsis identified using inpatient Medicare claims. Sepsis identified using inpatient Medicare claims. Sepsis identified using inpatient Medicare " The Grupo Español de Linfomas Trasplantes de Médula Ósea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups: low (LR)," Hepatitis B virus (HBV) infection causes hepatocellular carcinoma (HCC) Associations cancers established . We systematically assessed associations HBV infection cancers US elderly population . Gene expression profiling (GEP) microarrays enabled categorization of large B-cell lymphoma (DLBCL) DLBCL activated B-cell-like germinal center B-cell-like subclasses . Recently " The biological role extracellular vesicles (EVs) diffuse large B-cell lymphoma (DLBCL) initiation progression remains largely unknown . We characterized EVs secreted 5 DLBCL cell lines, primary DLBCL" " Aberrant microRNA (miRNAs) recently proposed important regulators acquiring resistance cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) diffuse large B-cell lymphoma (" " Panobinostat, oral pan-HDAC inhibitor, combined rituximab patients relapsed diffuse large B cell lymphoma . Panobinostat administered orally 3 times week every week every week 28-day cycle ." CXCR4 pathway recently suggested adverse prognostic marker diffuse large B-cell lymphoma . Biopsy results show CXCL12 correlated high microvessel density bone marrow involvement diagnosis . Chinese patients diffuse large B-cell lymphoma (DLBCL) analyzed cell origin (COO) immune characteristics using NanoString platform well MYC protein expression immunohistochemistry . Lower incidence germinal center B-cell ( " Assessing response therapy lymphoma important determining patients' prognosis, guiding subsequent treatment, may used outcome measure prognostic therapeutic trials . Traditionally, computed tomography mainstay response assessment predominantly performed end treatment, whereas recent guidelines propose recent guidelines" " All Danish DLBCL-patients were diagnosed 2003 2012 identified using Danish National Lymphoma Registry (LYFO) Patients stratified age (75-79; 80-84 85 + years), comorbidity score t ." " Entospletinib (GS-9973) oral, selective inhibitor spleen tyrosine kinase. The study included 43 patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) Participants received" Combination regimens anti-CD20 agents might improve outcomes patients relapsed refractory B-cell malignancies . Available comparative clinical evidence limited . Diffuse large B-cell lymphoma (DLBCL) presents rapidly enlarging lymph nodes . Numbed chin syndrome (NCS) first symptom disease . Bone marrow biopsy revealed poorly differentiated tumour infarction extensive my Plasmablastic lymphoma (PBL) high-grade lymphoma often affects oral cavity HIV-positive patients . prognostic determinants remain unknown . " Chimeric antigen receptor T cells demonstrate efficacy B-cell malignancies, leading US Food Drug Administration approval axicabtagene ciloleucel (October 2017) tisagenlecleucel (May 2018)" " Anti-CD20 based chemoimmunotherapy usually effective disease control . Standard treatment anti-CD20 based chemoimmunotherapy usually effective disease control . High-risk patients high-risk features (double hit lymphoma, transformed" " Primary mediastinal (thymic) large B cell lymphoma subtype diffuse large B cell lymphoma subtype diffuse large B cell lymphoma . Increasingly, initial therapy patients used dose-dense chemotherapy without radiation excellent results" Obtaining biopsy specimens pathologic diagnosis primary cardiac tumors challenging anatomic location risk tumor embolization . High-grade B-cell lymphomas are high-grade B-cell lymphomas . The aims present study establish maximally tolerated dose (MTD) histone deacetylase inhibitor valproate together R-CHOP . The study was conducted in patients with diffuse large B-cell lymphoma (DLBCL " The adolescents young adult (AYA) population represent group wherein mature B-cell lymphomas constitute significant proportion overall malignancies occur . Among aggressive B-cell non-Hodgkin lymphomas (NHLs), predominantly diffuse" Massive splenomegaly indicated spleen weight exceeding 1000 g largest spleen dimension greater 20 cm . Massive splenomegaly indicated spleen weight exceeding 1000 g largest spleen dimension greater 20 cm . " Colorectal cancer (CRC) third commonly diagnosed cancer, whereas lymphoma sixth leading cause cancer death, 90% corresponds non-Hodgkin's lymphoma (NHL)" Pirarubicin (tetrahydropyryranyl adriamycin [THP] anthracyclin less cardiotoxicity doxorubicin (DOX) Pirarubicin ( " HDAC enzyme functions human diffuse large B-cell lymphoma (DLBCL) remain largely unknown . HDAC6 plays oncogenic role DLBCL, evidenced promotion cell proliferation . Mechanistically, interaction HDAC6 HR23" " B-cell diffuse large B-cell lymphoma (ABC-DLBCL) aggressive lymphoproliferative disorder involving chronic NF-κB activation . Several mutations BCR MyD88 signaling pathway components, MyD88 L" CD4 CD4 is CD4 . CD4 is a CD4 . CD4 . CD4 is a CD4 . CD4 . CD4 is a CD4 . CD4 . CD4 is a CD4 . CD4 " Lymphoproliferative disorders often observed HIV-positive patients . Combination antiretroviral treatment (cART) antineoplastic chemotherapy beneficial, little known clinical outcome according different antiretroviral combinations ." " Patients rheumatoid arthritis (RA) greater risk developing Hodgkin lymphoma (HL) non-HL non-HL general population . Non-Hodgkin lymphoma common HL patients, diffuse large B cell lymphoma frequent" Study conducted 110 patients 2004 2014 CD20-positive DLBCL involving head neck area . Palatine tonsils frequently involved extranodal site head neck (29.1%) Palatine tonsils frequently involved extran " Exome sequencing 37 cutaneous DLBCLs, including 31 DLBCLs, including 31 DLBCLs, leg type (DLBCL-LT) 6 cutaneous DLBCLs-not otherwise specified (DL" " EBV-positive diffuse large B-cell lymphoma (DLBCL) often affects gastrointestinal tract . However, prognostic significance EBV associated primary gastric DLBCL (gDLBCL) established ." Composite lymphoma (CL) rare disease defined occurrence two distinct lymphomas within single tissue time . We present case 89-year-old male clinical history immunoglobulin M monoclonal gammopathy undetermined significance . " Salvage chemotherapy followed autologous stem cell transplantation (ASCT) standard second-line treatment relapsed refractory (R/R) DLBCL . Half patients eligible transplantation due to ineffective salvage treatment, half relapse" The expression patterns microRNAs plasma involved potential biomarkers several diseases . The expression patterns microRNAs plasma involved potential biomarkers several diseases . The goal study explore expression level miR-155 diffuse large B-cell lymphoma (DL " Antibody-drug conjugates (ADCs) tripartite molecules consisting monoclonal antibody, covalent linker, cytotoxic payload . ADC development aimed target specificity inherent antigen-antibody interactions deliver" Diffuse large B-cell lymphoma (DLBCL) double expression c-MYC BCL2 protein associated dismal outcome treatment R-CHOP . We investigated prognostic values c-MYC/BCL2 protein co " 100 patients (50 group) randomly selected . Rituximab CHOP, R-CHOP, R-CHOP, R-CHOP, were compared ." Diffuse large B cell lymphoma (DLBCL) heterogeneous. We aimed explore tumor microenvironment promotes lymphoma cell aggressiveness . We created coculture system using human DLBCL cells . " Sarcoidosis well-described disease associated various malignancies; however, correlation still fully clarified . Sarcoidosis well-described disease associated various malignancies; however, correlation still fully clarified ." We recently reported experience C-X-C-C-motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) multiple myeloma acute leukemia . checkpoint inhibitors also represents promising approach certain types hematologic malignancies . Treatment checkpoint inhibitors also associated substantial toxicities high costs subset patients appears derive clinical benefit treatments . " B-cell non-Hodgkin's lymphomas common hematological malignancies, carry uniformly poor prognosis relapsed/refractory setting . CD19 antigen expressed surface malignancies arising B cells, adoptive transfer" Survival improved among patients with diffuse large B-cell lymphoma (DLBCL) addition anti-CD20 antibody therapy . We aimed quantify trends remaining loss expectation life (LEL) due DLBCL national population-based level . Diffuse large B cell lymphoma (DLBCL) patients early relapse refractory disease poor outcome . We used proteomic mass spectrometry analyse global protein expression micro-dissected formalin-fixed paraffin- The utility clinical practice recently developed validated predictive model venous thromboembolism (VTE) events lymphoma patients . The study evaluated association ThroLy VTE patients treated with chemotherapy . Circulating saturated (SFA) monounsaturated fatty acids (MUFA) may influence non-Hodgkin lymphoma (NHL) risk modulating inflammation lymphocyte membrane stability . We conducted prospective study 583 incident " The combination rituximab, gemcitabine, oxaliplatin (R-GemOx) shown high efficacy low toxicity profile elderly patients relapsed refractory diffuse large B-cell lymphoma ." " Systemic hematopoietic disorders may present liver biopsy . Rare cases primary hepatic lymphoma (PHL) may encountered . PHL, confined liver without extrahepatic involvement, present solitary multiple nodules ." We conducted phase II study assess activity safety profile bendamustine rituximab elderly patients untreated diffuse large B-cell lymphoma (DLBCL) prospectively defined frail using simplified version Comprehensive Geriatric Assessment (CGA " This phase II, single-arm, multicenter study examined efficacy safety coltuximab ravtansine (an anti-CD19 antibody drug conjugate) 61 patients histologically documented ( 61 patients histologically documented (" " Dose-adjusted-EPOCH-R obviates need radiotherapy patients primary mediastinal B-cell lymphoma . End-of-treatment PET accurately identifies patients risk treatment failure, thereby confounding clinical decision making ." Terminal tissue differentiation function slan . Terminal tissue differentiation function slan . Terminal tissue differentiation function slan . Terminal tissue differentiation function slan . Terminal tissue differentiation function slan . Terminal tissue differentiation function slan . Terminal tissue differentiation function sl Low circulating cholesterol concentration associated elevated cancer incidence mortality . Low circulating cholesterol concentration associated elevated cancer incidence mortality . Low circulating cholesterol concentration associated elevated cancer incidence mortality . " Non-Hodgkin lymphoma (NHL) heterogeneous group lymphoid malignancies high incidence adolescents young adults (AYAs) NHL present specific set challenges including variations tumor biology, inconsistent treatment, pharmacodynamics, psychos" Growing number loci within human leukocyte antigen (HLA) region implicated non-Hodgkin lymphoma (NHL) etiology . HLA diversity beneficial homozygous HLA loci associated increased disease risk . Richter syndrome represents evolution chronic lymphocytic leukemia aggressive tumor . Richter syndrome is a chronic lymphocytic leukemia aggressive tumor . Richter syndrome is a chronic lymphocytic leukemia aggressive tumor . " PTEN cytoplasmic nuclear expression, PTEN gene deletion, PTEN gene deletion, PTEN mutations evaluated two independent cohorts of diffuse large B-cell lymphoma (DLBCL) Cytoplasmic PTEN" We aimed assess interobserver agreement interim PET (I-PET) end-of-treatment PET (EoT-PET) using Deauville score (DS) first-line diffuse large B-cell lymphoma (DL " CD20-negative diffuse large B-cell lymphoma (DLBCL) uncommon neoplasm, rare unclassifiable cases meet criteria well-established subtypes CD20-negative DLBCLs reported . CD20-negative" " Lymphomas MYC either BLC2 BLC2 BCL6 rearrangements MYC BCL-2 protein overexpression, classified double-hit (DHL) double-hit (DHL) double-express" One-third of B-cell lymphoma patients experience relapse/refractory disease first-line anthracycline-based immunochemotherapy . Optimal management remains unmet medical need . " Cutaneous B-cell lymphomas (CBCLs) heterogeneous group diseases variable presentations, prognoses, treatments . The proper identification CBCL hinges proper histopathologic clinical evaluation ." Peripheral neuropathy occurs approximately 5% patients lymphoma . Two major causes peripheral neuropathy associated lymphoma neurolymphomatosis paraneoplastic neuropathy paraneoplastic neuropathy paraneoplastic neuropathy dem 55-year-old male complained frequent back pain accompanied increasing weakness lower extremities admitted hospital's Neurosurgery Department . Magnetic resonance imaging revealed approximately 55-9mm lymphoma pressuring spinal cord anterior . " Randomised blind controlled clinical multicentric trial included biopsy-proven DLBCL patients . Seventy-two patients five different hospitals region Madrid, Spain, enrolled study January 2012 June 2015 . Thirty-six randomly allocated 18FDG PET" " Phase 1 dose-escalation/expansion study assessed safety, efficacy, pharmacokinetics, pharmacokinetics, pharmacodynamics . Itacitinib (formerly INCB039110), selective JAK1 inhibitor, selective PI" Richter syndrome (RS) development aggressive lymphoma patients chronic lymphocytic leukemia (CLL) Two pathologic variants RS recognized: namely . diffuse large B-cell lymphoma (DLBCL) variant rare Hodgkin lymphoma " In aggressive lymphomas, discrepancies survival reported experimental observational studies may reflect selective non-enrolment high-risk patients trials . We examined association time diagnosis chemotherapy overall survival . Across histologies, patients started chemotherapy within 7 days diagnosis often high" " Epstein-Barr virus causes various diseases elderly, including B-cell lymphoma Hodgkin's lymphoma diffuse large B-cell lymphoma . Here, show EBV acts trans noninfected macrophages tumor exosome secretion" " 57 patients central nervous system lymphoma thiotepa, busulfan, cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) 79 patients systemic non-Hodgkin lymph" Perinephric urinomas commonly arise following traumatic injury high-grade obstruction kidney stones lower urinary tract disorders . Perinephric urinomas commonly arise following traumatic injury high-grade obstruction kidney stones . " Vitreoretinal lymphoma is commonly diffuse large B-cell non-Hodgkin type, rare cancer high morbidity high mortality . Making tissue diagnosis vitreoretinal lymphoma major challenge clinicians due biological technical factors ." Recent studies shown dysregulation immune system may precede development B-cell lymphomas (BCL) immunocompetent individuals . " CD30+ diffuse large B-cell lymphoma (DLBCL) emerged new immunophenotypic variant A total 241 patients using >0% threshold, CD30 expression detected approximately 10% patient CD30+ DLBCL may" " Diffuse large B-cell lymphoma (DLBCL) remains significant clinical challenge, ∼30% patients cured . Over past decade, remarkable progress made understanding pathogenesis disease, spurred implementation powerful genomic technologies enabled definition genetic epigenetic landscape" " A 17-year-old male adolescent diagnosed diffuse large B cell lymphoma arising right humeral head . The lymphoma found isolated bone, small extraosseous component . After completion standard chemotherapy regimen, Positron Emission Tom" " Combination antiretroviral therapy (cART) drastically improved performance status, immune function, life expectancy HIV-infected individuals . In addition, incidence opportunistic infections AIDS-defining malignancies declined . Nevertheless, aggressive" " Of 3244 cases, mature B-cell neoplasms occupied 60.7% of cases, mature T/NK-cell neoplasms occupied 26.2% 8.1% . Hodgkin's lymphomas occupied 26." " Radiotherapy (RT) one modality salvage therapy, place currently well defined . Fifty-one patients were selected ." " 252 patients aged 80-100 years, diagnosed DLBCL grade 3B follicular lymphoma, treated 19 hospitals GELTAMO group . One hundred sixty-three patients (63%) treated chemotherapy included anthracyclines" Chemo- radiotherapy treatments helpful cure cancers also well known adverse effects secondary cancers . Breast cancers following Hodgkin lymphoma relatively well studied . Primary central nervous system lymphoma (PCNSL) uncommon extranodal manifestation non-Hodgkin's lymphoma presenting cerebellopontine angle (CPA) rare presentations limited reported cases literature . We report 60 " Non-Hodgkin Lymphoma (NHL) common hematologic malignancy . 199,000 people worldwide die NHL every year . US food drug administration (FDA) recently approved axicabtagene c" We assessed prognostic significance D-dimer patients diffuse large B cell lymphoma (DLBCL) We performed retrospective study including 254 patients newly diagnosed DLBCL . X-tile used generate cutoff value D-dimer . " Diffuse large B cell lymphomas (DLBCLs) heterogeneous tumors, originate highly proliferative germinal center B cells . These tumors, associated neo-vessels, lymphatics presumably expose cells particular fluid flow survival signals" Lymphomatoid granulomatosis (LYG) rare lymphoproliferative disorder characterized infiltration Epstein-Barr virus (EBV)-positive large atypical B-cells angiocentric fashion mixed inflammatory Neurolymphomatosis rare manifestation hematological malignancy characterized direct infiltration peripheral nervous system . The median survival time diagnosis 7 . Primary breast diffuse large B-cell lymphoma (PB-DLBCL) uncommon extranodal non-Hodgkin's lymphoma (NHL) uncommon extranodal non-Hodgkin's lymph The aim study identify differences proteome profiles diffuse large B-cell lymphoma (DLBCL) nongerminal center (non-GC) versus GC type search new markers drug targets . " PI3K inhibitors evaluated relapsed refractory Diffuse large B-cell lymphoma (DLBCL) patients . Rituximab shown influence B-cell receptor (BCR) signaling, investigated interaction anti-CD" The sphingosine-1-phosphate receptor S1PR2 downstream signaling pathway commonly silenced diffuse large B-cell lymphoma (DLBCL) The sphingosine-1-phosphate receptor S1 Statins shown induce phosphoprotein signature modifies MYC (myelocytomatosis viral oncogene) activation anti-inflammatory activity may impact risk Non-Hodgkin's lymphoma (NHL) We analyzed " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease variable outcomes . Despite majority patients cured combination chemoimmunotherapy, 30% eventually succumb disease ." " A retrospective study conducted investigate efficacy safety 2 frontline regimens, BR RD-R-CHOP, patients aged ≥75 years unfit R-CHOP . 26 patients received BR 34 RD-R-CHOP. No significant difference found" " World Health Organisation (WHO) classification applied human well veterinary medicine . We validated concordance classification systems veterinary human pathologist evaluate gastrointestinal lymphoma tissue 61 cats . In 59% cases, match respective diagnoses lymphoma subtype ." Gastrointestinal diffuse large B cell lymphoma (GI DLBCL) common gastrointestinal lymphoma . PD-1 protein expression tumor-infiltrating lymphocytes (TILs) evaluated immunohistochemical staining . PD " MALT-L nonneoplastic lymphocytes using thyroid liquid-based cytology (LBC) We observed LBC conventional specimens 35 MALT-L cases, 3 diffuse large B-cell cell lymphoma (DLBCL" Combination rituximab polychemotherapy improved prognosis . The primary endpoint 6-month overall response rate was 6-month overall response rate . The primary endpoint was 6-month overall response rate . " Adult T-cell leukemia-lymphoma (ATL-refractory T-cell malignancy) caused infection human T-cell leukemia virus type I (HTLV-I) Pathogenesis of ATL remains unclear, but" " Previous studies examined risks leukaemia selected lymphoid malignancies workers exposed extremely low frequency magnetic fields (ELF-MF) Most studies evaluated hematolymphopoietic malignancies combined category, analyses suggested effects may contained" " 5-aminolevulinic acid (5-ALA) proven extremely useful, reports use 5-ALA recently increased . We describe diagnosis 20 intracranial brain lesion cases 5-ALA-guided fluorescence" Patients with aggressive B-cell non-Hodgkin lymphoma (NHL) remain FDG-PET positive R-CHOP chemotherapy . Patients with advanced lymphoma grade 3 follicular lymphoma retrospectively reviewed Prince Wales Hospital This study aimed assess whether T-lymphokine-activated killer cell-originated protein kinase (TOPK) potent novel biomarker predict outcome patients primary central nervous system lymphoma (PCNSL) This study enrolled 20 Resistance targeted therapies become increasingly prevalent . Resistance to targeted therapies is a common mechanism . EZH2 inhibitors are resistant to diffuse large B-cell lymphoma (DLBCL) cells . " The Surveillance, Epidemiology End Results 18 database, inclusive national cancer statistics 1973 2013, provided quantitative tonsil cancer incidence data . An institutional retrospective chart review pediatric patients diagnosed tonsil malignancy January 2013 January 2017 identified supplementary qualitative clinical presentation" " During treatment diffuse large B-cell lymphoma (DLBCL) patients, treatment-related toxicities higher initial phase treatment (First cycle effect) Toxicities tumor lysis syndrome, deterioration performance status, febrile neutrop" " Inhibition Bruton's tyrosine kinase (BTK), BCR downstream target, therapeutically effective subgroup patients DLBCL . In lymphomas resistant BTK inhibition, show blocking BTK activity enhanced tumor dependencies alternative" " A linear progression model of follicular lymphomas (FL) FL1, FL2 FL3A favored, since FL3A often co-exist FL1/2 component . FL3B, contrast, thought closely related diffuse large" " Rituximab plus CHOP chemo cycles leads to hospital stay suspending next chemotherapy cycles . Eventually, leads prolonging hospital stay suspending next chemotherapy cycles ." International Prognostic Index (IPI) scoring system widely used prognostic tool diffuse large B-cell lymphoma (DLBCL) fails consistently identify patients poor outcomes . This retrospective study undertaken confirm clinical value new prognostic score compare " voxtalisib (also known XL765 SAR245409), pan-PI3K/mTOR inhibitor, is a pan-PI3K/mTOR inhibitor . Patients relapsed refractory lymphoma chronic lymphocytic" Diffuse large B-cell lymphoma (DLBCL) heterogeneous diagnostic category different molecular subtypes defined distinct gene expression patterns . Different molecular subtypes defined distinct gene expression patterns divergent mechanisms oncogenic activation . " CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass enlarged prostate . Prostate-specific antigen (PSA) alarmingly high 4750 μg/L (normal <4.0 μg" " Hepatitis B virus (HBV) infection endemic parts Asia, Africa, South America remains significant public health problem areas . Hepatitis B virus (HBV) infection is known leading risk factor development hepatocellular carcinoma" " Previous studies focused relationship between hepatitis B virus (HBV) infection non-Hodgkin lymphoma (NHL) However, results remain inconsistent somehow conflicting different subgroups . Aim study combine findings independent studies comprehensively assess association HB" Death-associated protein kinase (DAPK) serine/threonine kinase tumour suppressor gene . Diffuse large B-cell lymphomas inactivated DAPK hypermethylation CpG island known result " Statins increasingly prescribed prevent cardiovascular diseases . Early evidence shows preventive effect statins cancers, effect NHL risk unclear ." " Primary (localized) non-Hodgkin lymphoma (NHL) ovary extremely rare; cases reported literature . Report describes detailed clinical, histopathological, imaging findings, along review literature ." " Available prognosis scores patients diffuse large B-cell lymphoma (DLBCL) included limited number patients . Here, propose prognostic score overall survival (OS) group patients . Response rate whole group 77% ." " OPB-111077 novel inhibitor STAT3 mitochondrial oxidative phosphorylation exhibited promising anticancer activity preclinical models . Adverse events, frequently nausea, fatigue, vomiting, generally mild moderate intensity could medically managed ." " Diffuse large B cell lymphoma (DLBCL) malignancy B cells extranodal primary involvement estimated 30% 40% cases . DLBCL extremely rare, estimated incidence 0.5% extranodal lymph" Primary mediastinal B-cell lymphoma (PMBL) distinct B-cell lymphoma subtype unique clinicopathological molecular features . PMBL cells characterised several genetic abnormalities conduct constitutive activation Janus kinase 2/sign High-dose chemotherapy autologous stem cell transplantation (ASCT) current standard care relapsed non-Hodgkin lymphoma (NHL) Hodgkin lymphoma (HL) Hodgkin lymphoma (HL) Condition Double-hit lymphomas are high-grade diffuse large B-cell lymphomas with concurrent translocations involving myc bcl-2 and/or bcl-6 . A patient DHL often advanced disease presentation typically responds poorly standard CAR T cell therapies are approved by FDA . CAR T cell therapies include Kymriah Yescarta and Kymriah Yescarta . CAR T cell therapies are available in the US for CD19-expressing B cell ibrutinib resistance due to BTK has been shown to be resistant to ibrutinib resistance . Acquired ibrutinib resistance due to BTK . Richter syndrome might clonally related unrelated unrelated unrelated unrelated unrelated underlying CLL often showed mutations TP53 NOTCH1 genes . Richter transformation IBR treatment largely unknown . " Primary hepatic lymphoma (PHL) defined lympho-proliferative disorder limited liver without involvement spleen, lymph nodes, bone marrow blood . Diffuse large B-cell lymphoma (DLBCL) common hist" This Correspondence relates article Bobee et al . Using Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study . The sequential occurrence of 2 malignancies development nasopharyngeal carcinoma (NPC) lymphoma (NPC) lymphoma extremely rare coexistence raises question common etiologic factor . A 71-year-old previously The purpose study determine prognostic significance F-18 fluorodeoxyglucose (FDG) uptake dual-phase positron emission tomography/computed tomography (PET/CT) The purpose study determined prognostic significance F " Down regulation CD20 expression reported diffuse large B cell lymphoma (DLBCL) Therefore, important determine whether chemotherapy rituximab induces CD20 regulation effects survival ." " The anaplastic variant diffuse large B-cell lymphoma (A-DLBCL) morphologically defined remains enigmatic disease clinicopathologic distinctiveness . Case 1 immunohistochemically positive CD20, CD79a OCT-" Secondary CNS involvement (SCNS) profoundly adverse complication diffuse large B-cell lymphoma . SCNS occurred part first relapse 254 (87%) patients 254 (87%) patients 113 (39%) conc . The neutrophil:lymphocyte ratio (NLR) emerged prognostic patients hematological malignancies . 121 Peruvian patients treated for diffuse large B-cell lymphoma (DLCBL) treated rituxim Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV) is a form of Epstein-Barr virus . Epstein-Barr virus positive diffuse large B-cell lymphomas (EBV High-grade B-cell lymphoma is high-grade B-cell lymphoma . Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) elderly rare subtype B-cell neoplasms . Here report case 59-year-old man upper gastrointestinal bleeding . " CNS relapse reported 2-5% of diffuse large B-cell lymphoma (DLBCL) patients . Very studies address incidence risk factors CNS relapse elderly patients, challenging population treat given commonly associated comorbidities ." " Diffuse large B-cell lymphoma (DLBCL) prevalent disease subtype non-Hodgkin lymphoma, highly heterogeneous terms cytogenetic molecular features . Of 181 patients diagnosed DLBCL treated R-CH" " Carmustine shortage led increase use of alternative conditioning regimens prior autologous stem cell transplantation treatment lymphoma, including Bendamustine-based (BeEAM) The aim study evaluate safety BeEAM regimen large cohort" We examined associations autoimmunity B-cell NHL onset comparing AID history (determined self-report medication review supplemented chart review possible) among 435 adult B-NHL patients Hadassah-Hebrew University Medical Center patients " Gene mutations underlying molecular pathogenesis disease incompletely characterized . Here, describe novel somatic somatic somatic treatments ." Epstein-Barr virus (EBV) reactivation immunosuppressive therapy fludarabine targeted agents remains controversial . Among 31 RT cases classified diffuse large B-cell lymphoma (DLBCL) seven (23%) " Meta-analyzing of data from eligible cohort studies sought by August 31, 2016 . Separate analyses performed subtype hematological malignancy (non-Hodgkin lymphoma [NHL] subtypes, Hodgkin" We assessed efficacy radiation therapy (RT) management secondary central nervous system (CNS) lymphoma . The cohort comprised 44 patients who were diagnosed with systemic diffuse large B-cell lymphoma (DLBCL) secondarily involving brain and Follicular lymphoma aggressive behaving subtype - prototypically diffuse large B-cell lymphoma - confers substantially adverse prognosis . Follicular lymphoma aggressive behaving subtype - prototypically diffuse large B-cell lymphoma - Much focus is interaction programmed cell death ligand 1 (PD-L1) malignant B cells programmed cell death 1 (PD-1) effector T cells inhibiting antilymphoma immunity . We sought establish contribution natural killer " Chemotherapy given 3260/11,150 (29.2%) hospitalizations . Younger age, urban teaching hospitals, fewer chronic conditions, male sex, non-Medicare insurance, ""less likel""" " Carabin, key suppressor B-cell receptor signaling proliferation, inactivated B-cell lymphoma unknown mechanisms . P4HA2 undetectable in B-cell lymphoma ." Growing evidence links aggressiveness non-Hodgkin's lymphoma to aggressive non-Hodgkin's lymphoma . Toll-like receptor 9/MyD88 STAT3 transcription factor signaling . " Capture sequencing emerged alternative approach high testing accuracy . We compared capture hybridization amplicon sequencing approaches using fresh-frozen formalin-fixed, paraffin-embedded tumor samples . Next-generation sequencing panels increasingly used assess value gene" " Diffuse large B-cell lymphoma (DLBCL) aggressive disease, common type lymphoma adults . Effective clinical biomarkers DLBCL urgently needed ." " Vorinostat (VOR), histone deacetylase inhibitor, enhances anti-tumor effects . VOR (300 400 mg) given orally days 1 5 cycle R-EPOCH 10 high-risk high" " Approximately 30% 40% patients diffuse large B-cell lymphoma (DLBCL) either primary refractory disease relapse chemotherapy or primary refractory disease relapse chemotherapy . In transplant-eligible patients, disease sensitive salvage chemotherapy significantly benefit" A 62-year-old Korean female diagnosed diffuse large B cell lymphoma involving multiple organs . Her ABO/RhD type A+ genotype ABO*A.01/ABO*O.01/ABO* " We developed series orally efficacious IRAK4 inhibitors, based scaffold hopping strategy using rational structure based design . Efforts tackle low permeability high efflux previously reported pyrrolopyrimidine series (Scott et al., 2017)" 77-year-old patient isolated large B-cell bone lymphoma proximal phalanx little finger without rheumatoid arthritis methotrexate treatment . The patient treated digital amputation 6 months' follow-up showed relapse " HDACI modify acetylation status extensive proteome, acting general lysine deacetylase inhibitors (KDACI) thus potentially impacting various branches cellular metabolism . Despite proven clinical antineoplastic activity histone de" Antiviral therapy successfully decreased rate liver cirrhosis improved outcome patients hepatitis C-associated lymphomas . Mechanism behind association remains unclear . Diffuse large B-cell lymphoma maxillary sinus is non-specific signs . Symptoms may confused benign inflammatory conditions upper respiratory infections . Two radiologists retrospectively reviewed 72 PET/CT scans patients DLBCL referred institutions . They recorded discrepancies outside second-opinion reports regarding multiple preset criteria using kappa statistic (Κ) " The synchronous occurrence lung cancer patients gastric neoplasms relatively uncommon, especially cases synchronous coexistence small cell lung carcinoma diffuse large B-cell lymphoma stomach ." CAR-T cell therapies use autologous T cells . CAR-expressing T cells recognize specific tumor targets . Tisagenlecleucel (formerly CTL019) anti-CD19 CAR-T cell therapy recently approved High-grade B cell lymphomas concurrent activation . High-grade B cell lymphomas concurrent activation . High-grade B cell lymphomas concurrent activation . 28-year-old pregnant woman presented complaints altered bowel habit month . Diagnosed with high-grade B-cell lymphoma . After discussion multidisciplinary panel planned receive antenatal chemotherapy . " In postrituximab era, approximately half patients relapsed refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail achieve chemosensitive response standard salvage therapy . The Bruton ty" " Adoptive therapy ex vivo-expanded genetically modified antigen-specific T cells induce remissions patients relapsed/refractory cancer . The clinical success therapy depends upon efficient transduction expansion T cells ex vivo homing, persistence cyt" " Primary central nervous system lymphoma (PCNSL) rare malignancy usually arises context severe immunosuppression incompletely understood etiology, limiting effective treatments . 81-year-old immunocompetent man developed PCNS" " Primary pulmonary diffuse large B-cell lymphoma (PPL-DLBCL) rare clinical manifestations lack specificity . In report, present one case PPL-DLBCL complete clinical imaging data ." " PD-L1 immunohistochemistry useful predictor immunotherapy response, still used widely diagnostic setting ." 84-year-old woman presented severe postural hypotension . Skin biopsy revealed intravascular high grade B cell lymphoma . This successfully treated curative chemotherapy . " We aimed investigating relationship between classical Hodgkin lymphoma (cHL) and gray zone lymphoma (GZL) intermediate characteristics cHL PMBL, perspective aberration programed cell death 1 programed death ligands (PDL" " The diffuse large B-cell lymphoma (DLBCL) two major molecular subtypes, germinal center B-cell-like (GCB) non-GCB . These differing behavior affects overall patient survival ." " T-cell large granular lymphocytic (T-LGL) leukemia associated B-cell lymphomas (BCL) We aimed explore expand upon association BCLs. Among 432 patients T-LGL leukemia, 22 (" " The etiology of hypercalcemia non-Hodgkin lymphoma is often attributed to elevated serum levels . In single-center retrospective review, evaluated incidence of, outcomes associated with, hypercalcemia NHL ." Rubinstein-Taybi syndrome (RSTS) multiple congenital anomalies syndrome associated mutations CREBBP (70%) EP300 (5-10%) EP300 (5-10%) Previous reports suggested increased incidence of benign possibly 52-year-old man suffered progressive multifocal leukoencephalopathy (PML) human leukocyte antigen (HLA)-haploidentical transplantation post-transplantation cyclophosphamide (PTC Waldenström macroglobulinemia (WM) is diffuse large B-cell lymphoma . Majority patients harbor constitutively active mutation in innate immune-signaling adaptor myeloid differentiation primary response 88 " PD-1 antibody, PD-1 antibody, effective treatment lymphoma, including diffuse large B-cell lymphoma (DLBCL) Combination checkpoint blockades emerged new way treat lymphoma . Status checkpoint expression function DLBCL" " The role consolidative radiotherapy (RT) advanced diffuse large B-cell lymphoma (DLBCL) established . In population-based retrospective analysis patients DLBCL Western Norway 2003 2008, 170 consecutive patients admitted Haukeland University" " Treatment outcomes diffuse large B-cell lymphoma (DLBCL) following standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)" " Epstein-Barr virus (EBV) efficiently transforms primary human B cells immortalized lymphoblastoid cell lines (LCLs) LCLs provide unlimited sources DNA genetic investigation, difficult manipulate, instance low retroviral lent" Over half patients diffuse large B-cell lymphoma (DLBCL) cured standard R-CHOP treatment . Remaining patients refractory ultimately succumb progressive relapsed disease . " Chinese patients with diffuse large B-cell lymphoma (DLBCL) propose effective method comprehensive geriatric assessment (CGA) Patients were diagnosed de novo DLBCL Institute Hematology, Beijing Hospital, screened eligibility ." " Of series 15 Japanese patients (11 women, four men; median age 74 years, range 35-84 years) seven received MTX treatment autoimmune disease . Of series 15 Japanese patients (11 women, four men; median age 74 years" A 52-year-old man admitted hospital due general fatigue . Diagnosed with cervical inguinal lymph node swelling . Chromosomal analysis revealed complex karyotype including rare three-way translocation t(8;14;18 A 58-year-old woman intraocular relapse diffuse large B cell lymphoma . Weekly intravitreal rituximab (1 mg/0.1 ml) 4 weeks administered . 12 months last intravitreal " 80 year-old man with history of diffuse large B-cell malignant lymphoma presented hematuria back pain . Serial urine cytologies revealed urothelial malignant cells, cystoscopy showed large intravesical mass" Primary testicular lymphomas (PTL) prevalent type testicular cancer arising men age 60 . PTL accounts approximately 1-2% non-Hodgkin lymphomas present localized disease . Majority cases represent extranodal manifestation " Myc protein linked immune dysfunction, cancer development neoplastic transformation . Myc overexpression repeatedly linked immune disorders specific cancers . Myasthenia gravis, psoriasis, pemphigus vulgaris, atheros" Mantle cell lymphoma (MCL) relatively rare subtype B-cell non-Hodgkin lymphoma (NHL) poor prognosis despite recent advances immunochemotherapy molecular targeted therapeutics NHL . New therapeutic strategy M " High-dose chemotherapy autologous stem cell transplantation (ASCT) offer durable remission many patients relapsed high-risk lymphoma . However, elderly patients often considered ASCT candidates based age alone . A retrospective analysis patients with age" Auto-HCT patients relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) proven survival benefit . We studied survival differences among patients RR DLBCL post auto-HCT whose recur " Diffuse large B-cell lymphoma (DLBCL) common form non-Hodgkin's lymphoma . R-CHOP currently standard therapy DLBCL, prognosis refractory recurrent patients remains poor . In" Severe immune dysregulation seen autoimmune (AI) disease known act significant risk factor diffuse large B-cell lymphoma (DLBCL) Little known demographics clinical outcomes DLBCL arises setting setting AI disease . Vitamin D deficiency reported negative prognostic factor elderly patients aggressive B-cell lymphomas . In vitro data suggest vitamin D supplementation may enhance rituximab-mediated cytotoxicity . 42 cases of dogs treated either COP-type (35%) CHOP-type (64%) induction chemotherapy . The objective response rate induction therapy was 94% . The objective response rate was 94% . Loss major histocompatibility Class II expression (MHCII) decreased survival . MHCII transcription part regulated histone acetylation . We tested hypothesis combination histone deacetylase inhibitor (HDACI) standard chemotherapy " Recent genetic analysis showed MyD88 L265P mutation, related NF-κB signaling, genetic hallmark PCNSL . Role MyD88 mutation PCNSL defined." Metabolic heterogeneity neoplastic cells surrounding stroma described several epithelial malignancies . Metabolic phenotypes neoplastic lymphocytes neighboring stroma diffuse large B-cell lymphoma (DLBCL) unknown . " Diffuse large B-cell lymphoma (DLBCL) seriously threatens patients life morbidity increases high rate . Immune response disorder potential factor induces DLBCL, potential mechanism still fully understand ." NK cell activation one strategy improve immunotherapy non-Hodgkin's lymphoma . NKp44 patients diffuse large B-cell lymphoma (DLBCL) were patients with NKp44 patients . 30 new cases DLBC " The phase II JULIET trial suggests CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses patients relapsed refractory diffuse large B-cell lymphoma . After 6 months, rates" " When evaluating, evaluate your children's behavior, consider the role of a parent ." International Prognostic Index (IPI) variations (R-IPI NCCN-IPI) Cox proportional hazards (CPH) model used . Cox proportional hazards (CPH) model using . covariates nondichotom " 69-year-old man thoracic pseudoaneurysm caused diffuse large B-cell lymphoma . He large mass inside aortic arch inside aortic arch . Five weeks later, asymptomatic aneur" Central nervous system (CNS) relapse continues represent clinical challenge . Despite improvement survival survival of diffuse large B-cell lymphoma (DLBCL) introduction rituximab . " Primary mediastinal B-cell lymphoma (PMBCL) recognized distinct clinicopathologic entity predominantly affects adolescents young adults common female subjects . PMBCL considered subtype diffuse large B-cell lymphoma, considered subtype diffuse" " R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) remains ""gold standard"" in 2017 ." " Diffuse large B-cell lymphoma aggressive non-Hodgkin lymphoma subtype requires immediate treatment . Standard treatment usually combined immune chemotherapy rituximab, cyclophosphamide, doxorubicin," Previous epidemiological studies shown autoimmune diseases increase risk lymphoma development . But whether autoimmune diseases deteriorate outcomes lymphoma patients remains unclear . This study aimed identify clinical features lymphoma patients pre-existing autoimmune diseases . " The effective deployment of therapies diffuse large B cell lymphoma (DLBCL) requires rapid assimilation new biological data . We discuss targeting B cell receptor (BCR) signaling, emphasis identifying patients may benefit from maneuver maneuver best ." " 45 patients FLG3 treated first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) observed extended time interval . Overall response" Allogeneic stem cell transplantation (alloSCT) could overcome chemoresistance associated DEL/DHL . We hypothesized alloSCT could overcome chemoresistance associated DEL/DHL . " PET emerged critical accurate staging restaging lymphomas . Risk-adapted strategies appear improve outcome patients Hodgkin lymphoma, results less convincing non-Hodgkin lymphoma . Assessment metabolic tumor volume treatment may permit novel induction strategies ." Disease stage influences treatment decisions significantly . Disease stage influences treatment decisions significantly . FDG-PET/CT established first-line diagnostic imaging tool used staging lymphomas post-therapy response assessment Hodgkin lymphoma (HL) diffuse large B-cell lymphoma (DLBCL) Many subtypes lymphoid FDG-PET staging restaging lymphoma has been used in many studies . FDG-PET staging restaging patients lymphoma has been used in many studies . FDG-PET/CT performed interim time point therapy (iPET) performed interim time point therapy (iPET) Author reviewed rationale FDG-PET/CT performed interim time point therapy (iPET) " Richter Syndrome, aggressive lymphoma occurring patients chronic lymphocytic leukaemia (CLL) generally poor prognosis . anthracycline-based chemoimmunotherapy regimens designed treat de novo diffuse large B" " Primary urinary tract lymphoma (PUTL) uncommon disease case reports literature . PUTL incidence 1 case/1,000,000 people per year ." " Stage I splenic diffuse large B-cell lymphoma (DLBCL) rare data guide management . We utilized Surveillance, Epidemiology, End Results registry identify patients stage I splenic DLBCL diagnosed 1973-2013 . Patients divided" MYD88 mutations present 95% Waldenstrom Macroglobulinaemia patients . MyD88 mutations present 95% Waldenstrom Macroglobulinaemia patients . Diffuse large B cell lymphoma (DLBCL) common B cell malignancy . 30% patients present relapsed refractory disease first-line therapy . Cytotoxic CD4 is a form of chemotherapy that is " Allogeneic hematopoietic cell transplantation potentially curative option, true particularly case autologous stem cell transplantation remission achieved . Despite great improvements outcome patients lymphoma, may still relapse present primary refractory disease" " MONITOR-GCSF pan-European, multicenter, prospective, observational study aiming describe treatment patterns clinical outcomes . Patients receiving biosimilar filgrastim prophylaxis chemotherapy-induced neutropenia (CIN" Epstein-Barr virus positive remains uncertain impact congenital iatrogenic immunosuppression . Epstein-Barr virus-associated ribonucleic acid testing performed . Diffuse large B cell lymphoma (DLBCL) common type non-Hodgkin lymphoma worldwide . Common type DLBCL represents 80-85% cases focus review . Rare types lymphoma composed large B-cells A 44-year-old man presented us abrupt right lower lower leg pain . A computed tomography angiogram revealed segmental obstruction right common femoral artery . The embolectomy specimen contained several clusters degenerated round/oval The objective study identify prognostic factors dogs receiving CHOP-based chemotherapy primary nodal diffuse large B-cell lymphoma (DLBCL) The objective study identified prognostic factors dogs receiving CHOP-based chemotherapy primary nodal diffuse High parental age childbirth has been linked to childhood malignancies . Study found 5-year increment maternal age associated 3% increase incidence of offspring lymphoid neoplasms . Dysregulation DNA (cytosine-5)-methyltransferase 1 (DNMT1) associated pathogenesis various types cancer . It previously shown DNMT1 frequently expressed diffuse large B-cell lymphoma (DLBCL) " IMMU-140 anti-HLA-DR antibody-drug conjugate composed active metabolite irinotecan, SN-38, conjugated humanized anti-HLA-DR IgG . HLA-" " MicroRNA-224 (miR-224) frequently investigated discovered discovered vital significance prognosis patients various cancers . However, accurate prognostic value estimated worldwide. Herein, performed meta-analysis assess potential predictive value variety human tumors . Qual" Serum miRNA expression analysis analysis of serum samples patients patients DLBCL controls performed using Illumina sequencing technology . Differentially expressed miRNAs (DEMs) identified basis sequencing data . " The management of diffuse large B-cell lymphoma (DLBCL) gradually evolving since discovery 2 major forms, germinal center B-like (GCB) activated B-cell (ABC) types . The application various I" CD30 protein thought promote cell proliferation/survival downregulate immune response . CD30 protein thought promote cell proliferation/survival downregulate immune response . Twenty percent 40% de novo diffuse large B-cell lymphomas ( Autologous hematopoietic cell transplantation (auto-HCT) standard therapy relapsed classic Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma (DLBCL) long-term outcomes The success immunotherapy using immune checkpoint blockade solid tumors relapsed/refractory classical Hodgkin lymphoma chronic lymphocytic leukemia holds promise . The Janus Kinase (JAK) Signal Transducer Activator Transcription (STAT) pathways play important roles pathogenesis diffuse large B cell lymphoma (DLBCL) humans . STAT3 pathway deregulated DLBCL PD-1/programmed death-ligand 1 (PD-L1) expression expression is currently being tested in B-cell lymphomas . PD-1 blockade immunotherapy trials have shown unprecedented clinical efficacy treatment advanced cancers including he " Hairy cell leukemia (HCL) HCL-like disorders, including HCL variant (HCL-V), splenic diffuse red pulp lymphoma (SDRPL) HCL-like disorders, including HCL variant (" Lymphoproliferative disorders characterised human herpesvirus 8 (HHV8) Epstein-Barr virus (EBV) infection rare . Lymphoproliferative disorders (LPD) characterised human herpesv Large B-cell lymphoma common lymphoid neoplasm involving gastrointestinal tract . B-cell tumors outnumbering T-cell tumors wide margin . Atrophic gastritis frequent GML group whereas also trend intestinal metaplasia gastric dysplasia . Atrophic gastritis frequent GML group whereas also trend intestinal metaplasia gastric dysplasia . " The use surveillance computed tomography (CT) imaging patients diffuse large B-cell lymphoma remission neither effective cost-effective . The American Society Hematology Choosing Wisely (CW) campaign, particular, emphasizes lack benefit beyond 2" " The objective study create bioclinical model, based clinical molecular predictors event-free overall survival . The objective study create bioclinical model, based clinical molecular predictors event-free overall survival ." Malignant lymphomas presenting female genital tract extremely rare . Malignant lymphomas presenting female genital tract extremely rare . Relapses occur 10 20% patients . Prognostic models partially identify patients risk relapse . " Treatment dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy rituximab (DA-EPOCH-" We evaluated role consolidative radiotherapy (RT) patients undergoing high-dose chemotherapy (HDC) autologous stem cell transplantation (ASCT) relapsed refractory diffuse large B-cell lymphoma (DLBCL " A 53-year-old woman presented left eyelid ptosis 3 weeks' duration . She finished chemotherapy radiotherapy diffuse large B-cell lymphoma year previously . On ophthalmological examination, best-corrected visual acuity" Non-Hodgkin Lymphoma (NHLs) heterogeneous group tumours distinct treatment paradigms . Goal treatment is to maximize quality duration remission minimizing therapy-related toxicity . " DNMT1 target approved anti-cancer drugs including decitabine . However, prognostic value of DNMT1 protein expression remains unexplored . DNMT1 expressed majority DLBCL cases (n = 209/230, 90" Methylation p16 reported one epigenetic events contributing pathogenesis diffuse large B-cell lymphoma (DLBCL) occurring varying frequency . DLBCL aggressive high-grade malignancy accounts approximately 30% non-Hod The benefit radiotherapy (RT) chemotherapy limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial . We conducted randomized trial patients nonbulky limited-stage DLBCL patients nonbulky limited-stage " Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma . It includes three major subtypes termed germinal center B-cell-like, activated B-cell-like," Hepatitis C virus (HCV) causes chronic curable infection associated development marginal zone lymphoma (MZL) diffuse large B-cell lymphoma (DLBCL) DLBCL is frequent transformation indolent lymph Hepatitis C virus (HCV) also associated extrahepatic immune manifestations B-cell non-Hodgkin lymphoma (NHL) and follicular lymphoma . The causative role HCV NHL supported response " The aim study analyze initial features outcome FL/DLBCL patients rituximab era . All patients consecutively diagnosed single institution FL/DLBCL (n = 40), diagnosed single institution FL/DLBCL (n" " Maintenance therapy proven efficacy indolent non-Hodgkin lymphoma (NHL) role role diffuse large B-cell lymphoma (DLBCL) area ongoing investigation . While DLBCL potentially curable, >30" DLBCL subtype DLBCL unfavorable prognosis poor response treatment . GCB-like ABC-like subtypes different prognosis according gene-expression characteristics . " Rubinstein-Taybi syndrome (RSTS) rare, congenital syndrome known associated neoplasms various organ systems . Presented case patient RSTS, diagnosed birth, presented subtle symptoms lethargy change behavior ." Double-expressor lymphoma (DEL) diffuse large B cell lymphoma exhibits co-expression MYC BCL2 proteins immunohistochemistry . Patients double-expressor lymphoma poor prognosis standard chemoimmunotherapy Gene-engineered T cell therapies soon approved at least two types B cell malignancies pediatric adult patients . This represents triumph true bench bedside clinical translation therapy conceived early 1990s . " 51-year-old man presented with recent worsening months upper abdominal pain back radiation postprandial fullness . Laboratory analysis showed hyperamylasaemia, elevated lactate dehydrogenase inflammatory parameters ." Plasmablastic lymphoma (PBL) aggressive form non-Hodgkin's lymphoma (NHL) aggressive form non-Hodgkin's lymphoma (NHL) aggressive form non-Hodg Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) newly recognized provisional entity included mature B-cell neoplasm latest 2016 World Health Organization Classification . It self-limited growth potential high predile " Elderly patients (61-80 years) received 6 cycles CHOP-14 (cyclophosphamide, doxorubicin, vincristine prednisone 14-day intervals) randomized 8 cycles ritux" Diffuse large B cell lymphoma (DLBCL) common form blood cancer characterized striking degree genetic clinical heterogeneity . This heterogeneity poses major barrier understanding genetic basis disease response therapy . Reddy et al. report integrative genetic characterization of diffuse large B cell lymphomas (DLBCL) This provides first comprehensive overview DLBCL biology basis future precision medicine approaches disease . " Primary cardiac lymphoma rare type extranodal lymphoma involves heart and/or pericardium . It usually observed immunodeficient people . However, immunocompetent patients may also suffer disease ." " PD-L1 protein protein protein mRNA expression evaluated 64 PCNSL tissue samples . PD-L1 protein detected tumor cells 2 (4.1%) cases, and PD-L1/PD-1/PD-1-" 58-year-old immunocompetent woman presented complaints of recurrent generalised tonic-clonic seizures . Diagnosed with diffuse large B cell type primary dural lymphoma . Chemotherapy CHOP (cyclophosphamide " The primary endpoin was buparlisib 100 mg daily progression, intolerance, withdrawal consent . The primary endpoin was buparlisib 100 mg daily progression, intolerance, withdrawal consent ." Autologous stem cell transplantation considered standard care relapsed/refractory classical Hodgkin lymphoma . Auto-SCT considered standard care relapsed/refractory classical Hodgkin lymphoma . NLPHL transformed diffuse large Cytokine-release syndrome common complication patients received . Patients received haploidentical donor allogeneic haematopoietic cell transplantation (haplo-HCT) Although severe CRS haplo- " Diffuse large B-cell lymphoma (DLBCL) heterogeneous highly aggressive subtype non-Hodgkin's lymphoma . It commonly presents rapidly-growing, painless lymphadenopathy (LAD) Chemotherapy" " Plasmablastic lymphoma (PBL) rare hard treat disease . With current standard chemotherapeutic regimens, PBL associated median overall survival 12-15 months . We identified 21 patients, 11 received bortezom" Central nervous system (CNS) relapse diffuse large B-cell lymphoma (DLBCL) associated dismal prognosis . The R-CHOP 14 versus 21 trial compared R-CHOP administered two- versus three weekly previously untreated Several studies reported uneven results evaluating prognostic value bone marrow biopsy (BMB PET/CT part staging diffuse large B-cell lymphoma (DLBCL) The heterogeneity inclusion criteria taking account selection collinearity biases analysis models Canine diffuse large B-cell lymphoma (DLBCL) common aggressive hematologic malignancy . The lack conventional therapies sustainable efficacy warrants investigation novel therapeutics . AZD1480 CYT387 novel JAK1/ CHOP remains reference treatment lymphomas. CHOP remains reference treatment lymphomas. CHOP remains reference treatment lymphomas. 30-year-old patient lymphoma reported . Case illustrates role repeated comprehensive microbiological investigations contributed molecular techniques reaching aetiological diagnosis . Growing numbers of cancer survivors faced cardiac side effects anthracycline treatment . Need to explore optimal monitoring method early detection of cardiac toxicity . Neurolymphomatosis rare disorder characterised infiltration neoplastic lymphocytes peripheral nervous system . Treatment based methotrexate is available but various chemotherapy regimens currently available patients systemic disease . " 2504 patients oropharyngeal lymphoma identified using recent SEER database entry entry 1976 2016 . Demographic information, Ann Arbor stage, tumor histopathology location collected . Multivariate analysis used analyze patient tumor characteristics associated survival ." " Intravenous rituximab plus chemotherapy standard treatment diffuse large B-cell lymphoma . Subcutaneous formulation rituximab expected simplify shorten drug preparation administration, reduce treatment burden ." " The transcription factor BCL6 known driver oncogenesis lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL) Disruption interaction transcriptional repressors interferes oncogenic effects BCL6" " Patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) poor prognosis, even rituximab era . Study looked at whether LMR relapse predict clinical outcomes relapsed/refractory" Breast involvement Non Hodgkin Lymphoma rare entity accounts 2.2% extranodal lymphomas . Breast involvement Non Hodgkin Lymphoma rare entity accounts 2.2% extranodal lymphomas . There limited studies cytology diagnosis haematopoietic lymphoid tumours serosal effusion except occasional case reports . We reviewed 36 cases lymphoma diagnosed serosal effusion following algorithmic approach . An 18-year-old male castrated jaguar (Panthera onca) presented anorexia continuous bleeding oral cavity history fighting partner animal . Clinical evaluation revealed ulcerating lesions gingiva hard palate hemat " Epstein-Barr virus (EBV), originally discovered association association Burkitt lymphoma, originally discovered association Burkitt lymphoma, aetiologically linked remarkably wide range lymphoproliferative lesions malignant lymphomas B-, T" " Lenalidomide, immunomodulatory drug trials treatment ABC-DLBCL, targets transcription factor IKAROS degradation cereblon E3 ubiquitin ligase complex . Activated B-cell diffuse large B-" " Conventional statistical methods fail select relevant genes, predict poorly, ignore unknown interaction structure genes, computationally intractable . We develop new technique using marginal relationship g ." " We analyzed paired data tumors (Burkitt lymphoma, diffuse large B-cell lymphoma) features . We analyzed paired data tumors (Burkitt lymphoma, diffuse large B-cell lymphoma) features . We analyzed paired" Non-Hodgkin's Lymphoma (NHL) thoracolumbar spine different presentation . MRI revea revealed epidural mass level T12 vertebrae . B-cell lymphoid malignancy subtypes focusing immune perturbation . Severe immune suppression constitutes strong well-established risk factor aggressive subtypes . Severe immune suppression constitutes strong well-established risk factor aggressive subtypes . Se " da-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide vincristine, prednisone, rituximab) dose-intensified" Synchronous involvement central nervous system (CNS) diagnosis of systemic non-Hodgkin lymphoma (NHL) associated increased risk relapse despite complete remission initial therapy . High-dose chemotherapy CNS-directed conditioning regimen followed aut The pleiotropic cytokine interleukin (IL-10) best characterized ability downregulate inflammation promote peripheral tolerance . IL-10 also found maintain effector response CD8 . " PXD-101 would increase MHCII expression, synergize Zevalin, improve clinical outcomes . The objective single-arm phase II study evaluate PXD-101 would increase MHCII expression, synergize Zev" " In issue Grommes colleagues elegantly show irreversible inhibitor Bruton tyrosine kinase, ibrutinib, promotes high proportion durable responses ." " The 56-year-old male patient diagnosed diffuse large B cell lymphoma, clinically presenting visible tumor left breast showing axillary lymphadenopathy . Initial treatment patients remains surgery . Prompt diagnosis associating subsequent treatment combining chemotherapy radiotherapy utmost importance" " CUDC-907 first-in-class, oral small molecule inhibitor HDAC (class I II) PI3K (class Iα, β, δ) enzymes, demonstrated anti-tumor activity multiple pre" " Hemophagocytic lymphohistiocytosis (HLH) rare hyperinflammatory syndrome . It categorized familial acquired, commonly caused infections, malignancies, rheumatologic immunodeficiency disorders . Irrespective et" " Rituximab (R) cyclophosphamide, doxorubicin, vincristine prednisone (CHOP) current standard care first-line treatment . First-line treatment combination Ritux" Eleven -nineteen Lysine-rich leukemia (ELL) family member 3 (ELL3) dynamically up-regulated mature activated human B cells followed suppression B cells transition plasma cells part me . Primary CNS diffuse large B-cell lymphoma (PCNS-DLBCL) systemic DLBCL harbor mutations MYD88 CD79B . DNA methyltransferase (MGMT) methylated DLBCL . " Central nervous system (CNS) relapse devastating complication occurs 5% diffuse large B-cell lymphoma (DLBCL) patients . Currently, predictive biological markers. Currently, predictive biological markers." We investigated utility J chain myocyte enhancer factor 2B (MEF2B) diagnosis CHL; NLPHL; PMBL; T-cell/histiocyte-rich large B-cell lymphoma (TCRL " Cell-of-origin determination emerged important prognostic factor patients initially diagnosed diffuse large B cell lymphoma (DLBCL) Specifically, nongerminal center B cell-like (non-GCB) subtype, composed" " Neurokinin-1 receptor antagonists, aprepitant currently emerging powerful prophylactic agents chemotherapy-induced nausea vomiting (CINV) Therefore, important adjust anti-emetic regimens based personal risk factors patient, duration chemotherapy" " Multiple genomic mutations, especially involving NF-κB pathway, characterized primary cutaneous large B-cell lymphoma, leg type . However, genomic profiling remains limited given rarity ." " The combination rituximab chemotherapy improved outcome patients follicular lymphoma (FL) However, data Grade 3 FL (FL33) subtypes lacking ." Leg-type (PCLBCL-LT) suggests germinal center-experienced B lymphocyte (BCL2+ MUM1+ BCL6+/-) B-cell development immunoglobulin gene sequence Ocular adnexal lymphoma intraocular lymphoma intraocular lymphoma is often similar associated systemic lymphoma . Two cases represent Richter transformation chronic lymphocytic leukemia/small-cell lymphoma diffuse large B-cell lymphoma The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) currently evaluated phase II clinical trials treatment non-Hodgkin lymphoma (NHL) The EZH2 " PD-PPSS is rare, aggressive neoplasm, occurs 0.5% cases lung malignancies . Diff-Quik Papanicolaou stains showed cellular specimen clusters highly atypical small round blue cells adm" " Multiple myeloma DLBCL patients recruited population-based Victorian Cancer Registry . Data collected two telephone interviews: (T1) average 7 months postdiagnosis, (T2) average 8 months later . QoL examined T" Gastric Burkitt lymphoma subtype non-Hodgkin's lymphoma represents aggressive rare malignancy . Gastric Burkitt lymphoma subtype non-Hodgkin's lymphoma represents aggressive rare malignancy Distinction mature B-cell neoplasms difficult due overlapping immunologic features clinical manifestations . Study investigated whether quantifying mean fluorescence intensity four monoclonal antibodies flow cytometry panel useful differential diagnosis characterization disorders . " GP88 secretes 88kDa glycosylated protein, important functions, including inflammation tumorigenesis . GP88 expression survival outcomes patients malignant lymphoma (ML) were assessed ." Rheumatoid arthritis (RA) associated twofold increased risk Hodgkin's lymphoma (HL) non-Hodgkin's lymphoma (NHL) Rheumatoid arthritis (RA) associated twofold increased risk RASGRP1 guanine-nucleotide-exchange factor essential MAP-kinase mediated signaling lymphocytes . Second case of RASGRP1 deficiency patient homozygous nonsense mutation catalytic domain protein . Ep The discovery of frequent mutations genes modifying epigenome diffuse large B-cell lymphoma (DLBCL) highlighted outstanding role epigenetic deregulation disease . " Survival outcome elderly patients newly diagnosed diffuse large B-cell lymphoma remains suboptimal rituximab era . In systematic review, summarize available evidence relevant inclusion anthracycline upfront chemoimmunotherapy elderly patients highlight" Clonality testing immunoglobulin gene rearrangement analysis could implemented effectively useful technique conventional diagnosis lymphoma . European Biomedicine Health Concerted Action Project BMH4-CT98-3936 suggested gold standard method cl T cells expressing anti-CD19 chimeric antigen receptors (CARs) induce complete remissions (CRs) diffuse large B cell lymphoma (DLBCL) The long-term durability remissions are unknown . " B-cell lymphomas represent approximately 20% 25% primary cutaneous lymphomas . Cases include primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, primary cutaneous follicle center lymphoma, primary cut" Histologic prognostic factors described nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) Study examines histologic immunophenotypic variants clinical trial pediatric NLPHL . Fifty-eight cases showed typical nodular without serp Follicular lymphoma (FL) heterogeneous. Follicular lymphoma (FL) heterogeneous. Although FL Grade 3B (FL3B) treated aggressive FL (aggFL) optimal approach FL Grade 3A (FL Small number cases of diffuse large B cell lymphoma (DLBCL) arising within atrial myxoma reported immunocompetent patients showed aggressive histological features . We present four unusual cases of DLBCL arising within at " Globally, clinical laboratories employ pragmatic less ideal immunohistochemical (IHC) assay COO classification . Novel RNA-based platforms using routine pathology samples using routine pathology samples emerging new gold standard offer unique opportunities ." Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . 5-year survival rates first-line setting range 60% 70% . 50% patients become refractory This study compare clinical characteristics prognosis Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) lymph node DLBCL (LN-DLBCL) rituximab era . The Waldenström macroglobulinaemia (WM) rare poorly reported complication Waldenström macroglobulinaemia (WM) is rare poorly reported complication Waldenström macrogl " Intravascular lymphoma (IVL) rare entity. Most cases variant extranodal diffuse large B cell lymphoma, fewer 10% published cases T cell origin . Only intravascular B cell lymphoma recognized distinct entity recent" The incidence of transformation 30% period 10 years is 30% period 10 years . This risk persists even beyond initial decade diagnosis indent lymphoma . Pediatric solid organ transplant recipients 100 200 times higher risk non-Hodgkin lymphoma (NHL) general pediatric population . Transplant-related NHL may contribute considerably pediatric NHL burden United States . " PI3K pathway epigenetic regulation shown play pivotal role development progression of diffuse large B-cell lymphoma (DLBCL) In clinic, existing PI3K HDAC inhibitors show limited efficacy single agents toward DLBCL . We" " Naratuximab emtansine (IMGN529) is an experimental drug with promising preclinical clinical activity . IMGN529 shown promising preclinical clinical activity non-Hodgkin lymphoma, including diffuse large B" " The impact MYC proto-oncogene, basic helix-loop-helix (MYC) translocations (with without additional rearrangements involving B-cell lymphoma 2 [BCL2] BCL6 genes" The update 4th edition World Health Organization Classification Haematopoietic Lymphatic Tissues portends important new findings . The update 4th edition World Health Organization Classification Haematopoietic Lymphatic T " EZH1 functions catalytic subunit PRC2, two PRC2 complexes containing either EZH2 EZH1 or EZH2 . EZH1 tumorigenesis." Collision Epstein-Barr virus (EBV)-associated lymphoepithelioma-like carcinoma (LELC) non-Hodgkin's lymphoma stomach stomach extremely rare . Gastric endoscopy showed Lymphoma uncommon diagnosis EUS-FNA pancreas . Common diagnosis secondary involvement pancreas lymphoproliferative disorder . Endoscopic ultrasound-guided-fine needle aspiration (EUS-FNA) established first- 161 DLBCL patients received R-CHOP chemotherapy . Low MPV (MPV) associated clinicopathological factors assessed . Patients MPV < 9.1 fl experienced shorter progression-free survival (PFS) and shorter progression " Diffuse large B-cell lymphoma (DLBCL) common type canine lymphoma survival times currently <1 year . Tregs, characterized stable expression transcription factor FoxP3, suppress innate adaptive arms immune response . Treg" Intravascular large B-cell lymphoma (IVLBCL) rare type extranodal LBCL. It characterized proliferation tumour cells exclusively intraluminally small blood vessels different organs. The clinical manifestation depends type Primary central nervous system (CNS) lymphoma aggressive fatal extranodal non-Hodgkin lymphoma . Its prognosis poor disease fatal outcome compared systemic non-Hodgkin lymphoma . " Primary mediastinal large B cell lymphoma (PMLBCL) B cell non-Hodgkin lymphoma (B-NHL) shows morphologic, immunophenotypic, genetic similarities classical Hodgkin lymphoma" " Eleven chest wall swellings diagnosed lymphoid neoplasms fine needle aspiration (FNA) period 15 years (January 2000-December 2014) The age patients ranged 19 73 years (median, 46) The male-to -emale" " Low-grade follicular lymphoma (FL) annual risk transformation is 3% higher than the average risk of transformation . MYC expression might predict MYC breakpoint, study found ." Epstein-Barr virus (EBV) infection lytic replication known induce cellular DNA damage response . Epstein-Barr virus (EBV) infection lytic replication known induce cellular DNA damage response . " Cancer represents tissues consisting heterogeneous neoplastic, well reactive, well reactive, cell populations cancers histotype may show profound differences clinical behavior long recognized ." " Central nervous system (CNS) relapse non-Hodgkin lymphoma (NHL) rare serious complication carries poor prognosis . The use infusional etoposide, prednisone, prednisone, vinc" Lymphoma cases diagnosed 1984 2013 classified according to 2008 WHO classification system lymphoid neoplasms . Lymphoma cases diagnosed 1984 2013 classified according to 2008 WHO classification system lymphoid neoplasms . B-cell neoplasias proliferate autonomously due endogenous stimuli . B-cell lymphomas proliferate autonomously due to endogenous stimuli . Interferon-free direct antiviral agents (DAAs) showed high efficacy safety . The question arises whether not-and how-to treat HCV-positive patients suffering diffuse large B-cell lymphomas (DLBCLs 100 dogs intraocular lymphoma describe histomorphologic immunohistochemical features . The objectives retrospective study describe histomorphologic immunohistochemical features canine intraocular lymphoma . The objectives retrospective study describe proportion cases presumed solitary ocular lymph " Epstein-Barr virus (EBV)-mediated B cell transformation achieved predominantly action latent proteins . Recent evidence suggests lytic EBV replication also certain pathogenic role lymphomagenesis, least early phases cell transformation . Particularly, diffuse large" Review of Wnt signalling network development progression mature B-cell-derived haematological malignancies . Focus chronic lymphocytic leukaemia (CLL) related B-cell lymphomas . " GELA designed randomized phase 2 trial evaluating efficacy of rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP)" Diffuse large B-cell lymphoma (DLBCL) accounts 30% adult non-Hodgkin lymphomas . Epstein-Barr virus (EBV) -positive DLBCL elderly newly recognized subtype accounts 8 " Second hematologic cancers patients chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) well documented include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndrom" " PD-1/PD-L1 pathway inhibitors important landmark solid oncology . Among haematological malignancies, PD-1/PD-L1 inhibitors successful, far, treatment classical Hodgkin lymphoma . Such" " One-third patients with diffuse large B cell lymphoma (DLBCL) lymphomatous bone marrow involvement (BMI) time diagnosis, bone marrow aspirate/biopsy (BMAB) considered gold standard detect involvement" 75-year-old man refractory chronic lymphocytic leukemia presented multiple growing fatty abdominal masses . The patient underwent exploratory laparotomy mass resection due nonspecific imaging findings . " This study examined role random normal skin biopsy diagnosis intravascular lymphoma (IVL) adult Western patients clinically diagnosed hemophagocytic lymphohistiocytosis (HLH) In retrospective chart review study, analyzed" " The prognosis young patients with diffuse large B-cell lymphoma high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 3) treated R-CHOP (rituximab, cycloph" " Hematolymphoid malignancies breast commonly neoplasms mature B-lymphocytes, may arise primary disease secondary involvement systemic disease . Primary breast lymphomas account 0.04-0.5% breast malignancies," Diffuse large B-cell lymphoma (DLBCL) common aggressive subtype non-Hodgkin's lymphomas . Diffuse large B-cell lymphoma (DLBCL) common aggressive subtype non-H This study aimed describe patterns care outcomes . diffuse large B cell lymphoma (DLBCL) failure front line anthracycline-based immunochemotherapy (IC) Patients newly diagnosed lymphoma prospectively enrolled . " BAY 1238097 showed anti-proliferative activity large panel lymphoma-derived cell lines, median 50% inhibitory concentration 70 208 nmol/l . The compound showed strong anti-tumour efficacy ." It still unclear whether clinically exploitable differences biology behaviour early versus late relapses is exploitable . The study aimed analyse large population-based DLBCL cohort order identify (i) frequency late relapses (LR) parameters influencing risk . We used clustered regularly interspaced short palindromic repeats/Cas9-mediated genomic modification investigate B-cell receptor (BCR) signaling cell lines . Three manipulations altered BCR genes without affecting surface BCR levels showed We show activated B cell-like subtype DLBCL exceedingly rare children - contrast adults- associated outcome . We show activated B cell-like subtype DLBCL exceedingly rare children - contrast adults- associated outcome . " 10-year single-centre study of 63 consecutively treated patients . Cohort 1 patients received four cycles R-CHOP-21 (rituximab, cyclophosphamide, cyclophosphamide, daunor" MYC overexpression common feature diffuse large B-cell lymphoma (DLBCL) associated poor prognosis patients neoplasm . MYC overexpression common feature diffuse large B-cell lymphoma (DLBCL) Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) haematologic malignancy poor prognosis treated chemotherapy . We evaluated response survival benefits benefits chemoimmunotherapy EB " Non-Hodgkin's lymphoma (NHL) constitutes collection lymphoproliferative disorders diverse biologic, histologic, clinical features . Despite remarkable developments, autologous hematopoietic cell transplantation" Next-generation sequencing revealed key pathways deregulated lymphoma subtype . Novel therapy 'hit' central mechanisms lymphoma pathobiology . Immature colon carcinoma transcript-1 (ICT1) crucial member large mitoribosomal subunit mitochondrial ribosome . Its expression function human diffuse large B-cell lymphoma (DLBCL) remained elusive . Analysis " AKT signaling important proliferation survival tumor cells . AKT activation is a clinical significance in diffuse large B-cell lymphoma (DLBCL) Study found high levels p-AKT nuclear expression, observed 24.3% study cohort" Primary bone lymphoma rare disease (less 1% malignant bone tumors) It affects least 15% labor force 40% individuals whose occupation hazardous . " 281 patients >80 years old newly diagnosed DLBCL treated 4 referral institutions Switzerland Northern Italy . At median follow-up 5.5 years, 5-year progression-free survival 26% (95% confidence interval [CI], 20" Bruton tyrosine kinase (BTK) links B-cell antigen receptor (BCR) Toll-like receptors NF-κB . The role BTK primary central nervous system (CNS) lymphoma (PCNS Diffusion large B-cell lymphomas (DLBCL) aggressive non-Hodgkin's lymphomas (DLBCL) aggressive non-Hodgkin's lymphomas (NHL) translocations and/or " TP53 mutated 20-25% aggressive B-cell lymphoma (B-NHL) To date, studies addressed impact TP53 mutations prospective clinical trial cohorts . To evaluate impact TP53 mutation current risk models aggressive B-NHL" " International prognostic index (IPI) remained primary prognostic tool diffuse large B cell lymphoma (DLBCL) 20 years . Even though disease common older population, impact comorbidities, dose reductions, treatment-related adverse" " The 2016 revision of lymphoma classification lymphoma included new category lymphoma . The 2016 revision included new category lymphoma, separate diffuse large B-cell lymphoma ." Lymphadenopathy skin involvement in 82-year-old woman . Lymphadenopathy skin involvement in skin involved . Lymphadenopathy skin involvement in B-cell lymphoma high proliferation index . Obinutuzumab (OBZ) recombinant type II anti-CD20 immunoglobulin G1 Fc-optimized monoclonal antibody (mAb) recently approved chronic lymphocytic leukemia (C The goal study identified compare direct costs intravenous subcutaneous rituximab given patients diffuse large B-cell lymphoma Netherlands . T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) morphologic variant large B-cell lymphoma whose flow cytometry findings well characterized . Nineteen cases flow cytometric immunophenotyp " BCL-2 small-molecule inhibitor venetoclax shows promising clinical response rates several lymphomas, curative monotherapy ." Chronic lymphocytic leukaemia (CLL) chronic B-cell lympho-proliferative disorder lymphomatous transformations occur 5-15% patients . Rare cases transformation Hodgkin lymphoma (HL) reported literature " Relapses aggressive B-cell lymphomas pose higher risk affected patients potential treatment resistance usually rapid tumor growth . Recent advances, targeting Bruton tyrosine kinase, provided promising results small numbers cases, treatment majority patients remains challenging outcomes generally" Diffuse large B-cell lymphoma (DLBCL) common non-Hodgkin lymphoma . Main prognostic factor closely related germinal center B-cell-like subtype (GCB-DLBCL Pregnancy-associated diffuse large B-cell lymphoma (DLBCL) rare event . Cardiotoxicity known adverse effect antineoplastic agents especially doxorubicin . " Published data suggest patients early progression ibrutinib often emerge Richter's transformation (RT) rapidly fatal prognosis, mostly developing diffuse large B-cell lymphoma (DLBCL) In respect, known RT large DLBC" " Anaplastic lymphoma kinase (ALK) positive diffuse large B-cell lymphoma (ALK+DLBCL) rare, distinct aggressive subtype non-Hodgkin's lymphoma (NHL) These tumors considered" Diffuse large B-cell lymphoma (DLBCL) aggressive lymphoma heterogeneous outcomes . We analyzed 197 de novo DLBCL patients (91 M/106 F; median age 66 years) treated immunochemotherapy single Survival of diffuse large B-cell lymphoma (DLBCL) improved with rituximab treatment advances . We calculated standardized incidence ratios (SIR) 95% confidence intervals (CIs) SPMs among 23 8 46 lymphoma patients received peripheral blood stem cell mobilization EC regimen . 46 lymphoma patients received peripheral blood stem cell mobilization EC regimen . " Phase 2, multicenter study determine activity safety nonpegylated liposomal doxorubicin part ""R-COMP"" combination patients diffuse large B-cell lymphoma coexisting cardiac disorders . 50 evaluable patients" Overexpression BCL2 associated poor prognosis diffuse large B-cell lymphoma (DLBCL) Overexpression BCL2 associated poor prognosis . The assessment MYC immunohistochemistry (IHC) " B cell lymphomas' (BCL) current diagnosis usually based combination morphology, immunophenotype, recurrent cytogenetic aberration clinical features . However, even diagnostic tools, definitive diagnosis difficult achieve." Malignant lymphomas occurring human immunodeficiency virus (HIV) setting extensively studied since beginning HIV epidemic 35 years ago . Introduction highly active antiretroviral therapies (HAART) 1996 changed dramatically incidence HIV-related mal Intravascular lymphoma (IVL) was first described 1959 . IVL deserves title 'medicine's greatest imitator' Asian patients with diffuse large B-cell lymphoma (DLBCL) treated rituximab era . We performed retrospective analysis of 176 patients newly diagnosed DLBCL . The estimated overall survival (OS) progression-free survival Splenic infiltration often seen diffuse large B-cell lymphoma (DLBCL) rare studies clinicopathological features limited . We assessed 66 cases primary splenic DLBCL 309 control DLBCL cases . " Treatment options relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) limited, prognosis generally poor (overall response rate [ORR] 0% 25%; 2-year overall" International Extranodal Lymphoma Study Group-26 study evaluated prognostic role 18-fluorodeoxyglucose positron-emission tomography (PET) primary mediastinal large B-cell lymphoma . " High-dose rituximab (HD-R) combined carmustine, cytarabine, etoposide melphalan (BEAM) autologous stem cell transplant (ASCT) effective tolerable" " To compare sensitivity, specificity predictive value Deauville score (DS) vs. ΔSUVmax interim-treatment PET (iPET) end-treatment PET (ePET) Patients diffuse large B cell lymphoma (DLBCL" " Comparative genomic hybridization arrays (aCGH) still constitute simple reliable approach copy number analysis . The powerful algorithms analyze data freely provided scientific community many years, combining complex scripting task . The cghRA framework combines user-friendly graphical" The study clearly identifies original m. m. DNA sequencing . Epstein-Barr virus (EBV)-associated lymphoproliferations involving skin rare important group diseases broad spectrum behavior . They may include self-limiting spontaneously resolving disorders highly aggressive malignancies . " Prognostic models primary diffuse large B-cell lymphoma (DLBCL) resistant relapsing initial therapy rituximab plus cyclophosphamide, doxorubicin, vincristine, pred" Primary central nervous system lymphoma (PCNSL) comprises around 3-5% primary central nervous system (CNS) tumours . Around 1% non-Hodgkin lymphoma (NHL) is non-H The tumor suppressors B-lymphocyte-induced maturation protein-1 (BLIMP-1) p53 play crucial role B-cell lymphomas . Inactivation contributes pathogenesis of wide spectrum lymphoid malignancies " Selinexor, orally bioavailable, first-in-class inhibitor nuclear export protein XPO1, phase 1 trial assess safety determine recommended phase 2 dose (RP2D) Seventy-nine patients various . various . NHL" " Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) potent anti-tumor agent triggers apoptosis cells multiple types carcinoma normal cells . However, diverse mechanisms associated insensitivity" There limited information concerning impact physical activity obesity obesity non-Hodgkin lymphoma (NHL) prognosis . We examined associations pre-diagnosis physical activity body mass index (BMI) survival . Study first assessed factors associated DLBCL-specific mortality 2002-2012 . Survival diagnosis of diffuse large B-cell lymphoma (DLBCL) increasing since 2002 . Long-term outcomes patients modern treatment era still unknown . In patients diffuse large B-cell lymphoma (DLBCL) socioeconomic status (SES) associated outcome several population-based studies . The aim study investigate existence disparities treatment survival . " Protein kinase CK2 propels survival, proliferation stress response solid hematologic malignancies promotes ""non-oncogene addiction"" phenotype ." " Studies evaluated prognostic value body mass index (BMI) patients with diffuse large B-cell lymphoma recently reported . However, impact BMI survival outcomes remains controversial . We retrospectively analyzed data 406 diffuse large B-cell lymphoma patients" " Mocetinostat, isotype-selective HDAC inhibitor, induces accumulation acetylated histones, cell cycle arrest apoptosis several cancers . Phase 2 study evaluated mocetinostat patients relapsed/ref" " Richter syndrome is a rare disease that is chemotherapy-resistant and difficult to treat . Patients typically elderly, immunosuppressed present rapidly deteriorating performance status . RS remains area high unmet clinical need ." Enhancer zeste homolog 2 (EZH2) implicated pathogenesis several cancers . Gastrointestinal diffuse large B-cell lymphoma (GI DLBCL) common gastrointestinal lymphoma . EZH2 studied GI DL Bone marrow (BM) microenvironment patients diffuse large B-cell lymphoma (DLBCL) rarely studied . We aimed investigate significance infiltrating immune cells infiltrating immune cells . " A retrospective analysis carried 18 patients diagnosed primary brain lymphoma, histological subtype diffuse large B-cell lymphoma, initial Initial MRI appears method choice detecting brain disease patients primary brain lymphoma, whereas MRI appears method choice detecting brain disease" Diffuse large B-cell lymphoma (DLBCL) follicular lymphoma prevalent B-lymphocyte neoplasms abnormal activation Bruton tyrosine kinase (BTK)-mediated B-cell receptor signaling pathway contributes " T-cell-based immune therapy cancer generate durable clinical benefits patients, paired enhanced side effect profiles . Immune checkpoints inhibitors incorporated standard treatment protocols advanced solid tumors ." " Diffuse large B-cell lymphoma frequent histology diagnosis among non-Hodgkin B lymphomas cured 50-70% cases first-line chemotherapy regimen . Patients respond first-line treatment undergo numerous subsequent steps, culminating all" " Pembrolizumab, humanized PD-1-blocking antibody, dose 200 mg every 3 weeks . Twenty-five patients including 16 relapsed CLL 9 RT (all proven diffuse large cell lymphoma) patients enrolled," Post-transplant diffuse large B-cell lymphomas (PT-DLBCL) display similar genomic landscape DLBCL immunocompetent patients (IC-DLBCL) We investigated 50 post-transplant lymphop " ABBV-075 potent selective selective selective BET family bromodomain inhibitor recently entered phase I clinical trials . ABBV-075 demonstrated broad activity across cell lines tumor models, representing variety hematologic malignancies solid" " Non-Hodgkin lymphoma often diagnosed emergency presentation, route associated poor survival indicator diagnostic delay . Accounting around half NHLs, diffuse large B-cell lymphoma (DLBCL) particular interest since although potentially curable standard" " Decision-making models elderly patients diffuse large B-cell lymphoma (DLBCL) treated rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R" " Transformation aggressive lymphoma critical event clinical course follicular lymphoma (FL) patients . Understanding risk transformation would useful guiding monitoring patients, well evaluating novel treatment strategies could potentially prevent transformation ." " Ocular surface squamous neoplasia (OSSN) (14%), melanoma (12%), lymphoma (7%) rarely found children . Pre-disposing conditions include chronic solar radiation, immune deficiency (HIV), organ transplant" " The ocular adnexa include eyelids, conjunctiva, lacrimal apparatus, lacrimal apparatus, orbital soft tissue . Reactive lymphoid hyperplasia comprises 16% lymphoproliferative tumors ocular ad" UK NCRI R-CHOP14v21 randomized phase 3 trial demonstrate difference outcomes . Study looked at whether 2-3-weekly administration R-CHOP preferred first-line treatment elderly patients diffuse large B-cell lymphoma ( The 2015 Workshop Society Hematopathology/European Association Haematopathology submitted small large B-cell lymphomas (BCLs) The 2015 Workshop Society Hematopathology/European Association Haematopathology submitted small The 2015 Workshop Society Hematopathology/European Association Haematopathology aimed review immunodeficiency-related lymphoproliferative disorders plasmablastic plasma cell differentiation . The workshop panel reviewed human herpes virus 8 ( " Lymphoid enhancer binding factor 1 (LEF1) useful marker chronic lymphocytic B-cell leukemia (CLL/small lymphocytic lymphoma) Yet, still widely used diagnostic setting." " Inhibition monocarboxylate transporter 1 proposed therapeutic approach perturb lactate shuttling tumor cells . We examined monocarboxylate transporter 1 inhibitor AZD3965, currently phase I clinical studies, potential therapy" " Higher ratios pre-treatment peripheral blood absolute lymphocyte (ALC) absolute monocyte counts (AMC) associated improved outcomes lymphoma . Conversely, elevated pre-treatment serum cytokines associated inferior outcomes ." " Patients rheumatoid arthritis often develop methotrexate-associated lymphoproliferative disorders (MTX-LPD) MTX-LPD regresses spontaneously . In patients without spontaneous regression, additional chemotherapy required avoid disease" Global hypomethylation linked disease progression several cancers . DLBCL describe prognostic value . " Primary breast lymphoma (PBL) gained attention description breast implant-associated anaplastic large cell lymphoma (ALCL) Less known PBL incidence, treatment, survival lymphoma subtype ." " Hepatitis B virus (HBV) infection documented risk factor non-Hodgkin lymphoma (NHL) infection documented risk factor non-Hodgkin lymphoma (NHL) However, large cohort studies," We conducted study examine unstaged DLBCL United States . We used Surveillance Epidemiology End Result (SEER) 18 registries select patients . DLBCL diagnosed January 2000 December 2012 . " Primary central nervous system lymphomas (PCNSLs) relatively rare brain tumors . Accurate diagnosis usually made surgical biopsy . Treatment options include high-dose methotrexate chemotherapy, radiation therapy, stem cell therapy ." Collision tumors simultaneous occurrence one type neoplasm within anatomic space . Collision tumors simultaneous occurrence one type neoplasm within anatomic space . Collision tumors simultaneous occurrence one type neoplasm within anatomic space . The aim study measure usefulness of endobronchial ultrasound (EBUS) patients infected human immunodeficiency virus (HIV) The clinical spectrum likely diseases population varied differs patients infected HIV . The clinical significance of the clinical significance of the study is still relevant . Non-Hodgkin lymphoma occurs increasing frequency HIV/AIDS . South Africa highest incidence HIV/AIDS worldwide . Head neck lymphomas defined South African population . " Of 63 patients paranasal sinus lymphoma, 35 (56%) systemic involvement . Paranasal sinus lymphoma rare clinical entity." Aggressive non-Hodgkin lymphoma associated poor long-term survival relapse resistance chemotherapy . Aggressive non-Hodgkin lymphoma associated poor long-term survival relapse resistance chemotherapy . " Systemic reports descriptive epidemiology non-Hodgkin lymphoma (NHL) Southeast Asia scarce . A nationwide multi-institutional registry conducted compare histopathology, clinical features, survival Thai adult patients NHL using large registries" Galaxy tools represent many popular algorithms detecting somatic genetic alterations cancer genome exome data . We evaluated 285 paraffin-embedded samples patients (60-80 years age) enrolled Lymphoma Study Association trial LNH03-6B treated R-CHOP . We correlated COO defined transcriptome according to Wright " Gastric lymphoma rare, accounting 3% gastric neoplasms 10% lymphomas . Gastric lymphoma rare, accounting 3% gastric neoplasms 10% lymphomas . Gastric lymphoma rare, accounting 3%" Diffuse large-B cell lymphomas (DLBCL) follicular lymphomas (FL) represented subtypes among mature B-cell neoplasms . Methylation represents one major epigenetic mechanisms gene regulation . Silent information regulator Primary mediastinal large B-cell lymphoma (PMLBCL) distinct clinical biological disease types DLBCL . PMLBCL characterized diffuse proliferation medium large B-cells associated sclerosis . Rituximab CHOP " Pharmacological agents inhibit enzymes B-cell receptor (BCR) pathway increasing importance treatment B-cell malignancies . These include inhibitors Bruton tyrosine kinase (BTK), phosphatidylinositol 3-" LncRNA MALAT-1 regulated autophagy-related signaling pathway chemotherapy resistance . LncRNA MALAT-1 interfering stable transfected cell lines construcreded cell lines construcred . The link hepatitis C virus (HCV) infection development development B-cell non-Hodgkin lymphoma well established based number epidemiological studies . It supported observation lymphoma regression HCV eradication antiviral treatment . " Primary lymphoma female genital tract (PLFGT) rare entity . The aim population-based study elucidate clinico-pathological, demographic characteristics survival women PLFGT ." " TP53 deletion mutation frequent B-cell malignancies associated low response rate . TP53 deletion mutation frequent B-cell malignancies associated low response rate . MYC gain, absent post-GC malignancies, absent post-" " Anthracyclines (AC) still undeniable drugs lymphoma treatment, despite occasionally causing cardiotoxicity . Liposomal AC may reduce cardiotoxicity retaining clinical efficacy . Biomarker monitoring chemotherapy allows early detection of cardiac damage" Standard-dose is a standard-dose of the drug . Standard-dose is a form of formality for the drug . " The treatment diffuse large B cell lymphoma (DLBCL) generally based multidrug chemotherapy, instance therapy rituximab together cyclophosphamide, vincristine, doxorubicin, prednis" Low grade lymphoma may transform aggressive lymphoma transformation usually associated poor outcome . " Diffuse large B-cell lymphoma (DLBCL) common B-cell lymphoma subtype, Epstein-Barr virus (EBV)-positive subtype DLBCL known show aggressive clinical behavior EBV-negative one" High variability patient outcome of rituximab-based treatment partly explained rituximab concentrations . High variability patient outcome of treatment partly explained rituximab-based treatment partly explained rituximab concentrations . " All plasmablastic neoplasms identified 15-year retrospective search reviewed classified 'lymphoma', 'myeloma' 'indeterminate' The classification compared previously established clinical diagnosis ." TRPM4 ion channel regulates influx calcium cations (Ca Analysis publicly available DLBCL microarray data sets showed TRPM4 transcripts up-regulated DLBCL compared normal germinal centre B (GCB) cells . Higher Inherited chromosomally integrated human herpesvirus-6 characterised complete HHV-6 genome integration . Relationship ciHHV-6 diseases seems angina pectoris . " Pharmacokinetic (PK) studies suggest room improvement clinical use of rituximab individualized treatment . 29 newly diagnosed patients with diffuse large B-cell lymphoma treated rituximab combination cyclophosphamide, do" " Development secondary central nervous system involvement (SCNS) patients diffuse large B-cell lymphoma associated poor outcomes . We retrospectively analysed patients diffuse large B-cell lymphoma diagnosed 2001 2013, staged PET/CT treated R-CHOP" " Langerhans cell sarcoma (LCS) quintuple cancers extremely rare . In report, case quintuple cancers including LCS described ." " Nuclear factor (NF)-κB addiction found indolent lymphomas well diffuse large B-cell lymphomas, either activated B-cell like phenotype associated Epstein-Barr virus . Epstein-Barr virus-latency III program" Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) defined monoclonal EBV+ B-cell proliferation affecting patients without known immunosuppression . Non-neopl A 37-year-old woman Puerto Rico woman presented clinic symptoms abdominal distension progressively worsening 1 year . CT abdomen pelvis contrast performed revealed bilateral large heterogeneous pelvic adnexal masses large ascites right pleural effusion . Path " This phase 1/2 study evaluated safety, pharmacokinetic behavior anti-tumour activity ublituximab . Patients received ublituximab maintenance monthly cycles 3-5, every 3 months 2 years ." " Lenalidomide suitable candidate long-lasting maintenance oral drug, active DLBCL taken years acceptable toxicity profile . Patients relapsed diffuse large B-cell lymphoma (DLBCL) eligible autologous stem cell transplantation (" Age-related EBV-associated lymphoproliferative disorders form new clinicopathological group . Group associated diffuse large B-cell lymphoma characterised aggressive clinical presentation poor prognosis . " Inflammatory demyelination also reported patients clinically suspected primary central nervous system lymphoma (PCNSL) The presence of inflammation demyelination central nervous system (CNS) biopsy points towards limited, yet heterogeneous" " Mature B-cell non-Hodgkin lymphoma common subtype non-Hodgkin lymphoma childhood adolescence . B-cell non-Hodgkin lymphomas classified histological subtypes, Burkitt lymph" Eighty-six patients included. Eighty-six patients included. Non-Hodgkin B-cell lymphomas constituted 83% (n = 71) T-cell lymphomas constituted 83% (n = 71) Non Activated B-cell-like (ABC) germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent 2 major molecular DLBCL subtypes . They characterized differences clinical course diver microRNA-28 (miR-28) regulates GC reaction primary B cells impairing class switch recombination memory B plasma cell differentiation . Epstein-Barr virus (EBV) encodes 49 microRNAs (miRNAs) BART BHRF1 regions genome . EBV-encoded miRNAs reported EBV-positive cell lines nasopharynge We evaluated surgical trends gastric diffuse large B-cell lymphoma (gDLBCL) approval rituximab . We evaluated surgical trends gastric diffuse large B-cell lymphoma (gDLBCL) approval r " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin's lymphoma, multiple molecular subtypes . Activated B-cell-like DLBCL subtype accounts roughly one-third" Little known role pathway pathway diffuse large B-cell lymphoma (DLBCL) is little known pathway . Little known role pathway is inositol-requiring enzyme 1 (IRE1) downstream target X-box-binding protein Left ventricular (LV) twist considered essential part LV function . Secondary myocardial involvement diffuse large B-cell lymphoma rare occurrence . Secondary myocardial involvement diffuse large B-cell lymphoma rare occurrence . The incidence non-Hodgkin lymphoma patients 80 years age older 50 times higher 20- 24-year-olds . The incidence non-Hodgkin lymphoma patients 80 years age older 50 times higher 20-24 " Anti-CD19 chimeric antigen receptor T-cell therapy KTE-C19, 76% 51 patients diffuse large B-cell lymphoma responded treatment . After 3 months, 33% continued experience complete response ." Diffuse large B-cell lymphoma (DLBCL) heterogeneous subtype non-Hodgkin lymphoma . Recystria gene mutations recently identified patients DLBCL using next-generation sequencing technologies . Clinical analysis Low T3 syndrome defined low serum free T3 (FT3) level low normal serum free tetraiodothyronine (FT4) thyroid stimulating hormone levels . Multivariate Cox regression analysis used screen prognostic factors associated progression- " In treatment diffuse large B-cell lymphoma, persistently positive [ persistently positive [ B-cell lymphoma] is a persistent positive [ B-cell lymphoma]" Primary bone lymphoma primary adrenal lymphoma rare clinicopathological entities non-Hodgkin's lymphoma (NHL) We present first case diffuse large B-cell lymphoma involvement single bone adrenal glands alone adrenal Complex cancer signaling networks limits efficacy single-agent treatments . Complexity of cancer signaling networks limits efficacy single-agent treatments . Researchers used chronic active B-cell receptor (BCR) signaling to identify effective combinatorial therapies . " ZUMA-1 phase 1 study evaluated KTE-C19, autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy . Patients received low-dose conditioning chemotherapy concurrent cycl" " Abexinostat orally available hydroxamate-containing histone deacetylase inhibitor differs approved inhibitors . In phase II study, patients relapsed/refractory non-Hodgkin lymphoma chronic lymphocytic" " Objective: To evaluate stromal cells bone marrow microenvironment (BMM) bone marrow microenvironment (BMM) bone marrow trephine biopsy (BMTB) specimens . Focus fibronectin, tumor necrosis factor" Leizumab is a drug used to treat relapsed refractory B-cell chronic lymphocytic leukemia . The primary objective evaluate safety alemtuzumab Japanese patients . The major treatment-emergent adverse even Oral non-Hodgkin lymphoma frequently mimics odontogenic oral pathologies . Oral non-Hodgkin lymphoma frequently mimics odontogenic oral pathologies . Hepatitis C virus (HCV) infection causes hepatocellular carcinoma (HCC) subtypes non-Hodgkin lymphoma (NHL) Associations cancers established . We present case 91-year-old female unusual manifestation primary cutaneous diffuse large B-cell lymphoma . Dermatopathologic evaluation rendered correct diagnosis . " B-cell activation markers CXCL13, sCD23, sCD27, sCD30 associated future lymphoma risk ." The study included 1848 diffuse large B-cell lymphoma (DLBCL)patients treated chemotherapy/rituximab . The aims validate National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) Cell-free DNA shed blood tumor cells undergoing apoptosis . Study aimed tracking basal DLBCL genetic profile modification upon treatment using plasma cfDNA . " Plasmablastic lymphoma (PBL) uncommon variant diffuse large B-cell lymphoma characterized plasmacytoid features, aggressive tendencies, frequent association human immunodeficiency virus (HIV) infection immunocomprom" Pathological analysis cornerstone diagnosing malignant lymphoma . Status cytogenetic abnormalities frequently left unexamined evidence malignancy found . Epstein-Barr virus (EBV) infection associated B cell lymphomas humans . Epstein-Barr virus (EBV) infection associated B cell lymphomas humans . EBV convert human B cells long-lived lymphoblastoid 38-year-old Asian man presented insidious abdominal discomfort night sweats following recent travel India . Diagnosis was successful at tertiary centre via splenic biopsy . " The Advanced Lung Cancer Inflammation Index (ALI, body mass index × albumin/neutrophil-to-lymphocyte ratio) demonstrated prognostic factor survival . We retrospectively investigated usefulness ALI predict chemotherapy response" " Several effective immunosuppressant drugs rheumatoid arthritis (RA) are developing . Among methotrexate (MTX)-associated lymphoproliferative disorders, primary hepatic lymphoma (PHL) patients RA" PI3Kα PI3Kδ dramatically enhanced anti-tumor profile . PI3Kδ dramatically enhanced anti-tumor profile of diffuse large B cell lymphoma . Phase Ib GERSHWIN study assessed pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses Chinese patients B-cell lymphomas . " CREBBP acetyltransferase inactivates mutations CREBBP acetyltransferase highly frequent diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) and FL, two common germinal" Primary cutaneous follicle center lymphoma primary cutaneous diffuse large B-cell lymphoma primary cutaneous diffuse large B-cell lymphoma primary cutaneous diffuse large B-cell lymphoma primary cutaneous follicle center lymphoma primary The work presented Jiang colleagues addresses somatic mutations CREBBP disable acetylation cause unopposed deacetylation BCL6/SMRT/HDAC3 complexes enhancers B-cell signaling immune response genes . This opens " In 2011 reported rituximab plus miniCHOP (reduced-dose cyclophosphamide, doxorubicin, vincristine, prednisone) combination patients older 80 years diffuse large B-" Fine-needle aspiration biopsy (FNAB) systematically compared core needle biopsy (CNB) to core needle biopsy (CNB) We evaluated sensitivity FNAB diagnosing grading FLs using multiparameter approach CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) represents 5%-10% DLBCL cases . We studied 130 patients de novo DLBCL received frontline R-EPOCH " The prognosis of diffuse large B-cell lymphomas (DLBCL) transformed indolent lymphoma (TL) considered poorer de novo DLBCL . However, seems improved since introduction of rituximab ." " Signet-ring cell lymphoma (SRCL) rare morphologic variant non-Hodgkin lymphoma . SRCL date described types non-Hodgkin lymphoma, mostly single-case reports ." Cyclin D1 protein expression lymphocytes classically associated mantle cell lymphoma . CCND1 gene abnormalities well studied nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) Using double stain CD20/cycl Diffuse large B-cell lymphoma (DLBCL) frequently seen setting . CD30+ DLBCL sinusoidal pattern involvement reported pediatric PTLD . 9-year-old female child presented diffuse lymphadenopathy postheart " Pleomorphic mantle cell lymphoma (PMCL) morphologically mimics diffuse large B cell lymphoma (DLBCL) We screened 500 B cell lymphomas using immunohistochemical algorithm three markers (CD5, cyclin D" " JAKs non-receptor tyrosine kinases generally found association cytokine receptors . In canonical pathway, roles JAKs well established activating STATs response cytokine stimulation modulate gene transcription . In contrast, noncanonical" " Plasmablastic lymphoma (PBL) initially described 1997 oral cavity HIV positive patients . Initial description of PBL was originally described 1997 oral cavity HIV positive patients . Since original description, others cases reported ." Aim study evaluate patient preference satisfaction subcutaneous (s.c.) versus intravenous (i.v.) formulation rituximab given chemotherapy previously untreated patients . Patients received eight cycles rituximab according to 2 schedules " Tumor-infiltrating immune cells influence diffuse large B-cell lymphoma (DLBCL) outcomes . Little known significance of peripheral blood immune cell numbers, however, known significance of peripheral blood immune cell numbers ." Warthin-Finkeldey type giant cells first described autopsies performed in 1908 . The cells 8-15 nuclei without identifiable cytoplasm within lymphoid organs resembling megakaryocytes . The optimal follow-up strategy for primary central nervous system lymphoma (PCNSL) patients first-line therapy unclear . The optimal follow-up strategy for PCNSL patients first-line therapy unclear . Kinases downstream B-cell antigen receptor (BCR) represent attractive targets therapy non-Hodgkin lymphoma (NHL) Kinases downstream B-cell antigen receptor (BCR) represent attractive targets therapy non-H " Brentuximab vedotin (BV) antibody-drug conjucate (ADC) comprising CD30-directed antibody, conjugated microtubule-disrupting agent MMAE via protease cleavable" " Relapsed/refractory (R/R) aggressive lymphoma outcomes poor. There standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide" " Of 1347 neoplasms, 6.09% Hodgkin lymphoma, 6.09% Hodgkin lymphoma . Lymphoid neoplasms heterogeneous types lymphoma vary different geographic regions ." " Plasmablastic B-cell malignancies include plasmablastic lymphoma subsets multiple myeloma diffuse large B-cell lymphomaDLBCL. These diseases difficult diagnose treat, lack well-characterized cell line" Haflinger mare presented North Carolina State University Veterinary Teaching Hospital . Haflinger mare presented North Carolina State University Veterinary Teaching Hospital . Haflinger mare presented North Carolina State University Veterinary Teaching Hospital 2-week history lethargy . 3 " Evidence suggested early relapses (ie, within 1 year) approach portends exceptionally poor outcomes . However, data examining relapses > 1 year ASCT patients refractory relapsed DLBCL limited, particular, rituxim" " In retrospective study one institution, performed clinicopathological study cohort patients posttransplant lymphoproliferative disorder (PTLD) confined central nervous system . We also identified comparison cohort patients de novo primary diffuse large B-cell lymph" Cutaneous B-cell lymphomas (CBCLs) comprise group mature lymphoproliferative B-cell disorders . CBCLs fundamentally differ primary nodal systemic B-cell lymphomas . Given uncomplicated course excellent prog " Extranodal NK/T-cell lymphoma usually presents upper aerodigestive tract, involve skin secondarily . This article focus cutaneous lymphoproliferative disorders associated EBV ." " Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular biological subtypes . With standard chemoimmunotherapy, remains unacceptably high treatment failure rate certain DLBCL subsets ." " Rituximab-containing salvage chemotherapy followed high-dose therapy autologous stem cell transplant (ASCT) chemosensitive patients remains standard care patients . However, role patients achieving less complete response first-line therapy (primary" " MYC common driver event human cancers, tumors depend MYC maintain transcriptional programs promote cell growth proliferation . HDAC PI3K inhibition inducing cancer cell death also reported, involvement MYC regulation unclear ." Primary appendiceal lymphoma (PAL) extremely rare limited limited data available literature . PAL primarily afflicted males white race. Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) rare aggressive type diffuse large B-cell lymphoma (DLBCL) rare aggressive type diffuse large B-cell lymphoma (DLBC Radioimmunotherapy represents potential option consolidation chemoimmunotherapy patients diffuse large B-cell lymphoma candidates transplantation . " The treatment diffuse large B-cell lymphoma presence cardiac comorbidities challenging considering standard treatment regimen used . The use anthracycline doxorubicin associated arrhythmias cardiomyopathy, making patients" " Diffuse large B-cell lymphoma (DLBCL) commonest aggressive non-Hodgkin lymphoma . Approximately 5,000 cases annually annually UK. Diffuse large B-cell lymphoma (DLBCL)" " Up 50% patients Hodgkin lymphoma diffuse large B-cell lymphoma relapse, requiring additional therapy . Up 50% patients Hodgkin lymphoma diffuse large B-cell lymphoma relapse, requiring additional therapy ." " Inflammatory biomarkers, neutrophil lymphocyte ratio (NLR), lymphocyte monocyte monocyte ratio (LMR), Glasgow Prognostic Score (GPS) proposed predict prognosis . C-X-C motif" " Tumor-infiltrating neutrophils implicated malignant development progression, mechanisms ill defined . High APRIL expression DLBCL correlates reduced patient survival, pathway(s) dictating APRIL expression known ." Myc family targets epithelial ovarian cancer (EOC neuroblastoma) neuroblastoma . Myc transcriptional activity frequently deregulated human cancers . Myc-driven gene signature prognostic ability across multiple tumor types remains lacking . Elsevier Policy Article Withdrawal found http://www.elsevier.com/locate/withdrawalpolicy. This article withdrawn request author(s) and/or editor . " CD5-positive (CD5 MYD88, CD79B, CD79B, CD79A, CD79A, caspase recruitment domain family member 11 (CARD11) mutations examined samples . CD5-" " Non-Hodgkin lymphomas occurring children adolescents young adults (AYA) characterized various age-related differences tumor biology survival . Children generally present high-grade lymphomas, Burkitt lymphoma, diffuse large B-cell lymph" " A 14-year-old boy with significant medical history presents headaches vomiting found 2-cm left parietal lobe mass . Biopsy reveals diffuse large B-cell lymphoma (DLBCL) Cerebrospinal fluid cytology," " R-CHOP therapy fails, 20% suffer primary refractory disease (progress right treatment) whereas 30% relapse achieving complete remission (CR) Most refractory patients exhibit double-hit lympho ." " B cell-lymphoma-2 (Bcl-2) proteins emerging therapeutic targets variety cancers . Precision medicines, like BH3-mimetic drug venetoclax (ABT-199), antagonizes hydroph" Survival patients diffuse large B-cell lymphoma increased last decade result addition anti-CD20 anthracycline-based chemotherapy . Persistent differences survival within USA European countries suggesting non-biological factors play role . " The forkhead transcription factor FOXP1 generally regarded oncogene activated B cell-like diffuse large B-cell lymphoma . Previous studies suggested small isoform FOXP1 rather full-length FOXP1, may possess onc" " Richter transformation (RT) occurs 5-10% patients chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) associated poor outcome . Rarely, superimposed herpes simplex virus (" Plasmablastic lymphoma rare aggressive disease arises predominantly men associated immunodeficiency causes . Epstein-Barr virus infection MYC gene aberrations implicated development HIV-positive HIV-positive HIV-negative patients . The disease typically Richter syndrome small lymphocytic lymphoma (SLL) progressed CD3+ diffuse large B-cell lymphoma (DLBCL) Macrodissection small large cell lymphomatous components performed . Flow cytometric analysis along Skeletal muscle radiodensity (SMD) may better prognostic marker . Skeletal muscle radiodensity (SMD) may better prognostic marker . Lymphoma eyelid constitutes 5% ocular adnexal lymphoma . 56% lymphomas eyelid B-cell origin 44% T-cell origin . Recent studies show superior outcomes overweight obese patients . Recent studies show superior outcomes overweight obese patients . Study demonstrates underweight D patients are more likely to survive . Hyper-IgE syndrome (HIES) due DOCK8 deficiency autosomal recessive (AR) primary combined immunodeficiency results significant morbidity mortality young age . Different mutations DOCK8 gene lead variable severity disease . " Transformed lymphoma complex syndrome encompasses array different underlying low-grade lymphoproliferative conditions transforming aggressive disease . Over last decade, advances chemoimmunotherapy led new options ." Gray zone lymphoma (GZL) variable tumor cells spanning spectrum diffuse large B-cell lymphoma (DLBCL) classical Hodgkin lymphoma . The immunophenotype frequently discordant. The immunophenotype frequently discordant Double-hit lymphomas (DHLs) characterize unique subset B-cell non-Hodgkin lymphomas . DHLs typically presents older adults high-risk clinical features . This entity carries significantly inferior prognosis compared typical Diffuse large B-cell lymphoma (DLBCL) common type lymphoma western world . Current treatment regimens result curing approximately 50% 60% patients DLBCL . Surveillance PET beneficial majority patients . PET also used predict outcome pre-autologous transplant setting . PET pre-allogeneic setting less established benefit . " Second-line therapy options patients diffuse large B-cell lymphoma (DLBCL) refractory to, relapses after, current rituximab-containing primary therapy continue evolve . For younger patients, salvage therapy followed" Diffuse large B-cell lymphoma presents limited-stage disease approximately 30% cases . Therapy relied combined modality abbreviated chemotherapy followed involved-field radiotherapy (IFRT) " Major progress understanding diffuse large B-cell lymphoma (DLBCL) biology made last decade . Many specific compounds entered early phase clinical trials . Efforts needed to find accurate, fast, reproducible, affordable technique translate DLBCL" " Diffuse large B-cell lymphoma (DLBCL) represents common lymphoid malignancy adults, median age 60 70 years . Clinical behavior usually rapidly aggressive, extranodal involvement 40% cases . Chemoimmun" " Effusion-based lymphoma rare unique type large B-cell lymphoma presenting effusion without mass lesion . It shares many clinicopathological features primary effusion lymphoma (PEL), distinct PEL absence HHV8 association" Rare reports of gray zone lymphoma features intermediate classical Hodgkin lymphoma (CHL) DLBCL . Rare reports of rare case composite lymphoma (CHL NLPHL) progressing DLBCL . Diffuse large B cell lymphoma (DLBCL) common aggressive cancer caused malignant transformation B cells . Little information available on DLBCL pathogenesis . " Composite lymphoma (CL) is infrequently diagnosed entity two distinct types lymphomas occur synchronously organ anatomical site . Most commonly, CLs composed two non-Hodgkin B-cell lymphomas . We present case of case" Antibodies targeting programmed death 1 cytotoxic T-lymphocyte-associated protein-4 also investigated lymphoid malignancies . BCL6 drives malignant phenotype repressing proliferation DNA damage checkpoints blocking B-cell terminal differentiation . BCL6 mediates effects binding hundreds target genes repressing genes . 331 patients PTF defined primary progression upfront chemoimmunotherapy (PP) relapse < 6 months end therapy (RD) relapse < 6 months end therapy (early relapse) Median age 58 years response salvage 41.7% . Two Helicobacter pylori (HP)-independent gastric diffuse large B-cell lymphoma (DLBCL) tumours evidence mucosa-associated lymphoid tissue (MALT) But significance BAFF expression HP independence gastric Polyploidy diffuse large B-cell lymphoma (DLBCL) defined DLBCL either near-tetraploid greater number chromosomes detected G-band method . DLBCL polypoidy defined DLBC " 60-year-old man presented 2012 epidural mass, diagnosed diffuse large B-cell lymphoma (DLBCL) concurrent low-grade follicular lymphoma (DLBCL) concurrent low-grade follicular lymphoma (" Lymphoma one frequent cancers adolescent young adults . Hodgkin Lymphoma curable 90% cases . Recent pediatric adults protocols aimed decrease long term toxicities (mostly gonadic cardiovascular) secondary malignancies . Lymphomas may broadly divided non-Hodgkin (90%) Hodgkin (10%) types . Most lymphomas (90%) B cell origin also T cell natural killer cell . Aggressive lymphomas dangerous left untreated yet higher " We previously reported early-stage gastric diffuse large B-cell lymphomas (DLBCL) with mucosa-associated lymphoid tissue (DLBCL[MALT) without (""pure"" DLBCL) features MALT" " Periodontal disease chronic inflammatory condition associated chronic diseases, including cancer . 31% higher risk non-Hodgkin lymphoma among participants severe periodontal disease baseline ." Canine lymphomas among common tumors dogs bear remarkable similarity human disease . Canine lymphomas among common tumors dogs bear remarkable similarity human disease . The treatment EAEPT could induce loss mitochondrial membrane potential (MMP) increase ROS level . EAEPT could induce loss mitochondrial membrane potential (MMP) increase ROS level . " Diffuse large B-cell lymphoma patients 5% overall risk central nervous system events (relapse progression) 5% overall risk central nervous system events (relapse progression) account high morbidity frequently fatal outcomes, account high morbidity" Diagnosis primary central nervous system lymphoma (PCNSL) still elusive . Diagnosis primary central nervous system lymphoma (PCNSL) usually confirmed brain biopsy . 5-Aminolevulinic acid (5- We describe unusual presentation of plasmablastic lymphoma patient suffering osteoradionecrosis jaw . We report case case 64-year-old patient followed oncology oropharyngeal cancer treated combined procedure surgery radio- " Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity tumor behavior outcomes . Identification poor-risk groups remains challenging, biology underlying differences incompletely understood ." " High-grade B-cell lymphomas (HGBLs) MYC BCL2 and/or BCL6 rearrangements, so-called ""double-hit"" lymphomas (HGBL-DH), form" Hodgkin lymphoma presents different histopathologic growth patterns . Study compares angiogenesis different NLPHL patterns THRLBCL well lymphomas . Atypical variants NLPHL THRLBCL (n=10 per group " A recent studies investigated prognostic impact CD30 expression diffuse large B-cell lymphoma (DLBCL) patients treated rituximab, cyclophosphamide, doxorubicin, vincristine," " LR11 (also called SorLA SORL1) type I membrane protein, originally identified biomarker atherosclerosis Alzheimer's disease . We recently found LR11 specifically expressed Diffuse Large B-cell lymphoma (DLBCL" The histone methyltransferase EZH2 reported involved tumorigenesis systemic DLBCL implicated primary CNS DLBCL . The clinicopathological features 33 cases of primary CNS DLBCL were assessed . The tumor cells majority cases " Diffuse large B-cell lymphoma (DLBCL) common type lymphoma worldwide . World Health Organization classification includes several subtypes based combination clinical, immunohistochemical, genetic differences ." " AZD5153 is potent, selective, orally available BET/BRD4 bromodomain inhibitor possessing bivalent binding mode . AZD5153 liga liga is a potent, selective, orally available BET/BR" " 84-year-old man presented cutaneous lesions, malaise, B-symptoms, B-symptoms . Skin biopsy revealed neoplastic cells within lumen dermal vessels ." " Histone deacetylase 9 (HDAC9) expressed B cells, overexpression observed B-lymphoproliferative disorders, including B-cell non-Hodgkin lymphoma . We examined HDAC" Plasma-cell post-transplantation lymphoproliferative disorder (PC-PTLD) rare monomorphic PTLD entity divided plasma cell myeloma (PCM) plasmacytoma-like lesion (P MicroRNA well-established players post-transcriptional gene regulation . Information effects microRNA deregulation mainly relies bioinformatic prediction potential targets . " Hashimoto's thyroiditis (HT) frequently encountered condition clinical practice management generally uncomplicated patients stable dose thyroxine supplementation . However, complications thyroid lymphoma develop, though rare hence commonly forgotten physicians ." " A 55-year-old man with left flank pain, nausea vomiting weight loss . A CT scan private hospital revealed bilateral large adrenal masses . A Trucut biopsy adrenal gland revealed diffuse large B ." " 32-year-old man complained progressive growing, painful mass right parieto-occipital part head . Computed tomography magnetic resonance imaging revealed homogeneously enhanced mass partial bone destruction ." " Diffusion large B-cell lymphoma (DLBCL) was diagnosed in Sweden 2007 2012 . 751 DLBCL patients aged aged <60 years without central nervous involvement, diagnosed Sweden 2007 2012 . Overall survival estimated using multiv" " WHO lymphoma classification recognizes primary cutaneous follicular center cell lymphoma (PCFCCL) primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) Categorization primary cutaneous" " Burkitt lymphoma (BL) Diffuse Large B-Cell Lymphoma (DLBCL) account cases non-Hodgkin lymphoma (NHL) childhood . We report clinical characteristics, outcome prognostic factors children" A new subtype granzyme B (GrB)-producing regulatory B cells (B) A new subtype granzyme B (GrB)-producing regulatory B cells (B) A new subtype granzyme B (GrB)- Low-dose radiotherapy (LDRT) given 2 Gy is highly effective safe treatment palliation indolent lymphomas . We designed phase 2 trial LDRT patients DLBCL indication palliative radiation . Clinical response assessed Adaptor protein Bcl10 inducibly recruited CARD11 scaffold protein part multicomponent complex induces IκB kinase (IKK) activity NF-κB activation . NF-κB activation NF-κB is CD37 (tetraspanin TSPAN26) B-cell surface antigen widely expressed mature B cells . CD37 involved immune regulation tumor suppression function fully elucidated . " 29 primary sinonasal diffuse large B cell lymphoma (DLBCL) 29 primary sinonasal diffuse large B cell lymphoma (DLBCL) In training set, 82% non-germinal center B" " Diffuse large B-cell lymphoma (DLBCL) common lymphoma type . CD10, bcl-6, MUM1 expressed 16.3%, 71.2%, 71.9% cases, respectively, 27" This pooled analysis study aimed reveal prognostic relevance microRNAs (miRNAs) patients diffuse large B-cell lymphoma (DLBCL) We examined impact miRNAs clinical outcome . Metastatic tumours pituitary gland rare . Metastatic tumours pituitary gland rare . The frequent metastases breast lung. The frequent metastases breast lung. " Diffuse large B-cell lymphoma (DLBCL) is seen less commonly . Burkitt lymphoma is seen less commonly . Non-Hodgkin lymphoma (NHL) occurs site body, however diffuse extensive involvement" " Plasmablastic lymphoma (PBL) rare aggressive subtype non-Hodgkin lymphoma commonly occurs human immunodeficiency virus (HIV)-positive individuals, affects oral sites . Epstein-Barr virus infection" " Follicular lymphoma (FL) indolent B-cell non-Hodgkin lymphoma able transform germinal center-type diffuse large B-cell lymphoma . We describe four extraordinary cases FL, progressed T" " Rituximab first monoclonal antibody approved use US Food Drug Administration cancer . Its role treatment non-Hodgkin lymphoma, including chronic lymphocytic leukaemia, evolved significantly ." " Histone methylation demethylation regulates B-cell development, deregulation correlates tumor chemoresistance . Study found KDM6B levels associated worse survival patients with worse survival patients ." " The addition rituximab improved outcomes diffuse large B-cell lymphoma (DLBCL) The addition rituximab improved outcomes diffuse large B-cell lymphoma (DLBCL) However, remains limited information" Diffuse large B-cell lymphomas (DLBCLs) contain 2 major molecular subtypes; namely germinal center B-cell-like (GCB) activated B-cell-like (ABC) DLBCL Little known phylogenetic relationship diagnostic relapse clones diffuse large B-cell lymphoma (DLBCL) Little known phylogenetic relationship diagnostic relapse clones . We applied high throughput sequencing (HTS) VDJ locus Immunoglobulin heavy " 14 cases of EBV-positive grey zone lymphoma (GZL) Japan . The patients were 10 men four women median age 62 years . The patients were 12 patients (86%) advanced clinical stage, 11 (79%) B" " Histone deacetylase (HDAC) inhibitors proven useful therapeutic agents certain hematologic cancers . HDAC inhibition causes diverse cellular outcomes, identification cancer-relevant pathways within outcomes remains unresolved ." Somatic mutations CREBBP occur frequently B-cell lymphoma . Somatic mutations CREBBP occur frequently B-cell lymphoma . B-cell receptor (BCR) signaling plays pivotal role pathogenesis diffuse large B-cell lymphoma (DLBCL) targeting BCR pathway highly promising therapeutic strategy malignancy . The oncogenic microRNA miR- " Diffuse large B-cell lymphomas aberrations MYC, BCL2 and/or BCL6 genetic alterations protein expression represent group high grade B-cell lymphomas inferior outcomes treated standard RCHOP chemotherapy . As result" " Primary central nervous system lymphoma (PCNSL) distinct subtype extranodal lymphoma aggressive clinical course poor outcome . We hypothesized PCNSL might originate population B cells high IL-10-producing capacity, equivalent ""reg" PD-1 expression surface CD4 is a relationship between PD-1 expression surface CD4 and CD4 . PD-1 expression surface CD4 expression is a relationship between PD-1 expression surface CD4 expression . Richter's transformation (RT) transformation chronic lymphocytic leukemia (CLL) rapidly progressive B-cell lymphoma . This disease long recognized difficult-to-treat illness poor survival outcomes . " The impact patient body habitus sex outcomes on diffuse large B-cell lymphoma (DLBCL) remains controversial . We investigated impact body mass index (BMI), body surface area (BSA), age, sex clinical outcomes patients" " Prognostication patients diffuse large B-cell lymphoma (DLBCL) improved past decade variety clinical, morphologic, molecular, radiographic methods . This timely analysis, tailoring therapies based prognosis diagnosis ." Chronic lymphocytic leukemia (CLL) indolent mature mature B-cell neoplasm . Secondary de novo mature B-cell neoplasms arising patient pre-existing CLL described . ALK+ LBCL is a rare distinct type non-Hodgkin's lymphoma arises association alterations ALK gene . Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBC 89 patients with large B-cell lymphoma follicular lymphoma follicular lymphoma were treated with chemotherapy . The immunosuppressive effect of chemotherapy was assessed using immunosuppressive immunosuppressive immunosuppressive immunos " 27/678 (4%) internal reproductive organ involvement: uterus (n = 14), ovaries (n = 10) (n = 3) Overall, 27/678 (4%) internal reproductive organ involvement: uterus (n = 14" Non-Hodgkin lymphoma (NHL) increased in Central South American countries . We describe current patterns trends NHL incidence mortality Central South America . " Copanlisib, phosphatidylinositol 3-kinase inhibitor, phosphatidylinositol 3-kinase inhibitor, was studied in Phase I dose-escalation study . Patients received three weekly intraven" " We recently reported truncating deletion NFKBIE gene, encodes IκBε, negative feedback regulator NF-κB, clinically aggressive chronic lymphocytic leukemia (CLL) We recently reported truncating deletion NFKBI" Marginal zone lymphoma (MZL) mainly diagnosed based cytological appearance growth pattern tumor . Marginal zone B cells recently shown selectively express immunoglobulin superfamily receptor translocation-associated 1 (IRTA1) antibody " Auto-HCT is commonly used for patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) After auto-HCT, DLBCL patients often monitored surveillance imaging . Little evidence support practice ." " During treatment malignant lymphoma, cytopenia develop several reasons . In treatment cytopenia, various possibilities considered inadequate treatment causes exacerbation cytopenia . Herein, describe immune pancytopenia 3 months" " Approximately one-fourth cutaneous lymphomas B-cell derived generally classified three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), primary cut" This study aimed systematically review meta-analyze prognostic value interim (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) diffuse large B-cell Only studies investigated presence increased MYC gene copy number (ICN) prognostic indicator patients diffuse large B-cell lymphoma (DLBCL) results variable . We compared overall survival patients ICN MYC-negative patients investigated prog " Common variable immunodeficiency (CVID) comprises heterogeneous group disorders humoral immunity . Immune dysregulation causes susceptibility recurrent bacterial infections, well autoimmune lymphoproliferative disorders ." " Diffuse large B cell lymphoma (DLBCL) common subtype lymphoma . We recognize DLBCL corresponds biologically heterogeneous family diseases . Given potential cure DLBCL patients, appropriate diagnostic staging evaluation therapy is essential ." " Older patients with diffuse large B-cell lymphoma (DLBCL) risk severe chemotherapy-related morbidity mortality . Using Medicare claims linked population-based SEER registry (SEER-Medicare), studied patients DLBCL aged" Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) newly described entity occurring elderly iatrogenically immunocompromised patients . We describe case EBVMCU arising post Immune escape tolerance tumor microenvironment closely involved tumor progression . T-cell exhaustion mediated inhibitory signaling immune checkpoint molecules including programmed death-1 (PD-1) and programmed death-1 (PD-1) T-lymph " Diffuse large B-cell lymphoma (DLBCL) common subtype malignant lymphoma; derives germinal center B cells . Although DLBCL harbors many genetic alterations, synergistic roles alterations development lymphoma largely" " Diffuse large B cell lymphoma (DLBCL) common form B cell non-Hodgkin lymphoma worldwide comprises heterogeneous group malignancies . Over past decade, significant improvement achieved understanding molecular pathogenesis underlying disease ." Sciatic nerve neuropathy due infiltrating high grade B-cell lymphoma rare situation often reported . Sciatic nerve neuropathy due infiltrating high grade B-cell lymphoma rare situation often reported . We evaluated CD30 expression 116 cases aggressive B-cell lymphomas diagnosed in 2000 2012 . We studied CD30 expression types aggressive B-cell lymymas . We studied CD30 expression types aggressive B-cell lymas . Kaposi's sarcoma (KS) non-Hodgkin lymphoma (NHL) relative antiretroviral therapy (ART) relative antiretroviral therapy (ART) relative antiretroviral EZH2 histone methyltransferase mediates humoral immune response drives lymphomagenesis formation bivalent chromatin domains critical germinal center (GC) B cell promoters . " Sixty-one patients early-stage WR-DLBCL received chemotherapy followed IMRT retrospectively reviewed . Dosimetric parameters target volume critical normal structures evaluated, survival calculated ." Diffusion large B-cell lymphoma (DLBCL) underwent high-dose chemotherapy autologous stem cell transplant (HDC/ASCT) We analyzed consecutive patients DLBCL underwent HDC/ASCT May 1992 March MYC associated poor prognosis patients with poor prognosis patients with MYC associated poor prognosis . Little known outcomes patients demonstrate MYC rearrangement without evidence BCL2 BCL6 rearrangement (single hit) rearrang " Non-Hodgkin's lymphoma (NHL) common hematological malignancy . In India, incidence several-fold higher urban cancer registries compared rural areas . In developed nations, key differences presented in India i" " MYD88(L265P mutation found 2% 10% chronic lymphocytic leukemia, 29% activated B-cell type diffuse large B-cell lymphoma 90% Waldenström macroglobulinemia" Bendamustine combination rituximab (BR) associated high response rates acceptable toxicity . Bendamustine combination rituximab (BR) associated high response rates acceptable toxicity . Nodal marginal zone lymphoma (NMZL) rare non-Hodgkin lymphoma arises mature B-cells . We identified 56 patients treated institutions. The majority presented advanced stage disease (78·6%) over median " Hodgkin lymphoma (HL) malignancy germinal center (GC-B) B-cell origin . Study of long noncoding RNAs (lncRNAs) HL, studied lncRNA expression patterns normal" Primary mediastinal large B-cell lymphoma (PMBL) distinct subtype diffuse large B-cell lymphoma (DLBCL) shows overlap classical Hodgkin lymphoma (CHL) favorable prognosis compared mediastinal " Diffusion large B-cell lymphoma (DLBCL) rarely occurs patients Waldenström Macroglobulinemia (WM) rarely occurs patients . We identified 20 patients cohort 1,466 WM patients experienced hist" 35-year-old male male HIV infection AIDS presented skin lesions swelling throughout body . Computed tomography (CT) revealed innumerable enhancing soft tissue masses within subcutaneous soft tissues lymphadenopathy . Plasmablastic lymphoma variant " Malabaricone-A triggers apoptotic cell death, secondary 'turning on' cell signaling pathways . Malabaricone-A (MAL-A) triggers apoptotic cell death, secondary 'turning on' cell signaling" " YB-1 multifunctional protein, shown correlate resistance resistance treatment various tumor types . This study investigated expression biologic function YB-1 diffuse large B-cell lymphoma (DLBCL)" " The resulting risk model validated independent data set 1,597 patients DLBCL identified . The resulting risk model validated independent data set 1,597 patients DLBCL identified British Co." Many patients diffuse large B-cell lymphoma (DLBCL) relapse die disease . Prospective clinical trials demonstrated lenalidomide effective safe treatment option . We assessed longitudinal body composition changes in diffuse large B-cell lymphoma (DLBCL) survivors . We identified clinical variables associated long-term development sarcopenia visceral obesity . " Primary cutaneous follicle center lymphoma (pcFCL) usually presents reddish nodules, plaques, tumors head neck back . We report series 13 patients (7 male 6 female) with median age 58 years, mean age" Mean platelet volume (MPV) associated risk venous thromboembolism (VTE) increased mortality patients cancer . We evaluated association MPV VTE mortality patients treated diffuse large B-cell lymphoma (DLBC " 192 DLBCL patients aged > 60 years received first-line immunochemotherapy retrospectively evaluated . The treatment schedule, adverse events, survival outcomes analyzed overall stratified 4 age groups . Patient age age 75 years associated significantly lower complete remission" Use of Rituximab diffuse large B cell lymphoma (DLBCL) improved outcomes led questions regarding benefit consolidative radiation therapy (RT) This study sought determine changes RT utilization following incorporation Rituximab treatment early " Sarcopenia febrile neutropenia hospitalization, treatment-related mortality, ability complete standard number number cycles . Sarcopenia associated decreased overall survival in diffuse large B-cell (DLBCL) patients" Chromosomal translocations involving immunoglobulin (IG) locus proto-oncogene play major role diffuse large B-cell lymphoma (DLBCL) pathogenesis . Recurrent IG translocation partners DLBCL T cells kill microbial-infected malignant cells detection nonself antigens TCR . Tumor reactivity encoded genetically introducing chimeric antigen receptor (CAR) T cells . CARs composed antigen-binding domain intracellular Study examines efficacy communication skills training (CST) intervention help physicians address survivorship issues . " Non-Hodgkin lymphoma subtypes varies around world, large systematic comparative study never done . In study, evaluated clinical features relative frequencies non-Hodgkin lymphoma subtypes five developing regions world compared findings developed world" " Burkitt's lymphoma, involves c-myc gene (8q24) immunoglobulin heavy-chain (IgH) locus (14q32), accounts 90-95% chromosomal translocations . This" Diffusion large B-cell lymphoma (DLBCL) developed by one-third patients develop intractable disease . To improve clinical outcomes patients identify poor prognosis prior initial treatment order select optimal therapies . " 67-year-old patient underwent robotic excision of mobile left ventricular mass . Pathologic examination showed diffuse large B-cell lymphoma, early chemotherapy initiated . Follow-up cardiac positron emission tomography/computed tomography" " Epstein-Barr virus (EBV) associated several lymphoproliferative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL) and posttransplant lymphoprol" " Antiviral therapy altered prognosis patients human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) The authors analyzed National Cancer Data Base records 10,769 patients diagnosed HIV-" " B cell lymphomas express conventional B cell markers (CD20, CD79a PAX5) Rare cases B cell lymphomas express conventional B cell markers (CD20, CD79a PAX5)" " Cardiac involvement lymphomas uncommon, often missed due variability presentation . Timely diagnosis appropriate management patients crucial requires high index suspicion ." 92 patients DLBCL treated either R-CHOP like (n = 69) CHOP like (n = 69) CHOP like (n = 23) regimens stained possible targets proteasome inhibitors . The primary target molecule grey zone lymphoma (GZL) originally included 2008 World Health Organization classification B-cell lymphoma unclassifiable features . It recognized patients GZL may present clinically primary mediastinal localization systemic disease without mediastinal involvement Richter's transformation rare clinical condition occurring 5-10% patients chronic lymphocytic leukaemia (CLL) Poor prognosis median survival 10 months . FCGR3A (rs396991) FCGR3A (rs396991) FCGR2A (rs1801274) influence affinity Fc portion anti-CD20 immunoglobulin G1 monoc " We aimed analyse whether quantitative assessment peripheral blood lymphocyte CD19(+)CD20(+)CD22(+)CD79a(+) B cells, CD3(+)CD4(+)CD4(+)CD5(+)CD" Cancer cells exploit programmed death-1 (PD-1) immune checkpoint pathway avoid immune surveillance modulating T-lymphocyte activity . PD-1 blockade produced significant antitumor activity solid tumors . " Lestaurtinib, JAK2 inhibitor one hits screen, repressed survival BCL6-deficient cells vitro reduced growth proliferation xenografts . BCL6 deficiency DG75-AB7 induced JAK2 mRNA" " We retrospectively reviewed 156 patients newly diagnosed DLBCL patients . We assessed prognostic significance pretreatment C-reactive protein (CRP) concentration . Among 156 patients enrolled, increased CRP concentration increased CRP concentration ." " EZH2 overexpression implicated tumorigenesis candidate oncogene several tumor types . Recently, point mutations EZH2 Tyr641 Ala677 identified diffuse large B cell lymphoma follicular lymphoma follicular lymphoma ." " Hemophagocytosis-related (Asian variant) IVLBCL identified autopsy 62-year-old Hispanic woman, North America . Hemophagocytosis-related (Asian variant) IVLBCL identified autopsy" " Treatment of diffuse large B cell lymphoma (DLBCL) rituximab, anti-CD20 monoclonal antibody, resulted significantly improved patient responses longer event-free intervals higher overall survival rates . However, since" " Previous reports evaluated prognostic value serum beta-2 microglobulin (B2MG) level patients non-Hodgkin lymphoma . However, role predicting clinical outcome patients diffuse large B-cell lymphoma (DLBC" Flow cytometry (FC) may used adjuvant test . Cytomorphology alone often insufficient diagnosis lymphoma . Cytomorphology alone often insufficient diagnosis . " Occult hepatitis B virus (HBV) infection clinical challenge, relationship clinicopathologic features risk progression malignant lymphoma (ML) poorly defined . We estimated prevalence HBV infection 1,358 patients newly diagnosed ML. The occult HB" " The study compared patients with patients with disease-free survival (DFS) and a placebo-controlled trial . The study was a multicenter, phase III, randomized, double-blind, placebo-controlled trial ." Non-Hodgkin lymphoma increased risk venous thromboembolism (VTE) Current risk-prediction models classify NHL single entity . We aimed quantify difference VTE risk follicular lymphoma (FL) " Certain medical conditions affect risk non-Hodgkin lymphoma (NHL) Full range associations unknown . We implemented novel method (""medical condition-wide association study"" MedWAS"" comprehensively evaluate medical risk factors ." " Many malignant hematologic neoplasms directly indirectly involve skin lesions disfiguring, painful, compromise integumentary function . The majority lymphomas directly infiltrate skin T-cell origin B-cell lymphomas, hematologic ne" " Chronic lymphocytic leukemia (CLL) may progress large cell lymphoma, Richter syndrome (RS) The large cells RS may arise transformation original CLL clone (clonally related) represent new neoplasm (clon" Primary diffuse large B cell lymphoma commonly found (30-40% primary non-Hodgkin lymphomas bone) 30-40% primary non-Hodgkin lymphomas bone . The incidence cases peaks 60 70 years The majority diffuse large B-cell lymphoma (DLBCL) tumors contain mutations histone-modifying enzymes (HMEs) indicating potential therapeutic benefit . Preclinical data suggest HDIs augment effect rituximab . " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma . 40% 50% patients eventually succumb disease, demonstrating pressing need novel therapeutic options ." " Activating mutations MYD88 present 90% of patients Waldenström macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL) In WM, mutated MYD88 triggers" " A retrospective study enrolled pediatric NHL patients Children Cancer Hospital Egypt (CCHE) period July 2007 end June 2013 . For 115 pediatric patients diagnosed mature B cell NHL, 152 PET 152 CT scans done simultaneously ." " Non-Hodgkin lymphoma (NHL) constitutes collection lymphoproliferative disorders widely varying biological, histological, clinical features . Autologous hematopoietic cell transplantation (auto-HCT" " Histologically, follicular lymphoma (FL) grades 1, 2 3A composed two distinct cell types, centroblasts centrocytes . FL grade 3B composed centroblasts shown differ immunophenotype genetics FL" Central nervous system (CNS) involvement diffuse large B-cell lymphoma (DLBCL) relatively uncommon manifestation . Cases of cases CNS involvement occuring relapse primary therapy . Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) elderly provisional entity included 2008 WHO classification lymphoid neoplasms . Disease typically seen elderly thought associated chronic EBV infection severe immun FDG-PET/CT may obviate need bone marrow biopsy patients Hodgkin's lymphoma diffuse large B . FDG-PET/CT may obviate need bone marrow biopsy patients Hodgkin's lymphoma diffuse " Non-Hodgkin lymphoma (NHL) heterogeneous group lymphoid malignancies accounting significant portion cancers occurring children, adolescents young adults increasing incidence age . The adolescent young adult (AYA) population presents specific set characteristics" " Chronic active B cell receptor (BCR) signaling, hallmark activated B cell-like (ABC) subtype diffuse large B cell lymphoma (DLBCL) engages CARD11-MALT1-BCL10 (CBM" Smac-mimetics compounds target cellular Inhibitor APoptosis (cIAP) proteins . They induce tumor cell death . Radioimmunotherapy (RIT) unique therapeutic modality combines biologic radiolytic mechanisms induce tumor kill . RIT underutilized community outpatient setting. RIT agents dosed according recommended guidelines. Sphingosine-1-phosphate (S1P) potent lipid mediator produced metabolism sphingolipid sphingosine kinase . S1P implicated migration trafficking lymphocytes several lymphoid malignancies " Strong FOXP1 protein expression poor risk factor diffuse large B-cell lymphoma linked activated B-cell-like subtype, preferentially expresses short FOXP1 (FOXP1S) proteins . Short isoform generation function" " Diffuse large B-cell lymphoma (DLBCL) one leading causes cancer-related mortality, responds badly existing treatment . urgent need identify novel prognostic markers therapeutic targets for DLBCL ." " Busulfan, cyclophosphamide, etoposide (BuCyE) commonly used conditioning regimen autologous stem cell transplantation (ASCT) Study examined safety efficacy BuCyE individually adjusted busulfan based prec" Forty-six consecutive patients early-stage PG-DLBCL underwent IMRT chemotherapy . Majority patients subclassified non-germinal center B cell-like subtype . Survival rates depicted Kaplan-Meier method compared log-rank " Diffuse large B-cell lymphoma (DLBCL) one common aggressive types B-cell lymphoma . Deregulation proto-oncogene expression translocation, notably immunoglobulin heavy-chain locus (" Molecular classification of diffuse large B-cell lymphoma (DLBCL) critical . Numerous methodologies demonstrated DLBCL biologically heterogeneous despite morphological similarities . DLBCL biologically heterogeneous despite morphological similarities . This underlies disparate The added diagnostic prognostic value of routine bone marrow biopsy (BMB) patients . Patients newly diagnosed DLBCL underwent staging PET/CT BMB . " We reported efficacy salvage chemotherapy P-IMVP16/CBDCA patients diffuse large B cell lymphoma (DLBCL) previously received CHOP availability rituximab (R) Here, confirmed efficacy R combined P-" " 30% patients whose follicular lymphoma transforms aggressive diffuse large B-cell lymphoma (DLBCL) poor survival . MicroRNA regulates gene expression, regulates gene expression, critical functions growth progression many cancers contributes pathogenesis lymphoma ." " Paediatric B-cell non-Hodgkin lymphoma (B-NHL) compromises heterogeneous group histological entities Burkitt lymphoma common . In resource-rich countries, expected cure rate excess 85% application risk" " Follicular lymphoma (FL) represents 20% non-Hodgkin lymphomas worldwide approximately 30% non-Hodgkin lymphomas diagnosed United States . Patients frequently asymptomatic, this, combination long median" Doxorubicin may induce early late cardiotoxicity . Non-pegylated liposomal (NPL) doxorubicin may reduce cardiotoxicity . " Allogeneic HCT (alloHCT) often considered, although limited information available guide patient selection . 503 patients underwent alloHCT disease progression/relapse following prior autoHCT ." " GNA13 frequently mutated gene germinal center (GC)-derived B-cell lymphomas, including nearly quarter Burkitt lymphoma GC-derived diffuse large B-cell lymphoma . These mutations occur pattern consistent loss function ." Diffuse large B-cell lymphoma (DLBCL) represents common type aggressive non-Hodgkin lymphoma (NHL) and follicular lymphoma (FL) frequent indolent NHL . Aim study investigate whether Lymphoma considered early patients HIV history weight loss . Lymphoma considered early patients HIV history weight loss . " We performed phase II study evaluate efficacy combination chemotherapy consisting gemcitabine, dexamethasone oxaliplatin (GemDOx) biweekly regimen salvage therapy patients relapsed refractory aggressive non-Hodg" Pixantrone novel aza-anthracenedione structurally similar anthracyclines licenced R/R DLBCL National Institute Health Care Excellence (NICE)-approved following PIX301 trial . 12-year-old male castrated Domestic Shorthair cat presented Animal Medical Center Gifu Univeristy anorexia vomiting . Cytologic examination smears tonsil lymph nodes revealed numerous medium- large-sized lymph Distinct subgroups of diffuse large B-cell lymphoma (DLBCL) genetically resemble specific mature B-cell populations . The activated B-cell (ABC)-like subgroup resembles post-GC plasmablasts undergoing constit B-cell non-Hodgkin lymphomas plasmacytic differentiation diverse group entities extremely variable morphologic features . Diagnostic challenges arise differentiating lymphoplasmacytic lymphoma marginal zone lymphoma low-grade B- " MYC critical driver oncogene many cancers, deregulation forms translocation overexpression implicated lymphomagenesis progression diffuse large B-cell lymphoma (DLBCL) The MYC mutational profile profile roles DLBCL unknown" " Diffuse large B-cell lymphoma (DLBCL) is aggressive non-Hodgkin lymphoma (NHL) Most-common subtype NHL . DLBCL potentially curable, even diagnosed advanced stages ." " Immunoproliferative small intestinal disease (IPSID) extra-nodal B-cell lymphoma commonly described Mediterranean, Africa, Asia . It associated poverty poor sanitation, rarely encountered developed countries ." A 76-year-old woman presented mass left frontal region scalp scalp . Neurological examination found deficits . CT revealed osteolytic mass lesion left frontal cranial vault . Histological diagnosis diffuse large B-cell lymphoma . The age-adjusted annual incidence non-Hodgkin lymphoma (NHL) has risen worldwide . This trend may affected secular increase height sharp upswing adolescent overweight . " Decision-making behalf incapacitated patient end life complex process, particularly family-centric societies . Decision-making behalf incapacitated patient end life complex process, particularly family-centric societies ." Blinatumomab CD19/CD3 BiTE (bispecific T-cell engager) antibody construct treatment Philadelphia chromosome-negative acute B-lymphoblastic leukemia . We evaluated blinatumomab relapsed " HIV-infection known risk factor development extranodal lymphomas, mammary involvement still rarity . Radiologically, PBL appears well circumscribed, heteroechoic, noncalcifying mass ." Intravascular large B-cell lymphoma (IVL) rare subtype extranodal malignant lymphoma . The proliferation neoplastic B cells within small blood vessels causes eruptions symptoms variety organs . The random skin bi MicroRNAs play important roles in wide variety biologic processes . BCL6 transcriptional repressor emerged critical therapeutic target diffuse large B-cell lymphomas (DLBCL) mechanisms regulating BCL6 still unclear . Anti-CD19 BiTE(®) blinatumomab demonstrated clinical activity Philadelphia chromosome (Ph)-negative relapsed refractory (r/r) acute lymphoblastic leukemia (ALL) eventually resulting conditional approval U. Primary hepatic lymphoma represents 0.016% cases non-Hodgkin lymphoma . Liver organ could either involved widespread lymphoma rarely primary site lymphoma . Understanding clinicopathological features hepatic lymphoma would direct appropriate treatment " Bone marrow involvement (BMI) diffuse large B cell lymphoma (DLBCL) naively regarded adverse clinical factor . MTV PET/CT defined initial tumor burden target lesion target lesion ≥ standard uptake value, 2.5" " 76-year-old woman diagnosed with Epstein-Barr virus-positive diffuse large B-cell non-Hodgkin lymphoma elderly . She unusual presentation disease widespread skeletal muscle, masticatory muscle, parotid gland" " Dual expression MYC BCL2 immunohistochemistry (IHC) associated poor outcome diffuse large B-cell lymphoma (DLBCL) Dual translocation MYC BCL2, so-called ""double-hit lymph" " MYC IHC detects MYC protein fixed samples aggressive B-cell lymphomas and facilitates tumor subclassification . MYC IHC predicts underlying MYC rearrangements, stratifies patient outcome ." " 15 patients (median age, 52 years) received dosimetric therapeutic doses TST/I-131 TST . 15 patients (median age, 52 years) received dosimetric therapeutic doses TST/I-131" " In past decade, patients newly diagnosed diffuse large B-cell lymphoma treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine prednisone) therapy ." " Management of B-cell malignancies continues pose clinical challenge . In past years, rituximab (anti-CD20) emerged standard care induction treatment follicular lymphoma (FL), diffuse large B-cell lymphoma" " 35-year-old pregnant woman Crohn disease taking long-term thiopurine therapy developed placental insufficiency, intrauterine fetal death . 35-year-old pregnant woman Crohn disease taking long-term th" Diabetic foot ulcerations (DFU) represent major cause hospitalization amputation . Here report case foot lesion misdiagnosed DFU actually caused diffuse large B-cell lymphoma . De novo CD5+ diffuse large B-cell lymphomas (DLBCL) distinct subgroup DLBCL poor prognosis . Role of rituximab-containing therapy salvage stem cell transplantation patients' population remain Diffuse large B-cell lymphoma (DLBCL) heterogeneous group B-cell lymphomas . Exploring novel important biomarker indispensable understanding mechanism clinical course DLBCL. " A 52-year-old man treated with thiopurine therapy tumour necrosis factor (TNF) α inhibitor, attended surveillance colonoscopy, revealed transverse colon mass . Biopsies lesion showed diffuse large B" " Diffuse large B-cell lymphoma (DLBCL) heterogeneous disease defined transcriptional classifications, specific signaling survival pathways, multiple low-frequency genetic alterations . Preclinical model systems capture genetic functional . functional . heterogeneity of DL" " Blinatumomab, bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells CD19-positive B cells . This phase 2 study evaluated stepwise (9-28-112 μg/" We report case primary cardiac lymphoma presenting myopericarditis rapidly deteriorating biventricular heart failure ventricular arrhythmias . Computed tomography cardiac magnetic resonance (CMR) imaging showed extensive myocardial infiltration . " A hallmark diffuse large B-cell lymphoma (DLBCL) activated B-cell (ABC) type, molecular subtype characterized adverse outcome, constitutive activation transcription factor nuclear factor nuclear factor-κB (NF-κB" Rho family GTPases Cdc42 Rac1 activated ALK oncogenic activity . Increasing evidence suggests Rho family GTPases could critical role biology T-cell lymphoma . To assess prognostic value negative interim combined 2.F]. combined 2.F].fluoro-2-deoxy-d-glucose (18)F-FDG) positron-emission tomography/com We study efficacy fine-needle aspiration (FNA) diagnosing thyroid lymphoma . Primary thyroid lymphoma rare neoplasm accounting 1% 5% thyroid malignancies . " Fostamatinib patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) were originally treated with oral spleen tyrosine kinase inhibitor, fostamatinib two-arm, randomised" Primary central nervous system lymphomas (PCNSLs) primary testicular lymphomas (PTLs) extranodal large B-cell lymphomas (LBCLs) inferior responses current empiric treatment regimens . " Epstein-Barr virus-related post-transplant lymphoproliferative disorder (EBV-PTLD) uncommon, frequently fatal, complication allogeneic hematopoietic stem cell transplant . Patient developed polymorphic" " Risk-stratification diffuse large B-cell lymphoma (DLBCL) requires identification patients disease cured, despite initial treatment R-CHOP . We aimed develop novel, easily applicable, tissue-based prognostic biomarker based" " Study evaluated relative frequencies of non-Hodgkin lymphoma subtypes in North Africa, Middle East India . The median ages patients patients patients were median ages patients ." " B-cell activation markers associated with B-cell lymphomas (BCL) were found in HIV-infected patients general population . Current evidence general population however limited relies relatively small numbers of observations, especially specific histologies ." " Overexpression EZH2 frequently linked advanced metastatic stage cancers . Mechanisms oncogenic function context specific, may vary depending protein complexes EZH2 interacts with . Computational approach developed integrates protein-DNA binding data" Several serum parameters evaluated adding prognostic value clinical scoring systems . This retrospective bicenter analysis includes 515 unselected patients DLBCL treated rituximab anthracycline-based chemoimmunotherapy . " Relapsed refractory diffuse large B-cell lymphoma (rrDLBCL) fatal 90% patients, yet little known biology . Using exome sequencing, characterized mutation profiles characterized mutation profiles ." " Fibrinogen plays crucial role pathophysiology tumour cell growth, invasion metastasis . Fibrinogen plays crucial role pathophysiology tumour cell growth, invasion metastasis ." " Diffuse large B-cell lymphoma (DLBCL) is potentially curable standard standard R-CHOP chemoimmunotherapy . We era heterogeneity DLBCL defined genetically molecularly, rational subset-specific therapeutic targets guiding" The diffuse aggressive large B-cell lymphomas heterogeneous group B-cell malignancies . The diffuse aggressive large B-cell lymphomas heterogeneous group B-cell malignancies . Several problematic areas still exist diagnosis lymphomas due Immune checkpoint blockade therapy (CBT) born combination several elements: understanding important immune regulation pathways humans; recognition tumors engage pathways evade immune responses . Monoclonal antibodies targeting checkpoint receptors restore effective anti-tumor immunity . Helicobacter pylori status influences prognosis management gastric extranodal marginal zone lymphoma mucosa-associated lymphoid tissue (MALT lymphoma mucosa-associated lymphoid tissue) The low rate histologic H " Plasmablastic lymphoma (PBL) rare aggressive lymphoma arising frequently oral cavity HIV-infected patients . Rare cases PBL reported extra-oral sites, well HIV-negative patients ." A multicenter case-control survey performed identify predictors lymphoma . Cases patients developed lymphoma diagnosis primary SS mainly recruited from Club Rhumatismes et Inflammation network . " Hsp90 controls posttranscriptional dynamics of key messenger RNA (mRNA) species including encoding BCL6, MYC, BCL2 . Using proteomics approach, found Hsp90 binds maintains activity eIF4E" " Inhibition spleen tyrosine kinase (SYK) tonic B-cell receptor (BCR) signal-dependent diffuse large B-cell lymphomas (DLBCLs) inhibits cellular proliferation, decreases cholesterol biosynthesis" Double-hit lymphomas (DHLs) collectively defined B-cell non-Hodgkin lymphomas harboring rearrangements MYC well B-cell lymphoma 2 (BCL2) and/or B- Primary mediastinal B cell lymphoma (PMBCL) uncommon lymphoma trials small patient numbers . Radiation therapy (RT) standard immunochemotherapy early-stage disease never studied prospectively . " FDG-PET patients newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (" We recently defined event-free survival 24 months (EFS24) clinically relevant outcome patients DLBCL . We develop validate clinical risk calculator (IPI24) EFS24 . Epstein-Barr virus (EBV)-induced lymphoproliferative disorders (LPDs) lymphoid proliferations arising result loss effective EBV-specific cytotoxic T-cell response . LPDs may occur primary " Calcitriol (1,25-dihydroxyvitamin D) is 1,25-dihydroxyvitamin D . Calcitriol (1,25-dihydroxyvitamin D)" " Non-Hodgkin lymphoma Eastern Europe scarce literature . We studied 184 consecutive NHL patients diagnosed in Cluj-Napoca, Romania ." " Various hematolymphoid lesions involve sinonasal tract, including aggressive B, T, NK-cell neoplasms; myeloid sarcoma; low-grade lymphomas; indolent T-lymph" US National Cancer Institute generated data genome-wide association studies (GWAS) 49 492 cancer case patients 49 492 cancer case patients 34 131 control patients . We aim estimate heritability genetic correlation attributable additive effects common single-nucle " Bacteria induce human lymphomas, whereas lymphoproliferative disorders described patients Q fever . We observed lymphoma patient Q fever prompted us investigate association 2 diseases . We screened 1468 consecutive patients 2004 2014 French National Referral Center Q" " Plasmablastic lymphoma (PBL) uncommon, aggressive B-cell lymphoma mostly occurring oral cavity human immunodeficiency virus (HIV) positive patients . Few cases PBL reported association with inflammatory bowel disease (IB" " Therapeutic options include short- full-course R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) ± radiotherapy . The" " At age 86, featured patient started experiencing continuous, progressive high intensity pain frequent night localized right dominant hand . It associated paresthesia hypoesthesia, primarily thumb, index finger middle finger . Extranodal manifestations lymphoma well" " In multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m(2) every 3 months 2 years) versus observation evaluated CD20(+) B-cell lymphoma . Out 321 patients" Study of diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) dramatically enhanced recent attempts profile molecular features lymphomas . Discussion: How testing molecular features may impact DLBCL FL management clinical trials designed Current genomic technologies immensely improved disease classification prognostication major subtypes B-cell lymphomas . We illustrated genomic profiling identifiled by genomic profiling identifiled . " Large B cell lymphomas MYC BCL6/3q27 rearrangements, designated MYC/BCL6 DHL, uncommon . We studied clinicopathological features outcome 13 patients MYC/BCL6 DHL" PD-L1 expression tumour microenvironments diffuse large B cell lymphoma (DLBCL) was studied . PD-L1 expression tumour cells and/or tumour-infiltrating immune cells (mainly " Non-Hodgkin lymphomas heterogeneous group lymphoproliferative disorders B T cell origin treated chemotherapy drugs variable success rate virtually changed decades . Although new classes chemotherapy-free epigenetic metabolic drugs emerged, durable responses conventional new" The activating mutation MYD88 identified diffuse large B-cell lymphoma (DLBCL) The activating mutation MYD88 identified diffuse large B-cell lymphoma (DLBCL) We investigated mutational status gene amplification protein expression Plasmablastic lymphoma described subtype non-Hodgkin's lymphoma category diffuse large B-cell lymphoma . It classified WHO HIV-associated lymphoma oral cavity . Several cases reported non-HIV patients reported " Invasive tracheal aspergillosis (ITA) infection unique patients undergone lung transplantation . CT findings may show false-negative results, bronchoscopy recommended cases ." " To determine prognostic value pretreatment anemia, pretreatment elevated C-reactive protein (CRP) levels, pretreatment elevated C-reactive protein (CRP) levels, 6-month posttreatment anemia patients newly" " The spatial distribution mast cells inside tumor stroma little investigated . We compared diffuse large B cells lymphoma (DLBCL) systemic mastocytosis two different anatomical localizations . Results indicated that, despite high difference size exhibited mast cells" " B cell receptor (BCR) signalling important pathway diffuse large B cell lymphoma (DLBCL) In response BCR triggering, normal malignant B cells secrete chemokines CCL3 CCL4 . In response B" " Flow cytometric immunophenotyping (FCI) recognized rapid, sensitive, accurate method diagnosis B-cell lymphomas . FCI failed identify clonal B-cell population several cases of large B-cell lymphoma (DLBC" " DBCL patients received rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy 2003 2012 ." " DYRK2, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase gene, involved regulating many processes cell proliferation, cell differentiation cytokinesis . DYRK2 also plays important role many cancers" Huntingtin-interacting protein 1-related (HIP1R) endocytic protein involved receptor trafficking . It regulates cell surface expression receptor tyrosine kinases . Low HIP1R protein expression associated poorer survival of diffuse large " TAp63 expression follicular lymphoma (54%) diffuse large B cell lymphoma (34%) described correlated proliferative index . In non-Hodgkin's nodal lymphoma, TAp63 expression follicular lymphoma" We compared outcomes patients higher-risk diffuse large B-cell lymphoma (DLBCL) treated with up-front autologous stem cell transplantation (ASCT) salvage chemotherapy followed delayed ASCT relapse . " TP53 gene dysregulation important pathogenesis many human cancers, including malignant lymphomas, especially diffuse large B cell lymphoma (DLBCL) By regulating many downstream target genes molecules, TP53 governs major defenses tumor growth promotes cellular" " Follicular lymphoma (FL) indolent disease transforms 2% 3% patients per year aggressive, large cell lymphoma, critical event course disease associated increased lymphoma-related mortality . Early transformation cannot accurately predicted time FL diagnosis" " Non-Hodgkin lymphoma fourth common malignancy children, even higher incidence adolescents, primarily represented histologic subtypes . Survival rates exceeding 80% ." " There lack data effect rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy brain glucose metabolism diffuse large B-cell lymphoma" " Ongoing randomized clinical trials poised unseat long-entrenched standards care diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymph" " FOXP1 essential early B-cell development, whereas downregulation FOXP1 germinal center (GC) stage required GC B-cell function . Aberrantly high FOXP1 expression frequently observed diffuse large B-cell lymph" " Use radiation (RT) primary mediastinal large B-cell lymphoma (PMBCL) may predispose young patients risk cardiopulmonary toxicities secondary malignancies . We used Surveillance, Epidemiology End Results (SE" 18F-fluorodeoxyglucose PET/CT (PET/CT) is a current state-of-the-art staging staging diffuse large B-cell lymphoma (DLBCL) high sensitivity extranod Programmed cell death ligand 1 (PD-L1) expressed select diffuse large B-cell lymphoma (DLBCL) tumor cells . Little known pathway functions tumor microenvironment . " 164 patients randomized 1:1 receive six 21-day cycles rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy . 164" 129 DLBCL patients and 208 healthy controls enrolled study . They genotyped polymerase chain reaction-allele specific primers (PCR-ASP) method DNA direct sequencing . At locus G2677T/A " Primary central nervous lymphoma(PCNSL) rare form non-Hodgkin lymphoma confined central nervous system . Most lesions supratentorial periventricular, often involving deep structures corpus callosum basal gang" The purpose study evaluate utility PET/CT nodal peripheral T-cell lymphomas (PTCL) Patients newly diagnosed nodal PTCL (peripheral T-cell lymphoma NOS) seen five Danish hematology " Mantle cell lymphoma (MCL) distinct subtype non-Hodgkin lymphoma characterized overexpression cyclin D1 95% patients . MCL patients experience frequent relapses resulting median survival 3 5 years, requiring" Immune evasion plays central role pathophysiology classical Hodgkin lymphoma (cHL) Mutations CD58 gene contribute immune evasion diffuse large B cell lymphoma tumor cells . Study found alterations to CD58 gene also occur Hodgkin Reed " Hodgkin lymphoma (HL) first disease associated HLA variation . Familial aggregation, coupled ethnic variation incidence incidence suggests inherited susceptibility plays role development lymphoma ." Vascular endothelial growth factor level might correlated risk bone marrow involvement prognosis patients diffuse large B-cell non-Hodgkin's lymphoma . Vascular endothelial growth factor level might correlated risk bone marrow involvement prognosis patients " Hypoxoxia may impose HRS cell-like phenotype B cells, like HRS cell-like phenotype B cells . Hypoxia caused partial downregulation of several B cells ." " Home considered preferred place death many, patients haematological malignancies (leukaemias, lymphomas myeloma) die hospital often cancers reasons wholly understood ." Central nervous system (CNS) relapse occurs around 5% diffuse large B-cell lymphoma (DLBCL) cases . No biomarkers identify high-risk patients discovered . Few studies have considered lymphoid malignancies in Asian context . Aim study assess association HBV HCV risk lymphoid malignancies among Japanese adults . " RecAbs were generated from identical BCR 23 PCNSLs immunocompetent patients . None of the proteins showed self-reactivity upon testing common autoantigens . 87% of recAbs, in 20/23" 81 consecutive patients NHL 70 years age received AHSCT . Median age AHSCT 72.3 years [70-80]. Median age AHSCT 72.3 years [70-80]. Median age AHSCT 72. Bone marrow involvement lymphoma may prognostic therapeutic consequences . Bone marrow involvement lymphoma may prognostic therapeutic consequences . Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour poor prognosis . We conducted systematic sequencing 21 genes relevant NF-κB signalling network . " NCIC CTG LY12 randomized phase 3 trial comparing gemcitabine, dexamethasone, cisplatin (GDP) dexamethasone, cytarabine, cisplatin (DHAP" " 379/2652 patients transformed following initial FL diagnosis, including 147 pathologically confirmed 232 clinically suspected cases . 379/2652 (14.3%) patients transformed following initial FL diagnosis, including 147 pathologically confirmed 232 clinically suspected cases ." " World Health Organization classification non-Hodgkin lymphoma (NHL) introduced 2001 . We studied distribution NHL subtypes adults diagnosed 1998 2011, evaluated time trends, geo-demographic correlates, changes 5-year overall survival (" Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) uncommon type non-Hodgkin lymphoma . The therapeutic role splenectomy addition immunochemotherapy unknown . The International Extranodal Lymphoma Study Group (IELSG) 26 study designed evaluate role (18F-fluorodeoxyglucose) positron emission tomography/computed tomography (PET/CT The treatment strategy diffuse large B-cell lymphoma (DLBCL) elderly patients is problematic . Anthracycline-based chemotherapy curative intent performed 115 (85) patients . " The authors conducted single-arm, phase 2 trial combined temsirolimus bortezomib temsirolimus bortezomib patients relapsed refractory B-cell non-Hodgkin lymph" HIV-infected people remain increased risk of many cancers . HIV-infected people remain increased risk of many cancers . Non-AIDS-defining cancers increasing aging HIV-infected population . " Toll-like receptor 4 (TLR4) diffuse large B-cell lymphoma (DLBCL) correlation patient clinical characteristics, detected using immunohistochemistry 81 specimens patients patients DLBCL . The correlation protein expression levels clinical" " 157 adult patients DLBCL diagnosed Rabin Medical Center 2004-2008 treated R-CHOP immunochemotherapy retrospectively reviewed . Main clinical features cohort follows: mean age 63.0 years, 43% male, 63% stage III" Gray zone lymphoma (GZL) features classical Hodgkin lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma (DLBCL) Recently recognized entity reported present primarily mediastinal disease (MGZ Enolases glycolytic enzymes responsible ATP-generated conversion 2-phosphoglycerate phosphoenolpyruvate . Enolase 1 reported up-regulation several tumor tissues . Previous studies suggested many prognostic factors diffuse large B-cell lymphoma (DLBCL) Prognostic importance cell-of-origin discordant bone marrow involvement remains unclear . Aim study evaluate prognostic impact bone marrow involvement . " Emerging therapies targeting molecularly distinct GCB non-GCB/ABC subtypes need accurate subtyping assay routine use . Forty DLBCL formalin-fixed, paraffin-embedded tumors kn kn kn kn kn kn" " The purpose study analyze impact graft-versus-host disease (GVHD) relapse rate different lymphoma subtypes . Adult patients diagnosis Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma (FL), peripheral" " Current NF-κB targeting strategies lack cancer cell specificity . New novel inhibitor, piperlongumine, features direct binding NF-κB p65 subunit suppression p65 nuclear import . This accompanied NF-κB reporter activity" " In United States, autopsy rates diminished less 5% last half 20th century beginning 21st century . Many believe results unrecognized malignancies could explained patient's death ." " Study aims examine survival gastric lymphomas main subtypes, mucosa-associated lymphoid tissue lymphoma (MALT), diffuse large B-cell lymphoma (DLBCL), Germany United States. Data patients diagnosed 1997-2010" " SEER-18 data (2000-2011) identified patients cancers breast, prostate, lung, colorectum, bladder, melanoma, non-Hodgkin lymphoma, acute leukemia, and acute leukemia . We hypothesized" " The objective study investigate incidence clinical significance lymphoma-associated chromosomal translocations, particularly involving immunoglobulin heavy chain gene (IGH) locus, patients small-bowel diffuse large B-cell lymphoma (DLBCL" " Chromosome translocations involving immunoglobulin (IG) locus another gene, either BCL MYC, common events B-cell lymphoma . Rarely, lymphomas three IG loci simultaneously involved two different BCL" Diffuse large B-cell lymphoma (DLBCL) aggressive potentially fatal disease . Need accurate biomarkers select patients aggressive first-line treatments . The serum level soluble interleukin-2 receptor (sIL-2R) known reflect immune activity tumour volume . Release sIL-2R LBL extensively studied . Relationship sIL-2R release expression level IL Polatuzumab vedotin antibody-drug conjugate containing anti-CD79B monoclonal antibody conjugated microtubule-disrupting agent monomethyl auristatin E . We aimed " Diffuse large B cell lymphoma (DLBCL) complex disease comprising diverse subtypes genetic profiles . Possibly prevalence genetic alterations activating canonical NF-κB activity, role oncogenic lesions activate alternative NF-κB pathway DLBC" Malignant lymphoma head neck represents common non-epithelial head neck cancer . Malignant lymphoma head neck represents common non-epithelial head neck cancer . Approximately one third occur outside lymph nodes described sub-sites head neck " The management primary mediastinal large B-cell lymphoma (PMBCL) requires balance optimizing chances cure reducing risk long-term toxicities . The combination rituximab cyclophosphamide, doxorubic" We investigated rituximab maintenance therapy patients with diffuse large B-cell lymphoma (n=662) follicular lymphoma grade 3b (n=21) first complete remission . Patients randomized rituximab maintenance " 'Double-hit lymphomas' (DHL) defined concurrent concurrent MYC BCL2 (or, alternatively, BCL6) rearrangements, poor outcome compared standard-risk, diffuse large B-cell lymphomas (" Hepatitis C virus (HCV) infection associated development of diffuse large B-cell lymphoma (DLBCL) Patients hepatitis C virus (HCV) infection associated development of DLBCL . " High-dose chemotherapy (HDCT) autologous stem cell transplantation (ASCT) improved progression-free (PFS) overall survival (OS) MCL relapsed DLBCL . However, role CD34+ cell" Human Apo2-Ligand/TRAIL promising antitumor agent . " TRIM21 gene maps tumour suppressor locus . Overexpression associated decreased proliferation, TRIM21 gene maps tumour suppressor locus . TRIM21 expression levels assessed immunohistochemistry lymphoma biopsies" Non-Hodgkin lymphoma may affordable insurance inadequate insurance . New treatment options supportive care measures greatly improved survival patients . Rituximab chimeric anti-CD20 monoclonal antibody murine variable regions human IgG1 constant regions depletes B lymphocytes . It used increasing frequency treatment patients hematologic malignancies nonhemat " Serous effusions common manifestation diffuse large B-cell lymphoma (DLBCL) However, prognostic significance controversial ." " 27-year-old multipara underwent large loop excision transformation zone repeated finding low-grade squamous intraepithelial lesion identified routine cancer screening . CD20-positive, primary, diffuse large B-cell lymphoma infiltr" " Study group included 83 patients with diffuse large B-cell lymphoma (DLBCL) treated years 1995 2003 . Patients relapsed within nine months commencement treatment (defined poor prognosis, n=43) disease-free survival at least" Atypical man diffuse large B cell lymphoma . Initially presenting isolated ipsilateral facial pain mimicking trigeminal neuralgia due invasion Meckel's cave . Diagnoses are usually accompanied by ipsilateral facial pain mim " We reviewed outcomes patients treated 1 3 rituximab-containing regimens (cyclophosphamide, doxorubicin, vincristine, prednisone, prednisone, rituximab" " The role consolidative radiation therapy (RT) stage III IV diffuse large B-cell lymphoma (DLBCL) era rituximab well defined . There evidence patients bulky disease may benefit, patient selection criteria well established ." Stercoral perforation colon rare complication constipation . Secondary opioid-induced constipation . Mice engineered overexpress a pseudogene that produces aggressive malignancy resembling human diffuse large B cell lymphoma . This study reviewed meta-analysed prognostic value complete remission status end-of-treatment (18) F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV + DLBCL) elderly. Viral oncogenes host immunosenescence suggested causes causes Epstein-Barr virus-positive diffuse large FDG-PET/CT time initial staging help appropriate staging patients . FDG-PET/CT time initial staging help appropriate staging patients . " CDLBCL-LT is a primary cutaneous diffuse large B-cell lymphoma, leg type (cDLBCL-LT) affecting predominantly elderly patients, mostly women . The typical clinical presentation characterized solitary multiple multiple, rapidly" " PET scan performed three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) scored pos ." " Whole-body imaging, particular molecular imaging fluorine 18 (18)F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) is essential management lymphoma . Assessment treatment response allows clinicians to" PET-CT (positron emission tomography-computed tomography-computed tomography) emerged indispensable tool management patients diffuse large B-cell lymphoma (DLBCL) It standard imaging test initial staging superior CT determining The pathogenesis of diffuse large B-cell lymphoma (DLBCL) strongly linked perturbation epigenetic mechanisms . The germinal center (GC) B cells DLBCLs arise prone instability cytosine methylation " 27-year-old man presented slowly growing left testicular swelling associated mild pain period 3 months . He diagnosed treated treated epididymo-orchitis managed antibiotics . When later presented us, enlarged left testis normal sper" " Romidepsin, romidepsin, Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is cytotoxic in EBV-positive cells . Romidepsin" Diffusion large B-cell lymphoma cell line U-2932 comprises two subpopulations faithfully representing original tumor subclones . 58/221 genes differentially expressed two U-2932 clones . Ultrasonography showed large heteroechoic solitary liver mass mimicking focal nodular hyperplasia . Biopsy needed to confirm diagnosis . High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) standard care chemosensitive relapsed refractory diffuse large B-cell lymphoma (rel/ref DLBCL) At 3 " Outcomes patients diffuse large B-cell lymphoma (DLBCL) differ according site presentation . With effective chemotherapy, need consolidative radiation therapy (RT) controversial . We investigated influence influence primary bone presentation receipt consolidative RT consolidationative" Epstein-Barr virus (EBV) status retrospectively analysed use EBV-encoded small RNA (EBER) situ hybridization (ISH) EBV DNA analysis whole blood diffuse large B-cell lymphoma . " 76-year-old man history prefibrotic post-essential thrombocythemia myelofibrosis ruxolitinib . He developed anemia, thrombocytopenia, leukocy" " The purpose study evaluate role involved-lesion radiation therapy (ILRT) rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)" " Occult hepatitis B infection (OBI) characterized negative hepatitis B surface antigen (HBsAg) detectable hepatitis B virus (HBV)-DNA liver and/or serum, without hepatitis B core antibody (anti-HBc) HB" Primary cutaneous lymphomas (CL) children rare . Little known whether primary CL children are similar to adult counterparts . " Primary testicular diffuse large B cell lymphoma (PTL) aggressive malignancy occurs immune-privileged anatomical site testis . Breakpoint anatomy rearrangement partners undetermined, CIITA rearrangements reported previously PTL" Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL) rare disease nonimmunocompromised hosts . In review 231 cases malignant lymphoma (87 Hodg " There significant advances treatment patients lymphoma myeloma. There significant advances treatment patients lymphoma myeloma. Although improvements survival outcome clearly addressed clinical trials, studies includes patients otherwise healthy would eligible trials actual improvement survival ." This study compared CT-based (18)F-fluoro-2-deoxy-D-glucose PET/CT (FDG-PET/CT) to NCCN International Prognostic Index (NCC " There limited data guide choice high-dose therapy (HDT) regimen . We studied 4917 patients (NHL, n = 3905; HL, n = 1012) underwent AHCT 1995 2008 ." Canine lymphoma similar human non-Hodgkin's lymphoma (NHL) shared clinical presentation histopathological features . Canine diffuse large B-cell lymphoma (DLBCL) common type canine lymphoma . Anemia frequently identified time diagnosis patients diffuse large B-cell lymphoma (DLBCL) Anemia frequently identified time diagnosis patients diffuse large B-cell lymphoma (DLBCL) Anemia frequently identified time diagnosis patients . Studies " Phase II trial investigated overall response rate (ORR), event-free survival (EFS), overall survival (OS) treatment (90)Y-IT) followed rituximab maintenance therapy patients DLBCL candidates transplant ." " Low high-density lipoprotein cholesterol (HDL-C) risk factor coronary artery disease . Investigating mechanisms underlying acquired severe HDL deficiency noncritically ill patients (""disappearing HDL syndrome"") could provide new insights HDL metabolism ." " Ibrutinib potent irreversible inhibitor Bruton's tyrosine kinase (Btk), key kinase important signal transduction B-cell receptor (BCR) pathway . In preclinical studies, ibrutinib" " We report patient refractory diffuse large B-cell lymphoma developed irreversible, severe spinal neurotoxicity . Shortly after treatment, patient lost control bowel bladder function developed ascending, irreversible paraplegia . Infectious neoplastic diseases spinal cord" Plasmablastic lymphoma (PBL) aggressive lymphoma commonly associated HIV infection . PBL also seen patients immunodeficiencies well immunocompetent individuals . " Diffuse large B-cell lymphoma (DLBCL) treatable potentially curable malignancy increasing prevalence elderly . Older patients malignancy under-represented clinical treatment trials . Older patients often given reduced dose therapy, potentially negatively" HIV-positive patients diagnosed aggressive non-Hodgkin lymphoma (NHL) last two decades . We carried pooled analysis existing database patients AIDS-related lymphoma . Individual patient data obtained prior prospective phase II III clinical trials carried " In cancer cells, inhibition bromodomain extra-terminal (BET) family bromodomain-containing proteins novel epigenetic therapeutic approach . OTX015 showed antiponyonyonyb, a new BET b" " HLA-G-725C/G/T, HLA-G 14-base pair, HLA-G-725C/G/T, HLA-G 14-base pair, influence susceptibility to diffuse large" " While anthracycline-based treatment cure diffuse large B-cell lymphoma, patients age 80 receive doxorubicin due toxicity concerns . This study evaluated practice, patients age 80 older largely excluded clinical trials ." " Plasmablastic lymphoma (PBL) rare aggressive CD20-negative lymphoma . Despite improvements biology behind PBL, still represents challenge diagnostic therapeutic perspectives pathologists clinicians ." Diffuse large B-cell lymphoma (DLBCL) aggressive subtype non-Hodgkin lymphoma (NHL) common NHL subtype diagnosed worldwide . DLBCL 4000 cases conducted among individuals European ancestry recently identified Cyin D1-positive diffuse large B-cell lymphoma (DLBCL) IGH-CCND1 rearrangement discuss rationale differentiating entity blastoid pleomorphic variants mantle cell lymphoma (MCL) " HIV-related diffuse large B-cell lymphoma (DLBCL) may biologically different DLBCL general population . We compared, HIV status, expression prognostic significance selected oncogenic markers . Eighty HIV-infected DL" " B-cell lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), express CD30 . This phase 2, open-label study evaluated efficacy brentuximab vedotin, anti-CD" 72-year-old woman history diffuse large B cell lymphoma recent recurrence . She had history of diffuse large B cell lymphoma recent recurrence . She had cutaneous eruptions every treatment granulocyte colony-stimulating factor To determine prognostic value tumor necrosis computed tomography (CT) computed tomography (CT) was used to determine prognostic value . This retrospective study included 51 patients newly diagnosed DLBCL undergone unenhanced intravenous contrast- Intravascular large B-cell lymphoma (IVLBCL) classified rare type non-Hodgkin's B-cell lymphoma . Diagnosis IVLBCL difficult lack lymphadenopathy lesions need histologically confirmed " Bronchoalveolar lavage (BAL) often performed leukemia lymphoma patients pulmonary infiltrates . However, malignant hematopoietic infiltrates uncommon comprehensive cytologic study yet performed ." " 8 benign malignant malignant hematologic diseases encountered urine cytology retrospectively reviewed clinical, radiographic, cytologic findings . Bladder infiltration leukemia lymphoma rare mimic benign processes follicular cystitis (FC)" " Salvage therapy followed high-dose therapy (HDT) remains mainstay patients relapsed lymphoma . R-DexaBEAM (rituximab, dexamethasone, carmustine, etoposide" " Sjögren's syndrome (SS) strongly associated development malignant B cell lymphoma, particular mucosa-associated lymphoid tissue (MALT)-type lymphoma) Previously, shown ∼40% cases salivary gland M" Diffuse large B-cell lymphoma (DLBCL) extranodal natural killer/T-cell lymphoma (ENKTL) aggressive tumors . ENTKL rare United States often affects nasal cavity paranasal sin R-CHOP therapy could counteract prognostic gap GC type non-GC type . Activity rituximab may reduced conformational change CD20 statin-induced cholesterol depletion . The prognostic implications of infra-diaphragmatic (InD) versus supra-diaphragmatic (SpD) primary lesions limited-stage diffuse large B-cell lymphoma (DLBCL) remains unknown . " 30% of patients follicular lymphoma transform aggressive malignancy, commonly diffuse large B cell lymphoma . Rarely, FL transformation results clinical findings, histology, immunophenotype reminiscent B-lymphoblastic leukemia/ly" The influence hepatitis C virus (HCV) infection outcome patients diffuse large B cell lymphoma (DLBCL) treated rituximab-based chemotherapy controversial . We retrospectively analyzed characteristics clinical outcomes of 168 patients DLBCL Only small number patients aggressive B-cell lymphoma take part clinical trials . Elderly patients are under-represented in the Netherlands Cancer Registry . " Fowlicular lymphoma aggressive non-Hodgkin lymphoma critical biologic event profound implications natural history otherwise indolent disease . Outcomes patients transformed lymphoma historically poor; however, several studies rituximab era" " Majority patients diffuse large B-cell lymphoma (DLBCL) cured standard rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP" " We describe case central venous catheter-related fungemia caused Cryptococcus liquefaciens, non-neoformans non-gattii Cryptococcus, non-HIV patient . A 71-year-" Epstein-Barr virus (EBV) first human virus associated oncogenesis . In part II continuing medical e-mailing continues . The aim present study investigate feasibility measuring metabolic tumor burden using [F-18] fluorodeoxyglucose (18) F-FDG) positron emission tomography/computed tomography (PET/CT) patients rel " Diffuse large B-cell lymphoma (DLBCL) common subtype non-Hodgkin lymphoma elderly, increasing incidence . Although significant therapeutic advances recently made care older patients DLBCL, based upon results randomized clinical" The role allogeneic stem cell transplantation (SCT) management aggressive non-Hodgkin lymphoma (NHL) remains defined . The role allogeneic stem cell transplantation (SCT) management aggressive non- " Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) elderly defined adults older 50 years . EBV-positive DLBCL affect younger patients . We investigated prevalence, clinical characteristics survival" " Increasingly, targeted therapies developed treat malignancies . Increasingly, targeted therapies developed treat malignancies . To define targets, determine mechanisms response resistance, develop biomarkers successful investigation novel therapeutics ." " Burkitt lymphoma (BL) diffuse large B-cell lymphoma (DLBCL) aggressive tumors mature B cells . A subset B-cell lymphomas (BL) overlap BL DLBCL, categorized B-cell lymphoma" " Up-front rituximab-based chemotherapy improved outcomes non-Hodgkin lymphoma (NHL) Refractory relapsed relapsed NHL still accounts approximately 18,000 deaths United States . Autologous he" " The mammalian target rapamycin (mTOR) pathway regulates many major cellular processes . It regulates many major cellular processes implicated increasing number neoplasms, including lymphoma . Virtually patients study high mTOR scores germinal center phenotype" " 29 patients treated with bendamustine plus rituximab (BR) treated combination bendamustine plus rituximab (BR) July 2010 January 2014 evaluate overall response rate (ORR), progression-free" " As use of lenalidomide increases, poorly understood phenomenon lenalidomide-induced thyroid abnormalities increase . Study compared rates therapy-induced hypothyroidism with conventional chemotherapy (DLBCL-c) and lenalidomide" The present multicenter phase II trial evaluated safety efficacy pegylated liposomal doxorubicin (PLD) instead conventional doxorubicin standard R-CHOP (rituximab plus cycloph Azathioprine used immunosuppression myasthenia gravis (MG) developed brainstem lymphoma 4 years treated azathioprine . An 82-year-old man ocular MG azathioprine developed sub " Review focuses current state science and, particular, novel treatment strategies aimed improving outcomes pediatric patients lymphoma histiocytic disorders . Review focuses current state science and, particular, novel treatment strategies aimed improving outcomes pediatric patients lymphoma histiocy" The TP53 rs1625895 polymorphism efficiency R-CHOP therapy efficiency R-CHOP therapy . The G/G genotype TP53 is associated high probability R-CHOP therapy failure . 40 rheumatoid arthritis (RA) patients methotrexate (MTX)-associated large B cell lymphoproliferative disorders (MTX-BLPD) 40 patients MTX-BLPD lower 24 RA patients non " Cancer centers Brazil, Chile, Hungary, India, India, Italy, Philippines, Philippines, South Korea, Thailand followed common protocol based treatment R-CHOP ." Ceramide (Cer) sphingosine (Sph) interfere critical cellular functions relevant cancer progression cell survival . Sph synthetic stereoisomer L-threo-sphingosine (Lt-Sph) is evaluated " Differing large B-cell lymphoma (DLBCL) plagued heterogeneous responses standard therapy . Molecular mechanisms underlying unfavorable outcomes lymphoma patients remain elusive . Here, profiled 148 genomes 91 matching transcriptomes ." FDG-PET/CT proposed non-invasive alternative standard blind bone marrow biopsy (BMB) in patients newly diagnosed diffuse large B-cell lymphoma (DLBCL) Histopathology currently lacking . " Previous studies illustrated steady increase intracellular calcium concentration [Ca2+]i] important maintaining microtubules (MTs) rearrangement . However, little known effect calcium sensing receptor (CaSR)-mediated increase [Ca2" " Austria screened Tyrolean registry B cell non-Hodgkin's lymphomas regarding primary secondary lung involvement . Of 854 patients affected B cell lymphoma, 7.5% lung/pleural disease ." " Primary central nervous system (CNS) lymphoma rare form non-Hodgkin's lymphoma . Only 1% primary CNS lymphoma emerges spinal cord, prevalence primary lymphoma cauda equina unknown . Diagnosing primary lymph" Diffuse large B cell lymphoma (DLBCL) common form lymphoma United States. Diffuse large B cell lymphoma (DLBCL) common form lymphoma United States. DLBCL comprises biologically distinct subtypes including " Novel inhibitor IKKB kinase 2, LY2409881, LY2409881, preclinical models B- T-cell lymphoma, single agent combination histone deacetylase (HDAC)" Human aggressive B-cell non-Hodgkin lymphomas (NHL) encompass continuum Burkitt lymphoma diffuse large B-cell lymphoma (DLBCL) display considerable clinical biologic heterogeneity . Given clinical heterogeneity NHL need " There paucity data impact diagnostic treatment delays outcomes haematological malignancies, particularly patients diffuse large B-cell lymphoma (DLBCL) Patients waited median 4 weeks seeking medical attention ." " Despite enormous advances understanding aggressive lymphomas, clear progress has lagged behind B-cell malignancies . Despite challenges, progress made. FDA approved four drugs patients relapsed/refractory PTCL past 5 years ." Epstein-Barr virus-positive diffuse large B-cell lymphoma provisional entity 2008 World Health Organization classification tumors hematopoietic lymphoid tissues . Different geographic regions showed great disparities . This study aimed determine prognostic value whole-body maximum standardized uptake value (SUVmax) and whole-body metabolic tumor volume (MTV) pretreatment (18) F-fluoro-2-deoxy-d- " Cardiac myxoma is a common tumor, but it is extremely rare to diagnose . The patient was previously healthy 52-year-old man with acute onset transient dysarthria left hemiplegia . Echocardiography" " NF-κB family transcription factors regulates numerous cellular processes, including cell proliferation survival responses . NF-κB also emerged important oncogenic driver many malignancies, activated B-cell like diffuse large B cell lymphoma, among" Methotrexate (MTX) primary drug used management rheumatoid arthritis (RA) immune-mediated inflammatory diseases . In article present case gingival MTX-related LPD 60-year-old male RA . Inhibitors PI3K/mTOR histone deacetylases (HDAC) effective non-Hodgkin lymphoma (NHL) effective non-Hodgkin lymphoma (NHL) Inhib " Epstein-Barr virus (EBV) associated remarkably diverse range cancer types . Because EBV persists B cells asymptomatic host, easily envisaged contributes development B-cell lymphomas . EBV also found cancers, including T" Diffuse Large B-cell Lymphoma (DLBCL) common form Non-Hodgkin lymphoma characterized clinical biological heterogeneity attributable tumor cells complex tumor-microenvironment surrounding them . Tumor-associated macrophages " This study aimed determine objective response, toxicity, clinical outcome weekly rituximab consolidation four cycles R-CHOP21 elderly patients DLBCL." " Clinical outcomes were analyzed according results sFLC/sTLC measurements . Elevated sFLC abnormal κ/λ ratio present 42.6% (51/108) 4.6% (5/108) patients," " In rituximab era, conventional International Prognostic index (IPI) lost least part predictive power, National Comprehensive Cancer Network-IPI (NCCN-IPI) seems new valid prognosticator . Yet" Chronic lymphocytic leukemia (CLL) patients often results life-threatening immunosuppression . CLL still incurable disease due persistence residual leukemic cells . These patients may therefore benefit immunotherapy approaches aimed immunotherapy approaches aimed Forkhead transcription factor FOXP1 involved B-cell development function generally regarded oncogene activated B-cell-like subtype diffuse large B-cell lymphoma (DLBCL) mucosa-associated lymphoid tissue lymphoma " The aim current study evaluate prognostic value anemia, easily estimable parameter patients diffuse large B-cell lymphoma treated rituximab plus cyclophosphamide, doxorubicin, vincristine," Cancer biomarkers frequently evaluated using archived specimens collected previously conducted therapeutic trials . Routine collection banking high quality specimens expensive time-consuming process . Twenty-six patients developed central nervous system relapse . Central nervous system relapse-free survival rate significantly lower patients absolute monocyte counts . HDAC6 inhibitor ricolinostat (ACY1215) irreversible proteasome inhibitor carfilzomib (ACY1215) carfilzomib examined non-Hodgkin lymphoma (NHL) models International Prognostic Index (IPI) used decades diffuse large B-cell lymphoma (DLBCL) A retrospective cancer registry analysis North America showed significantly improved results . Adolescents young adults (AYAs) cancer inferior survival compared children . Non-Hodgkin's lymphoma (NHL) comprises approximately 7% cancer among AYAs . Non-Hodgkin's lymphoma The prognosis patients primary mediastinal large B-cell lymphoma improved recent years . optimal treatment strategy including role radiotherapy remains unknown . Marrow involvement demonstrated histologically confers poor prognosis identified staging PET cases . Marrow involvement demonstrated histologically confers poor prognosis identified staging PET cases . How information staging PET biopsy combined optimize outcome prediction remains unclear . " Epstein-Barr virus (EBV) infection resting B lymphocytes results growth transformation associates different B cell lymphomas . EBV-mediated B cell transformation involves large changes gene expression, including cellular miRNAs ." " MYC frequently deregulated oncogenes human malignancies . It encodes leucine zipper transcription factor . It modulates broad spectrum cellular genes responsible enhancing cell proliferation, cellular metabolism, growth, angiogenesis, metastasis" " We examined patient characteristics, treatment, outcomes among 341 newly diagnosed PTCL patients 2000 2011 . Outcomes compared matched cohort diffuse large B-cell lymphoma (DLBCL) patients . PTCL subtypes included PTCL" Metachronous/concomitant B-cell neoplasms distinct morphology usually considered clonally related . We retrospectively analyzed 4 cases of 4 cases of B-cell neoplasms discordant light-chain/heavy- High-dose therapy autologous stem cell transplantation (HDT-ASCT) offer potential long-term remission cure patients non-Hodgkin lymphoma (NHL) High-dose therapy autologous stem cell " Non-Hodgkin lymphoma comprises biologically clinically clinically heterogeneous subtypes . We pooled individual-level data 17 471 NHL cases 23 096 controls 20 case-control studies . We estimated associations, measured odds ratios, 11" " Although risk factors diffuse large B-cell lymphoma (DLBCL) suggested, independent effects, modification sex, association anatomical sites largely unknown . In pooled analysis 4667 cases 22639 controls 19 studies, used stepwise logistic regression" " Non-Hodgkin lymphoma (NHL) consists numerous subtypes . The etiology NHL incompletely understood, increasing evidence suggests risk factors may vary NHL subtype . International Lymphoma Epidemiology Consortium undertook NHL Subtypes" Next-generation sequencing studies of diffuse large B-cell lymphomas (DLBCLs) revealed novel targets genetic aberrations also high intercohort heterogeneity . Previous studies suggested prevalence disease subgroups cytogenetic profiles differ Western We treated 15 patients with CAR T cells genetically modified express anti-CD19 chimeric antigen receptor (CAR) T cells genetically modified express anti-CD19 chimeric antigen receptor (CAR) T cells genetically modified express anti-CD19 " Antibody therapy become standard care adult B cell lymphoma patients . Antibody therapy become standard care adult B cell lymphoma patients . In pediatric lymphoma patients, however, clinical experience monoclonal antibodies limited ." " SMIP-016, new anti-tumour agent, mouse/human chimeric fusion protein built ADAPTIR™ (modular protein therapeutic) platform targeting human CD37 . In CLL cells SMIP-016 exerted" Twenty-six cases large B-cell lymphoma base tongue oral cavity retrieved 2003 2012 . All cases classified based based 2008 World Health Organization criteria . Four different subtypes large B-cell lymphoma identified: pleomorphic variant m . " KMT2A gene, formerly known myeloid lymphoid leukemia/mixed-lineage leukemia gene, is commonly associated high-risk de novo therapy-associated B-cell T-cell lymphoblastic leukem" " Activated signal transducer activator transcription 3 (STAT3) regulates tumor growth, invasion, cell proliferation, angiogenesis, immune response, survival . We evaluated expression pSTAT3 de novo DLBCL using immunoh" The study used a diffusion-weighted MRI (DW-MRI) differentiating sinonasal lymphomas carcinomas . The study performed 23 patients sinonasal lymphomas . 28 patients carcinomas histologically confirmed 3 T MRI GB virus-C (GBV-C) non-Hodgkin lymphoma (NHL) was found to be linked to non-Hodgkin lymphoma . We evaluated association prospectively nested case-control study Richter's syndrome (RS) rare development aggressive lymphoid malignancy patient pre-existing chronic lymphocytic leukemia (CLL) patient pre-existing chronic lymphocytic leukemia (CLL) The purpose large retrospective study summarize 70-year-old man lymphoma presented right eye movement disorder . CT examinations showed 'ground-glass' appearance extending around right sphenoid sinus suggested fibrous dysplasia . Biopsy mass histologically proved diffusing large Potential false-negative staining BCL2 using standard monoclonal mouse 124 antibody hinders identification high-risk DLBCL patients . Transformation indolent non-Hodgkin lymphoma (NHL) diffuse large B cell lymphoma (DLBCL) historically associated poor prognosis . A small series autologous stem cell transplantation (ASCT) " Of 178 cases large B-cell lymphomas, eight cases large B-cell lymphomas poor B cells diffusely rich sheets PD-1+ T cells identified . These cases either initially misdiagnosed T-cell lymphoma substantiated" Approximately 50% patients diffuse large B-cell lymphoma (DLBCL) enter long-term remission standard chemotherapy . There remains critical need identify effective targeted therapeutics for DLBCL . The poor prognosis patients diffuse large B cell lymphoma (DLBCL) relapse within 1 year initial diagnosis created controversy role autologous transplantation (HCT) setting . We compared autologous HCT outcomes chemosensitive " Low expression miR-146b-5p miR-320d associated poor prognosis DLBCL patients . DLBCL patients treated standard cyclophosphamide, doxorubicin, vincristine," " 17-yr-old boy WAS received unrelated HSCT complete remission diffuse large B-cell lymphoma chemotherapy . Was X-linked primary immunodeficiency characterized microthrombocytopenia, eczema, recurrent infections" " First-line standard treatment diffuse large B-cell lymphoma (DLBCL) R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednis" " Dense-R-CHOP-14 trial evaluated prospective DENSE-R-CHOP-14 trial . Rituximab (375 mg/m(2) given days 0, 1, 4, 8, 15" Lymphoma common feline upper respiratory tract (URT) tumor . Primary nasal nasopharyngeal lymphomas evaluated distinct pathological entities . Data differing clinical behavior missing . Interferon regulatory factor 4 (IRF4) central transcriptional network activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) The aggressive lymphoma subgroup defined gene expression profiling . " 56-year-old woman developed toxic plasma levels methotrexate (MTX) following first cycle rituximab-cyclophosphamide, hydroxydanorubicin, oncovin, pred" " HIV-positive man presented acute vision loss right eye altered mental status . Ophthalmic evaluation revealed large mutton-fat keratitic precipitates, large mutton-fat keratitic precipitates, diffuse cream-colored vitre" " NCCN Clinical Practice Guidelines Oncology describe continuum cancer care United States, initial diagnosis treatment referral hospice beyond treatment . Many countries, regional national national clinical practice guidelines . NCCN-MENA (Middle East North Africa)" Dr. Andrew D. Zelenetz reviewed updates 2014 NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) Non-Hodgkin's Lymphomas . Zelenetz first discussed updates updates diffuse large B " Intravascular large B-cell lymphoma (IVLBCL) remains diagnostic challenge . Non-specific findings clinical, laboratory, imaging studies . FDG-PET repeated course clinical evolution ." " Hodgkin lymphoma curable disease curable disease vast majority cases cure rate approaching 85 95% initial therapy . However, patients experience relapse patients relapsed/refractory disease, prognosis remains poor active agents needed setting ." " Insulin enhancer binding protein-1 (ISL-1), LIM-homeodomain transcription factor, reported play essential roles promoting adult pancreatic β-cells proliferation . Recent studies indicate ISL-1 may also involve occurrence" CD30 expressed aggressive Epstein-Barr virus-associated forms B-cell non-Hodgkin lymphomas . The expression CD30 CBCLs may risk misinterpretation unequivocal indicator highly aggressive form disease . " Lenalidomide high activity relapsed refractory aggressive aggressive B-cell lymphomas . In phase 2 REAL07 trial, aimed establish safety efficacy combination lenalidomide R-CHOP21 ." " MicroRNAs (miRNAs) bind 3' untranslated regions (UTRs) messenger RNAs, interfere translation thereby regulate cell differentiation, apoptosis, tumorigenesis . Genetic polymorphisms 3' UTRs targeted mi" " The gastrointestinal (GI) tract common site extranodal B-cell lymphomas . However, unclear neoplastic lymphoid cells preferentially home there . We hypothesize expression GI-homing chemokine receptor CCR" " Histone methyltransferase EZH2 frequently mutated germinal center-derived diffuse large B-cell lymphoma follicular lymphoma follicular lymphoma . To characterize EZH2 mutations lymphomagenesis, generated mouse" " Plasmablastic lymphoma (PBL) reported rarely children . To date, 10 cases documented English-language literature . This study documents clinicopathologic features of PBL ." " Recent epidemiological investigations reported association telomere length (TL) number malignancies, including B-cell lymphoma (BCL) The reported results BCLs however were inconsistent . We carried nested case-control study to determine" " Despite advances immunohistochemical molecular diagnostics, persistent difficulties differentiating several subtypes non-Hodgkin lymphoma (NHL) classic Hodgkin lymphoma (CHL) Despite advances immunohistochemical molecular diagnostics" " Sequential immunohistochemistry (S-IHC) is novel, easy method allows study numerous proteins single tissue section . S-IHC is a method that allows study numerous proteins single tissue section ." The benefit of intrathecal therapy systemic rituximab outcome diffuse large B-cell lymphoma risk central nervous system disease is controversial . The benefit intrathecal therapy systemic rituximab outcome diffuse large B-cell The peripheral blood lymphocyte monocyte monocyte ratio (LMR) diagnosis used predict survival of diffuse large B-cell lymphoma (DLBCL) patients . The low LMR negative prognostic parameter overall survival (OS) event Study investigated whether FDG-PET/CT-based bone marrow assessment replaces blind bone marrow biopsy . 78 patients newly diagnosed DLBCL undergone FDG-PET/CT BMB . FDG-PET/CT images visually evaluated " T-cell lymphomas (TCLs) uncommon United States . accurate diagnosis TCL challenging requires morphologic interpretation, immunophenotyping, molecular techniques ." " Despite advances treatment, survival of diffuse large B-cell lymphoma (DLBCL) remains heterogeneous . We studied 33,032 DLBCL patients diagnosed 1988-2009 California vital status December 31, 2010 ." " Treatment-naïve patients lymphoma referred whole-body staging included prospective study . Group A included patients FDG-avid lymphoma (e.g., Hodgkin, diffuse large B-cell, follicular lymphoma), whereas Group" " The purpose study determine frequency BCL2, BCL6, BCL6, IGH, TP53, TP53, MYC protein expression rearrangements respective genes . Multiple rearrangements detected 40.9% cases of" Primary bone lymphoma (PBL) rare disease . We examined PBL cases seen at Moffitt Cancer Center 1998 2013 using 2013 World Health Organization criteria . Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) associated poor prognosis . Outcomes particularly poor following immunochemotherapy failure relapse within 12 months induction . " 323 patients diagnosed with acute myeloid leukaemia, diffuse large B-cell lymphoma myeloma myeloma myeloma May 2005 April 2008, died April 2010 . 323 patients diagnosed with acute myeloid leuka" There limited data outcomes autologous allogeneic hematopoietic cell transplantation (HCT) diffuse large B cell lymphoma transformed follicular lymphoma transformed follicular lymphoma . 63 year old male presented dysphagia & change voice . Computed tomography revealed 4.8 × 3.7 cm mass localized base tongue . Diagnosed diffuse large B cell lymphoma . Gain-of-function mutations enhancer Zeste homolog 2 (EZH2) occur frequently diffuse large B-cell lymphomas follicular lymphomas . We determined EZH2 codon 641 mutations Chinese follicular " To describe clinical, histopathologic, radiologic features recently identified cause enlargement infraorbital canal . Consecutive patients identified orbital databases Moorfields Eye Hospital, London, England, Royal Victorian Eye Ear Hospital, Melbourne, Australia" " The correlation between rheumatoid arthritis lymphoma and autoimmune disease malignancy has been observed . The correlation between rheumatoid arthritis lymphoma and generally, autoimmune disease malignancy-has long observed ." " Classical Hodgkin lymphoma (cHL) primary mediastinal large B-cell lymphoma (MLBCL) share similar histologic, clinical, genetic features . In recent studies, found disease-specific chromosome 9p24." " We retrospectively analyzed 14 composite lymphoma/lymphoid neoplasms (CL) B-cell/T-cell origins . Histopathologic evaluation demonstrated 6 patterns neoplastic distribution, including zone, inverted zone, diffuse mixed" " 484 patients, ages 60 years over, diagnosed relapsed/refractory DLBCL received ASCT 1993 2010 Japan Society Hematopoietic Cell Transplantation database . Median age 64 years (range, 60 78" " The authors analyzed survival among 3858 patients DLBCL ages 18 64 years diagnosed 2004 . They used data National Cancer Database, nationwide, hospital-based cancer registry . Kaplan-Maier curves compared patients private insurance, Medicaid, insurance." Bone marrow (BM) trephine biopsy part routine staging patients newly diagnosed diffuse large B cell lymphoma (DLBCL) The significance lymphoid monoclonal population flow cytometry (FC) BM aspirate presence negative " Many cancers apparently showing similar phenotypes actually distinct molecular level, leading different responses treatment . It recently demonstrated pathway-based approaches robust reliable genetic analysis cancers . Nevertheless, remains unclear whether function-based approaches useful deciphering molecular heterogeneities cancers" " c-JUN N-terminal Kinase (JNK) activated/phosphorylated upstream MAPK kinases (MKK) and, turn, phosphorylates activates major substrate c-JUN, member activ" " KAT6A (formerly MOZ) gene recurrently rearranged chromosomal translocations acute myeloid leukemia (AML) KAT6A known fused several genes, histone acetyltransferase (HAT) activity" CD79B MYD88 mutations analyzed Sanger sequencing 187 DLBCL tissue samples . CD79B MYD88 mutations analyzed Sanger sequencing 187 DLBCL tissue samples . The cell-of-origin determi cells were found " Only 2 cases anorectal Hodgkin lymphoma described far, affecting HIV-infected males showing Epstein-Barr virus infection ." " A specific predictor routine follow-up ascertain risk of relapse standard first-line chemotherapy non-Hodgkin's lymphoma (NHL) identified . Blood counts, lactate dehydrogenase (LDH) imaging studies, computed" Ferroptosis form nonapoptotic cell death key regulators remain unknown . GPX4 overexpression knockdown modulated lethality 12 ferroptosis-inducing small molecules . " Pathology reports rich narrative statements encode complex web relations among medical concepts . We aim automatically capture relations narrative text without supervision . We design novel framework translates sentences graph representations, automatically mines sentence subgraphs, automatically mines sentence subgraphs," AIDS-related lymphoma is AIDS-related lymphoma . The introduction combined antiretroviral therapy (ART) reduced mortality patients human immunodeficiency virus-1 infection worldwide . Malignant lymphoma severe frequent complication seen patients Lymphoma parotid gland relatively rare occurrence among head neck tumors . Presentation indistinguishable swellings parotid gland . Presentation indistinguishable swellings parotid gland . " miR-21 expression detected fluorescent quantity polymerase chain reaction (qPCR) 9 DLBCL cell lines . miR-21 early diagnosis, genotyping, treatment options well prognosis estimates Chinese DLBCL ." " We reported soluble LDL receptor relative 11 ligand-binding repeats (sLR11) promising biomarker follicular lymphoma (FL) In study, evaluated fluctuations serum sLR11 levels compared serum soluble urokinase-type pl" " Follicular lymphoma (FL) indolent disease, 30%-40% cases undergo histologic transformation aggressive malignancy . Pathogenesis process remains largely unknown . Whole-exome sequencing copy-number analysis shows dominant clone FL" MCL increased angiogenesis within tumor microenvironment . Emerging evidence indicates MCL increased angiogenesis within tumor microenvironment . We initiated phase II trial determine addition bevacizumab standard R-CHOP regimen could enhance antit " 82-year-old man had history of intermittent abdominal pain, nausea fatigue . Computed tomography scan abdomen revealed mass terminal ileum sign ""bowel within bowel"" Adult intussusception small intestinal lymphoma quite rare ." " Diffuse large B cell lymphoma (DLBCL) biologically heterogeneous clinically aggressive disease . We observe highly asymmetric loading bromodomain 4 (BRD4) enhancers, approximately 33% BRD4 localizing" The study looked at the prognostic implications of whole-body bone marrow MRI findings . The study looked at the effects of diffuse large B-cell lymphoma (DLBCL) patients negative blind bone marrow biopsy (BMB) " The tumor microenvironment, including tumor-infiltrating lymphocytes myeloid-derived cells, is important factor pathogenesis clinical behavior malignant lymphoma . However, prognostic significance peripheral lymphocytes monocytes lymphoma remains unclear" " Kaiso knockout mice show splenomegaly large diffused germinal centers (GC) in spleens . In spleens Kaiso knockout mice, Bcl6 (a transcriptional repressor plays critical role GC" " VSLI (Marqibo) active advanced advanced non-Hodgkin lymphoma (NHL) untreated aggressive NHL . Because favorable hematologic toxicity profile, VSLI might useful patients unable tolerate myelosupp" " Richter syndrome small intestine initially diagnosed follicular lymphoma gastrointestinal tract . Follicular colonization occasionally observed marginal zone lymphoma . In rare cases, also associated mantle cell lymphoma ." Diffuse large B-cell lymphomas (DLBCLs) rare tumors head neck often non-specific presentations significant morbidity mortality . In analysis use large cohort compare demographic disease-specific parameters affecting survival incidence DLBCLs . " Paraneoplastic cerebellar degeneration (PCD) type paraneoplastic neurological disorder (PND) associated many solid tumors, Hodgkin's lymphoma (HL) and rarely non-Hodgkin's lymph" T cell/histiocyte-rich large B cell lymphoma (THRLBCL) rare morphological variant diffuse large B cell lymphoma (DLBCL) accounting 1-3% of DLBCLs . We compared " Temozolomide (TMZ) is an oral DNA-alkylating agent routinely used therapy glioblastoma multiforme, active patients primary CNS lymphoma response rates low . The mechanisms contributing TMZ resistance unknown ." PD-1 expression determined expression distribution of PD-1 neoplastic B cells . PD-1 positive T cells prognostic significance types nodal B-cell lymphomas . " Some B-cell lymphomas show aberrant CD20 expression, rituximab use patients controversial . CD20 expressed B-cell lymphomas critical molecular target rituximab ." 59-year-old woman was diagnosed with Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (EBV+ DLBCL) elderly aggressive aggressive B-cell neoplasm related age-associated " Peripheral T-cell lymphoma (PTCL) rare heterogeneous group non-Hodgkin lymphomas (NHLs) prognosis remains dramatically poor, far standard treatment established . High-dose chemotherapy autolog" " CD31 considered one better, best, immunohistochemical marker endothelial cells thereby vascular neoplasia, thereby vascular neoplasia, was found to be unequivocally specific group tumors ." " Leptin receptor (OBR), p-STAT3 p-AKT patients with high expression OBR, p-STAT3 p-AKT . We investigated expression clinical significance of p-STAT3 p-AKT patients ." Diffuse Large B-Cell lymphoma (DLBCL) represents 30% non-Hodgkin lymphoma . Different subtypes DLBCL various prognostic implications . Recognition of molecular subtype DLBCL may associated Autologous allogeneic stem cell transplant (SCT) often considered patients relapsed refractory non-Hodgkin lymphoma (NHL) limited data use SCT treatment NHL pediatric setting . Reviewed 36 consecutive Guidelines group selected representative UK-based medical experts . " Diffuse large B-cell lymphoma (DLBCL) common form non-Hodgkin lymphoma, greatest challenge improving patient survival management chemorefractory disease upon relapse . Epigenetic dysregulation correlated more-" MALT1 mediates activation NF-κB response antigen receptor signaling . MALT1 paracaspase targets key proteins feedback loop mediating termination NF-κB response . Newly developed MALT1 small-molecule inhib Pyothorax-associated lymphoma (PAL) representative form diffuse large B-cell lymphoma associated chronic inflammation . Pal-2 first PAL cell line carries biclonal EBV infection abundant viral genome . Pal-2 " Eponym ""Tapia's syndrome"" indicates associated unilateral vocal cord tongue paralysis . Although mainly observed complication surgery anaesthesia, rarely occur secondary infectious neoplastic causes ." The choice therapy primary cutaneous B-cell lymphoma (PCBCL) relies correct histopathologic classification exclusion systemic disease . The choice therapy primary cutaneous B-cell lymphoma (PCBCL) relies correct histopathologic " Primary cutaneous B-cell lymphomas (PCBCLs) defined lymphomas B-cell phenotype present skin without evidence systemic extracutaneous disease initial presentation, adequate staging . In non-Hodgkin lymphomas," In diffuse large B-cell lymphoma (DLBCL) observed chemoresistance associated aberrant DNA methylation programming . Prolonged exposure low-dose DNMT inhibitors (DNMTI) reprogrammed chemoresistant cells " Using noninvasive phosphorus MR spectroscopic imaging, measured tumor content phospholipid-related phosphomonoesters (PME) measured using (31)P MRSI tumor masses . The PME value normalized nucleos" The gastrointestinal tract common site primary extranodal non-Hodgkin lymphoma (PG-DLBCL) was common site primary extranodal non-Hodgkin lymphoma . We retrospectively searched PG " The BCL6 transcriptional repressor required development germinal center (GC) B cells diffuse large B cell lymphomas (DLBCLs) Although BCL6 recruit multiple corepressors, transcriptional repression mechanism action normal" " A meta-analysis assesses evidence relating pre-diagnosis cigarette smoking OS . Among 523 NHL patients, worse OS suggested greater pre-diagnostic smoking habits compared never smokers . inferior OS observed greater number cigarettes smoked per day, years" " A recent report showed combination absolute lymphocyte count (ALC) absolute monocyte count (AMC) diagnosis gave prognostic score diffuse large B-cell lymphoma (DLBCL) However, model requires validation patient cohorts . We" Chinese American DLBCL cases were compared to those of Asian Caucasian patients . We used interphase FISH analyses determine incidence t(14;18) BCL6 MYC rearrangements . " Patients aggressive non-Hodgkin lymphoma (NHL) relapse autologous stem cell transplantation (ASCT) poor prognosis . Additional therapy often poorly tolerated, new treatment modalities needed ." " Vincristine sulfate liposome injection (VSLI) active relapsed refractory lymphomas, approved United States relapsed refractory adult acute lymphocytic leukaemia . VSLI (2·" " Lymphoplasmacytic lymphoma chronic lymphoproliferative disorder characterized proliferation plasma cells, small lymphocytes, plasmacytoid lymphocytes production monoclonal IgM . PCNSLs constitute 3-4" " Several recognizable variants clinically distinct features and, frequently, require specific treatment approaches . Recognition variants utilization appropriate treatments improve outcome patients ." " Canine multi-centric B-cell lymphoma shares similarities diffuse large B-cell (Non-Hodgkin's) lymphoma (NHL) people . In people NHL, lymphopenia diagnosis first relapse neutrophil" Functional imaging PET/CT used stage Hodgkin non-Hodgkin lymphomas . Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) often associated concurrent subsequent development T-cell/histiocyte-rich B cell receptor (BCR) signaling pathway components represent promising treatment targets . BCR signaling activates spleen tyrosine kinase (SYK) downstream pathways including PI3K/AKT NF-κB . Chemical SYK Rituximab added CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) standard chemotherapy untreated DLBCL . Therapeutic effect limited younger patients high-inter 71-year-old man Richter's syndrome (transformation chronic lymphocytic leukemia [CLL] diffuse large B-cell lymphoma) admitted hospital get second cycle rituximab/bendamustin treatment Chronic lymphocytic leukemia (CLL) patients 17p deletion comprise challenging subgroup associated poor overall survival . These patients treated alternative strategies . Reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT Gastrointestinal lymphoma (GIL) common extranodal form non-Hodgkin's lymphoma (NHL) common extranodal form non-Hodgkin's lymphoma (NHL) Programmed cell death ligand 1 (PD-L1) immunomodulatory molecule expressed antigen-presenting cells . PD-L1 expressed Reed-Sternberg cells comprising classical Hodgkin lymphoma (CHL) mal Autophagic activity lymphoid cells investigated follicular lymphomas (FL) and diffuse large B-cell lymphomas (DLBCL) in study . Autophagy self-degradation mechanism induced stress conditions eukaryotic " Primary gastrointestinal lymphoma accounts 30-40% extranodal lymphomas, comprises 1-8% gastrointestinal malignancies . Recently, incidence of intestinal follicular lymphoma increasing ." We retrospectively studied 93 consecutive cases of follicular lymphoma (FL) cases in Taiwan . Fifty-nine (63%) tumours low-grade (LG) and 34 (37%) high-grade (HG) tumours " DNA repair pathway genes may modify relationship body mass index (BMI) risk non-Hodgkin lymphoma (NHL) risk . Compared BMI <25, women BMI <25 significantly increased risk NHL among women carrying BRC" 58-year old Caucasian woman diagnosed sarcoidosis . 58-year old Caucasian woman diagnosed sarcoidosis . Low immunoglobulin levels found common variable immunodeficiency (CVID) diagnosed 1year later . " We evaluated prognostic significance CD43 (SPN), membrane glycoprotein, membrane glycoprotein, 140 patients diffuse large B-cell lymphoma (DLBCL) tissue microarray (TMA) immunostaining, gene" 78-year-old man underwent colectomy medically refractory pseudomembranous colitis . The malignant lymphocytes preferentially localized small colonic submucosal vasculature . 93 patients PCL retrospectively identified extensive review medical records 16-year period . The tumours found in 93 patients PCL retrospectively identified . " B-cell lymphoma, unclassifiable (B-UCL) features intermediate diffuse large B-cell lymphoma Burkitt lymphoma Burkitt lymphoma, poorly characterized entity . B-UCL treated Nebraska Lymphoma Study" " Meta-analysis performed focusing four major IL-10 gene variants promoter region: -3575T/A, -1082A/G, -819C/T -592C/A . A significant association IL-10" " Despite Revised International Prognostic Index's undoubted utility, significant clinical heterogeneity within R-IPI categories persists . We hypothesized direct quantification immunity within lymphomatous tissue would better permit stratification within R-IPI categories ." " Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) represents 5% Hodgkin lymphoma distinct clinico-pathological features . It typified presence lymphocyte predominant cells, CD20(+) , CD15(" " Burkitt's lymphoma (BL) highly malignant, aggressive non-Hodgkin's lymphoma derived germinal center B cells . Germinal center B cells devoid detectable nuclear LEF1 expression ." " The authors report remission of diffuse large B-cell lymphoma, follicular lymphoma, mucosa small intestine . They report remission of diffuse large B-cell lymphoma, follicular lymphoma recurred mucosa small intestine ." Spinal primary dural lymphoma (PDL) uncommon total 37 previous well-documented cases reported . Spinal primary dural lymphoma (PDL) uncommon total 37 previous well-documented cases reported . " Oridonin showed high activity induce generation generation of reactive oxygen species (ROS) ROS, important signaling molecules, involved immune defenses, cell repair proliferation ." " B-cell lymphomas concurrent translocations MYC BCL2 BCL6, also known ""double-hit lymphomas (DHL) are rare malignancies characterized aggressive clinical behavior poor prognosis . Previous reports suggest decreased CD" " Multidrug resistance (MDR) B-cell lymphomas still constitutes major obstacle effectiveness chemotherapy even anti-CD20 antibody therapy era . MDR1 exhibited significantly stronger expression RL, FL, DLBCL Raji B-cell" " PET indicated diffuse large B cell lymphomas (DLBCL) Hodgkin's disease . CT FDG-PET complementary characterizing residual masses characterizing residual masses: negative, PET scan indicates absence residual disease, positive . CT FDG" " Ixabepilone (BMS-247550, epothilone B analog), potent inhibitor tubulin disassembly, promising preclinical early-phase clinical activity drug-resistant malignancies . This multicenter phase" " In positron emission tomography era, traditional prognostic factors may apply patients relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) undergoing autologous stem cell transplantation (AS" " Lymphomas involvement soft tissues primary event rare . Lymphomas involvement soft tissues primary event rare . The published studies small sample size, reported case reports ." " MALT1 activity linked pathogenesis activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), chemoresistant form DLBCL . MALT1 activity linked pathogenesis activated B cell-like diffuse large" " ALK receptor protein-tyrosine kinase fully characterized 1997 . Physiological ALK participates embryonic nervous system development, expression decreases birth . ALK member insulin receptor superfamily closely related leukocyte tyrosine kinase (L" A retrospective analysis records patients primary pulmonary lymphoma January 2005 August 2011 performed . 25 patients referred radiology department CT-guided core needle biopsy . The success rate of diagnosis accurate histologic subtype obtained 21 patients success rate 84.0 " Lifestyle factors medical history known influence risk non-Hodgkin lymphoma (NHL) Whether factors affect prognosis NHL, especially subtypes, unclear . Study looked at population-based cohort 1,523 Swedish NHL patients ." Plasmablastic lymphoma (PBL) rare B-cell neoplasm aggressive clinical behavior predominantly occurs oral cavity human immunodeficiency virus (HIV)-positive patients . Recently recognized PBLs also affect individuals without HIV " Of 74 immunocompetent patients diagnosed July 2004 June 2011 North Shore University Hospital Long Island Jewish Medical Center primary central nervous system lymphoma, 71 (95.9%) diffuse large B-cell lymphomas (DLBCL)" OxPhos-DLBCL subset harbors signature genes involved mitochondrial metabolism . OxPhos-DLBCL harbors signature genes involved mitochondrial metabolism . OxPhos-DLBCLs display enhanced mitochondrial energy transduction . " One thousand one hundred thirteen patients diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunor" " FOXA1 overexpressed result gene amplification lung cancer, esophageal cancer, ER-positive breast cancer anaplastic thyroid cancer point-mutated prostate cancer . FOXA1 overexpression breast cancer prostate cancer associated good" " Primary cardiac lymphomas exceedingly rare . 55-year-old woman presented progressive shortness breath, fatigue, mild dizziness, dull chest ache, dull chest ache ." " The purpose study evaluate standard outpatient dose 131-Iodine tositumomab (75 cGy) combined high-dose carmustine, etoposide, cytarabine, melphalan (BEAM)" " The involvement ovaries lymphomatous processes relatively rare phenomenon. The involvement ovaries lymphomatous processes relatively rare phenomenon. Mostly, primary ovarian lymphomas diffuse large B cell type, whereas precursor lymphoblastic lymphomas extremely rare" " SF1126 peptidic pro-drug inhibitor pan-PI3K/mTORC . First-in-human study evaluated safety, dose limiting toxicities (DLT) maximum tolerated dose (MTD) maximum tolerated dose" " Cell signaling highly conserved serine/threonine kinase mammalian target rapamycin (mTOR) shown play critical role cell proliferation . We analyzed immunohistochemical expression mTOR, pmTOR bcl-2 55 patients" Plasmablastic lymphoma shares many morphologic features plasmablastic plasma cell myeloma . Activated MYC oncogene lymphomas may important pathogenetic element associated Epstein-Barr virus infection . " Two brothers, whose mother died gastric diffuse large B-cell lymphoma, were diagnosed with primary cutaneous large B-cell non-Hodgkin lymphoma skin head diagnosed . They treated immunochemotherapy according R-CH" " A retrospective review performed 86 patients extranodal head neck lymphoma, diagnosed Kaohsiung Medical University Hospital, 1990 2007 . We evaluated medical records analyzed possible factors affecting treatment outcomes, survival rate, free-from-dise" " Two patients developed acute, transient encephalopathy following administration of rhG-CSF and filgrastim . Head magnetic resonance imaging showed evidence blood-brain barrier (BBB) breakdown . Pres Pres Pres, compatible reversible reversible en" " Langerhans cell histiocytosis (LCH) adults first presenting skin rare . Guidelines staging, treatment follow-up lacking ." The purpose study investigate clinical significance FOXP1 p65 expression diffuse large B-cell lymphoma (DLBCL) Immunohistochemistry performed determine expression FOXP1 p65 protein 92 DLBCL tissues . Results showed positive FOX " Diffuse large B-cell lymphoma (DLBCL) occasionally presents circulating malignant cells . Twenty-nine newly diagnosed DLBCL presenting leukaemic phase identified 1996 2010, two institutions . Median age 48 years, patients presented" Two major classification systems segregate diffuse large B-cell lymphoma (DLBCL) subtypes based gene expression profiles . The development deductive classification system identifies subtypes patien . Monocytic myeloid-derived suppressor cells (M-MDSCs) suppresses host anti-tumour immunity plays role cancer tolerance . " Intraocular lymphoma (IOL) extremely rare tumor . In 18 cases, nine patients Kansai Medical University Takii Hospital 1991 2007, nine already reported hospitals . Most patients male, average age onset 60.4-year" Work-up post-transplant lymphoproliferative disorders (PTLDs) often involves bone marrow examinations . We evaluated 23 transplant patients PTLDs with BM examination results . Four of the patients showed BM involvement PTLDs " BCL2 suppresses apoptosis binding BH3 domain proapoptotic factors . Many tumor types, including B-cell lymphomas, dependent BCL2 survival become resistant apoptosis treatment ." " Mantle cell lymphoma (MCL) considered aggressive incurable B-cell malignancy . Lenalidomide, novel inmmunomodulatory drug (IMiD), promising therapeutic strategy patients relapsed/refract" A 73-year-old woman presented right heart failure . Computed tomography chest revealed 3 cm × 5 cm anterior mediastinal mass . Mediastinal biopsy revealed high-grade diffuse large B-cell lymphoma . " The cause of chronic fatigue syndrome (CFS) unknown thought associated immune abnormalities infection . Because cancer arise similar conditions, associations CFS cancer examined population-based case-control study among US elderly ." " Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) was used to characterize frequency clinicopathological features . We retrospectively stained 206 consecutive DLBCLs cyclin D1, identified three (1" " Prior studies describe increased incidence lymphoma celiac disease . However, studies differentiate among lymphoproliferative disorders (LPDs) Our aim determine incidences LPD subtypes celiac disease patients ." " Lymphomas showing MYC/8q24 rearrangement IGH@BCL2/t(14;18)(q32;q21) are also referred ""double-hit"" ""dual-hit"" """ " Central nervous system (CNS) involvement patients primary mediastinal large B-cell (PMLBCL) lymphoma rare event, occurring approximately 6% patients, occurring approximately 6% patients . The aim retrospective study describe incidence CNS" " MicroRNA-155 (miR-155), emerged significant impact biological characteristics lymphocytes, plays important roles B-cell malignancies, diffuse large B-cell lymphoma (DLBCL) DLBCL common non-H" Epstein-Barr virus (EBV) associated classical Hodgkin lymphoma (cHL) non-Hodgkin lymphoma B-cell type . While polymorphic variants EBV-positive large B-cell lymphoma ( " Twenty-two cases of primary breast DLBCL, diagnosed according to 2008 World Health Organization class, diagnosed according to 2008 World Health Organization class ." " Orbital lymphoma often low-grade histology; thyroid eye disease may predispose chlamydial infection suggested trigger . Commonly, stage IE, cases, managed radiotherapy alone using either kilovoltage portal conjunctival disease" Venous thromboembolism (VTE) may associated treatment failure rate quality life deterioration lymphoma patients . Majority data regarding VTE come retrospective studies done Western countries . " Clinical, histopathologic, immunohistochemical features correlated outcomes correlated outcomes . Clinical, histopathologic, immunohistochemical, immunohistochemical features correlated outcomes ." Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) poor prognosis . Novel drugs targeting constitutively activated NF-κB pathway characteristic ABC-DLBCL promising . Primary pleural lymphomas rare. 12-year-old immunocompetent girl presented hemorrhagic pleural effusion plaque-like thickening pleura . Role consolidation RT stage III-IV DLBCL controversial . Role consolidation RT is controversial . Clinical outcomes calculated using Kaplan-Meier method . Clinical outcomes calculated using Kaplan-Meier method . The use of random skin biopsy (RSB) diagnose intravascular large B cell lymphoma (IVLBCL) increased . 18 Japanese adults underwent RSB January 2008 December 2009 . A final diagnosis IVLBCL returned " Clinically chapter focus 3 important issues critical management diffuse large B cell lymphoma (DLBCL) 2012: risk stratification, interim PET-CT scanning role high dose therapy ASCT rituximab era patients relapsed primary" " mTOR pathway constitutively activated diffuse large B-cell lymphoma (DLBCL) mTOR inhibitors activity DLBCL, although response rates remain low . We evaluated DLBCL cell lines differential resistance mTOR inhibitor rapamy" " Intravascular large B cell lymphoma (IVLBCL) rare aggressive variant non-Hodgkin's lymphoma . IVLBCL systemic quite polymorphic, often makes difficult diagnose, thus delaying appropriate treatment ." Diffuse large B-cell lymphoma cured 50% patients . Positron emission tomographic scans improved accuracy staging restaging . Non-Hodgkin lymphomas (NHLs) heterogeneous group lymphoproliferative malignancies disseminate organs tissues tissues ordinarily contain lymphoid cells (extranodal sites) Primary extranodal NHL " A 67 year-old man hospitalized due chronic pain large mass anterior chest wall . His medical history showed chest trauma 1970, reconstitution scenario revealed blunt trauma swelling rib fracture side . Physical examination revealed isolated large anterior chest wall mass . Chest" " 712 newly diagnosed DLBCL patients treated chemoimmunotherapy 7 centers analyzed . GC non-GC profiles defined according to Hans algorithm . Non-GC profile showed trend towards worse overall survival (HR 1.24, 95%" Central nervous system (CNS) relapse uncommon complication diffuse large B-cell lymphoma (DLBCL) usually occurs within 2 years initial diagnosis . Pathophysiology poorly understood consensus definition high-risk patients high-risk patients CNS relapse " Diffuse large B-cell lymphomas (DLBCLs) biologically heterogeneous group various gene alterations reported . Aim study investigate frequency prognostic impact BCL2, BCL6, MYC rearrangements cyclophosphamide" " 98 cases aggressive B-cell lymphomas revealed recurrent deletion 19p13 nine cases . Six cases deletions encompassing region found array-comparative genomic hybridization data . Three cases even showed homozygous deletion, suggesting tumor suppress" " The widespread availability functional imaging clinical practice revolutionized care (staging, response assessment, surveillance) patients lymphoma . Using positron emission tomography/computed tomography (PET/CT) fludeoxyglucose F 18" The specific role chromosomal instability (CIN) tumorigenesis matter conjecture . The specific role chromosomal instability (CIN) tumorigenesis matter conjecture . The authors conducted retrospective cohort study examine prognostic utility PET-CT imaging uniform MCL patient cohort undergoing dose-intensive chemotherapy (R-HyCVAD) frontline s . The objective current analysis assess whether patient selection factors contributed improvement . The authors performed pooled analysis 2 consecutive trials included 150 patients HIV-associate . " Pneumocystis jirovecii pneumonia (PJP) adults receiving short-interval rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine pred" Lymphoproliferative disorders (LPDs) generally caused uncontrolled B-cell proliferation induced Epstein-Barr virus (EBV-LPD) LPD occurred 3 weeks use rabbit antithymocyte globulin administered severe " We developed controlled clinical trial assess efficacy toxicity adjuvant-involved field radiotherapy (IFRT) patients primary mediastinal B-cell lymphoma achieved complete response patients treated cyclophosphamide, doxorubicin," Richter syndrome describes development of non-Hodgkin's lymphoma (NHL) low-grade NHL . RS isolated brain rare brain rare poor prognosis . Macrophages rapidly engulf remove remove apoptotic cells limit release noxious cellular contents restrict autoimmune disease inflammation . Relationship between relationship autophagy phagocytosis remains unclear . " F-fluorodeoxyglucose PET important prognostic factor PGI DLBCL . PGI DLBCL is a relatively common disease . From 2006 2009, 165 Stage I E/II E PGI DLBCL" No literature data available concerning expression aquaporin-4 primary central central nervous system lymphomas . Relationship aquaporin-4 expression morphological characteristics blood vessels. " Diffuse large B-cell lymphoma (DLBCL) common subtype NHL Egypt . It represents 49% NHL presenting National Cancer Institute (NCI), Cairo University . CHOP regimen standard treatment used NHL since 1970s 30-" " Adult Burkitt lymphoma (BL) 'unclassifiable' lymphomas features intermediate BL diffuse large B-cell lymphoma (BL/DLBCL) ""unclassifiable"" lymphomas . We prospectively evaluated modified COD" " Hedgehog (HH) signaling pathway highly regulated signaling pathway . HH signaling required primitive hematopoiesis; however, conflicting data reported regarding role HH pathway adult hematopoiesis . HH signaling regulates intrathymic" " Chromosomal translocations involving MYC 8q24 found Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), B-cell lymphoma, unclassifiable, features intermediate DLBCL BL" " Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, germinal center B-cell (GCB) non-GCB types . We identified 62 patients DLBCL" " Autologous stem cell transplantation (ASCT) consolidation remains treatment choice patients relapsed diffuse large B cell lymphoma . Between 1990 2005, total 470 patient died from cancer ." " Malignant lymphomas female genital tract uncommon, development diffuse large B-cell lymphoma involving vagina involving vagina following treatment classic Hodgkin lymphoma extremely rare ." BCL2 expression activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CH " In Burkitt lymphoma (BL) aberrant c-Myc activity results IG-MYC translocations . However, MYC aberrations limited BLs negative prognostic impact . Study investigated extent aberrant c-Myc" Topoisomerase IIα protein expression gene alterations play roles prognostic factors in diffuse large B-cell lymphoma (DLBCL) We selected 102 patients DLBCL homogeneously treated CHOP chemotherapy followed up . 74-year-old patient successfully treated methotrexate (MTX)-ssbased polychemotherapy protocol (Bonn protocol) primary central nervous system lymphoma (PCNSL) 1996 . Diffuse large B-cell lymphoma (DLBCL) common subtype aggressive non-Hodgkin lymphoma . Despite recent chemotherapeutic advances half patients relapse . " Gene expression profiling major impact understanding biology of diffuse large B-cell lymphoma (DLBCL) Using technology, investigators identify biologic subgroups DLBCL provide unique targets rational therapeutic intervention . DLBCL provide unique targets rational therapeutic" Nasal diffuse large B-cell lymphoma (DLBCL) rare. Twenty-five patients included study . All patients received combination chemotherapy without radiotherapy . Primary breast diffuse large B-cell lymphoma (DLBCL) extremely rare presentation non-Hodgkin's lymphoma associated poorer clinical outcomes compared nodal DLBCL pre-rituximab era . The aim study " Between 1999 2009, 21 previously untreated patients received diagnosis PBL . All patients treated anthracycline-containing chemotherapeutic regimens, addition rituximab . 11 patients received consolidative radiation therapy induction treatment ." " EBV-positive diffuse large B-cell lymphoma (DLBCL) elderly entity recently included WHO classification lymphoid tumors . We reviewed experience clinical outcomes distinct subtype DLBCL . Between 2002 2009 and 2002, cases DLBC" Resistance glucocorticoid (GC) significant problem clinical management lymphoid malignancies . Addressing issue via mechanistic understanding relevant signaling pathways likely yield positive outcomes . There limited evidence-based literature help guide management patients lymphoma setting HCV reactivation . Primary breast lymphoma (PBL) rare disease comprises 0.04-0.53% primary malignant tumors breast . The frequent histological subtype diffuse large B-cell type (DLBCL) is 40-70% 48-year-old female involving thyroid gland . The patient thyroid swelling 15 years rapidly increased last 5 months . The patient thyroid swelling 15 years rapidly increased last 5 months . " Diffuse large B-cell lymphoma (DLBCL) often cured standard chemoimmunotherapy, great heterogeneity presentation outcomes . Sixty-five percent black patients compared 37% white patients ." Korean patients treated with rituximab for relapsed refractory B-cell non-Hodgkin's lymphomas . Patients received unlabeled rituximab 70 mg immediately prior administration therapeutic dose (med " Plasmablastic lymphoma (PBL) aggressive variant non-Hodgkin lymphoma initially reported oral cavity HIV-positive individuals . Since original description, several cases reported patients HIV infection . Despite recognition distinct subtype diffuse large" Anaplastic lymphoma kinase-positive large B-cell lymphoma rare non-Hodgkin lymphoma rare non-Hodgkin lymphoma rare non-Hodgkin lymphoma . The neoplastic Lenalidomide previously shown induce overall response rate (ORR) 28% patients relapsed/refractory DLBCL . It currently unknown response rates differ patients different DLBCL subtypes . Study aimed determine prevalence Epstein-Barr virus expression effect survival amongst diffuse large B-cell lymphoma (DLBCL) cases . Two large tertiary care centres identified cases 'Epstein-Barr virus-positive DLBCL " Peripheral T-cell lymphoma (PTCL) poorer prognosis than diffuse large B-cell lymphoma (DLBCL) Researchers administered CyclOBEAP regimen (cyclophosphamide, vincristine," " Primary cardiac lymphomas (PCL) extremely rare, diffuse large B-cell lymphoma highly aggressive subtype . Case initially diagnosed chronic right heart dysfunction . Despite adequate surgical debulking initial successful tricuspid annuloplasty" 64-year-old male patient angioimmunoblastic T-cell lymphoma (AITL) subsequently developed diffuse large B-cell lymphoma (DLBCL) Lymphoma different histologic type occur patient . The peripheral cannabinoid receptor (CB2) mainly detected B cells germinal centers (GCs) immune system . CB2 receptor expression is variable in the expression of diffuse large B-cell lymphomas . " Intravascular large B-cell lymphoma (IVL) characterized lymphoma cell proliferation lumina small vessels various organs . A high incidence neurologic symptoms associated central nervous system reported, peripheral nerve involvement (neurolymphomat" An autopsy case fatal complication percutaneous liver biopsy targeting rare type large B-cell lymphoma presented . A 79 year-old man referred hematology unit hospital anemia thrombocytopenia hepatosplen " Ambulatory Medical Assistance (AMA) project, monitoring procedure based standardized telephone intervention, aimed improve ambulatory care quality . aggressive B-cell lymphomas treated standard front-line R-CHOP therapy ." " The outcome patients diffuse large B-cell lymphomas improved dramatically last decade, opportunity improving therapy patients peripheral T-cell lymphoma exists begin study specific subtypes disease . It entirely possible patients different genetic subtypes diffuse large B-cell lymph" " Resampling techniques often used provide initial assessment accuracy prognostic prediction models developed using high-dimensional genomic data binary outcomes . Risk prediction important, however, medical applications frequently outcome measure right-censored time-to-event variable survival ." Analysis molecular data promises identification biomarkers improving prognostic models . We provide overview techniques regularized estimation transfer toward high-dime . We describe case giant right atrial large B-cell lymphoma treated initial surgical excision followed postoperative chemotherapy . The patient clinical evidence recurrence recurrence recurrence 87 months hospital discharge . Intravascular large B-cell lymphoma (IVLBCL) rare subtype diffuse large B-cell lymphoma . It characterized proliferation malignant lymphoid cells within small vessels various organs . The skin central nervous system commonly involved " Global gene expression profiling (GEP) used improve understanding lymphoma . Lymphoma classification changed several times time understanding normal malignant lymphocyte biology advanced . This improved prognostication, remain large diagnostic groups diverse outcomes ." Classification gene expression data plays significant role prediction diagnosis diseases . All genes contribute efficient classification samples . A robust feature selection algorithm required identify important genes help classifying samples efficiently . " Presence of Posterior reversible encephalopathy syndrome (Presence) described clinically acute neurologic deterioration characterized headache, change mental status seizures . Presence results vasogenic edema areas brain supplied posterior circulation . Methotrexate (MT" " CD99 immunoreactivity documented variety tumors, including lymphoid malignancies anaplastic large-cell lymphomas . Of 155 DLBCL patients, 60 (38.7%) positive CD99 were associated with advanced stage (p" Clinical studies indicate role allogeneic hematopoietic cell transplantation (alloHCT) patients refractory recurrent B-cell lymphoma (BCL) indicative graft-versus-tumor effect . relevance Diffuse large B cell lymphoma (DLBCL) comprises disease entities distinct genetic profiles . Major differences include genetic aberrations leading constitutive NF-κB activation interference terminal B cell differentiation BLIMP1 inactivation . " Protein lysates lymph nodes (n=239) patients diagnosis reactive hyperplasia (n=44), follicular lymphoma (n=63), diffuse large B-cell lymphoma (n=43), mantle cell lymphoma" " Burkitt lymphoma (BL) aggressive B-cell neoplasm extremely short doubling time mainly affects children young adults . Despite several characteristic features, none entirely specific BL differential diagnosis may include diffuse large B-cell lymphoma (DLBC" Peripheral T cell lymphomas (PTCL) demonstrated poorer prognosis diffuse large B cell lymphoma (DLBCL) due high frequency bone marrow involvement (BMI) due high frequency bone marrow involvement (BMI) " Treg cells are regulated regulatory T (Treg) cells C-C chemokine receptor 4 (CCR4) expressed cells . First, tumor cells function Treg cells, characterized expression CCR4, contributing tumor survival down" " Mashhad, Iran, studied 391 adult patients lymphoid malignancy . Patients reclassified using World Health Organization (WHO) classification ." " This study designed assess activity safety dose-adjusted infusional cyclophosphamide, doxorubicicin, vincristine, prednisone chemotherapy rituximab (DA-POCH-R) elderly" The use of F-fluorodeoxyglucose positron-emission tomography (PET) scan increased considerably clinical management non-Hodgkin lymphoma patients . Role prognostic factor chemotherapy established recently established recently . " The interaction endothelium malignant hematolymphoid cells within vessels eye result focal diffuse intravascular pathology . As result, correlation findings specific clinical ophthalmologic features vary ." " Bone marrow samples from 260 patients examined expression CD66 tumor cells . 104 lymphocytic leukemias, 28 mantle cell lymphomas, 28 follicular lymphomas, 22 follicular lymphomas, 15 marginal zone lymphomas (M" " 162 patients with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen relapsed . The late relapsing patients better prognostic characteristics diagnosis, stage I" Monoclonal B cell Lymphocytosis (MBL) previously detected evaluated fourth time 15-18 years since initial testing . All four environmental health study participants without hematologic malignancies without hematologic malign " 761 cases lymphoma (310 diffuse large B-cell [DLBCL]], 226 follicular [FL]], 225 Hodgkin [HL] 761 unaffected age sex matched controls recruited histories infection non-infection diagnoses ." " Lymphoid neoplasms diagnosed large oncology service Republic Korea 1989 2008 using World Health Organization classifications . Compared West, overall incidence lymphoid neoplasms lower, subtype distribution distinct Asia ." Toll-like receptors (TLRs) mammals well-known play important roles innate immunity . New roles TLRs suggested cells aberrant TLR expression may survival advantage normal cells . Lymphocytes one small number cell types express many TLRs The development gene expression profiling profiling . microarray techniques provided information . heterogeneity diffuse large B-cell lymphoma (DLBCL) patients . " 14-month-old female status-post OLT atypical presentation PTLD solitary renal mass . At eight-week post-transplant, presented elevated transaminases, CMV counts (73,000 copies/mL)," " Bortezomib rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, prednisone (R-CHOP) patients untreated diffuse large B-" " Hepatocyte growth factor (HGF) receptor MET essential embryonic development throughout postnatal life . Met activation, due overexpression, mutations, mutations, autocrine ligand production, contributes development progression variety human cancers ." " 51 patients underwent ASCT LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning relapsed (n = 34, 67%)" " The common type primary testicular lymphoma diffuse large B-cell type, poor prognosis relative extra-nodal diffuse large B-cell lymphomas (DLBCL) These constitute heterogeneous group lymphomas germinal center" " Since 1978, 100 case reports of composite lymphoma cited, many involving combinations low-grade B-cell lymphomas . To knowledge, cases large-cell transformation composite lymphoma yet described ." " Y-ibritumomab tiuxetan was followed by short-course chemotherapy consisting four cycles R-CHOP21 . Of 55 patients, 55 were treated seven Italian institutions short-course chemotherapy consisting four cycles R-CH" Thirteen cases CD4(+) CD56(+) hematologic malignancies prospectively encountered routine referral practices authors . Hematologic malignancies expressing CD4 CD56 commonly associated recently described CD4(+) CD56( " A 72-year-old man with a history of pulmonary tuberculosis presented 5-month history axonal neuropathy . He complained of chest pain, altered general status . CT-guided pleural biopsy revealed B-cell lymphoma ." The BCL6 transcriptional repressor frequently involved oncogene diffuse large B cell lymphoma (DLBCL) The BCL6 transcriptional repressor frequently involved oncogene diffuse large B cell lymphoma (DLBCL " SERT-ligands, including antidepressants chlomipramine fluoxetine, including antidepressants chlomipramine fluoxetine, were used in patients with lymphocytic leukaemia, mantle cell lymph" " Cytotoxic T lymphocytes (CTLs) genetically modified express CD19- CD20-specific, single-chain antibody-derived chimeric antigen receptors (CARs) display HLA-independent antigen-specific recognition/" " Polymorphisms GSTM1, GSTT1, GSTP1, GSTP1, GSTP1, GSTP1 are linked to treatment response, resistance, drug-related toxicity, affect clinical outcome . 94 Korean patients de" " R-CHOP regimen found improve outcome diffuse large B-cell lymphoma (DLBCL) R-CHOP regimen found improve outcome . However, provide satisfactory treatment outcome high-risk group ." " Fourteen patients primary ovarian lymphoma, eighteen patients secondary ovarian involvement . There significant difference survival rates . The localized bilateral ovarian involvement showed poorer survival compared stage III/IV patients secondary ovarian involvement ." " Primary gastrointestinal lymphomas relatively common, large majority occurring stomach . In commonest histological subtype, i.e. diffuse large B-cell lymphoma (DLCBL), chemotherapy widely applied past, either following surgery - recent years" The diagnosis gastrointestinal lymphoma made endoscopic biopsies vast majority cases . Definitive subtyping lymphoma according WHO classification use additional immunological molecular markers cornerstone decision making . Diffuse large B-cell lymphoma (DLBCL) aggressive malignancy variable response therapy . We used gene expression profiling investigate mechanism CD40 resistance cell lines . We found resistance correlated lack of Vav-1 inability activate NF " Using population-based cancer registry Orange San Diego Counties, We recruited 50 patients HIV systemic NHL (cases) 50 age, sex race-matched NHL patients without HIV (controls) diagnosed NHL 2002-2006 . Patients completed medical history" " Eighty-six eligible patients received sequential chemotherapy involved-lesion radiation therapy 1995 2006 . After median four cycles CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) r" We compared outcomes 916 diffuse large B cell lymphoma patients aged >or=18 years undergoing first autologous (n = 837) myeloablative (MA) allogeneic hematopoietic cell transplant " Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin's lymphoma . Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincrist" " Forty-eight patients NHL involving rare extranodal sites analyzed . The adrenal gland (n = 14), ovary (n = 13), pancreas (n = 11), pancreas (n = 11), uterus" " Non-pegylated liposomal doxorubicin associated lower cardiac toxicity . Non-pegylated liposomal doxorubicin associated lower cardiac toxicity conventional doxorubicin, reason used" " 38% primary large B-cell lymphoma (DLBCL) tested expressed active Src family kinases, targeted dasatinib . The expression of active Src family kinases (SFK) primary DLBCL tumors" " Patients affected autoimmune diseases (rheumatoid arthritis (RA), psoriasis, dermatomyositis) treated methotrexate (MTX) develop lymphoproliferative disorders (LPDs) Angioimmun" Methylation p57KIP2 gene biomarker detected 53 cases of diffuse large B cell lymphoma (DLBCL) Methylation p57KIP2 gene analyzed 63 cases DLBCL methylation-specific real- Forty-two patients primary gastric lymphoma underwent positron emission tomography (PET/CT) scans . 32 diffuse large B-cell lymphomas (DLBCL) 32 diffuse large B-cell lymphomas (DLBCL " We examined several immune-related disorders medications relation non-Hodgkin lymphoma (NHL) Multiethnic Cohort . Severe immune dysfunction established risk factor lymphoma, role moderate alterations immunity altered ." " Primary renal lymphoma is a rare entity characterized aggressive histopathology, early extra-renal infiltration poor prognosis . Primary renal lymphoma is a rare entity characterized aggressive histopathology, early extra-renal infiltration poor prognosis" FOXP1 reported correlate poor prognosis diffuse large B-cell lymphoma (DLBCL) Recently found FOXP1 expression occurs mucosa-associated lymphoid tissue (MALT) lymphomas . FOXP1 expression relationship morphology Children with primary immunodeficiency chromosomal breakage syndromes increased risk developing non-Hodgkin lymphomas . Use rituximab first-line monotherapy conjunction reduced chemotherapy considered reduce cytotoxic effects . " Adult pediatric primary mediastinal B-cell lymphoma (PMBCL) reviewed compared . Biologically, adult PMBCL similarities Hodgkin Lymphoma (HL) diffuse large B-cell lymphoma (DLBCL)" Diffuse large B-cell lymphomas (DLBCL) highly heterogeneous regard clinical presentation outcome . Deleted 6q21-24 gene deletion significantly associated highly favorable clinical response chemotherapy . SelMQC technique combined longitudinal Hadamard slice selection chemical shift imaging (CSI) yield slice-selective images lactate . The ability generate vivo maps lactate may significant diagnostic utility staging treatment planning wide variety cancers . Chemokine receptors mediate migration activation lymphocytes binding ligands . Chemokine receptors mediate migration activation lymphocytes binding ligands . " NHL risk population-based study 759 cases 589 frequency-matched controls . NHL incidence has increased dramatically since least 1950s . Use of blood transfusions, invasive surgical procedures anesthesia, impact immune function ." " Primary cutaneous follicle centre lymphoma (PCFCL) characterized excellent prognosis, primary cutaneous large B cell lymphoma, leg-type (PCLBCL leg-type), unfavourable prognosis . PCFC" Living cells viewed complex adaptive systems exhibit non-linear dynamics fractal features . We investigated fractal qualities normal malignant hematological cells potential tool characterizing cell phenotype clinical behavior . A mathematical algorithm optic tool fractal analysis nuclei developed " The JAK2(V617F mutation, found patients myeloproliferative disorders (MPD) yet evaluated lymphoproliferative disorders adequately sensitive techniques . We investigated whether low levels JAK2(V617F" Two Chinese women developed primary pulmonary ALCL developed two Chinese women . Both patients treated 6 cycles of chemotherapy . " FNAB mediastinum challenging location may harbor many lesions, including primary metastatic tumors . Image-guided transthoracic (percutaneous) FNAB less invasive mediastinoscopy endoscopic-guided" Post-transplant lymphoproliferative disorder (PTLD) central nervous system (CNS) poor prognosis . We report experience intrathecal administration rituximab 10-year-old kidney allograft recipient Primary lymphoma breast reported high local central nervous system recurrence rate . Need consolidation radiotherapy CNS prophylaxis . " Diffuse large B cell lymphoma (DLBCL) aggressive malignancy accounts nearly 40% lymphoid tumors . MicroRNAs over-expressed de novo DLBCL (n = 35), transformed DLBCL (" " Bilateral ovarian enlargement may reflect benign malignant processes ovary . Benign causes ovarian enlargement include luteomas, tumors mature cystic teratomas, fibrothecomas, cystadenomas rare conditions including cap" We report fine-needle aspiration (FNA) biopsy findings primary diagnosis lymphoproliferative disorders involving spleen . We analyzed six cases primary diagnosed lymphoma involving spleen cases . The majority gastric mucosa-associated lymphoid tissue (MALT) lymphoma develops Helicobacter pylori-associated chronic gastritis . Little still known regarding clinicopathologic features gastric MALT lymphoma associated H. " Basophils play important role allergic inflammation pathologically related hematological disturbances, iron deficiency anemia myeloproliferative disorders . Here, report case 33-year-old man bulky mass small intestine, multiple paraaort" " Anaplastic large cell lymphoma (ALCL) entity non-Hodgkin lymphomas (NHL) often occurs young children adolescents . In majority cases, ALCL T-cell origin contain t(2;5)(" " Hodgkin disease (HD) diffuse large cell lymphoma (LCL) fit model well . However, subset patients either refractory first-line treatment dev. may be refractory first-line treatment dev. However, change" " Cytogenetic analysis revealed 8 11 evaluable cases structural abnormality long arm chromosome 6, deletion addition material unknown origin . Breakpoints spanning region 6q12-6q23 ." MALT1 gene t(11;18)(q21;q21) t(14;18)(q32;q21) frequent structural chromosomal abnormalities MALT lymphomas . Among 122 diffuse large B-cell lymphomas Diffuse large B-cell lymphomas (DLBCL) represent common type adult malignant lymphoma western countries treated high dose combination chemotherapy . DLBCL is a common type adult malignant lymphoma western countries treated high dose combination " 81 lymphomas analyzed included 16 cases B-cell chronic lymphocytic leukemia, 11 mantle-cell lymphomas, 11 follicular lymphomas, 10 follicular lymphomas, 7 MALT lymphomas, 8 Burki lymphomas ." " Lymphoma thalassemia rarely reported, review English literature revealed four cases . Because anemia always masked regular transfusions thalassemic patients, physicians discover hidden malignancy late course disease ." " CARMA1, CARD9 and CARD9 play important roles lymphocyte activation, significance of CARMA1 remains unclear . By using reverse transcription-polymerase chain reaction analysis, expression levels of CARMA1, CARD9, B" Angioimmunoblastic T cell lymphoma arising setting 5 years immunosuppressive treatment progressive systemic sclerosis . The lymph node lesion accompanied large blastic B cells association Epstein-Barr virus . Southern blot study demonstrated clonal " Translocations involving band 3q27, affecting major breakpoint region (MBR) BCL6, common diffuse large B-cell lymphomas (DLBCL) Recent data suggest alternative breakpoint cluster region (ABR)" " Previous study demonstrated high expression of non-coding BIC gene vast majority Hodgkin's lymphomas . High levels miR-155 could demonstrated, indicating BIC processed microRNA HL . Most non-HL subtypes negative BIC" Anaplastic large-cell lymphoma (ALCL) presenting primary hepatic lymphoma exceedingly rare . The nuclei cells often eccentrically located appeared convoluted even multilobulated . Hodgkin's lymphoma (HL) Non-Hodgkin's lymphoma (NHL) represent models study multistep transformation process tumorigenesis development . We analyzed six lymphomas transforming events . HLs combined two cases The goals current study elucidate long-term outcome Helicobacter pylori eradication therapy gastric mucosa-associated lymphoid tissue (MALT) lymphoma) clarify therapeutic efficacy stomach-conserving treatments . Ninety- " Anaplastic large cell lymphomas (ALCLs) subdivided two subgroups basis expression ALK protein . ALK protein expression leads activation signal transducer activator transcription (STAT3) 3, commonly expressed ALK-" The role TP53 mutation transformation follicular lymphoma (FL) diffuse large B-cell lymphoma (t-FL) examined panel 91 lymph node biopsies derived 29 patients pre-transformation . The entire TP53 coding sequence Loss HLA class I class II expression B cell lymphomas mechanism escape cytotoxic T lymphocyte (CTL) immune response . " Diffuse large B cell lymphoma, T-cell-rich/histiocyte-rich variant (DLBL-TH) characterized presence neoplastic B cells set background containing numerous non-neoplastic T lymphocytes histi" A 27-year-old man developed autoimmune lymphoproliferative syndrome large-B-cell lymphoma heterozygous mutations Fas perforin (Prf1) genes . The Fas mutation inherited healthy father also carried healthy brother Small-cell carcinoma (SmC) high-grade non-Hodgkin's lymphoma (NHL) aggressive neoplasms require prompt diagnosis treatment . Twenty-seven metastatic SmC 50 NHLs cas . We retrospectively reviewed 74 fine-needle aspiration (FNA) cases presumptive non-Hodgkin lymphoma (NHL) cases . All cases cytology core-needle biopsy 53 cases concurrent flow cytometric analysis 21-year-old woman with diffuse large B-cell lymphoma developed acute anterior uveitis . She was treated with topical steroids and saline eye drops . Chemotherapy radiotherapy radiotherapy principal modalities treatment diffuse large B-cell non-Hodgkin's lymphoma (B-NHL) 30 years ago . Various treatment regimens designed years try to increase response cure rates . " Prolificative indices (PIs) provide valuable prognostic information setting . PI measurements depend proliferative activity neoplastic cells given lesion, also activity admixed reactive cells ." " We conducted controlled clinical trial evaluate efficacy toxicity toxicity toxicity toxicity of interferon-alpha 2b, cyclophosphamide, prednisone maintenance therapy patients aggressive diffuse large B cell lymphomas complete remission . 169 patients eligible study; end" Hepatitis C virus (HCV) implicated etiology of malignant lymphomas . Hepatitis C virus (HCV) implicated etiology malignant lymphomas . We estimated risk lymphoma associated detection of HCV infection . We studied 36 genes whose expression reported predict survival . The genes strongest predictors were those of 36 genes . The aim study analyze relations differentiation immunophenotypes status of BCL6/CD10/MUM1/CD138 . The aim study analyze relations differentiation immunophenotypes status . Primary extranodal lymphoma urinary bladder rare disorder diagnosed basis histopathology immunostaining . We report case diffuse B cell primary lymphoma urinary bladder review literature . " Non-Hodgkin lymphoma (NHL) represents heterogeneous group tumors vary regard biologic aggressiveness clinical course . In vitro studies, matrix metalloproteinase 9 (MMP9) reportedly expressed human NHL cells" We suggest new method aggregate survival trees order obtain better predictions breast cancer lymphoma patients . Predicted survival probability functions censored event free survival improved bagging survival trees . " Lymphoproliferative disorders (LPD) occasionally develop individuals immune deficiencies immunosuppressive conditions autoimmune diseases (AID) In study, clinicopathologic features virus status analyzed 53 cases LPD developing rheumatoid arthritis" " An integrated treatment delivery system conformal stereotactic radiosurgery (CSRS) radiotherapy (CSRT) developed collaboration involving Siemens Medical Systems, Inc., Tyco/Radionics, Inc., The University Texas M. D" " Case primary non-Hodgkin lymphoma right humerus occurred 21-year-old male patient impact right shoulder car accident July 1983 described . Seventeen years injury, due civil lawsuit, biopsy material revised ." P63 gene ectrodactyly-ectodermal dysplasia-clefting (EEC3) syndrome type 3 (EEC3) The p63 gene (P63) homology P53 known tumor- 68 cases of OAL lymphomas (OAL) were found in Korea . The majority ocular adnexal lymphomas (OAL) primary marginal zone B-cell lymphomas (MALT lymphomas) were OALs " An optimal treatment modality patients primary gastrointestinal lymphoma yet established . This study comprised 342 patients (75%) gastric lymphoma, 96 patients (22%) intestinal lymphoma, 17 patients (4%) gastric intestinal lymphoma ." " In search genes specifically expressed Reed-Sternberg (RS) cells Hodgkin lymphoma (HL) applied serial analysis gene expression (SAGE) technique . RT-PCR analysis confirms SAGE results . For one genes, high" " Epstein-Barr virus identified tumor immunocytochemical molecular methods . Chemotherapy without addition rituximab was minimally effective, adding radiotherapy chemotherapy reduced tumor size ." Peripheral T-cell lymphoma (PTCL) represents relatively small proportion lymphomas lower prevalence Western countries . The World Health Organization classification lymphoid neoplasms announced 1999 resolved criticisms lymphoma classification aroused new interest PTCL HLA class I molecules play important role initiating cellular anti-tumor immune response . HLA class I expression diffuse large B-cell lymphoma (DLBCL) central nervous system (CNS) testis common event . " Loss heterozygosity (LOH) major mechanism inactivation tumor-suppressor genes observed various solid tumors lymphomas . The human leukocyte antigen (HLA) region located chromosome band 6p21.3, loss alteration region" " Focal follicular features diffuse large B-cell lymphomas (DLBCLs) bound raise question follicular lymphoma (FL) diffuse areas . Monomorphous large tumor cells evenly spaced abundant, often clear cyt cytosyn" " A retrospective review of veterinary medical records identified 17 cases of canine IVL . Spinal cord ataxia, posterior paralysis, seizures and vestibular disease dominated clinical presentation . Haemorrhage, ischaemia, occasional f" " 52-year-old previously healthy Caucasian woman presented superior vena cava syndrome . She presented superior vena cava syndrome, secondary compression bulky anterior mediastinal mass involving right lung ." " In vitro studies indicate lymphomas, execution apoptosis involves activation effector caspases . New assay developed using antibodies using antibodies active caspase 3 p89, protein fragment generated caspase-specific cleavage poly-ADP" " The bcl-x gene product two forms, bcl-xl bcl-xs . The bcl-xl form, similar bcl-2, inhibits apoptosis . The bcl-xl form, similar" " Most follicular lymphomas transform diffuse lymphoma eventually, comprising significant proportion diffuse large B-cell lymphoma (DLBCL) One third DLBCLs believed FL derivation Western population . In East Asia, FL uncommon DLBC" Epididymitis diagnosed conservative therapy antibiotics anti-inflammatory drugs given . After 2 months therapy patient admitted department tumor suspected . Tumor markers normal . " Anaplastic large-cell lymphoma (ALCL) heterogeneous process may T-cell, B-cell, indeterminant (null) phenotype may may express anaplastic lymphoma kinase (ALK) oncoprotein" The patient presented solely obstructive biliary symptoms . The patient presented solely obstructive biliary symptoms . The patient presented solely obstructive biliary symptoms . The patient presented solely obstructive biliary symptoms . Angiotropic large cell lymphoma (ALCL) characterized intravascular proliferation malignant lymphoid cells small medium-sized blood vessels . Surgical intervention required diagnosis case. Successful treatment chemotherapy followed involved field radiation ensued maintained disease There relatively little information concerning use fine-needle aspiration (FNA) diagnose extranodal extramedullary hematopoietic malignancies . Seventy-one cases diagnosed FNA form basis study . Lymphoma ear rare. Malignant tumors ear rare. Malignant tumors ear rare. The common malignant tumors squamous cell carcinomas adenocarcinomas. Lymphoma ear rare. Nasopharyngeal carcinoma (NPC) strongly associated Epstein-Barr virus (EBV) The metastasis cervical lymph nodes represents frequent initial manifestation NPC . The usefulness EBV detection polymerase chain reaction (PCR) Four patients cutaneous CD4+ CD56+ lymphoma studied . Age first examination ranged 71 89 years (mean = 81.2 years) One patient female 3 males . AIDS-related non-Hodgkin's lymphomas (AIDS-NHLs) consistently derive B cells . Recently proposed inactivating mutations bax death agonist may contribute pathogenesis human tumors . " Fine-needle aspiration (FNA) found 4 cases anaplastic (Ki-1) large-cell lymphoma (ALCL) A primary diagnosis ALCL made FNA material 2 cases, one multifocal osse" " CD30 originally described marker Hodgkin's Reed-Sternberg cells Hodgkin's lymphoma . Expression CD30 mostly restricted virus-infected lymphocytes, neoplasms lymphoid origin subset activated T cells produce Th2-type" " Genetic alterations p107 gene, close relative retinoblastoma tumor suppressor gene, never identified human malignancies . When searched alterations human hematologic malignancies Southern blot analysis, 2 21 cell lines 1 88 primary disorders" The purpose study evaluate prognostic value clinical biological biological factors patients refractory/relapsed Diffuse Large B-Cell Lymphoma. The purpose study evaluate prognostic value clinical biological factors patients refractory/relapsed Diffuse " The study is a prospective, single-center, open-label clinical study . Elderly patients diffuse large B cell lymphoma treated first time ." The investigators perform retrospective microarray gene expression profiling study FFPE cohort DLBCL patients whole genome cDNA mediated Annealing Selection Ligation (WG-DASL) Assays also study pattern microRNA patients diffuse large B " Annually 450 patients diagnosed Diffuse Large B-cell Lymphoma (DLBCL), Denmark . Majority patients cured immunochemotherapy, 30 % relapse, pointing need targeted surveillance follow-up strategy ." A phase II trial evaluate efficacy safety combination bendamustine rituximab patients relapsed refractory diffuse large B-cell lymphoma patients . It hypothesized BR combination produce least 70% overall response rate . " This study two phases, dose escalation phase dose expansion phase . For dose escalation, primary objective estimate maximum tolerated dose AEB071 patients diffuse large b-cell lymphoma. The endpoint objective occurrence Dose Limiting Toxicity. For" Diffuse Large B Cell Lymphoma (DLBCL) treated R-CHOP chemotherapy era pegylated-filgrastim . The investigators prospectively collect clinical data treatment outcome patients DLBCL use prophylactic " GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP Versus Rituximab" Phase II open-labelled two-arm study comparing R-GEM-P LR-GEM second-line treatment Diffuse Large B-cell lymphoma . Eligible patients randomised 1:1 R-GEM- One-third of patients in rituximab era experience relapse/refractory disease first-line anthracycline-based immunochemotherapy (IChemo) Optimal management remains unmet medical need . " A single-center, open, single-arm clinical study efficacy safety safety . A novel targeted agent combination R-ICE treatment . combination R-ICE treatment . relapsed refractory diffuse Large B-cell lymphoma ." " Incorporation rituximab conventional chemotherapy (R-CHOP) revolutionalized frontline treatment diffuse large B-cell lymphoma (DLBCL) Despite majority patients cured, still remains substantial number patients (20-30" The main purpose study explore sequential therapeutic effect CD19-targeted CD20-targeted CD20-targeted chimeric antigen receptor T(CAR-T) cells treatment Diffuse Large B Cell Lymphoma . The purpose Phase I study evaluate safety maximum-tolerated dose (MTD) combination R-ESHAP lenalidomide salvage therapy patients relapsed refractory diffuse large B-cell lymphoma patients relapsed refractory The study was conducted to evaluate efficacy of recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection(HS006) CHOP(Hi-CHOP) versus Rituximab CHOP (R This study evaluate incidence of central nervous system (CNS) relapse metastasis patients with diffuse large B-cell lymphoma . " Dasatinib, administered orally continuous dose 100 mg daily, safe effective treating subjects failed prior therapies diffuse large B cell lymphoma (DLBCL) relapsed disease ." mitoxantrone hydrochloride hydrochloride liposome combination rituximab lenalidomide treatment relapsed refractory diffuse large B-cell lymphoma (DLBCL) was studied . " The open-label, multicenter, phase 2 trial explore efficacy safety combination lenalidomide R-CHOP preventing CNS relapse high-risk diffuse large B cell lymphoma ." " This study aimed evaluate efficacy of a new regimen consisting of rituximab, gemcitabine, dexamethasone, cisplatin (PV-RGDP) treatment diffuse large B-cell lymphoma ." AEB071 EVEROLIMUS patients CD79-mutant ABC subtype Diffuse Large B-Cell Lymphoma patients CD79-mutant ABC subtype Diffuse Large B-Cell Lymphoma . Study safety Denmark accounts almost 40% newly diagnosed NHL cases . Treatment combination chemotherapy monoclonal antibodies significantly improved prognosis past decade . " Phase 2 Study Abbreviated 3 Cycles Rituximab plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) Patients Completely Excised Localized" " R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine Prednisone) combined lenalidomide first-line treatment patients medium high risk/high risk" R-GemOx Versus R-miniCHOP first-line treatment elderly patients Diffuse large B cell lymphoma . The purpose study investigate efficacy safety R-GemOx Versus R-miniCHOP first-line treatment elderly The purpose study compare lenalidomide control drug to see one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer . " Pneumococcal infections remain frequent potentially fatal . To prevent them, two anti-pneumococcal vaccines exist: 13-valent conjugate vaccine (Prevenar®) 23-valent polysaccharide vaccine" " RCHOP without VELCADE adult patients previously untreated non-GCB Diffuse Large B-cell Lymphoma (DLBCL) RCHOP is a randomized, open-label, multi-center, phase 2" " CD19-CAR-T therapy new method treat DLBCL . KTE-C19, published New England Medical Journal December 2017, used treat relapsed refractory B-cell lymphoma ." This Phase 1b/2 study designed assess safety efficacy ibrutinib combination lenalidomide rituximab subjects relapsed/refractory diffuse large B-cell lymphoma (DLBCL) eligible transplant " Abexinostat, monotherapy patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) is being tested for efficacy safety . The study is being conducted in an open-label, single-arm" " Diffuse Large B-cell Lymphoma (DLBCL) malignant, aggressive lymphoid cancer . The incidence of DLBCL is approximately 450 cases per year . In 2/3 cases, complete remission achieved immunochemotherapy" " Vorinostat first new type chemotherapy drug, known histone deacetylase inhibitor, approved Food Drug Administration . Vorinostat alters cancer cell pathway preventing cancer cells reproducing ." " Open-label, multicenter, uncontrolled non-randomized study comparing 18F-FDG PET-Scan diffusion MRI assessment early therapeutic response Diffuse Large B-Cell Lymphoma ." The main purpose study evaluate safety efficacy R-CEOP-90/R-CEOP-70 versus R-CHOP-50 Treatment Diffuse Large B-cell lymphoma Follicular Lymphoma Grade 3B patients . Chidamide combined VDDT(vinorelbine，liposomal doxorubicin，liposomal doxorubicin，dexamethasone thalid " Patients previously untreated diffuse large B-cell lymphoma receive standard treatment R-CHOP (rituximab,cyclosphosphamide, doxorubicin, vincristine, prednison) 6 cycles," Selinexor (KPT-330) was a Phase 2b study of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) therapeutic options demonstrated clinical benefit " Diffuse large B cell lymphoma (DLBCL) common type non-Hodgkin lymphoma Korea . Although standard therapy, called 'R-CHOP', many obstacles use aggressive cytotoxic chemotherapeutic agents" " Phase 1/2, open-label, dose-escalation study assess safety tolerability GCS-100 combination etoposide dexamethasone . Patients relapsed refractory diffuse large B-cell lymphoma patients" MK 2206 patients relapsed refractory diffuse large B cell lymphoma. MK 2206 patients relapsed refractory diffuse large B cell lymphoma. The purpose study evaluate antitumor efficacy efficacy safety safety . Diffuse large B-cell lymphoma (DLBCL) common type non-Hodgkin lymphoma . Annual incidence increases age achieves 30 per 100 000 patients 65 years old over . Yangzhengxiaoji Capsule Combination Chemotherapy III/IV Diffuse Large B Cell Lymphoma . The purpose study evaluate efficacy safety . Yangzhengxiaoji Capsule Combination Chemotherapy III/IV Diff lenalidomide (Revlimid ®) combination dexamethasone combination dexamethasone combination dexamethasone . Patients relapsed refractory diffuse large B-cell lymphoma. Subjects relapsed ref RAD001 adjuvant therapy poor risk patients Diffuse Large B-Cell Lymphoma (DLBCL) achieved complete response first-line rituximab-chemotherapy . " The purpose study find effects, good and/or bad; rituximab, ifosfamide, carboplatin etoposide (RICE) followed gallium nitrate, rituximab dexam" Decitabine + R-CHOP Diffuse Large B-Cell Lymphoma is a Phase I/II trial of Decitabine + R-CHOP . Decitabine + R-CHOP Diffuse Everolimus oral mTOR inhibitor demonstrated preliminary efficacy safety in preclinical clinical studies . The safety effectiveness of Everolimus treatment DLBCL yet fully determined still determined still investigational . " Drugs used chemotherapy, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, work different ways . Radiation therapy uses high-energy x-rays kill cancer cells ." " This post-authorization safety investigation multicenter, non-interventional, prospective cohort study . This post-authorization safety investigation multicenter, non-interventional, prospective cohort study ." " This open-label, multicentre, randomised phase II trial relapsed refractory diffuse large B-cell lymphoma ." " A multicenter, prospective, randomized, open-label, controlled trial evaluate efficacy safety . Patients aged older equal 70 years equal 70 years ." The purpose study evaluate safety tolerability of INCB053914 combination INCB050465 relapsed refractory diffuse large B-cell lymphoma (DLBCL) The purpose study evaluate safety tolerability INCB053914 Patients with diffuse large B-cell lymphoma intermediate high risk of high risk of relapse treated with CNS prophylaxis . Patients with low risk of relapse without CNS prophylaxis (arm C) Phase 2 single-institution trial early systemic central nervous system prophylaxis high-risk diffuse large B-cell lymphoma . Phase 2 single-institution trial early systemic central nervous system prophylaxis high-risk diffuse The purpose study determine predictive value of mRNA signature liquid biopsy patients Diffuse Large B cell lymphoma. Diffuse Large B cell lymphoma. The purpose study determine predictive value mRNA signature liquid biopsy patients Diffuse Large B cell lymph Decitabine combined R±DHAP patients replase refractory Diffuse Large B cell lymphoma . Patients replase refractory Diffuse Large B cell lymphoma . A phase II study assess Maintenance Therapy Chidamide Chidamide Patients With Hepatitis B Virus . Patients With Hepatitis B Virus With Hepatitis B Virus . Patients With Hepatitis B Virus . With Hepatitis " CTA101 relapsed refractory diffuse large B-cell lymphoma patients . This single-center, non-randomized dose-escalation study evaluate safety efficacy CTA101 ." This study investigate treatment results obtained R-CHOEP young high-risk patients diffuse large B-cell lymphoma improved addition ibrutinib regimen . " Anlotinib Hydrochloride Capsules subjects diffuse large B-cell lymphoma . This open-label, single-center, single-arm study evaluate efficacy safety ." The purpose study confirm whether bispecific T-cell engager blinatumomab effective safe treatment patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) The purpose study confirm whether bispe " This open-label, randomized, parallel group study evaluate efficacy safety . Participants randomized receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) or rituximab 375 milligrams per" Metformin is an adjunct to RCHOP chemotherapy for newly diagnosed diffuse large-B cell lymphoma patients . Lenalidomide combination R-GemOx first-line treatment elderly patients Diffuse large B cell lymphoma. The purpose study investigate efficacy safety . Lenalidomide combination R-GemOx first-line treatment elderly patients " Mitoxantrone Hydrochloride Hydrochloride Liposome Injection plus Cyclophosphamide,Vincristine Prednison,Vincristine Prednison(CNOP) is safe effective treatment Diffuse Large" The study was conducted in a clinical journal on Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) The study was designed to evaluate objective response rate (ORR) The purpose study determine effective Yt90-Zevalin therapy patients diffuse large B-cell lymphoma achieved least unconfirmed partial remission 6 cycles CHOP therapy . Investigators analyzed clinical outcome of DLBCL patients according age group to determine impact EBV status . DLBCL patients according age group define impact EBV status clinical outcome . The purpose study determine predictive value model . model . model of Nomogram Prognostic Index (NPI) patients Diffuse Large B cell lymphoma . Acalabrutinib subjects relapsed refractory de Novo Activated B-cell (ABC) Subtype Diffuse Large B-Cell Lymphoma (DLBCL) Subjects relapsed refractory de Akt inhibitor MK2206 works treating patients relapsed refractory diffuse large B-cell lymphoma . Akt inhibitor MK2206 may stop growth cancer cells blocking enzymes needed to grow . " A phase II trial ifosfamide, etoposide, cytarabine, cytarabine, methotrexate (IVAM) chemotherapy refractory relapsed diffuse large B cell lymphoma ." " This prospective, single-center, open-label, single-arm clinical study is designed evaluate efficacy safety . Zanubrutinib, Lenalidomide Rituximab (ZR2) regimen is designed to" This modular study AZD2014 combination novel anti-cancer agents patients different subtypes relapsed refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients non-germinal centre B-cell-like " The Purpose This Study Compare Efficacy, Safety, Immunogenicity and Pharmacokinetics TQB2303 Rituximab Combination With CHOP Previously Untreated Patients Diffuse Large B-cell Lymphoma ." Diffuse large B-cell lymphoma prevalent subgroup within malignant lymphoma prevalent subgroup within malignant lymphoma . 7% patients affected doxorubicin cumulative doses 550mg/sqm. " TQ-B3525 tablet administered 20mg orally, daily 28-day cycle . TQ-B3525 subjects relapse/refactory diffuse large B-cell lymphoma received at least 2 lines therapeutic schedules including ritux" The purpose study investigate proportion cell-of-origin (COO) subtypes relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated BTK inhibitor lenalidomide biosimil Ofatumumab would enhance activity etoposide+ifosphamide mesna+cytarabine+methotrexate+methotrexate+lenograstim filgrastim (IVAC) " This Phase III, randomized, double-blind, placebo-controlled study compare efficacy, safety, pharmacokinetics polatuzumab vedotin plus R-CHP versus R-CHOP participants . R-CHOP participants" In Europe diffuse large B-cell lymphoma (DLBCL) rare disease whereas Italy not . Approximately 40% DLBCL patients refractory disease relapse initial response . This exploratory study embedded Phase Ib/II clinical trial . CD3 x 4-1BB x CD19 x PD-L1 tetra-specific T cell engager GNC-038 . GNC-038 rel " 270 untreated patients, age 18 65 years, age 18 65 years treated with pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rit" Study loncastuximab tesirine administered intravenously (IV) maintenance therapy . Patients relapsed diffuse large B cell lymphoma . " This phase II study is evaluating safety, tolerability efficacy of BKM120 patients . Patients relapsed refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) follicular lymph" " R-CHOP Acalabrutinib is an addition to the standard therapy Rituximab, Cyclophosphamide, Doxorubicin, Vincristine Prednisolone ." Study consists single arm explore efficacy safery zanubrutinib patients CD79B mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma . " Epcoritamab combined intravenous oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone (R-CHOP) R-CH" " Differing large B cell lymphoma. detect translocation c-Myc, Bcl-2 Bcl-6 FISH 481 gene mutation next generation sequencing. analyze relationship gene abnormalities ." " This Phase 1b/2, open-label, non-randomized multicenter study assess safety efficacy ibrutinib lenalidomide combination DA-EPOCH-R subjects relapsed/refractory Diffuse" DLCL patients baselne FDG-PET part initial staging (PET-1) Patients undergo 2 cycles chemotherapy R/CHOP . Patients undergo repeat FDG-PET scan (PET-2) 21 days after cycle 2 R The primary purpose study assess safety tolerability ociperlimab (BGB-A1217) combination tislelizumab (BGB-A317) combination tislelizumab (BGB-A " The investigators want investigate efficacy safety combination bendamustine rituximab patients previously untreated PTLD, monomorphic CD20 (+) diffuse large B-cell lymphoma . The investigators want investigate efficacy safety combination bendamustine" " This study multicenter, open-label study was a multicenter, open-label study . Participants relapsed refractory diffuse large B-cell lymphoma (DLBCL) participants relapsed refractory diffuse large B-" " This randomized, open-label, multicenter study evaluate efficacy safety navitoclax addition bendamustine rituximab patients relapsed diffuse large B-cell lymphoma . Patients randomized receive navitoclax addition bend" Purinostat mesylate injection (PM) novel highly potent Class I IIb HDAC-selective inhibitors . PM potential treat diffuse large B cell lymphoma . " This randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study efficacy safety VELCADE, Rituximab, Cyclophosphamide, Doxorubicin," GNC-038 participants were patients with recurrent refractory Diffuse Large B-cell lymphoma (DLBCL) Participants were also patients with recurrent refractory Diffuse Large B-cell lymphoma (DLBCL " YY-20394 combined GEMOX used cycle 21 days . The dose YY-20394 80mg/ day recommended phase 2, dose GEMOX treated according clinical standards ." Loncastuximab Tesirine (ADCT-402) is a Phase 2 study evaluating clinical efficacy safety . Patients relapsed refractory Diffuse Large B-Cell Lymphoma. " Study B9991011 multi-center, international, randomized, open label, 2 component (Phase 1b followed Phase 3), parallel-arm study avelumab combination various agents treatment Relapsed/Refractory (R/" " This Open label, Phase Ⅰb Study ATG-010 Combination With ATG-008 Patients Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)" R-CHOP therapy therapy DLBCL patients. Primary objective: To compare event free survival 3years R-CHOP plus Biocell Natural Killer Cell R-CHOP therapy . The purpose test was to test whether dose densified chemoimmunotherapy followed central nervous system (CNS) prophylaxis . Six courses rituximab-cyclophosphamide-doxorubicin The study conducted population 60 patients . 60 patients . were treated with R-CHOP planned part standard care . " This study evaluate safety, pharmacokinetics, preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy participants best response stable disease partial response . Participants best" " A retrospective, non-interventional cohort study used address study objectives . This study aimed provide better understanding real-world healthcare resource utilization (HRU) healthcare reimbursement costs associated CAR-T therapy ." " The primary objective phase 1 evaluate safety KTE-C19 atezolizumab combination regimens . The primary objective phase 2 evaluate efficacy KTE-C19 atezolizumab, measured complete response rate participants ref" " This Phase 2 study determine efficacy safety canfosfamide treatment relapsed refractory mantle cell lymphoma, diffuse large B cell lymphoma multiple myeloma multiple myeloma . The study conducted two stages 5-6 patients" " The purpose study learn effects three study medicines (PF-07901801, tafasitamab, lenalidomide) given together treatment diffuse large B-cell lymphoma (DLBCL) that is relapsed" " Duvelisib, oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change patient's T cells make efficient longer duration manufacturing CAR-T cells . This early phase I trial investigates well duvel" " This open-label, single arm, registered study ATG-010 Patients Relapsed/Refractory Diffuse Large B-Cell Lymphoma ." TGR-1202 ibrutinib work treating patients diffuse large B-cell lymphoma returned period improvement respond treatment . TGR-1202 ibrutinib may stop growth cancer cells blocking enzymes needed to grow cells " Glofitamab, Poseltinib, Lenalidomide combination therapy patients relapsed/refractory diffuse large B-cell lymphoma patients . Patients relapsed/refractory diffuse large B-cell lymphoma" " An open-label, prospective Phase III clinical study compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin etoposide (Pola-R-ICE) r" The purpose study assess efficacy safety tafasitamab plus lenalidomide adults diffuse large B-cell lymphoma (DLBCL) relapsed refractory at least 1 3 previous systemic DLBCL treatment regimens Study measure circulating tumor DNA (ctDNA) patients early stage diffuse large B cell lymphoma (DLBCL) Study aims to measure circulating tumor DNA (ctDNA) patients early stage diffuse large B cell lymphoma (DLBCL The purpose study explore effect broken Ganoderma lucidum spore powder improving quality life immune recovery patients chemotherapy . To observe adjuvant treatment broken wall Ganoderma lucidum spore powder patients diffuse large B-cell lymphoma standard The purpose study evaluate whether axicabtagene ciloleucel therapy improves clinical outcome compared standard care second-line therapy patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) This study conducted evaluate complete response rate Ibrutinib + R-CHOP patients . Epstein-Barr virus-positive diffuse large B-cell lymphoma . " Ibrutinib see well works compared placebo given stem cell transplant given stem cell transplant . Patients receive high doses chemotherapy kill cancer cells make room healthy cells . After treatment, stem cells returned patient replace blood-forming cells destroyed chemotherapy ." " Oral sphingosine kinase inhibitor ABC294640 is being tested for patients with diffuse large B-cell lymphoma (DLBCL) and other patients with virus-related (e.g., KSHV- EB" " This single-arm, Phase II study designed enroll treat 64 patients . All patients study receive ofatumumab bendamustine IV infusion 6 cycles (a cycle defined 21 days length) Patients receive IV infusion bendamustine IV" " The study evaluate cohort 120 patients (approximately 95 France, 15 Belgium, 5 Switzerland 5 Portugal). The anticipated study dates (start / end) are: 2010 - 2013 ." " Pilot clinical trial studies tumor-specific markers (clonotype), blood tests, positron emission tomography (PET/computed tomography) predicting treatment response . Different times chemotherapy patients diffuse large B-cell lymphoma come back (" CD19 t-haNK determine maximal tolerated dose designate recommended phase 2 dose designate recommended phase 2 dose subjects diffuse large B-cell lymphoma (DLBCL) CD19 t-haNK determine maximal tolerated dose designate recommended phase 2 " T-cells normal part immune system . To make T-cell medication, T-cells taken blood altered laboratory . They returned body. They returned body. They returned body. The altered T-cells latch specific part cancer cells hopefully kill" Phase II clinical trial observed efficacy safety of zanubrutinib combined standard chemotherapy treatment patients with diffuse large B cell lymphoma CD79A/CD79B genetic abnormality . MRI scan performed one cycle chemotherapy lymphoma accurately predicts outcome treatment . MRI scan performed one cycle chemotherapy lymphoma accurately predicts outcome treatment individual patients . This clinical trial multicentric prospective study assess clinical prognostic value sarcopenia patients older 70 years diffuse large B-cell lymphoma . The primary objective identify new prognostic biomarkers for DLBCL patients terms progression-free survival (PFS) The secondary objectives are to identify new biomarkers associated overall survival (OS) objective response rate (ORR) The study prospective clinical study investigates use new diagnostic methods localize aggressive lymphoma involving central nervous system(CNS) By measuring cell-free tumor DNA metabolomics cerebrospinal fluid blood patients systemic Diffuse Large B-cell L " A study determine safety, tolerability, anti-tumor effectiveness oral investigational drug treatment . The study will determine safety, tolerability, anti-tumor effectiveness oral investigational drug treatment ." This study multicentric randomized trial evaluating efficacy combination R-ACVBP patients 18 65 years low risk localized diffuse large B-cell lymphoma . " Glofitamab is being tested for safety tolerability in a phase Ib/II, parallel arm study . The study is being conducted in a multi-centre, multi-centre, phase Ib/II, parallel arm" This study aims investigate prognostic value 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics diffuse large B-cell lymphoma (DLBCL) additional " R-CHOP plus anti-VEGF drug, bevacizumab, is considered feasible for patients with stage II, III IV diffuse large B cell lymphoma (DLBCL) This study evaluates use of R-" This multi-center study open-label trial enroll single cohort relapsed/refractory diffuse large B cell lymphoma (DLBCL) patients ineligible autologous stem cell transplant (ASCT) patients . Patients receive dual checkpoint Epcoritamab is an investigational drug developed treatment for cancer patients . The purpose study assess safety of patients with relapsed refractory (R/R) diffuse large b-cell lymphoma (DLBCL) R R-ACVBP patients aged 18 59 years high risk diffuse large B-cell lymphoma . High risk diffuse large B-cell lymphoma . R-ACVBP patients aged 18 59 years high risk diffuse large B-cell The purpose study evaluate efficacy safety of R-miniCHOP elderly patients . The purpose study evaluate efficacy safety of R-miniCHOP elderly patients . " This multi-center, open-label, randomized study evaluate participant preference subcutaneous versus intravenous administration MabThera/Rituxan (rituximab) participants CD20+ diffuse large B-cell lymphoma" " The purpose study establish safety rituximab plus cyclophosphamide, doxorubicicin, vincristine, vincristine,prednisone (R-CHOP) HIV-infected" " This randomized, open-label, multicenter, Phase 2 clinical trial designed evaluate efficacy safety . Patients relapsed refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) failure second-line salvage therapy" " The probability achieve CR R-chemotherapy patients failing rituximab containing first line regimen quite low, particular cases non GCB profile . The probability achieve CR R-chemotherapy patients failing rituximab containing" This study multicentric randomized trial evaluating efficacy combination ACVBP+rituximab . ACVBP+rituximab compared combination CHOP+rituximab patients aged 18 59 years diffuse large B-cell lymphoma " The primary objective study was to characterize safety tolerability loncastuximab tesirine combination rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone" " This multicentric single arm phase II trial, investigate efficacy (in terms PFS) combination regimen rituximab-bendamustine association copanlisib patients affected relapsed/refractory DLBCL," " This study evaluate safety, efficacy, pharmacokinetics induction treatment treatment . Participants were relapsed refractory (R/R) follicular lymphoma (FL) follicular lymphoma (FL) rituximab combination pol" chemotherapy alone combined modality therapy treatment treatment treatment treatment localized CD20 (+ diffuse large B-cell lymphoma . chemotherapy alone combined modality therapy treatment treatment treatment treatment treatment treatment treatment treatment localized CD20 (+ diffuse large B-cell The purpose study evaluate complete response (CR) rate . Intensified 1st cycle Rituximab plus 3rd cycles Rituximab plus 3rd cycles R-CHOP DLBCL . PET scan performed two cycles of standard chemotherapy . PET scan performed two cycles of chemotherapy . PET scan performed two cycles of chemotherapy . PET scan performed two cycles of chemotherapy . " Monoclonal antibodies, rituximab, may interfere ability cancer cells grow spread . Lenalidomide may stimulate immune system ." R-CHOP given every 14 days compared R-CHOP given every 21 days . R-CHOP given every 21 days . R-CHOP given every 21 days . R-CHOP given every 14 days . Compared classical Phase Ib trial seeks find best dose possible side effects and/or benefits . Zanubrutinib designed block protein called Bruton Tyrosine Kinase order stop cancer growth . Zanubrutinib designed block protein called SyB L-0501 combination rituximab patients recurrent/relapsed diffuse large B-cell lymphoma patients recurrent/relapsed diffuse large B-cell lymphoma . The purpose study will determine efficacy SyB L- " EZM0414 is first-in-human (FIH) 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), efficacy study oral SET" The purpose study evaluate efficacy loncastuximab tesirine (ADCT-402) combined rituximab compared standard immunochemotherapy . Copanlisib hydrochloride nivolumab may stop growth tumor cells blocking enzymes needed to grow . Copanlisib hydrochloride may stop growth tumor cells blocking enzymes needed cell growth . This trial studies well nanochip technology (immuno-tethered lipoplex nanoparticle [ILN] biochip] biochip) works monitoring treatment response detecting relapse participants diffuse large B-cell lymphoma . Finding To explore clinical features efficacy evaluation large b-cell lymphoma old age. To explore clinical features efficacy evaluation large b-cell lymphoma old age. To explore clinical features efficacy evaluation large b-cell lymphoma old age. To explore " Panobinostat shown effects cancer laboratory studies . Panobinostat shown effects cancer laboratory studies . Panobinostat given participants various types cancers, including DLBCL, previous research studies ." " A multi-center, open-label, phase Ib study evaluate safety efficacy administration tisagenlecleucel combination pembrolizumab patients r/r DLBCL received 2 lines systemic therapy . Patients received 2 lines" " Ibrutinib may stop growth cancer cells blocking enzymes needed to grow . This phase I trial studies side effects best dose ibrutinib given together rituximab, ifosfamide, carboplatin," R-CHOP is a 6 cycle treatment for diffuse large B cell lymphoma (DLBCL) HIV infection . The treatment is administered every 14 days in highly active antiretroviral therapy (HAART) patients . Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% DLBCL overall cure rates ranging 50-60% modern dose-dense immunochemotherapy regimens R-CHOP14 . Study follow-up study update survival time data . Subjects received SyB L-0501 least Phase III Study SyB L-0501 combination rituximab . " A multi-center, open-label, phase Ib study evaluate safety tolerability administration tisagenlecleucel combination ibrutinib patients r/r DLBCL . Patients r/r DLBCL received two" Selumetinib may stop growth tumor cells blocking enzymes needed to grow . Phase II clinical trial studying well selumetinib works treating patients relapsed refractory diffuse large B-cell lymphoma . Researchers want learn combination drugs help . People with B-cell lymphoma central nervous system (CNS) have poor prognosis . " Idelalisib may also active relapsed DLBCL, particularly GCB subtype . Possibly, efficacy may related presence of specific mutations within B-cell receptor pathway ." " This study prospective, cross-sectional survey administered real patients remission DLBCL using 15-minute postal online survey . The project designed describe impact DLBCL remission health utility quality life . Data collection occur 4-month period ." " The purpose study examine efficacy LBH589 treating relapsed refractory DLBCL, added benefit combining rituximab LBH589 setting . Tissue samples accessible lymph nodes collected banked ." This study enrolled patients relapsed refractory diffuse large B cell lymphoma treated polatuzumab vedotin-based chemoimmunotherapies . Patients allowed use chemotherapy regimens Rituximab Bendam " The trial enroll 194 previously untreated DLBCL patients 20 months, objective send local investigator extensive molecular tumor characterization D38 at least 80% enrolled patients ." Clinical trial show incorporating ofatumumab instead rituximab combination etoposide cytarabine (OVA) was successful collecting autologous stem cells . The goal clinical trial show incorporating ofatumumab instead r Rituximab is a form of formulant chemotherapy that is combined with chemotherapy . It is a formulant form of formulant chemotherapy that is combined with a formulant formulant formulant . 36 patients recruited to study . 30 receive AZD2014 alone . 30 receive AZD2014 alone . 30 receive AZD2014 alone . 30 receive AZD2014 plus rituximab . Toripalimab Rituximab treatment relapsed refractory CD20 positive diffuse large B-cell lymphoma . Exploring efficacy safety . " This study done evaluate ME-401 improve treatment patients diffuse large b-celllymphoma (DLBCL) Many patients DLBCL treated standard care (R-CHOP) cured . However, little less half patients cancer come" " Phase I/II trial evaluates safety efficacy combination bendamustine, gemcitabine, nivolumab rituximab patients relapsed refractory diffuse large B-cell lymphoma ." Pegfilgrastim (6mg) administered day 3 cycle R-ACVBP regimen 4 cycles . Patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor age-adjusted international prog The purpose study compare safety efficacy Tafasitamab BEN versus RTX BEN adult patients relapsed refractory DLBCL. The purpose study compare safety efficacy Tafasitamab BEN versus RTX BEN adult patients relapsed " Phase II trial studies well pembrolizumab rituximab obinutuzumab . They bind protein called CD20, found B cells (a type white blood cell) types cancer cells . This may help" The radiation dose treatment volume safely reduced 30 Gy 20 Gy maintaining high rates local control patients negative PET scan following rituximab-containing chemotherapy . " azacytidine combination standard RCHOP therapy patients DLBCL. Patients treated azacytidine escalating doses days 1-5, followed standard dose rituximab plus CHOP chemotherapy day 8, every 21 days ." TAK-659 measured independent radiologic review committee (IRC)-assessed overall response rate (ORR) participants relapsed refractory DLBCL . " The purpose study evaluate response to safety tolerability subjects receiving investigational drugs, RAD001 LBH589 . Subjects Part 1 receive one drug four cycles followed 4 cycles followed 4 cycles second drug unless achieve complete remission . Subjects Part 2 receive drugs" azacitidine followed rituximab-GDP immunochemotherapy patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Patients treated 1 4 lines prior therapies relapsed/refract The purpose study determine efficacy safety ofatumomab combination ICE chemotherapy subjects relapsed/refractory DLBCL following failure combination rituximab anthracycline based chemotherapy . Participants option potentially curative stem cell therapy " Venetoclax is a new targeted anti-cancer drug . It works mimicking particular protein produced tumor interrupting normal processes, ultimately causing tumor cells to die ." " All calculations performed using Statistical Package Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA)" Phase II study evaluate whether reduction radiation dose field size maintain high rate local control minimizing risk acute late toxicity . " This multicenter, open-label, phase 2 study evaluate efficacy, safety, tolerability BGB-3111 (zanubrutinib) Chinese participants relapsed/refractory (R/R) diffuse large B" " Screening (up 28 days) and daily treatment disease progression, disease progression, unacceptable toxicity death, withdrawal consent, lost follow-up, study termination sponsor . Treatment (up 2 years), safety follow-up (30 days) and" " This phase I, open-label, single-arm, multicenter study assess safety efficacy JWCAR029 adult primary refractory DLBCL subjects China ." " The common option radiotherapy patients limited-stage DLBCL involved-field radiotherapy (IFRT) The limited radiotherapy field size changing IFRT reasonable margin gross tumor reported maintain high rates local disease control, minimizing risks radiation-" Involved-field radiotherapy (IFRT) effective chemotherapy common strategy patients stage III-IV DLBCL . The standard treatment approach patients stage III-IV DLBCL combination chemotherapy . C-CAR066 treatment r/r DLBCL received CD19 CAR-T therapy . C-CAR066 treatment r/r DLBCL received CD19 CAR-T therapy . " This trial Multicenter, randomized, double-blind, parallel, controlled, equivalence phase phase phase Ⅲ study ." " This phase I/II trial studies side effects best dose lenalidomide given combination rituximab nivolumab well work . Monoclonal antibodies, rituximab nivolumab," " This phase I/II trial tests safety tafasitamab, retifanlimab, rituximab (TRR) prephase treatment combination . Patients untreated diffuse large B-cell lymphoma ." Participants Achieving Objective Response Rate (Cheson 2007) Lonca-R unfit frail participants previously untreated DLBCL. The main objective trial assess efficacy tolerability . Lonca-R unfit frail participants previously untreated DLBCL. " Yt90 Zevalin combination CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) is effective first line treatment patients bulky stage II stage II stage III IV diffuse" Famedamatinib (200 mg twice day) is used to treat patients worsening unmanageable lymphoma specific type lymphoma specific type lymphoma called Diffuse Large B-Cell Lymphoma . Famedamatinib ( Trial Subjects (patients) receive single infusions pembrolizumab combination CXD101 every 3 weeks every 3 weeks . Two years later disease progression unacceptable toxicity develops . " This study is phase 1, dose finding, open-label study patients relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Patients eligible autologous stem cell transplant . The study also assess safety toxicity" " Primary Objective: Participants achieving Objective Response Rate . Secondary Objective: Progression Free Survival, Overall Survival, Response Duration, Response Response Rate, Response Duration, Response Response Rate, Response Duration, Response Response Rate, Response Response Rate," Aim study proves R-ESHAP regimen followed autologous stem cell transplantation salvage treatment patients refractory relapsed relapsed diffuse large B-cell lymphoma effective . Researchers want see drug called pembrolizumab may treat types lymphoma . " Rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) combination considered new gold standard first-line treatment elderly patients diffuse large B-cell" Bortezomib vorinostat may stop growth cancer cells blocking enzymes needed to grow cancer cells . Bortezomib vorinostat may stop growth cancer cells blocking enzymes needed to grow . " Carfilzomib given together rituximab, ifosfamide, carboplatin, etoposide see well works treating patients stage I-IV diffuse large B-cell lymphoma returned (relapsed)" " The development new diagnostic tools targeted therapy significantly improved management non-Hodgkin's malignant lymphomas thus long-term prognosis . However, study improved patient management, survival measurable indicator preservation quality life essential component ." " This Phase 1/2, multicenter, open-label study evaluate efficacy, safety various combinations selinexor participants RR DLBCL . The study conducted two phases: Phase 1 2.0 Phase 1 2.0 Phase 1" " Multicentric phase II trial evaluate efficacy safety ibrutinib combination rituximab, gemcitabine, oxaliplatin dexamethasone followed Ibrutinib maitenance patients refract" Researchers want to add another drug standard treatment see improve cure rate . Bortezomib may stop growth cancer cells blocking enzymes necessary to grow cancer cell growth . Phase II trial study of bortezomib treating patients with diffuse large B-cell lymphoma refractory previous chemotherapy . Approximately 500 subjects enrolled study . Subjects meet inclusion criteria randomized (1:1) Two groups receive JHL1101 combination CHOP regimen . Control group receive rituximab (MabThera) combination CHOP . " Elderly defined either age of 80 years age, or age 75 years frail . Elderly defined as either elderly patients untreated diffuse large B-cell lymphoma . Patients randomized 1:1 either standard treatment population, R-miniCHOP" " PET is powerful imaging modality diagnosis, staging, therapy monitoring variety cancers . Early identification refractory lymphoma patients provides basis stratification ." Glofitamab combination gemcitabine plus oxaliplatin (Glofit-GemOx) compared rituximabine plus oxaliplatin (R-GemOx) patients R/R The purpose study evaluate efficacy Thalidomide combined R-CHOP(RT-CHOP) combined R-CHOP(RT-CHOP) combined R-CHOP(RT-CHOP) combined R-CHOP The purpose study clarify impact impact rituximab clinical outcomes patients primary breast diffuse large B-cell lymphoma . Also investigate role prophylactic intrathecal chemotherapy using methotrexate reducing central nervous system (CNS This phase II study aimed clinical efficacy toxicity toxicity . 6th R-CHOP chemotherapy followed ibritumomab tiuxetan (Zevalin) followed ibritumomab tiuxetan (Zevalin) Pidilizumab is a drug that targets immune system . It change immune system finds cancer cells . The drug may kill remaining cancer cells . The goal clinical trial evaluate therapeutic efficacy Chidamide combined R-GDP . R-GDP is a clinical trial evaluating therapeutic efficacy Chidamide combined R-GDP . " This multicenter, double-blind, randomized study comparing efficacy, pharmacokinetics (PK) vs reference rituximab (MabThera) vs reference rituximab (MabThera) Compared efficacy" " This phase I trial studies side effects best dose avelumab, utomilumab, rituximab, ibrutinib, combination chemotherapy . Patients with diffuse large B-cell lymphoma mantle cell lymph" R-CHOP Plus Plus Courses R-CHOP Plus Courses Rituximab Versus Six Courses R-CHOP Plus Courses R-CHOP Plus Two Courses Rituximab Treatment Naive " A phase 2, multicenter, open-label, single arm clinical trial adults newly diagnosed aggressive high-risk DLBCL . Adults newly diagnosed aggressive high-risk DLBCL." Korean patients diffuse large B-cell lymphoma (DLBCL) treated R-CHOP . This study investigate impact comprehensive geriatric assessments using activity daily living (ADL) and Charlson's comorbidity index (CC This phase Ⅱ study erythropoietin management anemia caused chemotherapy patients Diffuse Large B-cell Lymphoma . The investigators want investigate hematopoietic response darbepoietin alfa " DPX-Survivac pembrolizumab is being tested for relapsed refractory DLBCL . The drug is being tested for safety efficacy in a Phase 2b, open label study ." " Phase I/II, open-label, multicenter, prospective study. Phase I/II, open-label, multicenter, prospective study. Phase I/II, open-label, multicenter, prospective study. Phase I" The clinical hypothesis MRD-negative response rate greater 10% would be scientific clinical interest . Achieving MRD-negative response rate 30% would be scientific clinical interest . " Immunotherapy monoclonal antibodies, rituximab, venetoclax, bortezomib work treating patients diffuse large B-cell lymphoma come back (relapsed) respond treatment (refractory)" " Half participants receive R±CEOP regimen containing 90mg/m2 epirubicin, half participants receive R±CEOP regimen containing 75mg/m2 epirubicin . Half participants receive R±CEOP" Copanlisib given together combination chemotherapy (R-GCD) given together combination chemotherapy (R-GCD) treating patients with diffuse large B-cell lymphoma come back (relapsed) Copanlisib may stop growth " Monoclonal antibodies, rituximab, block cancer cell growth different ways . Se-methyl-seleno-seleno-l-cysteine may help reduce side effects chemotherapy ." Korean patients diffuse large B-cell lymphoma (DLBCL) treated R-CHOP . This study validate impact comprehensive geriatric assessments using activity daily living (ADL) and instrumental activity daily living (IADL) survival " The purpose study evaluate zilovertamab vedotin respect objective response rate duration response . Safety tolerability also evaluated Phase 2, single arm, interventional study ." Carfilzomib given together rituximab combination chemotherapy see well work treating patients with diffuse large B-cell lymphoma . Carfilzomib may stop growth cancer cells blocking enzymes needed to stop cell growth . " CUDC-907 subjects 18 years older are 18 years older . CUDC-907 subjects 18 years older are subject to a Phase 2, open-label, multicenter trial . CUDC-907 subjects" The purpose of the study is to evaluate efficacy safety combination selinexor R-GDP (SR-GDP) patients RR DLBCL intended receive hematopoetic stem cell transplantation (HSCT) chimeric The purpose study measure rate complete response (CR UCR) end course immuno-chemotherapy . Overall survival survival Survival without relapse without relapse . Long-term incidence neurocognitive toxicity is neurocognitive toxicity . The primary objective study was to determine maximum tolerated doses (MTD) recommended Phase 2 dose (RP2D) The primary objective study was to determine maximum tolerated doses (MTD) recommended Phase 2 dose (RP2D) The The trial conducted according opti was conducted according opti . The trial was conducted according opti . " PD-1 blockade, using anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) and autologous stem cell transplant (ASCT) Patients relapsed refractory (R" " This Phase Ib/II, open-label, multicenter, non-randomized study evaluate safety, efficacy, pharmacokinetics . Participants FL achieve complete response (CR) partial response (PR) partial response (PR) end in" This study aims to assess efficacy shortened systemic chemotherapy patients completely excised CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) Ann Arbor Stage I II . " Bendamustine hydrochloride, obinutuzumab, dexamethasone work treating older patients with diffuse large B-cell lymphoma . Drugs used chemotherapy, bendamustine hydrochloride dexameth" " Diffuse large B-cell lymphoma commonest type aggressive non-Hodgkin's lymphoma . 20-30% patients still experience relapse . Curing relapsed disease much less successful, even use high doses chemotherapy stem cell" The primary objective study was to determine maximum tolerated dose (MTD) of blinatumomab combination pembrolizumab adults relapsed refractory (r/r) DLBCL . The purpose study test safety abexinostat different doses find work ibrutinib stop cancer growing . The purpose study test safety abexinostat different doses find work ibrutinib stop cancer growing . This randomized phase II trial studying two different combination chemotherapy regimens . Two different combination chemotherapy regimens . compare well work treating patients with diffuse large B-cell lymphoma . Phase 1/2 study evaluate safety efficacy . Loncastuximab Tesirine (ADCT-402) combination Ibrutinib participants Advanced Diffuse Large B-Cell Lymphoma Mantle Cell Lymphoma . " This research study evaluating combination two drugs, copanlisib venetoclax, possible treatment trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the drugs involved study are:" 60% patients diffuse large B cell lymphoma healed first-line treatment whatever age . For remaining 40% patients (relapses primary refractories): .38% patients cured 2nd line including autologous haematopo " The goal clinical research study find highest tolerable dose belinostat combined standard chemotherapy drugs (rituximab, cisplatin, cytarabine, cytarabine, dexamethasone) patients relapsed" Pilot phase I trial studies side effects pembrolizumab combination chemotherapy treating patients previously untreated . " First study, multiple clinical centers, exploring effects different combinations compounds (CC-122, CC-223 , CC-292 rituximab) treat Diffuse Large B Cell Lymphoma (DLBCL) Follicular" " Drugs used chemotherapy, cyclophosphamide, doxorubicin, vincristine, prednisone, prednisone, work different ways stop growth cancer cells . Monoclonal antibodies, rituxim" " Burkitt lymphoma/leukemia (BL) highly treatable, standard therapies require multiple doses intensive chemotherapy may require long hospital stays frequently severe side effects . New approaches needed expand ways to treat BL efficiency reduced side effects ." " Phase II, multi-centric, open-label, study. Phase II, multi-centric, open-label, study." " Pilot phase I trial studies side effects atezolizumab, gemcitabine, oxaliplatin, rituximab ." Research trial studies genes samples patients limited advanced diffuse large B-cell lymphoma . Studying samples tumor tissue patients cancer laboratory may help doctors identify learn biomarkers related cancer . The purpose study evaluate safety/tolerability efficacy itacitinib combination ibrutinib subjects relapsed refractory diffuse large B-cell lymphoma (DLBCL) subjects relapsed refractory diffuse large R-ICE trial studies side effects of best dose lenalidomide given together . R-ICE sees well work treating patients with diffuse large B-cell lymphoma . The purpose study assess safety efficacy parsaclisib subjects relapsed refractory diffuse large B-cell lymphoma . The purpose study assess safety efficacy parsaclisib subjects relapsed refractory diffuse large B-cell lymphoma This phase I trial studies side effects of vorinostat given together pembrolizumab . Parsaclisib may stop growth cancer cells blocking enzymes needed to grow . Rituximab monoclonal antibody may interfere ability cancer cells grow spread . The purpose study evaluate efficacy ibrutinib (PCI-32765) ibrutinib (PCI-32765) ibrutinib (PCI-32765) relapsed/refractory " This research done yet known dose romidepsin combination gemcitabine, dexamethasone, cisplatin (GDP) given safely patients peripheral T-cell lymphoma . This research also done clear addition new drug" " Monoclonal antibodies, rituximab, rituximab, block cancer cells different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cancer-killing substances ." This phase I/II trial studies best dose side effects mogamulizumab combination pembrolizumab . " Polatuzumab vedotin monoclonal antibody, polatuzumab, rituximab, ifosfamide, carboplatin, etoposide initial salvage therapy treating patients with diffuse large" CAR T cell treatment was followed by limited duration anti-PD1 antibody patients DLBCL . CAR T cell treatment was given to CAR T cell treatment targeting CD19 CD22 . " Phase II trial tests safety, side effects, best dose TTI-621 TTI-622 combination pembrolizumab . TTI-621 TTI-622 called fusion proteins . A fusion protein includes" Mosunetuzumab and/or polatuzumab vedotin are being tested in a phase II trial . The trial is testing whether mosunetuzumab and/or polatuzumab ved " This retrospective study aimed investigate combined prognostic values intratumoral metabolic heterogeneity (MH), disseminate feature (Dmax) total metabolic tumor volume (TMTV) 2-deoxy-2-2-[18F]fluoro-" " Monoclonal antibodies, epratuzumab rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cancer-killing substances them ." " Bortezomib may stop growth cancer cells blocking enzymes needed cell growth blocking blood flow cancer . Drugs used chemotherapy, doxorubicin hydrochloride liposome, work different ways stop growth cancer cells ." Study evaluated incidence of hepatitis B virus reactivation within first 6 months treatment rituximab . " The purpose research study evaluate new investigational drug, TAK-659, given combination standard chemotherapy, treatment Diffuse Large B-cell Lymphoma (DLBCL) The primary purpose study find appropriate safe dose study drug used combination" Patients Diffuse Large B-cell Lymphoma indication palliative radiotherapy treated low-dose radiation (2 x 2 Gy) Only symptomatic sites only . Primary endpoint study response rate Quality Life patients (QoL) The purpose trial compare efficacy safety inotuzumab Ozogamicin combination R-CVP R-G-CVP treatment . The purpose trial compare efficacy safety in . Diffuse Large B Cell Lymphoma (DLBC Patients randomized four different arms: R-MegaCHOP14x4 + R-MegaCHOP14x4 + R-MegaCHOP14x4 + R-MegaCHOP14x2; Arm 2BIS: This phase II multi-institutional trial explore safety efficacy of lenalidomide monotherapy given maintenance therapy following salvage chemo-immunotherapy patients relapsed refractory chemosensitive diffuse large B-cell lymphoma patients . " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer grow spread . Others block ability cancer grow spread ." " More half patients cured RCHOP-type immunochemotherapy protocol (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) Monitoring adverse effects, risk relapse" The purpose study evaluate whether 18F-FDG PET/CT-based prognostic model diffuse large B-cell lymphoma predict disease progression . The purpose study evaluate whether 18F-FDG PET/CT-based prognostic model TIM-3 Gal-9 tumor microenvironment . Previous transcriptomic study showed overexpression TIM-3 Gal-9 tumor microenvironment . This Phase I clinical trial studies side effects maximum tolerated dose (MTD) combination brentuximab vedotin (BV) lenalidomide (BV) lenalidomide (BV) lenalidom Oblimersen sodium may help chemotherapy work better making cancer cells sensitive drugs . Giving oblimersen sodium together combination chemotherapy may kill cancer cells . " Patients 70 years age previously untreated untreated diffuse large B-celllymphoma (DLBCL), intermediate (Burkitt-like) lymphoma, whose tumor cells show MYC rearrangement, whose tumor cells show MYC" SyB L-0501 combination rituximab patients relapsed/refractory diffuse large B-cell lymphoma patients relapsed/refractory diffuse large B-cell lymphoma . The purpose study will determine efficacy Zevalin compared observation alone participants PET-negative complete remission first-line R-CHOP R-CHOP therapy . " R-CHOP, given every two weeks, associated improvements response rate, progression-free survival, compared R-CHOP given every three weeks . The addition sargramostim allow safer adminIstration dose-intensified" " Phase 2/3, randomized, multisite, open-label, dose confirmation, expansion study evaluate safety, efficacy . Zilovertamab vedotin (ZV) combination standard care options treatment rrDLBCL." " The primary objective study evaluate efficacy doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (ACVBP) plus rituximab . Patients aged 60 65 years non" This study evaluate efficacy safety Bortezomib plus GDP treatment non-GCB DLBCL patients . This study evaluate efficacy safety Bortezomib plus GDP treatment non-GCB DLBCL patients . Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy . Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chem " Phase 2, two-arm, open-label study designed evaluate safety, clinical activity, predictive biomarkers durvalumab combination R-CHOP R2-CHOP ." " Study CX-659-401 multicenter, open-label, phase 2 study mivavotinib evaluated single-agent activity mivavotinib . DLBCL patients harboring MyD88 and/or CD79" " Part 1 clinical research study find highest tolerable dose lenalidomide combination obinutuzumab CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) given patients" " This open-label, multicenter, 2-part study determine recommended Phase 2 dose (RP2D) GSK2816126 . Part 1 conducted adult subjects relapsed/refractory diffuse large B cell lymphoma (DL" Venetoclax Plus Ibrutinib Rituximab patients Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Relapsed/Refractory Diffuse Large B Copanlisib patients relapsed refractory Diffuse large B-cell lymphoma (DLBCL) assess relationship efficacy (in terms objective response) Copanlisib patients relapsed refractory Diffuse large B- " This study is a single arm, single arm, open label clinical trial enroll patients untreated diffuse large B-cell lymphoma (DLCBL) Moderate high risk high risk poor outcome ." " The Catholic University Lymphoma Group (CULG) Protocol is based on The Catholic University Lymphoma Group (CULG) Protocol . After 1 cycle rituximab plus cyclophosphamide, doxor" Non-interventional multi-center study evaluate quality life (QOL) patient reported outcomes (PROs) among adults diffuse large b-cell lymphoma (DLBCL) following Chimeric Antigen Receptor (CAR) " This phase I trial studies side effects best dose loncastuximab tesirine combination carmustine, etoposide, cytarabine, melphalan (BEAM) chemotherapy regimen . Loncastux" R-CDOP regimen combined intrathecal methotrexate chemo-naive diffuse large B-cell lymphoma patients high-risk CNS relapse . Mantle cell lymphoma (MCL) diffuse large B-cell lymphoma (DLBCL) aggressive subtypes non-Hodgkin lymphoma . Flavopiridol investigational drug works differently standard chemotherapy may target " The purpose study evaluate ibrutinib administered combination rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) improves clinical outcome ." " The aims study are to evaluate benefits of addition bortezomib standard rituximab cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP)" LY317615 participants diffuse large B-cell lymphoma (DLBCL: sub-type Non-Hodgkins Lymphoma) LY317615 participants diffuse large B-cell lymphoma (DLBC The purpose study study study impact stem cell dose outcome autologous transplant . The purpose study study impact stem cell dose outcome autologous transplant . The primary objective study evaluate efficacy ASCT consolidation case bcl-2 overexpression case bcl-2 overexpression . Patients aged 60 years less low-intermediate risk diffuse large B-cell lymphoma responded ACVBP " STORM trial consists two parts . The STORM-trial consists of Temsirolimus combination Rituximab DHAP . The secondary objective evaluate progression free survival (PFS), overall survival (OS) Toxicity ." " PET scans given patients cancer undergoing treatment may help doctors predict patients respond treatment . Study will study patients with diffuse large B-cell lymphoma receiving rituximab together cyclophosphamide, doxorubicin, v" " Drugs used chemotherapy, gemcitabine hydrochloride, cyclophosphamide, vincristine sulfate, prednisolone, work different ways stop growth cancer cells . Monoclonal antibodies, rituxim" The primary objective study evaluate efficacy safety induction therapy R-ICE comparison R-DHAP 3 cycles adjusted successful mobilization stem cells patients previously treated diffuse large B-cell lymphoma CD20 . The primary objective study evaluate efficacy safety induction therapy R Study studying biomarkers of diffuse large B-cell lymphoma treated combination chemotherapy without rituximab . Studying samples tissue patients cancer laboratory may help doctors identify learn biomarkers related cancer . The purpose study comparing Efficacy Safety I-CHOP R-CHOP Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients . Patients. Patients. Patients. " Diffuse large B cell lymphoma (DLBCL) common non-Hodgkin's lymphoma, accounting 30% 50% patients . Although considered curable disease, still least 40 % patients fail first line chemotherapy ." " MEDI-551, used combination salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) Dexamethasone-cytarabine (DHAP) patients relapsed refractory DL" " Phase II trial studies effect rituximab, lenalidomide, acalabrutinib, tafasitamab alone combination chemotherapy . Patients newly diagnosed non-germinal center diffuse large B-" Metformin is used to treat DLBCL and add induction therapy to the treatment of DLBCL . " R-miniCHOP includes monoclonal antibody (a type protein) called rituximab, attaches lymphoma cells may help immune system kill cells . R-miniCHOP also includes prednisone anti-inflammatory" Investigators aiming explore lenalidomide combined R-CHOP combined R-CHOP (R2-CHOP) combined R-CHOP (R2-CHOP) in newly diagnosed patients . This observational study evaluate safety efficacy MabThera/Rituxan (rituximab) plus chemotherapy first-line treatment patients . Patients were patients with diffuse large B-cell lymphoma (DLBCL) follicular Positron emission tomography computed tomography may help detecting differences Hodgkin lymphoma diffuse large B-cell lymphoma cancer cells . " The purpose study assess overall response rate [ORR, including complete response (CR) partial response (PR)], daratumumab participants non-Hodgkin's lymphoma [a cancer lymph nodes (or tissues)-" This study treats patients with diffuse large B-cell lymphoma whose disease complete remission due previous treatment . Half patients received Zevalin half receive anti-cancer treatment . Half patients received Zevalin half receive anti-cancer treatment . MDV9300 patients relapsed refractory diffuse large B-cell lymphoma (DLBCL) achieved either stable disease partial remission following definitive salvage therapy . Patients treated salvage chemotherapy considered ineligible autologous stem cell transplant (AS Apatinib patients Relapsed Refractory Diffuse Large B Cell Lymphoma. Relapsed Refractory Diffuse Large B Cell Lymphoma. The purpose study evaluate efficacy safety Apatinib patients Relapsed Refractory Laboratory study looking biomarkers using tissue samples . Older patients diffuse large B-cell lymphoma treated combination chemotherapy without rituximab clinical trial ECOG-E4494 . " The aim protocol compare outcome patients DLBCL stage II bulky, III IV 1 3 adverse prognostic factors according International prognostic index . Patients eligibility criteria gave informed consent randomised CHOP-14- Rituximab x 8" " Monoclonal antibodies, rituximab, lenalidomide, ibrutinib chemotherapy works treating patients high-risk diffuse large B-cell lymphoma . High-risk large B-cell lymphoma type" The aim study evaluate efficacy toxicity dose-adjusted EPOCH-R patients MYC positive diffuse large B-cell lymphoma . The aim study evaluate efficacy toxicity dose-adjusted EPOCH-R patients MYC positive diffuse large B " Single-arm, multicenter Phase 2 study treat patients Recurrent refractory diffuse large B cell lymphoma infusion patient's T cells genetically modified express chimeric antigen receptor (CAR) bind tumour cells ." Aim study demonstrate high level biosimilarity MabionCD20 (MABION SA) reference product: MabThera (rituximab Hoffman-La Roche) patients CD20-positive diffuse large B-cell lymph This Phase 2 study evaluate combination denintuzumab mafodotin combination RCHOP RCHP . RCHOP RCHP compared front-line therapy patients with front-line therapy patients with diffuse large B-cell The objective show CPOP-R inferior CHOP-R . The objective show CPOP-R inferior CHOP-R . " Diffusion large B-cell lymphoma (DLBCL) aggressive potentially curable malignancy . The investigators plan use ZR2 regimen(rituximab, lenalidomide zanubrutinib)" " This multicenter, observational study evaluate correlation clinical biological factors . Patients receiving treatment according standard care local guidelines followed duration treatment (approximately 8 months) 1 year follow-up ." " IMO-8400 oligonucleotide specifically designed inhibit ligand activation TLRs 7,8, 9 . IMO-8400 oligonucleotide specifically designed inhibit ligand activation TLRs 7,8, 9 ." " The treatment-related toxicities, especially severe cardiac toxicities induced anthracycline drugs (doxorubicin) become major concern among elderly patients . The treatment-related toxicities, especially severe cardiac toxicities induced" " Gemcitabine, nucleoside analog used several malignancies, shown promising activity patients refractory Hodgkin's disease low-grade NHL . Rituximab demonstrated sensitize drug-resistant NHL cells ." Diffuse large B cell lymphoma (DLBCL) is common subtype non-Hodgkin lymphoma (NHL) Common subtype non-Hodgkin lymphoma (DLBCL) is common sub " Subjects asked complete Geriatric Assessment (GA) GAs designed gather information memory, nutritional status, mental health, level social support . GAs designed gather information memory, nutritional status, mental health, level social support ." " ABBV-319 adult participants relapsed refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), R/R follicular lymphoma (" " 18F-FLT PET/CT uses new tracer, fluorothymidine, taken cells actively proliferating dividing cancer cells ." The aim study optimize number cycles R-CHOP patients diffuse large B-cell lymphoma based interim results PET/CT . The purpose study compare standard dose radiation 45 Gray(Gy) 25 fractions to 36 Gray(Gy) 25 fractions . NHL-DLBCL addressed large cooperative trials showing improvement overall survival progression free survival combined modality treatment . Glofitamab and GemOx combination gemcitabine oxaliplatin (Glofit-GemOx Mosun-GemOx Mosun-GemOx) participants relapsed refractory (R/ This study evaluate efficacy Tafasitamab Lenalinomide associated Rituximab elderly patients frontline Diffuse Large B-Cell Lymphoma . It assessed Overall Response Rate (ORR) 3 cycles treatment according Lug " Zanubrutinib combination R-CHOP is being tested in a phase 2, single center clinical trial . The trial is being conducted in response to a newly diagnosed diffuse large B-cell lymphoma specific gene abnormality ." Chidamide single-agent treatment patients relapse refractory Diffuse Large B-Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Study Chidamide single-agent treatment patients relapse refract " The prospective, single-arm, multi-center, phase Ib/II clinical trial evaluate safety, tolerability, efficacy selinexor combination R-CHOP . The trial is followed by selinexor maintenance untreated EBV" " This single-arm, open-label phase 2 study iR2 treatment iR2 treatment for elderly patients untreated diffuse large B-cell lymphoma . The study is a single-arm, open-label phase 2 study iR" Lenalidomide plus R-CHOP21 (LR-CHOP21) is a prospective multicenter phase II pilot trial . Elderly patients untreated Diffuse Large B Cell Lymphoma (DLBCL) are treated with " Chidamide combination R-CHOP treatment de novo, elderly, high-risk diffuse large B cell lymphoma patients . The study is prospective, single-arm, open-label phase II study ." " A multicenter, prospective, randomized, open-label, controlled trial evaluate efficacy safety genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine," " R-CHOP- 14, R-CHOP- 14, R-CHOP-21 & consolidation PET-oriented radiotherapy (RT) radiotherapy (RT) diffuse large B cell lymphoma (DLBCL) patients" " This multicenter, randomized, open label parallel-group study evaluate efficacy safety subcutaneous versus intravenous MabThera/Rituxan (rituximab) combination CHOP chemotherapy patients . Patients randomized receive either M" " R-CHOP plus copanlisib is a prospective, multicenter, non-randomized, open-label, phase II study . R-CHOP patients diffuse large B-cell lymphoma (DLBCL) are" " The purpose study evaluate safety, tolerability, efficacy of MEDI4736 (durvalumab) alone combination . The purpose study evaluate safety, tolerability, efficacy of MEDI4736 (durvalumab)" " Chinese patients relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL) failed two lines systemic therapy . This study evaluate pharmacokinetics, safety, tolerability, efficacy glofitam" " Rituximab treatment de novo, low-risk, low-risk, non-bulky diffuse large B-cell lymphoma . This clinical trial compare efficacy safety four cycles R-CHOP followed four cycles R-" " This open-label, multicenter study evaluate efficacy safety of obinutuzumab [RO5072759 (GA101) combination CHOP (Cyclophosphamide, Doxorubicin, Vincrist" 2-arm study designed compare efficacy safety bevacizumab (Avastin) combination rituximab (MabThera) combination rituximab (MabThera) CHOP (cycl " The multicentre, open-label, phase II study ibrutinib 560 mg combination R-ICE treatment transplant-eligible relapsed/refractory diffuse large B-cell lymphoma ." " Monoclonal antibodies, ofatumumab, block cancer growth different ways . Bortezomib may stop growth cancer cells blocking enzymes needed cell growth ." " This clinical trial investigator-initiated multicenter, open-ended multicenter, open-ended clinical study order explore efficacy safety . The study will explore efficacy safety rituximab plus zanubrutinib len" " This study is an Open-labeled, multicenter Phase II study . Patients high risk diffuse large B cell lymphoma (DLBCL) were treated with Bortezomib maintenance therapy . Primary objective 3 years relapse free survival" " This open-label, randomized, multicentre study evaluate safety preliminary efficacy human anti-CD19 antibody Tafasitamab ." " This open-label, multicentre study characterize safety efficacy human anti CD19 antibody MOR00208 combination Lenalidomide combination Lenalidomide adult subjects relapsed/refractory Diffuse Large B-cell Lymphoma" This study plans recruit total 10-16 adult patients CD19 positive recurrent refractory DLBCL single autologous car-t cell therapy . There three dose groups study . The first dose group one patient. If dose limiting toxicity " This open-label, multicentre study Evaluate Safety Pharmacokinetics . Modified Tafasitamab IV Dosing Regimen Combined Lenalidomide (LEN) Patients Relapsed Refractory Diffuse Large B" " Glofitamab combination Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) is first line treatment for high-risk diffuse" " The purpose randomized, open-label study evaluate safety efficacy denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, etoposide) compared RICE alone" The purpose study compare efficacy R2-miniCHOP (Sub-cutaneous Rituximab-miniCHOP + lenalidomide) R-miniCHOP (Sub-cutaneous Rituximab- " Phase II trial evaluates whether loncastuximab tesirine rituximab followed dose-adjusted dose-adjusted doxorubicin, etoposide, vincristine, cyclophosph" " This randomized, placebo-controlled phase 3 study planned enroll approximately 235 treatment-naïve subjects high-risk Diffuse Large B-Cell Lymphoma (DLBCL) Subjects randomized 1:1 R-CHOP plus enzast" " This study multicenter, open-label study was a multicenter, open-label study . Participants relapsed refractory follicular lymphoma (FL) diffuse large B-cell lymphoma (DLBCL) The anticipated time" Study evaluate IgNGS different time points to different time points . It evaluated the correlation between IgNGS and conventional techniques . " Patients suffering diffuse large B-cell lymphoma (DLBCL) relapse within 12 months chemotherapy usually undergo salvage therapies, followed autologous transplant low success rate . These treatments relapse significant toxicities may tolerated well patients ." " This open-label, multicenter, global study designed assess safety, tolerability, preliminary efficacy, pharmacokinetics . The anticipated duration study approximately 4.5 years ." DPX-Survivac plus low dose cyclophosphamide 24 subjects recurrent diffuse large B-cell lymphoma (DLBCL) eligible transplant . DPX-Survivac plus low dose cyclophosphamide 24 subjects recurrent " ADC Therapeutics evaluate patients approval program . EAP patients relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) cannot treated currently available drugs, cell therapy, clinical trials ." " Ibritumomab tiuxetan (""Zevalin"") composed murine IgG1 monoclonal antibody (ibritumomab) covalently bound chelating agent tiuxetan . Study phase" " Forty percent patients diffuse large B cell lymphoma (DLBCL) primary refractory relapsed disease (R/R) For fit patients, standard treatment second line therapy high dose therapy autologous stem cell transplantation (AS" " The purpose study investigate impact rituximab primary breast DLBCL using matched pair analysis . Patients were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine," " Vorinostat given together rituximab combination chemotherapy see well works treating patients newly diagnosed stage II, stage III, stage IV diffuse large B-cell lymphoma ." " Immunotherapy became recent years major innovation care cancer patients, unprecedented improvement complete response survival, particularly hematological cancers . Since 2018, patients relapsed refractory lymphoma benefit immunotherapy based CAR-T cells (Chimeric Ant" The purpose study determine safety tolerability adding oral azacitidine chemotherapy combination R-ICE . This study also look whether disease outcomes improve combination . Participants study diffuse large B-cell lymphoma (DLBCL) come back gotten better treatment . Participants randomly assigned get either brentuximab vedotin placebo or brentuximab vedotin . " A non randomized, unblinded, open label phase 2 study is underway in patients relapsed/refractory diffuse large B cell lymphoma (DLBCL) PD-L1 genetic alterations . The study is being conducted in" " This study multi-center, open-label, single-arm, non-randomized phase II clinical study order evaluate safety efficacy . Patients are high-risk diffuse large B-cell lymphoma patients ." " AMG 562 adult subjects DLBCL, MCL, FL, FL. Evaluate safety tolerability of AMG 562 adult subjects . Estimate maximum tolerated dose (MTD) and/or biologically active dose (e" The purpose study learn study drug mocetinostat slow progression cancer people mutation CREBBP EP300 genetic makeup cancer . The potential side effects mocetinostat also studied . " The trial single arm, single arm, single-center, non-randomized phase I clinical trial designed evaluate safety efficacy C-CAR011 treatment refractory DLBCL ." " Phase II trial studies well giving rituximab,chidamide, zanubrutinib . Sequential chemotherapy works treating patients double express diffuse large B-cell lymphoma ." " Pola combination Bendamustine, Rituximab (BR) and Rituximab (BR) are used to assess clinical outcomes following treatment . Pola combination Bendamustine, Rituximab" " To determine safety efficacy (overall response rate) pembrolizumab patients relapsed refractory patients relapsed refractory ENKTL, EBV-DLBCL ." " The purpose study evaluate safety, tolerability clinical activity RO6870810 combination venetoclax co-administered rituximab participants relapse/refractory (R/R) diffuse large B-cell lymphoma (" " ImbruVeRCHOP-Trials Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial evaluate efficacy feasibility . The ImbruVeRCHOP-Trials" The aim study evaluate event free survival three years patients diffuse large B-cell lymphoma poor prognostic factors receiving R-MegaCHOP induction therapy . Patients positive PET three cycles R-MegaCHOP receive early salvage treatment R-IFE " Monoclonal antibodies, rituximab, locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Oblimersen may increase effectiveness chemotherapy drug making cancer cells sensitive drug ." The purpose study determine whether application low dose total body irradiation following chemo-immuntherapy following chemo-immuntherapy elderly patients aggressive non-Hodgkin's lymphoma would safe potentially benecicial adj " The primary objectives study evaluate safety, tolerability, pharmacokinetics (PK) preliminary efficacy idelalisib . The primary objectives study evaluate safety, tolerability, pharmacokinetics (PK) preliminary efficacy idelalisib ." Loncastuximab Tesirine (ADCT-402) is being tested for safety anti-tumor activity . The purpose of the study is to evaluate safety anti-tumor activity . 131-I apamistamab 75 mCi prior CAR T-cell infusion order determine maximum tolerated dose . Patients receive 131-I apamistamab 75 mCi prior CAR T-cell infusion order determine maximum Patients given conditioning chemotherapy regimen fludarabine cyclophosphamide followed single infusion CD19 CAR+ T cells . Patients given conditioning chemotherapy regimen fludarabine cyclophosphamide followed single infusion CD19 CAR+ T cells " About 40% Diffuse large B cell lymphoma relapse refractory, age prognostic factor DLBCL, age prognostic factor DLBCL, elderly patients capable received standard treatment, prognosis elderly patients poor especially aged 80 years" French Study Group Cutaneous Lymphomas Bordeaux managed Prof. Beatrice Vergier . The study performed single-center retrospective cohort 32 patients LBC-TJ treated . The study purpose compare R-CHOP versus R-mini-CEOP elderly patients with Diffuse Large B Cell Lymphoma (DLBCL) Diffuse Large B Cell Lymphoma (DLBCL) Diffuse Large " This study evaluates addition Atezolizumab to current therapy Rituximab, Gemcitabine Oxaliplatin (R-GemOx) Patients relapsed refractory Diffuse Large B-Cell" Patients previously untreated ABC type DLBCL were previously untreated . Patients were previously untreated ABC type DLBCL . " The aim project is to clarify whether DLBCL exhibits mutational diversity among different lymph node tumors one patient . It desired find whether possible difference lymph node tumors / tumors explain patients initially (at diagnosis) prognosis, sometimes completely different course" GemOx(Gemcitabineine Oxaliplatin) combination rituximab(R) combination rituximab(R) first-line treatment elderly patients DLBCL . GemOx(Gem " Central nervous system (CNS) relapse devastating event diffuse large B cell lymphoma (DLBCL) occurs 4%-7% DLBCL general rate considerably higher high-risk patients, resulting poor outcome .Effective methods CNS proph" The purpose study determine whether 30Gy Involved-field Radiotherapy (IFRT) is effective 40Gy treatment . The purpose study was to determine whether 30Gy Involved-field Radiotherapy (IFRT) was effective 40 " YM155 is a clinical study of type B cell lymphoma (DLBCL) to evaluate response rate, efficacy, safety tolerability ." " Sintilimab is a current 2nd line salvage therapy Rituximab, Gemcitabine Oxaliplatin (R-GemOx) Patients relapsed refractory Diffuse Large B-Cell L" " RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is given every 3 weeks, 18 weeks . It given every 3 weeks" Patients relapsed refractory large B-cell lymphoma asked take part study . Patients relapsed refractory large B-cell lymphoma asked take part study . " EBV-related GZL DLBCL: belong entity two different subtypes EBV-related lymphoma ? The aim study characterize compare clinical, pathological (histology, immunophenotype) molecular features ." " SGN-40 is an open-label, multidose trial SGN-40 designed to assess objective response rate assess toxicity patients relapsed DLBCL ." " Ibrutinib may stop growth cancer cells blocking enzymes needed cell growth . Monoclonal antibodies, rituximab, may interfere ability cancer cells grow spread ." " Patients receive either rituximab (standard treatment), or GA101 (study treatment) Patients receive either rituximab (standard treatment), or GA101 (study treatment) Patients receive either GA101 (study treatment)," " This study conducted compare efficacy safety ofatumumab addition salvage chemotherapy versus rituximab addition salvage chemotherapy . CD20 positive DLBCL subjects relapsing, persistent disease, first-line treatment rituximab combined" " Participants receive MabThera combination Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) CHOP-like chemotherapy according registered indication . Patients followed safety efficacy evaluation" Relapsed refractory primary DLBCL CNS is a primary primary primary . " This open label, multicenter, adaptive Phase 2 clinical study is an open label, multicenter, adaptive Phase 2 clinical study . The study consist of screening period, treatment period, end treatment visit, follow-up period ." " The purpose study determine recommended dose CMC544 administered combination rituximab (R-CMC544), alternance rituximab, gemcitabine oxaliplatin (R-GEMOX) First" PET 68Ga-citrate patients DLBCL BCLU. DLBCL BCLU. PET 68Ga-citrate patients DLBCL BCLU. PET 68Ga-citrate patients DLBCL BCL " NM-IL-12 evaluated immunotherapeutic concomitant hematopoietic regenerating properties treatment relapsed/refractory DLBCL, aggressive type B-cell non-Hodgkin's lymphoma" " Rituximab binds molecule called CD20, found B cells (a type white blood cell) types cancer cells . This may help immune system kill cancer cells . Hyaluronidase allows rituximab given injection" SAKK aims evaluate PET_CT ctDNA oriented therapy therapy DLBCL order test following working hypothesis . This multicenter study is part of a study of patients affected Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular . The purpose study feasibility R-COMP cohort patients are patients with " The goal clinical research study find highest tolerable dose lenalidomide given combination vorinostat, gemcitabine, busulfan, melphalan, melphalan, stem cell transplant, without ritux" DLBCL highest frequency lymphoid malignancies. DLBCL highest frequency lymphoid malignancies. Patients access various treatment options relapse. " This open-label, multicenter, non-randomized, study evaluate safety, efficacy, pharmacokinetics and pharmacokinetics . The study include initial dose-escalation phase followed expansion phase followed expansion phase ." " This study 3 parts. The purpose Part 1 study assess safety efficacy brentuximab vedotin combination RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine" Phase II study proposed assesses hypothesis replacing doxorubicin Myocet® R-CHOP regimen would yield comparable antitumour efficacy . " Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed compare efficacy safety safety . Humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide addition R-CH" Vincristine omitted standard R-CHOP regimen given overlapping toxicities brentuximab vedotin . Vincristine omitted standard R-CHOP regimen given overlapping toxicities brentuximab vedotin The purpose study evaluate whether semi-quantitative interpretation using liver SUVmax reference better interpret 18F-FDG PET/CT predict disease progression chemotherapy survival DLBCL . " Zanubrutinib highly specific, potent new Bruton's tyrosine kinase kinase ） inhibitor, minimal off-target inhibition kinases . Single-arm, open-label Phase II study evaluate efficacy safety" R-CHOP regimen combination intrathecal liposomal cytarabine systemic intermediate-dose methotrexate followed loco-regional radiotherapy . This trial phase II non-comparative study aimed determine feasibility toxicity " Study investigating new administration schedule Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone chemotherapy participants . Participants expect study 2.5 years (treatment 6 months 2 years" Blinatumomab is a potential therapy for DLBCL patients . The investigators hypothesize blinatumomab consolidation optimize effector target (E-T) ratio aid eradication remaining tumor cells . The purpose study evaluate safety efficacy BUCY+VP-16 BUCY myeloablative conditioning regimens . diffuse large B-cell lymphoma undergoing autologous hematopoietic stem cell transplantation . Oral Lenalidomide initiated day 1 cycle 1 dose 20 mg daily 21 days 7 days rest (28 days rest) total 4 cycles . Rituximab administered day 1 day 21 cycle dose 375 mg/m2 total 4 " This randomized, multi-center,phase III study evaluate ability thalidomide maintenance therapy prolong relapse-free survival . The study is being conducted in a randomized, multi-center,phase III study ." " Single-arm, open-label, dose escalation, phase I study aims to evaluate safety efficacy . Autologous Humanized Anti-CD19 Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-" " Single-arm, open-label, dose escalation, phase I study aims to evaluate safety efficacy . Autologous Humanized Anti-CD19 Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-" " Immunotherapy monoclonal antibodies, rituximab pembrolizumab, may help body's immune system attack cancer . Drugs used chemotherapy, lenalidomide, work different ways stop growth cancer cells ." " R-CHOP is a prospective, single arm, open label phase II clinical trial, safety efficacy Chidamide plus R-CHOP regimen accessed de novo DLBCL patients, received 2 courses R-CHOP achieved PR" " Busulfan designed kill cancer cells binding DNA binding DNA (the genetic material cells), may cause cancer cells die . Gemcitabine cladribine may help increase effect busulfan cancer cells allowing cells repair DNA damage caused busulf" Polatuzumab Vedotin combination BR (Bendamustine Rituximab) compared BR alone Chinese participants R/R DLBCL . Approximately 42 Chinese participants randomised treatment arms 2:1 ratio . " This phase Ib/II, multicenter, single-arm open-label study explore Selinexor combination standard care . Approximately 35 patients plan enrolled 6-8 study sites study ." CAR-T cells major therapeutic innovation management management patients relapsed refractory diffuse large B cell lymphoma (DLBCL) 3rd line more . Kymriah® Yescarta® first CAR-T Marketing Authorization coverage " Epcoritamab, also known GEN3013, investigated study antibody, also known GEN3013 . Since safety tolerability epcoritamab already studied previous studies humans, main purpose study evaluate efficacy ." " Monoclonal antibodies, rituximab bevacizumab, block cancer growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells grow spread ." CTL019 adult patients relapsed refractory DLBCL. CTL019 adult patients relapsed refractory DLBCL. CTL019 adult patients relapsed refractory DLBCL. CTL019 adult patients " Phase I/II trial studying side effects of bendamustine hydrochloride given together carboplatin, etoposide, rituximab ." " KRT-232, novel oral small molecule inhibitor MDM2, combined acalabrutinib treatment adults . Participants must relapsed/refractory (having failed prior therapy) Participants must relapsed/refractory" " China-only study investigate PK, efficacy safety of SC rituximab versus IV rituximab . Participants randomized receive eight cycles rituximab SC rituximab SC rituximab IV" " Phase Ib, open-label, multicenter study evaluates safety, efficacy, pharmacokinetics venetoclax combination Pola + R-CHP . Pola + R-CHP previously untreated participants BCL-2 IHC" Diffuse large B-cell lymphoma prevalent non-Hodgkin's lymphoma . Bortezomib CHOP every 2 weeks improve clinical efficacy . " Busulfan, etoposide, cytarabine melphalan (BuEAM) evaluated efficacy toxicity . The purpose study evaluate efficacy toxicity of busulfan, etoposide, cytarabine melph" The purpose study evaluate safety efficacy orelabrutinib combined R-CHOP regimen versus placebo R-CHOP regimen versus placebo . MCD subtype DLBCL. The purpose study evaluated safety efficacy orelabr " This phase II multicenter, open-label study polatuzumab vedotin administered IV infusion combination combination standard doses bendamustine (B) rituximab (R) rituximab (R" " Busulfan, etoposide, cytarabine melphalan (BuEAM) conditioning autologous stem cell transplantation patients non-Hodgkin lymphoma . The purpose study evaluate efficacy toxicity of bus" Lenalidomide plus RCHOP RICE treatment de novo treatment de novo . Lenalidomide plus RCHOP RICE treatment de novo . The purpose study test combination treatment acalabrutunib given together rituximab-ifosfamide-carboplatin-etoposide (R-ICE) The purpose study test combination treatment acal This study aims investigate treatment refractory relapsed DLBCL orelabrutinib gemox . The primary endpoint response rate (complete response rate overall response rate) survival time (OS PFS) toxicities . The " This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study evaluate safety, efficacy, pharmacokinetics . The study include initial dose-escalation phase followed expansion phase ." The study was conducted in advanced stage mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) patients . The study was conducted in conjunction with the clinical trials of CD34+ cell selection versus We compared efficacy safety modified NHL-BFM-90 regimen R-CHOP/CHOP regimen . We compared efficacy safety modified NHL-BFM-90 regimen R-CHOP/CHOP regimen pediatric (aged 0-14 " Phase II, multicenter, open-label study evaluate safety, efficacy pharmacokinetics novel BTK inhibitor, ICP-022 . Approximately 85 subjects R/R DLBCL. Each subject receive treatment orally every day 28-day" The purpose study determine whether Nivolumab effective treatment DLBCL patients failed ineligible ASCT . The purpose study will determine whether Nivolumab effective treatment DLBCL patients failed ineligible ASCT . Rituximab along full-dose CHOP chemotherapy shown improve outcome elderly patients nodal DLBCL . " This single arm, multicenter study evaluate safety, efficacy pharmacokinetic (PK) subcutaneous (SC) rituximab . Participants receive at least 4 doses rituximab 1400 mg SC month Induction period" This observational study designed characterise effectiveness lenalidomide monotherapy treatment R/R DLBCL compare results efficacy outcomes . L-MIND cohort effectiveness matched patient population treated systemic NCCN/ESMO guideline listed regimens administered routine clinical care . L-MIND cohort effectiveness matched patient population treated systemic NCCN/ESMO guideline listed regimens Inotuzumab ozogamicin combination rituximab prior autologous stem cell transplant (aSCT) patients relapsed/refractory diffuse large B-cell Non-Hodgkin's lymph " This non-interventional, retrospective cohort study using Flatiron Health Research Database (FHRD) data single-arm phase II JULIET clinical trial (NCT02445248)" " This study evaluate safety, efficacy, pharmacokinetics induction treatment treatment . Participants FL achieve complete response (CR), partial response (PR), stable disease (SD) end induction therapy receive post-induction treatment obinutuzumab" DA-EPOCH-R every 21 days x 4 cycles (CNS prophylaxis single triple therapy) Restage 4 cycles CT . Restage 4 cycles CT . " CT-P10 therapeutic equivalence trial is designed to provide initial evidence safety, pharmacokinetics, pharmacokinetics, pharmacodynamics, efficacy support pivotal CT-P10 therapeutic equivalence trial . CT-P10 is a first-" The purpose study determine whether treatment IBI110 single agent combination sintilimab demonstrates sufficient efficacy/safety r/r DLBCL. The purpose study determine whether treatment IBI110 single agent combination sintilimab demonstrates Lenalidomide plus ICE treatment is being used in relapsed DLBCL patients . This study evaluate efficacy safety . Lenalidomide plus ICE treatment is being used in relapsed DLBCL patients . " Patients CD30 positive DLBCL, primary refractory first relapse R-CHOP R-CHOP-like therapy receive brentuximab vedotin combination R-DHAP . Patients CD30 positive DLBCL" Aims: A nationwide study prospectively validate the complete histological molecular remission rate antibiotics 1st-line therapy early-stage Hp-positive gastric pure (de novo) DLBCL . Taiwan . " Patient's bone marrow blood collected stored peripheral stem cell transplant . Giving chemotherapy, carmustine, etoposide, cyclophosphamide, cyclophosphamide, transplant stops growth cancer cells stopping dividing killing them ." This single-arm single center study prospectively evaluate safety efficacy ultra-fraction radiotherapy bridging CAR-T therapy relapsed/refractory diffuse large b cell lymphoma . Atezolizumab previously successfully labeled radionucleotide Zirconium-89 (89Zr) studied solid malignancies (NCT02453984) Molecular imaging used noninvasive assessment biodist The purpose study evaluate feasibility efficacy rituximab-bendamustine (R-B)combination . Elderly patients affected diffuse large B-cell lymphoma defined frail according to CGA . " This study evaluate safety, efficacy, pharmacokinetics, pharmacokinetics, immunogenicity . Participants relapsed refractory (RR) FL rituximab + Atezo + Pola participants relapsed refractory" " Diffuse large B cell lymphoma common histology non-Hodgkin's malignant lymphomas (31% lymphomas), incidence 15 20 new cases per year per 100,000 inhabitants France . 60% patients cured standard regimen" " Monoclonal antibodies, rituximab, may block cancer growth different ways targeting certain cells . Drugs used chemotherapy work different ways stop growth cancer cells ." This single institution Phase I study determine maximum tolerated dose (MTD) E7777 given prior cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy Kym Phase I portion study evaluate efficacy saftey toripalimab plus rituximab treating untreated elderly diffuse large B cell lymphoma patients . Phase II portion study evaluate efficacy saftey toripalimab plus ritux OPB-111077 combination bendamustine rituximab patients r/r DLBCL. To investigate tolerability safety . " The purpose study find combination buparlisib ibrutinib lead better treatment results patients relapsed refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) Diffuse Large B-" The purpose trial evaluate efficacy safety adding Rituximab dose-dense High-Dose Chemotherapy (HDC) Autologous Stem Cell Transplantation (ASCT) first line treatment young patients DLBCL " This open-label, single-arm, single-arm, phase IIIb study evaluate safety switching intravenous (IV) subcutaneous (SC) administration rituximab first-line treatment . Participants CD20+ non" " The study was sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. formerly ProNAi Therapeutics, Inc. It is a nonrandomized, open label, phase II investigation PNT" " Monoclonal antibodies, nivolumab, interfere ability cancer cells grow spread . Monoclonal antibodies, nivolumab, interfere ability cancer cells grow spread ." " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cancer-killing substances ." " The phase 2 multi-cohort, un-controlled, non-randomized, open-labeled, open-labeled, multi-center study assessing antitumor activity safety . Participants aged 12 years older relapsed ref" The purpose study determine double autologous allogeneic allogeneic hematopoietic cell transplant may offer improved treatment option patients relapsed diffuse large B-cell lymphoma (DLBCL) may offer improved treatment option "atumumab used combination ifosfamide, carboplatin, etoposide (ICE) dexamethasone, cytarabine, cytarabine, cisplatin (DHAP) salvage chemotherapy reg" The primary purpose study help answer following research questions . The primary purpose study help answer following research questions . " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cancer-killing substances ." " MB-CART2019.1 compared standard care therapy therapy participants relapsed/refractory diffuse large B-cell lymphoma, eligible high-dose chemotherapy autologous stem cell transplantation ." The Purpose study evaluate efficacy safety R-GEMOX refractory/relapsed patients . The purpose study evaluate efficacy safety R-GEMOX refractory/relapsed patients . 5-azacitidine combination vorinostat patients relapsed refractory DLBCL . Combination therapy methyltransferase inhibitors histone deacetylase inhibitors highly synergistic DLBCL cells . Sunitinib may stop growth cancer cells blocking enzymes needed to stop enzymes needed to grow cancer cells . Sunitinib may stop growth cancer cells blocking enzymes needed to grow blood flow cancer . " The purpose study evaluate preliminary efficacy, safety, pharmacokinetics glofitamab (glofitamab) combination rituximab plus ifosfamide, carboplatin, etoposide (R-" " BMF-219, oral covalent menin inhibitor, oral covalent menin inhibitor, adult patients acute myeloid leukemia, acute lymphocytic leukemia KMT2A/ MLL1r, NPM1" The purpose study evaluate clinical activity tolerability combination obinutuzumab plus venetoclax patients relapsed refractory diffuse large B-cell lymphoma patients . " This trial single-center, single-arm, prospective clinical study investigate efficacy safety zanubrutinib maintenance therapy patients diffuse large B-cell lymphoma (DLBCL) Initial remission ." This study evaluate efficacy safety camrelizumab combination apatinib patients relapsed refractory diffuse large B cell lymphoma failed second line chemotherapy . Patients relapsed refractory diffuse large B cell lymphoma failed second line chemotherapy " This Phase 2 non-randomized, open label, uncontrolled, efficacy safety safety study . Study participants receive two priming doses 0.5mL DPX-Survivac 21 days apart 21 days apart six 0.1ml maintenance" " Phase 3 randomized, double-blind, placebo-controlled, placebo-controlled, study assessing efficacy safety . R-CHOP subjects were previously untreated non-germinal center diffuse large B-cell lymphoma ." " The primary objective study determine safety profile radiotherapy durvalumab, PD-L1 inhibitor . The primary objective study determine safety profile radiotherapy durvalumab, PD-L1 inhibitor ." The standard care therapy therapy therapy therapy therapy DLBCL relapsed setting RICE plan patient proceed transplant . This protocol add Revlimid first 7 days RICE therapy transplant maintenance to improve outcome survival . The investigators planed include 732 untreated CD20 positive diffused large B cell lymphoma adults . The investigators planed include 732 untreated CD20 positive diffused large B cell lymphoma adults . " Monoclonal antibodies, rituximab, block cancer cell growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cell-killing substances ." " SAR245409 determined objective response rate (ORR) patients 1 following relapsed refractory lymphoma leukemia subtypes: mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (C" Aim study evaluate efficacy safety tislelizumab combination lenalidomide patients relapsed refractory patients relapsed refractory Elderly Patients non-GCB Diffuse Large B Cell Lymphoma . " The purpose first-in-human study CX-2029 characterize safety, tolerability, pharmacokinetics (PK), pharmacokinetics (PK), pharmacodynamics (PD) antitumor activity CX-2029 . The" Rituximab predicted RNA protein gene expression presence biomarkers associated anti-tumor effects Rituximab . " This open-label, multicenter, randomized phase III trial is open-label, multicenter, randomized phase III trial . Patients will receive prephase oral prednisone 6 cycles Q21 immunochemotherapy ." " Combining chemotherapy stem cell transplantation may allow doctor give higher doses chemotherapy drugs kill tumor cells . Monoclonal antibodies, rituximab, locate tumor cells either kill deliver tumor-killing substances without harming normal cells ." Study Evaluating Efficacy Safety Preemptive Antiviral Therapy Tenofovir HBsAg-positive Patients Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy . " R-CHOP patients stage II, III IV and III IV diffuse large B cell lymphoma (DLBCL) are patients with stage II, III IV diffuse large B cell lymphoma (DLBCL) Patients are stage II" Study testing whether stratification patients according biological risk factors different treatment groups improve outcome patients clinically high diffuse large B-cell lymphoma (DLBCL) This study investigate strategy biomarker guided treatment for diffuse large B cell lymphoma . R-ACVBP DA-EPOCH-R patients newly diagnosed non-germinal b-cell-like diffuse large B-cell lymphoma . Patients newly diagnosed non-germinal b-cell-like diffuse " Rituximab combined ESHAP (etoposide, methylprednisolone, methylprednisolone, cytarabine, cytarabine, cisplatin) patients diffuse large B cell lymph" Zanubrutinib combined Tislelizumab treatment relapsed/refractory primary mediastinal large B-cell lymphoma . Epstein-Barr Virus-positive diffuse large B-cell lymphoma . REMIT trial investigate radiotherapy preferred bridging method prior to Tisagenlecleucel infusion . REMIT trial investigate radiotherapy preferred bridging method prior to Tisagenlecleucel infusion . " Diffuse large B-cell lymphoma (DLBCL) common type lymphoma common type lymphoma . The majority refractory patients PD-L1 expression due P53 mutations, account 10% DLBCL." " Burkitt's lymphoma (BL) high-grade B-grade B-cell lymphoma, unclassifiable, features intermediate diffuse large B-cell lymphoma BL . This retrospective study aimed evaluating safety efficacy rituximab" The purpose study administer novel cluster differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) patients relapsed resistant Diffuse Large B Cell Lymphoma (DLBCL Patients relapsed refractory diffuse large B-cell lymphoma starting second- third-line therapy receiving autologous stem cell transplant . " CTL019 is a multi-center, phase II study evaluating efficacy safety CTL019 Chinese adult patients relapsed refractory DLBCL ." MorphoSys' EAP requested contacting respective CRO Clinigen (tafasitamab@clinigengroup.com) Access MorphoSys´ EAP requested contacting respective CRO Clinigen (tafas " MAK683 patients advanced malignancies Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) advanced solid tumors effective standard treatment available . The purpose Phase I/II study" " Apoptosis specific form cell death leads clearance dead cells without causing inflammation injury normal adjacent tissues . Apoptosis also occurs response standard combination therapies rituximab, cyclophosphamide, doxorubicin, do" " Digital case management systems potential increase compliance protocol-driven treatment, reduce treatment abandonment . Digital case management systems potential increase compliance protocol-driven treatment, reduce treatment abandonment ultimately help close discrepancy pediatric cancer outcomes ." " The purpose multi-center,single arm,phase Ⅱ clinical trail determine safety efficacy . Chidamide R-GemOx(rituximab) and Gemcitabine plus oxaliplatin) regimen treatment transplant" " CMAB304(Retuxira), chimeric monoclonal antibody designed targeted CD20 treatment lymphoma diseases . This trial aimed observe safety efficacy CMAB304, added CMAB304 CHOP chOP ch ." " The purpose multi-center,single arm,phase Ⅱ clinical trail determine safety efficacy GVD±R (gemcitabine, oral vinorelbine doxorubicin liposome, without rit" Aim study assess efficacy safety G-CHOP combination ibrutinib . Aim is to assess efficacy safety G-CHOP combination ibrutinib . Aim is to assess efficacy safety G-CHOP combination ibrut Sintilimab R-CHOP regimen first-line treatment DLBCL patients . DLBCL patients are TP53 mutation PD-L1 positive . " Autologous peripheral blood stem cell transplantation combined high dose chemotherapy treatment choice given patients diffuse large-B cell lymphoma (DLBCL) following relapse disease . Although many people cured lymphoma therapy, disease comes back certain proportion patients" " The purpose small preliminary study gather preliminary data support large randomized controlled trial fatigue reduction diet intervention . The study employ individualized dietary counseling, provided dietitian (RD), phone video teleconferencing 8 sessions 3 months ." This Retrospective cohort study based PMSI data source . " Tucidinostat (formerly known chidamide) oral subtype-selective histone deacetylase inhibitor . This Randomized, Double-blind, Placebo-controlled Phase 3 trail studying efficacy safety ." Phase I trials studies side effects of pomalidomide given together nivolumab . Patients with cancer come back responded treatment . R-CHOP plus enzastaurin versus R-CHOP progression-free survival (PFS) time measured participants . Participants intermediate and/or high risk diffuse large B-cell lymphoma (DLBCL) receiving first National Cancer Institute suggests certain chemotherapy drugs may effective given continuous infusion vein rather standard method rapid intravenous injection . " Lenalidomide may stop growth cancer cells blocking blood flow cancer . Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry" " RNK05047 administered intravenous (IV) infusion subjects advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL) The first human, Phase 1/2 open-label multi-center, dose escalation expansion" " This open-label, single-arm, multicenter phase phase phase Ⅱ study designed evaluate efficacy safety F520 (PD-1) combined F007(rituximab biosimilar) patients Relapsed/Refractory" " The goal clinical research study learn addition 90Y Zevalin BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan) rituximab effective combination BEAM ritux" The purpose study investigate safety effectiveness plamotamab given tafasitamab lenalidomide relapsed refractory DLBCL. The purpose study was to investigate safety effectiveness plamotamab given taf There considerable international /national interest GEM-P regimen treatment patients relapsed/refractory lymphoma patients regimen would like undertake retrospective review sub-group patients diffuse large B cell lymphoma (DLBCL) " This multicenter, open-label, Phase 1/2 study conducted two parts . Phase 1 part comprised dose escalation expansion expansion parts establish MTD and/or recommended Phase 2 dose (RP2D) tazemetostat ." Main study (part 2) is Relapsed refractory diffuse large B-cell lymphoma . Main study (part 2) is Relapsed refractory diffuse large B-cell lymphoma . PTK787/ZK222584 adults relapsed refractory diffuse large cell lymphoma (DLCL) is a phase II open label study . All subjects receive PTK787/ZK222584 . Subjects tolerate The purpose study will determine whether specific subtype lymphoma responds optimally to rituximab chemotherapy . The purpose study will determine whether specific subtype lymphoma responds optimally to rituximab chemotherapy . This study aims evaluating feasibility safety administration autologous T cells modified introduction chimeric antigen receptor targeting B-cell surface antigen CD19 . Children adults adults relapsed/refractory B-cell acute lymphoblastic leukemia (B- " This study evaluates efficacy safety penpulimab plus lenalidomide, rituximab, gemcitabine oxaliplatin (R2-GemOx) patients relapsed/refractory diffuse large" Mitoxantrone HCL Liposome Injection patients diffuse large B-cell lymphoma lymphoma lymphoma lymphoma peripheral T cell . Patients diffuse large B-cell lymphoma lymphoma lymphoma lymphoma peripheral T cell . " This multicenter, open-label study evaluate safety efficacy pinatuzumab vedotin (DCDT2980S) pinatuzumab vedotin (DCDT2980S) polatuzum" " The goal clinical research study find highest tolerable dose drug lenalidomide (Revlimid, lenalidomide) given Rituxan® (rituximab) treatment relapsed mantle cell lymphoma . The safety" " Glofitamab administered combination obinutuzumab (G), rituximab (R) standard doses CHOP (G/R-CHOP R-CHOP) participants r/r NHL G/" " This A Phase II, Single-Arm, Open-Label, Multicentre Study Evaluate Safety Efficacy Tafasitamab Combined Lenalidomide Patients Relapsed Refractory Diffuse Large B-Cell L" " The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study participating centers South China Children's Cancer Group-Non-Hodgkin" Purinostat mesylate injection (PM) novel highly potent Class I IIb HDAC-selective inhibitors . PM potential treat diffuse large B cell lymphoma . Diffuse large B-cell lymphomas (DLBCLs) represent 25 30% adult non-Hodgkin lymphomas western countries . DLBCLs aggressive cancer potentially curable multi-agent chemotherapy . " Selinexor combined prednisone, etoposide lenalidomide and etoposide lenalidomide treatment relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient high" " Yescarta is a prospective, open-label, single-arm study evaluating safety efficacy defibrotide prevention CAR-T-associated neurotoxicity . Subjects relapsed refractory diffuse large B-cell lymphoma (DLBC" Early central nervous system (CNS) prophylaxis given beginning therapy young high risk diffuse large B-cell lymphoma (DLBCL) patients feasible could reduce risk of relapses . Atezolizumab shown promising activity relapsed DLBCL patients . Toxicity data atezolizumab available > 6000 patients manageable . " Managed Access Program (MAP) provide access to CTL019, acute lymphoblastic leukemia (ALL) diffuse large b-cell lymphoma (DLBCL) patients ." EPOCH R combination chemotherapy drug. It effective treating cases large B-cell lymphoma. It effective treating cases large B-cell lymphoma. The first effect MLN4924 treating large B-cell lymphoma. The second Monoclonal antibodies rituximab yttrium Y 90 ibritumomab tiuxetan locate cancer cells . They deliver radioactive cancer-killing substances without harming normal cells . Radiolabeled monoclonal antibodies locate tumor cells deliver tumor-killing substances radioactive iodine without harming normal cells . Phase I trial study effectiveness radiolabeled monoclonal antibodies treating patients large cell lymphoma previously treated . " The purpose study evaluate feasibility tolerability delivering full dose, time schedule dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, prednisone, ritux" " RCHOP-14 RCHOP-14 RCHOP-21 RCHOP-21 . Administration radiotherapy following chemotherapy strongly recommended . Administration radiotherapy following chemotherapy strongly recommended, based findings retrospective IELSG study, ." GA101-miniCHOP regimen treatment elderly unfit patients diffuse large B-cell non-Hodgkin's lymphoma . GA101-miniCHOP regimen treatment elderly unfit patients diffuse large B-cell non-Hodg " This first-in-human study evaluate feasibility, safety preliminary antitumor efficacy . CAR-T cells investigated combination ibrutinib chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)" " RTXM83-AC-01-11 study evaluated efficacy safety outcomes relation use Vivaxxia 6 treatment cycles (at investigator's discretion, 8 treatment cycles could administered), followed 9 months follow-up ." R2-GOD relapsed diffuse large-cell lymphoma relapsed diffuse large-cell lymphoma . Previous study showed Lenalidomide R-GDP could achieve response Relapse Refractory DLBCL. The goal project test feasibility Patient Preferences Shared Decision-Making encounter tool (PPSDM) clinical context . Diffuse Large B-Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Follicular " The purpose study evaluate efficacy, safety tolerability combination treatment ibrutinib MEDI4736 subjects relapsed refractory lymphomas . The purpose study evaluate efficacy, safety tolerability combination treatment ibrutinib MEDI" The purpose study determine whether people genes make likely respond chemotherapy and/or side effects chemotherapy diffuse large cell lymphoma . The purpose trial determine effect ofatumumab patients . Diffused Large B-Cell Lymphoma (DLBCL) ineligible transplant relapsed autologous transplant relapsed autologous transplant . " ASTX727 consists combination decitabine cedazuridine . Cedazuridine class medications called cytidine deaminase inhibitors . It prevents breakdown decitabine, making available body decitabine greater effect ." Diffuse large B-cell lymphoma (DLBCL) aggressive subset non-Hodgkin's lymphoma (NHL) Central nervous system (CNS) involvement patients NHL serious complication . Median survival 4-6 months " Carfilzomib designed block cancer cells repairing themselves . If cancer cells cannot repair themselves, may cause die . Carfilzomib designed block cancer cells repairing themselves ." The goal study identified dose schedule CC-486 safely administered R-CHOP . The goal study identified dose schedule CC-486 safely administered R-CHOP . This study evaluates addition selinexor (KPT-330) RICE chemotherapy treatment . treatment relapsed refractory aggressive B-Cell Lymphoma . Treatment relapsed refractory aggressive B-Cell Lymphoma . " A Phase 1/2 Study bbT369, dual targeting CAR T cell drug product gene edit, is a dual targeting CAR T cell drug product gene edit . Relapsed and/or Refractory B cell Non-Hod" " The purpose study evaluate safety, tolerability, dose-limiting toxicities (any harmful effect drug) (DLT) The purpose study evaluate safety, tolerability, dose-limiting toxicities (DLT), maximum tolerated dose" " The primary objective study to determine partial response rates toxicity profile bortezomib (VELCade, formerly PS-341) patients relapsed refractory diffuse large B-cell non-Hodgkin's lymphoma ." " The purpose trial evaluate safety, tolerability, efficacy pembrolizumab (MK-3475, KEYTRUDA®) pembrolizumab combination lenalidomide (Cohort 5 only) he" " Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Combining chemotherapy monoclonal antibody therapy, total-body irradiation, peripheral stem cell transplant may allow" Pixantrone + Rituximab was used to evaluate efficacy Pixantrone + Rituximab . Gemcitabine + Rituximab patients relapsed refractory diffuse large B-cell lymphoma " PBO-326 (Rituximab) Mabthera (Rituximab) combination was designed to assess pharmacokinetics, pharmacodynamics safety . CHOP previously untreated patients diffuse B cells Non Hodgkin lymph" " 90-yttrium ibritumomab tiuxetan combination chemotherapy compared combination chemotherapy alone stem cell transplant . Radioactive substances linked monoclonal antibodies, 90-yttrium ibritumomab tiuxet" " This open, non comparative, multicentre phase II trial, evaluate efficacy feasibility new sequential combination HD-MTX-AraC-based chemoimmunotherapy ." Rituximab monoclonal antibody targeting CD20 induces B-cell depletion resulting prolonged immune suppression . This leads frequent reactivation patients previous history exposure HBV carrier . Arginine methylation mediated protein arginine methyl-transferases (PRMTs) are important post-translational modification proteins involved diverse range cellular processes . Misregulation overexpression PRMT1 (a type I PR Multidimensional Geriatric Assessment (VGM) use Activity Daily Living (ADL) Activity Daily Living (ADL) and Instrumental Activity Daily Living (IADL) Cumulative Illness Rating Scale Geriatrics (CIR Avadomide (CC-122) R-CHOP could help controlling DLBCL patient population . " Phase I/Ib study designed establish safety maximum tolerated dose (MTD, also recommended phase II dose (RP2D) aurora kinase A inhibitor alisertib combined dose-adjusted (DA)-R-EPO" Phase I study designed determine recommended recommended recommended dose (RP2D) tazemetostat patients treated 8 cycles R-CHOP 21 . Phase I study designed determine recommended recommended dose (RP2D) tazemetostat The primary objective protocol estimate complete response rate three courses three courses . The primary objective protocol estimate complete response rate three courses three courses . " This dose-escalation study evaluating safety, pharmacokinetics preliminary efficacy venetoclax combination AMG 176 participants relapsed refractory acute myeloid leukemia (AML) participants . Non-Hodgkin's lymph" " Oncologists developing new treatment protocols to improve cure rates . EPOCH-R utilizes two major new strategies . Treatment approach utilizes continuous infusion chemotherapy four days, instead administered minutes hours ." PD-L1 inhibition durvalumab is being tested in a trial of high-risk DLBCL patients . The trial assess progression-free survival (PFS) two years autologous stem cell transplantation (ASCT Study justified known therapies really curative necessary look new treatment options . Patients eligible high-dose chemotherapy autologous stem cells transplantation . " The main purposes study include: Looking way body absorbs, distributes, gets rid 89Zr-DFO-REGN3767 ." JCAR017 participants were aggressive B-cell non-Hodgkin lymphoma (B-NHL) JCAR017 participants were aggressive B-cell non-Hodgkin lymphoma (B-NHL) The study examine safety profile SGN-CD19B administered single agent . Patients relapsed refractory aggressive aggressive B-cell non-Hodgkin lymphoma (NHL) subtypes diffuse large B-cell lymphoma " Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study . Participants diagnosed various subtypes non-Hodgkin lymphoma (NHL)" " This multi-center, open-label, single-arm study evaluate pharmacokinetics safety . Participants receive multiple doses obinutuzumab . Participants receive multiple doses of obinutuzumab ." Application positron emission tomography lymphoproliferative diseases today provides diagnostic therapeutic information major importance . The radiopharmaceutical used clinical practice exam fluorodeoxyglucose 18F-2-fluoro-2-deoxy AZD3965 type drug called monocarboxylate transporter 1 inhibitor used stop growth cancer cells . This first time type drug given patients . The purpose study evaluate effectiveness circulating DNA peripheral blood predicting prognosis relapse relapse DLBCL PTCL patients . MabThera (rituximab) added standard chemotherapy participants untreated Mantle Cell Lymphoma eligible autologous stem cell transplantation . Participants receive MabThera (372 mg/m^2 intravenously) Day In presently planned multicentre Phase III trial two therapies compared: Patients randomized intensified induction treatment . Patients randomized intensified induction treatment . Patients randomized intensified induction treatment . Patients randomized intensified induction treatment . Patients randomized intensified induction treatment . Patients randomized intensified induction The aim study identify incidence hepatitis B virus reactivation rate Diffuse Large B Cell high grade Follicular lymphoma patients prior resolved hepatitis B undergoing RCHOP immuno-chemotherapy . Ofatumumab monotherapy patients relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) Patients receive weekly infusions of Ofatumumab 1000 mg 8 weeks (induction phase) followed Rituximab followed auto-transplant HPC versus CHOP plus Rituximab first line therapy high risk patients DLBCL Non-Hodgkin's lymphomas . Multicentric randomized phase III study This study consists dose escalation/confirmation phase efficacy expansion phase . The dose escalation/confirmation phase determine safety tolerability establish preliminary recommended Phase 2 dose (RP2D) zilovertamab vedotin administered combination R- " Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before, standard treatment . This prospective descriptive monocentric study describes clonal evolution mutational pattern of cfDNA cohort patients ." " VAY736 alone combination therapies patients patients patients NHL platform trial . The purpose study assess safety, tolerability, pharmacokinetics (PK), immunogenicity preliminary efficacy VAY736 alone combination therapies patients patients NHL platform trial ." Patients undergoing CART-19 immunotherapy receive FDG-PET/CT responses . Patients receiving CART-19 immunotherapy receive CART-19 immunotherapy . " Bortezomib (PS-341) is an experimental drug called Bortezomib . In laboratory, PS-341 kills lymphoma cells makes sensitive chemotherapy . The EPOCH treatment regimen includes drugs doxorub" " Digital PCR was used to detect cell-free circulating tumoral DNA potentially aggressive primary cutaneous lymphomas . Patients mycosis fungoides, primary cutaneous T-cell lymphoma helper follicular phenotype primary cutaneous diffuse large B" Patients newly diagnosed patients DLBCL intermediate high risk. Purpose: evaluate efficacy chemotherapy regimens R-DA-EPOCH-21 R-mNHL-BFM-90 without autologous hematopoietic Research trial studies collecting tissue samples patients HIV-related malignancies . Researchers hope to identify biomarkers related cancer . " Fimepinostat (CUDC-907) is a phase 1, open-label, dose-escalation study . Patients relapsed and/or refractory diffuse large B-cell lymphoma (DLBC" SGN-35 patients certain type large B-Cell Lymphoma also studied . It known brentuximab vedotin better worse treatment might given . " Trial planned enroll 414 subjects, randomized two treatment groups ratio 1:1 receive test drug positive control ." " venetoclax combination DA-EPOCH-R patients aggressive B-Cell Lymphomas . Phase I, open label, single-arm, multi-center, dose-finding study ." " Granulocyte-macrophage colony stimulating factor (GM-CSF) combination Cytoxan, Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-Rit" " Venetoclax and selinexor are being tested in a phase Ib trial . Venetoclax inhibits protein body called bcl-2, slowing normal process old cells body cleared (called apoptosis) Selinexor" BTK inhibitor PCI-32765 given together rituximab bendamustine hydrochloride . The purpose study evaluate safety tolerability of MT-3724 combination gemcitabine oxaliplatin (GEMOX) participants relapsed refractory B-Cell NHL . The purpose study evaluate efficacy safety orelabrutinib combined rituximab and rituximab . The purpose study evaluate efficacy safety orelabrutinib combined rituximab� " The main objective study observed overall survival Rituximab Biosimilar HLX01 MabThera Combination With CHOP, previously untreated subjects CD20+ DLBCL . The secondary objective study observed progression-free survival" The study was conducted in a group of patients with relapsed/refractory DLBCL patients . The study was conducted in a group of patients with relapsed/refractory DLBCL patients . The study was conducted in R-CHOP chemotherapy is a pre-phase treatment for DLBCL patients newly diagnosed . A phase 2 trial pre-phase treatment R-CHOP chemotherapy is underway . Patients initially randomized 4 arms: R-DA-EPOCH; R-CEOP90; R-CEOP90; R-CEOP90; Arm IV: R-CEOP90 + auto-SCT . Patients This Phase II prospective trial addition rituximab reduced dose CHOP chemotherapy DLBC L patients aged 65 years over . The primary objective study assess efficiency SCT400 plus CHOP versus Rituximab plus CHOP versus Rituximab plus CHOP untreated CD20-positive DLBCL patients . The secondary objective study evaluate safety S 32% of patients high risk group achieved long term remission . Major improvements treatment childhood non-lymphoblastic lymphomas taken place last ten years . The purpose study determine safety tolerability combination therapy SGN-40 gemcitabine rituximab treatment lymphoma . This study also intended estimate well disease responds treatment . This randomized trial estimate activity R-ICE plus SGN-40 vs. R-ICE plus placebo patients DLBCL . The study assess safety tolerability measure additional clinical benefit observed patients receiving SGN-40 . Trial comparing two different methods collecting stem cells patients undergoing stem cell transplant diffuse large cell lymphoma . Patients undergoing stem cell transplant diffuse large cell lymphoma . " 70 patients diffuse large B-cell lymphoma, follicular lymphoma grade IIIB transformed indolent lymphoma receive 6 cycles described combination regimen . Obinutuzumab (GA101) combination Pixantrone patients relapsed" " GDC-0853 is being tested for relapsed refractory B-cell non-Hodgkin's lymphoma chronic lymphocytic leukemia . In dose-expansion part, GDC-0853 assessed subsets" " CC-122-NHL-001 study is a multicenter, open-label, phase Ib study dose escalation expansion parts . It evaluates safety, tolerability clinical pharmacokinetics and pharmacokinetics . The study also assessing preliminary efficacy" " TNB-486, CD19 x CD3 T-cell engaging bispecific antibody, TNB-486, CD19 x CD3 T-cell engaging bispecific antibody . Subjects relapsed refractory B-cell" " This single-arm, open-label, multicenter, dose escalation, phase 1-2 study alisertib (MLN8237) administered patients relapsed refractory diffuse large B-cell lymphoma (DLBC" Aim trial assess efficacy new anti-CD20 antibody (GA101) antibody (GA101) association . DHAP induction therapy high dose chemotherapy BEAM ASCT patients relapsed/refractory DLBCL patients relapsed/ref " Pesticide exposure disruption immune surveillance cancer cell . Risk factor identified like inducing immune deficiencies: chronic exposure HIV, immune suppressor therapies ." Myeloid cells expressing CD11b play critical role sustaining cancer progression . Fkn known ligand CX3CR1 triggers recruitment of CX3CR1-positive cells . ADAM17 inhibitor (INCB7839) rituximab consolidation therapy (INCB7839) rituximab consolidation therapy (HCT) patients diffuse large B cell lymphoma (DLBCL) patients " MEDI7247 patients selected hematological malignancies relapsed after, refractory prior standard therapy, standard salvage regimen available . To assess safety tolerability, describe dose-limiting toxicities, determine maximum tolerated dose (" " Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is gold-standard assessment disease patients . The use alternative methods, without radiation, whole-body magnetic" " The prospective, open-label, Phase III, multicenter, single-arm trial designed assess safety, pharmacokinetics, pharmacokinetics, pharmacodynamics and alternative dosing rate . The trial is designed to assess safety, pharmacokin" Part 1 (Phase Ib) Part 1 (Phase Ib) Part 1 (Phase II randomized) Part 2 (Phase II randomized) Part 2 (Phase II randomized) Part 2 (Phase II randomized) Part 2 (Phase II randomized) " The purpose study identify if, dose, ibrutinib may administered . R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)" Multi-center observational study assess addition Rituximab treatment previously untreated patients . Diffuse Large B-Cell Lymphomas(DLBCL) enrollment period 60 months . " 35-60% patients refractory treatment experience relapse first treatment . After standard treatment primary central nervous system lymphoma (PCNSL), high-dose methotrexate induction therapy, consolidation therapy, patients reach complete remission, within" The study was designed to explore effect maintenance therapy lenalidomide versus placebo progression-free survival (PFS) patients treated R-CHOP responding induction therapy . The purpose clinical trial learn experimental medicine (TTI-622) affects people various types blood cancers . The purpose clinical trial learn experimental medicine (TTI-622) affects people various types blood cancers . " This Phase I/II multicenter single arm non-randomized open label study . Brentuximab vedotin was given combination routine chemotherapy (rituximab, cyclophosphamide, doxorubicin" To determine disease-free survival (DFS) 2 arms (standard dose versus high dose rituximab) To determine treatment related mortality (TRM) untreated untreated non-germinal center diffuse large B cell lymphoma causes disease way patients respond pembrolizumab combined R-CHOP chemotherapy regimen . " The primary objectives study are to investigate safety tolerability, define recommended Phase 2 dose schedule (RP2DS) Magrolimab combination rituximab, gemcitabine, oxaliplatin (R-Gem" " In study, invesigators propose analyze 150 DLBCL patients, 50 MCL patients, 100 FL patients, 100 FL patients determine clinical utility ctDNA- well circulating tumor cell (CTC)-based MRD assessment CAR therapy" Ruxolitinib phosphate may stop growth cancer cells blocking enzymes needed to grow . Phase II trial studies well ruxolitinib phosphate works treating patients with diffuse large B-cell peripheral T-cell peripheral T-cell non- " Chimeric antigen receptor (CAR) T-cell therapy promising new treatment re-programs patient immune cells to target destroy cancer cells . Importantly, CAR T-cell therapy improved overall response rate durability patients refractory relapsed" " camrelizumab combined rituximab, vincristine, doxorubicin, cyclophosphamide prednisone treatment untreated primary extranodal DLBCL ." " Epcoritamab combination standard care (SOC) agents subjects B-cell Non-Hodgkin Lymphoma (B-NHL) A phase 1b/2, open-label, multinational, interventional" " The goal clinical research study learn safety effectiveness combination panobinostat, gemcitabine, busulfan, melphalan, or without rituximab . Patients non-Hodgkin's Hodgkin's Hodg" Aim study evaluate efficacy safety of zanubrutinib combination R-CHOP newly diagnosed untreated untreated Non-GCB DLBCL patients . Aim study evaluate efficacy safety zanubrutinib combination R-CH Part A study evaluates iopofosine I 131 (CLR 131) patients select B-cell malignancies . Part B (CLOVER-WaM) pivotal efficacy study evaluating IV adm adm adm adm adm adm adm adm The primary objective phase Ib study determine recommended recommended phase 2 dose (RP2D) entospletinib (ENTO) patients treated R-CHOP . The primary objective phase Ib study determine recommended phase 2 dose (RP2 " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cancer-killing substances ." " This study evaluate efficacy combination entospletininib idelalisib participants relapsed refractory hematologic malignancies . Participants enrolled one following hematological tumor types: chronic lymphocytic leukemia (CLL)," " Intrathecal methotrexate (ITMTX) traditionally used, but efficacy CNS prophylaxis is contradictory . High-dose intravenous methotrexate (IVMTX) suggested alternative approach ." Anti-PD-1 Antibody Plus Chidamide Rituximab Regimen Treatment Relapsed Refractory DLBCL . " Monoclonal antibodies, yttrium Y 90 ibritumomab tiuxetan rituximab, locate cancer cells or deliver radioactive cancer-killing substances without harming normal cells . Combining yttrium Y" " The 3 common types of lymphoma are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) follicular lymphoma (FL) and follicular lymphoma (FL) Treatment strategy often cur" " The primary endpoint complete response rate, second endpoints survival time (OS PFS) overall response rate . The primary endpoint complete response rate, second endpoints survival time (OS PFS) overall response rate ." " Pesticides are linked to non-Hodgkin lymphoma, including diffuse large B cell lymphoma (DLBCL) Pesticides are linked to non-Hodgkin lymphoma, including diffuse large B cell" The primary purpose study determine recommended dose (RD) birabresib (MK-8628) /OTX015 phase II studies . Participants were participants of the study . Participants enrolled for the study . " Onalespib may stop growth cancer cells blocking enzymes needed to grow cancer cells . Phase II trial studies well onalespib works treating patients . Patients with lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma" Cobomarsen (MRG-106) is an investigational drug . The drug is being tested for certain lymphomas leukemias . Cobomarsen inhibitor molecule miR-155 found high levels of cancer cells may " MBCART2019.1 cells adults relapsed refractory DLBCL receiving at least two lines therapy . This open label, single arm, phase II study determine efficacy, safety PK (persistence) MBCART2019." " This randomized, open label, phase III study evaluate ability rituximab maintenance therapy prolong event-free survival ." " Richter Syndrome (RS) presents histological aspect primitive Diffuse Large B-Cell Lymphoma (DLBCL) associated poor prognosis, due chemorefractoriness . RS presents histological aspect primitive Diffuse Large B" " This Phase 1/2 study performed two clinical centers US UK . It single arm, open label study evaluating VSLI plus rituximab adults aggressive relapsed refractory non-Hodgkin's lymphoma ." Researchers want to learn safe give people certain cancers copanlisib together rituximab combination chemotherapy (DA-EPOCH-R) " R-CDOP (Rituximab, Cyclophosphamide, Doxorubicin hydrochloride liposome, Vindesine, Prednisone) treatment newly diagnosed high tumor burden non-H" " Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), combination bendamustine rituximab (BR) subjects previously treated aggressive B cell non Hodgkin lymphoma (" Zevalin® Reduced Intensity Conditioning regimen followed allogenic stem cell support patients aggressive lymphomas responsive salvage chemotherapy regimen . " This Phase I, open-label multi-site trial designed evaluate safety administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) Programmed Death1 (PD-1) inhibitor Nivolumab" Lenalidomide added nivolumab usual drugs (rituximab methotrexate) patients primary central nervous system (CNS lymphoma) lymphoma . Lenalidomide may stop slow primary CNS lymphoma The study hypothesis added zevalin radioimmunotherapy conditioning regimen given prior BEAM high-dose chemotherapy autologous stem cell transplantation patients aggressive lymphoma reduced disease recurrence rate . " LUCAR-20S CAR-T cells relapsed refractory CD20+ diffuse large B-cell, follicular, mantle cell small lymphocytic lymphoma . An open label, single arm Phase I study evaluate safety" The purpose study determine whether duvortuxizumab ibrutinib combined safely establish maximum tolerated dose (MTD) Part 1 recommended Phase 2 dose (RP2D) Part 2.D participants were participants with large " This open-label, multicenter study evaluate safety tolerability, determine RP2Ds tafasitamab alone . Japanese participants previously untreated DLBC, tafasitimab combination lenalidomide plus R-CH" " The purpose study was to determine tolerability, initial safety profile and maximum tolerated dose . The purpose study was to determine tolerability, initial safety profile and antitumor activity ." The purpose study improve communication skills physicians transition lymphoma cancer patients end treatment survivorship . The purpose study is to improve communication skills physicians transition lymphoma cancer patients end treatment survivorship . The purpose study determine whether CD16- monocyte/CD16+ monocyte ratio could help predict prognosis DLBCL PTCL . " YESCARTA administered outpatient setting closely monitor subjects physical exams, wearable devices, wearable devices, telemedicine visits and telemedicine visits . We hope to demonstrate YESCARTA safely administered outpatient setting closely monitor subjects physical exams," An observational study evaluates patients undergoing six courses combination chemotherapy without rituximab radiation therapy . The study may help doctors predict patient's response treatment help plan best treatment . " Study evaluate safety tisagenlecleucel specification( OOS release commercial product . Study evaluate safety CTL019 patients treated within approved label Japan Health Authority Part 2. Only Part 1, addition safety, key efficacy CTL019" " Positron Emission Tomography (PET) imaging radioactive tracer called 18F-ISO-1 accurately identifies quickly cancer cells growing dividing . A second purpose study determine, taking pictures, taking pictures, tissues organs body take 18F" " The purpose study assess self-reported side effects neurocognitive (brain, mood thinking) functioning among patients treated commercial axi-cel therapy ." " The purpose study evaluate safety efficacy pembrolizumab (MK-3475) used combination dinaciclib (MK-7965) treatment relapsed refractory chronic lymphocytic leukemia (rrCLL), multiple" " A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating Safety, Tolerability, Preliminary Efficacy ATG-010 Combination Lenalidomide Rituximab (R2) Adult" The purpose study evaluate efficacy safety preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined high-dose BEAM . The purpose study evaluated " Monoclonal antibodies, rituximab, locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy, cyclophosphamide, doxorubicin, vincristine" Study evaluate ability largely self-administered geriatric assessment (GA) predict toxicity of toxicity non-Hodgkin Lymphoma (NHL) patients . NHL patients are patients with non-Hodgkin Lymphoma Primary CNS lymphoma (PCNSL) rare subtype diffuse large B-cell lymphoma . Most PCNSLs appear activated B-cell (ABC) origin . Most PCNSLs appear activated B-cell (ABC Entospletinib participants were patients with relapsed refractory hematologic malignancies . The primary objective study evaluated efficacy entospletinib participants relapsed refractory hematologic malignancies . Participants following " This multicenter, open-label, Phase 2 study assess efficacy safety tazemetostat participants relapsed refractory B-cell non-Hodgkin's lymphoma (NHL) EZH2 gene mutation" " This study evaluate safety, tolerability, pharmacokinetics, efficacy intravenous (IV) subcutaneous (SC) subcutaneous (SC) mosunetuzumab combination polatuzumab vedotin . Participants" SPARKLE study test efficacy two intensities light therapy cancer related fatigue . CRF is a prevalent distressing long-term complaint reported (non-) Hodgkin survivors . This clinical research study investigate prevention relapse patients using enzastaurin daily . " This phase I study BTK inhibitor CT-1530 patients relapsed refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) Waldenstrom's mac" SyB L-0501 combination Rituximab patients aggressive B-cell non-Hodgkin's lymphoma . The purpose study assess safety SyB L-0501 combination Rituximab patients aggressive B Tremelimumab MEDI4736 (durvalumab) and rituximab tested MEDI6469 set participants advanced solid tumors . Tremelimumab MEDI4736 (durvalumab) " Single agent odronextamab measured objective response rate (ORR) according Lugano Classification response malignant lymphoma (Cheson, 2014) The ORR was based on a central review following B-cell non-" " A phase II, multi-center study compare feasibility, clinical efficacy local manufacturing CD19-directed CAR T-cells (ARI-0001 CAR T-cells) to commercial produced CAR T-cells . Patients relapsed refractory (" " This Phase 1, first-in-human, open-label, multicenter study CC-97540, CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells . Subjects relapsed refractory" " Drugs used chemotherapy, doxorubicin, vincristine, cyclophosphamide, cyclophosphamide, work different ways stop growth cancer cells . Steroid therapy, prednisone, may effective treating cancer blocking" Only relapsed DLBCL patients 1st line induction treatment 6~8 cycles RCHOP-like chemo enrolled receive 3 cycles RICE salvage therapy . SyB L-0501RI administered intravenous rapid infusion combination combination rituximab . Safety investigated previously untreated patients low-grade B-cell non-Hodgkin's lymphoma (Lg-B-N Provide compassionate use odronextamab . " This study medicine called TAK-981 given rituximab, used treat adults relapsed refractory CD20-positive non-Hodgkin lymphoma ." Epcoritamab combination anti-neoplastic agents are explored . The purpose study assess safety tolerability . Adverse events change disease activity assessed . The purpose study determine efficacy Vismodegib drug treatment patients relapsed refractory B-cell lymphoma chronic lymphocytic leukemia (CLL) The purpose study determine efficacy Vismodegib drug treatment patients relapsed Vorinostat may stop growth cancer cells blocking enzymes needed to grow . This partially randomized phase I/II trial studies side effects . " The purpose study determine maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), safety tolerability . Participants relapsed/refractory (R/R) mature B-cell malignancies; combination zan" " Phase 1/2, open-label, multicenter, multicenter study conducted patients previously treated selected solid tumors . Patients receive escalating doses GSPT1 molecular glue degrader MRT-2359 ." Adult patients treated with third-generation RV-SFG.CD28.4-1BBzeta retroviral vector . Adult patients treated with CAR T cell doses (1-20×20^7) treated with RV- " The purpose study evaluate safety, pharmacokinetics, immunogenicity, efficacy zilovertamab vedotin given intravenously (IV) Participants previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute my" This study determine recommended dose birabresib (MK-8628) studies participants acute myeloid leukemia (AML) including AML de novo AML secondary myelodysplastic syndrome (MDS) participants " This study evaluate safety, efficacy, pharmacokinetics of mosunetuzumab combination tiragolumab, without atezolizumab, without atezolizumab . Participants relapsed refractory (" " This multi-center, open-label trial evaluate oral administration emavusertib (CA-4948) adult patients relapsed/refractory hematologic malignancies . Part A evaluate escalating doses emavusert" AUY922 designed block tumor growth blocking protein . AUY922 designed block tumor growth blocking protein . AUY922 designed block tumor growth blocking protein . Rituximab intensive induction (MegaCHOP/ESHAP) high-dose consolidation (BEAM) improves progression-free overall survival patients younger 65 years aggressive B-cell lymphoma aaIPI 2 3. The The names of the study interventions involved study are: Cyclophosphamide|Alemtuzumab . The names of the study interventions involved study are: .Cyclophosphamide|Alemtuzumab " This study evaluate safety, pharmacokinetics, preliminary efficacy of mosunetuzumab combination cyclophosphamide, doxorubicin, vincristine, prednisone (M-CHOP) and pol" " This open-label, multicenter, phase II study evaluate safety efficacy single-agent AT-101 patients relapsed refractory B-cell malignancies ." " This Phase 1, open-label study will assess safety tolerability, identify maximum tolerated dose (MTD) and identify maximum tolerated dose (MTD) Part 2 . Part 1 (Dose Escalation) Part 2 (D" " EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) Post-transplant Lymphoproliferative Disease (PTLD) failing first line treatment . EBV positive" CAT-8015 participants relapsed refractory advanced B-cell NHL (diffuse large B-cell lymphoma [DLBCL] and follicular lymphoma [FL] CLL) CLL . The primary objectives study " 12 total patients enrolled in the pembrolizumab CTL019 trial . Patients CD19+ diffuse large B-cell, follicular, mantle cell lymphomas relapsed/refractory CTL019 . Safety pemb" Patients eligible study receive R-DA-EDOCH induction therapy evaluated PET CT fourth cycle . Patients achieve CR interim-PET(Deauville score 1-3) receive either ASCT remaining 4 cycles R-DA-EDO This study assess efficacy safety of mosunetuzumab combination polatuzumab vedotin (M+P) participants relapsed refractory (R/R) diffuse-large B-cell lymphoma (DL " The common types mature B-cell lymphomas (MBLs) children Burkitt lymphoma (BL) diffuse large B-cell lymphoma (DLBCL) Initial treatment cures 90% - 95% children malignancies," This study designed explore safety tolerability RD14-01 patients relapsed and/or refractory B-cell non-Hodgkin lymphoma . And evaluate efficacy pharmacokinetics RD14-01 patients . " MabThera® TL011, combination CHOP patients diffuse large B cell lymphoma, was developed in the hope of improving the effectiveness of MabThera's drug . The study is a prospective international, multi-center," A phase II study evaluate combination Lenalidomide Rituximab front line therapy treatment elderly frail patients evaluated CGA Diffuse Large B-cells non-Hodgkin Lymphoma . A phase II study evaluate combination " Long-term follow-up study evaluate safety efficacy patients ever received lentiviral-based gene-edited immune cells . According health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) gene therapy clinical" " Lenalidomide antineoplastic pro-apoptotic effect also immunomodulatory, antiangiogenic properties . Lenalidomide antineoplastic pro-apoptotic effect also immunomodulatory, anti" This study determine first appropriate dose lenalidomide administer combination fixed doses obinutuzumab . The study aims determine efficacy combination 3 separate populations: relapsed/refractory aggressive lymphoma (diffuse large B-cell This innovative project allows study first time long-term living conditions patients diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) population data France . Patients selected three specialized hematology registries France: Rituximab proposed to be used against radiotherapy diffuse large B-cell lymphoma bulky disease . We assess efficacy of Rituximab in patients treated R-CHOP . " JWCAR029 adult R/R Non-Hodgkins Lymphoma subjects China . Phase II, open-label, single-arm, multicenter study asess efficacy safety ." " Diffuse large B-cell lymphomas (DLBCL) highly aggressive heterogeneous B-cell lymphoma would imminently fatal without treatment . Monoclonal anti-CD20 antibody, rituximab, combination" " STI-3031, anti-PD-L1 antibody, anti-PD-L1 antibody, was used in patients with advanced lymphomas biliary tract cancer . This study evaluates efficacy, measured objective response rate, STI" Monoclonal antibodies epratuzumab locate tumor cells either kill deliver tumor-killing substances without harming normal cells . Randomized phase II trial study effectiveness epratuzumab treating patients non-Hodgkin " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cancer-killing substances ." " The study aims assess whether low levels testosterone blood patients cured aggressive lymphoma, effectively treated Testosterone gel, treatment testosterone improve general quality life . The investigators hypothesize patients develop sexual dysfunction poor quality life suffering untreated reduced level testosterone ." " This Phase 1, non-randomized, open-label, dose-escalation expansion study, evaluating safety, tolerability, pharmacokinetics (PK), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical antit" Waldenstrom macroglobulinemia rare complication may occur Waldenstrom macroglobulinemia . Histological transformation diffuse large B-cell lymphoma rare complication may occur Waldenstrom macroglobul " This open-label, multicenter, phase 2 clinical trial evaluate efficacy safety brentuximab vedotin single agent patients CD30-positive non-Hodgkin lymphoma (NHL) The study also evaluate safety" " Polatuzumab vedotin monoclonal antibody works binding cancer cells binding cancer cells releasing another chemotherapy drug, called monomethyl auristatin E, causing cancer cells to die stop growing ." HDMTX plus Temozolomide is designed to be a tolerated treatment for PCNSL patients . PCNSL patients are still defined . The purpose phase 2 study evaluate efficacy safety NIR178 combination PDR001 multiple solid tumors diffuse large B-cell lymphoma (DLBCL) The purpose phase 2 study evaluate efficacy safety NIR178 combination PDR001 multiple solid " This study two parts distinct study objectives study design . In part A, odronextamab studied intravenous (IV) administration dose escalation dose expansion phase B-NHL CLL . In part B, odronext" Decitabine cytosine cytosine analogue specific DNA methyltransferase (DNMT) inhibitor . It directly inhibits DNMT phosphorylating DNA inhibits DNMT phosphorylating DNA inhibits DNMT . It reverses The goal clinical trial learn combination tazemetostat venetoclax people relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL) The main questions trial aims answer best dose venet " This study open-label, multicenter, phase 1, dose escalation study TAK-659 adult participants advanced solid tumor lymphoma malignancies . This study first administer TAK-659 humans ." " NT-I7 (efineptakinakin alfa), long-acting human IL-7, long-acting human IL-7, post-Tisagenlecleucel (Kymriah®) subjects rel" " Hepatitis C virus seropositivity increased risk developing marginal zone B-cell lymphoma (MZ), lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL), diffuse large B-cell lymph" " This open-label, single-arm study evaluated safety rituximab subcutaneously (SC) administered first line treatment follicular non-Hodgkin's lymphoma (NHL) and diffuse large B-cell" Tislelizumab maintenance therapy . Tislelizumab maintenance therapy . newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients . autologous hematopoietic stem cell transplantation Tislelizumab maintenance therapy . Tislelizumab maintenance therapy . newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients . autologous hematopoietic stem cell transplantation " The purpose study determine efficacy rituximab, gemcitabine, oxaliplatin dexametasone (R-GemOx) chemotherapy schedule ." Primary Central Nervous System Lymphoma (PCNSL) mainly diffuse large B-cell lymphoma activated B cells (ABC) type . Investigators hypothesize synergy lenalidomide rituximab shown systemic non- " R-CHOP treatment non-Hodgkin lymphoma (NHL) is a new treatment for non-Hodgkin lymphoma . In pilot study, observational data collected describe usual trajectory changes dietary intake, ability physically" Acalabrutinib small molecular inhibitor may interfere ability cancer cells grow spread . This phase Ib/II trial studies side effects efficacy maintenance acalabrutinib following cellular therapy . This observational study aims assess therapeutic responsiveness MabThera SC patients malignant lymphomas everyday clinical practice conditions . Patients previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) previously untreated CD This phase I trial studies side effects CD19/CD22 chimeric antigen receptor (CAR) T cells given together chemotherapy NKTR-255 . " Patients receive 6 8 cycles R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), GM-CSF ." Rituximab-CHOP (R-CHOP) dismal compared patients without myelocytomatosis (MYC) B cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 ( Interim PET/CT scans emerged powerful prognostic tool predicting treatment outcome Hodgkin's lymphoma (HL) diffuse large B cell lymphoma (DLBCL) and peripheral T cell lymphoma (PTCL) Interim PET " The goal clinical research study find highest tolerable dose belinostat given combination azacitidine, gemcitabine, busulfan, melphalan patients scheduled stem cell transplant. If diffuse large B-cell lymphoma" " This study is a multicenter, non randomized, single arm, open clinical trial . The selected disease relapsed / refractory NHL, disease classified highly aggressive lymphoma, invasive lymphoma inert lymphoma inert lymphoma, etc ." The purpose study obtain safety efficacy data using Bexxar patients relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL) The purpose study obtain safety efficacy data using Bexxar " Pixantrone rituximab, ifosfamide etoposide measured overall metabolic response rate 2 cycles treatment . 2 cycles treatment treatment permanent treatment discontinuation ." " The purpose study determine whether Nivolumab, combination brentuximab vedotin, safe effective patients certain subtypes non-Hodgkin's lymphomas CD30 expression responded treatment come back ." PET scan obtained 3 cycles standard chemotherapy regimen help guide treatment patients blood disease called Non-Hodgkin's Lymphoma . This research done see see PET scan obtained 3 cycles standard chemotherapy regimen help guide treatment patients blood disease called Non " Diffuse Large B-cell Lymphoma (DLBCL) frequent high grade lymphoma adults . Although immunotherapy improved prognosis, immunotherapy improved prognosis . 5-year overall survival ranging from 55 94% to 55 94" " Non hodgkin lymphoma lymphoma-derived malignancy makes 90% malignant lymphoma . The common types follicular lymphoma, diffuse large B-cell lymphoma ." Secondary central nervous system lymphoma (SCNSL) occurred 5% patients diffuse large B-cell lymphoma (DLBCL) The prognosis SCNSL poor. Median overall survival (mOS) since diagnosis CNSL 2 " EPOCH: Etoposide, VP-16, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC" " First-in-human study evaluate recommended dose clinical development, safety, tolerability, antineoplastic activity, immunogenicity, immunogenicity, pharmacokinetics pharmacodynamics . IKS03, CD19 targeting antibody-drug" " 110 patients were receiving outpatient chemotherapy treatment-related toxicities, patient-reported outcomes, healthcare utilization, healthcare utilization, inflammatory epigenetic markers . 110 patients were receiving outpatient chemotherapy treatment-related toxicities, patient-reported outcomes, healthcare utilization" PXD101 may stop growth cancer cells blocking enzymes needed to stop growth cancer cells blocking enzymes needed to grow . PXD101 is being tested in a phase II trial treating patients with aggressive B-cell non-Hodg " Central nervous system lymphoma (PCNSL) diffuse large B cell lymphoma (DLBCL) entity particularly poor prognosis (median survival less 3 years) They still poorly characterized biologically, largely rarity (300 cases / year" " Study evaluation post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion persistence patients DLBCL, PMBCL ALL undergoing CAR-T therapy ." Short-term calorie control seems safe potential increase cancer cell's sensitivity chemotherapy . More human trials needed translating intervention clinical practice . " Follicular lymphoma (FL) mantle cell lymphoma (MCL) rare lymphomas consist less 5% non-Hodgkin lymphoma Korea . FL histologic grade 1 2 relatively good prognosis, continual treatment needed" " ABBV-525 monotherapy is an investigational drug developed for B-Cell Malignancies . B-cell malignancies group cancers B lymphocytes, type white blood cell responsible fighting infections ." " This study involved patients cancer called diffuse large B cell lymphoma (DLBCL), NK T cell lymphomas (NK/TL) classical Hodgkin lymphoma (cHL) and classical Hodgkin lymphoma (cHL) Patients" " This study involved patients cancer called diffuse large B cell lymphoma (DLBCL), NK T cell lymphomas (NK/TL) classical Hodgkin lymphoma (cHL) and classical Hodgkin lymphoma (cHL) Patients" Primary central nervous system (CNS) lymphomas represent 5% primary brain tumors . Primary central nervous system (CNS) lymphomas represent 5% primary brain tumors . Positron Emission Tomography (PET/CT) is a new technology available for chemotherapy . The evaluation response treatment made Positron Emission Tomography (PET/CT) available . Presently PET scans CT scans performed treatment " This multicenter,open-label trial evaluate activity safety of intensive HIV+ patients Burkitt's lymphoma ." " Hepatic complication chemotherapy focused on hepatitis B virus (HBV) With adequate prophylaxis monitor, HBV-related hepatitis flares prevented . In contrast, cancer patients hepatitis C virus (HCV) infection traditionally considered relative safe receive" " KPG-818 combination dexamethasone adult subjects multiple myeloma (MM) subjects . KPG-818 monotherapy subjects selected hematological malignancies . This Phase 1, multicenter, open-" The main aim see adult participants newly diagnosed relapsed/refractory CD30+ lymphoma responded previous treatment China . The main aim see adult participants newly diagnosed relapsed/refractory CD30+ lymphoma responded previous treatment China This study evaluate safety efficacy favezelimab (MK-4280) combination pembrolizumab (MK-3475) using non-randomized study design participants following hematological malignancies . The recommended Phase I multi-center study evaluate safety FT596 given rituximab relapse prevention patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) diffuse large high-grade B cell lymphoma The prognosis of relapsed refractory lymphoblastic leukaemia (ALL) diffuse large B-cell lymphoma (DLBCL) poor conventional treatment complete response rates around 25-30% median progression-free survival ( " In malignant lesions, extravascular extracellular space (EES) diminished, due increased number cells . This restrict water diffusion, identified increased signal intensity (SI) native DWI ." The study was conducted in two Phase 2 trials . The primary objective was to characterize safety tolerability isatuximab combination cemiplimab . The primary objective was to assess complete remission (CR) rate isatuxim The purpose study determine safety establish recommended phase 2 dose (RP2D) combination ibrutinib nivolumab . Participants were chronic lymphocytic leukemia (CLL/SLL) and follicular cell lymphoma " This Phase 0/1 open-label, non-randomized, pharmacodynamic study patients advanced B-cell lymphoid malignancies . Patients advanced stage disease whose disease resistant refrara were patients with disease resistant refra ." Lymphomas classified Hodgkin's non-Hodgkin's lymphomas . Lymphomas classified Hodgkin's non-Hodgkin's lymphomas . Lymphomas classified Hodgkin's non-Hodgkin " TNFRSF8 (CD30-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, CD30- expressing lymphomas needed . TNFRSF8 (CD30)-expressing" " The goal study evaluate new approach immunotherapy NHL combining two antibodies, veltuzumab epratuzumab and epratuzumab . For treatment, epratuzumab also attached radioactive isotope called" " BZ019 relapsed refractory CD19+ B-cell Lymphoma. This open-label, multicenter, dose-escalation phase 1 study determine safety efficacy ." Primary central nervous system lymphoma (PCNSL) rare extranodal non-hodgkin's lymphoma confined central nervous system . PCNSL accounts 4% intracranial tumors 4% 6% non-H " Brentuximab vedotin antibody-drug conjugate targeting CD30, one surface antigens expressed lymphoma cells . The study mainly included Hodgkin lymphoma (n = 38) anaplastic large cell lymphoma" " The purpose study describe safety, tolerability early signs efficacy antibody-cytokine fusion protein IL12-L19L19L19 patients advanced metastatic solid carcinomas diffuse large B-cell lymphoma (DLBCL)" " Two-arm, open-label, phase Ib single-site study expansion cohorts testing addition mosunetuzumab intensive platinum-based salvage chemotherapy patients relapsed/refractory aggressive B cell lymphoma . Patients intending pursue consolid" " The purpose study assess whether patients likely fail R-CHOP, predicted mid-treatment PET scan, improved outcome switched standard salvage regimen R-ICE (rituximab, ifosfamide, carboplatin, etopos" " Genomics-based technology, DNA microarrays, precisely diagnose subsets lymphoma, leukemia multiple myeloma patients . There many attempts to classify lymphoid cancers ways useful clinical diagnosis treatment ." " This study designed monitor patients exposed CD19 CAR-T expressing IL7 CCL19 5 years following infusion . Assess long-term efficacy, including CAR- vector persistence, CAR- vector persistence, normal immunity rebuilding risk delayed adverse events" Tazemetostat taken orally BID continuously 28-day cycles study parts . Tazemetostat taken orally BID continuously 28-day cycles study parts . Researchers want see combination drugs help patients aggressive indolent B-cell lymphomas . " Blinatumomab (BLINCYTO) bi-specific T-cell engaging (BiTE®) antibody construct transiently links CD3-positive T cells CD19-positive B-cells, inducing T-cell activation" " Researchers want learn certain drugs work together treat B-cell lymphomas . The drugs venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide (ViPOR) are" " Subjects were treated with KTE-X19, KTE-X19, KTE-X19, KTE-X19, KTE-X19, KTE-X19, KTE-X19, K" " Lenalidomide may stimulate immune system different ways stop cancer cells growing . Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill" The primary objective study evaluate efficacy brexucabtagene autoleucel . The primary objective is to evaluate efficacy brexucabtagene autoleucel . The primary objective is to evaluate efficacy brexucabtag Monoclonal antibodies locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining chemotherapy peripheral stem cell transplant may allow doctor give higher doses " National Cancer Institute developed experimental therapy treating patients B cell lymphomas leukemias . Therapy involves taking white blood cells patient, growing laboratory large numbers, genetically modifying specific cells type virus (retrovirus) attack tumor cells . This type" Epacadostat administered nivolumab chemotherapy subjects squamous cell carcinoma head neck (SCCHN) non-small cell lung cancer (NSCLC) Phase 1 consists 2 parts. Part 1 dose-escal " Phase I clinical study multicenter, single-arm, open, non-randomized evaluation . Includes recombinant humanized anti-CD52 monoclonal antibody NHL T-PLL ." " ""CAR-T"" immunotherapy is based on T cells expressing chemical receptor specific antigen . This therapy absolutely improves outcomes of patients with non-Hodgkin's lymphoma ." This pilot study evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) patients relapsed refractory CD19+ leukemia lymphoma previously treated cell therapy . This study targeting pediatric patients aged 1 BI 894999 tested first time humans . Participants take tablets daily . Non-Hodgkin lymphomas blood cancers difficult treat . Examples include diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) More effective treatments needed diseases . " Ascorbic acid may make cancer cells sensitive chemotherapy . Drugs used chemotherapy, work different ways stop growth cancer cells ." Positron emission tomography (PET) scans may improve ability measure well cancer responded treatment . Positron emission tomography scans may improve ability measure well cancer responded treatment . Richter's syndrome (RS) life-threatening complication chronic lymphocytic leukemia (CLL) occurs 2-10% CLL patients . RS occurs 2-10% CLL patients incidence rate 0.5% per year . " AZD8186 orally-dosed, selective Phosphatidylinositol 3-kinase (PI3K)β/δ inhibitor binds PI3Kβ PI3Kδ, inhibits kinase activity" " To safely reduce burden therapy children, adolescents young adults mature B-NHL reducing number intrathecal (IT) injections introduction IT Liposomal Cytarabine (L-ARA-C, [Depocyt®) reducing" " BEAM regimen consists four chemotherapy drugs together (BCNU, etoposide, cyclophosphamide, melphalan) consists four chemotherapy drugs together (BCNU, etoposide, cyclophosphamide," " This study multicenter phase II trial primary objective assess anti-lymphoma activity atezolizumab associated BCL-2 inhibitor (GDC-199, venetoclax) anti-CD20 monoclonal" B-cell lymphoma treated with loncastuximab tesirine treatment real-world practice . " This study multi-center, open, single-arm phase I/II clinical study evaluate recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection . HX009 injection Chinese patients rel" " Monoclonal antibodies, rituximab, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cancer-killing substances ." " RO6870810 small molecule, non-covalent inhibitor bromodomain extra-terminal (BET) family bromodomains . Phase 1, non-randomized, dose-escalating, open" Cancer related fatigue (CRF) common cancer side effect severely interfere activities daily living long completion medical treatment . This study investigates novel low-cost/ low-burden intervention: systematic light exposure treat CRF . " BR101801 subjects are relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL/small lymphocytic leukemia (SLL) and peripheral T cell lymphoma (PTCL) BR101" FR901228 may stop growth cancer cells blocking enzymes needed to grow blocking blood flow cancer . Phase II trial studying well FR901228 works treating patients relapsed refractory non-Hodgkin's lymphoma . Phase IIa study estimate efficacy single infusion autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR 4-1BB . The duration active protocol intervention approximately 24 months screening visit . Study looking blood tissue samples patients aggressive non-Hodgkin B-cell lymphoma Hodgkin lymphoma . Study may help doctors learn changes occur DNA identify biomarkers related cancer . " Targeted drug therapies greatly improved outcomes patients relapsed refractory (R/R) chronic lymphocytic leukemia (CLL) non-Hodgkin's lymphoma . Single drug therapies limitations, therefore, current study evaluating" Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . It yet known whether combination chemotherapy effective without rituximab treating patients non-Hodgkin's Phase I trial studies highest possible dose memory enriched T cells given following standard stem cell transplant . Memory enriched T cells made patient's T cells genetically modified laboratory . " Non-Hodgkin's lymphoma (NHL) is sixth commonly diagnosed cancer in France . At present, sixth commonly diagnosed cancer France, 10 000 estimated new cases 5200 deaths annually ." The aim trial evaluate molecular characteristics MDD/MRD B-NHL pediatric patients . The aim trial evaluate molecular characteristics MDD/MRD B-NHL pediatric patients order identify one hand high risk group prescribe intensive treatment . One " Daratumumab monoclonal antibody specifically targets CD38 expressing cells, may help body's immune system attack cancer . Daratumumab monoclonal antibody specifically targets CD38 expressing cells, may help body's immune system" " AMG 655 combination bortezomib vorinostat is a multi-center, phase 1b study . Subjects enrolled one two arms based investigator selection . Subjects enrolled one two arms based investigator selection (either bortez" Phase 1 platform protocol designed evaluate various targeted agents treatment relapsed/refractory aggressive aggressive Non-Hodgkin's Lymphoma (NHL) NHL is a form of formulinary therapy that has relapsed/ref SB1518 given alone daily mouth subjects advanced lymphoid malignancies . SB1518 given alone daily mouth subjects advanced lymphoid malignancies . " CPI-0209 small molecule inhibitor EZH2. First-in-human, open-label, sequential dose escalation expansion study . CPI-0209 small molecule inhibitor EZH2. First-in-human, open" " The goal study determine safety clinical effect combined checkpoint inhibition administered autologous hematopoietic stem cell transplantation six clinical cohorts high risk recurrent disease . Investigators also analyze gut microbiome prior conditioning, throughout treatment, post treatment, post" Liposomal vincristine is being tested for patients with non-Hodgkin's lymphoma . The drug is being tested for its effectiveness in treating patients with refractory relapsed non-Hodgkin's " Monoclonal antibodies, rituximab, block cancer cell growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cell-killing substances ." " This study separated 3 distinct phases designated Phase 1 study, Phase 2 pivotal study, Phase 2 safety management study and Phase 2 safety management study . The primary objectives study are to evaluate safety axicabtagene ciloleucel reg" " KT-413 is being tested for safety, tolerability pharmacokinetics/ pharmacodynamics (PK/ PD) KT-413 patients R/R NHL. The Phase 1a stage study explore escalating doses single-agent KT-413." Phase I trial studies side effects of olaparib given together high-dose chemotherapy . The purpose study determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) TAK-659 venetoclax administered combination participants non-Hodgkin lymphoma (NHL) rel NKTR-255 is a combination chimeric antigen (CAR)-T cell therapy . NKTR-255 is a combination chimeric antigen (CAR)-T cell therapy . T cells infection fighting blood cells kill tumor cells . " The study was conducted by Lugano classification (Cheson, 2014) malignant lymphoma assessed independent central review . The primary objective was to evaluate objective response rate (ORR) of adult patients relapsed/refract" " This study designed Phase III, multicenter trial compared standard Rituxan plus BEAM transplant regimen with regimen adding Bexxar BEAM ." " ZN-d5 is being tested for safety, tolerability, clinical activity, clinical activity, pharmacokinetics (PK) pharmacodynamics (PD) ZN-d5 subjects Non-Hodgkin Lymphoma (" Phase II trial studies side effects of CAR-T cell treatment called axicabtagene ciloleucel . Patients large B-cell lymphoma come back (relapsed) responded treatment (refractory) Anakinra " This multicenter study long-term follow-up surviving patients expected complete completed completed two years follow-up treatment Iodine I 131 Tositumomab (BEXXAR) studies CP-97-011, CP-" " This multicenter, open-label, dose-escalation study evaluate safety, tolerability, pharmacokinetics, anti-tumor activity . Participants receive escalating doses of polatuzumab vedotin intravenously (IV" Medical oncology studies tend demonstrate benefit quality life early collaboration two specialties . " The purpose study was to determine well SNS01-T tolerated relapsed refractory multiple myeloma, B cell lymphoma plasma cell leukemia patients . Patients were given intravenous infusion various doses ." " New drug called ixazomib (also called MLN9708), given along common treatment combination, called Dose-Adjusted EPOCH-R . This type study called phase I/II trial . In phase I" This prospective observational study aims evaluate robustness persistence immune responses vaccination . It also defines factors associated impaired immune responses . " Single-center, open-label pragmatic clinical trial evaluate primary efficacy safety anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19) concurrent BTK inhibitor patients relapsed refractory B cell" B-cell non-Hodgkin lymphoma patients receive lenalidomide single drug lenalidomide combined rituximab (with without drugs) real-world setting . Describe treatment B-cell non- Phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) durvalumab safe combination work together treating patients non Oblimersen given together rituximab combination chemotherapy see well work treating patients relapsed refractory aggressive non-Hodgkin's lymphoma . Monoclonal antibodies rituximab locate cancer cells either The purpose research study determine safety tolerability TL-895 . Part 1 tested increasing doses TL-895 identify recommended safe dose . Part 2 study randomized (like flip coin) receive specific treatment dose . " Rituximab, Zanubrutinib, Lenalidomide combination will evaluate efficacy toxicity . Patients primary secondary CNS lymphoma, intend conduct prospective clinical study evaluate efficacy toxicity ." Patients relapsed refractory DLBCL MCL non-Hodgkin's lymphoma (NHL) Patients treated peptide receptor radionuclide therapy 90Y-Dotatoc . " This multiple center, non-randomized, open-label, phase 1/2 study . The primary objective Phase 1 evaluate safety PL001 find recommended Phase 2 dose (RP2D) The objective Phase 2 evaluate safety efficacy CD19" To establish population pharmacokinetic pharmacodynamic model rituximab children hemopathy. To optimize administration rituximab treatment children based pharmacokinetic model. To optimize administration rituximab treatment children based pharmacokin Flow cytometry sensitivity detecting neoplastic cells cerebrospinal fluid versus conventional cytology . The purpose study defines flow cytometry sensitivity detecting neoplastic cells cerebrospinal fluid versus conventional cytology . The purpose study see cancer treatment affects sexual reproductive function . The patient also asked participate blood draws see cancer treatment affects ovaries ability children (fertility) Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . It yet known whether combination chemotherapy effective without rituximab non-Hodgkin's lymphoma This research done assess effectiveness safety acalabrutinib combined lisocabtagene maraleucel (liso-cel) people relapsed/refractory aggressive B-cell lymphoma . Drugs used chemotherapy work different ways to stop growth tumor cells . Some block ability tumor cells grow spread . Others block ability tumor cells help kill carry tumor-killing substances . Peripheral stem cell transplant may able replace immune cells destroyed chemotherapy . Non-Hodgkin lymphoma (NHL) is one top ten high-incidence tumors world among ten prevalent cancers worldwide fastest growing incidence . VELCADE CHOP-R patients previously untreated diffuse large B cell mantle cell non-Hodgkin's lymphoma (NHL) were previously untreated . VELCADE CHOP-R patients previously untreated diffuse large Decitabine and valproic acid work different ways to stop growth cancer cells . Valproic acid may stop growth cancer cells blocking enzymes needed to grow . Decitabine and valproic acid may effective treatment non- JCAR017 works treating patients non-Hodgkin's lymphoma whose disease come back responded treatment . JCAR017 works treating patients non-Hodgkin's lymphoma whose disease come back responded treatment . B-cell non-Hodgkin's lymphoma (B-NHL) common type NHL . Although novel immunotherapies represented anti-CD20 monoclonal antibodies CAR-T cell therapies significantly improved prognosis Patients candidates evaluated HTLV III activity drug levels . Patients candidates evaluated HTLV III activity drug levels . Phase II trial studies well anakinra works preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome . chimeric antigen receptor T-cell-related encephalopathy syndrome chimeric antigen receptor T-cell therapy patients The purpose research replace one participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy . The purpose research replace one participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy . The telemed " Polatuzumab vedotin monoclonal antibody, polatuzumab, linked toxic agent called vedotin . Polatuzumab attaches CD79B positive cancer cells targeted way delivers vedotin kill" ENTO VCR participants relapsed refractory B-cell NHL . The primary objective study evaluate safety ENTO VCR participants relapsed refractory B-cell NHL . " This phase II study FDA-approved CAR-T products patients hematologic malignancies . Patients assigned Arm A B based age diagnosis. Overall remission rate, safety events endpoints calculated Arm A B separately ." Researchers hope new combination drugs may able help . Most drugs used treat cross blood-brain barrier . This makes hard treat hard treat . " Venetoclax may stop growth cancer cells blocking protein called Bcl-2 . Drugs used usual chemotherapy, rituximab, cyclophosphamide, doxorubicin, vincristine, prednis" Apolizumab rituximab (Rituxan) (Rituxan) (Rituxan) (Aolizumab) (Rituxan) (Rituxan) " This phase I/II, open-label, dose-escalation study designed evaluate safety, tolerability, efficacy . RO7227166 participants relapsed/refractory Non-Hodgkin's Lymphoma (r" PXD-101 (belinostat) combination radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) patients relapsed aggressive (high-risk) non-Hodg " Primary Central Nervous System Lymphoma (PCNSL) specific mutational profile comparison systemic diffuse large cells lymphoma (DLBCL) related expression immunohistochemical markers cyclon, NPM1, CD30," " This multi-center, phase I/II study determine efficacy safety of CRC01 adult patients . CRC01 adult patients relapsed refractory large B-cell lymphoma." CCI-779 is a new drug that works to stop cancer cells dividing stop growing and die . The drug is being tested in a phase II trial treating patients with relapsed refractory chronic lymphocytic leukemia . Phase II trial studies well nivolumab without varlilumab works treating patients aggressive B-cell lymphomas come back (recurrent) respond treatment (refractory) Sorafenib may stop growth cancer cells blocking blood flow . Sorafenib may stop growth cancer cells blocking blood flow . blocking enzymes needed cell growth . CHOP dose escalation is a study hypothesis intensification CHOP dose escalation . The planned dose 3000 mg/m2 4 times atandard one was only 4 cycles given . This study characterizes cardiac events following standard care chimeric antigen receptor T cell therapy patients aggressive B-Cell Lymphoma come back (relapsed) respond treatment (refractory) The purpose study evaluate anti-tumor activity alisertib (MLN8237) participants relapsed refractory non-hodgkin's lymphoma . Participants relapsed refractory non-hodgkin's Phase II trial study effectiveness of combination chemotherapy treating older patients non-Hodgkin's lymphoma . Combining one drug may kill tumor cells . The research study conducted test safety effectiveness experimental drug mosunetuzumab (Cohort 1) obinutuzumab glofitamab glofitamab (Cohort 1) given CAR (gen IMT-009 administered intravenous (IV) route participants . Participants were given intravenous (IV) route participants . The main goals study to: Find recommended dose IMT-009 safely given participants . The purpose study evaluate efficacy inotuzumab ozogamicin plus rituximab relapsed/refractory aggressive Non-Hodgkin lymphoma patients candidates intensive high-dose chemotherapy . This study multicenter phase II trial includes 2 cohorts patients who have at least 1 month CAR T-cells therapy . Patients enrolled receive pre-phase obinutuzumab followed experimental treatment:11 cycle glofitamab . Unity NHL - A Phase 2b Randomized Study Assess Efficacy Safety Combination Ublituximab + Umbralisib without Bendamustine Umbralisib alone . Patients Previously Treated Non-H Clinical trial evaluates influenza virus vaccination evaluating human immune response patients lymphoma . Evaluating immune response may increase understanding immune system changes patients receive treatment lymphomas . " Phase II trial studies effect zanubrutinib CAR T-cell therapy treating patients aggressive B-cell non-Hodgkin's lymphoma . Patients given new gene put makes able recognize CAR, protein surface cancer cells" " Multimenter, phase IV study will evaluate feasibility efficacy performing treatment adapted PET-CT patients stage I II DLBCL ." This phase I trial studies side effects huJCAR014 treating patients relapsed refractory B-cell non-Hodgkin lymphoma acute lymphoblastic leukemia . " Axicabtagene clioleucel (a CAR-T therapy) is a CAR-T therapy . It is a CAR-T therapy that aims to find effect, any, treating patients HIV-associated aggressive B-" Clinical trial studies blood sample markers reproductive hormones assessing ovarian reserve younger patients newly diagnosed lymphomas . Studying samples blood patients cancer laboratory may help measure effect curative therapy lymphoma ovarian failure . BN301 given intravenously every 3 weeks . BN301 given intravenously every 3 weeks . BN301 given intravenously every 3 weeks . Venetoclax and obinutuzumab given together obinutuzumab given together . B-cell non-Hodgkin lymphoma patients returned period improvement responding treatment . CAR-T subjects relapsed refractory CD30+ Non-Hodgkin Lymphoma are being tested for safety dose-limiting toxicity . CAR-T subjects relapsed refractory CD30+ Non-H Carfilzomib used combination with belinostat to treat relapsed refractory non-Hodgkin lymphoma (NHL) Participants relapsed refractory non-Hodgkin lymphoma (N The purpose study determine safety effectiveness using Iodine-131 Anti-B1 Antibody treatment patients large B-cell non-Hodgkin's lymphoma (NHL) Patients large B-cell non-Hod Rituximab is a hypothesized candidate candidate post-transplant therapy . Rituximab is a hypothesized candidate candidate post-transplant therapy . " R-DHAP consists monoclonal antibody called Rituximab chemotherapy consisting Dexamethasone, high dose Cytarabine, often called Ara-C, platinum based chemotherapy, either cisplatinum, or" " The combination mitoxantrone clofarabine reinduction therapy is safe, well tolerated effective children, adolescents young adults poor risk refractory/relapsed acute leukemia high grade non-Hodgkin lymphoma (" The goal Part 1 clinical research study find highest tolerable dose carfilzomib given combination lenalidomide rituximab patients relapsed refractory B-cell non-hodgkin lymphoma . The goal The purpose signal seeking study determine whether treatment PDR001 LAG525 demonstrates sufficient efficacy . The purpose signal seeking study determine whether treatment PDR001 LAG525 demonstrates sufficient efficacy . Pomalidomide given together dexamethasone given together dexamethasone . This phase I trial studies side effects best dose pomalidomide given together dexamethasone . This open-label Phase 1b/2 study patients chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or non hodgkin's lymphoma (NHL) failed prior standard care Randomized phase II/III trial compares effectiveness of combination chemotherapy without etoposide treating older patients non-Hodgkin's lymphoma previously treated . The main aim study improve methods clinical testing therapy lymphoma participants . The main aim study improve methods clinical testing therapy lymphoma participants . Duvelisib may stop growth tumor cells blocking enzymes needed cell growth . Duvelisib may stop growth tumor cells blocking enzymes needed cell growth . This phase I trial studies side effects best dose lenalidomide ibrutinib treating patients B-cell non-Hodgkin lymphoma returned (relapsed) responded treatment (refractory) Lenalidomide This phase I/II trial studies side effects best dose chimeric antigen receptor (CAR) This phase I/II trial studies side effects best dose chimeric antigen receptor (CAR) Phase I trial studies side effects best dose CD19/CD20 chimeric antigen receptor (CAR) T-cells given together chemotherapy . " This phase II trial studies side effects of cord blood-derived expanded allogeneic natural killer cells (umbilical cord blood natural killer cells) rituximab, high-dose chemotherapy, stem cell transplant treating patients B-" CAR-T therapy may offered people cancer comes back . CAR-T therapy may offered people cancer comes back . Researchers want collect cells people may become eligible CAR T-cell study future . " This study aims evaluate safety, tolerability, pharmacodynamic, pharmacodynamic, pharmacokinetic (PK) nemtabrutinib (formerly ARQ 531) tablets . Participants relapsed refractory hematologic malign" " Tazemetostat belinostat may stop growth tumor cells blocking enzymes needed to stop cell growth . This phase I trial tests safety, side effects, best dose tazemetostat belinostat treating patients lymphomas" Acalabrutinib axicabtagene ciloleucel is being tested for safety in a phase I/II trial . Acalabrutinib may stop growth tumor cells blocking key pathways needed cell " Research find best dose genetically modified T-cells, study safety treatment, see well works treating patients B cell non-Hodgkin lymphoma come back (relapsed) respond previous treatment (refractory)" This phase I trial studies safety side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells . CAR T-cells were given to patients high grade B-cell Brief summary: Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary. Brief summary " GemOxD routine treatment certain types lymphoma involves administration three drugs: gemcitabine, oxaliplatin, dexamethasone . Researchers want to find maximum tolerated dose of romidepsin ." " STRO-001 given intravenously every 3 weeks every 3 weeks . STRO-001 given intravenously every 3 weeks . First-in-human Phase 1 trial study safety, pharmacokinetics preliminary efficacy ." " Mosunetuzumab antibody engineered attach two target cells immune system: T cells normally perform tasks like killing virus-infected cells, cancerous B cells . Mosunetuzumab designed direct T cells kill cancerous B" " DDI potential oral Tazemetostat . Phase I, multi-center, open-label, multi-dose, two-part PK safety study ." " MLN8237 participants had advanced hematological malignancies limited standard treatment options . This open-label, multicenter, phase 1 study MLN8237 participants had advanced hematological malignancies ." " Drugs used chemotherapy, VNP40101M, work different ways stop growth cancer cells ." " This randomized, open label, multicenter phase III trial comparing efficacy, safety, tolerability tisagenlecleucel Standard Of Care adult patients aggressive B-cell Non-Hodgkin Lymphoma failure ." The purpose study evaluate safe effective combination two different drugs (brentuximab vedotin rituximab) patients certain types lymphoma . This study patients type lymphoma expresses tumor marker called CD30 and/or type MS-275 isotretinoin may stop growth cancer cells blocking enzymes necessary growth . MS-275 isotretinoin may help cancer cells develop normal cells . MS-275 isotretinoin may also stop growth solid tumors lymphomas " Phase III, randomized, double-blind, placebo-controlled, multicenter study clinical response fentanyl sublingual spray treatment breakthrough cancer pain . Patients titrated effective-dose fentanyl sublingual spray open-label titration period proceed double" " The purpose study assess efficacy safety tisagenlecleucel children adolescents relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) survival rates dismal, ~20" " Japanese participants diagnosed previously-treated B-cell lymphoma. Japanese participants diagnosed previously-treated B-cell lymphoma. The purpose study evaluate safety, tolerability, pharmacokinetics and pharmacokinetics of parsaclisib treatment ." " ALX148 combination rituximab lenalidomide, rituximab, lenalidomide, may induce changes body's immune system may interfere ability cancer cells grow spread . This phase I/II trial finds" CPX-351 drug yet approved . This drug tested adults yet children adolescents . This drug tested adults yet children adolescents . Bryostatin 1 plus vincristine plus vincristine is a new drug to treat cancer patients with cancer . Bryostatin 1 may help vincristine kill cancer cells making sensitive drug . Bryostatin 1 may " This single-center, open label, single dose study anti CD30 CAR-T cells injection treatment patients relapsed/refractory CD30+ lymphoma ." " The purpose research study evaluate safety, pharmacokinetics, pharmacokinetics, pharmacodynamics preliminary efficacy and preliminary efficacy of the investigational drug PLX2853 ." Radiation therapy uses high-energy x-rays damage cancer cells . Peripheral stem cell transplantation may allow doctor give higher doses of chemotherapy radiation kill cancer cells . The purpose study assess safety tolerability BMS-936564 (MDX-1338) The purpose study assess safety tolerability BMS-936564 (MDX-1338) relapsed Acute myelogenous This single-arm open-label phase I/II study determine relative superiority of CAR-T cells . Patients were competitively infused with CAR-T cells infused with a CAR-T cell . Sunitinib malate may stop growth cancer cells blocking enzymes needed cell growth blocking blood flow tumor . Sunitinib malate may stop growth cancer cells blocking enzymes needed cell growth blocking blood flow tumor . This study test safe combination drugs Romidepsin Pralatrexate patients lymphoid malignancies . Study continues accrual patients peripheral T-Cell lymphoma (PTCL) The purpose study determine recommended recommended phase 2 dose drug Vorinostat . The purpose study determined recommended phase 2 dose drug Vorinostat . The purpose study determined whether addition Vorinostat standard graft versus host disease (GVHD " Oral bid dosing highest tolerable dose toxicity, progression, withdrawal, withdrawal . Oral bid dosing highest tolerable dose toxicity, progression, withdrawal . Patients: B-cell lymphoma, refractory, diffuse, diffuse, nod" Opioid Titration Order Sheet allows healthcare providers adjust dose schedule pain medication may help improve pain treatment patients cancer . It yet known whether use Opioid Titration Order Sheet effective standard care treating pain caused cancer . Drug is an analogue of geldanamycin analogue to geldanamycin analogue treating patients advanced solid tumors non-Hodgkin's lymphoma . Drugs used chemotherapy work different ways stop tumor cells dividing stop tumor cells dividing B-cell non-Hodgkin lymphoma returned period improvement responded previous treatment . B-cell non-Hodgkin lymphoma returned period improvement responded previous treatment . TAK-228 is being studied to help control relapsed lymphoma . The safety drug also studied . Subjects receive Adicet Bio allogeneic . allogeneic . allogeneic CAR T cell product . Subjects receive Adicet Bio . allogeneic . allogeneic . T cell product . Subjects join study complete parent inter SEA-TGT (also known SGN-TGT) is a drug called a drug called a drug called a drug called a drug called a drug called a drug called SEA-TGT . It study SEA-TGT find The goal clinical research study learn loratadine control bone pain caused pegfilgrastim (a drug given chemotherapy help raise white blood cell counts) The goal clinical research study learn loratadine control bone pain caused " Protocol YY-20394-007 phase1 open-label, single-arm, multi-centre study assess safety efficacy . Participants relapse and/or refractory B cell malignant hematological tumor. eligible participants initiate" Imatinib mesylate is being tested for its effectiveness in treating patients with advanced cancer liver dysfunction . The drug is being tested for its effectiveness in treating patients with advanced cancer liver dysfunction . " Investigators expect radioimmunotherapy Zevalin plus busulfan, cyclophosphamide etoposide regimen improve survival ." " The drug investigated study antibody, GEN3009 . Main purpose evaluate safety of the drug ." CC-223 assess safety action new class experimental drug (dual mTOR inhibitors) patients advanced tumors unresponsive . " Methadone, morphine, oxycodone may help relieve pain caused cancer . It yet known whether methadone effective morphine oxycodone treating pain patients cancer ." irinotecan plus cyclosporine phenobarbital may enhance effectiveness irinotecan . Cyclosporine phenobarbital may enhance effectiveness irinotecan . Phase II trial studies well nivolumab works DA-REPOCH chemotherapy regimen treating patients aggressive B-cell non-Hodgkin lymphoma . KUR-502 subjects subjects refractory/relapsed B-cell NHL leukemia (ALL CLL) subjects refractory/relapsed B-cell NHL leukemia (ALL CLL) KUR-502 subjects were subjects ref CpG-STAT3 siRNA CAS3/SS3 (CAS3/SS3) combination localized radiation therapy treating patients B-cell non-Hodgkin lymphoma come back (relapsed) respond treatment ( The investigational drug clofarabine is an investigational drug one approved by the FDA . The drug is used to treat non-hodgkin's lymphoma patients who resisted chemotherapy . Chemoprotective drugs amifostine may protect normal cells side effects chemotherapy . " National Comprehensive Cancer Network suggest patients routinely screened fatigue initial visit regular intervals throughout following anti-cancer treatment . Fatigue major problem children, adolescents adults receiving intensive chemotherapy cancer patients undergoing hematopoietic stem cell transplantation (HSCT" Fenretinide and rituximab are being tested for B-cell non-Hodgkin lymphoma . Fenretinide and rituximab work different ways to stop growth cancer cells . R-CHOP trial aimed studying combination drug named Selinexor (selective inhibitor nuclear export) combination standard therapy B cell Non-Hodgkin's lymphoma called R-CHOP . Giving Selinexor plus " LP-168 small molecule inhibitor is being tested in a phase I, multi-center, open-label, dose-escalation study . LP-168 subjects relapsed refractory B-cell malignancies are being tested for" Combining chemotherapy monoclonal antibody therapy may kill cancer cells . Monoclonal antibodies rituximab locate cancer cells . Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing " Antiemetic drugs, aprepitant, granisetron, dexamethasone, may help lessen prevent nausea vomiting patients treated chemotherapy ." " Monoclonal antibodies, nivolumab, may interfere ability tumor cells grow spread . This I/II trial studies side effects best dose lenalidomide given together nivolumab see well work treating patients non" The purpose study evaluate safety tolerability of MT-3724 subjects . Subjects relapsed refractory B-Cell NHL relapsed refractory CLL (Part 1 only) relapsed refractory CLL (Part 1 only " Drugs used chemotherapy, FR901228, work different ways stop tumor cells dividing stop growing die . Drugs used chemotherapy, FR901228, work different ways stop tumor cells dividing stop growing die ." " The purpose study determine safety administering obinutuzumab single agent alone combination combination combination ifosfamide, carboplatin, etoposide (ICE) chemotherapy determine response rate treatment children, adolescents young adults (CAY" Phase I trial study effectiveness VNP40101M treating patients advanced metastatic cancer . Rationale: Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Phase I trial study effectiveness VNP40101M treating patients advanced solid tumors lymphomas . Rationale: Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . " INCAGN02385 participants advanced malignancies. The purpose study determine safety, tolerability, preliminary efficacy . INCAGN02385 participants advanced malignancies." " Phase I/II trial studies side effects of venetoclax given together carmustine, etoposide, cytarabine, melphalan stem cell transplant . Patients given chemotherapy stem cell transplant ." Phase II trial study combining doxorubicin topotecan with doxorubicin topotecan . Combining one drug may kill tumor cells . " Chemoprotective drugs, amifostine, may protect normal cells side effects chemotherapy . Phase I trial study of amifostine plus combination chemotherapy treating patients advanced cancer ." Pevonedistat ibrutinib may stop growth cancer cells blocking enzymes needed to grow . Pevonedistat ibrutinib may stop growth cancer cells blocking enzymes needed to grow . The main objective study evaluate safety efficacy ABBV-623 ABBV-992 given alone combination treating B-cell cancers . B-cell cancer aggressive rare cancer type immune cells (a white blood cell responsible fighting infections) " Patients receive one two conditioning regimens (BEAM CBV) receiving autologous stem cell transplant (ASCT) If patients achieve either complete, partial, stable response following ASCT, receive IV dose Polatuzumab Ved" Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . CMC-544 subjects B-cell Non-Hodgkin's Lymphoma (NHL) to test safety profile . Initial safety profile CMC-544 subjects B-cell Non-Hodgkin's Lymph Randomized phase III trial compares effectiveness of two combination chemotherapy regimens treating patients with intermediate-grade immunoblastic non-Hodgkin's lymphoma . People HIV 17 times likely get NHL people HIV . The disease may also different two groups . DSHNHL R3 randomized clinical phase II study . The main objective estimate efficacy rituximab prophylactic medication prevention graft-versus-host-disease graft-versus-host-dise " Phase I/II trial study of vinorelbine, paclitaxel, estramustine . Combining one drug may kill cancer cells ." " NX-1607 is first-in-human Phase 1a/1b multicenter, open-label oncology study . NX-1607 is being tested for advanced malignancies ." 3-AP gemcitabine (GEM) work different ways stop growth cancer cells . 3-AP may help gemcitabine kill cancer cells making cells sensitive drug . 3-AP may also stop growth tumor cells blocking enzymes " Drugs used chemotherapy, cisplatin, etoposide, gemcitabine, methylprednisolone, methylprednisolone, work different ways stop growth cancer cells . Giving one drug (combination chemotherapy) may" Oral clofarabine related two intravenous chemotherapy drugs used . Clofarabine related two intravenous chemotherapy drugs used disease works two different ways . It affects development new cancer cells blocking two enzymes cancer cells need reproduce . Cl " The goal clinical research study learn adding Zevalin (ibritumomab tiuxetan) low-intensity chemotherapy (the combination rituximab, bendamustine, fludarabine), followed all" " Loncastuximab tesirine is linked chemotherapy drug, called tesirine . Loncastuximab form targeted therapy attaches specific molecules (receptors) surface cancer cells, known CD19 receptors, delivers t" " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others block ability cancer cells help kill carry cancer-killing substances ." Phase I trial study effect combination chemotherapy body treating patients relapsed refractory aggressive non-Hodgkin's lymphoma . Combining one drug may kill cancer cells . " Interferon alfa, interferon alfa, may interfere growth cancer cells, combination chemotherapy, uses different ways stop tumor cells dividing stop growing die, may kill tumor cells . Reducing amount drugs used prevent transplant rejection may help" Phase I trial studying side effects of SB-715992 . Best dose SB-715992 treating patients with Hodgkin's non-Hodgkin's lymphoma . 18F-2-fluoro-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose - Positron Emission Tomography . Positron Emission Tomography plays key " CDX-1140 (CD40 antibody) CDX-1140 (CD40 antibody) CDX-301 (FLT3L), pembrolizumab, chemotherapy evaluate tolerability efficacy efficacy expansion cohorts . MT" Lenalidomide given together combination chemotherapy see well work treating patients with v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) MyC-associated B-cell lymphomas This pilot clinical trial studies gene therapy following combination chemotherapy treating patients with AIDS-related non-Hodgkin lymphoma . Placing genes shown laboratory inhibit growth spread immunodeficiency virus (HIV) patient's peripheral blood stem Tretinoin may help hematologic cancer cells develop normal white blood cells . Arsenals trioxide without tretinoin may help hematologic cancer cells develop normal white blood cells . Phase I trial study effectiveness flavopiridol treating patients refractory cancer . Phase I trial study found flavopiridol effective in treating refractory cancer . Interleukin-12 may kill tumor cells stopping blood flow stopping blood flow . White blood cells kill cancer cells . Interleukin-12 may kill tumor cells stopping blood flow . Drug trials are studying side effects of methoxyamine fludarabine phosphate . Methoxyamine fludarabine phosphate given together fludarabine phosphate may kill cancer cells . " This randomized phase II trial includes blood stem cell transplant unrelated donor treat blood cancer . The treatment also includes chemotherapy drugs, lower doses conventional (standard (standard) stem cell transplants)" This study 2 parts. This study 2 parts. The main aims 1st part study check people advanced solid tumors cancers immune system (lymphomas) side effects TAK-981 . The main aims 2nd part study learn condition EMD 121974 may stop growth cancer stopping blood flow tumor . EMD 121974 may stop growth cancer stopping blood flow tumor . " Obatoclax mesylate given together vincristine sulfate, doxorubicin hydrochloride, dexrazoxane hydrochloride, dexrazoxane hydrochloride . This phase I trial studying" Phase II trial giving rituximab together combination chemotherapy 90-Yttrium ibritumomab tiuxetan works treating patients stage I stage II lymphoma . Phase I trial study found high-dose cytarabine given deoxycytidine given deoxycytidine given deoxycytidine . Deoxycytidine may protect patients side effects high-dose cytarab The primary objective of phase I determine maximum tolerated dose (MTD) dose limiting toxicity (DLT) combinations oral 5-azacitidine romidepsin patients lymphoma . The safety toxicity combination evaluated throughout entire study . Bortezomib may stop growth cancer cells blocking enzymes necessary growth . It may also increase effectiveness tanespimycin making cancer cells sensitive drug . " Juno CAR T-cell product Juno-sponsored clinical trial . In study, patients followed 15 years last dose of CAR T cells evaluation delayed adverse events, presence persisting CAR T-cell vector sequences, presence persisting CAR T-cell" " Drugs used chemotherapy, dexamethasone, cisplatin, gemcitabine, cytarabine, cytarabine, work different ways to stop cancer cells dividing stop growing die . Combining chemotherapy autologous" " Phase I trial study effectiveness liposomal cytarabine treating young patients recurrent refractory meningeal leukemia, lymphoma, solid tumors ." Phase I trial studying side effects of SL-11047 . Drug is being used to treat relapsed refractory lymphoma patients . " Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells kill carry cancer-killing substances . Others interfere ability cancer cells grow spread ." Combining chemotherapy autologous peripheral stem cell transplantation may allow doctor give higher doses chemotherapy drugs kill cancer cells . Phase II trial study of combination chemotherapy plus peripheral stem cell transplantation treating patients relapsed non-Hodgkin's " This open-label Phase 1 study determine feasibility, safety, recommended maximum tolerated Dose (MTD) single infusion (MTD) single infusion RPM CD19 mbIL15 CAR-T cells adult patients . Approximately 24 subjects enrolled" The main purpose first human study CC-122 assess safety action new class experimental drug (Pleiotropic Pathway Modulator) patients advanced tumors unresponsive standard therapies determine appropriate dosing level regimen later-stage clinical trials . " Drugs used chemotherapy, CCI-779, work different ways stop cancer cells dividing stop growing die . Phase II trial studying how CCI-779 works treating patients with recurrent refractory B-cell non-Hodgkin's" Phase II trial studies well vorinostat combination chemotherapy donor stem cell transplantation work treating patients aggressive B-cell T-cell non-Hodgkin lymphoma come back (relapsed) Radiolabeled monoclonal antibodies locate cancer cells either kill deliver cancer killing substances without harming normal cells . Combining chemotherapy peripheral stem cell transplantation may allow doctor give higher doses chemotherapy drugs kill cancer cells . Phase I trial studying side effects of best dose of gemcitabine . Oblimersen may increase effectiveness gemcitabine making cancer cells sensitive drug . Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways kill cancer cells . Combining monoclonal antibody therapy chemotherapy may kill cancer MP470 may stop growth cancer cells blocking enzymes needed to grow . MP470 may stop growth cancer cells blocking enzymes needed to grow . Interleukin-12 may kill tumor cells stopping blood flow . White blood cells stimulating person's white blood cells kill cancer cells . Gossypol given together paclitaxel carboplatin given together paclitaxel carboplatin . Gossypol given together paclitaxel carboplatin treating patients solid tumors metastatic cannot removed surgery . This study designed long-term follow-up study participants receive genetically modified autologous CAR-T cells . Genetic testing specific enzyme may help doctors determine whether side effects response chemotherapy related person's genetic makeup . Genetic testing specific enzyme may help doctors determine whether side effects response chemotherapy related person's genetic makeup . " Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells help kill carry cancer-killing substances . Others interfere ability cancer cells grow spread ." Phase I trial studying side effects of vorinostat given together decitabine . " PXD101 bortezomib may stop growth cancer cells blocking enzymes needed cell growth . PXD101 may also cause cancer cells look like normal cells, grow spread slowly ." Bortezomib may stop growth cancer cells blocking enzymes necessary growth . Bortezomib may increase effectiveness flavopiridol making cancer cells sensitive drug . Phase I trial studying side effects of 17-DMAG . Drug is used to treat patients with metastatic unresectable solid tumors lymphomas . The purpose study determine rate response drugs bortezomib (Velcade) vorinostat (Zolinza) The purpose study determine rate response drugs bortezomib (Velcade) vorinostat RO4929097 given together capecitabine given together capecitabine treating patients refractory solid tumors . RO4929097 may stop growth tumor cells blocking enzymes needed cell growth . Radiolabeled drugs yttrium Y 90 SMT 487 locate tumor cells and deliver tumor-killing substances without harming normal cells . yttrium Y 90 SMT 487 is being tested in Phase I trial study . " Antiemetic drugs, aprepitant, ondansetron, dexamethasone, may help lessen prevent nausea vomiting patients undergoing stem cell transplant ." " Drugs used chemotherapy, FAU, work different ways stop growth cancer cells . Drugs used chemotherapy, FAU, work different ways stop growth cancer cells . FAU is either killing cells or stopping dividing cells ." Copanlisib may stop growth tumor cells blocking enzymes needed cell growth . Copanlisib given together nivolumab works treating patients Richter's transformation transformed non-Hodgkin lymphoma . 10-propargyl-10-deazaaminopterin was used in Phase II trial study . 10-propargyl-10-deazaaminopterin was used to treat patients with non-Hodgkin's " A significant number patients non-Hodgkin lymphoma (NHL) cured available treatments eventually relapse . Those patients might able tolerate bone marrow toxicity, limiting treatment options . Preclinical vitro studies demonstrated synergism venetoclax cop" Phase II trial studying effectiveness donor peripheral blood stem cell transplant treating patients hematologic cancer . Phase I trial studying side effects of 17-N-allylamino-17-demethoxygeldanamycin . 17-N-allylamino-17-demethoxygeldanamycin treating patients advanced Ibrutinib may stop growth cancer cells blocking enzymes needed to grow . This phase I trial studies side effects best dose selinexor given together ibrutinib . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give higher doses of drugs kill cancer cells . Monoclonal antibodies locate cancer cells either kill deliver cancer- Radiolabeled monoclonal antibodies locate cancer cells deliver cancer-killing substances without harming normal cells . Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy treating patients lymphoma leukemia responded previous chemotherapy Phase II trial studying well topotecan hydrochloride works treating children meningeal cancer . Children's meningeal cancer responded previous treatment . The purpose study collect long-term safety efficacy data . Participants treated ibrutinib provide ongoing access to ibrutinib participants currently enrolled ibrutinib studies completed according parent protocol . Participants currently enrolled ibrut Bortezomib may stop growth cancer cells blocking enzymes needed to grow . Bortezomib given together gemcitabine may kill cancer cells . Phase II trial study effectiveness of combination chemotherapy . Combining one drug may kill tumor cells . Patients with Hodgkin's disease non-Hodgkin's lymphoma responded previous treatment . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining one drug may kill cancer cells . Phase I/II trial studies whether stopping cyclosporine mycophenolate mofetil better reducing risk of graft-versus-host disease (GVHD) previous approach mycophenolate mofetil stopped cycl " Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, ethanol may help prevent blockages infections forming patients central venous access catheters ." Ibrutinib may stop growth cancer cells blocking enzymes needed to stop cell growth . It yet known whether safe patients HIV infection receive ibrutinib also taking anti-HIV drugs . Keratinocyte growth factor may prevent symptoms mucositis patients receiving radiation therapy chemotherapy . Keratinocyte growth factor may prevent symptoms mucositis patients receiving radiation therapy chemotherapy. Combining chemotherapy bone marrow transplantation may allow doctor give higher doses chemotherapy drugs kill cancer cells . Phase II trial study effectiveness combination chemotherapy consisting busulfan cyclophosphamide followed bone marrow transplantation treating patients acute chronic leukemia myelod This expanded access protocol conducted sites qualified approved treat subjects lisocabtagene maraleucel . Sometimes lisocabtagene maraleucel manufactured drug pass testing results called lisocabtagene maraleu Phase II trial study effectiveness of combination chemotherapy treating patients AIDS-related lymphoma . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining one drug may kill cancer cells . " Phase I/II trial studies side effects of best dose anti-cluster differentiation (CD)20 radioimmunotherapy (RIT) RIT attaches radioactive material drug designed target CD20, brings radioactive material cancer cells kill cells ." " Phase I trial study effectiveness combining topotecan, fluorouracil, leucovorin . Combining one drug may kill tumor cells ." PDX101 may stop growth cancer cells blocking enzymes needed cell growth blocking blood flow cancer . PDX101 may stop growth cancer cells blocking enzymes needed needed cell growth blocking blood flow cancer . GS-0189 (formerly FSI-189) monotherapy combination rituximab participants relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) participants relapsed/ Phase I trial study combining ZD0473 doxorubicin with ZD0473 doxorubicin . Phase I trial study effectiveness combining ZD0473 doxorubicin treating patients advanced solid " Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells kill carry cancer-killing substances them . Others interfere ability cancer cells grow spread . Radiation therapy uses high-energy x-rays" Phase I trial studying side effects of azacitidine plus phenylbutyrate . Trials include patients with advanced metastatic solid tumors who responded to previous treatment . Combining one drug giving drugs different ways may kill cancer cells . Radiation therapy uses high-energy x-rays damage cancer cells . It yet known combination chemotherapy regimen followed radiation therapy effective treating aggressive non-Hodgkin's lymphoma " Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells kill carry cancer-killing substances . Others interfere ability cancer cells grow spread ." Motexafin gadolinium may increase effectiveness doxorubicin making tumor cells sensitive drug . Motexafin gadolinium may increase effectiveness doxorubicin making tumor cells sensitive drug . NX-5948 patients advanced B-cell malignancies are first in a human dose escalation cohort expansion . The study is designed to evaluate safety preliminary efficacy for advanced B-cell malignancies . Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . " This phase 1, open-label, dose-escalation, multicenter study evaluate safety tolerability of SGN-CD19A patients . Patients relapsed refractory B-lineage non-Hodgkin lymphoma" " The trial open-label, multi-center safety preliminary efficacy trial epcoritamab Japan is open-label, multi-center safety preliminary efficacy trial . The purpose dose-escalation part trial determine maximum tolerated dose (MTD" The purpose study evaluated safety tolerability of BGB-11417 monotherapy . The purpose study evaluated safety tolerability of BGB-11417 monotherapy . The study evaluated BGB-11417 monotherapy selected B-cell mal " CPI-613 (6,8-bis[benzylthio]octanoic acid) given together bendamustine hydrochloride rituximab . Rituximab may find cancer cells help kill" " Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cancer-killing substances ." Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining chemotherapy peripheral stem cell transplantation